<SEC-DOCUMENT>0001370053-20-000026.txt : 20200506
<SEC-HEADER>0001370053-20-000026.hdr.sgml : 20200506
<ACCEPTANCE-DATETIME>20200506161424
ACCESSION NUMBER:		0001370053-20-000026
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200506
DATE AS OF CHANGE:		20200506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAPTYSBIO, INC
		CENTRAL INDEX KEY:			0001370053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203828755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37985
		FILM NUMBER:		20852773

	BUSINESS ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-362-6295

	MAIL ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYSBIO INC
		DATE OF NAME CHANGE:	20080828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>anab-3312020x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:A67B65FBF9FA59FBAF4D5AD43518FA71,x:f9baa1ce42274cd4b12b588afa6fb510-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:anab="http://www.anaptysbio.com/20200331" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="Fact-E60DA6B901555B799B2AF2928FB48776-wk-Fact-E60DA6B901555B799B2AF2928FB48776">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="Fact-BBC7D637EB39559C82EB0B771D3EE29D-wk-Fact-BBC7D637EB39559C82EB0B771D3EE29D">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="Fact-AD58188957C55CCB9976EFCC90F87C30-wk-Fact-AD58188957C55CCB9976EFCC90F87C30">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" id="Fact-D59480E12DE3550588A625E834F4A14A-wk-Fact-D59480E12DE3550588A625E834F4A14A">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:AmendmentFlag" id="Fact-D9C83308CAC15E2C8343E35CC2F1991A-wk-Fact-D9C83308CAC15E2C8343E35CC2F1991A" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-FC07F35B543A534D81CE9C0E438E51D8-wk-Fact-FC07F35B543A534D81CE9C0E438E51D8">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-D9D6BAFB97BF598AA26FE76103115931-wk-Fact-D9D6BAFB97BF598AA26FE76103115931">Q1</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalYearFocus" id="Fact-26CD4B1F4C3B52ECADAF493F86EC3519-wk-Fact-26CD4B1F4C3B52ECADAF493F86EC3519">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:EntityCentralIndexKey" id="Fact-80DCC4AA3CC25D70971D04D98D94287D-wk-Fact-80DCC4AA3CC25D70971D04D98D94287D">0001370053</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-08BA1CCC32B450DF8C8A10D6A9654D29-wk-Fact-08BA1CCC32B450DF8C8A10D6A9654D29">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-FE7D96DEFC825610834B227DD287F63C-wk-Fact-FE7D96DEFC825610834B227DD287F63C">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-572287BF03FE528488A6A2E065D8BB2E-wk-Fact-572287BF03FE528488A6A2E065D8BB2E">500000000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-4ABE2D4364765C1BAD3CFB7CDDFB3FD6-wk-Fact-4ABE2D4364765C1BAD3CFB7CDDFB3FD6">27255000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesIssued" id="Fact-52295793578C53F39482A3A89C087FD3-wk-Fact-52295793578C53F39482A3A89C087FD3">27277000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-DDCFD020ED8D50F98321AD1AC30ACB42-wk-Fact-DDCFD020ED8D50F98321AD1AC30ACB42">27255000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesOutstanding" id="Fact-BBAEDDA80E8051148DCC37837518B0A1-wk-Fact-BBAEDDA80E8051148DCC37837518B0A1">27277000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesOutstanding" id="Fact-A1A6CC5D1E0A51B7A526AEEA234D1B23-wk-Fact-A1A6CC5D1E0A51B7A526AEEA234D1B23">27277115</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q1QTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-1A51CA1C23A05DA1A6BB66E67AD6E18B-wk-Fact-1A51CA1C23A05DA1A6BB66E67AD6E18B">115000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q1YTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-6920FAB1439250D499171782B1AF83AE-wk-Fact-6920FAB1439250D499171782B1AF83AE">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-0BEBDC9C11CD525691E684ED3C34BA90-wk-Fact-0BEBDC9C11CD525691E684ED3C34BA90">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-8FAE29D91BD85E138DC41E2837FEF59C-wk-Fact-8FAE29D91BD85E138DC41E2837FEF59C">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-F0EEB1E38B8E571F9EA3071B99A0A752-wk-Fact-F0EEB1E38B8E571F9EA3071B99A0A752">10000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-9B69D23FA5195FF9BB713E60C773BD3B-wk-Fact-9B69D23FA5195FF9BB713E60C773BD3B">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-519EFA70A50A5A41BF9D1801A73CE48F-wk-Fact-519EFA70A50A5A41BF9D1801A73CE48F">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesIssued" id="Fact-4D13B8F6426C5737A826C57778849BE0-wk-Fact-4D13B8F6426C5737A826C57778849BE0">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-523D44B7DD8757B99D96DFEEFE479014-wk-Fact-523D44B7DD8757B99D96DFEEFE479014">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-B7DAE6CDEE6754A0A86B9A329032E0AE-wk-Fact-B7DAE6CDEE6754A0A86B9A329032E0AE">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q1QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact-BFCF40578B1C5A53B0D83349CE92A34B-wk-Fact-BFCF40578B1C5A53B0D83349CE92A34B">0</ix:nonFraction><ix:nonNumeric contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-0634B36B302E542090F13AB2AE09B4EA-wk-Fact-0634B36B302E542090F13AB2AE09B4EA">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact-3CAE2F4BB3E652F38544EC95AAC8743E-wk-Fact-3CAE2F4BB3E652F38544EC95AAC8743E">P10Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="anab-20200331.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2May4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-05-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_anab_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_anab_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_us-gaap_TypeOfArrangementAxis_anab_Phase1ClinicalTrialInitiationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase1ClinicalTrialInitiationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q2QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2014Q1_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q4Nov01-Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-01</xbrli:startDate>
			<xbrli:endDate>2014-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Mar01-Mar31_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-03-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2011Q4YTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-01-01</xbrli:startDate>
			<xbrli:endDate>2011-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3ClinicalTrialInitiationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2011Q4_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q3QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3clinicaltrialinitiationsecondindicationDomain">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3clinicaltrialinitiationsecondindicationDomain</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2015Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3ClinicalTrialInitiationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2015Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_FilingofMMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingofMMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_FilingofNDAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingofNDAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2014Q4Dec24_us-gaap_DebtInstrumentAxis_anab_TermALoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermALoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q1Jan31_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2014Q4Dec24_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q4Dec24-Dec24_us-gaap_DebtInstrumentAxis_anab_TermALoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermALoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-24</xbrli:startDate>
			<xbrli:endDate>2014-12-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q4Dec24-Dec24_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-24</xbrli:startDate>
			<xbrli:endDate>2014-12-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2014Q4Dec24_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q1Jan31_us-gaap_DebtInstrumentAxis_anab_TermBLoansAndTermCLoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermBLoansAndTermCLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan01-Jan01_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Jan26-Jan26_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-26</xbrli:startDate>
			<xbrli:endDate>2017-01-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_anab_EmployeeAndNonemployeeStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anab:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Jan1_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_anab_LeaseArrangementAxis_anab_OneOfficeLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="anab:LeaseArrangementAxis">anab:OneOfficeLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-05-04</xbrli:startDate>
			<xbrli:endDate>2020-05-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001370053</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-05-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="installment">
		<xbrli:measure>anab:installment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="lease">
		<xbrli:measure>anab:lease</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="milestone">
		<xbrli:measure>anab:milestone</xbrli:measure>
	</xbrli:unit><xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit><xbrli:unit id="renewal_option">
		<xbrli:measure>anab:renewal_option</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="USD_PER_sqft">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>utreg:sqft</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>anab:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="target">
		<xbrli:measure>anab:target</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s518819CFCA6955B2A81E9339DE5F15A7"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.30952380952381%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">UNITED STATES </span></div><div style="line-height:120%;text-align:center;font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="line-height:120%;text-align:center;font-size:16pt;"><span style="font-family:inherit;font-size:16pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.30952380952381%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:14pt;"><span style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d26767353e446-wk-Fact-C0AB596C56F554D295E361C149473310" name="dei:DocumentType" contextRef="FD2020Q1YTD"><span style="font-size:14pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:14pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.30952380952381%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d26767353e478-wk-Fact-E34C679CDE4B5FFDBD0A445587FBB375" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Quarterly Report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d26767353e488-wk-Fact-A9996D0C8C5159DCAE4EA646B4C0B710" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q1YTD" format="ixt:datemonthdayyearen">March 31, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OR </span></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d26767353e508-wk-Fact-CD3C58A444C85184A3DDE6CDB439C636" name="dei:DocumentTransitionReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Transition report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;to&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d26767353e530-wk-Fact-4C2F23B4B18D5B569808173988391576" name="dei:EntityFileNumber" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">001-37985</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.30952380952381%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d26767353e550-wk-Fact-C97C6E68A7595614B4CC7984FDEDA0F3" name="dei:EntityRegistrantName" contextRef="FD2020Q1YTD"><span style="font-size:18pt;font-weight:bold;">ANAPTYSBIO,&#160;INC</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;">.</span><span style="font-family:inherit;font-size:24pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.30952380952381%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d26767353e588-wk-Fact-6BF1C69E925B580CBC2402B5128BD1BE" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q1YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d26767353e598-wk-Fact-CA2A81DBC1465BA787B2EAC02B56B797" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q1YTD">20-3828755</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</span></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</span></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification Number)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d26767353e625-wk-Fact-F860818978EA58348210AA894F010670" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">10421 Pacific Center Court</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d26767353e630-wk-Fact-4F9BB36900555DEE89B4CEA26BC847F9" name="dei:EntityAddressAddressLine2" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">Suite 200</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d26767353e636-wk-Fact-89C06BF15F6E59CABFD7E9EB1C60B128" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">San Diego</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d26767353e641-wk-Fact-BCCA4ED20EF3546F8C57793B82F971F0" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">CA</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d26767353e646-wk-Fact-388D902F7A2C588484D5298AF41B893C" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">92121</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices and zip code) </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d26767353e658-wk-Fact-FFFA208ABBA757AC9ADE2222FC43184F" name="dei:CityAreaCode" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">858</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d26767353e663-wk-Fact-9BD16D2F461C5F7888BB87F1595D45C7" name="dei:LocalPhoneNumber" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">362-6295</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">  </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.30952380952381%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:27%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26767353e718-wk-Fact-D4D8D49C44335293BFC2540AA2EC81FB" name="dei:Security12bTitle" contextRef="FD2020Q1YTD">Common Stock, $0.001 par value </ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26767353e723-wk-Fact-765BBC91F5AF5960BC5EF5081704736D" name="dei:TradingSymbol" contextRef="FD2020Q1YTD">ANAB</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26767353e728-wk-Fact-85B5483E50855A518663CA652FD815F4" name="dei:SecurityExchangeName" contextRef="FD2020Q1YTD" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days:&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26767353e735-wk-Fact-77067CAD3F5F522096A24CF0EDFE16DC" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q1YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:14pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26767353e750-wk-Fact-183FFE6375B25750AD41D7A4BBCBF117" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q1YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:14pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26767353e783-wk-Fact-4CA5FB21896B5BD1B47BD42D457CCB31" name="dei:EntityFilerCategory" contextRef="FD2020Q1YTD" format="ixt-sec:entityfilercategoryen">Large Accelerated Filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated&#160;Filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated Filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller&#160;Reporting&#160;Company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d26767353e885-wk-Fact-FE6976362F4D5586A12B44D858195C35" name="dei:EntitySmallBusiness" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Growth Company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d26767353e957-wk-Fact-8EDAFE7D4AF45B32B8046D7B3BDA412C" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d26767353e968-wk-Fact-D86E2B31AAA4559E98ACAC1A4C82F013" name="dei:EntityShellCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:14pt;">&#9746;</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">May&#160;4, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26767353e984-wk-Fact-B79261DD62885F24B93AFA9A37035120" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q2May4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">27,277,115</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Registrant&#8217;s Common Stock outstanding. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.30952380952381%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sC7F8949064935564AE022EBB4C6AF669"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">ANAPTYSBIO, INC.</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:76%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Page Number</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sCBE31FD172D659EDB9C98C88CC703CE9"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 1.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCBE31FD172D659EDB9C98C88CC703CE9"><span style="font-family:inherit;font-size:10pt;">Consolidated Financial Statements (unaudited)</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sCBE31FD172D659EDB9C98C88CC703CE9">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4D0B4EFD69AA536BB5DB5D5E33D88966"><span style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s4D0B4EFD69AA536BB5DB5D5E33D88966">1</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE3037976AA595942AB7F3D7FEB863F64"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sE3037976AA595942AB7F3D7FEB863F64">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50C1CBCF4110593BB40371614D54ED20"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholder&#8217;s Equity for the Three Months Ended March 31, 2020</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s50C1CBCF4110593BB40371614D54ED20">3</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAAA2DD442A0D53C4AB5B0EA18DE2C3FE"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholder&#8217;s Equity for the Three Months Ended March 31, 2019</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sAAA2DD442A0D53C4AB5B0EA18DE2C3FE">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s78F518B761C95C659CA926445F5C49D0"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s78F518B761C95C659CA926445F5C49D0">5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s555BD3A521B555F3AE83748326927F9A"><span style="font-family:inherit;font-size:10pt;">Notes to the Unaudited Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s555BD3A521B555F3AE83748326927F9A">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s4289C287075B53D1A81029511E64285C"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4289C287075B53D1A81029511E64285C"><span style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s4289C287075B53D1A81029511E64285C">20</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sC65CF7DFF64E5E419079FE3895DD39DF"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 3.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC65CF7DFF64E5E419079FE3895DD39DF"><span style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sC65CF7DFF64E5E419079FE3895DD39DF">27</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s78430F3372D55FCAA38C86316F366F8F"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 4.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s78430F3372D55FCAA38C86316F366F8F"><span style="font-family:inherit;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s78430F3372D55FCAA38C86316F366F8F">27</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s118DB723078D504FA687F470918DBB3A"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s118DB723078D504FA687F470918DBB3A"><span style="font-family:inherit;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s118DB723078D504FA687F470918DBB3A">28</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s0748DA5DCF35551CA5697E6E33A2AC9E"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 1A.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0748DA5DCF35551CA5697E6E33A2AC9E"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s0748DA5DCF35551CA5697E6E33A2AC9E">28</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s8D603E57A0C35281B273EBD87AF89D32"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8D603E57A0C35281B273EBD87AF89D32"><span style="font-family:inherit;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s8D603E57A0C35281B273EBD87AF89D32">60</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sEC5C5315CCE05DFCAE6533E7D2454FEA"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 3.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEC5C5315CCE05DFCAE6533E7D2454FEA"><span style="font-family:inherit;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sEC5C5315CCE05DFCAE6533E7D2454FEA">60</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s75C04C59E53F527FA59B61AB7A808E59"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 4.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s75C04C59E53F527FA59B61AB7A808E59"><span style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s75C04C59E53F527FA59B61AB7A808E59">61</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s6185009038D45FA68B13E4F85D4AD86A"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 5.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6185009038D45FA68B13E4F85D4AD86A"><span style="font-family:inherit;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s6185009038D45FA68B13E4F85D4AD86A">61</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s8511B959395A5CE8A29B1A7F8952F8AD"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 6.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8511B959395A5CE8A29B1A7F8952F8AD"><span style="font-family:inherit;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s8511B959395A5CE8A29B1A7F8952F8AD">61</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1BF7766EA9B75349BC15B4A34025BA9F"><span style="font-family:inherit;font-size:10pt;">Exhibit Index</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s1BF7766EA9B75349BC15B4A34025BA9F">61</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9C94CDA976F157B5BC378D9F11725758"><span style="font-family:inherit;font-size:10pt;">Signatures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s9C94CDA976F157B5BC378D9F11725758">62</a></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sC552FA1D56A3577DB344AF18876323D7"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</span></div><div><a id="sCBE31FD172D659EDB9C98C88CC703CE9"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1. CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div><a id="s4D0B4EFD69AA536BB5DB5D5E33D88966"></a></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ANAPTYSBIO, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except par value data) </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="8" style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">ASSETS</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e607-wk-Fact-C9BED6B1EAD35B2FB791B26FFA9C26CD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">165,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e626-wk-Fact-C85187F818CE5C4086A4DCA40A58C3EB" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Receivable from collaborative partners</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e641-wk-Fact-4DE11D2C534C5479985687891D68CD25" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e660-wk-Fact-4671C832C00158F28A649D3C6F1C25A1" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e680-wk-Fact-3B4585770839581886FC9B338BE2BAD4" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">197,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e699-wk-Fact-D8D00AAF1CBB5E92BD96B2E953F5F7F6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203,210</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e719-wk-Fact-C5B2BBD7BE755D8FA09B2B0717D1910B" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e738-wk-Fact-CB5E40B446785FCEAFC8AD92B46CE723" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:54px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e758-wk-Fact-EA755D82DFEA5F36BBADB6CF4EB6289D" name="us-gaap:AssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">371,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e777-wk-Fact-0BDA1F96E7E75CBD9F45423B58D4B543" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">377,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e797-wk-Fact-77B923B2F7545A5BA7333B80DC4C00CB" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e816-wk-Fact-9AD56001338F58CCA9EA54AE0A88A978" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e836-wk-Fact-578EA6D879C355B39D7F8D3A6460601A" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e855-wk-Fact-8C4B6D52E2CD58BA91E444618E3EE2EB" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e876-wk-Fact-A5D34AAB9374532CA22E939CF0BB760D" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e895-wk-Fact-E787FC069CE45BB98F83B39334F47832" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e915-wk-Fact-34A4AE007E415134802B1718B4616866" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e934-wk-Fact-017A99AFD29D50B988171FBBEE0E12B1" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e959-wk-Fact-F3012D8301BC542E99B62919A8C187BA" name="us-gaap:Assets" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">424,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e978-wk-Fact-0FD64F1F33E150058FD836B4FBAB7BD5" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">435,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1080-wk-Fact-783F5F96CAA454EE8F2D5CD91FDEAFCF" name="us-gaap:AccountsPayableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1099-wk-Fact-A9829F4EB622541E9ED482F778DEE63E" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1114-wk-Fact-3D7922185AD859C8A5A768570583D1F3" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,781</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1133-wk-Fact-097AF68DBD7C51DFA9CF38C3E6D66D81" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,052</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Notes payable, current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1153-wk-Fact-BA1C8653AB8351B29C90FEDFF98986ED" name="us-gaap:NotesPayableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1172-wk-Fact-987CE74637AD52FFB4AD130C4EC7E37D" name="us-gaap:NotesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1192-wk-Fact-D0E792A54D4E5D959D50A4EAA29DACD9" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1211-wk-Fact-D63E42920E4854BA8F41C32C9FFEE1A1" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">871</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:54px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1231-wk-Fact-85AF4EA0F75A54808245314DB193655E" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1250-wk-Fact-54D870E573FD58F1A19AA66887171560" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1270-wk-Fact-7CCB0E9E0B0F51A789DC32181F97B230" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1289-wk-Fact-1B847BFE32E0551FA85F69368BB68896" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1351-wk-Fact-0F6FFF1221CE5A6CBEBB0EE3B6E6FA86" name="us-gaap:PreferredStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1370-wk-Fact-2EAC4663585F583091D2B6C2E5AE2460" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock, $0.001 par value, 500,000 shares authorized, 27,277 shares and 27,255 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1390-wk-Fact-45D82D2ED70F50C6841AF7F27D0194D1" name="us-gaap:CommonStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1409-wk-Fact-69F355CE0F655AD79B41322D2F1BE001" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional paid in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1429-wk-Fact-0A5A5C39F0645BF3B3E8C38CA9065936" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">651,680</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1448-wk-Fact-AB1CDE97FEE15134A724EA254599CB23" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">648,669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1468-wk-Fact-52DC2CBD7F47553682091A74682F47D8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1487-wk-Fact-B0455D64BEE752D2954E67D1CFBE51B4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26769083e1507-wk-Fact-E235366FBB4B5D14A3A388BD595F384C" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">252,288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26769083e1527-wk-Fact-DCDD3EFC48FF59D7B2826F6293595DFD" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">244,026</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1548-wk-Fact-BA3D0040F9635C9BA0B03ADDE6DC28BC" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">400,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1567-wk-Fact-8D8A49415E1F513098893930951B11A5" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">405,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total liabilities and stockholders&#8217; equity </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1592-wk-Fact-5473D9397D6356F39D634AE405BAB64A" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">424,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26769083e1611-wk-Fact-C14C9B6C514E59058CDDF9E223D1675E" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">435,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;See accompanying notes to unaudited consolidated financial statements. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE3037976AA595942AB7F3D7FEB863F64"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ANAPTYSBIO, INC. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data) </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Collaboration revenue</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e529-wk-Fact-0A9DC609564D58618F3F124F99BDD9B6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e548-wk-Fact-6F9DBA3DF66A5662B9E2E0216F32756B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e604-wk-Fact-D6D940F8A70350229D223CC3F222A7C7" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,968</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e623-wk-Fact-8434DB7277A8556C9134D62EDF25EC14" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,631</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e643-wk-Fact-68ABEFF5ABCE50C69AC0D9F2434B2DF6" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e662-wk-Fact-629E6BD63FA05BA3A38A1B7374D8596D" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e682-wk-Fact-0C442EB0A7E65C9FAFA63235798759DE" name="us-gaap:OperatingExpenses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e701-wk-Fact-DED983BD839A587A99C3A548E386F2E1" name="us-gaap:OperatingExpenses" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:54px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e721-wk-Fact-D7BAA8E44FE75F8D859B2BEA86996098" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e741-wk-Fact-94F1D5E283C6557896265871BFAA3CD6" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">24,772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other income (expense), net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:12px;text-indent:6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e803-wk-Fact-C3621DA26EEA568CB75E156BD3B4A50C" name="us-gaap:InterestExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e822-wk-Fact-EEC92EE2FDC5590DBE2B9B508CC5EB83" name="us-gaap:InterestExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e843-wk-Fact-3E176A4E677A53E182CB3730C8632518" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e862-wk-Fact-C21238D1B5AF5DAE9DD12B96EB17D448" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e883-wk-Fact-CDCAA968147C519A8F26BA9844608AA1" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e902-wk-Fact-D79EC1A2B2EB53BBA2C8DF45A6BA1120" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e922-wk-Fact-3B76152191D95D38AFA1568CEB8A919A" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e941-wk-Fact-992A0CD182655F7BBA6A9560EC15C8E7" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:54px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e961-wk-Fact-8F1EAFFD699358C5B0DE87EE5BF0EDE7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e981-wk-Fact-D48F370442D5527696B09B759AB78423" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Provision for income taxes </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e1002-wk-Fact-5C711A9621255F37A0D5908CD5CEE0FD" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e1021-wk-Fact-7EBE7BA160E65773B6A08BA18D6690CA" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e1041-wk-Fact-4FEC981DE04E5C0996F403AB89D9CED4" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e1061-wk-Fact-4398CD5ED3735E11A4522B2CFF2F0A8B" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized income on available for sale securities, net of tax of $0 and $115, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e1123-wk-Fact-E4BD09B150ED5D9DAADF6D2BEEEAE564" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e1142-wk-Fact-3381CCE14AEC5988AF65FE7EF4564770" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:54px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e1167-wk-Fact-74CAADCB477356C39DD82D28B8228C77" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e1187-wk-Fact-BC36955CDC215E90B09B456766CCC4B3" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,651</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss per common share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e1249-wk-Fact-3FD1F6269EA2515EB5E10F8D1675DA41" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26772186e1269-wk-Fact-FCEA7715C5B0509ABDF775AC6E4DA30F" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted-average number of shares outstanding:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e1327-wk-Fact-19175D5CB4C2586CA4F2DA3BC03C34BA" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2020Q1YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">27,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26772186e1346-wk-Fact-75FCDD3564E35449BD5A71A728072039" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">26,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited consolidated financial statements.</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s50C1CBCF4110593BB40371614D54ED20"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ANAPTYSBIO, INC.</span></div><div style="line-height:120%;text-align:center;font-size:9.7pt;"><span style="font-family:inherit;font-size:9.7pt;font-weight:bold;">CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:37%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated Other Comprehensive Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e696-wk-Fact-E651F449067D5B3CA8826391975A0933" name="us-gaap:SharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">27,255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e715-wk-Fact-530D3202E4E553A7B82A21DB731955C6" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e734-wk-Fact-CC1C07EDEB835E9B844119AB68EF5311" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">648,669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e754-wk-Fact-8C812027341A5B78A6FC9F3CC8DBDDCC" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d26772871e773-wk-Fact-8D148D109B1E5A82ACEA80E34FF43FAC" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">244,026</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e793-wk-Fact-8D8A49415E1F513098893930951B11A5" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">405,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Shares issued under employee stock plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e809-wk-Fact-E6C1C3C0BE7F51E184623261B9C56631" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e842-wk-Fact-AFC30CE026FA53DA85D0F860F114E7A1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e900-wk-Fact-58D1465B086C5F9A9D11BE59A6692DDC" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e954-wk-Fact-B8AD9BD33AD55441BB5B2D38F6C6AFE8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e1012-wk-Fact-BBD3E282B3E653FAA499C7E9502D4D49" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Comprehensive income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e1086-wk-Fact-4AB2CDD39E4B59CF8AC326531E160428" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e1124-wk-Fact-87251A1814D45997A539309B4946E3D8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d26772871e1217-wk-Fact-0951CD6D27355141BF76AB4D2BD86F6D" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d26772871e1237-wk-Fact-4FEC981DE04E5C0996F403AB89D9CED4" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Balance, March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e1259-wk-Fact-A293B6BBAFAC5054851159079E173763" name="us-gaap:SharesOutstanding" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">27,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e1278-wk-Fact-4C6981913B1A553BA12215D8F00F69D6" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e1297-wk-Fact-024236C3EE93548AA530397E3D30E810" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">651,680</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e1317-wk-Fact-013C6309AB4D5FA386873964AF8C483F" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d26772871e1336-wk-Fact-3B8D1EC0B45C52C5A837B17F15F25BB1" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">252,288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26772871e1356-wk-Fact-BA3D0040F9635C9BA0B03ADDE6DC28BC" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">400,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAAA2DD442A0D53C4AB5B0EA18DE2C3FE"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ANAPTYSBIO, INC.</span></div><div style="line-height:120%;text-align:center;font-size:9.7pt;"><span style="font-family:inherit;font-size:9.7pt;font-weight:bold;">CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:37%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated Other Comprehensive (Loss) Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e694-wk-Fact-4A3ECDFBC3E356158C0FA507A7D32C1E" name="us-gaap:SharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">26,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e713-wk-Fact-C667A395DB6A527BB2B92F8846EFD660" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e732-wk-Fact-DC6CBFD1F7885C5185706030021CEE8C" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">633,251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d26773816e752-wk-Fact-EA1FA5AAA76C5A5D82D6EE21AC6E6087" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d26773816e772-wk-Fact-B82DCE8DC91E563789FB4BB5A2CF8DF2" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">146,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e792-wk-Fact-56573CE8610259B9AC99A7E5797B510B" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Shares issued under employee stock plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e808-wk-Fact-F9F6F49595425DFD9984F2A5DC0C2C90" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e841-wk-Fact-659A5E19EF075232A3B75F216051E5A5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e899-wk-Fact-97BF1F7DC9355E38B140299194A1D40C" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e953-wk-Fact-9F6CE1A90C0D5889900BCDA5DCEBDE76" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e1011-wk-Fact-97D6D85BC08B54F4976C1A7DDA674A9D" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Comprehensive income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e1085-wk-Fact-A10F174A6E0C57E29307F494C2C8765E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e1123-wk-Fact-B94C0999068952D9830476E9DF1B4EDB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d26773816e1216-wk-Fact-5EFF4B5A789A593688256AA73618E6B3" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d26773816e1236-wk-Fact-4398CD5ED3735E11A4522B2CFF2F0A8B" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Balance, March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e1258-wk-Fact-A943FDE478E65245A87D515B437CDDCB" name="us-gaap:SharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">27,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e1277-wk-Fact-76322A5F32CB50859FE0DAF77300094D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e1296-wk-Fact-8679A2238555533FA0E5EB55AC34A9EE" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">636,692</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e1316-wk-Fact-E745883D33E755E2AE8E6DB71A099440" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d26773816e1335-wk-Fact-4620434DBD015AD6910739A3C0260E00" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">168,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d26773816e1355-wk-Fact-DA5B79B04EF950E0B777BA366113939A" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">468,155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s78F518B761C95C659CA926445F5C49D0"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ANAPTYSBIO, INC. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands) </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e569-wk-Fact-4FEC981DE04E5C0996F403AB89D9CED4" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e589-wk-Fact-4398CD5ED3735E11A4522B2CFF2F0A8B" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e646-wk-Fact-F589F8A8BB1C5DA0B490C8D95EBFBE48" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e665-wk-Fact-CB6164149F0A5FF1A86C2F7CE613F1BA" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e685-wk-Fact-1341CD9F811D57208C64AF7D213B450A" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e704-wk-Fact-4DCA0F193B3D5FD08CB6F86FBAB8A919" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accretion/amortization of investments, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e724-wk-Fact-FC9ED541CEF85970AEB550A8896F4648" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e744-wk-Fact-8D3EAB13B11356C1AC1D9C11665B96F7" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,028</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-cash interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e765-wk-Fact-E6B4627648545C5FA6AB57EAE82491E7" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e784-wk-Fact-1B5802E56B195306B73A653FEE140432" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Receivable from collaborative partners</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e845-wk-Fact-5039B0A0573456A4BD6E1338A6186502" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e865-wk-Fact-2A8E4B7BBED75982A741CD9D2C139E6E" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e886-wk-Fact-B6483139C70350E28DFB0FBCC03EA07D" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e905-wk-Fact-59ACAA87723C5616936B42B402A9B8E3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:36px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e926-wk-Fact-9AAB934E3A925521840AB3B4ED7B1176" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e946-wk-Fact-1DDB395FA1D257298BDC9FC83516594F" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,076</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:54px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e966-wk-Fact-A7FDA391383A59868332C2D5F723B296" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15,112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e986-wk-Fact-E37D6892380850779A8325715CCAE992" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisition of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1048-wk-Fact-65BDD8C163A158FBA08FDBF7E94B21AF" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,013</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1068-wk-Fact-B2634A51C27F53A98431E2E600DCCFDD" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,763</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sales and maturities of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1089-wk-Fact-F36040249D3A526EAAE2F320FE4FB9C4" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1108-wk-Fact-9E3A3305783B55A099799BAB4676FC83" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">89,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1128-wk-Fact-F86ACCA50B135FE6BC28B770CFA359E3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1148-wk-Fact-F249B0C326F35C8AADEF0AB29CB2DE9D" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:54px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash provided by investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1169-wk-Fact-B7EFDCF509C75AC9B8653E6086382020" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,751</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1188-wk-Fact-3A3F3395D6FD57B2AEB4570F3A27841E" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from issuance of common stock, upon the exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1249-wk-Fact-D5B5F6C10CD55C65B282E946AC157003" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1268-wk-Fact-D148CD3EAD5B5198AFAB055BF1E6AE9D" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Payments on notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1288-wk-Fact-083CEB20BC465A09B7C1ACD3D17D55E0" name="us-gaap:RepaymentsOfNotesPayable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1308-wk-Fact-DE3CE51CA15050178A8B08F80BD0C7DD" name="us-gaap:RepaymentsOfNotesPayable" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:54px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash used in financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1330-wk-Fact-4385F4123BCC5553A99B1A376DD53722" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1350-wk-Fact-D12EE98B593F56B3AF9E8E35DEEA4BDA" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:73px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net decrease in cash, cash equivalents, and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1371-wk-Fact-351AE854EBD75A3886D62E7544AA1392" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d26771629e1391-wk-Fact-AFAEF339DC53505E950BA871F011AA9E" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash, cash equivalents and restricted cash, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1412-wk-Fact-5ABAA88CB93E56EC8077A3086C7BA9BC" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171,077</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1431-wk-Fact-B2995FA9763B5CD79CC6733B1644F320" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">113,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash, cash equivalents and restricted cash, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1456-wk-Fact-CB118AB1E12B5BC5A66C3507702FC0A0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">165,377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1475-wk-Fact-0C393FBFEFA651F9A69C532EBCD6A958" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1536-wk-Fact-EB7906AF8263515AAC17AC84DE2F1A67" name="us-gaap:InterestPaidNet" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1555-wk-Fact-BBDE983B6B695125ADCCE8CE9F36F10C" name="us-gaap:InterestPaidNet" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-cash investing and financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts accrued for property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1616-wk-Fact-110489D227995E898B67D1A80CECCA46" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d26771629e1635-wk-Fact-45BE0D9C2B5C55C6853FAB57E4B829AA" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to unaudited consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s555BD3A521B555F3AE83748326927F9A"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ANAPTYSBIO, INC. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS </span></div><div><a id="sC7B5369BD86351C78963A29682C5DDAB"></a></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:NatureOfOperations" id="TextSelection-6C4907F6889D5AECBA5E1EF63B26E2D6-0-wk-Fact-45DDFB6FBCC6518D8FE99BDBFACA7961" continuedAt="TextSelection-6C4907F6889D5AECBA5E1EF63B26E2D6-1" escape="true">Description of the Business </ix:nonNumeric></span></div><ix:continuation id="TextSelection-6C4907F6889D5AECBA5E1EF63B26E2D6-1"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in November 2005. We are a clinical stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;">. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, we have devoted our primary effort to raising capital and research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Management believes its currently available resources will provide sufficient funds to enable the Company to meet its operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div></ix:continuation><div><a id="s95E3B19237F55D338BFACA0E1932477D"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-81C0A1870BE05A86A652D840BF134129-0-wk-Fact-0385C59A84DE5F35ABDD157AEE2E2DA3" continuedAt="TextSelection-81C0A1870BE05A86A652D840BF134129-1" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="TextSelection-81C0A1870BE05A86A652D840BF134129-1" continuedAt="TextSelection-81C0A1870BE05A86A652D840BF134129-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-C61CF9B9028F5346BD7C085511157B75-0-wk-Fact-76F4CFAF741151CFA35E8F0C5B34BA42" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus pandemic, or COVID-19, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and social distancing guidelines, causing some businesses to suspend operations and or experience a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, included in our Annual Form 10-K. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-43A6134398095F15867A0D32D28BD5A0-0-wk-Fact-9D8A6E9FD34E51DCB65096E2960FBD6D" continuedAt="TextSelection-43A6134398095F15867A0D32D28BD5A0-1" escape="true"><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Consolidation</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><ix:continuation id="TextSelection-43A6134398095F15867A0D32D28BD5A0-1" continuedAt="TextSelection-43A6134398095F15867A0D32D28BD5A0-2"><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26767811e454-wk-Fact-4936F932B19A5D5E8F42355497EDC556" name="us-gaap:NumberOfReportableSegments" contextRef="FD2020Q1YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-43A6134398095F15867A0D32D28BD5A0-2"> reportable segment and our functional and reporting currency is the U.S. dollar. </ix:continuation> </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-81C0A1870BE05A86A652D840BF134129-2" continuedAt="TextSelection-81C0A1870BE05A86A652D840BF134129-3"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:UseOfEstimates" id="TextSelection-8DDB2D23507E5F2292AC0042926D96F0-0-wk-Fact-438FAF813C3553CFAAE52A1F93145A03" escape="true"><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-40AC86DE7CFB5DA49974FF8D4FB17122-0-wk-Fact-F46BD7732F4356E4A9C49F3E461B6836" escape="true"><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Common Share </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-1CBD175961C85CC98F9B374D678DCD39-0-wk-Fact-619763284653579FAD29CEE7A1ED462A" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26767811e620-wk-Fact-9DB2A8962F885F70AE9E0BB33DDA00DB" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26767811e634-wk-Fact-F8F5F661C5745766878D26D2AAD5528E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,359</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-C49C71A09BE05FF099C053D4FE490CA8-0-wk-Fact-46403080BD9457EFA3104D3D61DF3245" continuedAt="TextSelection-C49C71A09BE05FF099C053D4FE490CA8-1" escape="true"><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Recently Adopted</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board &#8220;FASB&#8221; issued ASU 2019-12,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes (Topic 740)</span><span style="font-family:inherit;font-size:10pt;"> intended to simplify the accounting for income taxes. The guidance removes the following exceptions: 1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, 2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, 3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary and 4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: 1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, 2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, 3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), 4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date and 5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)</span><span style="font-family:inherit;font-size:10pt;">,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (AFS) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-C49C71A09BE05FF099C053D4FE490CA8-1"><ix:continuation id="TextSelection-81C0A1870BE05A86A652D840BF134129-3"><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the recent coronavirus (COVID-19) pandemic on expected credit losses.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF6178E9DA642512C98E2DDCEAE5DDC78"></a></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="TextSelection-03E3A93B29C8551CA60711D5B84FD1C9-0-wk-Fact-475906EC5B865EDC8D44B7F87B826E9E" continuedAt="TextSelection-03E3A93B29C8551CA60711D5B84FD1C9-1" escape="true">Balance Sheet Accounts and Supplemental Disclosures </ix:nonNumeric></span></div><ix:continuation id="TextSelection-03E3A93B29C8551CA60711D5B84FD1C9-1"><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-03770FF8A9F35395BCEF23D6ED352B58-0-wk-Fact-75D2CF5386845046AD06FAA80026F4DE" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e496-wk-Fact-7DACA2FB9D0254D488EF8AE6CE84E0D7" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_anab_LaboratoryEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,018</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e515-wk-Fact-10F940F5E0ED5A9D9691FEB7341BD523" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_anab_LaboratoryEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e530-wk-Fact-90C6B11D5E425BAB97FD1D35857DCE8B" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">820</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e549-wk-Fact-D241B94B98F955E39716BB6F61459382" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e569-wk-Fact-722162846EEA52BEB222EB9E0C6ADDF2" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e588-wk-Fact-DC9ECBD642755F279C40258A09552EC0" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e608-wk-Fact-B569219BDC765F5F8829950525A02125" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e627-wk-Fact-893F5EFC35DF51F1A817D59C82557A63" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26766690e647-wk-Fact-E05A2616C7465A65BD7C0CE24A44DFED" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26766690e667-wk-Fact-116C1858C69F5882A6D9C7CE717A9EA4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e693-wk-Fact-77B923B2F7545A5BA7333B80DC4C00CB" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e712-wk-Fact-9AD56001338F58CCA9EA54AE0A88A978" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Expenses </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-B373AA924C7F51909CA1BBC5D4AF340B-0-wk-Fact-F5F81CFDA034506FBC3916E0F6A83D8B" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e808-wk-Fact-B3AA0C5EA305511AB3FCBD8228FDF877" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e827-wk-Fact-560A85B81E1956B8BD6280DC3D788534" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e842-wk-Fact-D71A337ED9645668AA2A1C6B563B7886" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e861-wk-Fact-44F9CD800F7451AABCE164673FD5B79B" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">435</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued research, development and manufacturing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e881-wk-Fact-0359B6E1DCCE585C8BF1AC0FFF020D81" name="anab:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e900-wk-Fact-8429E31BA2FF5893B875B1F958760F64" name="anab:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e920-wk-Fact-A37A1F4E117B5482856FF64E3B569EF3" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e939-wk-Fact-7A0FF367929953379282ACE9294F6C91" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e964-wk-Fact-3D7922185AD859C8A5A768570583D1F3" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,781</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26766690e983-wk-Fact-097AF68DBD7C51DFA9CF38C3E6D66D81" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,052</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s7740D89C952B5167ADB78EE3B5C17F5D"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-BCFA8C8EC8AF53E98A3EAF1FD18824F4-0-wk-Fact-7ED8CD0F5618594F84C50A04A5E24B79" continuedAt="TextSelection-BCFA8C8EC8AF53E98A3EAF1FD18824F4-1" escape="true">Collaborative Research and Development Agreements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BCFA8C8EC8AF53E98A3EAF1FD18824F4-1" continuedAt="TextSelection-BCFA8C8EC8AF53E98A3EAF1FD18824F4-2"><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">TESARO Collaboration </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2014, we entered into a Collaboration and Exclusive License Agreement, or the TESARO Agreement, with TESARO, Inc. and TESARO Development, Inc., or collectively, TESARO, an oncology-focused biopharmaceutical company now a part of GlaxoSmithKline. Under the terms of the agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy antibodies for subsequent preclinical, clinical, regulatory and commercial development to be performed by TESARO. Under the terms of the agreement, TESARO paid an upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e422-wk-Fact-8263B42E33BC5BB8B99D43358DFD7788" name="anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" contextRef="D2014Q1Mar01-Mar31_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">17.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in March 2014 and agreed to provide funding to us for research and development services related to antibody discovery programs for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26774710e426-wk-Fact-76F70CAD9597597C96475B484486586B" name="anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" contextRef="FI2014Q1_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="target" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> specific targets. In November 2014, we and TESARO entered into Amendment No.&#160;1 to the Agreement to add an antibody discovery program against an undisclosed </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26774710e430-wk-Fact-CAB6E6FF426D5053ACCF6CEB71442CC5" name="anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" contextRef="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="target" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">th target for an upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e434-wk-Fact-538A1DC2B1C25F118687EF3D49D3DAD6" name="anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" contextRef="D2014Q4Nov01-Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each development program, we are eligible to receive milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e441-wk-Fact-067A67823B4F52B9AC433BBE3EF6A332" name="anab:RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" contextRef="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">18.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> if certain preclinical and clinical trial events are achieved by TESARO, up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e445-wk-Fact-5D057425E6EF5222836C3E35391CAFBB" name="anab:RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" contextRef="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">90.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e449-wk-Fact-17813BF5692C5048B70BA0DAA639A252" name="anab:RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" contextRef="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">165.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration. Unless earlier terminated by either party upon specified circumstances, the agreement will terminate, with respect to each specific developed product, upon the latter of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26774710e453-wk-Fact-CDAA68DD7000514E933E3AF34CCEFB44" name="anab:RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" contextRef="D2014Q4Nov01-Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" format="ixt-sec:duryear">12</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. Prior to the adoption of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">, we determined that the upfront license fees and research funding under the agreement, as amended, should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In December 2015, we determined that the research and development services would be extended through December 31, 2016. As a result, the period over which the unrecognized license fees and milestones were recognized was extended through December 31, 2016, and have since been recognized in full. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-BCFA8C8EC8AF53E98A3EAF1FD18824F4-2" continuedAt="TextSelection-BCFA8C8EC8AF53E98A3EAF1FD18824F4-3"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, TESARO, is a customer.&#160;We identified the following material promises under the TESARO Agreement: (1) the licenses under certain patent rights relating to six discovery programs (four targets) and transfer of certain development and regulatory information, (2) R&amp;D services and (3) Joint Steering Committee meetings. We considered the research and discovery capabilities of TESARO for these specific programs, TESARO&#8217;s inability to sub-license, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of the contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception of the arrangement. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price includes the upfront payment, research reimbursement revenue, and milestones earned to date, which are allocated in their entirety to the single performance obligation. We earned and recognized </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26774710e471-wk-Fact-EF84024C840E136F21F775FA94621A09" name="anab:RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" contextRef="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="milestone" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> clinical milestones for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e475-wk-Fact-922F31F6B98777166EB6E56957306F9B" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2020Q1YTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3ClinicalTrialInitiationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. No other future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials, an outcome that is difficult to predict, and the licensees&#8217; efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the IP license granted to TESARO and therefore have also been excluded from the transaction price. We will re-evaluate the variable transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-6B4B51DBFFB05B0FA4CFCE35588C8DBD-0-wk-Fact-A466B153E55255F7A1A9D0C21939BCED" continuedAt="TextSelection-415D97C873C05E1FBDAB8777B0B4D859-0" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones recognized through </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> under the TESARO Agreement are as follows:</span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:38%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-PD-1 <br/>(TSR042/Dostarlimab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-TIM-3 <br/>(TSR022/Cobolimab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-LAG-3 <br/>(TSR033/Encelimab)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Milestone Event</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Initiated </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:8pt;">&#160;toxicology studies using good laboratory practices (GLPs) </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e615-wk-Fact-560D21D8285D52A88DD3C39A7464EA7F" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2015Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'15</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e630-wk-Fact-1D5C7242C7C854468543B5798BC1EAF9" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2015Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'15</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e645-wk-Fact-DB8CA7B03FB75EF1B2B8FED8AE1EEE54" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2016Q3QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q3'16</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IND clearance from the FDA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e661-wk-Fact-40132960711D5213B897843718DDEF3C" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2016Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q1'16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e676-wk-Fact-39D5AD298F6059F3A4C7E37AB07AEBBE" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2016Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e691-wk-Fact-A7299B2D6ABE510089F54C901FF09E09" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2017Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'17</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 2 clinical trial initiation</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e707-wk-Fact-D4704D68F34A524E878D498B67EA012A" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2017Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'17</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e722-wk-Fact-2615FE9D5BCC5D878F5763AD79ECF3B7" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2017Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'17</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e737-wk-Fact-2C5A097A96795B7F2B0175F037C3F778" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2019Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'19</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 3 clinical trial initiation - first indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e753-wk-Fact-755EBA34416C54A7BFE787A135D2A273" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3ClinicalTrialInitiationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q3'18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 3 clinical trial initiation - second indication</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e799-wk-Fact-09BC5AB9B26B5F1F8B8CE016BE8F3BAC" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3clinicaltrialinitiationsecondindicationDomain" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'19</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Filing of the first NDA - first indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e845-wk-Fact-D159AFCBC93D79A5901075E269982E2D" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_FilingofNDAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q1'20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Filing of the first MAA - first indication</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e891-wk-Fact-52E824B77E6123635F37A4E04F6DE500" name="anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" contextRef="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_FilingofMMAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q1'20</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e939-wk-Fact-9642B58EEA4D5A26AF65510C33450F79" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e943-wk-Fact-3C2EB306E7A959E482110BC81D4B7C14" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in revenue under this agreement during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Antibody Generation Agreement with Celgene Corporation </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2011, we entered into a license and collaboration agreement with Celgene, now a part of Bristol-Myers Squibb, or the Celgene Agreement, to develop therapeutic antibodies against multiple targets. We granted Celgene the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-BCFA8C8EC8AF53E98A3EAF1FD18824F4-3"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The agreement provided for an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e965-wk-Fact-4D384D16CDC95059B85434586CB44294" name="anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" contextRef="FD2011Q4YTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from Celgene, which we received in 2011 and recognized through 2014, milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774710e969-wk-Fact-B2DC4B777A335FADB4E615F5D8D256A2" name="anab:RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" contextRef="FI2011Q4_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">53.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We assessed this arrangement in accordance with ASC Topic 606 and concluded that the contract counterparty, Celgene, is a customer.&#160;We identified the following material promises under the Celgene Agreement: (1) the licenses under certain patent rights relating to four targets and transfer of certain development and regulatory information, (2) R&amp;D services, (3) a written report documenting findings and (4) Steering Committee meetings. We considered the research and discovery capabilities of Celgene, Celgene&#8217;s inability to sub-license the four targets, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of the contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the report of findings and steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception the arrangement. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price includes the upfront payment, success fees, expense reimbursement, and milestones earned to date, which are allocated in their entirety to the single performance obligation.&#160;None of the future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors, including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials and the licensees&#8217; efforts.&#160;Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the IP license granted to Celgene and therefore have also been excluded from the transaction price.&#160;We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><ix:continuation id="TextSelection-415D97C873C05E1FBDAB8777B0B4D859-0"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones achieved through </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> under the Celgene Agreement are as follows:</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:80%;"></td><td style="width:11%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-PD-1 <br/>(CC-90006)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Milestone Event</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Completion of first </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:8pt;">&#160;toxicology studies using GLPs</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e1049-wk-Fact-FEE4E92DD8B65C4192500252CD2FE7B7" name="anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned" contextRef="FD2016Q2QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'16</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 1 clinical trial initiation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d26774710e1065-wk-Fact-692E8206D3115E029D0E992079F9A094" name="anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned" contextRef="FD2016Q4QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_us-gaap_TypeOfArrangementAxis_anab_Phase1ClinicalTrialInitiationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'16</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from future contingent milestone payments will be recognized when it is more likely than not that the revenue will not be reversed in future periods. Cash is generally received within 30 days of milestone achievement. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26774710e1083-wk-Fact-4B1F3B42D6BE58A6B7319E381582988A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> revenue recognized under this agreement during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><a id="s96692D642EBD582BB0B624C9C1980124"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-D2035C5C90D356448A48847D09F9548A-0-wk-Fact-20F75194FD675B0A88F5856B6E4595AC" continuedAt="TextSelection-D2035C5C90D356448A48847D09F9548A-1" escape="true">Notes Payable </ix:nonNumeric></span></div><ix:continuation id="TextSelection-D2035C5C90D356448A48847D09F9548A-1" continuedAt="TextSelection-D2035C5C90D356448A48847D09F9548A-2"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;24, 2014, we entered into a Loan and Security Agreement, as amended from time to time, the Loan Agreement, with a bank and a financial institution whereby we may borrow up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774703e418-wk-Fact-2FB64D27EC9E5D24BD270115FDB95069" name="anab:DebtInstrumentMaximumBorrowingCapacity" contextRef="I2014Q4Dec24_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26774703e422-wk-Fact-D65EDC41CC0D5F6D8220D3C0FD3E4E23" name="anab:DebtInstrumentNumberOfLoanInstallments" contextRef="D2014Q4Dec24-Dec24_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" unitRef="installment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> separate draws of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774703e426-wk-Fact-544BB83C6E375EFBB9B9CFA4F9229C03" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2014Q4Dec24_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> each. The Term A Loans, for an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774703e430-wk-Fact-3F79E4E3DEE85263AF1A929AD44C9424" name="us-gaap:ProceedsFromNotesPayable" contextRef="D2014Q4Dec24-Dec24_us-gaap_DebtInstrumentAxis_anab_TermALoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, were drawn on December&#160;24, 2014 with a fixed interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26774703e434-wk-Fact-D90C3BA8E3BF522591E93CD28A67D15D" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2014Q4Dec24_us-gaap_DebtInstrumentAxis_anab_TermALoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.97</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, the Loan Agreement was amended to combine Term B Loans and Term C Loans for a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774703e441-wk-Fact-135A1539CFDF5A5599AE3E6E33D867B4" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2016Q1Jan31_us-gaap_DebtInstrumentAxis_anab_TermBLoansAndTermCLoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> available for draw through December 31, 2016 and delay the beginning of our Term A Loans&#8217; principal repayments from February&#160;1, 2016 until February&#160;1, 2017. The Term B Loans and Term C Loans became available for draw on July&#160;1, 2016. In December 2016, we further amended the Loan Agreement to (i)&#160;allow for the Term B Loans and Term C Loans to be drawn on December&#160;30, 2016, (ii)&#160;delay principal repayments of all Term Loans until February&#160;1, 2018 and (iii)&#160;amend the interest rate for each Term Loan. The Term B Loans and the Term C Loans were drawn on December&#160;30, 2016, and Term A, B and C Loans are now collectively referred to as the Term Loans. Principal repayments began in February 2018, and were paid in full, without penalty or premium on January 1, 2020.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><ix:continuation id="TextSelection-D2035C5C90D356448A48847D09F9548A-2" continuedAt="TextSelection-D2035C5C90D356448A48847D09F9548A-3"><span style="font-family:inherit;font-size:10pt;">The costs incurred to issue the Term Loans were deferred and were included in the discount to the carrying value of the Term Loans in the accompanying balance sheet. The Term Loans also included a final payment fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26774703e448-wk-Fact-22D6FA9514845D16B220F5B252D5707D" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="I2016Q1Jan31_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D2035C5C90D356448A48847D09F9548A-3"> due at the earlier of prepayment or the maturity date of the Term Loans. The deferred costs and the final payment fee were amortized to interest expense over the expected term of the Term A Loans using the effective interest method.</ix:continuation> </span></div><div><a id="sC4EB25D2C0F55D4BAFDF23FE93A73C6B"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-452DF80E8DB252A898A56435BE68D0F4-0-wk-Fact-55587BE3E4F9576E80B77F792E737755" continuedAt="TextSelection-452DF80E8DB252A898A56435BE68D0F4-1" escape="true">Fair Value Measurements and Available for Sale Investments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-452DF80E8DB252A898A56435BE68D0F4-1" continuedAt="TextSelection-452DF80E8DB252A898A56435BE68D0F4-2"><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our financial instruments consist principally of cash, cash equivalents, restricted cash, short-term and long-term investments, receivables, accounts payable, and notes payable. Certain of our financial assets and liabilities have been recorded at fair value in the consolidated balance sheet in accordance with the accounting standards for fair value measurements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:16px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-65E8970DE3675F82BDA3E3ACFA6B5D1C-0-wk-Fact-F3C44DD849585791BCC81906C36A21BA" continuedAt="TextSelection-65E8970DE3675F82BDA3E3ACFA6B5D1C-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at End of Period Using:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Market<br/>Prices for<br/>Identical&#160;Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Other&#160;Observable<br/>Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">At March 31, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e731-wk-Fact-80FA241C4BAF5A079A609BF4307E8C8C" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">151,542</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e750-wk-Fact-F83FE14E420156E495D810BD4FFE649C" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">151,542</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e769-wk-Fact-51BBD123E8725BBE9AD2DB06DBA31F55" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e789-wk-Fact-8ED3B883F64156C68B0F880FB5B125CB" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e806-wk-Fact-5C47FB6313C95FFE8337B6E4B799B870" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e825-wk-Fact-FDED3C0BAA9151BEAB2C53C7C608E24B" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e844-wk-Fact-CCAF5287079C5285BD26A26F965160C5" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e864-wk-Fact-E4C0831EF348549DA24898A0EDD56FB3" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e886-wk-Fact-605CE8DE222153A796DBC72168F5084A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e905-wk-Fact-09E62CDF3B8655BCB5DD91FE3AEF52D7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e924-wk-Fact-37F305BC269D544EAF0A12EE338A6D0A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e944-wk-Fact-FD8DE654F33451B48079994A054FAEB1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e966-wk-Fact-562E2DD60B8C56D597F8DC5FB7C19C54" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e985-wk-Fact-204F8C467E075A90BCD40F4D185422BA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1004-wk-Fact-6357FCEBA5FF55FE8BFF11BE9F2ECCA6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1024-wk-Fact-BD8C1312C0F25B079AC0A8B11E6534BA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agency securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1046-wk-Fact-C05B4A4CCDD157349C357591468900DC" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1065-wk-Fact-1FAD0DE53EE75E0AADEAC17BB682B597" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1084-wk-Fact-B4268A407B85522FABA30C1CF89D1025" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1104-wk-Fact-B9FA1AEA88C35352AD28F1E7F15E424A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1126-wk-Fact-329C44F21A175AF2A9EE401125A904A8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,873</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1145-wk-Fact-1E210E0CDE3F5053B8BF39F696D9A75B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1164-wk-Fact-491AA8BCF4A55182BB57B7B7D334F564" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,873</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1184-wk-Fact-FE8CC6AD59675B78AB9D7D8EC2C37BFF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">At December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1293-wk-Fact-E9E6FF6BF2CA58F6AE498BBC585DA821" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1312-wk-Fact-84EBFA808F765B6FA3F75FFC055434BD" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1331-wk-Fact-DBE756C9321753FDA1D9B884C6D6C32D" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1351-wk-Fact-9671537B6B2753459D91AA0EAC21B3F2" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1369-wk-Fact-AD1430056DF45826B251DFCFE5075C7B" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1388-wk-Fact-F01BB9969E6D5D11B91F5C2660698AD7" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1407-wk-Fact-1DB961B9AD4257A9B0DF255E12101217" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1427-wk-Fact-9120483FC69559B08F126E77A4232B14" name="anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1449-wk-Fact-9C118DAA1AB654C49DED1EDB4B4875DF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">96,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1468-wk-Fact-CE5958091D5B5FDEBFE1E5184831026D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">96,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1487-wk-Fact-1BAA0CCFEA4B50BDB8BE80C2D7157A3E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1507-wk-Fact-45BB2ED3B8D25279B550BC1CF8E88A6F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1529-wk-Fact-3B493B35C40757C398902A6C3559985A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1548-wk-Fact-C9E5D86ABDCF51FDA501456F65798222" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1567-wk-Fact-0345C2D8092456E99FB5EB8D25379752" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1587-wk-Fact-FB5C39E0E2095EECAD4AED3D3AFFB2EB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Agency securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1609-wk-Fact-3C4613A81B965029B35C7D4670E4BA9D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1628-wk-Fact-FD013F516C7B5B41B9B2ABBA6A1EC868" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1647-wk-Fact-E584CE2DABC4520AB8942D61AB67FA9B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1667-wk-Fact-8F77100D711F5EECB10166E94B09602C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1689-wk-Fact-1D08604CF13E5744ABDEDB9A2FE2C991" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,030</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1708-wk-Fact-26D84DB2F3935BDAB825F32A13F3ABDE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1727-wk-Fact-CCB5EDE18C5A5485AB8BF01813567D36" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,030</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e1747-wk-Fact-80FBFA9EDA7554F7AEAD02C82341A12B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-452DF80E8DB252A898A56435BE68D0F4-2" continuedAt="TextSelection-452DF80E8DB252A898A56435BE68D0F4-3"><ix:continuation id="TextSelection-65E8970DE3675F82BDA3E3ACFA6B5D1C-1" continuedAt="TextSelection-65E8970DE3675F82BDA3E3ACFA6B5D1C-2"><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.</span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-65E8970DE3675F82BDA3E3ACFA6B5D1C-2" continuedAt="TextSelection-65E8970DE3675F82BDA3E3ACFA6B5D1C-3"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-65E8970DE3675F82BDA3E3ACFA6B5D1C-3"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date. </span></div></ix:continuation></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to estimate that value: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Marketable Securities.</span><span style="font-family:inherit;font-size:10pt;"> For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. For fair values determined by Level 2 inputs, which utilize quoted prices in less active markets for similar assets, the level of judgment required to estimate fair value is also considered relatively low. </span></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="TextSelection-5160FD969B56550C9477FCEF9F821B2F-0-wk-Fact-54D286C2A91A5EAE9F0AF121117B9E47" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of our other financial instruments estimated as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are presented below: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2021-wk-Fact-7E7BD79B277457A39C6622B9BBA7504D" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2040-wk-Fact-63225103ACE858F5B55ADA0FCAF57E07" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2059-wk-Fact-5C709E9AF8485F38A8B6782A27826217" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2079-wk-Fact-A8554548ACAB53FDB44926E3DC8B64F5" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following methods and assumptions were used to estimate the fair value of our notes payable: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Notes Payable</span><span style="font-family:inherit;font-size:10pt;">&#8212;We use the income approach to value the aforementioned debt instrument. We use a present value calculation to discount principal and interest payments and the final maturity payment on these liabilities using a discounted cash flow model based on observable inputs. We discount these debt instruments based on what the current market rates would offer us as of the reporting date. Based on the assumptions used to value these liabilities at fair value, these debt instruments are categorized as Level 2 in the fair value hierarchy. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;The carrying amounts of certain of our financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term nature. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Available for Sale</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.S. Treasury securities, which we classify as available-for-sale investments. These investments are carried at fair value and are included in the tables above. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="TextSelection-248334431A8555C7AD67A832EE253D6B-0-wk-Fact-C07168D96BB8527E9A7B4C2AF8573791" continuedAt="TextSelection-248334431A8555C7AD67A832EE253D6B-1" escape="true">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of </ix:nonNumeric></span><ix:continuation id="TextSelection-248334431A8555C7AD67A832EE253D6B-1" continuedAt="TextSelection-248334431A8555C7AD67A832EE253D6B-2"><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></ix:continuation></div><ix:continuation id="TextSelection-248334431A8555C7AD67A832EE253D6B-2" continuedAt="TextSelection-248334431A8555C7AD67A832EE253D6B-3"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agency securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2245-wk-Fact-B527F50D92F95C1BBEEF4DE272869B42" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,754</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2264-wk-Fact-5AA38C90AA9B55B7A89F59A6381717B5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e2283-wk-Fact-2DB70CC29373573D8618141A9E6E66F5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2304-wk-Fact-87DDE2EB6F625D82941D2D0352A039B8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2321-wk-Fact-D44FC38F1B5957EFBFF76EF8CCFD70B6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2340-wk-Fact-C222D4FFC8755904B94BC7871DE5B3F3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2359-wk-Fact-F78B787A684C5DDDB231EDE733155899" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2379-wk-Fact-F11C56811A4654FD985917BE39B1CB35" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2401-wk-Fact-4A9CAA51A0605DB793B69B4B09C6D3F2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2420-wk-Fact-C580852B94535EC6B9E74A9D72162284" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e2439-wk-Fact-92074E9BC40253499A5BC4851B44A962" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2460-wk-Fact-3AC957E72F2358428A759CB7D94C8749" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,873</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2482-wk-Fact-BBAF81D6F169546283DCDF3EE6F2FFF7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">111,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2501-wk-Fact-35887D21737A59E6853012E315B14DD4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2520-wk-Fact-AF257DA5F51652579F50588206F5999F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2540-wk-Fact-C072DE42442C540199D4AA2AD8B3C904" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2565-wk-Fact-DCBAF090C43450D3AF1BDDC51D2EFE9C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">246,029</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2584-wk-Fact-127CE8DF8FB552C9BEB83D09ACC3DEC4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e2603-wk-Fact-46DEAE5E5F6B5372B1F9C1C15CFEDC3E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e2624-wk-Fact-E2B50C28D92A5134A1092F6038701159" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">247,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding agency securities, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26781279e2637-wk-Fact-687B008618725BA08DCBDCC96EE45F41" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> have maturity dates of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26781279e2641-wk-Fact-92E9EDE076F254998AB3917C139D0153" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26781279e2649-wk-Fact-563B66355C0D5061B4010928A6FFCED4" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding certificates of deposit, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26781279e2665-wk-Fact-18806EB3DEFE5CD595C66C82279AF2CC" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26781279e2669-wk-Fact-A2E70829610E567C8CD977EFB2FEE43D" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26781279e2677-wk-Fact-C7D8B7E0E110587EAEBC3C720EDDC6CE" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding commercial and corporate</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">obligations, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26781279e2697-wk-Fact-F232641CCE1451C7BE066799542F489B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> have maturity dates of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26781279e2701-wk-Fact-9F57336DD3AC553ABE5D383ED75C9FFE" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26781279e2709-wk-Fact-D1DDDA82C84751AF8C3FE58E114EEAA8" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-248334431A8555C7AD67A832EE253D6B-3" continuedAt="TextSelection-248334431A8555C7AD67A832EE253D6B-4"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-248334431A8555C7AD67A832EE253D6B-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding U.S. Treasury securities, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26781279e2725-wk-Fact-3E128BCB2FAA55BEB60FDCA9C0B31DE9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">94.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> have maturity dates of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26781279e2729-wk-Fact-B1E93726C3605282B627A6D198A6A7BE" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26781279e2737-wk-Fact-7101163B54FE5C4BBFA5DE18A1624BFF" name="anab:AvailableforsaleDebtSecuritiesRemainingMaturity" contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="TextSelection-7D3D40B18C87995223E2C80D61979AFC-0-wk-Fact-CB3CCC8A519FFD096AE5C811591CB515" escape="true"><ix:continuation id="TextSelection-452DF80E8DB252A898A56435BE68D0F4-3"><div style="line-height:120%;padding-top:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;</span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3171-wk-Fact-1B709B1997B3B0045253C813A1690727" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e3190-wk-Fact-852B7105F0F1D15FC2C8C8147D69390B" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3210-wk-Fact-D228D3BBFB396481256FC813FF9F98D4" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3230-wk-Fact-923CD332A3FB106417D5C814B7D35499" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3249-wk-Fact-0521DE41A1AA42B49F6CC8143B623193" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e3269-wk-Fact-07FAE0E4E86DF1E215DDC814FB679474" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3285-wk-Fact-3E6D937182D654464E7DC813A16FFF01" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e3304-wk-Fact-81BBF42A6500A15E36AFC8147D5F8F70" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3324-wk-Fact-7B1E5E32ADF6C16A8D28C813FF6B15D1" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3344-wk-Fact-E0902B622F1ECBC26668C814B80B50A9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3363-wk-Fact-B6CFF3677F0BCDAECF11C8143B1F4FB8" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e3382-wk-Fact-26E7B73286FA8C9AB699C814FBB35EF5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3409-wk-Fact-5CD867354F8B8B825F14C813A1659A24" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e3428-wk-Fact-3F95AC804B7F6190191BC8147D630FC2" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3448-wk-Fact-E9DB7C2636DE920ABA1BC813FF528BE6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3468-wk-Fact-63B7AA8E9339354E2A5EC814B7BB124B" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3487-wk-Fact-D215D7330D1DB14FF06AC8143B1C8EE1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e3507-wk-Fact-04CD55A9212F714B8886C814FB6A3A6A" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3926-wk-Fact-B583E119FE9263E17F66C8174237BD41" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e3945-wk-Fact-1BAD8000B712B8BB1B02C81744ABF3B6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3965-wk-Fact-B5A57BF4388548A563C6C81747278DE2" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e3985-wk-Fact-77DA9BFA10BEBC7A7761C817495DEA02" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e4004-wk-Fact-16D99BFCDF5A6F22B1A6C8174BB7B2A5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e4024-wk-Fact-19818FD8BB9B7BA4CDD8C8174DDB237A" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Treasury Securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e4040-wk-Fact-D81C29E534E9A46244A9C8174F3A9543" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e4059-wk-Fact-5E7D597B0EA63F8CBD27C81752262892" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e4079-wk-Fact-D74A0A4A194638524DBAC81754BE26A9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e4099-wk-Fact-CBB02CE4123D60DF9518C8175730DF09" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e4118-wk-Fact-FE37D3A3A9F1351B79AFC81759C5DA83" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e4137-wk-Fact-571502F0306C171F331FC8175C5FDE61" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e4164-wk-Fact-85F63FCA34937A6C13D8C8175DE1BFA8" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,594</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e4183-wk-Fact-834B02C917B18AAC891AC8175EFBB570" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e4203-wk-Fact-B27C96AFE5778B3D0343C817609B2226" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e4223-wk-Fact-20E5D17BC563E2D6DFB3C81761CAC15F" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781279e4242-wk-Fact-7BDD7C7E90FBACE33169C81762E2C667" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,594</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26781279e4262-wk-Fact-84AC22D77DE5BFBF942CC81764110846" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="s414D7C9DAAA4513F93B6611899A6154C"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-339135DB7EF95965BA823D8EA1C1EFCD-0-wk-Fact-62A010E9CCE55143AE832116A4322826" continuedAt="TextSelection-339135DB7EF95965BA823D8EA1C1EFCD-1" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="TextSelection-339135DB7EF95965BA823D8EA1C1EFCD-1"><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776405e421-wk-Fact-9DF8B73F03F252F1946B6D40B8C83E60" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock authorized, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776405e425-wk-Fact-8A2F84FBA563578B83E9611C2771CE6B" name="us-gaap:CommonStockSharesIssued" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">27,277,115</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares were issued and outstanding as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. <ix:nonNumeric contextRef="FD2020Q1YTD" name="anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="TextSelection-7D38CC01C1FA5240951EA1AFFFF0460D-0-wk-Fact-3C626677165150F7A2ECC398CE248B11" continuedAt="TextSelection-7D38CC01C1FA5240951EA1AFFFF0460D-1" escape="true">Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at </ix:nonNumeric></span><ix:continuation id="TextSelection-7D38CC01C1FA5240951EA1AFFFF0460D-1" continuedAt="TextSelection-7D38CC01C1FA5240951EA1AFFFF0460D-2"><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows: </span></ix:continuation></div><ix:continuation id="TextSelection-7D38CC01C1FA5240951EA1AFFFF0460D-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:86%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issued and Outstanding:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776405e480-wk-Fact-7470C53251935ED6B3F501C1F0681471" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,866,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares Reserved For:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017 Equity Incentive Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776405e511-wk-Fact-7C1F5492286F5A0CABC4EF724513FCDF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2020Q1_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,118,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017 Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776405e526-wk-Fact-6AA34DF981775CADA5549B269C402381" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2020Q1_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">997,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776405e541-wk-Fact-F4EA6FC7DC635DA4B379FFBC1DF9419F" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,982,943</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="s6B8FD8E106D25DB08403AAA9A39764B7"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-477F9B7D41845478B70F93C9DF3E2457-0-wk-Fact-FBB7FF7DF10F55D6BEF5BAF82FFFD8F6" continuedAt="TextSelection-477F9B7D41845478B70F93C9DF3E2457-1" escape="true">Equity Incentive Plans </ix:nonNumeric></span></div><ix:continuation id="TextSelection-477F9B7D41845478B70F93C9DF3E2457-1" continuedAt="TextSelection-477F9B7D41845478B70F93C9DF3E2457-2"><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Equity Incentive Plan</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Equity Incentive Plan, or the 2017 Plan. The 2017 Plan became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017, and replaced our existing 2006 Equity Incentive Plan, or the 2006 Plan. Under the 2017 Plan we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then our employees, officers, directors or consultants. In addition, the number of shares of stock available for issuance under the 2017 Plan will be automatically increased each January 1, beginning on January 1, 2018, by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e421-wk-Fact-707EA98E7DA4541EA5492B3D5F036C1A" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" contextRef="D2017Q1Jan26-Jan26_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The 2017 Plan automatically increased by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e425-wk-Fact-C03EF072E59352E29739B34C0E5E0B6A" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease" contextRef="D2019Q1Jan1_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,090,203</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares as of January 1, 2020.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-477F9B7D41845478B70F93C9DF3E2457-2" continuedAt="TextSelection-477F9B7D41845478B70F93C9DF3E2457-3"><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Employee Stock Purchase Plan or the ESPP. The ESPP became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017. In addition, the number shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2018, by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e435-wk-Fact-77BAA87161265A3F9068C667C40FD84F" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" contextRef="D2018Q1Jan01-Jan01_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The ESPP automatically increased by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e439-wk-Fact-06F36AAE76AF5940B984862E76460542" name="anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease" contextRef="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">272,550</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares as of January 1, 2020.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options granted to employees and non-employees generally vest over a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year period while stock options granted to directors vest over a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26776966e453-wk-Fact-F23897115484527F9B21747A3FA11C6C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="FD2020Q1YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> period. Each have a maximum term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26776966e457-wk-Fact-AB41819BA1295DB08435881FFA310D20" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-95CC3F64A6E557B9990F5326642B574B-0-wk-Fact-1C485C6528865018807C681741DCF39A" continuedAt="TextSelection-95CC3F64A6E557B9990F5326642B574B-1" escape="true">A summary of the activity related to stock option awards during the </ix:nonNumeric></span><ix:continuation id="TextSelection-95CC3F64A6E557B9990F5326642B574B-1" continuedAt="TextSelection-95CC3F64A6E557B9990F5326642B574B-2"><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> is as follows: </span></ix:continuation></div><ix:continuation id="TextSelection-95CC3F64A6E557B9990F5326642B574B-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares<br/>Subject to<br/>Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average<br/>Exercise<br/>Price per<br/>Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value&#160;(in<br/>thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e570-wk-Fact-F01065A9A9A359E998D6A3C94B89C961" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,039,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e589-wk-Fact-78296963D56051C2886CF10544BF32EB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">29.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e632-wk-Fact-F31C578806A559F7852F64C56EA5CF78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2020Q1YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">115,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e651-wk-Fact-B3B9BF916E8B591E85CD6F2030A3559D" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercises</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26776966e697-wk-Fact-74C437BABEFE50B4AC0858C26AF67BD4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,033</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e717-wk-Fact-1F797D38EF8854E9948CB472A832B3AA" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeitures and cancellations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26776966e763-wk-Fact-B7AC59F7646C5ED2901FFA06AA04E559" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="FD2020Q1YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">266,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e783-wk-Fact-0CF782B96F68575FAB64A9C9233499D8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">37.14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e829-wk-Fact-7470C53251935ED6B3F501C1F0681471" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,866,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e848-wk-Fact-06D1978477C15F5E9D6E7A92900563C8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2020Q1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26776966e862-wk-Fact-9D15E9696CCF518E8A695A050CD58669" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">7.30</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e878-wk-Fact-F7E4D794382D5D7D98A2239563EE28C2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e893-wk-Fact-7AEEF2D09D0E5BA39A6859E5BEF16144" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,423,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e912-wk-Fact-AB702E4CFF6955B88C527C4BA0D00F64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2020Q1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">26.04</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26776966e926-wk-Fact-78EDB19DBEB657E9A3061787153BAF2A" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">5.33</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e942-wk-Fact-21B6EE2C69B557A6AED7F1C96E425443" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,565</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-09855F8DAF1B5DC48C034A5A83BD75E9-0-wk-Fact-D2225605F1885C859AC89CD2BCC60A37" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1070-wk-Fact-658AC999015D500BA444863833268272" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1090-wk-Fact-1A324E60A49B5A83810219D26194604A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1111-wk-Fact-037507A138D4508AAA0C2DB1E4C1ADF8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">92.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1131-wk-Fact-21F3F829D33C56128CEFDCD7A55188D8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">68.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1152-wk-Fact-288EC00E94015549BAD84E2FC30F3FCA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1172-wk-Fact-C9479A3F408F56B0A2E1DBFA6DBCCA6F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26776966e1193-wk-Fact-C6DDAABEF2E6541A85CE0B5FB1B9A52E" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26776966e1212-wk-Fact-837B2CFF2453544D8FC0C2793A3DE197" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average grant date fair value per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1237-wk-Fact-885D1C3F10B55FC68133B590B50054E7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1256-wk-Fact-0FE45E14980B528E9CF022765A3DA362" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">43.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine the appropriate risk free interest rate, expected term for employee stock based awards, contractual term for non-employee stock based awards, and volatility assumptions. The weighted-average expected option term for employee and non-employee stock based awards reflects the application of the simplified method, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches. Estimated volatility incorporates historical volatility of our stock price as well as similar entities whose share prices are publicly available. The risk free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the stock based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-477F9B7D41845478B70F93C9DF3E2457-3" continuedAt="TextSelection-477F9B7D41845478B70F93C9DF3E2457-4"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="TextSelection-2287628479885FA187F5BC115CD1F8F0-0-wk-Fact-BD2E05EC2C2756EF9B327D7C1D926F12" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total non-cash stock based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1390-wk-Fact-1BF01FA6EC375D82BCA4DC6CFDDEDCDA" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1409-wk-Fact-28C535E42BA657FDBEE5EE3A79B8CFD9" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1424-wk-Fact-1EE2A60856AF52BFBEAC86F9FF182CF5" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1443-wk-Fact-6F88B8023AF25B12B5A6C06CABDD0EBC" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1468-wk-Fact-1341CD9F811D57208C64AF7D213B450A" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26776966e1487-wk-Fact-4DCA0F193B3D5FD08CB6F86FBAB8A919" name="anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-477F9B7D41845478B70F93C9DF3E2457-4" continuedAt="TextSelection-477F9B7D41845478B70F93C9DF3E2457-5"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26776966e1509-wk-Fact-834B283AAF3E5498AF89D261922355AB" name="anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26776966e1513-wk-Fact-008C43B58EAF52089AD5A324CABF5E76" name="anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_anab_EmployeeAndNonemployeeStockOptionsMember" format="ixt-sec:duryear">3.13</ix:nonNumeric> years</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-477F9B7D41845478B70F93C9DF3E2457-5">.</ix:continuation> </span></div><div><a id="s0294D04A72435598967C52BFFC70A31C"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-77FE4A1089D750DDBDE469D1EE8B16D5-0-wk-Fact-72221154CBA7555B8BBB72BE143ADDA1" continuedAt="TextSelection-77FE4A1089D750DDBDE469D1EE8B16D5-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-77FE4A1089D750DDBDE469D1EE8B16D5-1" continuedAt="TextSelection-77FE4A1089D750DDBDE469D1EE8B16D5-2"><div style="line-height:120%;padding-top:8px;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e420-wk-Fact-D60F961D46025394B568F0B7315CBCDE" name="anab:LesseeOperatingLeaseNumber" contextRef="FD2020Q1YTD" unitRef="lease" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> non-cancellable office leases with remaining lease terms of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26775584e424-wk-Fact-69BB7B12AA015690BADC30A57FED5BF2" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2020Q1" format="ixt-sec:duryear">1.5</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">, each of which are classified as operating leases. Both leases expire in 2021. Only one of our leases has remaining renewal options, which includes </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e428-wk-Fact-06731957843B5EA4BA59A7FDE027EDFC" name="anab:LesseeOperatingLeaseOneYearRenewalOptionsNumber" contextRef="FI2020Q1_anab_LeaseArrangementAxis_anab_OneOfficeLeaseMember" unitRef="renewal_option" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> options to renew for one additional year. The exercise of lease renewal options is at our sole discretion, which we currently do not anticipate exercising and as such were not recognized as part of our ROU asset and lease liabilities. Our lease payments are fixed, and we recognize lease expense for these leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e432-wk-Fact-8B687E0A74445CDE92603E40C4878A78" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2020Q1" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">8.59</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="anab:AssetsAndLiabilitiesLesseeTableTextBlock" id="TextSelection-6276D00A16775007AD633A6CB9BD1A23-0-wk-Fact-5C162183AC415006AF0847BF90C1647B" escape="true"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification on the Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating ROU assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e546-wk-Fact-FE1324DBD54058B2A5941DC10EB92E6C" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e565-wk-Fact-9E8FCE003C4DF46AB8CB761D8973E5D7" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e595-wk-Fact-C276E7829392517B987BA8E3F5CD3EA3" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e614-wk-Fact-02CD49E4AB00A9FB62DD761D8A8AAFC8" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">871</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e649-wk-Fact-10B2EFEB941658FE97F3412EDDE9AF75" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e668-wk-Fact-08F1E58BBC1E186B6B0C761D8B6AB969" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-30BD109268A85ED2B4FFAB1357414ECC-0-wk-Fact-F425BE24CA4450C7995264A40688958B" escape="true"><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following costs are included in our cash flow statement (in thousands):</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification on the Cash Flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e849-wk-Fact-3ED36EC0F921553AA5273CEBE9B199B7" name="us-gaap:OperatingLeaseCost" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e868-wk-Fact-AD0DC805D404564FA4ED761DCCE2D7B2" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e898-wk-Fact-C4C731283CFE59D0B0F61D51E5AC4D84" name="us-gaap:OperatingLeasePayments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e917-wk-Fact-35D2733672E95B3040AC761DCE0D39A9" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-DB76DECCB72B5385B6326D392BE7B57A-0-wk-Fact-BF2A4D31219B5B5991AB2ABE19413147" continuedAt="TextSelection-DB76DECCB72B5385B6326D392BE7B57A-1" escape="true"><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the future minimum annual obligations under non-cancellable operating lease commitments in excess of one year are as follows (in thousands):</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><ix:continuation id="TextSelection-77FE4A1089D750DDBDE469D1EE8B16D5-2"><ix:continuation id="TextSelection-DB76DECCB72B5385B6326D392BE7B57A-1"><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e988-wk-Fact-DA42439B6C5A523C9518071EC4CB051B" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">729</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e1003-wk-Fact-111684EF74C554DDA1880E7E6AB3DEC4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">676</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e1023-wk-Fact-1122742D25AA5ACFAAA5C55D9BEF2BAF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e1043-wk-Fact-7AB315004BCF525C92E69AF437206AED" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e1063-wk-Fact-B1D062AE6F6C5DAA8921F3A1169D2FC4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e1083-wk-Fact-C22DD8366ECE5A1590FADD1982316E9C" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum payments required</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e1103-wk-Fact-7C884F20CE275A9EAFB060CF7E7907E1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,405</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d26775584e1123-wk-Fact-704CA98C97D555CD916193FD425D844E" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26775584e1149-wk-Fact-6F447400C1DC5071A597F96C25819303" name="us-gaap:OperatingLeaseLiability" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:24px;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder Lawsuit</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 25, 2020, a putative shareholder class action complaint was filed in the United States District Court for the Southern District of California against us and three of our current or former officers.&#160;The complaint purports to assert claims under Section 10(b) of the Exchange Act, Exchange Act Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019, or the Class Period.&#160; The complaint alleges that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab drug that artificially inflated our stock price.&#160;The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses.&#160;We believe that the claims in the action are without merit.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><a id="s7873959ab1d243539b1269278e5b23bb"></a></div><div><br/></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:SubsequentEventsTextBlock" id="TextSelection-2D26A9FC285BEE915C95C820CAE3B32C-0-wk-Fact-64E2E7BCA2A82BF08F83C820D6DB397A" continuedAt="TextSelection-2D26A9FC285BEE915C95C820CAE3B32C-1" escape="true">Subsequent Events </ix:nonNumeric></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-2D26A9FC285BEE915C95C820CAE3B32C-1" continuedAt="TextSelection-2D26A9FC285BEE915C95C820CAE3B32C-2"><span style="font-family:inherit;font-size:10pt;">On May 4, 2020, we entered into a lease agreement, or Lease Agreement, with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121. Under the Lease Agreement, we agreed to lease approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781317e414-wk-Fact-F37328D0F92D943A977EC8257F916139" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">45,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of space in the 10770 Wateridge Circle Building for a term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26781317e418-wk-Fact-1C074022B90290195034C822B3EB0471" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" contextRef="I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" format="ixt-sec:durmonth">124</ix:nonNumeric> months</span></span><span style="font-family:inherit;font-size:10pt;">, beginning on March 1, 2021 (or on such later date as described in the Lease Agreement). The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26781317e422-wk-Fact-8A595BB37168CE843095C8277BE64547" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" contextRef="I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">, as well as a one-time option we have to terminate the lease after </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d26781317e426-wk-Fact-AA6ABB3975DA6C59AD07C8317EF2F88E" name="anab:LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" contextRef="D2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen">seven years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> with the payment of a termination fee. The monthly base rent will be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d26781317e430-wk-Fact-738BE16AC27616305A1DC82A5EF17225" name="anab:RentPerSquareFoot" contextRef="D2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="USD_PER_sqft" decimals="2" scale="0" format="ixt:numdotdecimal">4.20</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per rentable square foot, and will be increased by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d26781317e435-wk-Fact-DCF25D5630953B81A6B5C82CA4F8914D" name="anab:AnnualRentIncreasePercent" contextRef="D2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-2D26A9FC285BEE915C95C820CAE3B32C-2"> annually. </ix:continuation>We are also responsible for real estate taxes, building insurance, maintenance and our pro rata share of direct expenses and utilities under the Lease Agreement.</span></div><div><a id="s63460C80039F55C3AEE3E44E02144F7B"></a></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This Quarterly Report on Form 10-Q (Quarterly Report) contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act), and section 27A of the Securities Act of 1933, as amended (Securities Act). The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan&#8221; and &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The forward-looking statements in this report include, among other things, statements about:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our plans to develop and commercialize antibodies, including our lead product candidates: etokimab for patients with respiratory disorders and ANB019 for patients with generalized pustular psoriasis, or GPP, and palmoplantar pustulosis, or PPP;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of the coronavirus, or COVID-19, pandemic on our business and the U.S. and global economies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the likelihood that the clinical data generated in any study we performed, are performing or plan to perform in a non-US jurisdiction will be subsequently accepted by the </span><span style="font-family:inherit;font-size:10pt;color:#231f20;">U.S. Food and Drug Administration, or FDA</span><span style="font-family:inherit;font-size:10pt;"> and/or by foreign regulatory authorities outside of the jurisdiction where the study was being performed;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and ability of our collaborators to develop and commercialize our partnered product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential benefits and advantages of our product candidates and approaches versus those of our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to execute on our strategy, including advancing our lead product candidates, identifying emerging opportunities in key therapeutic areas, continuing to expand our wholly-owned pipeline and retaining rights to strategic products in key commercial markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing of and our ability to obtain and maintain regulatory approvals for etokimab and ANB019 and our other product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to develop our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the rate and degree of market acceptance and clinical utility of any approved product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the size and growth potential of the markets for any approved product candidates, and our ability to serve those markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our commercialization, marketing and manufacturing capabilities and strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory developments in the United States, the United Kingdom, Australia and other foreign countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of competing therapies that are or may become available;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to attract and retain key scientific or management personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our use of the net proceeds from our public offerings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors,&#8221; and elsewhere in this Quarterly Report. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements to conform these statements to actual results or to changes in our expectations, except as required by law.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">You should read this Quarterly Report with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless the context indicates otherwise, as used in this Quarterly Report, the terms &#8220;AnaptysBio,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to AnaptysBio, Inc., a Delaware corporation, and its subsidiaries taken as a whole, unless otherwise noted. AnaptysBio is our common law trademark. This Quarterly Report contains additional trade names, trademarks and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4289C287075B53D1A81029511E64285C"></a></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited consolidated financial statements and related notes for the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, included in Part I, Item&#160;1 of this report and with our audited consolidated financial statements and related notes thereto for the year ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, included in the Company&#8217;s Form 10-K. This discussion and other sections of this Quarterly Report contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#8220;Risk Factors&#8221; included in Part II, Item&#160;1A of this Quarterly Report. You should also carefully read &#8220;Special Note Regarding Forward-Looking Statements&#8221;.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a clinical stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;">. Our strategy is to advance the development of our proprietary product candidates, and where applicable, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights. Our most advanced wholly-owned antibody programs, etokimab, ANB019, ANB030 and ANB032, are designed to modulate therapeutic targets that are genetically associated with human inflammatory disorders.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Etokimab, our anti-IL-33 antibody previously referred to as ANB020, inhibits the activity of the interleukin-33 cytokine, or IL-33, which we believe is broadly applicable to the treatment of respiratory disorders. We are conducting a randomized, placebo-controlled Phase 2 trial of etokimab in approximately 100 adult patients with CRSwNP, also referred to as the ECLIPSE trial, which is a debilitating atopic disorder associated with elevated IL-33 pathway signaling. We have over-enrolled this trial beyond the first 100 patients to compensate for lost patient visits due to the COVID-19 pandemic, and hence anticipate interim top-line data from this trial to be available in the third quarter of 2020. We have previously completed a Phase 2a randomized, placebo-controlled, single dose study of etokimab in 25 severe adult eosinophilic asthma patients. We presented full data from this trial at the 2019 European Academy of Allergy and Clinical Immunology (EAACI), which demonstrated that a single dose of etokimab resulted in rapid and sustained lung function improvement as measured using Forced Expiratory Volume in One Second, or FEV1, patient reported outcomes associated with asthma symptoms, as measured using the Asthma Control Questionnaire 5. As a result of the topline data from our recently completed Phase 2b etokimab ATLAS trial in moderate-to-severe atopic dermatitis, the Company has decided to discontinue further clinical development in atopic dermatitis.  We have also postponed initiation of a previously announced Phase 2b etokimab clinical trial in eosinophilic asthma until data is available from the aforementioned ECLIPSE trial.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ANB019 antibody inhibits the interleukin-36 receptor, or IL-36R, and is being developed for the treatment of rare inflammatory diseases including generalized pustular psoriasis, or GPP, and palmoplantar pustulosis, or PPP. We completed a Phase 1 clinical trial in healthy volunteers, which was presented at EAACI 2018, where ANB019 was well-tolerated by all subjects, no dose-limiting toxicities were observed, and no serious adverse events were reported among any subjects in the trial. We are conducting an open-label, multi-dose, single-arm Phase 2 trial of ANB019 in up to 10 GPP patients, also referred to as the GALLOP trial, where an interim analysis, announced in September 2019, was conducted after the first two patients completed 16-weeks (Day 113) with ANB019 monotherapy. Both patients achieved the primary endpoint of disease improvement at Day 29 and Day 113 without requiring rescue therapy. Patients demonstrated rapid and sustained modified Japanese Dermatology Association (mJDA) improvement and complete clearance of skin pustules from Day 8 through Day 113. C-reactive protein, or CRP, levels decreased to nearly normal in both patients and genotypic testing of these two patients indicated that ANB019 may be broadly applicable to pustular disease patients without a requirement for genetic screening. Enrollment is ongoing in GALLOP and we anticipate additional clinical data and a regulatory strategy update for the development of ANB019 in GPP during the second half of 2020. We are also conducting a randomized, double-blind, placebo-controlled approximately 50-patient multi-dose trial of ANB019 in PPP, also referred to as the POPLAR trial, where top-line data are anticipated in the second half of 2020. While we do not believe that the aforementioned timelines are materially impacted by the COVID-19 pandemic at this point, some of the sites involved in the GALLOP and POPLAR trials have been affected by the COVID-19 pandemic, and we</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">will continue to monitor the situation over the upcoming months.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our third wholly-owned program, ANB030, is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases. Genetic mutations in the PD-1 pathway are known to be associated with increased susceptibility to human inflammatory diseases, and hence we believe that ANB030 is applicable to diseases where PD-1 checkpoint receptor function may be under-represented. We presented preclinical data for ANB030 at the 2019 Federation of Clinical Immunological Societies (FOCIS) Annual Meeting in June 2019. Our Investigational New Drug Application, or IND, for ANB030 has been cleared, and we anticipate initiation of a Phase 1 healthy volunteer clinical trial in the first half of 2020.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our fourth wholly-owned program is an anti-BTLA modulator antibody, known as ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. Mutations in the BTLA signaling pathway are associated with human inflammatory disease and we believe ANB032 silences pro-inflammatory signaling by modulating BTLA binding to HVEM. We anticipate filing an IND for ANB032 in the second half of 2020.  </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our wholly-owned antibody programs, multiple AnaptysBio-developed antibody programs have been advanced to preclinical and clinical milestones under our collaborations. We have received to date approximately $100.0 million in cash receipts from collaborations. Our collaborations include an immuno-oncology-focused collaboration with TESARO, Inc. and TESARO Development, Ltd., or collectively TESARO, now a part of GlaxoSmithKline or GSK, and an inflammation-focused collaboration with Celgene Corporation, or Celgene, now part of Bristol-Myers Squibb. A Biologics License Application, or BLA, for our most advanced partnered program, which is an anti-PD-1 antagonist antibody called dostarlimab, was submitted by GSK and accepted by the FDA for endometrial cancer. In addition, the European Medicines Agency, or EMA, recently accepted GSK&#8217;s Marketing Authorization Application, or MAA, for dostarlimab in the EU for endometrial cancer. We anticipate marketing approval of dostarlimab by the FDA for endometrial cancer during 2020. Dostarlimab is also under development at GSK for a number of additional oncological indications. For more information about these collaborations, see Part I-Note 4, Collaborative Research and Development Agreements, above.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes certain key information about our wholly-owned and partnered product candidates:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:36px;"><img src="pipelineq12020a.jpg" alt="pipelineq12020a.jpg" style="height:442px;width:684px;"></img></div><div style="line-height:120%;text-align:center;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, in December 2019, a strain of coronavirus was reported in Wuhan, China, and began to spread globally, including to the United States and Europe, in the following months. The World Health Organization has declared COVID-19 to be a pandemic and a public health emergency of international concern. The full impact of the COVID-19 outbreak is inherently </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">uncertain at the time of this report. The COVID-19 outbreak has resulted in travel restrictions and in some cases, prohibitions of non-essential activities, disruption and shutdown of businesses and greater uncertainty in global financial markets. As COVID-19 has spread, it has significantly impacted the health and economic environment around the world and many governments have closed most public establishments, including restaurants, workplaces and schools. Our ongoing clinical trials have been, and may continue to be, affected by the closure of offices, or country borders, among other measures being put in place around the world. The inability to travel and conduct face-to-face meetings can also make it more difficult to enroll new patients in ongoing or planned clinical trials. Any of these circumstances will potentially have a negative impact on our financial results and liquidity in fiscal 2020. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The COVID-19 pandemic has caused us to modify our business practices (including but not limited to curtailing or modifying employee travel, moving to full remote work, and cancelling physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, patients and business partners.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The extent of the impact of the COVID-19 on our future liquidity and operational performance will depend on certain developments, including the duration and spread of the outbreak, the impact on our trials, patients and collaboration partners, and the effect on our suppliers.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Components of Operating Results </span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Revenue</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not generated any revenue from product sales. Our revenue has been derived from amortization of upfront license payments, research and development funding and milestone payments under collaboration and license agreements with our collaborators. From inception through </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we have received </span><span style="font-family:inherit;font-size:10pt;">$99.6 million</span><span style="font-family:inherit;font-size:10pt;"> in cash in non-dilutive funding from our collaborators.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses consist of costs associated with our research and development activities, including drug discovery efforts, preclinical and clinical development of our programs, and manufacturing. Our research and development expenses include: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">External research and development expenses incurred under arrangements with third parties, such as Contract Research Organizations, or CROs, consultants, members of our scientific and therapeutic advisory boards, and Contract Manufacturing Organizations, or CMOs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related expenses, including salaries, benefits, travel and stock-based compensation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License and sub-license fees. </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expense research and development costs as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have been received.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are conducting research and development activities primarily on inflammation programs. We have a research and development team that conducts antibody discovery, characterization, translational studies, IND-enabling preclinical studies and clinical development. We conduct some of our early research and preclinical activities internally and plan to rely on third parties, such as CROs and CMOs, for the execution of certain of our research and development activities, such as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;"> toxicology and pharmacology studies, drug product manufacturing and clinical trials.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have completed Phase 1 and 2a trials for etokimab and Phase 1 trials for ANB019 and have ongoing Phase 2 clinical trials as well</span><span style="font-family:inherit;font-size:10pt;color:#231f20;">.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expense</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation for our executive, finance, legal, business development, human resource and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, travel expenses and professional fees for auditing, tax and legal services. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense consists of floating interest payments and amortization of discounts on our outstanding notes payable relating to our Loan and Security Agreement with Oxford Finance LLC and Silicon Valley Bank, as amended, which we refer to as the Loan Agreement. </span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Income</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income consists primarily of interest earned on our short-term and long-term investments, and is recognized when earned.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K filed with the SEC on March 2, 2020.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations - Comparison of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration Revenue </span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized </span><span style="font-family:inherit;font-size:10pt;">$15.0 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$0.0 million</span><span style="font-family:inherit;font-size:10pt;"> in collaboration revenue for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, related to two milestones associated with dostarlimab, the anti-PD-1 antagonist antibody partnered with TESARO.  The first milestone was for $10.0 million for successful filing of the first NDA in a first indication and the second milestone was for $5.0 million for successful filing of the first MAA in a first indication.  We expect that any collaboration revenue we generate will continue to fluctuate from period to period as a result of the timing and amount of milestones from our existing collaborations. </span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses were </span><span style="font-family:inherit;font-size:10pt;">$21.0 million</span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$20.6 million</span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> for an increase of $0.4 million, primarily due to a $0.5 million&#160;increase in clinical expenses and a&#160;$0.2 million&#160;increase in outside services for preclinical and manufacturing expenses, offset by a $0.1 million decrease in salaries and related expenses, including stock compensation expense, and a $0.2 million decrease in other research and development expenses.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not track fully burdened research and development costs separately for each of our drug candidates. We review our research and development expenses by focusing on external development and internal development costs. External development expenses consist of costs associated with our external preclinical and clinical trials, including pharmaceutical development and manufacturing. Included in preclinical and other unallocated costs are external corporate overhead costs that are not specific to any one program. Internal costs consist of salaries and wages, share-based compensation and benefits, which are not tracked by product candidate as several of our departments support multiple product candidate research and development programs. The following table summarizes the external costs attributable to each program and internal costs:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/(Decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">External Costs</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Etokimab</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,921</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,515</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">406</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ANB019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,191</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,037</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">154</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ANB030</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">667</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,483</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(816</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preclinical and other unallocated costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,605</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,947</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">658</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total External Costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,384</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,982</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">402</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internal Costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,584</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,649</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(65</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20,968</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20,631</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">337</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses were </span><span style="font-family:inherit;font-size:10pt;">$4.3 million</span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$4.1 million</span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> for an increase of $0.2 million, primarily due to a $0.2 million increase in personnel costs including stock compensation expense and a $0.2 million increase in insurance expense, offset by a $0.2 million decrease in professional fees.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that our general and administrative expenses will increase for the foreseeable future as we incur additional costs associated with being a publicly traded company, including legal, auditing and filing fees, additional insurance premiums, investor relations expenses and general compliance and consulting expenses. We also expect our intellectual property related legal expenses, including those related to preparing, filing, prosecuting and maintaining patent applications, to increase as our intellectual property portfolio expands. </span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense was </span><span style="font-family:inherit;font-size:10pt;">$0.0 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$0.3 million</span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.  The decrease in interest expense during the period is due to the final payment made on our Term Loans on January 1, 2020.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Income </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income was </span><span style="font-family:inherit;font-size:10pt;">$1.9 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$3.0 million</span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, which primarily related to our short-term and long-term investments, the balance of which decreased during the period as a result of ongoing clinical trial programs. The decrease in interest income is also attributable to lower interest rates during the three months ended March 31, 2020.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net was income of less than $0.1 million during both the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and primarily related to foreign exchange transactions through our Australian subsidiary and with our foreign CROs and CMOs.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From our inception through </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we have received an aggregate of </span><span style="font-family:inherit;font-size:10pt;">$738.5 million</span><span style="font-family:inherit;font-size:10pt;"> to fund our operations which included </span><span style="font-family:inherit;font-size:10pt;">$619.8 million</span><span style="font-family:inherit;font-size:10pt;"> from the sale of equity securities, </span><span style="font-family:inherit;font-size:10pt;">$99.6 million</span><span style="font-family:inherit;font-size:10pt;"> from our collaboration agreements and </span><span style="font-family:inherit;font-size:10pt;">$19.1 million</span><span style="font-family:inherit;font-size:10pt;"> from venture debt. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;">$412.7 million</span><span style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents and investments. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our existing cash, cash equivalents and investments, we are eligible to earn milestone and other contingent payments for the achievement of defined collaboration objectives and certain nonclinical, clinical, regulatory and sales-based events, and royalty payments under our collaboration agreements. Our ability to earn these milestone and contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of our collaborators&#8217; research and development activities and is uncertain at this time. Our rights to payments under our collaboration agreements are our only committed external source of funds. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may seek to obtain additional financing in the future through equity or debt financings or through collaborations or partnerships with other companies. If we are unable to obtain additional financing on commercially reasonable terms, our business, financial condition and results of operations will be materially adversely affected. </span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Funding Requirements </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our primary uses of capital are, and we expect will continue to be, third-party clinical and preclinical research and development services, including manufacturing, laboratory and related supplies, compensation and related expenses, legal, patent and other regulatory expenses and general overhead costs. We have entered into agreements with certain vendors for the provision of services, including services related to commercial manufacturing, that we are unable to terminate for convenience.&#160;Under such agreements, we are contractually obligated to make certain minimum payments to the vendors, with the amounts to be based on the timing of the termination and the specific terms of the agreement.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a publicly traded company, we incur significant legal, accounting and other expenses that were not required as a private company.&#160;In addition, the Sarbanes-Oxley Act of 2002, as well as rules&#160;adopted by the SEC and The Nasdaq Global Stock Market, requires public companies to implement specified corporate governance practices that were inapplicable to us as a private company. These rules&#160;and regulations have increased our legal and financial compliance costs, have made and will continue to make certain activities more time-consuming and costly. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and investments totaled </span><span style="font-family:inherit;font-size:10pt;">$412.7 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">$428.5 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We believe that our existing cash, cash equivalents and investments will fund our current operating plan at least into 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flows for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020 and 2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(15,112</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(16,099</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,751</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,657</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,339</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,301</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net decrease in cash, cash equivalents, and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(5,700</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(7,743</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Activities </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$15.1 million</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to our net loss of </span><span style="font-family:inherit;font-size:10pt;">$8.3 million</span><span style="font-family:inherit;font-size:10pt;">, adjusted for addbacks for non-cash expenses of </span><span style="font-family:inherit;font-size:10pt;">$3.1 million</span><span style="font-family:inherit;font-size:10pt;"> which includes stock-based compensation and net decreases in working capital of </span><span style="font-family:inherit;font-size:10pt;">$10.0 million</span><span style="font-family:inherit;font-size:10pt;">. Net cash used in operating activities during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$16.1 million</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to our net loss of </span><span style="font-family:inherit;font-size:10pt;">$22.1 million</span><span style="font-family:inherit;font-size:10pt;">, adjusted for non-cash expenses of </span><span style="font-family:inherit;font-size:10pt;">$2.1 million</span><span style="font-family:inherit;font-size:10pt;"> which includes stock-based compensation and net increases in working capital of </span><span style="font-family:inherit;font-size:10pt;">$3.9 million</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investing Activities </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by investing activities during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020 and 2019</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$10.8 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$9.7 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, primarily relates to the timing of our investment maturity, which was used to fund our operating expenses.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Activities</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The net cash used in financing activities during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$1.3 million</span><span style="font-family:inherit;font-size:10pt;"> primarily related to principal and final payments of </span><span style="font-family:inherit;font-size:10pt;">$1.4 million</span><span style="font-family:inherit;font-size:10pt;"> made on our Term Loans, offset by </span><span style="font-family:inherit;font-size:10pt;">$0.04 million</span><span style="font-family:inherit;font-size:10pt;"> in proceeds from the issuance of common stock upon the exercise of stock options. The net cash used in financing activities during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$1.3 million</span><span style="font-family:inherit;font-size:10pt;"> primarily related to principal payments of $1.9 million made on our Term Loans, offset by $0.6 million in proceeds from the issuance of common stock upon the exercise of stock options. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations </span></div><div style="line-height:120%;padding-top:8px;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have two non-cancellable office leases with remaining lease terms of approximately </span><span style="font-family:inherit;font-size:10pt;">1.5</span><span style="font-family:inherit;font-size:10pt;"> years, each of which are classified as operating leases. Both leases expire in 2021. Only one of our leases has remaining renewal options, which includes three options to renew for one additional year. The exercise of lease renewal options is at our sole discretion, which we currently do not anticipate exercising and as such were not recognized as part of our ROU asset and lease liabilities. Our lease payments are fixed, and we recognize lease expense for these leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was </span><span style="font-family:inherit;font-size:10pt;">8.59%</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the future minimum annual obligations under non-cancellable operating lease commitments are </span><span style="font-family:inherit;font-size:10pt;">$0.7 million</span><span style="font-family:inherit;font-size:10pt;"> for both the remainder of fiscal years ending 2020 and 2021, respectively.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Commitments and Contingencies</span></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into agreements with certain vendors for the provision of goods and services, which includes manufacturing services with contract manufacturing organizations and development services with contract research organizations. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Guarantees and Indemnifications</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We enter into standard indemnification arrangements in the ordinary course of business. Pursuant to certain of these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party for third-party claims in connection with our breach of the agreement, our negligence or willful misconduct in connection with the agreement, or any trade secret, copyright, patent or other intellectual property infringement claim with respect to our technology. The term of these indemnification arrangements is generally perpetual. The maximum potential amount of future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in the future, but have not yet been made.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We indemnify our officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving in such capacity, as permitted under Delaware law, in accordance with our certificate of incorporation and bylaws, and pursuant to agreements providing for indemnification entered into with our officers and directors. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The maximum amount of potential future indemnification of directors and officers is unlimited; however, we currently hold director and officer liability insurance. This insurance allows the transfer of risk associated with our exposure and may enable us to recover a portion of any future amounts paid.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that the fair value of these indemnification obligations is minimal. Accordingly, we have not recognized any liabilities relating to these obligations for any period presented.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC65CF7DFF64E5E419079FE3895DD39DF"></a></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there have been no material changes surrounding our market risk, including interest rate risk, inflation risk, and foreign currency exchange risk from the discussion provided in Item 7A. Quantitative and Qualitative Disclosures About Market Risk of our Fiscal </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> Form 10-K.</span></div><div><a id="s78430F3372D55FCAA38C86316F366F8F"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4. CONTROLS AND PROCEDURES </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, or the &#8220;Exchange Act&#8221;, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, our management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the quarter ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9B5525FAB32E57018A0C83577181BBC7"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</span></div><div><a id="s118DB723078D504FA687F470918DBB3A"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1. LEGAL PROCEEDINGS </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 25, 2020, a putative shareholder class action complaint was filed in the United States District Court for the Southern District of California against us and three of our current or former officers.&#160;The complaint purports to assert claims under Section 10(b) of the Exchange Act, Exchange Act Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019, or the Class Period.&#160; The complaint alleges that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab drug that artificially inflated our stock price.&#160;The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses.&#160;We believe that the claims in the action are without merit.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. Subject to the above-mentioned lawsuit, we are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business should such litigation be resolved unfavorably. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</span></div><div><a id="s0748DA5DCF35551CA5697E6E33A2AC9E"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1A. RISK FACTORS </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this report, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. </span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Discovery and Development of Our Product Candidates</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial viability. Results from our initial clinical trials may not be representative of the results we will experience in later clinical trials. If we or our collaborators are unable to complete development of or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are using our proprietary technology platform to develop therapeutic antibodies, including our wholly-owned product candidates, as well as other programs that are being developed by our collaborators. However, all of our wholly-owned and partnered product candidates are in the early stages of development, and, for a wide variety of reasons discussed below, may fail in development or suffer delays that adversely affect their commercial viability.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. For example, results from our initial Phase 2a clinical trial of etokimab in moderate-to-severe atopic dermatitis patients was not representative of the results we experienced in our later Phase 2b trial. Similarly, we reported interim results of our GALLOP Phase 2 clinical trial of ANB019, which included data for two patients who had completed the Day 113 trial period. While we believe these results are likely to be representative of subsequent patients in the trial, the results we have observed to date may not be predictive of results once all 10 patients have completed the trial. If our later clinical trials are unsuccessful, our product candidates may be delayed in development or fail entirely, which would have a material adverse impact on our business.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have elected to structure our initial Phase 2a clinical trials with etokimab as investigational studies that enroll a relatively limited number of patients and are intended to allow us to better assess patient responses and potential efficacy results before designing and commencing Phase 2b clinical trials. We believe the results we have observed in the initial Phase 2a clinical trials of etokimab in severe adult eosinophilic asthma may suggest a reasonable basis for continuing development of etokimab in this indication through a larger Phase 2b clinical trial. However, as a result of the recently announced topline data </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">from our ATLAS trial in atopic dermatitis, we have decided to postpone the initiation of our planned Phase 2b etokimab clinical trial in eosinophilic asthma, a multi-dose, randomized, double-blinded, placebo-controlled trial in 300-400 patients, until we have the opportunity to analyze the results from our currently ongoing Phase 2 trial of etokimab in CRSwNP. Our Phase 2a trials involved relatively small patient populations, for example 25 patients in our Phase 2a trial in severe adult eosinophilic asthma. The results we have observed in this smaller patient populations may not be predictive of results we will experience in later studies. Furthermore, the average results reported from our Phase 2a trial in severe eosinophilic asthma (for example, the average change in FEV1 reported) were subject to significant variability due to the small number of patients enrolled, and as expected were not statistically significant. In addition, we elected to structure our initial Phase 2a clinical trial in eosinophilic asthma as a single dose study, which may not be representative of the efficacy and/or safety observed in subsequent multi-dose Phase 2, Phase 2b or Phase 3 clinical trials.</span></div><div style="line-height:120%;padding-top:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, later studies may also include different design elements that could contribute to us experiencing different results than we have observed in our Phase 2a trials. One such design element may be differences in efficacy endpoints between Phase 2a trials and subsequent Phase 2, Phase 2b or Phase 3 clinical trials. For instance, while our single dose Phase 2a clinical trial of etokimab in eosinophilic asthma demonstrated efficacy in terms of FEV1 improvement versus placebo, we did not structure that trial to assess efficacy in terms of exacerbation reduction, which is the endpoint historically used by the FDA for drug approval in asthma, and hence our future Phase 2, Phase 2b or Phase 3 trials in asthma may not demonstrate efficacy in exacerbation reduction leading to potential delays or failure to obtain approval of etokimab in asthma. In addition, the initial results we have report from our Phase 2a clinical trials have included interim analyses and top-line results at early timepoints, which may not accurately predict the final results of these clinical trials or the results of future clinical trials. For instance, our single dose Phase 2a trial of etokimab in atopic dermatitis demonstrated certain levels of EASI-50 response upon interim analysis at Day 29, but this EASI-50 response level was not maintained at the end of this clinical trial at Day 140.  In another example, interim analysis data from our Phase 2a study of severe adult eosinophilic asthma demonstrated FEV1 improvement over placebo at Day 64, but this FEV1 improvement was not maintained at the same levels through study completion at the Day 127 timepoint.</span></div><div style="line-height:120%;padding-top:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, our rationale for conducting clinical trials of etokimab in multiple indications is that we believe etokimab&#8217;s mechanism of action, the inhibition of IL-33, has the potential be effective for treatment of a range of atopic inflammatory disorders.  However, in light of the recently announced topline data from our ATLAS trial of etokimab in atopic dermatitis, it is possible that our assumptions regarding the effectiveness of etokimab&#8217;s mechanism of action may be incorrect, and that etokimab may be ineffective in certain inflammatory disorders or may be ineffective in treating inflammatory disorders generally.  If this were the case, then results from our ongoing Phase 2 clinical trial of etokimab in CRSwNP, and results from any other clinical trials of etokimab that we conduct, are less likely to be positive.</span></div><div style="line-height:120%;padding-top:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> If our later clinical trials of etokimab or ANB019 are unsuccessful, whether for one of the reasons mentioned above or otherwise, etokimab or ANB019 may be delayed in development or fail entirely, which would have a material adverse impact on our business.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The success of our current product candidates, and any other product candidates we may develop in the future, will depend on many factors, including the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtaining regulatory permission to initiate clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">successful enrollment of patients in, and the completion of, our planned clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">receiving marketing approvals from applicable regulatory authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establishing commercial manufacturing capabilities and/or making arrangements with third-party manufacturers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">enforcing and defending intellectual property rights and claims;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">achieving desirable therapeutic properties for our product candidates&#8217; intended indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">effectively competing with other therapies; and</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would harm our business.</span></div><div style="line-height:115%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments for the relevant disease. We may not be able to initiate our planned clinical trials if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the U.S. Food and Drug Administration, or FDA, or foreign regulatory authorities. More specifically, some of our product candidates, including ANB019, initially target indications that are very rare, which can prolong the clinical trial timeline for the regulatory process if sufficient patients cannot be enrolled in a timely manner.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212529;font-weight:bold;">The COVID-19 pandemic has had a material impact on the U.S. and global economies and could have a material adverse impact on our employees, contractors, and patients, which could adversely and materially impact our business, financial condition and results of operations. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212529;">The World Health Organization has declared the outbreak of the novel coronavirus that causes COVID-19 disease a pandemic and public health emergency of international concern. In March 2020, the President of the United States declared a State of National Emergency due to the COVID-19 outbreak. In addition, many jurisdictions have limited, and may further limit, social mobility and gathering. As the COVID-19 pandemic develops, governments (at national, state and local levels), corporations and other authorities may continue to implement restrictions or policies that could adversely impact consumer spending, global capital markets, the global economy and our stock price. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212529;">The COVID-19 pandemic has caused us to modify our business practices (including but not limited to curtailing or modifying employee travel, moving to full remote work, and cancelling physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees and patients. In the first quarter of 2020, the shelter-in-place orders stemming from the COVID-19 pandemic have caused disruptions to our corporate operations. A prolonged disruption or any further unforeseen delay in our operations or within any of our business activities could continue to result in reduced participation in ongoing trials or delays in enrolling our planned trials, as we rely on </span><span style="font-family:inherit;font-size:10pt;">contract research organizations (for non-clinical and clinical activities), or CROs, and contract manufacturing organizations, or CMOs, to conduct our clinical trials and to manufacture our product candidates.  If our CROs are unable to continue ongoing trials or to enroll new patients for new trials, or if our CMOs are unable to obtain sufficient quantities of reagents or manufacture adequate drug quantities, our clinical trials could be materially delayed or disrupted. </span><span style="font-family:inherit;font-size:10pt;color:#212529;"> We may also encounter delays from the FDA and other regulatory authorities in our clinical development efforts.  We could also be adversely affected if government authorities impose additional restrictions on public gatherings, human interactions, mandatory closures, seek voluntary closures, restrict hours of operations or impose curfews, restrict the import or export of products or if reagent suppliers issue mass recalls of products. Moreover, there is no certainty that such measures will be sufficient to mitigate the risks posed by the virus or otherwise be satisfactory to government authorities. We cannot say with certainty how long these measures will remain in place, or what the total impact on our business may be.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212529;">Further, in reaction to the spread of COVID-19 in the United States and internationally, many patients and medical facilities are delaying or canceling elective procedures, adding further strain to health care budgets globally. Additionally, the disruption and volatility in the global and domestic capital markets may increase the cost of capital and limit our ability to access capital. Both the health and economic aspects of the COVID-19 virus are highly fluid and the future course of each is uncertain. For these reasons and other reasons that may come to light if the COVID-19 pandemic and associated protective or preventative measures expand, we may experience a material adverse effect, either directly or indirectly through our CROs, CMOs, collaboration partners or patients, on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change.</span></div><div style="line-height:115%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We have only limited data regarding the safety profile of our wholly-owned product candidates when dosed in humans. Our ongoing and planned clinical trials or those of our collaborators may reveal significant adverse events, toxicities or </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:115%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="line-height:115%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to obtain marketing approval for any of our product candidates, we must demonstrate the safety and efficacy of the product candidate for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. If our product candidates are associated with undesirable side effects in preclinical studies or clinical trials or have characteristics that are unexpected, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span></div><div style="line-height:115%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have conducted various preclinical studies of our product candidates, but we do not know the predictive value of these studies for humans, and we cannot guarantee that any positive results in preclinical studies will successfully translate to human patients. We have only completed early Phase 1 and Phase 2a clinical trials for etokimab, and subsequent patient trials with etokimab are currently ongoing. We also have only recently completed a Phase 1 clinical trial with ANB019 and subsequent patient trials with ANB019 are currently ongoing. It is not uncommon to observe results in human clinical trials that are unexpected based on preclinical testing, or to observe results in later stage clinical trials that are unexpected based on early clinical trials. Many product candidates fail in clinical trials despite promising preclinical and early clinical results. In addition, top-line results of a clinical trial, which generally reflect preliminary reviews of primary efficacy and/or safety results, do not necessarily predict final results, and any top-line findings or assessments are subject to change pending the completion of final data review procedures. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. </span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some patients in our clinical trials have experienced adverse events, including serious adverse events. The most frequent treatment-emergent adverse events reported were mild dizziness or vomiting in patients subsequent to placebo dosing, and mild headache, strep throat, upper respiratory tract infection, or in one case, severe neutropenia which was acute and not persistent in patients post-etokimab administration. In addition, we reported that one patient dropped out of the GALLOP Phase 2 clinical trial for ANB019 due to diagnosis with&#160;Staphylococcal aureus&#160;bacteremia on Day 3 post-ANB019 administration, which was a serious adverse event deemed to be possibly drug-related. Subjects in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or in our Phase 1 or Phase 2a clinical trials. The observed potency and kinetics of our product candidates in preclinical studies may not be observed in human clinical trials. We have tested the dosing frequency and route of administration of our product candidates in preclinical studies, which will inform our dosing strategy for future clinical trials, however such dose and route of administration may not result in sufficient exposure or pharmacological effect in humans, and may lead to unforeseen toxicity not previously observed in preclinical testing. If preclinical studies of our product candidates fail to provide preliminary evidence of safety to the satisfaction of regulatory authorities or do not otherwise produce satisfactory results, we may incur additional costs or experience delays in initiating and/or advancing the development and commercialization of our product candidates. Further, if clinical trials of our product candidates fail to demonstrate efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="line-height:115%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If further significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trial, patients may drop out of our trial, or we may be required to abandon the trial or our development efforts of that product candidate altogether. We, the FDA, or other applicable regulatory authorities, or an Institutional Review Board, or IRB, may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, if any of our product candidates obtain marketing approval, toxicities associated with our product candidates may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional warnings being added to the labeling, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early stage clinical testing.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to commercialize and generate revenue from our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to continue to develop our product candidates, and to have the potential to achieve and sustain profitability, depends on the FDA and foreign regulatory authorities permitting us to conduct human clinical trials and, if our products are safe and effective, obtaining approval from the FDA and foreign regulatory authorities to market them and subsequently successfully commercializing them, either alone or with our collaborators. The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and foreign regulatory authorities. Though we have cleared an IND and CTA to conduct clinical trials for both etokimab and ANB019 in the United States and United Kingdom, respectively, before commencing clinical trials in the United States for any other product candidate, we must submit an IND to the FDA; foreign regulatory authorities enforce similar requirements for initiation of clinical trials in other countries. An IND or foreign equivalent requires extensive preclinical studies, and there is no guarantee that the FDA or foreign regulatory authorities will allow clinical trials to proceed based on the IND or equivalent submission. For example, although we have initiated toxicology studies for our product candidates, the FDA in the United States, the Therapeutic Goods Administration in Australia or other foreign regulatory authorities, as applicable, may not allow our clinical trials to proceed in the regulatory authority&#8217;s jurisdiction if we are unable to show safety margins acceptable to the particular regulatory authority in appropriate animal species in our preclinical toxicology studies.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we or our collaborators initiate and complete clinical trials for our product candidates, these product candidates will not be permitted to be marketed in the United States until approval of a Biologics License Application, or BLA, from the FDA, is received, and will not be permitted to be marketed in other countries without marketing approval from foreign regulatory authorities. Obtaining approval of a BLA or other marketing approvals is often a lengthy, expensive and uncertain process over which the FDA and foreign regulatory authorities have substantial discretion. Other than submitting and receiving acceptance for initiation of our previous and current clinical trials in Australia, the United States and United Kingdom, we have not yet discussed with the FDA or foreign regulatory authorities the development plans for any of our product candidates or the designs of any of our later-stage clinical studies. We thus may not have the full benefit of the FDA&#8217;s or foreign regulatory authorities&#8217; current thinking on trial designs or product development for our target indications. For example, we believe a small pivotal trial, potentially with less than 100 patients, may be sufficient to demonstrate substantial evidence of efficacy of ANB019 in generalized pustular psoriasis, or GPP, patients. However, we have not yet discussed clinical trial design for this indication with the FDA, and the FDA may disagree with our proposed trial design, including the number of patients necessary to demonstrate efficacy and/or may require us to conduct more than one pivotal study in order to obtain approval of a BLA. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. Products, on average, take 10 to 15 years to be developed from the time they are discovered to the time they are approved and available for treating patients. The start or end of a clinical trial is often delayed or halted for many reasons, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">imposition of a clinical hold for safety reasons or following an inspection of clinical trial operations or site by the FDA or other regulatory authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">manufacturing challenges;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">insufficient supply or quality of product candidates or other materials necessary to conduct clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and contract research organizations, or CROs, or failure by such CROs or trials sites to carry out the clinical trial in accordance with our agreed-upon terms;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">non-clinical or clinical sites becoming unavailable due to political, economic or public health events, such as the recent coronavirus outbreak;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical sites electing to terminate their participation in one of our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inability or unwillingness of patients or medical investigators to follow clinical trial protocols;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">required clinical trial administrative actions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">slower than anticipated patient enrollment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changing standards of care;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">safety concerns;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">availability or prevalence of use of a comparative drug or required prior therapy; or</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical outcomes or financial constraints.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical or other studies or clinical trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Moreover, regulatory authorities may determine that the clinical and other benefits of a product candidate do not outweigh the safety or other risks. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may also cause delays in or prevent the approval of an application.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we experience any of the issues described above, or other similar or related issues, we may:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be delayed in obtaining marketing approval for our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">not obtain marketing approval at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain marketing approval in some countries and not in others; obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be subject to additional post-marketing testing requirements; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">have the product removed from the market after obtaining marketing approval.</span></div></td></tr></table><div style="line-height:118%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may not be successful in our efforts to use our technology platform to expand our pipeline of product candidates and develop marketable products.</span></div><div style="line-height:118%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. Our business depends on our successful development and commercialization of the limited number of internal product candidates we have in preclinical and early-stage clinical development. Even if we are successful in continuing to build our pipeline, development of the potential product candidates that we identify will require substantial investment in additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in multiple jurisdictions, building a commercial organization, and significant marketing efforts before we generate any revenue from product sales. Furthermore, such product candidates may not be suitable for clinical development, including as a result of their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we cannot validate our technology platform by successfully developing and commercializing product candidates based upon our technological approach, we may not be able to obtain product or partnership revenue in future periods, which would adversely affect our business, prospects, financial condition and results of operations.</span></div><div style="line-height:118%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of our current focus on our lead product candidates, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. Our understanding and evaluation of biological targets for the discovery and development of new product candidates may fail to identify challenges encountered in subsequent preclinical and clinical development. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></div><div style="line-height:118%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We have recently commenced clinical development of etokimab, ANB019 and ANB030, and have no other history of conducting clinical trials or commercializing biotechnology products, which may make it difficult to evaluate the prospects for our future viability.</span></div><div style="line-height:118%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations to date have been largely limited to financing and staffing our company, developing our technology and developing our wholly-owned product candidates, and other product candidates in partnerships with our collaborators. As a company, we have only very limited experience conducting clinical trials and have not had previous experience commercializing product candidates, including submitting a BLA to the FDA. In part because of this lack of experience, we </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:118%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cannot be certain that planned clinical trials will begin or be completed on time, if at all, that our planned development programs would be acceptable to the FDA or other regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized. Clinical trials and commercializing our wholly-owned product candidates will require significant additional financial and management resources, and reliance on third-party clinical investigators, CROs, consultants or collaborators. Relying on third-party clinical investigators, CROs or collaborators may result in delays that are outside of our control.</span></div><div style="line-height:118%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, we may not have the financial resources to continue development of, or to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:118%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:118%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:118%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:118%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conditions imposed by the FDA or foreign regulatory authorities regarding the number, scope or design of our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in enrolling research subjects in clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">high drop-out rates of research subjects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">inadequate supply or quality of clinical trial materials or other supplies necessary for the conduct of our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">greater than anticipated clinical trial costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">poor effectiveness or unacceptable side effects of our product candidates during clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">serious and unexpected drug-related side effects experienced by participants in our planned clinical trials or by individuals using drugs similar to our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">varying interpretations of data by the FDA and foreign regulatory authorities.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consequently, any predictions you make about our future success or viability based on our short operating history may not be as accurate as they could be if we had a longer operating history or an established track record in conducting clinical trials or commercializing products.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The biotechnology industry is highly competitive and subject to rapid and significant technological change. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical and biotechnology companies, established biotechnology companies, specialty biotechnology companies, emerging and start-up companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or approval from the FDA or foreign regulatory authorities or discovering, developing and commercializing products in our field before we do.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For asthma, our competitors include omalizumab (Xolair; Roche), which has received FDA approval and functions by inhibiting the binding between free IgE and FceRI; antibodies that bind IL-5 and inhibit its interaction with the IL-5 receptor such as mepolizumab (Nucala; Glaxosmithkline) and reslizumab (Cinqair; Teva), both of which the FDA has approved for the add-on maintenance treatment in patients with severe eosinophilic asthma; antibodies such as benralizumab (FASENRA, AstraZeneca) that bind the IL-5 receptor; antibodies that bind the IL-4 receptor and inhibit its signaling through IL-4 and IL-13 cytokines such as dupilumab (Dupixent; Regeneron/Sanofi), which has been approved by the FDA for use with other asthma medicines for the&#160;maintenance treatment&#160;of moderate-to-severe asthma&#160;in patients aged 12 years and older whose asthma is not controlled&#160;with their current asthma medicines; antibodies that bind to IL-13 such as lebrikizumab (Dermira), tralokinumab (AstraZeneca, LEO Pharma) and anrukinzumab (Pfizer), which are in clinical testing; antibodies that bind the IL-4 receptor alpha chain, such as AMG 317 (Amgen) in clinical testing; ST2-binding antibodies including Roche&#8217;s RG6149 and GSK&#8217;s GSK3772847, and Regeneron&#8217;s IL-33 antibody (REGN3500) each in clinical development for asthma and chronic obstructive pulmonary disease; a recently announced IL-33 related program by AstraZeneca (MEDI3506) in a Phase 1 clinical trial indicated for chronic obstructive pulmonary disease; DP-2 antagonists including fevipiprant (Novartis) under development for asthma and GB001 (Gossamer Bio) under development for asthma; and an anti-TSLP antibody called tezepelumab (AMG 157, MEDI9929, Amgen/AstraZeneca) being developed by Amgen and AstraZeneca for asthma.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our competitors in CRSwNP include dupilumab (Regeneron/Sanofi), mepolizumab (GSK), benralizumab (AstraZeneca), omalizumab (Novartis), GB001 (Gossamer Bio) and PF-06817024 (Pfizer), each of which are in clinical testing.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For GPP and PPP, our competitors include marketed therapies such as secukinumab (Cosentyx; Novartis), which binds IL-17A; ustekinumab (Stelara; Janssen), which blocks IL-12 and 23 cytokine function; and acitretin (Soriatane; GlaxoSmithKline), as well as therapies in development such as guselkumab (Janssen), which blocks IL-23 cytokine function, gevokizumab (Xoma 052) and canakinumab (Ilaris, Novartis), which binds IL-1 beta, anakinra (Kineret; Swedish Orphan Biovitrum AB), a recombinant form the IL-1 receptor antagonist and an anti-IL-36 receptor antibody called BI-655130 (Boehringer Ingelheim).</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our anti-inflammatory checkpoint modulator antibody programs, our competitors include CC-90006 (Celgene/BMS) which is an anti-PD-1 agonist antibody developed under our partnership with Celgene, a BTLA modulator antibody called LY3361237 being developed by Eli Lilly and a PD-1 agonist antibody also being developed by Eli Lilly.  </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, an abbreviated pathway for the approval of biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product is approved under a BLA. To date, several biosimilar products have been approved under the BPCIA, but no interchangeable biological products have been approved. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that if any of our product candidates are approved as a biological product under a BLA it should qualify for the 12-year period of exclusivity. However, there is a risk that the FDA will not consider any of our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, are less expensive or capture significant market share prior to or during our commercialization. Our competitors also may obtain FDA or other regulatory approval for </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for planned clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biotechnology industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our product candidates may not achieve adequate market acceptance among physicians, patients, health care payors and others in the medical community necessary for commercial success.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, health care payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the efficacy and safety profile as demonstrated in planned clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing of market introduction of the product candidate as well as competitive products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the clinical indications for which the product candidate is approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">restrictions on the use of our products, if approved, such as boxed warnings or contraindications in labeling, or a risk evaluation and mitigation strategy, or REMS, if any, which may not be required of alternative treatments and competitor products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acceptance of the product candidate as a safe and effective treatment by physicians, clinics and patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential and perceived advantages of product candidates over alternative treatments, including any similar generic treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of treatment in relation to alternative treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">relative convenience and ease of administration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the frequency and severity of adverse events;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effectiveness of sales and marketing efforts; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unfavorable publicity relating to the product candidate.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, health care payors and patients, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If companion diagnostics for our product candidates for which such diagnostics are required, are not successfully, and in a timely manner, validated, developed or approved, we may not achieve marketing approval or realize the full commercial potential of our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If companion diagnostics are developed in conjunction with clinical programs, the FDA may require regulatory approval of a companion diagnostic as a condition to approval of the product candidate. For example, if we use a genetic test to determine which patients are most likely to benefit from ANB019 for the treatment of GPP or PPP by designing our pivotal trial or trials of ANB019 in that indication to require that subjects test positive for specific genetic mutations as a criterion for enrollment, then we will likely be required to obtain FDA approval or clearance of a companion diagnostic, concurrent with approval of ANB019, to test for those genetic mutations; we may also be required to demonstrate to the FDA the predictive utility of the companion diagnostic&#8212;namely, that the diagnostic selects for patients in whom the biologic therapy will be effective or more effective compared to patients not selected for by the diagnostic. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. We do not </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">currently have any agreement in place with any third party to develop or commercialize companion diagnostics for any of our product candidates. Companion diagnostics are subject to regulation by the FDA and foreign regulatory authorities as medical devices and require separate regulatory approval or clearance prior to commercialization.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we or our partners, or any third party, are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the development of our product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our planned clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our product candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific genetic alterations targeted by our product candidates.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, although we believe genetic testing is becoming more prevalent in the diagnosis and treatment of various diseases and conditions, our product candidates may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either due to the additional cost of the companion diagnostic or the need to complete additional procedures to identify genetic markers prior to administering our product candidates.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of these events were to occur, our business would be harmed, possibly materially.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The manufacture of biologics is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The process of manufacturing biologics is complex, highly-regulated and subject to multiple risks. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our manufacturer is not in compliance with FDA laws and regulations, including those governing current good manufacturing practices, or cGMPs, the FDA may deny BLA approval until the deficiencies are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we or our collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. Moreover, we source certain of the raw materials needed for our product candidates from China. Although we have not experienced any supply interruptions to date, it is possible that the recent coronavirus outbreak could cause such interruptions in the future. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Scaling up a biologic manufacturing process is a difficult and uncertain task, and we may not be successful in transferring our production system or the manufacturer may not have the necessary capabilities to complete the implementation and development process. If we are unable to adequately validate or scale-up the manufacturing process with our current manufacturers, we will need to transfer to other manufacturers and complete the manufacturing validation process, which can be lengthy and costly. If we are able to adequately validate and scale-up the manufacturing process for our product candidates with contract manufacturers, we will still need to negotiate with such contract manufacturers agreements for commercial supply, and it is not certain we will be able to come to agreement on terms acceptable to us.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Position and Capital Needs</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for commercial sale, and to date we have not generated any revenue or profit from product sales.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are an early-stage biotechnology company with a limited operating history. We have no approved products. To date, our revenue has been primarily derived from our TESARO and Celgene research collaboration and license agreements, and we are significantly dependent on such collaborators for the successful development of product candidates in these collaborations. Our ability to generate revenue and become profitable depends upon our ability, alone or with our collaborators, to successfully complete the development of our product candidates for our target indications and to obtain necessary regulatory approvals.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, we have incurred significant operating losses in every year except fiscal year 2014. We had </span><span style="font-family:inherit;font-size:10pt;">$15.0 million</span><span style="font-family:inherit;font-size:10pt;"> in collaboration revenue and our net loss was </span><span style="font-family:inherit;font-size:10pt;">$8.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$22.1 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, with no collaboration revenue. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$252.3 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have financed our operations primarily through our initial public offering of common stock in January 2017, our follow-on public offerings of common stock in October 2017 and September 2018, private placements of our preferred stock and the issuance of debt. We have devoted substantially all of our efforts to research and development. We have only recently initiated clinical development for two of our product candidates and expect that it will be many years, if ever, before we have a product candidate ready for commercialization. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and the net losses we incur may fluctuate significantly from quarter to quarter. Our revenue has been historically derived from amortization of upfront payments, research and development funding and milestone payments under collaboration and license agreements with our collaborators. Our ability to generate future product revenue from our current or future product candidates depends on a number of additional factors, including our ability (or as applicable our collaborators&#8217; ability) to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue research and preclinical development of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">identify additional product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintain existing and enter into new collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conduct additional preclinical studies and initiate clinical trials for our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain approvals for the product candidates we develop or developed under our collaboration arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintain, expand and protect our intellectual property portfolio;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">hire additional executive, clinical, quality control and scientific personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain coverage and adequate product reimbursement from third-party payors, including government payors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acquire or in-license other product candidates and technologies; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">achieve market acceptance for our or our collaborators&#8217; products, if any.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are unable to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability because of the numerous risks and uncertainties associated with product development. In addition, our expenses could increase significantly beyond expectations if we are required by the FDA or other regulatory authorities to perform studies or trials in addition to those that we currently anticipate. Even if ANB019 and etokimab, or any of our other product candidates, are approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of any product candidate. </span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently only in the clinical development stages for our most advanced product candidates. In order to become and remain profitable we must, alone or with our collaborators, develop and eventually commercialize a product or products </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">with significant market potential. This may require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, successfully developing companion diagnostics, obtaining marketing approval for these product candidates and manufacturing, marketing and selling those products for which we may obtain marketing approval. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain or expand our research and development efforts, expand our business or continue our operations. A decline in the value of our company would also cause you to lose part or even all of your investment.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a research and development company, our operations have consumed substantial amounts of cash since our inception. We expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we continue our discovery and preclinical development to identify new clinical candidates, and we and our collaborators conduct clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we incur additional costs associated with operating as a public company. We believe that our existing cash, cash equivalents and investments will fund our current operating plan at least into 2023. However, circumstances may cause us to consume capital more rapidly than we currently anticipate. For example, as we continue to move our product candidates through preclinical studies, submit INDs or foreign equivalents and conduct clinical development, we may have adverse results requiring us to find new product candidates, or our collaborators may not elect to pursue the development and commercialization of any of our product candidates that are subject to their respective agreements with us. Any of these events may increase our development costs more than we expect. We may need to raise additional funds or otherwise obtain funding through product collaborations to continue development of our product candidates.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we need to secure additional financing, such additional fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we do not raise additional capital when required or on acceptable terms, we may need to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significantly delay, scale back or discontinue the development or commercialization of our product candidates or cease operations altogether;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek strategic alliances for research and development programs at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">relinquish, or license on unfavorable terms, our rights to technologies or future product candidates that we otherwise would seek to develop or commercialize ourselves; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">eliminate staff to conserve resources.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we need to conduct additional fundraising activities and we do not raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects. Our forecast of the period of time through which our financial resources will adequately support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#8220;Risk Factors&#8221; section. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Our future funding requirements, both short and long-term, will depend on many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates and future product candidates we may develop;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number and size of clinical trials needed to show safety, efficacy and an acceptable risk/benefit profile for any of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and foreign regulatory authorities, including the potential for such authorities to require that we perform more studies or trials than those that we currently expect;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to maintain existing and enter into new collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost to establish, maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing of any patents or other intellectual property rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effect of competing technological and market developments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">market acceptance of any approved product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of recruiting and retaining key employees;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs and fees associated with any delays or cancellations of forecasted manufacturing batches;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost and timing of selecting, auditing and potentially validating manufacturing sites for commercial-scale manufacturing; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of establishing sales, marketing and distribution capabilities for our product candidates for which we may receive regulatory approval and that we determine to commercialize ourselves or in collaboration with our collaborators.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we cannot expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our business, financial condition and results of operations could be adversely affected.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations, or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Managing Growth, Operations and Macroeconomic Conditions</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We must attract and retain highly skilled employees in order to succeed.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. This is especially critical as we ramp up our hiring needs entering into later stage product development of our product candidates. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan, harm our operating results and adversely affect our ability to successfully commercialize our product candidates. In particular, we believe that our future success is highly dependent upon the contributions of our senior management, particularly our President and Chief Executive Officer, as well as our senior scientists. We also appointed Eric Loumeau, our General Counsel, to serve as interim Chief Financial Officer in August 2019, and until we appoint a permanent chief financial officer, this transition may be disruptive and may require additional attention from our senior management. The loss of services of any of these individuals, who all have at-will employment arrangements with us, could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates, if approved. The competition for qualified personnel in the biotechnology field is intense and, as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. In addition, certain members of our senior management team have worked together for only a relatively short period of time, and it may be difficult to evaluate their effectiveness, on an individual or collective basis, and ability to address future challenges to our business.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates and our business will be limited.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The manufacture of biotechnology products is complex and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter any loss of our master cell banks or if any of our third-party manufacturers encounter other difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide product candidates for clinical trials or our products to patients, once approved, could be delayed or stopped.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The manufacture of biotechnology products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We and our contract manufacturers must comply with cGMP regulations and guidelines for the manufacturing of biologics used in clinical trials and, if approved, marketed products. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up and validating initial production. Furthermore, if microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Delays in raw materials availability and supply may also extend the period of time required to develop our products.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of our therapeutic antibodies are manufactured by starting with cells which are stored in a cell bank. We have one master cell bank for each antibody manufactured in accordance with cGMP and multiple working cell banks and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of our product candidates or products and could have an adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We currently have no marketing and sales force. If we are unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to effectively sell or market our product candidates, if approved, or generate product revenue.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able to obtain regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market. With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate development and growing our capability to conduct clinical trials. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="line-height:119%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We conduct certain operations through our Australian wholly-owned subsidiary. If we are unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations will suffer.</span></div><div style="line-height:119%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2015, we formed a wholly-owned Australian subsidiary, AnaptysBio Pty Ltd, or AnaptysBio Pty, to develop and commercialize our ANB019 and etokimab antibody program in Australia. We have no assurance that the results of any clinical trials that we conducted for our product candidates in Australia will be accepted by the FDA or foreign regulatory authorities for development and commercialization approvals.</span></div><div style="line-height:119%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, current Australian tax regulations provide for a refundable research and development, or R&amp;D, tax credit equal to 43.5% of qualified expenditures. We have received $9.3 million USD in R&amp;D tax credits since the inception of our operations in Australia, and currently do not intend to submit for any additional tax credits. If we are ineligible or unable to retain the research and development tax credits received thus far and are required to repay all or a portion of the credit, our business and results of operation would be adversely affected.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may be vulnerable to disruption, damage and financial obligation as a result of system failures.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite the implementation of security measures, any of the internal computer systems belonging to us, our collaborators or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our own, in collaborators&#8217; or in third-party service vendors&#8217; operations could result in a material disruption of our drug discovery and development programs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our or our collaborators&#8217; regulatory approval efforts and significantly increase our costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability as a result, our drug discovery programs and competitive position may be adversely affected and the further development of our product candidates may be delayed. Furthermore, we may incur additional costs to remedy the damages caused by these disruptions or security breaches.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our operations, or the third parties upon whom we depend, are vulnerable to interruption by fire, earthquake, power loss, telecommunications failure, terrorist activity, health epidemics or pandemics and other events beyond our control, which could harm our business.</span></div><div style="line-height:118%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our facilities are located in San Diego, California, which is a seismically active region, and has also historically been subject to wildfires and electrical blackouts as a result of a shortage of available electrical power. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major earthquake, fire, power loss, terrorist activity, health epidemics or pandemics such as the recent coronavirus outbreak or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. We maintain multiple copies of each of our antibody sequences and electronic data records, most of which we maintain at our headquarters. If our facility was impacted by a seismic or wildfire event, we could lose some of our antibody sequences, which would have an adverse effect on our ability to perform our obligations under our collaborations and discover new targets.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, integral parties in our supply chain are geographically concentrated and operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe and/or serious adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Dependence on Third Parties</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our existing collaborations, including those with TESARO and Celgene, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into collaborations with TESARO and Celgene to develop several of our product candidates. We have also entered into antibody generation and/or development collaborations with various collaborators, including TESARO and Celgene, under which we have generated therapeutic quality antibodies using our technology platform and conducted certain preclinical studies in collaboration. We are currently aware that TESARO and Celgene have advanced multiple antibodies generated through our collaboration into clinical trials. If our collaborators terminate any of our collaborations, we may not receive all or any of this funding, which would adversely affect our business or financial condition. Our operational obligations under each of our collaborations has ended.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, both TESARO and Celgene recently were acquired by large pharmaceutical companies. GlaxoSmithKline plc completed the acquisition of TESARO on January 22, 2019 and Bristol-Myers Squibb Co. completed the acquisition of Celgene Corp on November 20, 2019. There can be no assurance that these collaborators, following their respective acquisitions by third parties, or such third-party acquirers, will continue to develop and commercialize these product candidates consistent with and with similar timelines as done previous to the acquisitions or that they will comply with the covenants, restrictions, sub-license and other agreement provisions, which, if they don&#8217;t comply, could lead us into disputes and potentially trigger breaches of our agreements with other partners.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are unable to predict the success of our collaborations. Our collaborators have discretion in determining and directing the efforts and resources, including the ability to discontinue all efforts and resources, they apply to the development and, if approval is obtained, commercialization and marketing of the product candidates covered by such collaborations. As a result, our collaborators may elect to de-prioritize our programs, change their strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to us. Our collaborators may have other marketed products and product candidates under collaboration with other companies, including some of our competitors, and their corporate objectives may not be consistent with our best interests. Our collaborators may also be unsuccessful in developing or commercializing our products. If our collaborations are unsuccessful, our business, financial condition, results of operations and prospects could be adversely affected. In addition, any dispute or litigation proceedings we may have with our collaborators in the future could delay development programs, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate substantial expense.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may not succeed in establishing and maintaining additional development and commercialization collaborations, which could adversely affect our ability to develop and commercialize product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our current licensing arrangements with TESARO and Celgene, a part of our strategy is to enter into additional strategic product development and commercialization collaborations in the future, including collaborations to broaden and accelerate clinical development and potential commercialization of our product candidates. We may face significant competition in seeking appropriate development partners, and the negotiation process is time-consuming and complex. Moreover, we may not succeed in our efforts to establish collaborations or other alternative arrangements for any of our other existing or future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and/or third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy or to be commercially viable. Even if we are successful in our efforts to establish new collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering into new collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, if we fail to establish and maintain additional collaborations related to our product candidates:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the development of certain of our current or future product candidates may be terminated or delayed;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our cash expenditures related to development of certain of our current or future product candidates would increase significantly and we may need to seek additional financing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be required to hire additional employees or otherwise develop expertise, such as sales and marketing expertise, for which we have not budgeted; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we will bear all of the risk related to the development and commercialization of any such product candidates.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If third parties on which we depend to conduct our planned preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with adverse effects on our business, financial condition, results of operations and prospects.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on third party clinical investigators, CROs, CMOs, and consultants to design, conduct, supervise and monitor key activities relating to, discovery, manufacturing, non-clinical studies and clinical trials of our product candidates, and we intend to do the same for future activities relating to existing and future programs. Because we rely on third parties and do not have the ability to conduct all required discovery, manufacturing, preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of discovery, manufacturing, preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs, CMOs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties we contract with might not be diligent, careful or timely in conducting our discovery, manufacturing, preclinical studies or clinical trials, resulting in discovery, manufacturing, preclinical studies or clinical trials being delayed or unsuccessful, in whole or in part.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could have an adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We rely completely on third parties to manufacture our nonclinical, clinical and future commercial drug supplies of any approved products.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We outsource the manufacture of our product candidates. We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. If we were to experience an unexpected loss of supply of our product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, our business would be harmed, and we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, we may be required to manufacture additional supplies of our product candidates to the extent our estimates of the amounts required prove inaccurate, we suffer unexpected losses of product candidate supplies, or we are required to have fresh product candidate supplies manufactured to satisfy regulatory requirements or specifications. Any significant delay or discontinuation in the supply of a product candidate, or the raw material components thereof, due to the need to replace a contract manufacturer or other third-party manufacturer, could considerably harm our business and ability to generate revenue and delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any delays in our preclinical or clinical development could lead to delays or cancellations of forecasted manufacturing batches, which would typically result in significant fees owed by us to the manufacture and an uncertainty as to when the manufacturer will have the availability for a new time slot to manufacture the batch, which could lead to further delays in the development of the product candidate and have an adverse effect on our business.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reliance on third-party manufacturers entails additional risks, including the possible breach of the manufacturing agreement by the third party, and the possible termination or nonrenewal of the agreement by the manufacturer at a time that is costly or inconvenient for us. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected product candidates could be significantly delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We depend on a small number of suppliers for the raw materials necessary to produce our product candidates. The loss of these suppliers, or their failure to supply us with these raw materials, would materially and adversely affect our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend on the availability of key raw materials for our product candidates from a small number of third-party suppliers. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">candidates, we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials. We do not have any control over the availability of raw materials. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved products.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any regulatory approvals that we may receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and good clinical practices, or GCPs, for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and foreign regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">restrictions on the products, manufacturers or manufacturing process;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">warning or untitled letters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">civil and criminal penalties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">injunctions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspension or withdrawal of regulatory approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">product seizures, detentions or import bans;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">voluntary or mandatory product recalls and publicity requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">total or partial suspension of production;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">imposition of restrictions on operations, including costly new manufacturing requirements; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refusal to approve pending BLAs or supplements to approved BLAs.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human Services&#8217; Office of Inspector General, state attorneys general, members of Congress and the public. Violations, including promotion of our products for unapproved (or off-label) uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the government. Additionally, comparable foreign regulatory authorities will heavily scrutinize advertising and promotion of any product candidate that obtains approval outside of the United States.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the United States, engaging in the impermissible promotion of our products for off-label uses can also subject us to false claims litigation under federal and state statutes, which can lead to civil and criminal penalties and fines and agreements </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">that materially restrict the manner in which a company promotes or distributes drug products. These false claims statutes include the federal False Claims Act, which allows any individual to bring a lawsuit against a biotechnology company on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government prevails in the lawsuit, the individual will share in any fines or settlement funds. Since 2004, these False Claims Act lawsuits against biotechnology companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements regarding certain sales practices promoting off-label drug uses involving fines in excess of $1.0 billion. This growth in litigation has increased the risk that a biotechnology company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid and other federal and state health care programs. If we do not lawfully promote our approved products, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have an adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects could decline.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We plan to seek Orphan Drug Designation for ANB019 or certain of our other product candidates and we may not be able to obtain or maintain Orphan Drug Designation or obtain the benefits associated with Orphan Drug status, including market exclusivity.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We plan to seek Orphan Drug Designation for ANB019 or certain of our other product candidates. Regulatory authorities in some jurisdictions, including the United States and the European Union, or EU, may designate biologics for relatively small patient populations as Orphan Drugs. Under the Orphan Drug Act, the FDA may designate a biologic as an Orphan Drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. Generally, if a biologic with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the biologic is entitled to a period of marketing exclusivity, which precludes the FDA, in the United States, or the European Medicines Agency, or EMA, in the EU, from approving another marketing application for a drug containing the same active moiety for the same indication for that time period. The applicable period is seven years in the United States and ten years in the EU. The EU exclusivity period can be reduced to six years if a biologic no longer meets the criteria for Orphan Drug Designation or if the biologic is sufficiently profitable so that market exclusivity is no longer justified. Orphan Drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. In addition, the Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. Also, regulatory approval for any product candidate may be withdrawn and other candidates may obtain approval before us.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not been granted Orphan Drug Designation for ANB019 for any indication, and may not be able to obtain designation or any of the potential benefits associated with it. For example, we plan to seek FDA Orphan Drug Designation for ANB019 for the treatment of GPP and PPP, which will likely require that we demonstrate to FDA that GPP and PPP are distinct diseases from psoriasis generally (a non-rare disease) or that use of ANB019 may be appropriate for the treatment of GPP and PPP but not appropriate for use in the general psoriasis population.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we obtain Orphan Drug Designation, we may not receive Orphan Drug exclusivity, and such exclusivity, if obtained, may not effectively protect the candidate from competition because different drugs or biologics can be approved for </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the same condition and only the first biologic with an Orphan Drug Designation to receive regulatory approval for a particular indication will receive marketing exclusivity. Even after a drug or biological with Orphan Drug Designation is approved, the FDA can subsequently approve another biologic containing the same active moiety (which in the case of an antibody is the principal molecular structure) for the same condition if the FDA concludes that the later biologic is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Any drugs we develop may become subject to unfavorable third-party reimbursement practices and pricing regulations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The availability and extent of coverage and adequate reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar health care management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only at limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, because CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly examining the medical necessity and reviewing the cost effectiveness of medical drug products. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific drug products on an approved list, known as a formulary, which might not include all FDA approved drugs for a particular indication. We or our collaborators may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement and the timing of achieving a reimbursement determination will be.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics including our product candidates. In many countries, particularly the countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce health care costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on health </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">care costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the health care market.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to CMS and private payors, professional organizations such as the American Medical Association can influence decisions about reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, some of our target indications, such as GPP, are rare diseases with small patient populations. In order for therapeutics that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such therapeutics must be higher, on a relative basis, to account for the low volume of sales. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate that accounts for the smaller potential market size.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently enacted legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA. In addition, the current administration and Congress have previously sought, and will likely continue to seek, legislative and regulatory changes, including repeal and replacement of all or certain provisions of the ACA. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, the current administration signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, among other things, amends the ACA, effective January 1, 2019, to increase from 50% to 70% the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. Congress may consider other legislation to repeal or replace elements of the ACA.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may face difficulties from changes to current regulations and future legislation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">More recently, President Trump has signed an executive order and made statements that suggest he plans to seek repeal of all or portions of the ACA. There is uncertainty with respect to which legislation, if any, will be enacted and the impact President Trump&#8217;s Administration may have, if any, and any changes likely will take time to unfold, and could have an impact on coverage and reimbursement for health care items and services covered by plans that were authorized by the ACA. However, we cannot predict the ultimate content, timing or effect of any health care reform legislation or the impact of potential legislation on us. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and other health care funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Likewise, the annual Medicare Physician Fee Schedule update, which, until recently, was based on a target-setting formula system called the Sustainable Growth Rate, or SGR, was adjusted to reflect the comparison of actual expenditures to target expenditures. Because one of the factors for calculating the SGR was linked to the growth in the U.S. gross domestic product, or GDP, the SGR formula often resulted in a negative payment update when growth in Medicare beneficiaries&#8217; use of services exceeded GDP growth. Congress repeatedly intervened to delay the implementation of negative SGR payment updates. For example, on April 1, 2014, with the enactment of the Protecting Access to Medicare Act of 2014, Congress prevented the 24 percent cut that was to occur by continuing the previously implemented 0.5 percent payment increase through December 31, 2014 and maintaining a zero percent payment update from January 1, 2015 through March 31, 2015. However, on April 14, 2015, Congress passed the Medicare Access and CHIP Reauthorization Act of 2015, which was signed into law by President Obama on April 16, 2015. This law repeals the SGR methodology from the physician payment formula, institutes a 0% update to the Medicare Physician Fee Schedule for the January 1 to July 1, 2015 period, a 0.5% payment update for July 2015 through the end of 2019, and a 0% payment update for 2020 through 2025, along with a merit-based incentive payment system beginning January 1, 2019, that will replace current incentive programs. For 2026 and subsequent years, the payment update will be either 0.75% or 0.25%, depending on which Alternate Payment Model the physician participates.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that the ACA, as well as other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other health care reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our business entails a significant risk of product liability, and our ability to obtain sufficient insurance coverage could have an adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other health care laws and regulations, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Health care providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state health care laws and regulations include the following:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal health care program such as Medicare and Medicaid;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any health care benefit program or making false statements relating to health care matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report to CMS annually information regarding payments and other transfers of value to physicians and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information was initially made publicly available on a searchable website in September 2014 and is disclosed on an annual basis; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures. For example, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual health care practitioners in these states. Other states prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals. Still other states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain pricing information, including information pertaining to and justifying price increases, or prohibit prescription drug price gouging. And states such as California, Connecticut, Nevada, and Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes. Other states are considering similar proposals. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, the collection and use of health data in the EU is governed by the General Data Protection Regulation (GDPR), which became fully applicable in May 2018. The GDPR extends the geographical scope of EU Data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and new rights for individuals. The GDPR is new and guidance, interpretation and application under the GDPR are still developing. Failure to comply with the GDPR may result in substantial fines and other administrative penalties. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">mechanisms ensuring compliance with the GDPR. The GDPR is new and the pending EU ePrivacy Regulation is expected to establish, new requirements applicable to the handling of personal data and imposes penalties for non-compliance of up to the greater of &#8364;20 million or 4% of worldwide revenue. Additionally, in June 2018, California passed the California Consumer Privacy Act, or CCPA, which provides new data privacy rights for consumers and new operational requirements for companies effective in 2020. The costs of compliance with, and other burdens imposed by, the GDPR, CCPA and other U.S., EU and worldwide laws may impose onerous requirements on our business and, if our efforts to comply with such laws are not successful, our business could be adversely affected.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded health care programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health care programs.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Intellectual Property</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our market.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success depends in significant part on our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; ability to establish, maintain and protect patents and other intellectual property rights and operate without infringing the intellectual property rights of others. We have filed numerous patent applications both in the United States and in foreign jurisdictions to obtain patent rights to inventions we have discovered. We have also licensed from third parties rights to patent portfolios. Some of these licenses give us the right to prepare, file and prosecute patent applications and maintain and enforce patents we have licensed, and other licenses may not give us such rights. The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors, licensees or collaborators. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our current or future licensors, licensees or collaborators fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent rights are highly uncertain. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. In the past, we have not always been able to obtain the full scope of patent protection we have initially sought in our patent applications, and as described above and as is </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">typical for most biotechnology patent prosecution, we have been required to narrow or eliminate patent claims as part of the patent prosecution process. In addition, some patent applications that we or our licensors have filed have not resulted in issued patents because we or our licensors have abandoned those patent applications as changes in business and/or legal strategies dictated.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications on or before March 15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of the patent. However the applicable authorities, including the FDA and the U.S. Patent and Trademark Office, or USPTO, in the United States, and any equivalent foreign regulatory authority, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our or our licensors&#8217; or collaborators&#8217; intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors or collaborators may not be able to prevent third parties from practicing our and our licensors&#8217; or collaborators&#8217; inventions in all countries outside the United States, or from selling or importing products made using our and our licensors&#8217; or collaborators&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our and our licensors&#8217; or collaborators&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors or collaborators have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our and our licensors&#8217; or collaborators&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us and our licensors or collaborators to stop the infringement of our and our licensors&#8217; or collaborators&#8217; </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patents or marketing of competing products in violation of our and our licensors&#8217; or collaborators&#8217; proprietary rights generally. Proceedings to enforce our and our licensors&#8217; or collaborators&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our and our licensors&#8217; or collaborators&#8217; efforts and attention from other aspects of our business, could put our and our licensors&#8217; or collaborators&#8217; patents at risk of being invalidated or interpreted narrowly and our and our licensors&#8217; or collaborators&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors or collaborators. We or our licensors or collaborators may not prevail in any lawsuits that we or our licensors or collaborators initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and inherently uncertain.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our licensors&#8217; or collaborators&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; or collaborators&#8217; issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, future and recent past changes in the patent laws in the U.S. and abroad could impact or could increase the uncertainties and costs surrounding the prosecution of our and our licensors&#8217; or collaborators&#8217; patent applications and the enforcement or defense of our or our collaborators&#8217; issued patents, which could have an impact on our business and financial conditions.  For example, over the past decade, the Supreme Court and the U.S. Court of Appeals for the Federal Circuit have rendered decisions in several patent cases such as Association for Molecular Pathology v. Myriad Genetics, Inc. (Myriad I), BRCA1- &amp; BRCA2-Based Hereditary Cancer Test Patent Litig., (Myriad II), Mayo Collaborative Services v. Prometheus Laboratories, Inc., and Alice Corporation Pty. Ltd. v. CLS Bank International, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&#8217; or collaborators&#8217; ability to obtain patents in the future, these type of changes in the patent laws have created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#8217; or collaborators&#8217; ability to obtain new patents or to enforce existing patents and patents that we and our licensors or collaborators may obtain in the future.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have an adverse effect on our business.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because we collaborate with various collaborators on the development and commercialization of one or more of our product candidates and because we rely on third parties to manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our wholly-owned technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future may be granted rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential or trade secret information from any such publication. Our existing collaborative research and development programs may require us to share trade secrets under the terms of our research and development collaborations or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third parties may infringe our or our licensors&#8217; or collaborators&#8217; patents or misappropriate or otherwise violate our or our licensors&#8217; or collaborators&#8217; intellectual property rights. In the future, we or our licensors or collaborators may initiate legal proceedings to enforce or defend our or our licensors&#8217; or collaborators&#8217; intellectual property rights, to protect our or our licensors&#8217; or collaborators&#8217; trade secrets or to determine the validity or scope of intellectual property rights we own or control. Also, third parties may initiate legal proceedings against us or our licensors or collaborators to challenge the validity or scope of intellectual property rights we own or control. These proceedings can be expensive and time-consuming, and many of our or our licensors&#8217; or collaborators&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaborators. In addition, in an infringement proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#8217; or collaborators&#8217; patents do not cover the technology in question. Furthermore, an adverse result in any litigation or administrative proceeding could put one or more of our or our licensors&#8217; or collaborators&#8217; patents at risk of being invalidated, held unenforceable or interpreted narrowly.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, despite our or our licensors&#8217; or collaborators&#8217; efforts, we or our licensors or collaborators may not prevent third parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the United States. In addition, litigation and administrative proceedings could result in substantial costs and diversion of management resources, which could harm our business and financial results.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings regarding patent and other intellectual property rights in the pharmaceutical industry including opposition, derivation, reexamination, inter partes review or interference proceedings, or other preissuance or post-grant proceedings. Such proceedings may be provoked by third parties or by us or our licensors or collaborators to protect or enforce our or our licensors&#8217; or collaborators&#8217; patents or patent applications. Additionally, third-party preissuance submission of prior art to the USPTO or other foreign jurisdictions may jeopardize the issuance or scope of our or our licensors&#8217; or collaborators&#8217; patent applications. An unfavorable outcome in any such proceedings could require us or our licensors or collaborators to cease using the related technology, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors or collaborators a license on commercially reasonable terms or at all, and we could be forced to stop commercializing our product candidates. Even if we or our licensors or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors or collaborators.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, if the breadth or strength of protection provided by our or our licensors&#8217; or collaborators&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Even if we successfully defend such litigation or proceeding, we may incur substantial costs, and it may distract our management and other employees. We could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of shares of our common stock.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If we breach the license agreements related to our product candidates, we could lose the ability to continue the development and commercialization of our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial success depends upon our ability, and the ability of our licensors and collaborators, to develop, manufacture, market and sell our product candidates and use our and our licensors&#8217; or collaborators&#8217; wholly-owned technologies without infringing the proprietary rights of third parties. A third party may hold intellectual property, including patent rights that are important or necessary to the development of our products. As a result, we are a party to a number of technology licenses that are important to our business and expect to enter into additional licenses in the future. For example, we have in-licensed the rights to certain intellectual property relating to SHM under our in-license agreement with the Medical Research Council, which is the subject of issued patents and pending patent applications in certain countries. If we fail to comply with the obligations under these agreements, including payment and diligence terms, our licensors may have the right to terminate these agreements, in which event we may not be able to develop, manufacture, market or sell any product that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all, or cause us to lose our rights under these agreements, including our rights to intellectual property or technology important to our development programs.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the priority of invention of patented technology.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights, or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on the success of our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third parties may initiate legal proceedings against us or our licensors or collaborators alleging that we or our licensors or collaborators infringe their intellectual property rights, or we or our licensors or collaborators may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, including in oppositions, interferences, reexaminations, post-grant reviews, inter partes reviews or derivation proceedings in the United States or other jurisdictions. These proceedings can be expensive and time-consuming, and many of our or our licensors&#8217; or collaborators&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaborators.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. An unfavorable outcome could require us or our licensors or collaborators to cease using the related technology or developing or commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors or collaborators a license on commercially reasonable terms or at all. Even if we or our licensors or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors or collaborators. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our inability to protect our confidential information and trade secrets would harm our business and competitive position.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be harmed.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened, and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Ownership of Our Common Stock</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The market price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading price of our common stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of competitive products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory actions with respect to our products or our competitors&#8217; products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">actual or anticipated changes in our growth rate relative to our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">results of preclinical studies and clinical trials of our product candidates or those of our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory or legal developments in the United States and other countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the recruitment or departure of key personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the level of expenses related to any of our product candidates or clinical development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments with respect to our existing collaboration agreements and announcements of new collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disputes, breaches and terminations of our manufacturing agreements, collaborations agreements or other important agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the results of our efforts to in-license or acquire additional product candidates or products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcement or expectation of additional financing efforts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sales of our common stock by us, our insiders or our other stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in the structure of health care payment systems;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">market conditions in the biotechnology sector; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">general economic, industry and market conditions.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the stock market in general, and the Nasdaq Global Select Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We have broad discretion in the use of the net proceeds from our public offerings and may not use them effectively.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management has broad discretion in the application of the net proceeds from our public offerings, and you will be relying on the judgment of our management regarding the application of these proceeds. Our management might not apply the net proceeds from our public offerings in ways that ultimately increase the value of your investment. If we do not invest or apply the net proceeds from our public offerings in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The market price of our common stock is volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been, and may in the future be, the target of this type of litigation. For example, a purported securities class action is pending in the United States District Court for the Southern District of California against us and certain of our officers and directors. The suit purports to allege claims for allegedly misleading statements regarding our business and financial results. Regardless of the outcome, these matters or future litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We incur increased costs and devote substantial management time as a result of operating as a public company.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses have increased and will continue to increase. We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and the Nasdaq Global Select Market. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations substantially increase our legal and financial compliance costs and make some activities more time-consuming and costly. The increased costs increase our net loss. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these and future requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal controls on an annual basis. If we have material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We have only recently compiled the systems, processes and documentation necessary to comply with Section&#160;404 of the Sarbanes-Oxley Act. We will need to maintain and enhance these processes and controls as we grow, and we may require additional management and staff resources to do so. Additionally, even if we conclude our internal controls are effective for a given period, we may in the future identify one or more material weaknesses in our internal controls, in which case our management will be unable to conclude that our internal control over financial reporting is effective. Irrespective of compliance with Section&#160;404, any failure of our internal control over financial reporting could have a material adverse effect on our reported operating results and harm our reputation. Internal control deficiencies could also result in a restatement of our financial results.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. We also have registered all shares of common stock that we may issue under our equity incentive plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Provisions in our restated certificate of incorporation and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our restated certificate of incorporation and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish a classified board of directors so that not all members of our board are elected at one time;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">permit only the board of directors to establish the number of directors and fill vacancies on the board;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">prohibit cumulative voting; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:49px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, Section 203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trial results or operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We plan to use potential future operating losses and our federal and state net operating loss, or NOL, carryforwards to offset taxable income from revenue generated from operations or corporate collaborations. However, our ability to use NOL carryforwards could be limited as a result of additional issuances of equity securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We plan to use our current year operating losses to offset taxable income from any revenue generated from operations or corporate collaborations. To the extent we have taxable income, we plan to use our NOL carryforwards to offset income that would otherwise be taxable. However, under the Tax Reform Act of 1986, the benefits from the use of our NOL carryforwards may be impaired or limited under Section 382 of the Internal Revenue Code of 1984, as amended, or the Code, if we incur a cumulative ownership change of more than 50%, as interpreted by the U.S. Internal Revenue Service, over a three-year period. In September 2015, we completed a Section 382 and 383 ownership change analysis through December 31, 2014 and determined that there was an ownership change in 2007 that may limit the utilization of approximately $5.3 million and $5.4 million in federal and state NOLs, respectively, and $0.2 million in both federal and state research tax credits. We extended the analysis period of the study through December 31, 2018, noting an additional ownership change during fiscal 2017 that may limit the utilization of federal and state NOLs. Our use of federal NOL carryforwards could be limited further by the provisions of Section 382 of the Code depending upon the timing and amount of additional equity securities that we have issued or will issue. State NOL carryforwards may be similarly limited. Any such disallowances may result in greater tax liabilities than we would incur in the absence of such a limitation, and any increased liabilities could adversely affect our business, results of operations, financial condition and cash flow.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The legislation significantly changes U.S. tax law by, among other things, lowering the corporate income tax rates. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. Additionally, the Tax Reform Act will no longer allow deductions for compensation in excess of $1 million for certain employees, even if paid as commissions or performance-based compensation. We may be subject to these limitations as provided for under Section 162(m) of the Internal Revenue Code in the future. The Tax Reform Act also limits the amount taxpayers are able to deduct for federal NOL carryforwards generated in taxable years beginning after December 31, 2017 to 80% of the taxpayer&#8217;s taxable income. The law also generally repeals all carrybacks. However, any NOLs generated in taxable years after December 31, 2017 can be carried forward indefinitely. Losses arising in taxable years beginning before December 31, 2017 may still be carried back two years and are subject to their current expiration period. As of December 31, 2019, we have federal NOLs of approximately $239.4 million, which expire beginning December 31, 2028 through December 31, 2037, if not used to reduce income taxes payable in the future. The federal net operating loss carryover includes $95.5 million of net operating losses generated in 2019. Federal net operating losses generated in 2019 carryover indefinitely and may generally be used to offset up to 80% of future taxable income in the year it is utilized. </span></div><div><a id="s8D603E57A0C35281B273EBD87AF89D32"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><a id="sEC5C5315CCE05DFCAE6533E7D2454FEA"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><a id="s75C04C59E53F527FA59B61AB7A808E59"></a></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4. MINE SAFETY DISCLOSURES </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable. </span></div><div><a id="s6185009038D45FA68B13E4F85D4AD86A"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;5. OTHER INFORMATION </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 4, 2020, we entered into a lease agreement, or Lease Agreement, with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121.&#160;Under the Lease Agreement, we agreed to lease approximately 45,000 square feet of space in the 10770 Wateridge Circle Building for a term of 124 months, beginning on March 1, 2021 (or on such later date as described in the Lease Agreement). The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional five years, as well as a one-time option we have to terminate the lease after seven years with the payment of a termination fee. The monthly base rent will be $4.20 per rentable square foot, and will be increased by 3% annually. We are also responsible for real estate taxes, building insurance, maintenance and our pro rata share of direct expenses and utilities under the Lease Agreement.</span></div><div><a id="s8511B959395A5CE8A29B1A7F8952F8AD"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;6. EXHIBITS </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, below. </span></div><div><a id="s1BF7766EA9B75349BC15B4A34025BA9F"></a></div><div style="line-height:120%;padding-top:24px;text-align:center;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exhibit <br/>Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exhibit Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed Herewith</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="anab-33120x10qxexx311.htm"><span style="font-family:inherit;font-size:9pt;">Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">31.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="anab-33120x10qxexx312.htm"><span style="font-family:inherit;font-size:9pt;">Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32.1*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="anab-33120x10qxexx321.htm"><span style="font-family:inherit;font-size:9pt;">Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32.2*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="anab-33120x10qxexx322.htm"><span style="font-family:inherit;font-size:9pt;">Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="wateridgelease.htm"><span style="font-family:inherit;font-size:9pt;">Wateridge Lease Agreement.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">X</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Report Instance Document - The Instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Taxonomy Calculation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Taxonomy Label Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Presentation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cover Page Interactive Data File -  (formatted in Inline XBRL and contained in Exhibit 101)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9C94CDA976F157B5BC378D9F11725758"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:6%;"></td><td style="width:37%;"></td><td style="width:4%;"></td><td style="width:53%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ANAPTYSBIO, INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 6, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Hamza Suria</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hamza Suria</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Executive Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 6, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Eric Loumeau</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eric Loumeau</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interim Chief Financial Officer and General Counsel</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>2
<FILENAME>wateridgelease.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8907DA70C66DB9452E86D1CD6E2C5C31"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LEASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BETWEEN</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WATERIDGE PROPERTY OWNER, LP,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a Delaware limited partnership</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(LANDLORD)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">AND</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ANAPTYSBIO, INC., </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a Delaware corporation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(TENANT)</font></div><div style="line-height:120%;padding-bottom:64px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">May 4, 2020</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10770 WATERIDGE CIRCLE <br>SAN DIEGO, CALIFORNIA</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="safe6bc995d254b4abc9d500d5618ad5f"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:74%;"></td><td style="width:13%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TERMS AND DEFINITIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Address</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Address</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Premises</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initial Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Vehicle Parking Spaces</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Improvement Allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Early Occupancy Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commencement Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Percentage</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Security Deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Broker(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permitted Use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building Area</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PREMISES AND COMMON AREAS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Premises</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rentable Area</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Areas</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Reservation of Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TERM</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initial Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DELIVERY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RENT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Late Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional Late Payment Remedies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RENT ADJUSTMENT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definitions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Calculation Methods and Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of Tenant&#8217;s Percentage of Operating Expenses and Real Property Taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Review of Annual Reconciliation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECURITY DEPOSIT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Security Deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Letter of Credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">USE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:74%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laws/CC&amp;&amp;R&#8217;s</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hazardous Materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Odors and Exhaust</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MOLD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOTICES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Method of Delivery</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receipt of Notices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statutory Service of Notice</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BROKERS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HOLDING OVER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TAXES ON TENANT&#8217;S PROPERTY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Personal Property and Fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional Taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CONDITION OF PREMISES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ALTERATIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alterations and Major Alterations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Removal of Alterations and Tenant&#8217;s Personal Property</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">REPAIRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord Obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIENS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ENTRY BY LANDLORD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UTILITIES AND SERVICES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Premises Utilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janitorial Service</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord Exculpation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limitations on Tenant&#8217;s Utilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Area Water</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Energy Tracking</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reservation of Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Abatement of Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INDEMNIFICATION AND EXCULPATION OF LANDLORD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DAMAGE TO TENANT&#8217;S PROPERTY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INSURANCE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Insurance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Standard of Insurance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord Insurance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subrogation Waivers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DAMAGE OR DESTRUCTION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Damages</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination of Lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent Abatement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:74%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Damage Near End of Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Waiver of Statute</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMINENT DOMAIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent Taking</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Temporary Taking</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Waiver of Statute</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DEFAULTS AND REMEDIES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Default</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord Remedies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional Remedies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of Default</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Right to Cure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Waiver of Redemption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Default</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NO WAIVER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASSIGNMENT AND SUBLETTING</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer Procedure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Consent; Consent Standards; No Release</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Costs; Transfer Premiums</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rights Not Transferable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permitted Transfers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SUBORDINATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESTOPPEL CERTIFICATE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Estoppel Certificate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Failure to Deliver</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INTENTIONALLY OMITTED</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SURRENDER OF PREMISES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PERFORMANCE BY TENANT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PARKING</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIMITATION ON LIABILITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CONFIDENTIALITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MISCELLANEOUS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rules and Regulations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conflict of Laws</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Successors and Assigns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mortgagee Protection</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definition of Landlord</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification of Tenant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Force Majeure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Terms and Headings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:74%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Examination of Lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Time</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior Agreement; Amendments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Severability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recording</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification for Lenders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quiet Enjoyment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant as Corporation, Partnership or Limited Liability Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CASp Disclosure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SIGNAGE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXECUTIVE ORDER 13224</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WAIVER OF JURY TRIAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT REPRESENTATIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARTICLE 41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ADDITIONAL PROVISIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Environmental Assessments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Early Access</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right of First Refusal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination Option</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA46BCD49066E2491B1E7D1CD6E922A7A"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIST OF EXHIBITS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.57264957264957%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:10%;"></td><td style="width:3%;"></td><td style="width:56%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION REFERENCE</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-I</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outline of Premises</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A-II</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Project Site Plan</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work Letter Agreement</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sch. B-1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Space Plan</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit B</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Memorandum of Lease Terms</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">D</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Letter of Credit Terms</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">E</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Tenant Estoppel Certificate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rules and Regulations</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">G</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Parking Rules and Regulations</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">H</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserved</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">--</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sABFC937F5BF72BCAC4C5D1CD6EA84F04"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THIS LEASE AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Lease</font><font style="font-family:inherit;font-size:10pt;">&#8221;) is made as of May 4, 2020 (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), by and between WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Landlord</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and ANAPTYSBIO, INC., a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant</font><font style="font-family:inherit;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARTICLE 1 <br></font><font style="font-family:inherit;font-size:10pt;">&#32;TERMS AND DEFINITIONS&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the purposes of this Lease, the following terms shall have the following definitions and meanings:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord</font><font style="font-family:inherit;font-size:10pt;">: Wateridge Property Owner, LP, a Delaware limited partnership</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord&#8217;s Address</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wateridge Property Owner, LP <br>c/o Bioscience Properties, Inc.  <br>514 Via De La Valle, Suite 300A  <br>Solana Beach, CA 92075</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attention: Steve Bollert</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant</font><font style="font-family:inherit;font-size:10pt;">:  AnaptysBio, Inc., a Delaware corporation</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant&#8217;s Address</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Prior to the Commencement Date</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. <br>10421 Pacific Center Court, Suite 200 <br>San Diego, CA 92121 <br>Attn: Eric Loumeau</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">As of the Commencement Date</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. <br>10770 Wateridge Circle, Suite 210 <br>San Diego, CA 92121 <br>Attn: Eric Loumeau </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Building</font><font style="font-family:inherit;font-size:10pt;">:  That certain</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">two (2)-story building located at 10770 Wateridge Circle, San Diego, California 92121.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Premises</font><font style="font-family:inherit;font-size:10pt;">:  Approximately 45,057 rentable square feet of area (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Rentable Square Feet</font><font style="font-family:inherit;font-size:10pt;">&#8221;), subject to adjustment in accordance with </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2.2</font><font style="font-family:inherit;font-size:10pt;">&#32;below, in Suite number 210 in the Building.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Initial Term</font><font style="font-family:inherit;font-size:10pt;">:  One hundred twenty-four (124) months.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant&#8217;s Vehicle Parking Spaces</font><font style="font-family:inherit;font-size:10pt;">:  One hundred thirty-six (136) parking spaces (consisting of three (3) parking spaces which shall be reserved for Tenant&#8217;s visitors and one hundred thirty-three (133) unreserved parking spaces) within the</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Parking Area (defined in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 33</font><font style="font-family:inherit;font-size:10pt;">&#32;below) at no additional charge during the Initial Term, subject to the terms and conditions of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 33</font><font style="font-family:inherit;font-size:10pt;">&#32;below.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant Improvement Allowance</font><font style="font-family:inherit;font-size:10pt;">:  (i) Up to One Hundred Ninety Dollars ($190.00) per Rentable Square Foot of the Premises (i.e., up to $8,560,830.00) (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Initial Allowance</font><font style="font-family:inherit;font-size:10pt;">&#8221;), plus (ii) at Tenant&#8217;s election and subject to repayment as provided herein, an additional amount of up to a maximum of Fifteen Dollars ($15.00) per Rentable Square Foot of the Premises (i.e., up to $675,855.00) (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Additional Allowance</font><font style="font-family:inherit;font-size:10pt;">&#8221;), plus (iii) all or a portion of the Abated Rent Amount (as defined below) which Tenant timely elects to apply to the Tenant Improvements (in lieu of abated rent) (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Abated Rent Allowance</font><font style="font-family:inherit;font-size:10pt;">&#8221;), to be contributed by Landlord toward the cost of constructing the Tenant Improvements </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pursuant to the Work Letter Agreement described in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2.1</font><font style="font-family:inherit;font-size:10pt;">&#32;below.  The Initial Allowance and, if applicable, the Additional Allowance and the Abated Rent Allowance, shall be collectively referred to herein as the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant Improvement Allowance</font><font style="font-family:inherit;font-size:10pt;">.&#8221;  If Tenant elects to use the Additional Allowance or a portion thereof, (a) such amount shall be amortized over the Initial Term on a straight line basis at an annual percentage rate of eight percent (8%) and payable by Tenant as a component of Basic Rent, and (b) as a condition to Landlord providing any portion of the Additional Allowance, Tenant shall be obligated to apply and convert an equal amount of the Abated Rent Allowance on a per rentable square foot basis, pari passu (e.g., if Tenant elects to use $5.00 per Rentable Square Foot of the Additional Allowance, Tenant must also elect to apply a portion of the Abated Rent Amount equal to $5.00 per Rentable Square Foot toward the cost of the Tenant Improvements), and the amount of Basic Rent to be abated pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 5.1</font><font style="font-family:inherit;font-size:10pt;">&#32;below shall be reduced accordingly.  Tenant shall notify Landlord of its election to use the Additional Allowance and a corresponding portion of the Abated Rent Allowance prior to commencement of construction of the Tenant Improvements.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Early Occupancy Date</font><font style="font-family:inherit;font-size:10pt;">:  The earlier to occur of (i) the date upon which Tenant first commences the conduct of business in the Premises for the Permitted Use, and (ii) the later to occur of (x) the date on which the Tenant Improvements are Substantially Complete pursuant to the terms and conditions of, and as that term is defined in, the Work Letter Agreement, and (y) March 1, 2021 (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Estimated Completion Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  Beginning on the Early Occupancy Date, Tenant shall have the right to occupy and use the Premises on all of the same terms and conditions of this Lease except as expressly provided herein.  The period between the Early Occupancy Date and the Commencement Date (as defined below) shall be referred to herein as the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Early Occupancy Period</font><font style="font-family:inherit;font-size:10pt;">&#8221;.  During the Early Occupancy Period, Tenant shall have no obligation to pay Basic Rent.  All other terms and provisions of this Lease (including, without limitation, the obligation to pay separately metered utilities and all Additional Rent) shall apply to the Premises both during the Early Occupancy Period and thereafter.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commencement Date</font><font style="font-family:inherit;font-size:10pt;">:  The date which is two (2) weeks following the Early Occupancy Date.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic Rent</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:16%;"></td><td style="width:28%;"></td><td style="width:28%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Months of Initial Term</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic Rent per Rentable Square Foot ($/mo)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Monthly Installments of Basic Rent ($/mo)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Annual  <br>Basic Rent ($/yr)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-12*</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.20</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$189,239.40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,270,872.80</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13-24</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.33</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$194,916.58</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,338,998.96</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25-36</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.46</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$200,764.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,409,168.96</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37-48</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.59</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$206,787.00</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,481,444.00</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49-60</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.73</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$212,990.61</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,555,887.32</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61-72</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.87</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$219,380.33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,632,563.96</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73-84</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$5.02</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$225,961.74</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,711,540.88</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85-96</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$5.17</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$232,740.59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,792,887.08</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97-108</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$5.32</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$239,722.81</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,876,673.72</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109-120</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$5.48</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$246,914.49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2,962,973.88</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121-124</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$5.64</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$254,321.92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$3,051,863.04</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*Provided that Tenant is not in default under this Lease beyond any applicable notice and cure period, monthly installments of Basic Rent shall be abated for months two (2) through seven (7) of the Initial Term, for a total &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Abated Rent Amount</font><font style="font-family:inherit;font-size:10pt;">&#8221; of $1,135,436.40, pursuant to the terms and conditions of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 5.1</font><font style="font-family:inherit;font-size:10pt;">&#32;below.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant&#8217;s Percentage</font><font style="font-family:inherit;font-size:10pt;">:  24.55%.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Security Deposit</font><font style="font-family:inherit;font-size:10pt;">: $254,321.92; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Letter of Credit Amount</font><font style="font-family:inherit;font-size:10pt;">:  $2,000,000.00. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Broker(s</font><font style="font-family:inherit;font-size:10pt;">):  Avison Young (Brian Cooper), representing Tenant, and Jones Lang LaSalle (Chad Urie, Tim Olson and Grant Schoneman), representing Landlord.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Permitted Use</font><font style="font-family:inherit;font-size:10pt;">:  Office, laboratory and research and development and all uses ancillary thereto, and no other use, subject to compliance with all applicable Laws (defined below).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Building Area</font><font style="font-family:inherit;font-size:10pt;">:  183,565 Rentable Square Feet.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> PREMISES AND COMMON AREAS&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Premises</font><font style="font-family:inherit;font-size:10pt;">.  Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Premises outlined on the Floor Plan attached hereto, marked </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit&#160;&#8220;A-I&#8221;</font><font style="font-family:inherit;font-size:10pt;">, and incorporated herein by this reference (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Outline of Premises</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The Premises are located in the Building, which, together with the Parking Area, is located on the parcel or parcels of real property (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Project Site</font><font style="font-family:inherit;font-size:10pt;">&#8221;) outlined on the Project Site Plan attached hereto, marked as </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit&#160;&#8220;A-II&#8221;</font><font style="font-family:inherit;font-size:10pt;">, and incorporated herein by this reference (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Project Site Plan</font><font style="font-family:inherit;font-size:10pt;">&#8221;) (all of which, together with the Building Common Areas and the Project Common Areas, as hereinafter defined, are collectively referred to as the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Project</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The Premises are leased in their &#8220;AS-IS&#8221; condition in accordance with </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 14</font><font style="font-family:inherit;font-size:10pt;">; provided however, the Premises will be improved by Landlord with the Tenant Improvements described in the Work Letter Agreement, a copy of which is attached hereto, marked as </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit&#160;&#8220;B&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;and incorporated herein by this reference (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Work Letter Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The Premises are agreed, for the purposes of this Lease, to have approximately the number of Rentable Square Feet designated in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.6</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment as described in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2.2</font><font style="font-family:inherit;font-size:10pt;">&#32;below.  The parties hereto agree that this Lease is upon and subject to the terms, covenants and conditions herein set forth.  Each of Landlord and Tenant covenants as a material part of the consideration for this Lease to keep and perform each and all of said terms, covenants and conditions by it to be kept and performed.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rentable Area</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Landlord and Tenant stipulate and agree that: (a) subject to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2.2.2</font><font style="font-family:inherit;font-size:10pt;">&#32;below, the Rentable Square Feet contained in the Building is as specified in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.17</font><font style="font-family:inherit;font-size:10pt;">, and (b) the Rentable Square Feet of the Building shall include all of, and the Rentable Square Feet of the Premises shall include a portion of (such portion to be equitably determined by Landlord) the total square feet contained in any common areas (e.g., lobbies, mail room, fire control room, etc.) of the Building.  The initial Monthly Basic Rent and Tenant&#8217;s Percentage specified in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.13</font><font style="font-family:inherit;font-size:10pt;">&#32;of this Lease are based upon the approximate Rentable Square Feet of the Premises set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.6</font><font style="font-family:inherit;font-size:10pt;">&#32;and the Rentable Square Feet of the Building set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.17</font><font style="font-family:inherit;font-size:10pt;">.  The Memorandum of Lease Terms (as defined in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 3</font><font style="font-family:inherit;font-size:10pt;">) shall indicate, among other things, the actual Rentable Square Feet of the Premises, as set forth in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2.2.1</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2.2.&#160;&#160;&#160;&#160;Landlord reserves the right (a) to modify the standards utilized hereunder for the measurement of Rentable Square Feet (so long as any such modification is reasonably consistent with then prevailing Institutional Owner Practices (defined below)) and (b) consistent with any such modifications of measurement standards, to adjust the Rentable Square Feet of the Premises and the Building and/or portions thereof and any economic terms set forth herein (such as Tenant&#8217;s Percentage) calculated on the basis thereof; provided that Landlord shall have no right to adjust the Basic Rent then in effect as a result of any such modification.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Areas</font><font style="font-family:inherit;font-size:10pt;">.  Tenant and its employees, invitees and agents shall have the nonexclusive right to use in common with Landlord and other tenants or occupants of the Project and their respective employees, invitees and agents, subject to the Rules and Regulations referred to in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 36.1</font><font style="font-family:inherit;font-size:10pt;">&#32;below and all covenants, conditions and restrictions affecting the Project, any of the following areas which may be appurtenant to the Premises (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Common Areas</font><font style="font-family:inherit;font-size:10pt;">&#8221;):</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">2.3.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;any common entrances, lobbies, shared entry lobbies and corridors, shared restrooms, service areas, elevators, stairways, accessways and/or ramps which may be located in the Building, and any common pipes, wires and appurtenant equipment which may be serving the Premises (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Building Common Areas</font><font style="font-family:inherit;font-size:10pt;">&#8221;); and</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">2.3.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the Parking Area and any loading and unloading areas, trash areas, service areas, parking areas, roadways, sidewalks, walkways, plazas, parkways, driveways, landscaped areas and similar areas and facilities from time to time situated within the Project (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Project Common Areas</font><font style="font-family:inherit;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord&#8217;s Reservation of Rights</font><font style="font-family:inherit;font-size:10pt;">.  Landlord reserves for itself, and for the owner(s) and operator(s) of the Project or any portion thereof, the right from time to time without material interference with Tenant&#8217;s Permitted Use or access to the Premises:</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">2.4.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;to install, use, maintain, repair and replace pipes, ducts, conduits, wires and appurtenant meters and equipment for service to other parts of the Building above the ceiling surfaces, below the floor surfaces, within the walls and in the central core areas of the Premises, and to relocate any pipes, ducts, conduits, wires and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">appurtenant meters and equipment which are located in the Premises or elsewhere, and to expand the Building and/or the Parking Area (after which expansion there shall be an appropriate adjustment made to Tenant&#8217;s Percentage); provided in no event shall such reservation of rights reduce the Rentable Square Feet of the Premises;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">2.4.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;to make changes in its sole and absolute discretion to the Common Areas, including, without limitation, changes in the location, size, shape and number of driveways, entrances, parking spaces, parking areas, loading and unloading areas, ingress, egress, direction of traffic, landscaped areas and walkways;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">2.4.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;to close temporarily any of the Common Areas for maintenance purposes and to avoid claims of prescriptive rights so long as reasonable access to the Premises remains available;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">2.4.4</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;to designate other land outside the boundaries of the Building or the Project to be a part of the Project Common Areas;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">2.4.5</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;to add additional buildings and improvements to the Project Common Areas;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">2.4.6</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;to use the Common Areas while engaged in making additional improvements, repairs or alterations to the Building, the Parking Area or the Project, or any portion thereof; and</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">2.4.7</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;to do and perform such other acts and make such other changes in, to or with respect to the Project or any portion thereof as Landlord and/or the owner(s) and/or operator(s) thereof may deem to be appropriate.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> TERM&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Initial Term</font><font style="font-family:inherit;font-size:10pt;">.  The &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Initial Term</font><font style="font-family:inherit;font-size:10pt;">&#8221; of this Lease shall be for the period designated in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.7</font><font style="font-family:inherit;font-size:10pt;">, commencing on the Commencement Date and ending on the last day of the month in which the expiration of such period occurs, unless sooner terminated as hereinafter provided; provided that if the Commencement Date occurs on a day other than the first day of any calendar month, for purposes of calculating the date (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expiration Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;) on which the Term is scheduled to expire and the timing of all scheduled increases in Basic Rent during the Term, the Commencement Date shall be deemed to be the first day of the calendar month following the Commencement Date.  The Commencement Date, the date upon which the Initial Term of this Lease shall end unless sooner terminated pursuant to the provisions hereof, the Rentable Square Feet in the Premises and Tenant&#8217;s Percentage as determined pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section&#160;2.2</font><font style="font-family:inherit;font-size:10pt;">&#32;above shall be specified in a Memorandum of Lease Terms, which shall be in the form of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit&#160;&#8220;C&#8221;</font><font style="font-family:inherit;font-size:10pt;">, attached hereto and incorporated herein by this reference (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Memorandum of Lease Terms</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and shall be executed by Tenant as soon as practicable after the Commencement Date.  As used herein, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall refer to the Initial Term as it may be extended by written agreement of Landlord and Tenant, including, without limitation, as a result of Tenant&#8217;s exercise of the Option in accordance with </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 3.2</font><font style="font-family:inherit;font-size:10pt;">&#32;below.   </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Option Term</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall have the right and option (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to extend the Term of this Lease for one (1) additional period of five (5) years (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Option Term</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The Option Term shall commence on the day immediately succeeding the expiration date of the Initial Term and shall end on the day immediately preceding the fifth (5</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">) anniversary of the first day of such Option Term.  Notwithstanding any provision of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 3.2</font><font style="font-family:inherit;font-size:10pt;">&#32;to the contrary, the Option shall be personal to the original Tenant under this Lease (i.e., AnaptysBio, Inc.) (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Original Tenant</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and to any Permitted Transferee.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">3.2.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant shall exercise the Option by giving written notice to Landlord of its election to do so not earlier than fifteen (15) months and not later than twelve (12) months prior to the expiration of the Initial Term.  The giving of such notice of extension by Tenant shall automatically extend the Term of this Lease for such Option Term, and no instrument of renewal or extension need be executed.  In the event that Tenant fails to give timely notice to Landlord, this Lease shall automatically terminate at the end of the Initial Term and Tenant shall have no further option to extend the Term of this Lease.  The Option shall be exercisable by Tenant only on the express condition that (i) at the time of the exercise, and at all times prior to the commencement of the Option Term, Tenant shall not be in Default under any of the provisions of this Lease, and (ii) Tenant shall not have been ten (10) or more days late in the payment of Monthly Basic Rent more than once during any twelve (12) consecutive month period during the Term.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">3.2.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The Option Term shall be on all the terms and conditions of this Lease, except that: (i) Tenant shall have no further right or option to extend the Term as provided by this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 3.2</font><font style="font-family:inherit;font-size:10pt;">&#32;and (ii) the Basic Rent for the Option Term shall be equal to the Fair Market Rental Value of the Premises for such Option Term, determined pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Subsection 3.2.3</font><font style="font-family:inherit;font-size:10pt;">&#32;below.  If Tenant subleases any portion of the Premises or assigns or otherwise transfers any interest under this Lease to anyone other than a Permitted Transferee, the Option shall lapse.  If Tenant subleases any portion of the Premises or assigns or otherwise transfers any interest of Tenant under this Lease to any person or entity other than a Permitted Transferee after the exercise of the Option but prior to the commencement of the Option Term (whether with or without Landlord&#8217;s consent), the Option shall lapse and the Term of this Lease shall expire as if the Option was not exercised.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">3.2.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;For the purposes hereof, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Fair Market Rental Value</font><font style="font-family:inherit;font-size:10pt;">&#8221; of the Premises shall mean the prevailing annual market rental value (which rental value determination may include increases in Rent during the Option Term) for Class &#8220;A&#8221; office and laboratory/research and development space of comparable size, quality and location in comparable first-class office and laboratory/research and development buildings located in the Sorrento Mesa submarket of San Diego, California, as of the date of commencement of the Option Term (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Comparable Transactions</font><font style="font-family:inherit;font-size:10pt;">&#8221;), taking into consideration the amenities offered in or near the Project and the amount, availability and cost of parking; provided, however, that in calculating the Fair Market Rental Value, no consideration shall be given to (1) the fact that Landlord is or is not required to pay a real estate brokerage commission in connection with Tenant&#8217;s exercise of its right to lease the Premises during the Option Term or the fact that landlords are or are not paying real estate brokerage commissions in connection with such comparable space, and (2) any period of rental abatement, if any, granted to tenants in comparable transactions in connection with the design, permitting and construction of tenant improvements in such comparable spaces.  The Fair Market Rental Value shall additionally include a determination as to whether, and if so to what extent, Tenant must provide Landlord with financial security, such as a letter of credit or security deposit, for Tenant&#8217;s Rent obligations in connection with Tenant&#8217;s lease of the Premises during the Option Term.  Such determination shall be made by reviewing the extent of financial security then generally being imposed in Comparable Transactions from tenants of comparable financial condition and credit history to the then existing financial condition and credit history of Tenant (with appropriate adjustments to account for differences in the then-existing financial condition of Tenant and such other tenants).  </font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">3.2.4</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Promptly after receiving Tenant&#8217;s notice of its election to exercise the Option to extend the Term of this Lease, Landlord shall provide Tenant with Landlord&#8217;s good faith estimate of the Fair Market Rental Value of the Premises for the Option Term (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Fair Market Rental Value Notice</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  In the event that Tenant objects to Landlord&#8217;s determination of the Fair Market Rental Value within ten (10) business days following Tenant&#8217;s receipt of Landlord&#8217;s Fair Market Rental Value Notice, Landlord and Tenant shall attempt to agree upon the Fair Market Rental Value using their best good faith efforts.  If Landlord and Tenant fail to reach agreement within ten (10) business days following Tenant&#8217;s objection to the Fair Market Rental Value (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Outside Agreement Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), then each party shall make a separate determination of the Fair Market Rental Value within five (5) business days after the Outside Agreement Date, and such determinations shall be submitted to arbitration in accordance with </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Subsection 3.2.4(A)</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Subsection 3.2.4(G)</font><font style="font-family:inherit;font-size:10pt;">&#32;below.</font></div><div style="line-height:120%;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">A)&#160;&#160;&#160;&#160;Landlord and Tenant shall each appoint one arbitrator who shall be a real estate broker or attorney who shall have been active over the five (5) year period ending on the date of such appointment in the leasing of office and laboratory/research and development properties in the Sorrento Mesa submarket of San Diego, California.  The determination of the arbitrators shall be limited solely to the issue of whether Landlord&#8217;s or Tenant&#8217;s submitted Fair Market Rental Value is the closest to the actual Fair Market Rental Value, as determined by the arbitrators, taking into account the requirements of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Subsection 3.2.3</font><font style="font-family:inherit;font-size:10pt;">.  Each such arbitrator shall be appointed within fifteen (15) days after the applicable Outside Agreement Date.</font></div><div style="line-height:120%;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">B)&#160;&#160;&#160;&#160;The two (2) arbitrators so appointed shall within ten (10) days of the date of the appointment of the last appointed arbitrator agree upon and appoint a third arbitrator who shall be qualified under the same criteria set forth hereinabove for qualification of the initial two (2) arbitrators.</font></div><div style="line-height:120%;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">C)&#160;&#160;&#160;&#160;The three (3) arbitrators shall within thirty (30) days of the appointment of the third arbitrator reach a decision as to whether the parties shall use Landlord&#8217;s or Tenant&#8217;s submitted Fair Market Rental Value and shall notify Landlord and Tenant thereof.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">D)&#160;&#160;&#160;&#160;The decision of the majority of the three (3) arbitrators shall be binding upon Landlord and Tenant.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">E)&#160;&#160;&#160;&#160;If either Landlord or Tenant fails to appoint an arbitrator within fifteen (15) days after the applicable Outside Agreement Date, then the arbitrator appointed by one of them shall reach a decision, notify Landlord and Tenant thereof and such arbitrator&#8217;s decision shall be binding upon Landlord and Tenant.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">F)&#160;&#160;&#160;&#160;If the two (2) arbitrators fail to agree upon and appoint a third arbitrator, or if both parties fail to appoint an arbitrator, then the appointment of the third arbitrator or any arbitrator shall be dismissed and the matter to be decided shall be forthwith submitted to arbitration under the provisions of the American Arbitration Association, but subject to the instruction set forth in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Subsection 3.2.4</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">G)&#160;&#160;&#160;&#160;The cost of the arbitration shall be paid by Landlord and Tenant equally.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;  <br>DELIVERY&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord will endeavor to tender possession of the Premises to Tenant with the Tenant Improvements Substantially Complete on or before the Estimated Completion Date; provided, that if the date on which Landlord actually tenders possession of the Premises to Tenant in such condition does not occur on or before the Estimated Completion Date, this Lease shall not be void or voidable, the Term of this Lease shall not be extended, and Landlord shall not be liable to Tenant for any loss or damage resulting therefrom; provided further that Landlord shall use commercially reasonable efforts to tender to Tenant delivery of possession of the Premises in such condition as soon as reasonably possibly after the Estimated Completion Date.  Notwithstanding the foregoing, if Landlord is unable to deliver possession of the Premises to Tenant on or before the date which is six (6) months after the Estimated Completion Date (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Outside Delivery Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), then Tenant shall have the right to terminate this Lease by delivering Notice thereof to Landlord no later than five (5) business days after the Outside Delivery Date, which termination shall be effective thirty (30) days after the date of such Notice, provided that if Landlord delivers possession of the Premises to Tenant within such thirty (30) day period, then Tenant&#8217;s notice to terminate shall be deemed void and this Lease shall continue in full force and effect.  If this Lease is terminated in accordance with the immediately preceding sentence, Landlord shall promptly return to Tenant any unapplied portion of the Security Deposit and any pre-paid Rent.  Tenant&#8217;s failure to deliver a Notice of termination within five (5) business days after the Outside Delivery Date shall be deemed Tenant&#8217;s waiver of its right to terminate this Lease due to a delay in delivery of the Premises.  Notwithstanding anything contained herein to the contrary, the Outside Delivery Date shall be extended on a day-for-day basis for any delay to the extent caused solely by an event of Force Majeure and/or a Tenant Delay; provided that if such event of Force Majeure arises as a result of the Orders (as defined herein), the Outside Delivery Date shall not be extended beyond the date that is four (4) months after the Orders are no longer effective.  As used herein, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Orders</font><font style="font-family:inherit;font-size:10pt;">&#8221; means (i) that certain Executive Order N-33-20 issued on March 19, 2020 by Governor Gavin Newsom, as amended from time to time (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">California Order</font><font style="font-family:inherit;font-size:10pt;">&#8221;), (ii) that certain Order, dated March 27, 2020, issued by the County of San Diego Health and Human Services Agency, as amended from time to time (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">County Order</font><font style="font-family:inherit;font-size:10pt;">&#8221;), (iii) that certain City of San Diego Executive Order No.  2020-1, dated March 16, 2020, as amended from time to time (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">City Order</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and (iv) any law, ordinance, or regulation enacted during the Term that has the same effect as the California Order, the County Order and/or the City Order or otherwise prevent in-person workforces in the Premises.  If Tenant is entitled to terminate this Lease in accordance with this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 4</font><font style="font-family:inherit;font-size:10pt;">&#32;but elects not to so terminate this Lease, and provided that Tenant is not in default under this Lease beyond any applicable notice and cure period, Tenant shall be entitled to receive a credit to be applied to the Basic Rent next due and payable under this Lease in an amount equal to fifty percent (50%) of the Holdover Penalty (as defined below), if any, actually charged to Tenant and paid by Tenant under (a) that certain Sublease, dated May 18, 2018, by and between Tenant and Trex Enterprises Corporation, a California corporation (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Trex</font><font style="font-family:inherit;font-size:10pt;">&#8221;), for certain premises located at 10455 Pacific Center Court, San Diego, California 92121 (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Trex Sublease</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and/or (b) that certain Office Lease, dated April 19, 2011, by and between Tenant and Kilroy Realty, L.P., a Delaware limited liability company (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Kilroy</font><font style="font-family:inherit;font-size:10pt;">&#8221;), for certain premises located at 10421 Pacific Center Court, San Diego, California 92121, as amended by that certain First Amendment to Office Lease, dated September 10, 2015 (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Kilroy Lease</font><font style="font-family:inherit;font-size:10pt;">&#8221;) (collectively, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Prior Leases</font><font style="font-family:inherit;font-size:10pt;">&#8221;), to the extent attributable to the period of time commencing on the date that any Holdover Penalty is incurred under any Prior Lease and the actual date on which possession of the Premises is delivered to Tenant with the Tenant Improvements Substantially Complete (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Actual Delivery Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), but excluding the number of days of delay arising from a Tenant Delay.  As used in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 4</font><font style="font-family:inherit;font-size:10pt;">, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Holdover Penalty</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean the additional base rent actually charged by Trex and/or Kilroy, as applicable, as a result of Tenant&#8217;s holdover beyond the term of any Prior Lease and paid by </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant, up to the maximum amounts set forth below, as evidenced by an invoice or other formal notice delivered by Trex and/or Kilroy, as applicable, a copy of which shall be delivered to Landlord hereunder.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maximum Monthly</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Holdover Penalty</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord&#8217;s Share (50%) of Maximum Monthly  <br>Holdover Penalty</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trex Sublease</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$16,517.28</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8,258.64</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kilroy Lease</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$25,115.84</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12,557.92</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In no event shall Landlord be liable for any other amounts charged to Tenant under the Prior Leases (including, without limitation, consequential damages), other than an amount equal to fifty percent (50%) of the Holdover Penalty as expressly set forth herein.  For clarification and the avoidance of doubt, if Landlord delivers the Premises to Tenant with the Tenant Improvements Substantially Complete on or before the Outside Delivery Date, as the same may be extended pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 4</font><font style="font-family:inherit;font-size:10pt;">, or if Tenant terminates this Lease in accordance with this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 4</font><font style="font-family:inherit;font-size:10pt;">, then Landlord shall have no obligation to pay for any portion of the Holdover Penalty.  The remedies set forth in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 4</font><font style="font-family:inherit;font-size:10pt;">&#32;shall be Tenant&#8217;s sole and exclusive remedies at law or equity for the matters described herein.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br>RENT&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic Rent</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall pay Landlord as consideration for the use and enjoyment of the Premises the Basic Rent designated in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.11</font><font style="font-family:inherit;font-size:10pt;">&#32;(subject to proration as hereinafter provided) in equal monthly installments, each in advance on the first day of each calendar month during the Term commencing on the Commencement Date, except that the first month&#8217;s Rent shall be paid to Landlord upon delivery to Landlord of a copy of this Lease, executed by Tenant.  If the Term of this Lease commences on a day other than the first day of a calendar month or ends on a day other than the last day of a calendar month, then the Rent for such period shall be prorated on the basis of a thirty (30) day month.  Notwithstanding the foregoing, and provided that Tenant is not in default under this Lease beyond any applicable notice and cure period, the monthly installment of Basic Rent for the Premises shall be abated during months two (2) through seven (7) of the Initial Term (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Abatement Period</font><font style="font-family:inherit;font-size:10pt;">&#8221;), subject to adjustment thereof as provided in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.9</font><font style="font-family:inherit;font-size:10pt;">&#32;above.  All other terms and provisions of this Lease (including, without limitation, the obligation to pay separately metered utilities and all Additional Rent) shall apply to the Premises both during the Abatement Period and thereafter.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Rent</font><font style="font-family:inherit;font-size:10pt;">.  In addition to the Basic Rent, Tenant agrees to pay as Additional Rent (defined below) the amount of Rent adjustments and other charges required by this Lease.  Other charges to be paid by Tenant hereunder, including, without limitation, payments for Operating Expenses, Real Property Taxes, insurance, insurance deductibles and repairs shall be considered &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Additional Rent</font><font style="font-family:inherit;font-size:10pt;">&#8221; for purposes of this Lease.  The term &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Rent</font><font style="font-family:inherit;font-size:10pt;">&#8221; as used in this Lease shall mean Basic Rent and Additional Rent and all other amounts payable by Tenant pursuant to this Lease.  When no other time is stated herein for payment, payment of any amount due from Tenant to Landlord hereunder shall be made within ten (10) business days after Tenant&#8217;s receipt of Landlord&#8217;s invoice or statement therefor.  All Rent shall be paid to Landlord, without prior demand and without any deduction or offset except as specified herein, in lawful money of the United States of America, via Automated Clearing House (ACH) or to such other person or at such other place as Landlord may from time to time designate in writing.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Late Payment</font><font style="font-family:inherit;font-size:10pt;">.  If Tenant fails to pay any installment of Rent when due or in the event Tenant fails to make any other payment for which Tenant is obligated under this Lease when due, such late amount shall accrue interest and Tenant shall pay Landlord as Additional Rent interest on such amount at an annual rate (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Default Rate</font><font style="font-family:inherit;font-size:10pt;">&#8221;) equal to the lesser of:  (a) the then prevailing prime rate of Bank of America NT &amp; SA (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Prime Rate</font><font style="font-family:inherit;font-size:10pt;">&#8221;) plus six (6) percentage points or (b) the maximum rate permitted by law from the date such amount became due until such amount is paid.  If the format or components of the Prime Rate are materially changed, or if the Prime Rate ceases to exist, Landlord shall substitute a prime rate or alternative base rate of interest that is maintained by the Bank of America NT &amp; SA or similar financial institution which Landlord determines in its reasonable business judgment.  In addition to said interest, Tenant shall pay to Landlord concurrently with any installment of Rent, or other payment, not paid within five (5) days of the date upon which it is due, and Landlord may demand same from Tenant, as Additional Rent, a late charge equal to eight percent (8%) of the late amount to compensate Landlord for the extra costs incurred as a result of such late payment; provided that no such late charge shall be due with respect to the first delinquent payment in any twelve (12) month period provided that such payment is made within ten (10) days after delivery of written notice from </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord that such amount is due.  THE PARTIES AGREE THAT ANY SUCH LATE PAYMENT MAY CAUSE LANDLORD TO INCUR ADMINISTRATIVE COSTS AND OTHER DAMAGE, THE EXACT AMOUNT OF WHICH WOULD BE IMPRACTICABLE OR EXTREMELY DIFFICULT TO ASCERTAIN, AND THAT SUCH INTEREST AND LATE CHARGE REPRESENT A FAIR AND REASONABLE ESTIMATE OF THE DETRIMENT THAT LANDLORD WILL SUFFER BY REASON OF LATE PAYMENT BY TENANT.  Acceptance of any such interest and late charge shall not constitute a waiver of any Tenant Default with respect to the overdue amount, or prevent Landlord from exercising any of the other rights and remedies available to Landlord hereunder or at law.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Late Payment Remedies</font><font style="font-family:inherit;font-size:10pt;">.  Any payment returned to Landlord shall be subject to a handling charge of $50.00.  If Tenant fails to pay an installment of Basic Rent within ten (10) days following the date the same is due on any three (3) or more occasions during any twelve (12) month period, Landlord shall have the right, in addition to any other rights or remedies it may have hereunder or at law, to require Tenant thereafter to pay installments of Basic Rent quarterly in advance.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> RENT ADJUSTMENT&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Definitions</font><font style="font-family:inherit;font-size:10pt;">.  For the purposes of this Lease, the following terms shall be defined as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Expenses</font><font style="font-family:inherit;font-size:10pt;">:  &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Operating Expenses</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall consist of all costs of operation, management, ownership, insurance, maintenance and repair of the Project, including without limitation the Building, the Common Areas and all other portions of the Project, including any expansions thereof by Landlord or by the owner(s) and/or the operator(s) thereof.  Operating Expenses shall include, without limitation, the following:  (a) any and all non-tax assessments payable by Landlord for, or costs or expenses incurred by Landlord in connection with, the Building or the Project pursuant to any covenants, conditions or restrictions, reciprocal easement agreements, tenancy-in-common agreements or similar restrictions and agreements affecting the Building or the Project; (b) assessments and any taxes or assessments hereafter imposed in lieu thereof; (c) Rent taxes and gross receipts taxes (whether assessed against Landlord or assessed against Tenant and paid by Landlord, or both); (d) water and sewer charges; (e) accounting, legal and other consulting fees incurred by Landlord in connection with the Project or any portion thereof; (f) the net cost and expense of insurance, and any associated insurance deductibles, for which Landlord and/or the owner(s) and/or the operator(s) of the Project is (are) responsible or any first mortgagee with a lien affecting the Premises reasonably deems necessary in connection with the operation of the Building or the Project; (g) utilities, including, but not limited to, any and all costs and fees associated with the installation, maintenance, repair, or replacement of intrabuilding network telephone and data cable; (h) janitorial services, security, labor, utilities surcharges or any other costs levied, assessed or imposed by, or at the direction of, or resulting from statutes, including, but not limited to, the Americans with Disabilities Act (42 U.S.C. Section 12101 et seq.), or regulations or interpretations thereof promulgated by, any federal, state, regional, local or municipal governmental authority, agency or subdivision (each, a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Governmental Authority</font><font style="font-family:inherit;font-size:10pt;">&#8221;) in connection with the use or occupancy of the Project or any portion thereof; (i) costs and expenses incurred or suffered by Landlord in connection with transportation or energy management programs; (j) the cost (amortized over such period as is customary under sound institutional real estate property management procedures (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Institutional Owner Practices</font><font style="font-family:inherit;font-size:10pt;">&#8221;), together with interest at a rate (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Interest Rate</font><font style="font-family:inherit;font-size:10pt;">&#8221;) equal to the Prime Rate plus two (2) percentage points on the enumerated balance):  (i) of any capital improvements or replacements intended as labor&#8209;saving devices or to effect other economies in the maintenance or operation of, or stability of services to, the Building (including Building Common Areas) or the Project Common Areas by Landlord or by the owner(s) and/or the operator(s) thereof, or (ii) of replacing any equipment, systems or materials needed to operate the Project or any portion thereof at the same quality levels as prior to the improvement or replacement or as mandated by revisions or governmental interpretations of any applicable Laws (defined below) or (iii) which are designed to reduce Operating Expenses or to comply with Laws; (k) costs incurred in the management of the Project, including supplies, materials, equipment, on-site management office rent, wages and salaries of employees used in the management, operation and maintenance thereof, payroll taxes and similar governmental charges with respect thereto, and a Building management fee (not to exceed three percent (3%) of gross receipts, grossed up to reflect ninety-five percent (95%) occupancy); (l) all costs and expenses for air-conditioning, waste disposal, heating, ventilating, elevator repair and maintenance, supplies, materials, equipment, and tools incurred in connection with the Project or any portion thereof (except as the same is payable to Landlord by tenants of the Project under their leases for space in the Project); (m) repair and maintenance of the roof and structural portions of the Building and the Common Areas, including the plumbing, heating, ventilating, air conditioning and electrical systems installed </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or furnished by Landlord; (n) maintenance costs of the Building, the Common Areas and the Project or any portion thereof, including utilities and payroll expenses, rent of personal property used in maintenance and all other upkeep; (o) costs and expenses of gardening and landscaping the Project or any portion thereof; (p) maintenance of signs located in or about the Project (other than Tenant&#8217;s signs or the signs of other tenants or occupants of the Building who are responsible to maintain their own signs); (q) personal property taxes levied on or attributable to personal property of Landlord or the owner(s) and/or operator(s) of the Project used in connection with the Project; (r) reasonable audit or verification fees incurred in connection with the Project; and (s) the costs and expenses of repairs (including latent defects), resurfacing, maintenance, painting, lighting, cleaning, refuse removal, security and similar items incurred with respect to the Project, including appropriate reserves.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating Expenses shall not include:  (A) depreciation on the Building or equipment therein; (B) Landlord&#8217;s executive salaries; (C) real estate broker&#8217;s commissions and advertising costs in connection with leasing space in the Project; (D) legal fees and disbursements incurred for collection of tenant accounts or negotiation of leases, or relating to disputes between Landlord and other tenants and occupants of the Building or Project; (E) the cost of any capital improvements unless specifically permitted by this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.1.1</font><font style="font-family:inherit;font-size:10pt;">, parts (a) through (s), inclusive; (F) amounts received by Landlord on account of proceeds of insurance to the extent the proceeds are reimbursement for expenses which were previously included in Operating Expenses; (G) payments of principal and interest on any mortgages upon the Project or Building; (H) payments of ground rent pursuant to any ground lease covering the Project or Building; (I) the costs of gas, steam or other fuel; operation of elevators and security systems; heating, cooling, air conditioning and ventilating; chilled water, hot and cold domestic water, sewer and other utilities or any other service work or facility, or level or amount thereof, provided to any other tenant or occupant in the Project which either (x) is not required to be supplied or furnished by Landlord to Tenant under the provisions of this Lease or (y) is supplied or furnished to Tenant pursuant to the terms of this Lease with separate or additional charge; (J) any cost that is expressly excluded from Operating Expenses in an express provision contained in this Lease;  (K) initial improvements or alterations to tenant spaces in the Project; (L) the cost of providing any service directly to and paid directly by a single individual lessee, or costs incurred for the benefit of a single lessee; (M) costs incurred due to Landlord&#8217;s breach of a law or ordinance; (N) repairs necessitated by the gross negligence or willful misconduct of Landlord or Landlord&#8217;s employees, agents, or contractors; (O) charitable or political contributions and membership fees or other payments to trade organizations; (P) Landlord&#8217;s general overhead expenses not related to the Project; (Q) Landlord&#8217;s costs of any services provided to lessees or other occupants for which Landlord is actually reimbursed by such lessees or other occupants (other than reimbursement through Operating Expenses) as an additional charge or rental over and above the basic rent (and escalations thereof) payable under the lease with such lessee or other occupant; (R) costs (i.e., interest and penalties) incurred due to Landlord&#8217;s default of this Lease or any other lease, mortgage, or other agreement, in each case affecting the Project; (S) payments to subsidiaries or affiliates of Landlord, or to any other party, in each case as a result of a non-arm's length transaction, for management or other services for the Project, or for supplies or other materials for the Project, to the extent that such payments exceed arm&#8217;s length competitive prices in the market where the Premises are located for the services, supplies or materials provided; (T) costs or expenses incurred in connection with the financing or sale of the Project or any portion thereof; (U) costs of environmental testing, monitoring, removal or remediation of any Hazardous Materials in the Project that are in existence at the Project prior to the Commencement Date except to the extent caused by Tenant; (V)  the costs of acquiring investment-grade art; and (W) any item that, if included in Operating Expense, would involve a double collection for such item by Landlord.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">6.1.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Real Property Taxes</font><font style="font-family:inherit;font-size:10pt;">: &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Real Property Taxes</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean and include any form of assessment, re-assessment, license fee, license tax, business license fee, commercial rent tax, levy, charge, penalty, tax or similar imposition, imposed by any authority having the direct power to tax, including any Governmental Authority, or any school, agricultural, lighting, drainage or other improvement or special assessment district thereof, as against any legal or equitable interest of Landlord in the Building, the Premises or the Project, including but not limited to the following:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">(A</font><font style="font-family:inherit;font-size:12pt;">)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;any tax on Landlord&#8217;s &#8220;right&#8221; to other income from the Project or any portion thereof or as against Landlord&#8217;s business of leasing the Project or any portion thereof;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">B)&#160;&#160;&#160;&#160;any assessment, tax, fee, levy or charge in substitution, partially or totally, of any assessment, tax, fee, levy or charge previously included within the definition of real estate tax, including but not limited to, any assessments, taxes, fees, levies and charges that may be imposed by any Governmental Authority for such services as fire protection, street, sidewalk or road maintenance, refuse removal and for other governmental services formerly provided without charge to property owners or occupants, it being the intention of Tenant and Landlord that all such new and increased assessments, taxes, fees, levies and charges be included within the definition of &#8220;Real Property Taxes&#8221; for the purposes of this Lease;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">C)&#160;&#160;&#160;&#160;any assessment, tax, fee, levy or charge allocable to or measured by the area of any premises in the Project or the Rent payable hereunder and under any other leases for premises in the Building, the Parking Area or the Project, including without limitation any gross income tax or excise tax levied by any Governmental Authority or any political subdivision thereof, with respect to the receipt of such Rent, or upon or with respect to the possession, leasing, operating, management, maintenance, alteration, repair, use or occupancy by tenants of their premises in the Project, or any portion thereof; and</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">D)&#160;&#160;&#160;&#160;any assessment, tax, fee, levy or charge upon this transaction or any document creating or transferring an interest or an estate in the Project or any portion thereof, or based upon a reassessment of the Project or any portion thereof by virtue of a &#8220;change in ownership&#8221;, and as a result thereof, and to the extent that in connection therewith, the Building is reassessed for real estate tax purposes by the appropriate Governmental Authority pursuant to the terms of Proposition 13 (as adopted by the voters of the State of California in the June, 1978 election, or any successor statute).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding any provision of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.1.2</font><font style="font-family:inherit;font-size:10pt;">&#32;expressed or implied to the contrary, &#8220;Real Property Taxes&#8221; shall not include (a) Landlord&#8217;s federal or state income, franchise, inheritance or estate taxes, or (b) fines, penalties and/or interest incurred as a result of Landlord&#8217;s failure to pay any Real Property Tax when due.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">6.1.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant&#8217;s Percentage</font><font style="font-family:inherit;font-size:10pt;">.  &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Percentage</font><font style="font-family:inherit;font-size:10pt;">&#8221; means the percentage set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.13</font><font style="font-family:inherit;font-size:10pt;">; provided, however, that Landlord reserves the right from time to time during the Term of this Lease to recalculate Tenant&#8217;s Percentage, in which case Tenant&#8217;s Percentage shall mean that numeric figure obtained by dividing the Rentable Square Feet of the Premises, as adjusted pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2.2</font><font style="font-family:inherit;font-size:10pt;">, by the total Rentable Square Feet of the Building.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Calculation Methods and Adjustments</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">6.2.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Subject to the provisions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.2</font><font style="font-family:inherit;font-size:10pt;">, all calculations, determinations, allocations and decisions to be made hereunder with respect to Operating Expenses and Real Property Taxes shall be made on a triple net basis in accordance with the good faith determination of Landlord applying sound accounting and property management principles consistently applied which are consistent with Institutional Owner Practices.  If the Project is not at least one hundred percent (100%) occupied during all or a portion of the any year, Landlord shall make an appropriate adjustment to the components of Operating Expenses for such year to determine the amount of Operating Expenses that would have been incurred had the Project been ninety-five percent (95%) occupied; and the amount so determined shall be deemed to have been the amount of Operating Expenses for such year.  Landlord shall have the right to equitably allocate some or all Operating Expenses among particular classes or groups of tenants in the Project or Building (for example, retail tenants) to reflect Landlord&#8217;s good faith determination that measurably different amounts or types of services, work or benefits associated with Operating Expenses, as applicable, are being provided to or conferred upon such classes or groups.  All discounts, reimbursements, rebates, refunds, or credits (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Reimbursements</font><font style="font-family:inherit;font-size:10pt;">&#8221;) attributable to Operating Expenses or Real Property Taxes received by Landlord in a particular year shall be deducted from Operating Expenses or Real Property Taxes, as applicable, in the year the same are received; provided, however, if such practice is consistent with Institutional Owner Practices, Landlord may treat Reimbursements generally (or under particular circumstances) on a different basis. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">6.2.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;As of the date of this Lease, Tenant shall pay Additional Rent under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 6</font><font style="font-family:inherit;font-size:10pt;">&#32;based on the Operating Expenses and Real Property Taxes for the Project.  If the Project at any time contains more than one building, Landlord shall have the right, from time to time, to equitably allocate some or all of the Operating Expenses and/or Real Property Taxes for the buildings comprising the Project among the Building and some or all of the other buildings of the Project.  In such event, Landlord shall reasonably determine a method of allocating such Operating </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses and/or Real Property Taxes attributable to the Building and/or such other building(s) of the Project to the Building and/or such other building(s) and Tenant shall be responsible for paying its proportionate share of such expense(s) which are allocated to the Building.  Landlord shall also have the right, from time to time, to require Tenant to pay Tenant&#8217;s Percentage of Operating Expenses and Real Property Taxes based solely on the Operating Expenses and Real Property Taxes for the Building.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payment of Tenant&#8217;s Percentage of Operating Expenses and Real Property Taxes</font><font style="font-family:inherit;font-size:10pt;">.  This shall be a triple net Lease and Basic Rent shall be paid to Landlord absolutely net of all costs and expenses, except as specifically provided to the contrary in this Lease.  The provisions for payment of Tenant&#8217;s Percentage of Operating Expenses and Tenant&#8217;s Percentage of Real Property Taxes are intended to pass on to Tenant, and reimburse Landlord for, all costs and expenses of the nature described in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:10pt;">&#32;incurred in connection with the ownership, operation, management, insurance, maintenance and repair of the Project.  For each calendar year of the Term, Tenant shall pay Tenant&#8217;s Percentage of the Operating Expenses and Tenant&#8217;s Percentage of the Real Property Taxes paid or incurred by Landlord for such year as Additional Rent.  Tenant shall pay such amounts as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">6.3.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimate of Annual Operating Expenses and Real Property Taxes</font><font style="font-family:inherit;font-size:10pt;">.  At the beginning of each calendar year, or as soon thereafter as practicable, Landlord shall deliver to Tenant a reasonable estimate (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Estimated Statement</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of Tenant's Percentage of Operating Expenses and Tenant's Percentage of Real Property Taxes for the then current calendar year.  Landlord may revise its estimates of Tenant's Percentage of Operating Expenses and Tenant's Percentage of Real Property Taxes for any year from time to time in its reasonable discretion, and upon receipt of a revised Estimated Statement, Tenant shall begin making payments under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.1</font><font style="font-family:inherit;font-size:10pt;">&#32;in accordance with such revised estimates.  For each calendar year during the Term of this Lease, or portion thereof, Tenant shall pay to Landlord the estimated Tenant&#8217;s Percentage of Operating Expenses and the estimated Tenant's Percentage of Real Property Taxes, as specified in the Estimated Statement.  These estimated amounts shall be divided into twelve (12) equal monthly installments.  Tenant shall pay to Landlord, concurrently with the regular monthly Basic Rent payment next due following the receipt of such an Estimated Statement, an amount equal to one monthly installment multiplied by the number of months from the commencement of the calendar year for which such estimates were prepared to the month of such payment, both months inclusive, less any amounts paid under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.1</font><font style="font-family:inherit;font-size:10pt;">&#32;after commencement of such calendar year based on the last Estimated Statement delivered by Landlord.  Subsequent payments under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.1</font><font style="font-family:inherit;font-size:10pt;">&#32;shall be payable concurrently with the regular monthly Rent payments for the balance of that calendar year and shall continue until the next Estimated Statement is delivered by Landlord.  Failure of Landlord to deliver an Estimated Statement for any calendar year shall not relieve Tenant of its obligation to make estimated payments of Tenant's Percentage of Operating Expenses and Tenant's Percentage of Real Property Taxes under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.1</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">6.3.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Annual Reconciliation</font><font style="font-family:inherit;font-size:10pt;">.  At the end of each calendar year or as soon thereafter as practicable Landlord shall deliver to Tenant a statement (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Annual Reconciliation</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of (a) the actual annual Operating Expenses and Tenant&#8217;s Percentage of Operating Expenses for the preceding year, and (b) the actual annual Real Property Taxes and Tenant&#8217;s Percentage of Real Property Taxes for the preceding year.  If for any year, the sum of Tenant&#8217;s Percentage of Operating Expenses and Tenant&#8217;s Percentage of Real Property Taxes (as specified in the Annual Reconciliation) is less than the total amount of the estimated payments made by Tenant under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.1</font><font style="font-family:inherit;font-size:10pt;">&#32;above for such year, then any such overpayment, or overpayments, shall be credited toward the monthly Rent next falling due after determination by Landlord of such overpayment or overpayments and shall be paid to Tenant in a lump sum for periods after the expiration of the Term.  Similarly, if for any year, the sum of Tenant&#8217;s Percentage of Operating Expenses and Tenant&#8217;s Percentage of Real Property Taxes (as specified in the Annual Reconciliation) is more than the total amount of the estimated payments made by Tenant under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.1</font><font style="font-family:inherit;font-size:10pt;">&#32;above for such year, then any such underpayment, or underpayments, shall be paid by Tenant to Landlord concurrently with the next regular monthly Basic Rent payment coming due after Tenant&#8217;s receipt of the Annual Reconciliation (or if the Term shall have expired or terminated, within thirty (30) days following Tenant&#8217;s receipt of such Annual Reconciliation).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">6.3.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Survival of Reconciliation.  </font><font style="font-family:inherit;font-size:10pt;">Even though the Term shall have expired and Tenant shall have vacated the Premises, when the final determination of Tenant&#8217;s Percentage of actual annual Operating Expenses, and/or of Tenant&#8217;s Percentage of actual annual Real Property Taxes, for the year in which this Lease terminates is delivered to Tenant, (a) Tenant shall immediately pay any amounts payable to Landlord under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.2</font><font style="font-family:inherit;font-size:10pt;">&#32;above (as a result of any underpayments by Tenant under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.1</font><font style="font-family:inherit;font-size:10pt;">&#32;above), and/or (b) conversely, Landlord shall promptly </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">rebate any amounts payable to Tenant under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.2</font><font style="font-family:inherit;font-size:10pt;">&#32;(as a result of any overpayments under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.3.1</font><font style="font-family:inherit;font-size:10pt;">&#32;above) provided that no Tenant Default existed at the expiration or earlier termination of this Lease.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Review of Annual Reconciliation</font><font style="font-family:inherit;font-size:10pt;">.  Provided that Tenant is not then in default with respect to its obligations under this Lease and provided further that Tenant strictly complies with the provisions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:10pt;">, Tenant shall have the right, at Tenant&#8217;s sole cost and expense and upon thirty (30) days prior Notice (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Review Notice</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to Landlord delivered no later than sixty (60) days after an Annual Reconciliation is delivered to Tenant, to reasonably review or audit Landlord&#8217;s supporting books and records (at Landlord&#8217;s manager&#8217;s corporate offices) for any portion of the Operating Expenses or Real Property Taxes for the particular year covered by such Annual Reconciliation, in accordance with the procedures set forth in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:10pt;">.  To the extent that any amounts specified in such Annual Reconciliation were not previously paid, Tenant shall pay all such amounts to Landlord simultaneously with Tenant&#8217;s delivery the Review Notice.  Any review or audit of records under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:10pt;">&#32;shall be at the sole expense of Tenant, shall be conducted by independent certified public accountants of national standing which are not compensated on a contingency fee or similar basis relating to the results of such review or audit and shall be completed within sixty (60) days after Landlord provides Tenant with access to Landlord&#8217;s supporting books and records.  Tenant shall, within thirty (30) days after completion of any such review or audit, deliver Notice to Landlord specifying the items described in the Annual Reconciliation that are claimed to be incorrect by such review or audit (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Dispute Notice</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The right of Tenant under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:10pt;">&#32;may only be exercised once for each year covered by any Annual Reconciliation, and if Tenant fails to deliver a Review Notice within the sixty (60) day period described above or a Dispute Notice within the thirty (30) day period described above, or if Tenant fails to meet any of the other above conditions of exercise of such right, the right of Tenant to review or audit a particular Annual Reconciliation (and all of Tenant&#8217;s rights to make any claim relating thereto) under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:10pt;">&#32;shall automatically be deemed waived by Tenant.  Tenant acknowledges and agrees that any records of Landlord reviewed or audited under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:10pt;">&#32;(and the information contained therein) constitute confidential information of Landlord, which shall not be disclosed other than to Tenant&#8217;s accountants performing the review or audit and principals of Tenant who receive the results of the review or audit.  If Landlord disagrees with Tenant&#8217;s contention that an error exists with respect to the Annual Reconciliation in dispute, Landlord shall have the right to cause another review or audit of that portion of the Annual Reconciliation to be made by a firm of independent certified public accountants of national standing selected by Landlord (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Accountant</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  In the event of a disagreement between the two accounting firms, the review or audit of Landlord&#8217;s Accountant shall be deemed to be correct and shall be conclusively binding on both Landlord and Tenant.  In the event that it is finally determined pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.4</font><font style="font-family:inherit;font-size:10pt;">&#32;that a particular Annual Reconciliation overstated amounts payable by Tenant under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 6</font><font style="font-family:inherit;font-size:10pt;">&#32;with respect to the applicable year by more than five percent (5%), Landlord shall reimburse Tenant for the reasonable costs of Tenant&#8217;s accountant and Landlord shall be liable for the costs of Landlord&#8217;s Accountant.  In all other cases, Tenant shall reimburse Landlord for the reasonable costs of Landlord&#8217;s Accountant. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> SECURITY DEPOSIT&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Security Deposit</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall deposit with Landlord, upon delivery to Landlord of a copy of this Lease executed by Tenant, the Security Deposit designated in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.14</font><font style="font-family:inherit;font-size:10pt;">.  Said sum shall be held by Landlord as security for the full and faithful performance by Tenant of all of the terms, covenants and conditions of this Lease to be kept and performed by Tenant during the Term hereof and any extension hereof.  Landlord shall have the right, but not the obligation, to apply all or any portion of the Security Deposit for the payment of Rent or any other sum due hereunder, to cure any default by Tenant of its obligations with respect to the restoration and surrender of the Premises or to cure any Tenant Default at any time, in which event Tenant shall be obligated to restore the Security Deposit to its original amount within ten (10) business days, and Tenant&#8217;s failure to do so shall be deemed to be a Default under this Lease.  Tenant hereby irrevocably waives and relinquishes any and all rights, benefits, or protections, if any, Tenant now has, or in the future may have, under Section 1950.7 of the California Civil Code, any successor statute, and all other provisions of law, now or hereafter in effect, including, but not limited to, any provision of law which:  (a) establishes the time frame by which a landlord must refund a security deposit under a lease, or (b) provides that a landlord may claim from a security deposit only those sums reasonably necessary to remedy defaults in the payment of Rent, to repair damage caused by a tenant, or to clean the subject premises.  Tenant acknowledges and agrees that:  (i) any statutory time frames for the return of a security deposit are superseded by the express period identified in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 7.1</font><font style="font-family:inherit;font-size:10pt;">&#32;and (ii) rather than be so limited, Landlord may claim from the Security Deposit:  (A) any and all sums expressly identified in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 7.1</font><font style="font-family:inherit;font-size:10pt;">, and (B) any additional sums reasonably necessary to compensate Landlord for </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any and all losses or damages caused by Tenant&#8217;s default of this Lease, including, but not limited to, all damages or Rent due upon termination of this Lease pursuant to Section 1951.2 of the California Civil Code, as amended and recodified from time to time.  Landlord shall not be required to keep the Security Deposit separate from its general funds, and Tenant shall not be entitled to interest on such Security Deposit.  Within thirty (30) days following the expiration of the Term, Landlord shall (provided that Tenant is not in Default under this Lease) return the Security Deposit to Tenant, less such portion as Landlord shall have applied in accordance with this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 7.1</font><font style="font-family:inherit;font-size:10pt;">.  Should Landlord sell its interest in the Premises during the Term hereof and if Landlord deposits with (or gives a credit to) the purchaser thereof the then balance of the Security Deposit held by Landlord, Landlord shall be released from any further liability with respect to the Security Deposit.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Letter of Credit</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">If at any time during the Term (a) the balance of Tenant&#8217;s cash, cash equivalents and Eligible Investments (as defined below) is less than One Hundred Million Dollars ($100,000,000.00) or (b) Tenant is unable to continue as a going concern, as each is determined by Tenant&#8217;s audited financial statements and/or disclosed by any of Tenant&#8217;s SEC filings (including, without limitation, any 10-Q or 10-K), Tenant shall immediately deliver Notice thereof to Landlord and, within ten (10) business days thereafter, Tenant shall deposit with Landlord the Letter of Credit (as defined in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit &#8220;D-2&#8221;</font><font style="font-family:inherit;font-size:10pt;">) in the Letter of Credit Amount as set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.14</font><font style="font-family:inherit;font-size:10pt;">&#32;above.  As used herein, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Eligible Investments</font><font style="font-family:inherit;font-size:10pt;">&#8221; mean U.S. government obligations, corporate obligations, bank instruments, FDIC-backed bank debt and U.S. treasury and U.S. government agency institutional money market funds.  The Letter of Credit shall comply with the requirements of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit &#8220;D-2&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;attached hereto and incorporated by reference herein.  If Tenant fails to provide such Letter of Credit within the ten (10) business day period set forth above, such failure shall be deemed a Tenant Default, without notice or opportunity to cure.  If the Letter of Credit is delivered to Landlord as required under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 7.2</font><font style="font-family:inherit;font-size:10pt;">, and subsequent to such delivery, (i) the balance of Tenant&#8217;s cash, cash equivalents and Eligible Investments exceeds One Hundred Million Dollars ($100,000,000.00) and (ii) Tenant confirms its ability to continue as a going concern, as each is determined by Tenant&#8217;s audited financial statements and/or Tenant&#8217;s SEC filings, Landlord shall return the Letter of Credit to Tenant within thirty (30) days after Tenant&#8217;s written request therefor.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> USE&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall use the Premises for the Permitted Use set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.16</font><font style="font-family:inherit;font-size:10pt;">&#32;above, and shall not use or permit the Premises to be used for any other purpose without the prior written consent of Landlord.  Nothing contained herein shall be deemed to give Tenant any exclusive right to such use in the Project or any portion thereof (excluding only the Premises).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Laws/CC&amp;R&#8217;s</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.2.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant shall not use or occupy the Premises in violation of any applicable laws, regulations, rules, orders, statutes or ordinances of any Governmental Authority, office, board or private entity in effect on or after the Effective Date and applicable to the Project or the use or occupancy of the Project, including, without limitation, the rules, regulations and requirements of the Pacific Fire Rating Bureau, and of any similar body, the Americans with Disabilities Act (42 U.S.C. Section 12101 et seq.) (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">ADA</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and Hazardous Material Laws (as defined in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 8.3.7</font><font style="font-family:inherit;font-size:10pt;">&#32;below) (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Laws</font><font style="font-family:inherit;font-size:10pt;">&#8221;) or in violation of any government-issued permit for the Building or Project or any of the Rules and Regulations (as defined below), and shall, upon Notice from Landlord, discontinue any use of the Premises which is declared by any Governmental Authority having jurisdiction to be a violation of any Laws, or of any government-issued permit for the Building or Project.  Tenant shall cause the Premises to comply with all applicable Laws and shall comply with any direction of any Governmental Authority having jurisdiction which shall, by reason of the nature of Tenant&#8217;s use or occupancy of the Premises, impose any obligation (including, but not limited to, any obligation imposed pursuant to the ADA), upon Tenant or Landlord with respect to the Premises or with respect to the use or occupancy thereof; provided, however, unless resulting from an Alteration performed by Tenant or by Tenant&#8217;s specific use of the Premises (as opposed to general office and laboratory/research and development use), Tenant shall not be responsible for any obligation imposed by the ADA after completion of the initial Tenant Improvements with respect to the Common Areas of the Building and the Premises (except its prorata share of compliance costs included in Operating Expenses).  Tenant shall comply with all rules, orders, regulations and requirements of the Pacific Fire Rating Bureau or any other organization performing a similar function.  Tenant shall not do or permit to be done in or about the Premises anything which causes the insurance on the Premises, the Building or the Project or any portion </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">thereof to be canceled or the cost thereof increased.  Tenant shall promptly, upon demand, reimburse Landlord for any additional premium charged for any insurance policy by reason of Tenant&#8217;s failure to comply with the provisions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 8.2</font><font style="font-family:inherit;font-size:10pt;">.  In determining whether increased premiums are a result of Tenant&#8217;s use of the Premises, a schedule issued by the organization computing the insurance rate on the Project or the Tenant Improvements showing the various components of such rate shall be conclusive evidence of the several items and charges which make up such rate.  Tenant shall promptly comply with all reasonable requirements of the insurance authority or any present or future insurer relating to the Premises.  Tenant shall not do or permit anything to be done in or about the Premises which will in any way obstruct or interfere with the rights of Landlord or other tenants or occupants of the Building, the Parking Area or the Project, or injure or unreasonably annoy them, or use or allow the Premises to be used for any improper, immoral, unlawful or objectionable purpose, nor shall Tenant cause, maintain or permit any nuisance in or about the Premises or the Project.  Tenant shall comply with all restrictive covenants and obligations created by private contracts that affect the use and operation of the Premises, the Building, the Common Areas or any other portion of the Project.  Tenant shall not commit or suffer to be committed any waste in or upon the Premises or the Project and shall keep the Premises in first class repair and appearance.  If any governmental license or permit shall be required for the proper and lawful conduct of Tenant&#8217;s business in the Premises, Tenant, at its expense, shall procure, maintain and comply with the terms and conditions of each such license or permit.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Without limiting the generality of the foregoing:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">A)&#160;&#160;&#160;&#160;Landlord and Tenant agree to cooperate, and Tenant shall use its commercially reasonable efforts to participate in governmentally mandated regulations applicable to businesses located in the area or to the Project.  Neither this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 8.2.1(A)</font><font style="font-family:inherit;font-size:10pt;">&#32;nor any other provision of this Lease, however, is intended to or shall create any rights or benefits in any other person, firm, company, Governmental Authority or the public.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">B)&#160;&#160;&#160;&#160;Landlord and Tenant agree to cooperate and comply with any and all guidelines or controls imposed upon either Landlord or Tenant by any Governmental Authority.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:10pt;">C)&#160;&#160;&#160;&#160;All costs, fees, assessments and other charges paid by Landlord to any Governmental Authority in connection with any program of the types described in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sections 8.2.1(A)</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">8.2.1(B) above</font><font style="font-family:inherit;font-size:10pt;">, and all costs and fees paid by Landlord to any Governmental Authority or third party pursuant to or to effect such program, shall be included in Operating Expenses for the purposes of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 6</font><font style="font-family:inherit;font-size:10pt;">, whether or not specifically listed in such </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 6</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">(D</font><font style="font-family:inherit;font-size:12pt;">)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant shall be liable for all penalties, noncompliance costs or other losses, costs or expenses incurred by Landlord primarily as a result of Tenant&#8217;s failure to comply with any of the provisions of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sections 8.2.1(A)</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">8.2.1(C)</font><font style="font-family:inherit;font-size:10pt;">&#32;above.  Any such amount shall be payable by Tenant to Landlord within ten (10) business days after Landlord&#8217;s demand therefor as Additional Rent.  Failure of Tenant to pay any amount due pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section&#160;8.2.1(D)</font><font style="font-family:inherit;font-size:10pt;">&#32;when due shall be deemed a Tenant Default pursuant to this Lease.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.2.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant shall be responsible for all structural engineering required to determine structural load for any of Tenant&#8217;s furniture, fixtures, equipment, other personal property, Alterations and Tenant Improvements; provided that Landlord reserves the right to prescribe the weight and position of all file cabinets, safes and heavy equipment which Tenant desires to place in the Premises so as to properly distribute the weight thereof.  Further, Tenant&#8217;s business machines and mechanical equipment which cause vibration or noise that may be transmitted to the Building structure or to any other space in the Building shall be so installed, maintained and used by Tenant as to eliminate such vibration or noise.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hazardous Materials</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.3.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant shall not cause or permit any Hazardous Materials (as defined in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 8.3.7</font><font style="font-family:inherit;font-size:10pt;">&#32;below) to be brought upon, kept or used in or about the Premises, the Building or the Project in violation of applicable Laws by Tenant or any of its employees, agents, representatives, contractors or invitees (collectively with Tenant, each a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant Party</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  If (a) Tenant breaches such obligation, (b) the presence of Hazardous Materials as a result of such a breach results in contamination of the Project, any portion thereof, or any adjacent property, (c) contamination of the Premises otherwise occurs during the Term or any extension or renewal hereof or holding over hereunder or (d) </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">contamination of the Project occurs as a result of Hazardous Materials that are placed on or under or are released into the Project by a Tenant Party, then Tenant shall indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnified Parties (as defined in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1.2</font><font style="font-family:inherit;font-size:10pt;">&#32;below) harmless from and against any and all Claims (as defined in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 20</font><font style="font-family:inherit;font-size:10pt;">&#32;below) of any kind or nature, including (i) diminution in value of the Project or any portion thereof, (ii) damages for the loss or restriction on use of rentable or usable space or of any amenity of the Project, (iii) damages arising from any adverse impact on marketing of space in the Project or any portion thereof and (iv) sums paid in settlement of Claims that arise before, during or after the Term as a result of such breach or contamination.  This indemnification by Tenant includes costs incurred in connection with any investigation of site conditions or any clean-up, remedial, removal or restoration work required by any Governmental Authority because of Hazardous Materials present in the air, soil or groundwater above, on, under or about the Project.  Without limiting the foregoing, if the presence of any Hazardous Materials in, on, under or about the Project, any portion thereof or any adjacent property caused or permitted by any Tenant Party results in any contamination of the Project, any portion thereof or any adjacent property, then Tenant shall promptly take all actions at its sole cost and expense as are necessary to return the Project, any portion thereof or any adjacent property to its respective condition existing prior to the time of such contamination; provided that Landlord&#8217;s written approval of such action shall first be obtained, which approval Landlord shall not unreasonably withhold; and provided, further, that it shall be reasonable for Landlord to withhold its consent if such actions could have a material adverse long-term or short-term effect on the Project, any portion thereof or any adjacent property.  Tenant&#8217;s obligations under this Section shall not be affected, reduced or limited by any limitation on the amount or type of damages, compensation or benefits payable by or for Tenant under workers&#8217; compensation acts, disability benefit acts, employee benefit acts or similar legislation. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.3.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Landlord acknowledges that it is not the intent of this Article to prohibit Tenant from operating its business for the Permitted Use.  Tenant may operate its business according to the custom of Tenant&#8217;s industry so long as the use or presence of Hazardous Materials is strictly and properly monitored in accordance with applicable Laws.  As a material inducement to Landlord to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord (a) a list identifying each type of Hazardous Material to be present at the Premises that is subject to regulation under any environmental applicable Laws (other than customary quantities of typical office and cleaning supplies, provided no permits or approvals from, and no notice or disclosure to, any Governmental Authorities is required in connection with the presence of such supplies at the Premises), (b) a list of any and all approvals or permits from Governmental Authorities required in connection with the presence of such Hazardous Material at the Premises and (c) correct and complete copies of (i) notices of violations of applicable Laws related to Hazardous Materials and (ii) plans relating to the installation of any storage tanks to be installed in, on, under or about the Project (provided that installation of storage tanks shall only be permitted after Landlord has given Tenant its written consent to do so, which consent Landlord may withhold in its sole and absolute discretion) and closure plans or any other documents required by any and all Governmental Authorities for any storage tanks installed in, on, under or about the Project for the closure of any such storage tanks (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hazardous Materials Documents</font><font style="font-family:inherit;font-size:10pt;">&#8221;). Tenant shall deliver to Landlord updated Hazardous Materials Documents, within fourteen (14) days after receipt of a written request therefor from Landlord, not more often than once per year, unless (m) there are any changes to the Hazardous Materials Documents or (n) Tenant initiates any Alterations or changes its business, in either case in a way that involves any material increase in the types or amounts of Hazardous Materials.  For each type of Hazardous Material listed, the Hazardous Materials Documents shall include (t) the chemical name, (u) the material state (e.g., solid, liquid, gas or cryogen), (v) the concentration, (w) the storage amount and storage condition (e.g., in cabinets or not in cabinets), (x) the use amount and use condition (e.g., open use or closed use), (y) the location (e.g., room number or other identification) and (z) if known, the chemical abstract service number.  Notwithstanding anything in this Section to the contrary, Tenant shall not be required to provide Landlord with any Hazardous Materials Documents containing information of a proprietary nature, which Hazardous Materials Documents, in and of themselves, do not contain a reference to any Hazardous Materials or activities related to Hazardous Materials.  Landlord may, at Landlord&#8217;s expense, cause the Hazardous Materials Documents to be reviewed by a person or firm qualified to analyze Hazardous Materials to confirm compliance with the provisions of this Lease and with applicable Laws.  In the event that a review of the Hazardous Materials Documents indicates non-compliance with this Lease or applicable Laws, Tenant shall, at its expense, diligently take steps to bring its storage and use of Hazardous Materials into compliance.  Notwithstanding anything in this Lease to the contrary or Landlord&#8217;s review into Tenant&#8217;s Hazardous Materials Documents or use or disposal of hazardous materials, however, Landlord shall not have and expressly disclaims any liability related to Tenant&#8217;s or other </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">tenants&#8217; use or disposal of Hazardous Materials, it being acknowledged by Tenant that Tenant is best suited to evaluate the safety and efficacy of its Hazardous Materials usage and procedures.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.3.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;At any time, and from time to time, Landlord shall have the right to conduct appropriate tests of the Project or any portion thereof to demonstrate that Hazardous Materials are present or that contamination has occurred due to the acts or omissions of a Tenant Party.  Tenant shall pay all reasonable costs of such tests if such tests reveal that Hazardous Materials exist at the Project in violation of Tenant&#8217;s obligations under this Lease.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.3.4</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant shall not install or utilize any underground or other storage tanks storing Hazardous Materials on the Premises without Landlord&#8217;s prior written consent, which consent may be withheld in Landlord&#8217;s sole and absolute discretion.  Subject to the foregoing, if underground or other storage tanks storing Hazardous Materials installed or utilized by Tenant are located on the Premises, or are hereafter placed on the Premises by Tenant (or by any other party, if such storage tanks are utilized by Tenant), then Tenant shall monitor the storage tanks, maintain appropriate records, implement reporting procedures, properly close any underground storage tanks, and take or cause to be taken all other steps necessary or required under the applicable Laws.    </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.3.5</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant shall promptly report to Landlord any actual or suspected presence of mold or water intrusion at the Premises.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.3.6</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant&#8217;s obligations under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 8.3</font><font style="font-family:inherit;font-size:10pt;">&#32;shall survive the expiration or earlier termination of the Lease.  During any period of time needed by Tenant or Landlord after the termination of this Lease to complete the removal from the Premises of any Hazardous Materials, Tenant shall be deemed a holdover tenant and subject to the provisions of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 8.3</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.3.7</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;As used in this Lease, the term &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hazardous Material</font><font style="font-family:inherit;font-size:10pt;">&#8221; means any toxic, explosive, corrosive, flammable, infectious, radioactive, carcinogenic, mutagenic or otherwise hazardous substance, material or waste that is or becomes regulated by applicable Laws or any Governmental Authority, and the term &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Hazardous Material Laws</font><font style="font-family:inherit;font-size:10pt;">&#8221; means and includes all now and hereafter existing statutes, laws, ordinances, codes, regulations, rules, rulings, orders, decrees, directives, policies and requirements by any federal, state or local governmental authority regulating, relating to, or imposing liability or standards of conduct concerning public health and safety, the environment or any Hazardous Material, including, without limitation, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended (42 U.S.C. Section 9601 et seq.), Resource Conservation and Recovery Act, as amended (42 U.S.C. Section 6901 et seq.), and California Health and Safety Code (Sections 25100, 25249.5, 25316 and 39000, et seq. in each case).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.3.8</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Lease, Landlord shall have sole control over the equitable allocation of control areas (as defined in the California Building Standards Code) within the Project for the storage of Hazardous Materials.  Without limiting the foregoing, if the use of Hazardous Materials by Tenant is such that Tenant utilizes fire control areas in the Project in excess of Tenant&#8217;s Percentage, then Tenant shall, at its sole cost and expense and upon Landlord&#8217;s written request, establish and maintain a separate area of the Premises classified by the California Building Standards Code as a &#8220;Group H&#8221; occupancy area for the use and storage of Hazardous Materials, or take such other action as is necessary to ensure that its share of the fire control areas of the Building and the Project is not greater than Tenant&#8217;s Percentage.  Notwithstanding anything in this Lease to the contrary, Landlord shall not have and expressly disclaims any liability related to Tenant&#8217;s or other tenants&#8217; use or disposal of fire control areas, it being acknowledged by Tenant that Tenant and other tenants are best suited to evaluate the safety and efficacy of its Hazardous Materials usage and procedures.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Odors and Exhaust</font><font style="font-family:inherit;font-size:10pt;">.  Tenant acknowledges that Landlord would not enter into this Lease with Tenant unless Tenant assured Landlord that under no circumstances will any other occupants of the Building or the Project (including persons legally present in any outdoor areas of the Project) be subjected to odors or fumes (whether or not noxious), and that the Building and the Project will not be damaged by any exhaust, in each case from Tenant&#8217;s operations.  Landlord and Tenant therefore agree as follows:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.4.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant shall not cause or permit (or conduct any activities that would cause) any release of any odors or fumes of any kind from the Premises.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.4.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If the Building has a ventilation system that, in Landlord&#8217;s judgment, is adequate, suitable, and appropriate to vent the Premises in a manner that does not release odors affecting any indoor or outdoor part of the Project, Tenant shall vent the Premises through such system.  If Landlord at any time determines that any existing ventilation system is inadequate, or if no ventilation system exists, Tenant shall in compliance with applicable Laws vent all fumes and odors from the Premises (and remove odors from Tenant&#8217;s exhaust stream) as Landlord requires.  The placement and configuration of all ventilation exhaust pipes, louvers and other equipment shall be subject to Landlord&#8217;s approval.  Tenant acknowledges Landlord&#8217;s legitimate desire to maintain the Project (indoor and outdoor areas) in an odor-free manner, and Landlord may require Tenant to abate and remove all odors in a manner that goes beyond the requirements of applicable Laws.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.4.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant shall, at Tenant&#8217;s sole cost and expense, provide odor eliminators and other devices (such as filters, air cleaners, scrubbers and whatever other equipment may in Landlord&#8217;s judgment be necessary or appropriate from time to time) to completely remove, eliminate and abate any odors, fumes or other substances in Tenant&#8217;s exhaust stream that, in Landlord&#8217;s judgment, emanate from Tenant&#8217;s Premises.  Any work Tenant performs under this Section shall constitute Alterations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.4.4</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant&#8217;s responsibility to remove, eliminate and abate odors, fumes and exhaust shall continue throughout the Term.  Landlord&#8217;s construction of the Tenant Improvements shall not preclude Landlord from requiring additional measures to eliminate odors, fumes and other adverse impacts of Tenant&#8217;s exhaust stream (as Landlord may designate in Landlord&#8217;s discretion).  Tenant shall install additional equipment as Landlord requires from time to time under the preceding sentence.  Such installations shall constitute Alterations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">8.4.5</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If Tenant fails to install satisfactory odor control equipment within ten (10) business days after Landlord&#8217;s demand made at any time, then Landlord may, without limiting Landlord&#8217;s other rights and remedies, require Tenant to cease and suspend any operations in the Premises that, in Landlord&#8217;s determination, cause odors, fumes or exhaust.  For example, if Landlord determines that Tenant&#8217;s production of a certain type of product causes odors, fumes or exhaust, and Tenant does not install satisfactory odor control equipment within ten (10) business days after Landlord&#8217;s request, then Landlord may require Tenant to stop producing such type of product in the Premises unless and until Tenant has installed odor control equipment satisfactory to Landlord.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> MOLD&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant agrees to maintain the Premises in a manner that prevents the occurrence of an infestation of mold, mildew, microbial growths, and any associated mycotoxins in the Premises, and shall comply, at a minimum, with the following:  (a) subject to the terms and conditions of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 20</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 21</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.4</font><font style="font-family:inherit;font-size:10pt;">&#32;below, Tenant agrees to immediately fix/abate any water intrusion in the Premises, except to the extent caused by Landlord, another tenant or any third party not within Tenant&#8217;s control, or to the extent such water intrusion is caused by an event within Landlord&#8217;s express maintenance and repair obligations under this Lease; (b) Tenant agrees to use all reasonable care to close all windows and other openings in the Premises to prevent outdoor water from penetrating into the interior unit; (c) Tenant agrees to clean and dry any visible moisture on windows, walls, and other surfaces, including personal property, as soon as reasonably possible; (d) Tenant agrees to keep the Premises free of dirt and debris that could reasonably be expected to harbor mold; (e) Tenant agrees to regularly clean and sanitize kitchens and other surfaces within the Premises where water, moisture condensation, and mold can collect; (f) Tenant agrees not to interfere with regular air flow and circulation throughout the Premises; (g) Tenant agrees to limit the indoor watering of plants; (h) Tenant agrees to prevent the overflow or release of water from bathrooms or kitchens, including but not limited to toilets, sinks, kitchen appliances, and other receptacles of water; (i) Tenant agrees not to obstruct fresh air supply to furnace, air conditioner or heater ducts; (j) Tenant agrees to maintain and not obstruct ventilation at all locations in the Premises; (k) Tenant agrees to use commercially reasonable efforts to prevent the clogging of all plumbing within the Premises; (l) Tenant agrees not to engage in any conduct that could reasonably be expected to promote or create mold growth; (m) Tenant agrees to report within forty-eight (48) hours the following to Landlord to the extent Tenant has actual knowledge thereof:  (i) any non-working fan, heater, air conditioner or ventilation system; (ii) plumbing leaks, drips, sweating pipes, wet spots; (iii) overflows from bathroom, kitchen, or other facilities, including, but not limited to, tubs, showers, shower enclosures, toilets, sinks, kitchen appliances, or other receptacles of water, especially in cases where the overflow may have permeated walls, floors, ceilings or fixtures; (iv) water intrusion of any kind; (v) any mold or black or brown spots or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">moisture on surfaces inside the Premises; (vi) broken plumbing systems or standing water near structures within the Premises; and (vii) any odors consistent with mold growth within the Premises.  Tenant agrees not to commence any mold investigation, testing, remediation or repair without first obtaining the prior written consent of Landlord which shall not be unreasonably withheld, conditioned or delayed.  If Landlord consents to any mold investigation, remediation or repair by Tenant, Tenant agrees to not use any methods of mold investigation, testing, remediation and repair that are speculative and not generally accepted within the scientific community, and Landlord reserves the right to approve any and all third parties retained by Tenant to conduct any such mold investigation, testing, remediation and repair.  As of the Effective Date such speculative and generally unaccepted methods of investigation, testing, remediation and repair include:  (A) any use of settled dust vacuum sampling; (B) any use of interior wall cavity air sampling; (C) Tenant&#8217;s use of do-it-yourself mold investigation kits; and (D) use of any other methods that have not been peer reviewed and generally accepted within the scientific community.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> NOTICES&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Method of Delivery</font><font style="font-family:inherit;font-size:10pt;">.  Any notice, consent, approval or objection required or permitted by this Lease (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notice</font><font style="font-family:inherit;font-size:10pt;">&#8221;) shall be in writing and may be delivered:  (a) in person (by hand or by messenger or courier service) or (b) by certified or registered mail or United States Postal Service Express Mail, with postage prepaid, or (c) by a nationally recognized overnight delivery service that provides delivery verification, or (d) by facsimile transmission, addressed to Tenant at the Premises and to Landlord at each of the addresses designated in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.2</font><font style="font-family:inherit;font-size:10pt;">, and shall be deemed sufficiently given if served in a manner specified in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 10</font><font style="font-family:inherit;font-size:10pt;">.  Either party may specify a different address for Notice purposes by Notice to the other.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Receipt of Notices</font><font style="font-family:inherit;font-size:10pt;">.  Any Notice sent by registered or certified mail, return receipt requested, shall be deemed given on the date of delivery shown on the receipt card, or if no delivery date is shown, the postmark thereon.  Notices delivered by United States Postal Service Express Mail or overnight delivery service that guarantees next day delivery shall be deemed given on the next business day after delivery of the same to the United States Postal Service or overnight delivery service.  If any Notice is transmitted by facsimile transmission or similar means, the same shall be deemed served or delivered upon telephone confirmation of receipt of the transmission thereof, provided a copy is also delivered on or before the next business day via one of the methods in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section&#160;10.1(a)-(c)</font><font style="font-family:inherit;font-size:10pt;">&#32;above.  If any Notice is received on a Saturday, Sunday or legal holiday, it shall be deemed received on the next business day.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Statutory Service of Notice</font><font style="font-family:inherit;font-size:10pt;">.  When a statute permits, or requires, service of a notice in a particular manner, service of that notice (or a similar Notice permitted, or required, by this Lease) in the manner permitted, or required, by this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 10</font><font style="font-family:inherit;font-size:10pt;">&#32;shall replace and satisfy the statutory service&#8209;of&#8209;notice procedures, including, but not limited to, those required by California Code of Civil Procedure Section 1162, or any similar or successor statute.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;  <br>BROKERS&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant warrants that it has had no dealings with any real estate broker, finder or agent in connection with the negotiation of this Lease except for the broker(s) whose name(s) is (are) set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.16</font><font style="font-family:inherit;font-size:10pt;">, whose commission shall be payable by Landlord pursuant to one or more separate agreements, and that it knows of no other real estate broker, finder or agent who is or might be entitled to a commission in connection with this Lease.  Tenant shall be solely responsible for the payment of any fee due to any other broker, finder, agent or other party claiming under Tenant, and shall hold Landlord free and harmless against any liability in respect thereto, including attorneys&#8217; fees and costs incurred by Landlord in connection therewith.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> HOLDING OVER&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If Tenant holds over after the expiration or earlier termination of the Term hereof without the express written consent of Landlord, Tenant shall become a Tenant at sufferance, at a Basic Rent equal to one hundred fifty percent (150%) of the Rent payable during the last month of the Term, and otherwise subject to the terms, covenants and conditions herein specified, so far as applicable.  Acceptance by Landlord of Rent after such expiration or earlier termination without Landlord&#8217;s prior written consent shall not waive Landlord&#8217;s right to evict Tenant without thirty </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30) days prior written notice.  The foregoing provisions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article&#160;12</font><font style="font-family:inherit;font-size:10pt;">&#32;are in addition to and do not affect Landlord&#8217;s right of reentry or any rights of Landlord hereunder or as otherwise provided by law.  If Tenant fails to surrender the Premises upon the expiration or earlier termination of this Lease, Tenant shall indemnify, defend and hold Landlord harmless from all Claims, including, without limitation, any claim made by any succeeding tenant founded on or resulting from such failure to surrender, lost profits and other consequential damages, and any and all attorneys&#8217; fees and costs incurred by Landlord in connection Tenant&#8217;s failure to surrender the Premises in accordance with the provisions of this Lease on the expiration or earlier termination of this Lease.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> TAXES ON TENANT&#8217;S PROPERTY&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Personal Property and Fixtures</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall be liable for and shall pay before delinquency, all taxes levied against any of Tenant&#8217;s Personal Property (defined below) placed by Tenant or any Tenant Party in or about the Premises.  If any such taxes on Tenant&#8217;s Personal Property are levied against Landlord or Landlord&#8217;s property, or if the assessed value of the Premises, Building or Project is increased by the inclusion therein of a value placed upon such Tenant&#8217;s Personal Property, and if Landlord, after Notice to Tenant, pays the taxes based upon such increased assessment, which Landlord shall have the right to do regardless of the validity thereof (but only under proper protest if so requested by Tenant), Tenant shall, upon demand, repay to Landlord the taxes so levied against Landlord, or the portion of such taxes resulting from such increase in the assessment.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant Improvements</font><font style="font-family:inherit;font-size:10pt;">.  If any Alterations installed in the Premises by or on behalf of Tenant are assessed for real property tax purposes at a valuation higher than the valuation at which the initial Tenant Improvements are assessed, then the real property taxes and assessments levied against the Building or Project by reason of such excess assessed valuation shall be deemed to be taxes levied against Tenant&#8217;s Personal Property and shall be governed by the provisions of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 13.1</font><font style="font-family:inherit;font-size:10pt;">&#32;above.  If the records of the County Assessor are available and sufficiently detailed to serve as a basis for determining whether the Alterations are assessed at a higher valuation than the Tenant Improvements, such records shall be binding on both Landlord and Tenant.  If the records of the County Assessor are not available or sufficiently detailed to serve as a basis for making said determination, the actual cost of construction shall be used.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;.  Tenant shall pay to Landlord, within ten (10) business days of Landlord&#8217;s demand therefor, and in such manner and at such times as Landlord shall direct from time to time by written notice to Tenant, any excise, sales, privilege or other tax, assessment or other charge (other than income or franchise taxes) imposed, assessed or levied by any Governmental Authority upon Landlord on account of:  (a) the Rent payable by Tenant hereunder (or any other benefit received by Landlord hereunder), including, without limitation, any gross receipts tax, license fee or excise tax levied by any Governmental Authority, (b) this Lease, Landlord&#8217;s business as a lessor hereunder, and the possession, leasing, operation, management, maintenance, alteration, repair, use or occupancy of any portion of the Premises (including, without limitation, any applicable possessory interest taxes), (c) this transaction or any document to which Tenant is a party creating or transferring an interest or an estate in the Premises, or (d) otherwise in respect of or as a result of the agreement or relationship of Landlord and Tenant hereunder.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> CONDITION OF PREMISES&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant acknowledges and agrees that:  (a) Tenant has inspected the Project, the Building and the Premises and accepts them in their &#8220;AS IS, WHERE IS&#8221; condition, (b) neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the Premises, the Building, the Parking Area or any other portion of the Project or with respect to the condition thereof or the suitability of the same for the conduct of Tenant&#8217;s business, (c) except as expressly provided in the Work Letter Agreement and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 16.2</font><font style="font-family:inherit;font-size:10pt;">&#32;below, Landlord shall have no obligation to alter, remodel, improve, repair, decorate or paint the Premises or any part thereof, or any portion of the Building or Project and (d) except as expressly provided in this Lease, Landlord shall have no obligation to provide Tenant with any allowance, rent credit or abatement in connection with Tenant&#8217;s entering into this Lease.  The taking of possession of the Premises by Tenant shall conclusively establish that the Project, the Building and the Premises were at such time in good order and clean condition and that Landlord shall have discharged all of its obligations under the Work Letter Agreement (other than the obligation to complete punch list items), and the execution of this Lease by Tenant shall </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conclusively establish that the Premises, the Building, the Project and the Parking Area were in good and sanitary order, condition and repair at such time, except for latent defects, if any.  Without limiting the foregoing, Tenant&#8217;s execution of the Memorandum of Terms shall constitute a specific acknowledgment and acceptance of the various start-up inconveniences that may be associated with the use of the Building, the Parking Area and other portions of the Project, such as certain construction obstacles (e.g., scaffolding), delays in use of freight elevator service, unavailability of certain elevators for Tenant&#8217;s use, uneven air-conditioning services and other typical conditions incident to recently constructed (or recently modified) office and laboratory/research and development buildings.  Tenant (for itself and all other claiming through Tenant) hereby irrevocably waives and releases its right to terminate this Lease under Section 1932(l) of the California Civil Code.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> ALTERATIONS&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Alterations and Major Alterations</font><font style="font-family:inherit;font-size:10pt;">.  Except for Permitted Alterations, Tenant shall make no alterations, additions, or improvements in or to the Premises (collectively, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Alterations</font><font style="font-family:inherit;font-size:10pt;">&#8221;) without Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed for all Alterations other than Major Alterations (which shall be granted in Landlord&#8217;s sole discretion), and then only by licensed contractors or mechanics approved by Landlord in writing, which approval shall not be unreasonably withheld, conditioned or delayed (provided that any contractors performing any Major Alterations shall be subject to approval by Landlord in its sole and absolute discretion).  Tenant shall submit to Landlord plans and specifications for any proposed Alterations to the Premises, and may not make such Alterations until Landlord has approved such plans and specifications and the contractor performing any Alterations in writing.  Tenant shall construct such Alterations in accordance with the plans and specifications approved by Landlord and in compliance with all applicable Laws, and shall not amend or modify such plans and specifications without Landlord&#8217;s prior written consent.  If any proposed Alterations require the consent or approval of any lessor of a superior lease or the holder of a mortgage encumbering the Premises, Tenant acknowledges that such consent or approval must be secured prior to the construction of such Alterations.  Tenant agrees not to construct or erect partitions or other obstructions that might interfere with Landlord&#8217;s free access to mechanical installations or service facilities of the Building or interfere with the moving of Landlord&#8217;s equipment to or from the enclosures containing said installations or facilities.  All Alterations shall be done at such times and in such manner as Landlord may from time to time reasonably designate.  Tenant will pay the entire cost and expense of all Alterations, including, without limitation, for any painting, restoring or repairing of the Premises or the Building necessitated by the Alterations, and Landlord&#8217;s actual out-of-pocket third party review and Landlord&#8217;s supervision fee in an amount equal to five percent (5%) of the cost of the Alterations in question (except for Permitted Alterations).  Tenant will also obtain and/or require: (a) builder&#8217;s &#8220;all-risk&#8221; insurance (or the equivalent thereof) in an amount at least equal to the replacement value of the Alterations; (b) liability insurance insuring Tenant and each of Tenant&#8217;s contractors against construction related risks in at least the form, amounts and coverage required of Tenant under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 22</font><font style="font-family:inherit;font-size:10pt;">; and (c) if requested by Landlord, demolition (if applicable) and payment and performance bonds in an amount not less than the full cost of the Alterations.  The insurance policies described in clause (b) of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 15.1</font><font style="font-family:inherit;font-size:10pt;">&#32;must name Landlord, Landlord&#8217;s lender (if any), Bioscience Properties, Inc. (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Property Manager</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and other parties reasonably requested by Landlord as additional insureds, specifically including completed operations.  Tenant covenants and agrees that all Alterations done by Tenant shall be performed in full compliance with all Laws.  If any Governmental Authority requires any alterations or modifications to the Building or the Premises as a result of Tenant&#8217;s Permitted Use of the Premises or as a result of any Alteration to the Premises made by or on behalf of Tenant, Tenant will pay the cost of all such alterations or modifications.  If any such Alterations involve any modifications to (i) the structural portions of the Building, (ii) the mechanical, electrical, plumbing, fire/life safety or heating, ventilating and air conditioning systems of the Building (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Building Systems</font><font style="font-family:inherit;font-size:10pt;">&#8221;) or (iii) any portion of the Building outside of the interior of the Premises (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Major Alteration</font><font style="font-family:inherit;font-size:10pt;">&#8221;), it shall be reasonable for Landlord to withhold its consent to any such Major Alterations and it shall be reasonable for Landlord to condition its consent to any Major Alterations on Landlord making the Major Alterations, provided that Landlord may first require Tenant to deposit with Landlord an amount sufficient to pay the cost of the Major Alterations (including, without limitation, reasonable overhead, administrative costs and profit).  Before commencing any work, Tenant shall give Landlord at least ten (10) days&#8217; Notice of the proposed commencement of such work and shall, if required by Landlord, deliver a copy of the completion and payment bond required by Landlord in form, substance and amount satisfactory to Landlord.  &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Permitted Alterations</font><font style="font-family:inherit;font-size:10pt;">&#8221; means only usual and customary maintenance and repairs of Leasehold Improvements if and to the extent that such maintenance and repairs:  (A) are </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of a type and extent which are customarily permitted to be made without consent by landlords acting consistently with Institutional Owner Practices leasing similar space for similar uses to similar tenants, (B) are in compliance with the Rules and Regulations and all applicable Laws, (C) are not Major Alterations, and (D) do not cost more than Fifty Thousand and 00/100 Dollars ($50,000.00) in each instance.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Removal of Alterations and Tenant&#8217;s Personal Property</font><font style="font-family:inherit;font-size:10pt;">.  The Tenant Improvements together with all Alterations upon the Premises made by Tenant after the Commencement Date, including, without limitation, all wall coverings, built-in cabinet work, paneling and the like (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Leasehold Improvements</font><font style="font-family:inherit;font-size:10pt;">&#8221;), shall, at Landlord&#8217;s election, either be removed by Tenant or shall become the property of Landlord and shall remain upon, and be surrendered with, the Premises at the end of the Term hereof; provided, however, that if Landlord, by Notice to Tenant given at the time Landlord approves any Alteration, requires Tenant to remove any such Leasehold Improvements, Tenant shall repair all damage resulting from such removal or, at Landlord&#8217;s option, shall pay to Landlord the cost of such removal, as reasonably estimated by Landlord, prior to the expiration of the Term of this Lease.  All articles of personal property and all business and trade fixtures, cabling, machinery and equipment, furniture and movable partitions owned by Tenant or any other Tenant Party or that are installed by or for Tenant or any other Tenant Party at its expense in the Premises (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Personal Property</font><font style="font-family:inherit;font-size:10pt;">&#8221;) shall be and remain the property of Tenant and shall be removed by Tenant prior to the expiration of the Term, and Tenant shall repair all damage to the Premises, if any, resulting from such removal.  If Tenant shall fail to remove any of the foregoing from the Premises prior to termination of this Lease for any cause whatsoever, Tenant shall be deemed to be holding over in the Premises without the consent of Landlord and Landlord may, at its option, remove the same in any manner that Landlord shall choose, and store the same without liability to Tenant for loss thereof.  In such event, Tenant agrees to pay to Landlord upon demand, any and all expenses incurred in such removal (including court costs and attorneys&#8217; fees) and storage charges thereon, for any length of time that the same shall be in Landlord&#8217;s possession or control.  Landlord may, at its option, without Notice, sell such property, or any of the same, at a private sale and without legal process, for such price as Landlord may obtain and apply the proceeds of such sale to any amounts due under this Lease from Tenant to Landlord and/or to all expenses, including attorneys&#8217; fees and costs, incident to the removal and/or sale thereof.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> REPAIRS&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant Obligations</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall, when and if needed, at Tenant&#8217;s sole cost and expense and subject to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 15</font><font style="font-family:inherit;font-size:10pt;">&#32;above, make all repairs to the Premises and every part thereof to maintain the Premises in the condition and repair that existed as of the Commencement Date, reasonable wear and tear and casualty damage excepted, and free from any Hazardous Materials.  Except as expressly set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 16.2</font><font style="font-family:inherit;font-size:10pt;">&#32;below, all Supplemental Equipment and all Building Systems located within and exclusively serving the Premises shall be maintained, repaired and replaced as needed by Tenant at Tenant&#8217;s sole cost and expense and Landlord shall have no liability for the operation, repair, maintenance or replacement of any Supplemental Equipment, nor shall Landlord have any liability for the operation, repair or maintenance of any Building Systems located within and/or exclusively serving the Premises.  &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Supplemental Equipment</font><font style="font-family:inherit;font-size:10pt;">&#8221; means any items that are installed within the Premises by or at the direction of Tenant or that exclusively serve the Premises (other than standard Building Systems), including, without limitation:  (A) any supplemental, specialty or non-Building standard electrical (including lighting), mechanical, plumbing, heating, ventilation and air conditioning systems, fixtures and equipment; (B) any supplemental, specialty or non-Building standard fire, life, safety or security systems, fixtures and equipment; and (C) all video, audio, communications or computer systems, fixtures and equipment (including cabling).  Without limiting the foregoing, Tenant shall maintain, at its sole cost and expense, a contract for the regular maintenance and repair of the heating, ventilation and air conditioning systems, fixtures and equipment located within and/or exclusively serving the Premises.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord Obligations</font><font style="font-family:inherit;font-size:10pt;">.  Landlord shall maintain, repair and replace the structural portions of the Building (including, without limitation, the roof structure, roof membrane, slab and exterior walls) outside of the Premises, the Parking Area and the Building Systems (other than Building Systems and/or components thereof located within and/or exclusively serving the Premises), and the costs incurred by Landlord in performing such maintenance, repairs and replacements shall be included in Operating Expenses (except to the extent expressly excluded pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 6.1</font><font style="font-family:inherit;font-size:10pt;">&#32;above).  For purposes of clarification, Landlord shall have no obligation to repair, maintain or replace any part of the Premises, any Building Systems located within and/or exclusively serving the Premises or any Supplemental Equipment.  Landlord shall not be liable for any failure to make any repairs or replacements or to perform any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintenance to the extent that the need for such repairs, replacements or maintenance is caused by the negligence or willful misconduct of any Tenant Party.  Except as provided in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Articles 23</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">24</font><font style="font-family:inherit;font-size:10pt;">&#32;hereof, there shall be no abatement of Rent and no liability of Landlord by reason of any injury to or interference with Tenant&#8217;s business arising from the making of any repairs, alterations, improvements or replacements in or to any portion of the Building or the Premises or in or to fixtures, appurtenances and equipment therein.  Tenant waives the right to make repairs and replacements at Landlord&#8217;s expense under any Law now or hereafter in effect including Section 1941 and 1942 of the California Civil Code (as the same may be amended from time to time) and any successor statute and similar Law now or hereafter in effect.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> LIENS&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant shall not cause or permit to be filed against the Premises, the Building or the Project or of any portion thereof or against Tenant&#8217;s leasehold interest in the Premises any mechanics&#8217;, materialmen&#8217;s or other liens, including without limitation any state, federal or local &#8220;superfund&#8221; or Hazardous Materials cleanup lien imposed as a result of the presence of Hazardous Materials in, on or about the Premises, the Building or any other portion of the Project.  Landlord shall have the right at all reasonable times to post and keep posted on the Premises any notices that it deems necessary for protection from such liens.  Tenant shall discharge any lien filed against the Premises or against the Building for work claimed to have been done for, or materials claimed to have been furnished to, Tenant, by bond or otherwise, within ten (10) business days after the filing thereof, at the cost and expense of Tenant.  If any such liens are filed and Tenant fails to discharge them pursuant to the foregoing sentence, Landlord may, without waiving its rights and remedies based on such breach of Tenant and without releasing Tenant from any of its obligations hereunder, cause such lien(s) to be released by any means it shall deem proper, including payments in satisfaction of the claim giving rise to such lien or by obtaining a corporate statutory mechanic&#8217;s lien release bond in an amount equal to one hundred fifty percent (150%) of such lien claim.  Tenant shall:  (a) pay to Landlord, immediately upon Notice from Landlord, any cost or expense, including, without limitation, attorneys&#8217; fees and costs, incurred by Landlord by reason of Tenant&#8217;s failure to discharge any such lien, together with interest thereon at the maximum rate per annum permitted by Law from the date of such payment by Landlord and (b) shall indemnify, defend and hold the Landlord Indemnified Parties harmless from and against any liens.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 18</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> ENTRY BY LANDLORD&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord reserves and shall upon at least twenty-four (24) hours prior notice to Tenant (except in the case of an emergency) have the right to enter the Premises during Tenant&#8217;s normal business hours (except in the case of an emergency, in which case such entry may be at any time) to supply any service to be provided by Landlord to Tenant hereunder, to inspect the same, to show the Premises to prospective purchasers, lenders, or investors and during the last twelve (12) months of the Term or following a default by Tenant to prospective tenants, to post notices of non-responsibility, to alter, improve or repair the Premises or any other portion of the Building and/or the Project, as provided in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2.4</font><font style="font-family:inherit;font-size:10pt;">&#32;above, or for any other reasonable purpose, all without being deemed guilty of any eviction of Tenant and without abatement of Rent.  Landlord may, in order to carry out such purposes, erect scaffolding and other necessary structures where reasonably required by the character of the work to be performed, provided that the business of Tenant shall be interfered with as little as is reasonably practicable.  Tenant hereby waives any claim for damages for any injury or inconvenience to or interference with Tenant&#8217;s business, for any loss of occupancy or quiet enjoyment of the Premises and for any other loss in, upon and about the Premises, the Building or the Project on account of Landlord&#8217;s entry or work permitted by this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 18</font><font style="font-family:inherit;font-size:10pt;">&#32;or by </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2.4</font><font style="font-family:inherit;font-size:10pt;">&#32;above.  Landlord shall at all times have and retain a key with which to unlock all doors in the Premises, excluding Tenant&#8217;s vaults and safes.  Landlord shall have the right to use any and all means that Landlord may deem proper to open said doors in an emergency in order to obtain entry to the Premises.  Any entry to the Premises obtained by Landlord by any of said means, or otherwise, shall not be construed or deemed to be a forcible or unlawful entry into the Premises, or an eviction of Tenant from the Premises or any portion thereof, and any damages caused on account thereof shall be paid by Tenant.  Landlord shall use commercially reasonable efforts to minimize any interference with Tenant&#8217;s business in connection with any entry onto the Premises pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 18</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 19</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> UTILITIES AND SERVICES&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Premises Utilities</font><font style="font-family:inherit;font-size:10pt;">.  Notwithstanding anything to the contrary in this Lease, Tenant shall pay for the cost of all water (including the cost to service, repair and replace reverse osmosis, de-ionized and other treated water), electricity, gas, heating, ventilation and air-conditioning (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">HVAC</font><font style="font-family:inherit;font-size:10pt;">&#8221;), light, power, telephone, internet service, cable television, other telecommunications and other utilities supplied to the Premises, together with any fees, surcharges and taxes thereon.  All such utilities and services provided to the Premises that are separately metered shall be paid by Tenant directly to the supplier of such utilities or services.  If any such utility is not separately metered to Tenant, Tenant shall pay Tenant&#8217;s Percentage of all charges of such utility jointly metered with other premises as Additional Rent or, in the alternative, Landlord may, at its option, monitor the usage of such utilities by Tenant and charge Tenant with the cost of purchasing, installing and monitoring such metering equipment, which cost shall be paid by Tenant as Additional Rent.  Landlord may base its bills for utilities on reasonable estimates; provided that Landlord adjusts such billings promptly thereafter or as part of the next Annual Reconciliation to reflect the actual cost of providing utilities to the Premises.  In the event that the Building or Project is less than fully occupied during a calendar year, Tenant acknowledges that Landlord may extrapolate utility usage that varies depending on the occupancy of the Building or Project (as applicable) to equal Landlord&#8217;s reasonable estimate of what such utility usage would have been had the Building or Project, as applicable, been one hundred percent (100%) occupied during such calendar year; provided, however, that Landlord shall not recover more than one hundred percent (100%) of the cost of such utilities.  Landlord may, in Landlord&#8217;s sole and absolute discretion, at any time and from time to time, contract, or require Tenant to contract, for utility services (including generation, transmission, or delivery of the utility service) with a utility service provider(s) of Landlord&#8217;s choosing.  Tenant shall fully cooperate with Landlord and any utility service provider selected by Landlord.  Upon at least twenty four (24) hours&#8217; prior Notice and only during Tenant&#8217;s normal business hours, Tenant shall permit Landlord and the utility service provider to have reasonable access to the Premises and the utility equipment serving the Premises, including lines, feeders, risers, wiring, pipes, and meters.    </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Janitorial Service</font><font style="font-family:inherit;font-size:10pt;">.  Tenant, at its sole cost and expense, shall enter into an agreement for regular janitorial services for the Premises with a company which is fully bonded and insured and approved by Landlord in its reasonable discretion.  Tenant shall keep the Premises at all times in a clean and orderly condition, at Tenant&#8217;s expense and to the reasonable satisfaction of Landlord.  Unless otherwise agreed to by Landlord, no one other than persons approved by Landlord shall be permitted to enter the Premises for the purpose of providing janitorial or cleaning service.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord Exculpation</font><font style="font-family:inherit;font-size:10pt;">.  Landlord&#8217;s failure to furnish or cause to be furnished any service which Landlord is required or elects to provide under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 19</font><font style="font-family:inherit;font-size:10pt;">&#32;shall not result in any liability to Landlord.  Landlord shall not be responsible or liable for any loss, damage, or expense that Tenant may incur as a result of any change of utility service, including any change that makes the utility supplied less suitable for Tenant&#8217;s needs, or for any failure, interruption, stoppage, or defect in any utility service.  In addition, except as expressly set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 19.8</font><font style="font-family:inherit;font-size:10pt;">&#32;below, Tenant shall not be entitled to any abatement or reduction of Rent, no eviction of Tenant shall result from and Tenant shall not be relieved from the performance of any covenant or agreement in this Lease by reason of any such change, failure, interruption, stoppage or defect.  In the event of any such failure, interruption, stoppage or defect of a service which Landlord is required to provide hereunder, Landlord shall diligently attempt to cause service to be resumed promptly.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Limitations on Tenant&#8217;s Utilities</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall not, without Landlord&#8217;s prior written consent, use any device in the Premises (including data processing machines) that will in any way (a) increase the amount of ventilation, air exchange, gas, steam, electricity or water required or consumed in the Premises based upon Tenant&#8217;s Percentage of the Building or Project (as applicable) beyond the existing capacity of the Building or the Project usually furnished or supplied for the Permitted Use or (b) exceed Tenant&#8217;s Percentage of the Building&#8217;s or Project&#8217;s (as applicable) capacity to provide such utilities or services.  If Tenant shall require utilities or services in excess of those usually furnished or supplied for tenants in similar spaces in the Building or the Project by reason of Tenant&#8217;s equipment or extended hours of business operations, then Tenant shall first procure Landlord&#8217;s consent for the use thereof, which consent shall not be unreasonably withheld, conditioned or delayed (except that Landlord may condition such consent upon the availability of such excess utilities or services), and Tenant shall pay as Additional Rent an amount equal to the cost of providing such excess utilities and services.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Area Water</font><font style="font-family:inherit;font-size:10pt;">.  Landlord shall provide water in the Common Area for, to the extent applicable, lavatory and landscaping purposes only, which water shall be from the local municipal or similar source; provided, however, that if Landlord reasonably determines that Tenant requires, uses or consumes water provided to the Common Area for any purpose other than ordinary lavatory purposes, Landlord may install a water meter (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant Water Meter</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and thereby measure Tenant&#8217;s water consumption for all purposes.  Upon such determination by Landlord, Tenant shall pay Landlord for the costs of any Tenant Water Meter and the installation and maintenance thereof during the Term.  If Landlord installs a Tenant Water Meter, Tenant shall pay for water consumed, as shown on such meter, as and when bills are rendered.  If Tenant fails to timely make such payments, Landlord may pay such charges and collect the same from Tenant.  Any such costs or expenses incurred or payments made by Landlord for any of the reasons or purposes stated in this Section shall be deemed to be Additional Rent payable by Tenant and collectible by Landlord as such.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Energy Tracking</font><font style="font-family:inherit;font-size:10pt;">.  Within ten (10) business days following Landlord&#8217;s written request therefor, Tenant shall deliver to Landlord copies of any invoices for utility services provided to the Premises and related information reasonably requested by Landlord in connection with the requirements of California Public Resources Code Section 25402.10, the corresponding regulations adopted by the California Energy Commission and provided in California Code of Regulations, Title 20, Division 2, Chapter 4, Article 9, Sections 1680-1684, and any supplemental and/or successor statute or regulations concerning the reporting of energy usage and efficiency relative to commercial buildings.  Tenant acknowledges that any utility information for the Premises, the Building and the Project may be shared with third parties, including Landlord&#8217;s consultants and Governmental Authorities.  In addition to the foregoing, Tenant shall comply with all applicable Laws related to the disclosure and tracking of energy consumption at the Premises.  The provisions of this Section shall survive the expiration or earlier termination of this Lease.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reservation of Rights</font><font style="font-family:inherit;font-size:10pt;">.  Landlord reserves the right, upon Notice to Tenant (except in the event of an emergency, in which case no notice shall be required), to temporarily stop service of the plumbing, ventilation, air conditioning and utility systems, when Landlord deems necessary or desirable, due to accident, emergency or the need to make repairs, alterations or improvements, until such repairs, alterations or improvements shall have been completed, and Landlord shall further have no responsibility or liability for failure to supply plumbing, ventilation, air conditioning or utility service when prevented from doing so by Force Majeure (as defined in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 36.8</font><font style="font-family:inherit;font-size:10pt;">&#32;below).  Without limiting the foregoing, it is expressly understood and agreed that any covenants on Landlord&#8217;s part to furnish any service pursuant to any of the terms, covenants, conditions, provisions or agreements of this Lease, or to perform any act or thing for the benefit of Tenant, shall not be deemed breached if Landlord is unable to furnish or perform the same by virtue of Force Majeure.  In the case of all such service interruptions, Landlord shall use commercially reasonable efforts to minimize any interference with Tenant&#8217;s business.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Abatement of Rent</font><font style="font-family:inherit;font-size:10pt;">.  In the event that Tenant is prevented from using, and does not use, the Premises or any material portion thereof for more than five (5) consecutive business days as a result of a failure to provide any utilities to the Premises which Landlord is required to provide under this Lease, to the extent within Landlord&#8217;s sole control (an &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Abatement Event</font><font style="font-family:inherit;font-size:10pt;">&#8221;), then Tenant shall give Landlord written Notice of such Abatement Event, and if such Abatement Event continues for an additional five (5) consecutive business days after Landlord&#8217;s receipt of any such Notice (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Eligibility Period</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and Landlord does not diligently commence and pursue to completion the remedy of such Abatement Event, then, except to the extent covered by business interruption or similar insurance carried or required to be carried by Tenant hereunder, Basic Rent shall be abated or reduced, as the case may be, after expiration of the Eligibility Period for such time that Tenant continues to be so prevented from using, and does not use, the Premises or a portion thereof, in the proportion that the rentable area of the portion of the Premises that Tenant is prevented from using, and does not use, bears to the total rentable area of the Premises.  If, however, Tenant reoccupies any portion of the Premises during such period, the Basic Rent allocable to such reoccupied portion, based on the proportion that the rentable area of such reoccupied portion of the Premises bears to the total rentable area of the Premises, shall be payable by Tenant from the date Tenant reoccupies such portion of the Premises.  Such right to abate Basic Rent shall be Tenant&#8217;s sole and exclusive remedy at law or in equity for an Abatement Event.  Except as expressly provided in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 19.8</font><font style="font-family:inherit;font-size:10pt;">, nothing contained herein shall be interpreted to mean that Tenant is excused from paying Rent due hereunder. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 20</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> INDEMNIFICATION AND EXCULPATION OF LANDLORD&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant shall indemnify, defend and hold harmless the Landlord Indemnified Parties (as defined in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1.2</font><font style="font-family:inherit;font-size:10pt;">&#32;below) from and against any and all claims, demands, penalties, fines, liabilities, actions (including, without limitation, informal proceedings), settlements, judgments, damages, losses, costs and expenses (including attorneys&#8217; fees and costs) of whatever kind or nature, known or unknown, contingent or otherwise, incurred or suffered by or asserted against such Landlord Indemnified Party (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Claims</font><font style="font-family:inherit;font-size:10pt;">&#8221;) arising from or in connection with, directly or indirectly, (a) any cause whatsoever in the Premises (including, but not limited to, Claims resulting in whole or in part from the ordinary negligence of the Landlord Indemnified Party), except to the extent directly caused by the gross negligence or intentional misconduct of such Landlord Indemnified Party, (b) the presence at or use or occupancy of the Premises or Project by a Tenant Party, (c) any act, neglect, fault or omission on the part of any Tenant Party, or (d) a breach or default by Tenant in the performance of any of its obligations hereunder.  Payment shall not be a condition precedent to enforcement of the foregoing indemnity.  In case any action or proceeding shall be brought against any Landlord Indemnified Party by reason of any such Claim, Landlord shall provide written notice of such Claim to Tenant and Tenant shall have the right to assume the defense of any Claim with respect to which Landlord is entitled to indemnification hereunder.  If Tenant assumes such defense, (i) such defense shall be conducted by counsel selected by Tenant and reasonably approved by Landlord; (ii) Tenant shall have the right to control said defense and shall not be required to pay the fees or disbursements of any counsel engaged by Landlord; and (iii) Tenant shall have the right, without the consent of Landlord, to settle such Claim, but only provided that such settlement involves only the payment of money, does not include an admission of fault or guilt and is subject to a confidential settlement agreement, and Tenant pays all amounts due in connection with or by reason of such settlement.  Landlord shall have the right to participate in the defense of such Claim at the expense of Landlord, but Tenant shall have the sole right to control such defense.  In no event shall (A) Landlord settle any Claim without the consent of Tenant so long as the Tenant is conducting the defense thereof in accordance with this Lease, or (B) if a Claim is covered by Tenant&#8217;s insurance, Landlord shall not knowingly take or omit to take any action that would cause the insurer not to defend such Claim or to disclaim liability in respect thereof.  Tenant, as a material part of the consideration to Landlord, hereby assumes all risk of damage to property (including, without limitation, any damage to personal property or scientific research, including loss of records kept by Tenant within the Premises (in each case, regardless of whether such damage is foreseeable)) or injury to Tenant or any other Tenant Parties in, upon or about the Premises, the Building, the Parking Area or the Project from any cause whatsoever and hereby waives all Claims (including consequential damages and claims for injury to Tenant&#8217;s business or loss of income arising out of any loss of use of the Premises, the Building, the Parking Area or the Project or any equipment or facilities therein, or relating to any such damage or destruction of personal property as described in this Section) in respect thereof against each Landlord Indemnified Party, except that which is solely caused by, or solely the result of: (i) any Landlord Default (defined below), (ii) the grossly negligent acts of such Landlord Indemnified Party, or (iii) the willful misconduct of such Landlord Indemnified Party.  Except to the extent arising from the gross negligence or willful misconduct of Landlord, Landlord shall not be liable for any damages arising from any act, omission or neglect of any other tenant in the Building or the Project, or of any other third party.  Without limitation on other obligations of Tenant that survive the expiration of the Term, the clauses of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article&#160;20</font><font style="font-family:inherit;font-size:10pt;">&#32;shall survive the expiration or earlier termination of this Lease until all Claims against the Landlord Indemnified Parties involving any of the indemnified matters are fully, finally, and absolutely barred by the applicable statutes of limitations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 21</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> DAMAGE TO TENANT&#8217;S PROPERTY&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the provisions of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 20</font><font style="font-family:inherit;font-size:10pt;">&#32;or anything to the contrary in this Lease, no Landlord Indemnified Party shall be liable for loss or damage to any property by theft or any other cause whatsoever, any injury or damage to persons or property resulting from fire, explosion, falling plaster, steam, gas, electricity, electrical or electronic emanations or disturbance, water, rain or leaks from any part of the Building or from the pipes, or caused by dampness, vandalism, malicious mischief or by any other cause of whatever nature, unless caused by or due to the gross negligence or willful misconduct of such Landlord Indemnified Party.  In no event shall any Landlord Indemnified Party be liable for any loss, the risk of which is covered by Tenant&#8217;s insurance or is required to be so covered by this Lease; nor shall any Landlord Indemnified Party be liable for any such damage caused by other persons in the Building or caused by operations in construction of any private, public, or quasi-public work; nor shall any Landlord Indemnified Party be </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">liable for any latent defect in the Premises or in the Building.  Tenant shall immediately give Notice to Landlord in case of the occurrence of any fire or accidents in or about the Premises, the Building or any other portion of the Project of which Tenant has actual knowledge, or the discovery of any defects therein (including, without limitation, any latent defect in the Premises) or in any fixtures or equipment that are the property of Landlord or Tenant.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Without limiting the foregoing, Tenant acknowledges that safety and access control devices, services and programs provided by Landlord, if any, while intended to deter crime and ensure safety, may not in given instances prevent theft or other criminal acts, or ensure safety of persons or property.  Landlord shall not be liable for injuries or losses caused by criminal acts of third parties, and the risk that any safety or access control device, service or program may not be effective, or may malfunction, or be circumvented by a criminal, is assumed by Tenant with respect to Tenant&#8217;s property and interests, and Tenant shall obtain insurance coverage to the extent Tenant desires protection against such criminal acts and other losses, as further described in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 22</font><font style="font-family:inherit;font-size:10pt;">.  Tenant agrees to cooperate in any reasonable safety or security program developed by Landlord or required by Law.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 22</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> INSURANCE&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant&#8217;s Insurance</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall, during the Term hereof (and during any period that Tenant may enter, occupy and/or use the Premises prior to the Commencement Date and any holdover period), at its sole cost and expense, keep in full force and effect the following insurance:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Property insurance insuring against any perils included within the classification &#8220;All Risk,&#8221; including, without limitation, fire, windstorm, cyclone, tornado, hail, explosion, riot, riot attending a strike, civil commotion, aircraft, vehicle, smoke damage, vandalism, malicious mischief and sprinkler leakage, excluding damage from earth movement, nuclear hazards, war, flood and earthquakes.  Such insurance shall insure all property owned by Tenant or any other Tenant Party, for which Tenant or any other Tenant Party is legally liable or that was installed at the expense of Tenant or any other Tenant Party, and which is located in the Building, including, without limitation, furniture, furnishings, installations, fixtures and equipment, any other personal property, and in addition, all improvements and betterments to the Premises, including all Leasehold Improvements, in an amount not less than one hundred percent (100%) of the full replacement cost thereof.  For the purposes of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1.1</font><font style="font-family:inherit;font-size:10pt;">, the Premises shall consist of the floor area shown in the Outline of Premises, consisting of the cubic space spanning from the floor slab to the bottom surface of the floor slab of the floor immediately above the Premises (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Upper Slab</font><font style="font-family:inherit;font-size:10pt;">&#8221;), without any offsets or deductions that are included for the Permitted Use of Tenant.  Such cubic space shall include the plenum space which is bounded by the lower surface of the Upper Slab and the suspended ceiling of the Premises.  In the event that there shall be a dispute as to the amount that comprises full replacement cost, the decision of Landlord or any mortgagees of Landlord shall be conclusive.  Such policy shall name Landlord, any mortgagees of Landlord and any other additional parties designated by Landlord as loss payees, as their respective interests may appear.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Commercial General Liability Insurance insuring Tenant on the current ISO CG 00 01 occurrence form or any equivalent reasonably acceptable to Landlord against any liability arising out of the lease, use, occupancy or maintenance of the Premises, the Building or the Project, or any portion of the foregoing.  Such insurance shall be in the following minimum limits: $2,000,000 per occurrence and $2,000,000 in the aggregate and shall be endorsed to have the aggregate apply on a per location/per project basis and shall cover injury (including mental anguish) to or death of one or more persons and damage to tangible property (including loss of use) including blanket contractual liability, broad form property damage (including coverage for explosion, collapse and underground hazards), $1,000,000 personal &amp; advertising injury, and $2,000,000 Products Completed Operations.  The policy shall not include any exclusions or limitations other than those incorporated in the standard form.  The policy shall insure the hazards of the Premises and Tenant&#8217;s operations thereon, Tenant&#8217;s independent contractors and Tenant&#8217;s contractual liability (including, without limitation, the indemnity contained in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 20</font><font style="font-family:inherit;font-size:10pt;">&#32;hereof) and shall:  (i) name Landlord (Wateridge Property Owner, LP); SB LWR Investors, LLC; the Property Manager; any additional entity Landlord may designate from time to time; and their respective partners, parents, affiliates, divisions and subsidiaries, and each of their respective directors, officers, principals, partners, shareholders, members, managing members, agents, employees, successors and assigns (together with Landlord, collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Landlord Indemnified Parties</font><font style="font-family:inherit;font-size:10pt;">&#8221;) as additional insureds; and (ii) include coverage for cross liability claims between Named Insureds (i.e., &#8220;Named Insured vs. Named Insured&#8221; Cross Liability Coverage Endorsement if required for coverage and no exclusion for cross liability claims between Named Insureds).  Such </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">insurance shall indicate that defense costs shall be outside of the policy limits, and shall not contain any exclusions or restrictions applicable to operations of the type contemplated by this Lease.  In addition to any insurance required of Tenant, Tenant shall secure, pay for and maintain or cause Tenant&#8217;s contractors and sub-contractors to secure, pay for and maintain insurance during any construction or work to the Premises performed by or on behalf of Tenant at a minimum equal to the limits of liability required by Tenant.  Tenant&#8217;s products and completed operations insurance shall be maintained for a minimum period equal to the greater of (i) the period under which a claim can be asserted under any applicable statutes of limitations and/or repose or (ii) three (3) years after Substantial Completion of the Tenant Improvements.  Tenant&#8217;s contractual liability insurance shall include coverage sufficient to meet the indemnity obligations included herein.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Worker&#8217;s Compensation Insurance in compliance with statutory requirements of the state(s) in which the employee resides, is hired and in which this Lease takes place, which insurance shall apply to all persons employed by Tenant, and Employer&#8217;s Liability insurance in amounts not less than $1,000,000 per accident, $1,000,000 per disease, and $1,000,000 disease-policy limit.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.1.4.&#160;&#160;&#160;&#160;Business interruption insurance and extra expense coverage on ISO coverage form CP 00 30 or equivalent reasonably acceptable to Landlord, which shall cover Tenant&#8217;s monetary obligations under this Lease and any direct or indirect loss of earnings attributable to perils insured against in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1.1</font><font style="font-family:inherit;font-size:10pt;">&#32;above for a period of at least twelve (12) months. If Tenant fails to obtain business interruption insurance, it is understood and agreed upon that Tenant is fully responsible for its own business interruption exposure whether insured or not.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.5</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Comprehensive Automobile Liability Insurance including coverage for all owned, leased, hired and non-owned vehicles with a minimum combined single limit of $1,000,000 per occurrence for bodily injury and property damage liability.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.6</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Umbrella/Excess Liability Insurance policy with a per occurrence and annual aggregate limit of $5,000,000</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">per location/project.  The limits of liability required in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1.2</font><font style="font-family:inherit;font-size:10pt;">&#32;above for Commercial General Liability can be provided in a combination of a Commercial General Liability policy and an Umbrella Liability policy.  Coverage shall be in excess of Commercial General Liability, Auto Liability and Employers&#8217; Liability insurance with such coverage being on a follow form basis, concurrent to and not more restrictive than underlying insurance. Tenant shall, by specific&#160;endorsement to its Umbrella/Excess Liability policy, cause the coverage&#160;afforded to the Landlord Indemnified Parties thereunder to be first tier umbrella/excess&#160;coverage above the primary&#160;coverage afforded to the Landlord Indemnified Parties as set&#160;forth in this Lease and not concurrent with or excess to any other&#160;valid and collectible insurance available to the Landlord Indemnified Parties whether&#160;provided on a&#160;primary or excess basis.  It is the specific intent of the parties&#160;that Tenant procure the excess carriers&#8217; agreement to waive and/or&#160;forego any viable &#8220;horizontal exhaustion&#8221; rights it might have in regard to&#160;any&#160;insurance any Landlord Indemnified Party might carry for its own benefit or on behalf of&#160;any other Landlord Indemnified Party.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.7</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If Tenant sells or dispenses alcoholic beverages as part of its business, Liquor Liability Insurance with limits of not less than $5,000,000 per occurrence; provided the foregoing shall not be required with respect to consumption of alcoholic beverages in the Premises by Tenant, its employees, or invitees.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.8</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Medical malpractice insurance at limits of not less than $1,000,000 each claim during such periods, if any, that Tenant engages in the practice of medicine at the Premises.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.9</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Pollution Legal Liability insurance if Tenant stores, handles, generates or treats Hazardous Materials, as reasonably determined by Landlord, on or about the Premises.  Such coverage shall include bodily injury, sickness, disease, death or mental anguish or shock sustained by any person; property damage including physical injury to or destruction of tangible property including the resulting loss of use thereof, clean-up costs, and the loss of use of tangible property that has not been physically injured or destroyed; and defense costs, charges and expenses incurred in the investigation, adjustment or defense of claims for such compensatory damages.  Coverage shall apply to both sudden and non-sudden pollution conditions including the discharge, dispersal, release or escape of smoke, vapors, soot, fumes, acids, alkalis, toxic chemicals, liquids or gases, waste materials or other irritants, contaminants or pollutants into or upon land, the atmosphere or any watercourse or body of water.  Claims-made coverage is permitted, provided the policy retroactive date is continuously maintained prior to the Commencement Date (or such earlier date that Tenant </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">has access to the Premises), and coverage is continuously maintained during all periods in which Tenant occupies the Premises.  Coverage shall be maintained with limits of not less than $1,000,000 per incident with a $2,000,000 policy aggregate.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.10</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Any other form or forms of insurance as Tenant or Landlord or any mortgagees of Landlord may reasonably require from time to time in form, in amounts and for insurance risks against which a prudent tenant would protect itself. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.11</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant may place all or any of the foregoing insurance coverages under blanket insurance policies carried by Tenant provided that no other loss which may also be insured by such blanket insurance shall affect the insurance coverages required hereby and so long as such policy complies with the amount of coverage required hereunder and otherwise provides the same protection as would a separate policy insuring only Tenant&#8217;s insurance obligations in compliance with the provisions of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1</font><font style="font-family:inherit;font-size:10pt;">&#32;hereof.  In addition, Tenant shall deliver to Landlord a certificate specifically stating that such coverages apply to Landlord, the Premises, the Building and the Project.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.1.12</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If Tenant shall hire or bring a vendor or contractor onto the Premises to perform any alterations, work or improvements, Tenant agrees to have a written agreement with such vendor or contractor whereby such vendor or contractor will be required to carry the same insurance coverages for Commercial General Liability, Auto and Worker&#8217;s Compensation, Employer&#8217;s Liability and Pollution Legal Liability insurance as required of Tenant herein.&#160; Tenant shall also require that such vendor&#8217;s or contractor&#8217;s insurance meet the same additional terms as required of Tenant herein with regards to adding the Landlord Indemnified Parties and all mortgagees as additional insureds, maintaining primary and non-contributory coverage, waiving all rights of recovery and subrogation, and making certificates of insurance available as evidence of all policies during the term of their work and in advance of all applicable renewals.  Tenant shall not allow any vendors or contractors to begin work prior to obtaining certificates evidencing all insurance requirements contained herein.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Standard of Insurance</font><font style="font-family:inherit;font-size:10pt;">.  All policies shall be written in a form satisfactory to Landlord, and the Commercial General Liability, Comprehensive Automobile Liability, Umbrella/Excess Liability, Liquor Liability (if applicable) and Pollution Legal Liability policies required under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1</font><font style="font-family:inherit;font-size:10pt;">&#32;shall name all Landlord Indemnified Parties as additional insureds on a primary and non-contributory basis.  In addition, if Tenant places any such required coverages under a blanket insurance policy as set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1.11</font><font style="font-family:inherit;font-size:10pt;">, the blanket policy shall name all Landlord Indemnified Parties as additional insureds on a primary and non-contributory basis.  All insurance policies required under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1</font><font style="font-family:inherit;font-size:10pt;">&#32;shall be issued by companies authorized to do business in the State of California with an A.M. Best&#8217;s Rating of at least A-/VIII.  No deductibles or Self-Insured Retention (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SIR</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of Tenant shall exceed $25,000 without Landlord&#8217;s prior written approval.  All deductibles and SIR are the responsibility of Tenant and must be shown on the certificate of insurance.  On or before the date which is ten (10) days after the execution of this Lease, and prior to or on the renewal of such policies thereafter, Tenant shall deliver to Landlord copies of policies or certificates evidencing the existence of the amounts and forms of coverage satisfactory to Landlord.  No such policy shall be cancelable or reducible in coverage except after thirty (30) days prior Notice to Landlord.  Any insurance limits required by this Lease are minimum limits only and not intended to restrict the liability imposed on any Tenant for liability under this Lease.  Tenant shall, within thirty (30) days prior to the expiration of such policies, furnish Landlord with renewals or &#8220;binders&#8221; thereof, or Landlord may order such insurance and charge the cost thereof to Tenant as Additional Rent.  If Landlord obtains any insurance that is the responsibility of Tenant under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 22</font><font style="font-family:inherit;font-size:10pt;">, Landlord shall deliver to Tenant a written statement setting forth the cost of any such insurance and showing in reasonable detail the manner in which it has been computed and Tenant shall remit said amount to Landlord within ten (10) business days.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord Insurance</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:12pt;">3.1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;During the Term of this Lease, Landlord shall insure the Building and the Parking Areas (to the extent Landlord is the owner thereof) (excluding any property which Tenant is obligated to insure under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sections 22.1</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">22.2</font><font style="font-family:inherit;font-size:10pt;">&#32;hereof) against damage with All-Risk insurance (which may, but shall not be required to, insure against earthquake damage) and public liability insurance, all in such amounts and with such deductibles as Landlord considers appropriate.  Landlord may, but shall not be obligated to, obtain and carry any other form or forms of insurance as Landlord or Landlord&#8217;s mortgagees may determine advisable.  Notwithstanding any contribution by Tenant to the cost </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of insurance premiums, as provided herein, Tenant acknowledges that it has no right to receive any proceeds from any insurance policies carried by Landlord.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.3.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If any of Landlord&#8217;s insurance policies shall be canceled or cancellation shall be threatened or the coverage thereunder reduced or threatened to be reduced in any way because of Tenant&#8217;s specific use of the Premises or any part thereof by Tenant or any assignee or subtenant of Tenant or by anyone Tenant permits on the Premises and, if Tenant fails to remedy the condition giving rise to such cancellation, threatened cancellation, reduction of coverage, threatened reduction of coverage, increase in premiums, or threatened increase in premiums, within forty-eight (48) hours after Notice thereof, Landlord may, at its option, but without any obligation so to do, enter upon the Premises and attempt to remedy such condition, and Tenant shall promptly pay the cost thereof to Landlord as Additional Rent.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subrogation Waivers</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.4.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subrogation Waiver &#8211; Policies Other than Property Insurance</font><font style="font-family:inherit;font-size:10pt;">.  Tenant hereby waives all rights against the Landlord Indemnified Parties, Landlord&#8217;s contractors (and their subcontractors of every tier), and their respective employees and agents, for any claims that arise from Tenant&#8217;s work or activities and for recovery of damages under Tenant&#8217;s insurance policies required under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1</font><font style="font-family:inherit;font-size:10pt;">&#32;or any other insurance policy carried by Tenant related to the Premises or this Lease (excluding Tenant&#8217;s property insurance, which is addressed hereunder in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.4.2</font><font style="font-family:inherit;font-size:10pt;">).  Tenant shall obtain an endorsement effecting the foregoing waiver with respect to its workers compensation and employers liability insurance.  If any other policy implicated by the waiver in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.4.1</font><font style="font-family:inherit;font-size:10pt;">&#32;does not allow Tenant to waive rights of recovery against others prior to a loss, Tenant shall obtain an endorsement effecting the applicable waiver.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">22.4.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subrogation Waiver &#8211; Property Insurance</font><font style="font-family:inherit;font-size:10pt;">.  Landlord and Tenant waive all rights against each other for damages caused by fire or other causes of loss occurring on and after the date on which this Lease is executed to the extent such damages are covered (or are required to be covered) by any property insurance required under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 22</font><font style="font-family:inherit;font-size:10pt;">&#32;(including business income and loss of rent insurance) or otherwise carried by such party in relation to the Premises, the Building or the Project, regardless of whether such insurance is specifically required under this Lease.  Tenant&#8217;s waiver in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.4.2</font><font style="font-family:inherit;font-size:10pt;">&#32;also extends to the Landlord Indemnified Parties.  Each party shall obtain an endorsement pursuant to which its insurers waive their subrogation rights against the parties specified in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.4.2</font><font style="font-family:inherit;font-size:10pt;">.  If a property insurance policy implicated by the waiver in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.4.2</font><font style="font-family:inherit;font-size:10pt;">&#32;does not allow the insured to waive rights of recovery against others prior to a loss, the insured shall cause the policy to be endorsed to provide for such waiver.  The waivers in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.4.2</font><font style="font-family:inherit;font-size:10pt;">&#32;will be effective as to a person or entity even though that person or entity would otherwise have a duty of indemnification, did not pay the insurance premium directly or indirectly, or did not have an insurable interest in the property damaged.  To the extent that either party self-insures for its insurance obligations under this Lease (e.g., maintains a deductible amount), such party shall be treated as an independent insurer with full waiver of subrogation.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 23</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;  <br>DAMAGE OR DESTRUCTION&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">23.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Damages</font><font style="font-family:inherit;font-size:10pt;">.  If the Building and/or the Premises are damaged by fire or other perils covered by Landlord&#8217;s insurance, Landlord shall:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">23.1.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In the event of one hundred percent (100%) destruction of the Premises (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Total Destruction</font><font style="font-family:inherit;font-size:10pt;">&#8221;), at Landlord&#8217;s option, as soon as reasonably possible thereafter, commence repair, reconstruction and restoration of the Building and/or the Premises and prosecute the same diligently to completion, in which event this Lease shall remain in full force and effect; provided, however, that (a) Landlord may elect by Notice to Tenant given within ninety (90) days after such destruction not to repair, reconstruct or restore the Building and/or the Premises, in which case, this Lease shall terminate as of the date of such Total Destruction, and (b) if such repair, reconstruction and restoration cannot reasonably be expected to be completed within two hundred seventy (270) days after such Total Destruction Tenant shall have the right to terminate this Lease upon written notice to Landlord delivered within thirty (30) days after such destruction.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">23.1.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In the event of a partial destruction of the Building and/or the Premises and if the damage thereto is such that the Building and/or the Premises is capable of being repaired, reconstructed or restored within a period of ninety (90) days from the date of Landlord&#8217;s discovery of such damage, and if Landlord will receive insurance proceeds sufficient to cover the total cost of such repairs, reconstruction or restoration, Landlord shall commence and proceed diligently with the work of repairs, reconstruction and restoration of the Building and/or the Premises or both, as the case may be, and this Lease shall continue in full force and effect.  If such work of repair, reconstruction and restoration shall require a period longer than ninety (90) days or exceeds twenty-five percent (25%) of the full replacement cost of the Building and/or the Premises, or both, as the case may be, or if insurance proceeds will not be sufficient to cover the cost of such repairs, reconstruction and restoration, then Landlord either may elect to so repair, reconstruct or restore and this Lease shall continue in full force and effect or may elect not to repair, reconstruct or restore and this Lease shall then terminate as of the date of such partial destruction.  Under any of the conditions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 23.1.2</font><font style="font-family:inherit;font-size:10pt;">, Landlord shall give Notice to Tenant of its intention regarding repairs within said ninety (90) day period.  If damage is due to any cause other than fire or other peril covered by extended coverage insurance, Landlord may elect to terminate this Lease.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">23.1.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;In any case where Landlord elects to repair, restore or reconstruct the Premises following the occurrence of any damage to which this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 23</font><font style="font-family:inherit;font-size:10pt;">&#32;applies, then Tenant shall assign to Landlord the proceeds of its property insurance attributable to the Leasehold Improvements.  If the cost of restoring the Leasehold Improvements exceeds the amount of the proceeds of Tenant&#8217;s property insurance that are received by Landlord, Tenant shall promptly pay the amount of such deficiency to Landlord upon demand. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">23.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Termination of Lease</font><font style="font-family:inherit;font-size:10pt;">.  Upon any termination of this Lease under any of the provisions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 23</font><font style="font-family:inherit;font-size:10pt;">, the parties shall be released without further obligation to the other from the date possession of the Premises is surrendered to Landlord except for items which have therefore accrued and/or are then unpaid or items which expressly survive the expiration or sooner termination of this Lease.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">23.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rent Abatement</font><font style="font-family:inherit;font-size:10pt;">.  In the event of any casualty, the Rent payable under this Lease shall be abated proportionately with the degree to which Tenant&#8217;s Permitted Use of the Premises is impaired either during the period of such repair, reconstruction or restoration or until termination of the Lease pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 23</font><font style="font-family:inherit;font-size:10pt;">, but only to the extent that Landlord is compensated for such loss by the insurance carried or required to be carried pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 22.1.4</font><font style="font-family:inherit;font-size:10pt;">&#32;above.  Notwithstanding the foregoing, there shall be no abatement of Rent if such damage is caused primarily by the negligence or intentional wrongdoing of Tenant or any Tenant Party.  Tenant shall not be entitled to any compensation or damages for loss in the use of the whole or any part of the Premises and/or any inconvenience or annoyance occasioned by such damage, repair, reconstruction or restoration.  If Landlord is obligated to or elects to repair or restore as herein provided, Landlord shall be obligated to repair or restore only those portions of the Building and the Premises which were originally provided at Landlord&#8217;s expense, and the repair and restoration of items not provided at Landlord&#8217;s expense shall be the obligation of Tenant.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">23.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Damage Near End of Term</font><font style="font-family:inherit;font-size:10pt;">.  Notwithstanding anything to the contrary contained in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 23</font><font style="font-family:inherit;font-size:10pt;">, if material damage to the Premises occurs during the last twelve (12) months of the Term, either party may elect, no earlier than sixty (60) days after the date of the damage and not later than ninety (90) days after the date of such damage, to terminate this Lease by written notice to the other effective as of the date specified in the notice, which date shall not be less than ten (10) business days nor more than sixty (60) days after the date such notice is given.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">23.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Waiver of Statute</font><font style="font-family:inherit;font-size:10pt;">.  In the event of damage to the Premises and/or the Building, Tenant shall not be released from any of its obligations under this Lease except to the extent and upon the conditions expressly stated in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 23</font><font style="font-family:inherit;font-size:10pt;">.  Tenant hereby waives the provisions of California Civil Code Section 1932, Subsection 2, and Section&#160;1933, Subsection 4, and any other statute or court decision relating to the abatement or termination of a lease upon destruction of the Premises and the provisions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 23</font><font style="font-family:inherit;font-size:10pt;">&#32;shall govern in case of such destruction.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 24</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> EMINENT DOMAIN&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Permanent Taking</font><font style="font-family:inherit;font-size:10pt;">.  If all of the Premises, or such part thereof as shall substantially interfere with Tenant&#8217;s Permitted Use and occupancy thereof, shall be taken for any public or quasi-public purpose by any lawful power or authority by exercise of the right of appropriation, condemnation or eminent domain, or sold to prevent such </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">taking (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Taking</font><font style="font-family:inherit;font-size:10pt;">&#8221;), either party shall have the right to terminate this Lease by Notice to the other effective as of the date possession is required to be surrendered to said authority.  Tenant shall not assert any claim against Landlord or the taking authority for any compensation because of such Taking, and Landlord shall be entitled to receive the entire amount of any award without deduction for any estate or interest of Tenant.  If the amount of property or the type of estate taken shall not substantially interfere with the conduct of Tenant&#8217;s business, Landlord shall be entitled to the entire amount of the award without deduction for any estate or interest of Tenant, Landlord shall restore the Premises to substantially their same condition prior to such partial Taking, and Basic Rent shall be reduced, effective as of the date the condemning authority takes possession, in the same proportion which the Rentable Square Feet of the portion of the Premises so taken bears to the Rentable Square Feet of the entire Premises before the Taking.  Nothing contained in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 24.1</font><font style="font-family:inherit;font-size:10pt;">&#32;shall be deemed to give Landlord any interest in any award made to Tenant for the taking of personal property and fixtures belonging to Tenant or for relocation costs and expenses.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Temporary Taking</font><font style="font-family:inherit;font-size:10pt;">.  Notwithstanding anything to the contrary in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 24.1</font><font style="font-family:inherit;font-size:10pt;">&#32;above, in the event of Taking of the Premises or any part thereof for temporary use, (a) this Lease shall be and remain unaffected thereby and Rent shall not abate, and (b) Tenant shall be entitled to receive for itself such portion or portions of any award made for such use with respect to the period of the Taking which is within the Term, provided that if such Taking shall remain in force at the expiration or earlier termination of this Lease, Tenant shall then pay to Landlord a sum equal to the reasonable cost of performing Tenant&#8217;s obligations under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 15.</font><font style="font-family:inherit;font-size:10pt;">2 above and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 31</font><font style="font-family:inherit;font-size:10pt;">&#32;below with respect to surrender of the Premises and, upon such payment, shall be excused from such obligations.  For purpose of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 24</font><font style="font-family:inherit;font-size:10pt;">, a &#8220;temporary&#8221; Taking shall be defined as a Taking for a period of two hundred seventy (270) days or less and a &#8220;permanent&#8221; Taking shall be defined as a Taking for a period of more than two hundred seventy (270) days.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Waiver of Statute</font><font style="font-family:inherit;font-size:10pt;">.  Tenant (for itself and all others claiming through Tenant) hereby irrevocably waives and releases its rights under Section 1265.130 of the California Code of Civil Procedure.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 25</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> DEFAULTS AND REMEDIES&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant Default</font><font style="font-family:inherit;font-size:10pt;">.  The occurrence of any one or more of the following events, upon the expiration of any applicable time period, shall constitute a default hereunder by Tenant (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant Default</font><font style="font-family:inherit;font-size:10pt;">&#8221;):</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.1.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Abandonment of the Premises by Tenant.  Notwithstanding the provisions of California Civil Code Section 1951.3, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Abandonment</font><font style="font-family:inherit;font-size:10pt;">&#8221; is defined to include, but not limited to, any absence by Tenant from the Premises for thirty (30) days or longer while in default pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 25.1</font><font style="font-family:inherit;font-size:10pt;">;</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.1.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The failure by Tenant to make any payment of Rent or any other payment required to be made by Tenant hereunder, as and when due, where such failure shall continue for a period of three (3) business days after Landlord&#8217;s delivery of Notice thereof;</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.1.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The failure by Tenant to obtain and keep in force at all times any insurance Tenant is required to obtain and keep in force under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 22</font><font style="font-family:inherit;font-size:10pt;">&#32;where such failure is not cured within three (3) business days after Landlord&#8217;s delivery of Notice of such failure;</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.1.4</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Hypothecation, assignment or other transfer of this Lease or subletting of the Premises, or attempts of such actions in violation of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 27</font><font style="font-family:inherit;font-size:10pt;">&#32;of this Lease;</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.1.5</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The failure by Tenant to deliver any certificate, instrument or statement that is required to be delivered by Tenant under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 28,</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 29</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 36.16</font><font style="font-family:inherit;font-size:10pt;">&#32;within the time frames required in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 28,</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 29</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 36.16</font><font style="font-family:inherit;font-size:10pt;">, as applicable, which Tenant fails to cure within five (5) business days after Landlord&#8217;s delivery of Notice thereof;</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.1.6</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The failure by Tenant to observe or perform any of the express or implied covenants or provisions of this Lease to be observed or performed by Tenant, other than as specified in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sections 25.1.1 &#8211; 25.1.5</font><font style="font-family:inherit;font-size:10pt;">&#32;above or </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 25.1.7</font><font style="font-family:inherit;font-size:10pt;">&#32;below, where such failure shall continue for a period of thirty (30) days after Landlord&#8217;s delivery of Notice thereof; provided that if the nature of any such failure is such that more than thirty (30) days are reasonably required for its cure, then no Tenant Default shall be deemed to occur if (and for so long as) Tenant commences the cure of such failure within said thirty (30) day period and thereafter diligently prosecutes such cure to completion within ninety (90) days after Landlord&#8217;s delivery of Notice thereof; or</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.1.7</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The (a) making by Tenant of any general assignment for the benefit of creditors; (b) filing </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">by or against Tenant of a petition to have Tenant adjudged a bankrupt or a petition for reorganization or arrangement under any Law relating to bankruptcy; (c) appointment of a trustee or receiver to take possession of substantially all of Tenant&#8217;s assets located at the Premises or of Tenant&#8217;s interest in this Lease; (d) attachment, execution or other judicial seizure of substantially all of Tenant&#8217;s assets located at the Premises or of Tenant&#8217;s interest in this Lease; or (e) Tenant&#8217;s convening of a meeting of its creditors or any class thereof for the purpose of effecting a moratorium upon or composition of its debts, or any class thereof; provided that no Tenant Default will be deemed to occur under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 25.1.7</font><font style="font-family:inherit;font-size:10pt;">&#32;if (i) any petition described in clause (a) above that filed against (rather than by) Tenant, is dismissed within thirty (30) days) after filing, (ii) in the event any trustee or receiver shall take possession of substantially all of Tenant&#8217;s assets located at the Premises or Tenant&#8217;s interest in this Lease, possession of the same is restored to Tenant within thirty (30) days or (iii) any attachment, execution or other judicial seizure described in clause (d) above is discharged within thirty (30) days.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any Notice from Landlord required hereby shall be in lieu of, and not in addition to, any Notice required under California Code of Civil Procedure Section 1161 regarding unlawful detainer actions or any similar successor statute.  Accordingly, Tenant (for itself and all others claiming through Tenant) hereby expressly and irrevocably waives the notice requirements of California Code of Civil Procedure Section 1162 that would otherwise govern notices required under Section 1161, and agrees that any notice provided pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 25.1</font><font style="font-family:inherit;font-size:10pt;">&#32;shall replace and satisfy any such requirements of Section 1162.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord Remedies</font><font style="font-family:inherit;font-size:10pt;">.  In the event of any such Tenant Default, in addition to any other remedies available to Landlord at law or in equity, including, without limitation, the remedies available under California Civil Code Section 1951.2 and any successor statute, Landlord shall have the immediate option to terminate this Lease and all rights of Tenant hereunder.  In the event that Landlord shall elect to so terminate this Lease then Landlord may recover from Tenant:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.2.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The worth at the time of award of any unpaid Rent which had been earned at the time of such termination; plus</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.2.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the worth at the time of award of the amount by which the unpaid Rent which would have been earned after termination until the time of award exceeds the amount of such Rent loss that Tenant proves could have been reasonably avoided; plus</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.2.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the worth at the time of award of the amount by which the unpaid Rent for the balance of the Term after the time of award exceeds the amount of such Rent loss that Tenant proves could be reasonably avoided; plus</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.2.4</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#8217;s failure to perform Tenant&#8217;s obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including but not limited to the cost of recovering possession of the Premises, expenses of reletting, including necessary repair, renovation and alteration of the Premises, reasonable attorneys&#8217; fees and any other reasonable costs; and</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">25.2.5</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;at Landlord&#8217;s election, such other amounts in addition to or in lieu of the foregoing as may be permitted from time to time by applicable Law.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As used in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sections 25.2.1</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">25.2.2</font><font style="font-family:inherit;font-size:10pt;">&#32;above, the &#8220;worth at the time of award&#8221; is computed by allowing interest at the Default Rate.  As used in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 25.2.3</font><font style="font-family:inherit;font-size:10pt;">&#32;above, the &#8220;worth at the time of award&#8221; is computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Discount Rate</font><font style="font-family:inherit;font-size:10pt;">&#8221;) at the time of award plus one percent (1%).  If the format or components of the Discount Rate are materially changed, or if the Discount Rate ceases to exist, Landlord shall substitute a discount rate which is maintained by the Federal Reserve Bank of San Francisco or similar financial institution and which is most nearly equivalent to the Discount Rate.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Remedies</font><font style="font-family:inherit;font-size:10pt;">.  If any such Tenant Default occurs, Landlord may utilize the remedy described in California Civil Code Section 1951.4 (which provides landlord may continue the lease in effect after a tenant&#8217;s breach and abandonment and recover Rent as it becomes due, if tenant has the right to sublet or assign subject to reasonable limitations).  Accordingly, in the event of any Tenant Default and abandonment of the Premises by Tenant, if Landlord </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">does not elect to terminate this Lease on account of such Tenant Default, then Landlord may from time-to-time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including the right to recover all Rent as it becomes due.  In the event of the Abandonment of the Premises by Tenant or in the event that Landlord utilizes the remedy described in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 25.3</font><font style="font-family:inherit;font-size:10pt;">&#32;above or shall take possession of the Premises pursuant to legal proceeding or pursuant to any notice provided by Law, then if Landlord does not elect to terminate this Lease as provided above, Landlord may from time to time, without terminating this Lease, either recover all Rent as it becomes due or relet the Premises or any part thereof for the Term of this Lease on terms and conditions as Landlord in its sole discretion may deem advisable with the right to make alterations and repairs to the Premises.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If Landlord shall elect to so relet, such reletting shall not relieve Tenant of any obligation hereunder, except that the rents received by Landlord from such reletting shall be applied as follows:  (a) first, to the payment of any indebtedness other than Rent due hereunder from Tenant to Landlord; (b) second, to the payment of any cost of such reletting; (c) third, to the payment of the cost of any alterations and repairs to the Premises; (d) fourth, to the payment of Rent due and unpaid hereunder and (e) the residue, if any, shall be held by Landlord and applied to payment of future Rent as the same may become due and payable hereunder.  Should that portion of such rents received from such reletting during any month, which is applied to the payment of Rent hereunder, be less than the Rent payable during that month by Tenant hereunder, then Tenant shall pay such deficiency to Landlord immediately upon demand therefor by Landlord.  Such deficiency shall be calculated and paid monthly.  Tenant shall also pay to Landlord, as soon as ascertained, any costs and expenses, including attorneys&#8217; fees, incurred by Landlord in such reletting or in making such alterations and repairs not covered by the rents received from such reletting.  During the continuance of a Tenant Default, Landlord shall have the right to market the Premises to potential new tenants and may show the Premises to such potential new tenants during normal business hours.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notice of Default</font><font style="font-family:inherit;font-size:10pt;">.  Tenant hereby acknowledges that default by Tenant hereunder, and Landlord&#8217;s election to prepare and serve a Notice of any such default hereunder (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notice of Default</font><font style="font-family:inherit;font-size:10pt;">&#8221;), will cause Landlord to incur costs not contemplated by this Lease, and costs in addition to any costs which may be reimbursed to Landlord by any provision which may be contained herein relative to the payment of interest or late charges on amounts due hereunder.  Accordingly, Landlord shall be entitled to reasonable attorneys&#8217; fees and all other costs and expenses incurred in the preparation and service of a Notice of Default and consultations in connection therewith, with respect to which Landlord and Tenant agree that Seven Hundred Fifty Dollars ($750.00) is a reasonable minimum sum per such occurrence, whether or not legal action is subsequently commenced in connection with any such default.  It is further hereby specifically agreed by and between Landlord and Tenant that any and all such fees and costs shall be deemed Additional Rent hereunder, and may, at the option of Landlord, be included in any Notice of Default hereunder.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord&#8217;s Right to Cure</font><font style="font-family:inherit;font-size:10pt;">.  If Tenant should fail to make any payment or perform any of its other obligations hereunder, Landlord, without being under any obligation to do so and without thereby waiving such default, may make such payment and/or remedy such other default for the account of Tenant (and enter the Premises for such purpose):  (a) immediately and without notice in the case:  (i) of emergency, (ii) of a default by Tenant of its obligations under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 8.3</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 15.2</font><font style="font-family:inherit;font-size:10pt;">&#32;and/or </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 31</font><font style="font-family:inherit;font-size:10pt;">, (iii) where such default unreasonably interferes with any other tenant in the Building or Project, (iv) a failure to satisfy or otherwise discharge any lien, or (v) where such default will result in the violation of Law or the cancellation of any insurance policy maintained by Landlord and (b) in any other case if such default continues beyond the applicable notice and cure period specified in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 25.1</font><font style="font-family:inherit;font-size:10pt;">&#32;above, and thereupon Tenant shall be obligated to, and hereby agrees to pay Landlord, upon demand, all costs, expenses, and disbursements incurred by Landlord in taking such remedial action, together with an amount equal to five percent (5%) thereof for Landlord&#8217;s overhead and administrative expenses, and the sum of such costs, together with interest thereon at the rate described in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 5.3</font><font style="font-family:inherit;font-size:10pt;">&#32;from the date of Landlord&#8217;s payment thereof, shall be deemed Additional Rent.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Waiver of Redemption</font><font style="font-family:inherit;font-size:10pt;">.  Tenant (for itself and all others claiming through Tenant) hereby irrevocably waives and releases its rights to redemption and reinstatement under any present or future case law or statutory provision (including, without limitation, Sections 473, 1174 and 1179 of the California Code of Civil Procedure and Section 3275 of the California Civil Code) in the event that Tenant is dispossessed from the Premises for any reason.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord&#8217;s Default</font><font style="font-family:inherit;font-size:10pt;">.  Landlord&#8217;s failure to perform or observe any of its obligations under this Lease shall constitute a default by Landlord under this Lease (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Landlord Default</font><font style="font-family:inherit;font-size:10pt;">&#8221;) only if Landlord, or the Holder (defined below) of any Security Instrument (defined below) covering the Premises, fails to perform obligations required of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord within thirty (30) days after Notice by Tenant to Landlord (and to each Holder pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 36.5</font><font style="font-family:inherit;font-size:10pt;">&#32;below), specifying wherein Landlord has failed to perform such obligations in reasonable detail; provided, however, that if the nature of Landlord&#8217;s obligation is such that more than thirty (30) days are required for performance, then no Landlord Default shall occur if Landlord commences performance within such thirty (30) day period and thereafter diligently prosecutes the same to completion (or if any Holder of any Security Instrument commences and prosecutes the cure pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 36.5</font><font style="font-family:inherit;font-size:10pt;">&#32;below).  In no event shall Tenant be entitled to terminate this Lease by reason of any Landlord Default, and Tenant&#8217;s remedies shall be limited to an action for monetary damages at law.  Without limiting the foregoing, in recognition that Landlord must receive timely payments of Rent and operate the Building and Project, Tenant shall have no right of self-help to perform repairs or any other obligation of Landlord and, except as expressly provided in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Articles 23</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">24</font><font style="font-family:inherit;font-size:10pt;">, shall have no right to withhold, set-off, or abate Rent.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 26</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> NO WAIVER&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All rights, options and remedies of Landlord contained in this Lease shall be construed and held to be cumulative, and not one of them shall be exclusive of the other, and Landlord shall have the right to pursue any one or all of such remedies or any other remedy or relief which may be provided by Law, whether or not stated in this Lease.  The waiver by Landlord of any breach of any term, covenant or condition herein contained shall not be deemed to be a waiver of any subsequent breach of the same or any other term, covenant or condition herein contained, nor shall any custom or practice which may grow up between the parties in the administration of the terms hereof be deemed a waiver of or in any way affect the right of Landlord to insist upon the performance by Tenant in strict accordance with said terms.  The subsequent acceptance of Rent hereunder by Landlord shall not be deemed to be a waiver of any preceding breach by Tenant of any term, covenant or condition of this Lease, other than the failure of Tenant to pay the particular Rent so accepted, regardless of Landlord&#8217;s knowledge of such preceding breach at the time of acceptance of such Rent.  No acceptance by Landlord of a lesser sum than the Basic Rent and Additional Rent or other sum then due shall be deemed to be other than on account of the earliest installment of such Rent or other amount due, nor shall any endorsement or statement on any check or any letter accompanying any check be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the balance of such installment or other amount or pursue any other remedy provided in this Lease.  Without limiting the foregoing, Tenant (for itself and all others claiming through Tenant) acknowledges that this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 26</font><font style="font-family:inherit;font-size:10pt;">&#32;imparts actual notice to Tenant, pursuant to California Code of Civil Procedure Section 1161.1(c), that Landlord&#8217;s acceptance of partial payment of Rent shall not constitute a waiver of any rights available under this Lease or at law or equity, including, without limitation, the right to recover possession of the Premises.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 27</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> ASSIGNMENT AND SUBLETTING&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transfer</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall not voluntarily or by operation of law: (a) sublease all or any part of the Premises (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sublease</font><font style="font-family:inherit;font-size:10pt;">&#8221;), (b) assign this Lease (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:10pt;">&#8221;), or (c) enter into any other agreement or arrangement:  (i) that permits a third party (other than Tenant&#8217;s employees and occasional guests) to enter, occupy or use any portion of the Premises or remove any of Tenant&#8217;s Personal Property therefrom or (ii) otherwise assigns, transfers, mortgages, pledges, hypothecates, encumbers or permits a lien to attach to Tenant&#8217;s interest under this Lease or in the Premises (each of the foregoing (a), (b) and (c), a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transfer</font><font style="font-family:inherit;font-size:10pt;">&#8221;), without first obtaining Landlord&#8217;s prior written consent in accordance with this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 27</font><font style="font-family:inherit;font-size:10pt;">.  In addition, for purposes of this Lease a &#8220;Transfer&#8221; (which shall be subject to the provisions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 27</font><font style="font-family:inherit;font-size:10pt;">) shall also include:  (A) a direct or indirect transfer, assignment, pledge, or hypothecation of a Controlling (defined below) interest in Tenant and/or (B) the dissolution of the entity that constitutes Tenant without its immediate reconstitution.  &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Control</font><font style="font-family:inherit;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Controlling</font><font style="font-family:inherit;font-size:10pt;">&#8221; means possession of the direct or indirect power to direct or cause the direction of the management and policies of a person or entity.  No consent to an assignment, encumbrance or sublease shall constitute a waiver of any provision of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 27</font><font style="font-family:inherit;font-size:10pt;">&#32;or consent to any future assignment, encumbrance or transfer.  Any Transfer without Landlord&#8217;s prior written consent shall be voidable at Landlord&#8217;s election and shall constitute a Tenant Default.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transfer Procedure</font><font style="font-family:inherit;font-size:10pt;">.  If Tenant desires to make any Transfer requiring Landlord&#8217;s consent, then at least thirty (30) days prior to the date when Tenant desires the Transfer to be effective (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transfer Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;) Tenant shall give Landlord a Notice (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transfer Notice</font><font style="font-family:inherit;font-size:10pt;">&#8221;) setting forth:  (a) the name, address and business of the person or entity to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">which the Transfer is proposed (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Proposed Transferee</font><font style="font-family:inherit;font-size:10pt;">&#8221;); (b) information (including references) concerning the character, ownership and financial condition of the Proposed Transferee; (c) the proposed Transfer Date (which shall not be later than 90 days following the Transfer Notice); (d) any ownership or commercial relationship between Tenant and the Proposed Transferee; and (e) the consideration and all other material terms and conditions of the proposed Transfer, all in such detail as Landlord shall reasonably require.  If Landlord reasonably requests additional detail (including, without limitation, financial statements of the proposed Transferee or a current estoppel certificate from Tenant), the Transfer Notice shall not be deemed to have been received until Landlord receives such additional detail, and Landlord may withhold consent to any proposed Transfer until such information is provided to it.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recapture</font><font style="font-family:inherit;font-size:10pt;">.  In the event Tenant requests to assign this Lease or sublease fifty percent (50%) or more of the Rentable Square Feet of the Premises for all or substantially all of the remainder of the then-existing Term, then, within thirty (30) days of Landlord&#8217;s receipt of the Transfer Notice and all information specified in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 27.2</font><font style="font-family:inherit;font-size:10pt;">&#32;above, Landlord may, at its option, in its sole and absolute discretion, by Notice to Tenant, elect to terminate this Lease (a) in its entirety in the case of an assignment or (b) as to the portion of the Premises to be sublet in the case of a sublease.  If Landlord elects to terminate this Lease as aforesaid, Tenant shall have the right to rescind its request for consent to such assignment or sublease by delivering Notice to Landlord within five (5) business days after delivery of Landlord&#8217;s recapture notice, in which case, the consent request shall be void and this Lease shall remain in full force and effect.  If this Lease shall be terminated pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 27.3</font><font style="font-family:inherit;font-size:10pt;">, the Term shall end on the Transfer Date as if that date had been originally fixed in this Lease for the expiration of the Term.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord&#8217;s Consent; Consent Standards; No Release</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">27.4.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Unless Landlord elects to exercise any of its rights under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 27.3</font><font style="font-family:inherit;font-size:10pt;">&#32;above, Landlord shall, by Notice to Tenant, elect to: (a) consent to such proposed Transfer upon the terms and to the Proposed Transferee; or (b) refuse to give its consent to the proposed Transfer.  Landlord shall not unreasonably withhold its consent to any Proposed Transfer; provided that, without limiting other situations in which it may be reasonable for Landlord to withhold its consent to any proposed Transfer, it shall be deemed reasonable for Landlord to withhold its consent to any proposed Transfer if Landlord determines in its sole discretion that: (i) the Proposed Transferee does not have sufficient financial strength or stability to perform all obligations under this Lease, and to perform them without any higher risk of default than Tenant; (ii) the intended use of the Premises (or the applicable portion thereof) by the Proposed Transferee is inconsistent or incompatible with other uses in the Building or in the Project; (iii) the intended use of the Premises (or the applicable portion thereof) by the Proposed Transferee will require alteration of the Premises; (iv) the intended use of the Premises (or the applicable portion thereof) by the Proposed Transferee will violate this Lease or any Laws governing the Premises or the Building or Project; (v) the Proposed Transferee has the power of eminent domain, is a Governmental Authority or an agency or subdivision of a foreign government; (vi) either the Proposed Transferee, or any person which directly or indirectly controls, is controlled by, or is under common control with the Proposed Transferee:  (A) occupies space in the Project or has negotiated with Landlord or any of its affiliates within the preceding one hundred eighty (180) days (or is currently negotiating with Landlord or any of its affiliates) to lease space in the Building or Project or (B) does not intend to occupy the Premises or the applicable portion thereof; (vii) at the time Tenant delivers the Transfer Notice, there exists an uncured Tenant Default; (viii) the proposed Transfer would cause Landlord to be in violation of another lease or agreement to which Landlord is a party or would give an occupant of the Building or Project a right to cancel or modify its lease; (ix) any ground lessor or mortgagee whose consent to such Transfer is required fails to consent thereto; (x) the use of the Premises (or the applicable portion thereof), the Building or the Project by the Proposed Transferee would, in Landlord&#8217;s reasonable judgment, significantly increase pedestrian traffic in and out of the Building and/or the Project, generate increased loitering in Common Areas, increase security risk, or require any alterations to the Building or the Project to comply with applicable Laws; (xi) the Proposed Transferee would be a competitor to another tenant in the Building; (xii) the Proposed Transferee has been required by any prior landlord, lender or Governmental Authority to take material remedial action in connection with Hazardous Materials contaminating a property, which contamination resulted from Proposed Transferee&#8217;s action or omission or use of the property in question; or (xiii) the Proposed Transferee is subject to a material enforcement order issued by any Governmental Authority in connection with the use, disposal or storage of Hazardous Materials. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">27.4.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant further agrees that Landlord may condition its consent to any proposed Transfer upon satisfaction of any of the following conditions:  (a) delivery to Landlord of a true copy of a fully executed sublease, assignment of lease or other instrument pursuant to which the applicable Transfer is made (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transfer Instrument</font><font style="font-family:inherit;font-size:10pt;">&#8221;); (b) </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delivery to Landlord of original executed copies (by Tenant and the Transferee (defined below)) of Landlord&#8217;s form of Consent to Sublease (in the case of a Sublease) or Assignment and Assumption of Lease and Consent (in the case of an Assignment) or other instrument under which Landlord grants consent to the applicable Transfer (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Consent Instrument</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and (c) receipt by Landlord of all sums and amounts to which Landlord is entitled under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 27.5</font><font style="font-family:inherit;font-size:10pt;">&#32;below.  Tenant acknowledges and agrees that any Consent Instrument may, without limitation:  (i) in the case of a Sublease or Assignment, require the person or entity to which the Transfer is made (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transferee</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to be bound by all of the terms and provisions of this Lease and to perform all of the obligations of Tenant hereunder applicable to the Premises, or the portion thereof that is the subject of the applicable Transfer; (ii) in the case of an Assignment, include waivers by Tenant of all applicable suretyship defenses, including, but not limited to, those contained in Sections 2787 to 2855, inclusive, of the California Civil Code; and (iii) in the case of a Sublease:  (A) provide that such Sublease is subject and subordinate to this Lease to all Security Instruments encumbering the Building or the Project, (B) require the Transferee to, upon demand by Landlord following the occurrence of any Tenant Default, remit directly to Landlord, all monies payable from such Transferee to Tenant in connection with such Sublease and (C) provide that in the event of termination of this Lease for any reason, including without limitation a voluntary surrender by Tenant, or in the event of any reentry or repossession of the Premises by Landlord, Landlord may, at its option, either:  (x) terminate the sublease or (y) take over all of the right, title and interest of Tenant, as sublessor, under such sublease, in which case such sublessee shall attorn to Landlord, but that nevertheless Landlord shall not: (1) be liable for any previous act or omission of Tenant under such sublease, (2) be subject to any defense or offset previously accrued in favor of the sublessee against Tenant, or (3) be bound by any previous modification of any sublease made without Landlord&#8217;s written consent, or by any previous prepayment by sublessee of more than one month&#8217;s rent.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">27.4.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If Landlord grants its consent to any proposed Transfer described in any Transfer Notice, Tenant may during the thirty (30) days thereafter consummate such Transfer with the Proposed Transferee upon the terms and conditions described in the applicable Transfer Notice; provided, however, that any material change in such terms shall be subject to Landlord&#8217;s consent as provided in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 27</font><font style="font-family:inherit;font-size:10pt;">.  No Assignment or Sublease or other Transfer (whether with or without Landlord&#8217;s consent) shall relieve Tenant or any assignee or sublessee from any obligation under this Lease whether or not accrued as of the date of the Assignment or Sublease (and, to the extent such Tenant is deemed a surety of an assignee, Tenant hereby waives all applicable suretyship defenses, including, but not limited to, those contained in Sections 2787 to 2855, inclusive, of the California Civil Code.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord&#8217;s Costs; Transfer Premiums</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">27.5.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If Tenant requests Landlord&#8217;s consent to a proposed Transfer under the provisions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 27</font><font style="font-family:inherit;font-size:10pt;">, Tenant shall, upon demand, reimburse all of Landlord&#8217;s reasonable expenses, costs and attorneys&#8217; fees incurred in connection with processing such request for consent, whether or not Landlord grants consent to such proposed Transfer; provided that such costs and expenses shall not exceed $3,000 per request.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">27.5.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;If Landlord consents to a Transfer, Tenant shall pay to Landlord fifty percent (50%) of any rent or other consideration attributable to occupancy realized by Tenant pursuant to such Transfer in excess of (i) the Rent payable by Tenant under this Lease, (ii) any reasonable tenant improvement allowance or other economic concession (e.g., space planning allowance, moving expenses, free or reduced rent periods, etc.) actually incurred by Tenant in connection with such Transfer, (iii) any reasonable advertising costs and brokerage commissions actually incurred by Tenant in connection with such Transfer, and (iv) any reasonable legal fees actually incurred by Tenant in connection with such Transfer.  Landlord shall have the right to audit the books, records and papers of Tenant relating to any Transfer, and if the amount of such Additional Rent shall be found understated, Tenant shall immediately pay such deficiency upon demand and, if understated by more than two percent (2%), Tenant shall also pay Landlord&#8217;s costs of such audit. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rights Not Transferable</font><font style="font-family:inherit;font-size:10pt;">.  All:  (a) options to extend or renew the Term and/or to expand the Premises, if any, contained in this Lease or any addendum or amendment hereto or letter of agreement; (b) all rights to any signage at the Project in any location outside of the Premises, if any, contained in this Lease or any addendum or amendment hereto or letter of agreement; (c) all rights to above standard (or discounted) parking at the Project, if any, contained in this Lease or any addendum or amendment hereto or letter of agreement; and (d) all rights to receive any above standard services or utilities, if any, contained in this Lease or any addendum or amendment hereto or letter of agreement, are personal to the Original Tenant or a Permitted Transferee, and may not be transferred in connection with any Transfer </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or exercised by any Transferee (other than a Permitted Transferee).  Consent by Landlord to any Transfer shall not include consent to the assignment or transfer of any such options, rights or privileges (and such options, rights, or privileges shall terminate upon such assignment or subletting), unless Landlord, in its sole and absolute discretion, specifically grants in writing such options, rights, privileges or services to such assignee or subtenant.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Permitted Transfers</font><font style="font-family:inherit;font-size:10pt;">.  Notwithstanding the foregoing, Tenant may Transfer its interest in this Lease or the Premises to (a) an affiliate of Tenant (an entity which is controlled by, controls, or is under common control with Tenant), (b) an entity which acquires all or substantially all of the assets or interests (partnership, stock or other) of Tenant, or (c) an entity which is the resulting entity of a merger or consolidation of Tenant, provided that (i) the financial condition (including, without limitation, the credit) of such transferee entity is, in Landlord&#8217;s reasonable judgment, the same or greater than that of the Original Tenant both as of the Effective Date of this Lease and as of the date of the proposed Transfer; (ii) Tenant notifies Landlord of such Transfer at least thirty (30) days prior thereto and promptly thereafter supplies Landlord with any documents or information reasonably requested by Landlord regarding such Transfer or such entity; and (iii) such Transfer is not a subterfuge by Tenant to avoid its obligations under this Lease or otherwise effectuate any &#8220;release&#8221; by Tenant of such obligations.  The condition set forth in clause (i) above shall not be required in the case of a Transfer to an affiliate pursuant to clause (a) above provided that, if a Letter of Credit has not theretofore been delivered to Landlord and such Transfer is reasonably expected to trigger the requirement for a Letter of Credit under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 7.2</font><font style="font-family:inherit;font-size:10pt;">&#32;above, then the effectiveness of such Transfer shall be conditioned upon delivery of such Letter of Credit to Landlord; otherwise, Tenant shall deliver reasonable proof to Landlord that such Transfer will not trigger the requirement for a Letter of Credit.  A Transfer made in accordance with this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 27.7</font><font style="font-family:inherit;font-size:10pt;">&#32;shall be referred to as a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Permitted Transfer</font><font style="font-family:inherit;font-size:10pt;">&#8221; and the transferee shall be referred to as a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Permitted Transferee</font><font style="font-family:inherit;font-size:10pt;">.&#8221;  &#8220;Control,&#8221; as used in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 27.7</font><font style="font-family:inherit;font-size:10pt;">, shall mean the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities of, or possession of the right to vote, in the ordinary direction of its affairs, of more than fifty percent (50%) of the voting interest in, any person or entity.  No Transfer under this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 27.7</font><font style="font-family:inherit;font-size:10pt;">&#32;shall relieve Tenant from any of its obligations under this Lease whether or not accrued as of the date of Transfer.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 28</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> SUBORDINATION&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Without the necessity of any additional documents being executed by Tenant for the purpose of effecting a subordination, and at the election of Landlord, or any current or future mortgagee or holder of deed of trust with a lien on the Building or the Project or any ground lessor with respect to the Building or the Project (each, a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Holder</font><font style="font-family:inherit;font-size:10pt;">&#8221;), this Lease shall be subject and subordinate at all times to:  (a) all ground leases or underlying leases which may now exist or hereafter be executed affecting the Building, the Project, or the land upon which the Building and the Project are situated, or both; and (b) the lien of any mortgage or deed of trust which may now exist or hereafter be executed in any amount for which the Building, the Project, the land upon which the Building and the Project are situated, ground leases or underlying leases, or Landlord&#8217;s interest or estate in any of said items is specified as security (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Security Instruments</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  Notwithstanding the foregoing, Landlord shall have the right to subordinate or cause to be subordinated such ground leases or any such liens to this Lease.  In the event that any ground lease or underlying lease terminates for any reason or any mortgage or deed of trust is foreclosed or a conveyance in lieu of foreclosure is made for any reason, Tenant shall, notwithstanding any subordination, attorn to and become the tenant of the successor-in-interest to Landlord, at the option of such successor-in-interest to Landlord.  Tenant covenants and agrees to execute and deliver, within ten (10) business days after demand by Landlord therefor, any customary and reasonable documents necessary to evidence the priority or subordination of this Lease with respect to any such Security Instruments, and Landlord shall have the right, but not the obligation, to cause any such additional documents to be recorded in the official records of the county in which the Project is located.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 29</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> ESTOPPEL CERTIFICATE&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant Estoppel Certificate</font><font style="font-family:inherit;font-size:10pt;">.  Within ten (10) business days following any written request which Landlord may make from time to time, Tenant shall execute and deliver to Landlord a statement, in a form substantially similar to the form of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit&#160;&#8220;E&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;attached hereto, and incorporated herein by this reference (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant Estoppel Certificate</font><font style="font-family:inherit;font-size:10pt;">&#8221;) certifying: (a) the Commencement Date of this Lease; (b)&#160;that this Lease is unmodified and in full force and effect (or, if there have been modifications hereto, that this Lease is in full force and effect, and stating the date </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and nature of such modifications); (c) the date to which the Rent and other sums payable under this Lease have been paid; (d) that to the actual knowledge of Tenant, there are no current defaults under this Lease by Landlord except as specified in Tenant&#8217;s statement; and (e) such other matters as are reasonably included in such statement by Landlord.  Landlord and Tenant intend that any statement delivered pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 29</font><font style="font-family:inherit;font-size:10pt;">&#32;may be relied upon by any mortgagee, lessor, beneficiary, purchaser or prospective purchaser of the Building or the Project or any interest therein.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Failure to Deliver</font><font style="font-family:inherit;font-size:10pt;">.  Tenant&#8217;s failure to deliver such statement within such time shall be conclusive upon Tenant:  (a) that this Lease is in full force and effect, without modification except as may be represented by Landlord, (b) that there are no uncured defaults in Landlord&#8217;s performance, (c) that not more than one (1) month&#8217;s Rent has been paid in advance and (d) that the statements included in the Tenant Estoppel Certificate are true and correct, without exception.  Additionally, any such failure to timely deliver a Tenant Estoppel Certificate shall constitute an immediate Tenant Default hereunder.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 30</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> INTENTIONALLY OMITTED</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 31</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> SURRENDER OF PREMISES&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the expiration or earlier termination of the Term hereof, Tenant shall peaceably surrender the Premises and all Leasehold Improvements therein, excepting only any of the same that are required to be removed in accordance with </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 15.2</font><font style="font-family:inherit;font-size:10pt;">&#32;above, to Landlord broom-clean, in good order, repair and condition (reasonable wear and tear and casualty damage excepted), with all of Tenant&#8217;s Personal Property removed and free of any Hazardous Materials, and shall otherwise comply with all of the requirements of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 15.2</font><font style="font-family:inherit;font-size:10pt;">&#32;above and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 41.1</font><font style="font-family:inherit;font-size:10pt;">&#32;below.  The voluntary or other surrender of this Lease by Tenant, or a mutual cancellation thereof, shall not work a merger, and shall, at the option of Landlord, operate as an assignment to it of any or all subleases or subtenancies.  The delivery of keys to any employee of Landlord or to Landlord&#8217;s agent or any employee thereof shall not be sufficient to constitute a termination of this Lease or a surrender of the Premises.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 32</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> PERFORMANCE BY TENANT&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All covenants and agreements to be performed by Tenant under any of the terms of this Lease shall be timely performed by Tenant at Tenant&#8217;s sole cost and expense and without any abatement of Rent.  If Tenant shall fail to pay any sum of money owed to any party other than Landlord, for which it is liable hereunder, or if Tenant shall fail to timely perform any other act on its part to be performed hereunder Landlord may, without waiving or releasing Tenant from obligations of Tenant, but shall not be obligated to, make any such payment or perform any such other act to be made or performed by Tenant pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 25.5</font><font style="font-family:inherit;font-size:10pt;">&#32;above.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 33</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> PARKING&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning on the Commencement Date, Tenant and Tenant&#8217;s business visitors (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Parking Invitees</font><font style="font-family:inherit;font-size:10pt;">&#8221;) shall be entitled to use the number of Tenant&#8217;s Vehicle Parking Spaces set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section&#160;1.8</font><font style="font-family:inherit;font-size:10pt;">&#32;during the Initial Term, which Tenant&#8217;s Vehicle Parking Spaces shall be located in the surface parking area of the Project (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Parking Area</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  Subject to availability, as determined by Landlord in its sole discretion, Tenant may elect to use up to an additional fifteen (15) parking spaces in the Parking Area by delivery of written notice to Landlord, provided that Landlord delivers a written response thereto indicating the number of spaces, if any, available for Tenant&#8217;s use and the dates upon which such spaces are available; provided further that Landlord shall have the right to reduce the number of such additional parking spaces at any time upon thirty (30) days&#8217; prior notice to Tenant.  There shall be no direct charge attributable to Tenant&#8217;s use of the Parking Area, other than any taxes imposed by any governmental authority in connection with the renting of parking spaces by Tenant or the use of the Parking Area by Tenant.  Tenant&#8217;s continued right to use the Parking Area is conditioned upon Tenant abiding by the Parking Rules and Regulations set forth on </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit &#8220;G&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;as amended from time to time for the orderly operation and use of the Parking Area, including any sticker, parking pass or other identification system established by Landlord, Tenant&#8217;s cooperation in seeing that Tenant&#8217;s employees and visitors also comply with the Parking Rules and Regulations and Tenant not being in default under this Lease (beyond </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any applicable notice and cure periods).  Landlord specifically reserves the right to change the size, configuration, design, layout and all other aspects of the Parking Area at any time and Tenant acknowledges and agrees that Landlord may, from time to time, close-off or restrict access to the Parking Area for purposes of permitting or facilitating any such construction, alteration or improvements; provided, however, in connection with any such access restrictions, the same shall be without incurring any liability to Tenant and without any abatement of Rent under this Lease to the extent Landlord provides any reasonably required temporary, alternate parking in close proximity to the Project.  Landlord may delegate its responsibilities hereunder to a parking operator in which case such parking operator shall have all the rights of control attributed hereby to Landlord.  Any parking passes issued to Tenant pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article&#160;33</font><font style="font-family:inherit;font-size:10pt;">&#32;shall be provided to Tenant solely for use by Tenant&#8217;s own personnel and such passes may not be transferred, assigned, subleased or otherwise alienated by Tenant without Landlord&#8217;s prior approval.  Tenant may validate visitor parking by such method or methods as Landlord may establish, at the validation rate from time to time generally applicable to visitor parking. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 34</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> LIMITATION ON LIABILITY&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">34.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Landlord&#8217;s Liability</font><font style="font-family:inherit;font-size:10pt;">.  In consideration of the benefits accruing hereunder, Tenant and all of its successors and assigns covenant and agree that, in the event of any actual or alleged failure, breach or default hereunder by Landlord:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">34.1.1</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The sole and exclusive remedy shall be against Landlord&#8217;s interest in the Building and Project;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">34.1.2</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Intentionally omitted;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">34.1.3</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No writ of attachment, execution, possession, or sale, will ever be levied against the assets of Landlord, except the Building;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">34.1.4</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;The obligations under this Lease do not constitute personal obligations of any Landlord Indemnified Party (other than Landlord), and Tenant shall not seek recourse against any Landlord Indemnified Party (other than Landlord) or any of their personal assets (other than Landlord's interest in the Building and Project) for satisfaction of any liability in respect to this Lease (and, without limiting the foregoing, neither the negative capital account of any Landlord Indemnified Party, nor any obligation of any Landlord Indemnified Party to restore a negative capital account or to contribute capital to Landlord, shall at any time be deemed to be the property or an asset of Landlord, and neither Tenant nor any of its successors or assigns shall have any right to collect, enforce or proceed against or with respect to any such negative capital account of an Landlord Indemnified Party&#8217;s obligation to restore or contribute); and</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">34.1.5</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;These covenants and agreements are enforceable by Landlord and the other Landlord Indemnified Parties.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 35</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CONFIDENTIALITY&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">Tenant agrees that the terms and conditions of this Lease and any documents or information delivered hereunder are confidential and constitute proprietary information.  Disclosure of the terms and conditions hereof or any documents or information delivered hereunder could adversely affect the ability of Landlord to negotiate with other tenants or potential tenants of the Building.  Tenant and its partners, officers, members, managers, directors, employees, agents, advisors, representatives and attorneys, shall not disclose the terms and conditions of this Lease or any documents or information delivered hereunder to any other person without the prior written consent of Landlord except (a) pursuant to an order of a court of competent jurisdiction, (b) to its lenders or prospective lenders, (c) to accountants who audit its financial statements or prepare its tax returns, (d) to its attorneys, insurers, to any Governmental Authority or person to whom disclosure is required by applicable Law and (e) in connection with any action brought to enforce the terms of this Lease on account of the breach or alleged breach hereof.  In the event that Tenant concludes that it is obligated by Law to disclose the terms of this Lease (e.g., pursuant to a filing with the Securities and Exchange Commission (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SEC</font><font style="font-family:inherit;font-size:10pt;">&#8221;) or the New York Stock Exchange), Tenant shall provide written notice to Landlord before any public disclosure, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and the parties shall use their commercially reasonable efforts to cause a mutually agreeable release or announcement to be issued.  The foregoing shall not preclude communications or disclosures by Tenant necessary to implement the provisions of this Lease or to comply with the accounting and disclosure obligations of the SEC or the rules of the New York Stock Exchange.  If Tenant determines that it is required to file this Lease, a summary thereof, or a notification thereof, and/or descriptions related thereto, to comply with the requirements of an applicable stock exchange, SEC regulation, or any Governmental Authority, including the SEC, Tenant shall use commercially reasonable efforts to provide the maximum amount of advance written notice of any such required disclosure to Landlord with a minimum advance notice period of five (5) business days.  Tenant will provide Landlord with a copy of this Lease marked to show provisions for which Tenant intends to seek confidential treatment.  Tenant shall reasonably consider and incorporate Landlord&#8217;s comments thereon to the extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed.    </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 36</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> MISCELLANEOUS&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rules and Regulations</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall faithfully observe and comply with the &#8220;Rules and Regulations&#8221;, a copy of which is attached hereto, marked </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit&#160;&#8220;F&#8221;</font><font style="font-family:inherit;font-size:10pt;">, and incorporated herein by this reference (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Rules and Regulations</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and all modifications thereof and additions thereto made from time to time by Landlord.  Landlord shall not be responsible to Tenant for the violation or nonperformance by any other tenant or occupant of the Building or the Project of any of said Rules and Regulations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Conflict of Laws</font><font style="font-family:inherit;font-size:10pt;">.  This Lease shall be governed by and construed pursuant to the Laws of the State of California (without reference to its conflicts of laws rules or principles).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Successors and Assigns</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">Except as otherwise provided in this Lease, all of the covenants, conditions and provisions of this Lease shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, personal representatives, successors and assigns (subject to the restrictions on Tenant&#8217;s right to assign, sublet or transfer contained in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 27</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Professional Fees</font><font style="font-family:inherit;font-size:10pt;">.  If Landlord should bring suit for possession of the Premises, for the recovery of any sum due under this Lease, or because of the breach of any provisions of this Lease, or for any other relief against Tenant hereunder, or in the event of any other litigation between the parties with respect to this Lease, then all reasonable costs and reasonable expenses, including, without limitation, actual professional fees such as appraisers&#8217;, accountants&#8217;, and attorneys&#8217; fees, incurred by the prevailing party therein shall be paid by the other party, which obligation on the part of the other party shall be deemed to have accrued on the date of the commencement of such action and shall be enforceable whether or not the action is prosecuted to judgment.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mortgagee Protection</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall give Notice to any beneficiary of a deed of trust or mortgage covering the Premises whose address shall have been furnished to Tenant of any default on the part of Landlord under this Lease, and shall offer such beneficiary or mortgagee a reasonable opportunity to cure the default, in no event less than sixty (60) days, including time to obtain possession of the Premises by power of sale or a judicial foreclosure if necessary to effect a cure.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Definition of Landlord</font><font style="font-family:inherit;font-size:10pt;">.  The term &#8220;Landlord&#8221;, as used in this Lease, so far as covenants or obligations on the part of Landlord are concerned, shall be limited to mean and include only the owner or owners, at the time in question, of the fee title of the Premises or the lessees under any ground lease, if any.  In the event of any transfer, assignment or other conveyance or transfers of any such title, the original landlord herein named (and in case of any subsequent transfers or conveyances, the then grantor) shall be automatically freed and relieved from and after the date of such transfer, assignment or conveyance of all liability as respects the performance of any covenants or obligations on the part of Landlord contained in this Lease thereafter to be performed.  Without further agreement, the transferee of such title shall be deemed to have assumed and agreed to observe and perform any and all obligations of Landlord hereunder, during its ownership of the Premises.  Landlord may transfer its interest in the Premises without the consent of Tenant and such transfer or any subsequent transfer shall not be deemed a violation on Landlord&#8217;s part of any of the terms and conditions of this Lease.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identification of Tenant</font><font style="font-family:inherit;font-size:10pt;">.  If more than one person or entity executes this Lease as Tenant:  (a) each of them shall be jointly and severally liable for observing and performing all of the terms, covenants, conditions, provisions and agreements of this Lease to be observed and performed by Tenant, and (b) the term &#8220;Tenant&#8221; as used in this Lease shall mean and include each of them jointly and severally.  The act of or Notice from, or Notice or refund to, or the signature of any one or more of them, with respect to the tenancy of this Lease, including but not limited to any renewal, extension, expiration, termination or modification of this Lease, shall be binding upon each and all of the persons executing this Lease as Tenant with the same force and effect as if each and all of them had so acted, so given or received such Notice or refund, or so signed.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Force Majeure</font><font style="font-family:inherit;font-size:10pt;">.  Each party shall have no liability whatsoever to the other party on account of any of the following (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Force Majeure</font><font style="font-family:inherit;font-size:10pt;">&#8221;):  (a) the inability of such party to fulfill, or any delay in fulfilling, any of its obligations under this Lease by reason of strike, other labor trouble, governmental preemption or priorities or other controls in connection with a national or other public emergency, or shortages of fuel, supplies or labor resulting therefrom, governmental or permitting delays, inclement weather, casualty, pandemic (including, without limitation, the COVID-19 pandemic), earthquake, war, riot, civil commotion, terrorism or any other cause, whether similar or dissimilar to the above, beyond such party&#8217;s reasonable control (financial condition excepted); or (b) any failure or defect in the supply, quantity, character, or maintenance of electricity, water, intrabuilding network telephone and data cable service, or other service furnished to the Premises by reason of any requirement, act or omission of the public utility or others furnishing the Building with such service, or for any other reason, whether similar or dissimilar to the above, beyond such party&#8217;s reasonable control.  If this Lease specifies a time period for performance of an obligation of such party, that time period shall be extended by the period of any delay in such party&#8217;s performance caused by any of the events of Force Majeure described above.  Notwithstanding the foregoing, nothing in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 36.8</font><font style="font-family:inherit;font-size:10pt;">&#32;shall relieve Tenant from the obligation to pay any Rent or extend the time for payment of any Rent.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Terms and Headings</font><font style="font-family:inherit;font-size:10pt;">.  The words &#8220;Landlord&#8221; and &#8220;Tenant&#8221; as used herein shall include the plural as well as the singular.  Words used in any gender include other genders.  The Article and Section headings of this Lease are not a part of this Lease and shall have no effect upon the construction or interpretation of any part hereof.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Examination of Lease</font><font style="font-family:inherit;font-size:10pt;">.  Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for lease, and it is not effective as a lease or otherwise until execution by and delivery to both Landlord and Tenant.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Time</font><font style="font-family:inherit;font-size:10pt;">.  Time is of the essence with respect to the performance of every provision of this Lease in which time is a factor. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prior Agreement; Amendments</font><font style="font-family:inherit;font-size:10pt;">.  This Lease contains all of the agreements of the parties hereto with respect to any matter covered or mentioned in this Lease, and no prior agreement or understanding pertaining to any such matter, written or verbal, shall be effective for any purpose.  No provisions of this Lease may be amended or added to except by an agreement in writing signed by the parties hereto or their respective successors-in-interest.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Severability</font><font style="font-family:inherit;font-size:10pt;">.  Any provision of this Lease which shall prove to be invalid, void or illegal shall in no way affect, impair or invalidate any other provision hereof, and such other provisions shall remain in full force and effect.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recording</font><font style="font-family:inherit;font-size:10pt;">.  Tenant shall not record this Lease or a short form memorandum hereof without the consent of Landlord (in its sole and absolute discretion), which consent may be conditioned upon Tenant&#8217;s delivery to Landlord of a fully executed quitclaim releasing Tenant&#8217;s interest in the Premises, the Project or any portion thereof.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Modification for Lenders</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;.  If, in connection with obtaining construction, interim or permanent financing for the Project the lender shall request reasonable modifications in this Lease as a condition to such financing, Tenant will not unreasonably withhold, delay or condition its consent thereto, provided that such modifications do not (a) materially increase the obligations or costs of Tenant hereunder, (b) materially adversely affect the leasehold interest hereby created or Tenant&#8217;s rights hereunder, or (c) modify the size, location or access to the Premises.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements</font><font style="font-family:inherit;font-size:10pt;">.  At any time during the Term of this Lease that Tenant&#8217;s financial statements are not publicly available, Tenant shall, upon ten (10) business days&#8217; Notice from Landlord, provide Landlord with its current financial statements and financial statements of the two (2) years prior to the year in which Landlord&#8217;s Notice </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">was given (together with, if Tenant's obligations under this Lease are guaranteed, the guarantor's current financial statements and financial statements of the two (2) years prior to the year in which Landlord&#8217;s Notice was given); provided Tenant shall not be required to provide such financial statements more than once in each consecutive twelve (12) month period during the Term unless (a) Tenant is in default under this Lease, or (b) requested in connection with a proposed sale, transfer, financing or refinancing of the Project or any portion thereof.  Such statements shall be prepared in accordance with generally accepted accounting principles and, if such is the normal practice of Tenant, shall be audited by an independent certified public accountant.  All financial statements shall be certified as true and correct by Tenant&#8217;s chief financial officer and Tenant agrees that Landlord may share such financial statements with prospective lenders or purchasers of the Property.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quiet Enjoyment</font><font style="font-family:inherit;font-size:10pt;">.  Landlord covenants and agrees with Tenant that, upon Tenant paying the Rent required under this Lease and performing all of the covenants and provisions on Tenant&#8217;s part to be observed and performed under this Lease, Tenant shall during the Term, peaceably and quietly have, hold and enjoy the Premises in accordance with this Lease without interference by any persons lawfully claiming by or through Landlord.  The foregoing covenant is in lieu of any other covenant express or implied.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.18</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant as Corporation, Partnership or Limited Liability Company</font><font style="font-family:inherit;font-size:10pt;">.  If Tenant is a corporation, partnership or limited liability company, Tenant and the persons executing this Lease on behalf of Tenant represent and warrant that it is an entity duly qualified to do business in California and that the individuals executing this Lease on Tenant&#8217;s behalf are duly authorized to execute and deliver this Lease on its behalf, in the case of a corporation, in accordance with its by-laws and with a duly adopted resolution of the board of directors of Tenant, a copy of which shall be delivered to Landlord upon execution hereof by Tenant, in the case of a partnership, in accordance with the partnership agreement and the most current amendments thereto, if any, copies of which shall be delivered to Landlord upon execution hereof by Tenant, and, in the case of a limited liability company, in accordance with its governing documents and any documents required thereby, copies of which shall be delivered to Landlord upon execution hereof by Tenant, and that this Lease is binding upon Tenant in accordance with its terms. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36.19</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASp Disclosure</font><font style="font-family:inherit;font-size:10pt;">.  For purposes of Section 1938 of the California Civil Code, Landlord hereby discloses to Tenant that the Building Common Areas, Project Common Areas and Premises, as of the date of this Lease, have not been inspected by a Certified Access Specialist (CASp), as that term is defined in California Civil Code Section 55.52.  In accordance with subsection (e) of Section 1938 of the California Civil Code, Tenant is further notified as follows: </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 37</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> SIGNAGE&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord retains absolute control over the exterior appearance of the Building and the Project and the exterior appearance of the Premises as viewed from the Building Common Areas and Project Common Areas.  Tenant will not install, or permit to be installed, any drapes, furnishings, signs, lettering, designs, advertising or any items that will in any way alter the exterior appearance of the Building, the Project or the exterior appearance of the Premises as viewed from the Building Common Areas and Project Common Areas.  Any sign, advertising, design, or lettering installed by Tenant shall be considered an Alteration and shall be subject to the provisions of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 15</font><font style="font-family:inherit;font-size:10pt;">; provided that Landlord shall have the right to withhold its consent to the same in its sole and absolute discretion.  Subject to the foregoing, Landlord shall, at Tenant&#8217;s sole cost and expense, (i) place Tenant&#8217;s name on the Building&#8217;s monument sign, (ii) install </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">one (1) Building standard tenant suite identification sign adjacent to the door to the Premises, and (iii) place Tenant&#8217;s name in the Building&#8217;s main lobby directory, provided that Landlord shall retain absolute control over the appearance and design of such suite identification sign and lobby directory.  All signage rights granted to Tenant under this Lease are personal to the original Tenant named herein, and may not be assigned or transferred without Landlord&#8217;s prior written consent, which consent Landlord may withhold in its sole and absolute discretion.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 38</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> EXECUTIVE ORDER 13224&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant hereby represents and warrants to Landlord that Tenant is not:  (a) in violation of any Anti-Terrorism Law (defined below); (b) conducting any business or engaging in any transaction or dealing with any Prohibited Person (defined below), including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Prohibited Person; (c) dealing in, or otherwise engaging in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224; (d) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate any of the prohibitions set forth in any Anti-Terrorism Law; or (e) a Prohibited Person, nor are any of its partners, members, managers, officers or directors a Prohibited Person.  As used herein, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Anti-Terrorism Law</font><font style="font-family:inherit;font-size:10pt;">&#8221; is defined as any Law relating to terrorism, anti-terrorism, money laundering or anti-money laundering activities, including, without limitation, Executive Order No. 13224 and Title 3 of the USA Patriot Act.  As used herein &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Executive Order No. 13224</font><font style="font-family:inherit;font-size:10pt;">&#8221; is defined as Executive Order No. 13224 on Terrorist Financing effective September 24, 2001, and relating to &#8220;Blocking Property and Prohibiting Transactions With Persons Who Commit, or Support Terrorism.&#8221;  &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Prohibited Person</font><font style="font-family:inherit;font-size:10pt;">&#8221; is defined as:  (i) a person or entity that is listed in the Annex to Executive Order No. 13224; (ii) a person or entity with whom Tenant or Landlord is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law; or (iii) a person or entity that is named as a &#8220;specially designated national and blocked person&#8221; on the most current list published by the U.S. Treasury Department Office of Foreign Assets Control at its official website, http://www.treas.gov/ofac/t11sdn.pdf or at any replacement website or other official publication of such list.  &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">USA Patriot Act</font><font style="font-family:inherit;font-size:10pt;">&#8221; is defined as the &#8220;Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001&#8221; (Public Law 107-56).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 39</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> WAIVER OF JURY TRIAL&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, LANDLORD AND TENANT WAIVE THE RIGHT TO A TRIAL BY JURY.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 40</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT REPRESENTATIONS&#160;&#160;&#160;&#160;  </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant represents and warrants to Landlord as of the date hereof and continuing thereafter as follows: </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;The execution and delivery of this Lease by Tenant will not result in a breach of the terms or provisions of, or constitute a default (or a condition that, upon notice or lapse of time, or both, would constitute a default) under Tenant&#8217;s organizational documents, and will not constitute a violation of any Law applicable to Tenant.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;The person executing this Lease on Tenant&#8217;s behalf is duly authorized to so act; that Tenant is duly organized, is qualified to do business in the jurisdiction in which the Building is located, is in good standing under the Laws of the state of its organization and the Laws of the jurisdiction in which the Building is located, and has the power and authority to enter into this Lease; and that all action required to authorize Tenant and such person to enter into this Lease has been duly taken.  </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Any financial statements provided by Tenant are true, correct and complete in all material respects and do not omit to state a fact that would be material to Tenant&#8217;s financial condition.  There has been no material adverse change in Tenant&#8217;s financial condition since Tenant provided such financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Tenant is in compliance with all applicable anti-money laundering Laws, including, without limitation, the USA Patriot Act, and the Laws administered by the United States Treasury Department&#8217;s Office of Foreign Assets Control, including, without limitation, Executive Order No. 13224.  Tenant is not owned or controlled directly or indirectly by any person or entity, on the SDN List published by the United States Treasury Department&#8217;s Office of Foreign Assets Control and Tenant is not a person otherwise identified by any Governmental Authority as a person with whom a U.S. Person is prohibited from transacting business.  As of the date hereof, a list of such designations and the text of Executive Order No. 13224 are published under the internet website address www.ustreas.gov/offices/enforcement/ofac.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 41</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160; <br> ADDITIONAL PROVISIONS</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">41.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Environmental Assessments</font><font style="font-family:inherit;font-size:10pt;">.  Upon Substantial Completion of the Tenant Improvements, Landlord, at its sole cost and expense, shall cause a Phase I environmental assessment regarding the Project to be prepared (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Phase I Assessment</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and shall provide a copy of the same to Tenant.  The Phase I Assessment shall serve as the &#8220;baseline&#8221; for determining the environmental condition of the Project upon Tenant&#8217;s occupancy thereof unless such Phase I Assessment recommends further testing.  In addition to the surrender obligations set forth elsewhere in this Lease (including, without limitation, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 15.2</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 31</font><font style="font-family:inherit;font-size:10pt;">), upon the expiration or earlier termination of this Lease, Tenant, at its sole cost and expense, shall (a) cause a Phase I environmental assessment (or similar non-invasive assessment) of the Project (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Phase I Surrender Assessment</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to be performed and deliver the results thereof to Landlord no later than thirty (30) days following such expiration or earlier termination (but in no event shall the Phase I Surrender Assessment be dated more than ten (10) days prior to such expiration or earlier termination); and (b) if and to the extent recommended by the Phase I Surrender Assessment and consented to by Landlord in writing, cause a Phase II environmental assessment (or similar additional assessment) of the Project (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Phase II Surrender Assessment</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to be performed and deliver the results thereof to Landlord no later than thirty (30) days following the date of the Phase I Surrender Assessment.  In addition, Landlord shall have the right, in its sole and absolute discretion, to hire, or to cause Tenant to hire, an environmental consultant to conduct a physical inspection of the Project (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Environmental Inspection</font><font style="font-family:inherit;font-size:10pt;">&#8221;) upon the expiration or earlier termination of this Lease, which inspection shall be at Tenant&#8217;s sole cost and expense.  The Phase I Surrender Assessment and any Phase II Surrender Assessment and/or Environmental Inspection, as the same compare to the Phase I Assessment, shall be used to, among other things, determine the extent of Tenant&#8217;s compliance (or noncompliance) with </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 8.3</font><font style="font-family:inherit;font-size:10pt;">&#32;above as of the dates thereof. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">41.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Early Access</font><font style="font-family:inherit;font-size:10pt;">.  Following twenty-four (24) hours&#8217; notice to Landlord and upon receipt of written approval by Landlord (which shall not be unreasonably withheld or delayed), Landlord shall permit Tenant and its agents to enter the Premises approximately thirty (30) days prior to the Commencement Date (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Early Access Period</font><font style="font-family:inherit;font-size:10pt;">&#8221;) for the sole purpose of installing, at Tenant&#8217;s sole cost and expense, its furniture, fixtures, equipment and cabling in the Premises; provided, however, that in no event shall such early access, regardless of when provided, extend or otherwise affect the Commencement Date.  Any such entry shall be in a manner and upon terms and conditions and at times satisfactory to Landlord&#8217;s representative.  The foregoing license to enter the Premises prior to the Commencement Date is, however, conditioned upon Tenant&#8217;s contractors and their subcontractors and employees working in harmony and not interfering with the work being performed by Landlord.  If at any time such entry shall cause disharmony or interfere with the work being performed by Landlord, this license may be withdrawn by Landlord upon twenty-four (24) hours written notice to Tenant.  Tenant shall be liable for any damages caused by Tenant&#8217;s activities at the Premises.  Such license is further conditioned upon the compliance by Tenant&#8217;s contractors with all requirements imposed by Landlord on third party contractors, including, without limitation, the maintenance by Tenant and its contractors and subcontractors of workers&#8217; compensation and public liability and property damage insurance in amounts and with companies and on forms satisfactory to Landlord, with certificates of such insurance being furnished to Landlord prior to proceeding with any such entry.  The entry shall be deemed to be under all of the provisions of this Lease except as expressly set forth in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 41.2</font><font style="font-family:inherit;font-size:10pt;">.  During the Early Access Period, Tenant shall have no obligation to pay Basic Rent or electricity costs (provided Tenant&#8217;s electricity usage during such Early Access Period is not excessive).  Landlord shall not be liable in any way for any injury, loss or damage which may occur to any such work being performed by Tenant, the same being solely at Tenant&#8217;s risk.  All costs and expenses in connection with or arising out of the performance of any work by Tenant during such early entry shall be borne by Tenant, and all payments therefor shall be made by Tenant promptly as they become due.  Tenant shall, at its sole cost and expense, comply with all applicable laws, ordinances, regulations and policies governing its work.  Except to the extent arising from the gross negligence or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">willful misconduct of Landlord, Tenant shall defend, indemnify and hold Landlord and its members, agents, employees, partners, and their respective employees, partners, officers, directors, agents, representatives, successors and assigns, harmless from and against any and all suits, claims, actions, losses, costs, liabilities or expenses (including reasonable attorneys&#8217; fees and claims for workers&#8217; compensation) to the extent arising out of or in connection with any and all work during such early entry (including, but not limited to, claims for breach of warranty, personal injury or property damage).  Landlord shall have the right, in Landlord&#8217;s sole and absolute discretion, to settle, compromise, or otherwise dispose of any and all suits, claims, and actions against any of the indemnified parties arising out of or in connection with the work performed by Tenant during any early entry.  Tenant shall coordinate such entry with Landlord&#8217;s building manager and, except as expressly set forth in this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 41.1</font><font style="font-family:inherit;font-size:10pt;">, such entry shall be made in compliance with all terms and conditions of this Lease and the Rules and Regulations attached hereto.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">41.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Right of First Refusal</font><font style="font-family:inherit;font-size:10pt;">.  Effective as of the Effective Date, provided that (a) Tenant is not in default under this Lease beyond applicable notice and cure periods and (b) Tenant occupies one hundred percent (100%) of the Premises, then Landlord agrees that prior to leasing Suite 110 in the Building, which consists of approximately 16,585 rentable square feet (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Offer Space</font><font style="font-family:inherit;font-size:10pt;">&#8221;), to a third party for the first time, Landlord shall submit a copy of the first bona fide offer to lease such Offer Space from a third party that Landlord is willing to accept (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Offer</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to Tenant.  Tenant shall have a one-time right (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">ROFR</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to elect to lease the entire space identified in the Offer, on terms and conditions identical to those contained in the Offer (except as indicated below), provided that Tenant delivers written notice exercising its ROFR within five (5) business days following delivery of the copy of the Offer from Landlord to Tenant.  If Tenant duly and timely exercises the ROFR, Landlord and Tenant shall promptly amend this Lease to include the Offer Space on terms and conditions identical to those contained in the Offer, except that (a) the term of the lease relative to the Offer Space shall be coterminous with the Lease for the Premises, (b) the Tenant&#8217;s Vehicle Parking Spaces shall be increased on a pro rata basis following delivery of the Offer Space to Tenant, and (c) any concessions in the Offer (e.g., any improvement allowance) shall be equitably reduced to correspond with a reduced amortization period equal to the remaining portion of the existing Term.  Once Landlord has delivered an Offer to Tenant pursuant to the above, if for any reason Tenant fails to duly and timely exercise the ROFR, or if Tenant properly exercises such right but thereafter for any reason does not enter into the amendment of the Lease within thirty (30) days after exercise of the ROFR (unless the delay is caused by Landlord), then Landlord shall be free to lease the Offer Space to another tenant (whether pursuant to the Offer described above or upon different terms or at a different time) without any obligation pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 41.3</font><font style="font-family:inherit;font-size:10pt;">&#32;and the ROFR shall terminate and be of no further force or effect.  The ROFR shall be subject to the any superior rights of any existing tenants existing in writing as of the date of this Lease, shall apply during the Initial Term only (and not during any Option Term or other expansion term), shall be personal to the Original Tenant (or any Permitted Transferee) and may not be exercised or assigned, voluntarily or involuntarily, by or to any person or entity other than such Original Tenant or Permitted Transferee and shall not be assignable separate and apart from this Lease.  Time is of the essence with respect to the ROFR.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">41.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Termination Option</font><font style="font-family:inherit;font-size:10pt;">. Tenant shall have a one (1) time option to terminate this Lease (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Termination Option</font><font style="font-family:inherit;font-size:10pt;">&#8221;) effective on the last day of the eighty-fourth (84</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">) full month of the Initial Term (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Termination Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), provided that (a) Tenant shall give Landlord written notice (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Termination Notice</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of its exercise of the Termination Option, if at all, no less than twelve (12) months prior to the Termination Date, (b) Tenant shall not be in default under the terms of this Lease (after the lapse of any applicable notice and cure periods) at the time Tenant delivers the Termination Notice to Landlord or at any time between delivery of the Termination Notice and the Termination Date, (c) concurrently with Tenant&#8217;s delivery of the Termination Notice to Landlord, Tenant shall pay to Landlord fifty percent (50%) of the Termination Fee (as hereinafter defined), and (d) on or prior to the Termination Date, Tenant shall pay to Landlord the remaining fifty percent (50%) of the Termination Fee.  As used herein, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Termination Fee</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall mean a termination fee in the amount of (i) Three Million Eight Hundred Thirty-Nine Thousand Four Hundred Twenty-Six and 10/100 Dollars ($3,839,426.10) (i.e., fifteen (15) months of the Basic Rent payable hereunder as of the Termination Date) plus (ii) fifteen (15) months of Tenant&#8217;s Percentage of Operating Expenses and Real Property Taxes payable hereunder as of the Termination Date.  The Termination Option is personal to the Original Tenant, may be exercised only by the Original Tenant, and may not be transferred in connection with any Transfer or exercised by any Transferee.  Time is of the essence with respect to the Termination Option.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">signatures on following page</font><font style="font-family:inherit;font-size:10pt;">]</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the parties have executed this Lease as of the Effective Date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:42%;"></td><td style="width:7%;"></td><td style="width:9%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LANDLORD:</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WATERIDGE PROPERTY OWNER, LP,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Delaware limited partnership</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HSRE-BPI I GP, LLC</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Delaware limited liability company, its general partner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Stephen M. Gordon</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stephen M. Gordon</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized Signatory</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT:</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ANAPTYSBIO, INC.,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Delaware corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Its:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interim CFO and General Counsel</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sCA4176A398C552477D99D1CD6F3C206A"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT &#8220;A-I&#8221;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OUTLINE OF PREMISES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="newleaseimage1.gif" alt="newleaseimage1.gif" style="height:308px;width:614px;"></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;A-I&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sD54E586CE6EAC6DCB5D3D1CD6F51562D"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT &#8220;A-II&#8221;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROJECT SITE PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following site plan is intended only to show the approximate general outline of the Project, which is subject to change in accordance with the Lease.  This site plan is not to be scaled and any measurements or distances shown thereon are approximations only.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="newleaseimage2.gif" alt="newleaseimage2.gif" style="height:374px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;A-II&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s2CD1BED7CB2AEB0A1168D1CD6F6591FF"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT &#8220;B&#8221;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WORK LETTER AGREEMENT</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THIS WORK LETTER AGREEMENT is entered into as of May 4, 2020, by and between WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Landlord</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and ANAPTYSBIO, INC., a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant</font><font style="font-family:inherit;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R E C I T A L S:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A.&#160;&#160;&#160;&#160;Concurrently with the execution of this Work Letter Agreement, Landlord and Tenant have entered into a lease (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Lease</font><font style="font-family:inherit;font-size:10pt;">&#8221;) covering certain premises (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Premises</font><font style="font-family:inherit;font-size:10pt;">&#8221;) more particularly described in the Lease.  Except as otherwise defined herein, all capitalized terms shall have the meanings ascribed to them in the Lease.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B.&#160;&#160;&#160;&#160;In order to induce Tenant to enter into the Lease (which is hereby incorporated by reference to the extent applicable) and in consideration of the mutual covenants hereinafter contained, Landlord and Tenant hereby agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant Improvements</font><font style="font-family:inherit;font-size:10pt;">.  Reference herein to &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant Improvements</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall include all work to be done in the Premises pursuant to the Space Plan and Construction Documents (defined below), including, but not limited to, partitioning, doors, ceilings, floor coverings, wall finishes (including paint and wallcovering), electrical (including lighting; switching; outlets; telephone, but excluding any and all telephone and data wire and cable of any type or kind), plumbing, heating, ventilating and air conditioning, fire protection, cabinets and other millwork.  Landlord shall install a shared emergency generator for the Building (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Emergency Generator</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and an emergency generator conduit connecting the Emergency Generator to the Premises; provided, however, that Tenant shall be responsible for Tenant&#8217;s pro-rata share of the cost thereof, which pro-rata share shall be based on the ratio of the capacity of the Emergency Generator which is dedicated to the Premises as the same relates to the total capacity of the Emergency Generator (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Emergency Generator Share</font><font style="font-family:inherit;font-size:10pt;">&#8221;), which Tenant&#8217;s Emergency Generator Share shall be deducted from the Tenant Improvement Allowance.  In no event shall the Tenant Improvements include any actions required to cause the Building to be in compliance with applicable laws unless such compliance is required solely as a result of construction of the improvements contemplated by the Construction Documents.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tenant Improvement Allowance; Excess Costs</font><font style="font-family:inherit;font-size:10pt;">.  The Tenant Improvements shall be constructed by Landlord at Tenant&#8217;s sole cost and expense, subject to the Tenant Improvement Allowance.  Tenant may elect to use a portion of the Tenant Improvement Allowance not to exceed Five and 00/100 Dollars ($5.00) per Rentable Square Foot of the Premises (i.e., up to $225,135.00) toward the cost of Tenant&#8217;s cabling in the Premises.  In the event that the Tenant Improvement Allowance exceeds the cost of the Tenant Improvements, any remaining portion of the Tenant Improvement Allowance shall accrue to the sole benefit of Landlord, it being agreed that Tenant shall not be entitled to any credit, offset, abatement or payment with respect thereto.  Landlord shall be entitled to deduct from the Tenant Improvement Allowance a construction management fee for Landlord&#8217;s oversight of the Tenant Improvements in an amount equal to three percent (3%) of the total cost of the Tenant Improvements.  Any and all amounts incurred by Landlord in connection with the Tenant Improvements in excess of the Tenant Improvement Allowance, and any and all increased costs and expenses incurred by Landlord that arise out of any change requested by Tenant pursuant to </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Paragraph 7</font><font style="font-family:inherit;font-size:10pt;">&#32;below or any Tenant Delay (defined below), shall be deemed &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Excess Costs</font><font style="font-family:inherit;font-size:10pt;">.&#8221;  Any and all Excess Costs shall be deemed Rent under the Lease and Tenant shall pay to Landlord such Excess Costs within ten (10) business days after demand therefor, prior to the commencement of the construction of the Tenant Improvements.  Tenant&#8217;s failure to timely pay any Excess Costs shall constitute a Tenant Default under the Lease.  The statements of costs submitted to Landlord by Landlord&#8217;s contractors shall be conclusive for purposes of determining the actual cost of the items described therein.  Landlord shall reasonably cooperate with Tenant, if requested by Tenant, to reduce costs of finishes and other non-structural improvements, provided that the quality of the same is commensurate with the quality of other improvements in the Building.   </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Work Schedule</font><font style="font-family:inherit;font-size:10pt;">.  Within a reasonable period of time after the mutual execution of the Lease, Landlord shall deliver to Tenant, for Tenant&#8217;s review and approval, a schedule (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Work Schedule</font><font style="font-family:inherit;font-size:10pt;">&#8221;) setting forth a timetable for the planning and completion of the installation of the Tenant Improvements to be constructed in the Premises.  The Work Schedule shall set forth each of the various items of work to be done by or approval to be given by Landlord and </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;B&#8221;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">Tenant in connection with the completion of the Tenant Improvements.  The Work Schedule shall be submitted to Tenant for its approval and, upon approval by both Landlord and Tenant, such Work Schedule shall become the basis for completing the Tenant Improvements.  If Tenant fails to provide written approval of the Work Schedule, as it may be modified after discussions between Landlord and Tenant, within five (5) business days after the date the Work Schedule is first delivered to Tenant by Landlord, the Work Schedule shall be deemed approved.  All changes to the Work Schedule shall be mutually and reasonably agreed upon, in writing, by Landlord and Tenant.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Space Plan</font><font style="font-family:inherit;font-size:10pt;">.  Landlord and Tenant have substantially approved the space plan attached to this Work Letter Agreement as </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Schedule B-1</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Space Plan</font><font style="font-family:inherit;font-size:10pt;">&#8221;) for the installation of Tenant Improvements to be constructed in the Premises by Landlord.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Construction Documents</font><font style="font-family:inherit;font-size:10pt;">.  Based upon the approved Space Plan, Landlord&#8217;s architect and/or space planner shall prepare final working drawings and/or construction documents for the Tenant Improvements containing architectural drawings, structural and mechanical, plumbing, fire sprinkler, electrical engineering drawings and any other documents necessary to obtain required permits for the Tenant Improvements (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Construction Documents</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  Landlord shall submit the Construction Documents to Tenant for its review and approval.  If Tenant fails to approve the Construction Documents within five (5) business days after delivery by Landlord thereof the Construction Documents shall be deemed approved.  All changes to the Construction Documents shall be mutually and reasonably agreed upon, in writing, by Landlord and Tenant.  Landlord&#8217;s supervision and/or performance of any work for or on behalf of Tenant or Landlord&#8217;s approval of the Space Plan and/or Construction Documents and any revisions thereto shall not be deemed to be a representation by Landlord that the Tenant Improvements will be adequate for Tenant&#8217;s use.  Tenant hereby acknowledges and agrees that (i) Landlord makes no representation or warranty with respect to the design of the Tenant Improvements or any portion thereof; (ii) certain design elements of the Tenant Improvements may increase the risk of injury to persons and/or damage to the Premises and Tenant&#8217;s personal property and equipment contained therein; and (iii) any such injury and/or damage shall be subject to the waiver of liability set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sections 20</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Lease.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost of Space Plan and Construction Documents</font><font style="font-family:inherit;font-size:10pt;">.  All costs of preparing and revising the Space Plan and the Construction Documents shall be deducted from the Tenant Improvement Allowance. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Plan and Construction Documents</font><font style="font-family:inherit;font-size:10pt;">.  Any changes requested by Tenant in the Construction Documents or other plans and specifications after approval thereof by Tenant shall be subject to Landlord&#8217;s approval (which approval shall not be unreasonably withheld, conditioned or delayed) and, if approved, shall be prepared at Tenant&#8217;s sole cost and expense, and any excess costs resulting from such changes shall also be at Tenant&#8217;s sole cost and expense.  Furthermore, Tenant shall be liable for any resulting delays in completing the Tenant Improvements and for any increased cost in completing the Tenant Improvements, if any, resulting from such delays.  Any such delays shall be &#8220;Tenant Delays&#8221; and shall impact the Commencement Date of the Lease as provided in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Paragraph 10</font><font style="font-family:inherit;font-size:10pt;">&#32;below.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Finishes</font><font style="font-family:inherit;font-size:10pt;">.  Landlord&#8217;s architect shall provide Tenant with finish options for the Tenant Improvements (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finish Options</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and Tenant shall select the options it desires to use from such Finish Options within three (3) business days after receipt thereof.  If Tenant desires to use finishes different from those provided in the Finish Options, such request shall be subject to Landlord&#8217;s reasonable approval and any increase in costs resulting therefrom shall be Excess Costs.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Construction of Tenant Improvements</font><font style="font-family:inherit;font-size:10pt;">.  After the Construction Documents have been prepared and approved, the final pricing has been approved and a building permit for the Tenant Improvements has been issued, Landlord shall cause its contractor to begin installation of the Tenant Improvements in accordance with the Construction Documents.  The general contractor shall be either Level 10, C-2 or Bycor; if Landlord proposes a different general contractor, such general contractor shall be subject to Tenant&#8217;s  approval, which shall not be unreasonably withheld or delayed beyond three (3) business days following notice thereof by Landlord.  Landlord shall supervise the completion of such work and shall use commercially reasonable efforts to secure substantial completion of the work in accordance with the Work Schedule.  The cost of such work shall be paid as provided in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Paragraph 2</font><font style="font-family:inherit;font-size:10pt;">&#32;above.  Landlord shall not be liable for any direct or indirect damages as a result of delays in construction beyond Landlord&#8217;s reasonable control, including, but not limited to, acts of God, inability to secure governmental approvals or permits, governmental restrictions, strikes, availability of materials or labor or delays by Tenant (or its architect or anyone performing services on behalf of Tenant).  </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;B&#8221;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Substantial Completion.  </font><font style="font-family:inherit;font-size:10pt;">The Tenant Improvements shall be deemed &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Substantially Complete</font><font style="font-family:inherit;font-size:10pt;">&#8221; (and &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Substantial Completion</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall be deemed to have occurred) upon the date upon which (i) construction of the Tenant Improvements in the Premises has been substantially completed pursuant to the Construction Documents, with the exception of any minor punch list items (which punch list items shall be approved by Tenant) and any Tenant fixtures, work-stations, built-in furniture, or equipment to be installed by Tenant, (ii) a temporary or permanent certificate of occupancy or other equivalent approval from the local governmental authority has been issued permitting occupancy of the Premises (such as sign off on the building inspection cards or a &#8220;safe to occupy&#8221; approval) for the Permitted Use (excluding any Tenant-required validation of Tenant&#8217;s facilities), (iii) Tenant has access to the Premises from the parking facilities and has access and use of the parking facilities, and (iv) all building systems serving the Premises are complete and Landlord is providing service to the Premises in accordance with the Lease.  If there shall be a delay in Substantial Completion of the Tenant Improvements as a result of:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Tenant&#8217;s request for materials, finishes or installations other than those readily available;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Tenant&#8217;s request to deviate from the Finish Options;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Tenant&#8217;s changes in the Construction Documents after approval by Tenant; </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Tenant&#8217;s failure to timely perform any obligation or provide any approval required of Tenant hereunder; </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e)&#160;&#160;&#160;&#160;Tenant&#8217;s failure to timely pay any Excess Costs; or</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(f)&#160;&#160;&#160;&#160;any negligent or willful act or omission of Tenant or any Tenant Party;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(each of the foregoing, a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant Delay</font><font style="font-family:inherit;font-size:10pt;">&#8221;), then the Commencement Date of the Term of this Lease shall be the date that the Tenant Improvements would have been Substantially Complete but for such Tenant Delay, as reasonably determined by Landlord.  The Tenant Improvements shall be deemed Substantially Complete notwithstanding the fact that minor details of construction, mechanical adjustments or decorations that do not materially interfere with Tenant&#8217;s use and enjoyment of the Premises remain to be performed (items normally referred to as &#8220;punch list&#8221; items).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assignment of Warranties</font><font style="font-family:inherit;font-size:10pt;">.  Upon Substantial Completion of the Tenant Improvements, Landlord shall assign to Tenant all warranties which Landlord receives for the Tenant Improvements, to the extent assignable.  In the event Tenant notifies Landlord of any defect(s) in the Tenant Improvements during the twelve (12) month period following the Commencement Date, Landlord shall repair such defect(s) at Landlord&#8217;s sole cost and expense, except to the extent such defects are covered by any warranties assigned to Tenant, in which case Tenant shall look solely to the applicable contractor or subcontractor for the correction of such defects; provided, however, that Landlord shall use commercially reasonable efforts to enforce any such warranties during such twelve (12) month period.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">signatures on following page</font><font style="font-family:inherit;font-size:10pt;">]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;B&#8221;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sF1C59BEA3A0168802B37D1CD6F7BF12E"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, this Work Letter Agreement is executed as of the date first written above.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:42%;"></td><td style="width:7%;"></td><td style="width:9%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LANDLORD:</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WATERIDGE PROPERTY OWNER, LP,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Delaware limited partnership</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HSRE-BPI I GP, LLC</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Delaware limited liability company, its general partner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Stephen M. Gordon</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stephen M. Gordon</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized Signatory</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT:</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ANAPTYSBIO, INC.,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Delaware corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Its:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interim CFO and General Counsel</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;B&#8221;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sA38179A7FD554F8AD2F7D1CD6F8EC0E4"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE &#8220;B-1&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SPACE PLAN</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><img src="newleaseimage3.gif" alt="newleaseimage3.gif" style="height:466px;width:726px;"><font style="font-family:inherit;font-size:10pt;background-color:#ffff00;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ACCEPTED: ________________, 2020</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:42%;"></td><td style="width:7%;"></td><td style="width:9%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT:</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ANAPTYSBIO, INC., a Delaware corporation</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interim CFO and General Counsel</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On conference April 24, 2020, Landlord and Tenant agreed that the most recent requested changes to the Space Plan (not reflected above) will be incorporated into the Space Plan.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SCHEDULE &#8220;B-1&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s2598EAF6BBBDB9289094D1CD6FA03039"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT &#8220;C&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM OF MEMORANDUM OF LEASE TERMS</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">MEMORANDUM OF LEASE TERMS</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Re:&#160;&#160;&#160;&#160;Lease Agreement (&#8220;Lease&#8221;) dated _______________, 2020, between WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership, Landlord, and ANAPTYSBIO, INC., a Delaware corporation, Tenant, concerning Suite 210 located at 10770 Wateridge Circle, San Diego, California 92121 (&#8220;Premises&#8221;).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dear ____________:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the Lease, we wish to advise and/or confirm as follows (terms with initial capital letters which are not separately defined herein shall have the meanings ascribed to them in the Lease):</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;">That the Premises have been accepted herewith by Tenant as being &#8220;Substantially Complete&#8221; in accordance with the subject Lease and that there is no deficiency in construction.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;">That Tenant has possession of the Premises and acknowledges that under the provisions of the Lease, the Term of said Lease shall commence as of, and the Commencement Date is, _______________________________, and the Expiration Date is ___________________________.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:10pt;">That in accordance with the Lease, Rent commenced to accrue on _________________________.  If the Commencement Date of the Lease is other than the first day of the month, the first billing will contain a pro rata adjustment.  Each billing thereafter shall be for the full amount of the monthly installment as provided for in the Lease.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:10pt;">Rent is due and payable in advance on the first day of each and every month during the Term of Lease.  Your Rent checks should be made payable to address set forth in the Lease.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:10pt;">The number of Rentable Square Feet within the Premises is _________ square feet.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:10pt;">The number of Rentable Square Feet within the Building is ________ square feet.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Percentage is ______________%.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:10pt;">Tenant elected to use $____________ of the Additional Allowance.  Accordingly, the Basic Rent shall be increased by $___________ per month. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:10pt;">Tenant elected to convert $____________ of the Abated Rent Amount to Abated Rent Allowance.  Accordingly, the amount of the Abated Rent Amount that will be applied toward Basic Rent is $___________.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:10pt;">Based on the Additional Allowance used by Tenant, the Basic Rent shall be as set forth in the following schedule:</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;C&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:16%;"></td><td style="width:28%;"></td><td style="width:28%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Months of Initial Term</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic Rent per Rentable Square Foot ($/mo)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Monthly Installments of Basic Rent ($/mo)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Annual  <br>Basic Rent ($/yr)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13-24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25-36</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37-48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49-60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61-72</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73-84</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85-96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97-108</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109-120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121-124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AGREED AND ACCEPTED: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:4%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TENANT:</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LANDLORD:</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ANAPTYSBIO, INC.,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WATERIDGE PROPERTY OWNER, LP,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Delaware corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a Delaware limited partnership</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="6" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:    </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Its:   </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="6" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:   HSRE-BPI I GP, LLC</font></div><div style="padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;a Delaware limited liability company, </font></div><div style="padding-left:29px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;its general partner</font></div><div style="padding-left:58px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:58px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:58px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:  ________________________________</font></div><div style="padding-left:58px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:  Stephen M. Gordon</font></div><div style="padding-left:28px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:    Authorized Signatory</font></div><div style="padding-left:28px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:    </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">SAMPLE ONLY <br>NOT FOR EXECUTION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;C&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s871D313C78A40A5254F5D1CD6FD0DD61"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT &#8220;D&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LETTER OF CREDIT TERMS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;">Within the period of time set forth in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 7.2</font><font style="font-family:inherit;font-size:10pt;">&#32;of this Lease, Tenant shall deliver to Landlord, as collateral for the full performance by Tenant of all of its obligations under this Lease and for all losses and damages Landlord may suffer as a result of any Tenant Default under this Lease, including, but not limited to, any post lease termination damages under Section 1951.2 of the California Civil Code, a standby, irrevocable letter of credit (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Letter of Credit</font><font style="font-family:inherit;font-size:10pt;">&#8221;), on a form acceptable to Landlord in its sole but reasonable discretion and containing the terms required herein, with a face amount in the Letter of Credit Amount designated in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 1.14</font><font style="font-family:inherit;font-size:10pt;">&#32;of this Lease, naming Landlord as beneficiary.  The Letter of Credit shall be issued by a money-center, solvent and nationally recognized bank, with a branch office in Southern California (unless the Letter of Credit contains a draw-by-fax provision), that will negotiate a letter of credit, and whose deposits are insured by the FDIC (as defined below).  The issuing bank shall be acceptable to Landlord in Landlord&#8217;s reasonable discretion, and shall permit multiple and partial draws on the Letter of Credit.  If at any time any of the issuing bank&#8217;s Fitch Ratings (or other comparable ratings to the extent the Fitch Ratings are no longer available) have been reduced below a &#8220;BBB+&#8221; rating or there is otherwise a material adverse change in the financial condition of the issuing bank, Tenant shall promptly deliver to Landlord a replacement Letter of Credit, which complies with the provisions of this Lease, from a different issuing bank acceptable to Landlord in Landlord&#8217;s reasonable discretion.  Tenant shall cause the Letter of Credit to be continuously maintained in effect (whether through replacement, renewal or extension) in the Letter of Credit Amount through the date (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Letter of Credit Expiration Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;) which is thirty (30) days after the expiration of the Term of this Lease, or any extension thereof.  If the Letter of Credit held by Landlord expires earlier than the Letter of Credit Expiration Date (whether by reason of a stated expiration date or a notice of termination or non-renewal given by the issuing bank), Tenant shall deliver a new Letter of Credit or certificate of renewal or extension to Landlord not later than thirty (30) days prior to the expiration date of the Letter of Credit then held by Landlord.  Any renewal or replacement Letter of Credit shall comply with all of the provisions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit &#8220;D-2&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;and shall remain in effect (whether through replacement, renewal or extension) in the Letter of Credit Amount through the Letter of Credit Expiration Date upon the same terms as the expiring Letter of Credit or such other terms as may be acceptable to Landlord in its sole but reasonable discretion.  The term of the Letter of Credit shall be for at least one (1) year and shall contain an &#8220;evergreen clause&#8221; that prevents the expiration of the Letter of Credit without due notice from the issuer.  The &#8220;evergreen clause&#8221; shall provide for a period of no less than thirty (30) days&#8217; notice to Landlord prior to the expiration date or nonrenewal.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;">Landlord shall have the immediate right to draw from the Letter of Credit an amount up to the then-aggregate face amount of the Letter of Credit, in whole or in part, at any time and from time to time upon the occurrence of any of the following events (each of the following being a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Letter of Credit Draw Event</font><font style="font-family:inherit;font-size:10pt;">&#8221;): (a) if such amount is due to Landlord under the terms and conditions of this Lease, beyond applicable notice and cure periods; (b) if Landlord incurs any costs following the expiration or any earlier termination of the Term in connection with its performance of any obligations that Tenant has failed to perform in a timely manner (including, without limitation, under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 15.2</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Article 31</font><font style="font-family:inherit;font-size:10pt;">&#32;of this Lease), whether or not a Tenant Default occurs as a result of Tenant&#8217;s failure to timely perform such obligations; (c) if the Letter of Credit held by Landlord expires (or is set to expire) earlier than the Letter of Credit Expiration Date (whether by reason of a stated expiration date or a notice of termination or non-renewal given by the issuing bank), and Tenant fails to deliver to Landlord, at least fifteen (15) days prior to the expiration date of the Letter of Credit then held by Landlord, a renewal or substitute Letter of Credit that is in effect and that complies with the provisions of this Lease, including the Letter of Credit Amount required under this Lease (such failure in this clause (c) hereinafter being referred to as a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Renewal Failure</font><font style="font-family:inherit;font-size:10pt;">&#8221;); (d) the occurrence of any event described in </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 25.1.7</font><font style="font-family:inherit;font-size:10pt;">&#32;of this Lease (whether or not a Tenant Default occurs as a result thereof); and/or (e) if: (i) any of the issuing bank&#8217;s Fitch Ratings (or other comparable ratings to the extent the Fitch Ratings are no longer available) have been reduced below a &#8220;BBB+&#8221; rating, or (ii) there is otherwise a material adverse change in the financial condition of the issuing bank, and Tenant has failed to provide Landlord with a replacement Letter of Credit that complies with the provisions of this Lease, including the Letter of Credit Amount required under this Lease, within ten (10) business days following Landlord&#8217;s written demand therefor (with no other notice or cure or grace period being applicable thereto, notwithstanding anything in this Lease to the contrary) (such failure in this clause (e) hereinafter being referred to as an &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Issuing Bank Replacement Failure</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  No condition or term of this Lease shall be deemed to render the Letter of Credit conditional to justify the issuer of the Letter of Credit in failing to honor a drawing upon such Letter of Credit </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;D&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">in a timely manner.  In addition, in the event the issuing bank is placed into receivership or conservatorship by the Federal Deposit Insurance Corporation or any successor or similar entity (as applicable, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">FDIC</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and the FDIC does not honor the commitments of such issuing bank, then, effective as of the date such receivership or conservatorship occurs, the Letter of Credit shall be deemed to fail to meet the requirements of this Lease and, within ten (10) business days following Landlord&#8217;s notice to Tenant of such receivership or conservatorship (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Letter of Credit FDIC Replacement Notice</font><font style="font-family:inherit;font-size:10pt;">&#8221;), Tenant shall replace the Letter of Credit with a substitute letter of credit from a different issuer (which issuer shall be acceptable to Landlord in its reasonable discretion) and that complies in all respects with the requirements of this Lease.  If Tenant fails to replace the Letter of Credit with a conforming, substitute letter of credit pursuant to the terms and conditions of this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:10pt;">&#32;as a result of a Renewal Failure or an Issuing Bank Replacement Failure, then, notwithstanding anything in this Lease to the contrary, Landlord shall have the right to declare a Tenant Default under this Lease for which there shall be no notice or grace or cure periods being applicable thereto (other than the aforesaid notice and ten (10) business day period).  Tenant shall be responsible for the payment of any and all costs incurred with the review of any replacement Letter of Credit (including, without limitation, Landlord&#8217;s reasonable attorneys&#8217; fees), which replacement is required pursuant to this </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:10pt;">&#32;or is otherwise requested by Tenant.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:10pt;">Tenant hereby acknowledges and agrees that Landlord is entering into this Lease in material reliance upon the ability of Landlord to draw upon the Letter of Credit upon the occurrence of any Letter of Credit Draw Event.  Upon the occurrence of any Letter of Credit Draw Event, Landlord may, but without obligation to do so, and without notice to Tenant, draw upon the Letter of Credit, in part or in whole, to cure any such Letter of Credit Draw Event and/or to compensate Landlord for any and all damages of any kind or nature sustained or which Landlord reasonably estimates that it will sustain resulting from Tenant&#8217;s Default under this Lease or other Letter of Credit Draw Event, and/or to compensate Landlord for any and all damages arising out of, or incurred in connection with, the termination of this Lease, including, without limitation, those specifically identified in Section 1951.2 of the California Civil Code.  The use, application or retention of the Letter of Credit, or any portion thereof, by Landlord shall not prevent Landlord from exercising any other right or remedy provided by this Lease or by any applicable law, it being intended that Landlord shall not first be required to proceed against the Letter of Credit, and such Letter of Credit shall not operate as a limitation on any recovery to which Landlord may otherwise be entitled.  Tenant agrees not to interfere in any way with payment to Landlord of the proceeds of the Letter of Credit, either prior to or following a &#8220;draw&#8221; by Landlord of any portion of the Letter of Credit, regardless of whether any dispute exists between Tenant and Landlord as to Landlord&#8217;s right to draw upon the Letter of Credit.  No condition or term of this Lease shall be deemed to render the Letter of Credit conditional to justify the issuer of the Letter of Credit in failing to honor a drawing upon such Letter of Credit in a timely manner.  Tenant agrees and acknowledges that:  (a) the Letter of Credit constitutes a separate and independent contract between Landlord and the issuing bank, (b) Tenant is not a third party beneficiary of such contract, (c) Tenant has no property interest whatsoever in the Letter of Credit or the proceeds thereof, and (d) in the event Tenant becomes a debtor under any chapter of the U.S. Bankruptcy Code, Tenant is placed into receivership or conservatorship, and/or there is an event of a receivership, conservatorship or a bankruptcy filing by, or on behalf of, Tenant, neither Tenant, any trustee, nor Tenant&#8217;s bankruptcy estate shall have any right to restrict or limit Landlord&#8217;s claim and/or rights to the Letter of Credit and/or the proceeds thereof by application of Section 502(b)(6) of the U.S. Bankruptcy Code or otherwise.  If Landlord draws on the Letter of Credit due to a Renewal Failure or an Issuing Bank Replacement Failure and is holding those proceeds of the Letter of Credit before application due to any other Letter of Credit Draw Event (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Letter of Credit Proceeds</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and has not elected to terminate this Lease due to Tenant&#8217;s failure to deliver a replacement letter of credit as required under </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:10pt;">&#32;above, then Landlord agrees to return to Tenant the Letter of Credit Proceeds, provided that Tenant is not then in Default under this Lease (other than as a result of Tenant&#8217;s failure to deliver the replacement letter of credit) concurrently with Tenant&#8217;s delivery to Landlord of a substitute letter of credit in the Letter of Credit Amount that complies in all respects with the requirements of this Lease (including, in the case of a Letter of Credit Issuing Bank Replacement Failure, a substitute Letter of Credit from a different issuer, which issuer shall be acceptable to Landlord in its reasonable discretion).  Nothing contained in the immediately preceding sentence shall imply that Landlord waives any right to declare a Tenant Default under this Lease due to Tenant&#8217;s failure to provide a replacement letter of credit in accordance with </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:10pt;">&#32;above following the occurrence of a Renewal Failure or an Issuing Bank Replacement Failure.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:10pt;">Landlord may, at any time and without notice to Tenant and without first obtaining Tenant&#8217;s consent thereto, transfer all or any portion of its interest in and to the Letter of Credit to another party, person or entity, including Landlord&#8217;s assignee, successor, transferee or mortgagee and/or to have the Letter of Credit reissued in the name of </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;D&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s assignee, successor, transferee or mortgagee.  If Landlord transfers its interest in the Building and transfers the Letter of Credit (or any proceeds thereof then held by Landlord) in whole or in part to the transferee, Landlord shall, without any further agreement between the parties hereto, thereupon be released by Tenant from all liability therefor.  The provisions hereof shall apply to every transfer or assignment of all or any part of the Letter of Credit to a new landlord.  In connection with any such transfer of the Letter of Credit by Landlord, Tenant shall execute and submit to the issuer of the Letter of Credit such applications, documents and instruments as may be necessary to effectuate such transfer.  Tenant shall be responsible to pay any then-applicable transfer fee in connection with such transfer.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:10pt;">Landlord and Tenant acknowledge and agree that in no event or circumstance shall the Letter of Credit or any renewal of it or any proceeds of it be:  (a) deemed to be or treated as a &#8220;security deposit&#8221; within the meaning of California Civil Code Section 1950.7, (b) subject to the terms of California Civil Code Section 1950.7, or (c) intended to serve as a &#8220;security deposit&#8221; within the meaning of California Civil Code Section 1950.7.  Landlord and Tenant:  (i) further acknowledge and agree that the Letter of Credit is not intended to serve as a security deposit and California Civil Code Section 1950.7 and any and all other laws, rules, and regulations applicable to security deposits in the commercial context (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Security Deposit Laws</font><font style="font-family:inherit;font-size:10pt;">&#8221;) shall have no applicability or relevancy to the Letter of Credit, and (ii) waive any and all rights, duties, and obligations either party may now or in the future have relating to or arising from the Security Deposit Laws.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;D&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sB372847A06E752496347D1CD6FEE61E4"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT &#8220;E&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM OF TENANT ESTOPPEL CERTIFICATE</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">TENANT ESTOPPEL CERTIFICATE</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Estoppel Certificate is given to [___________________, a _____________] (together with any successors and assigns, collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Landlord</font><font style="font-family:inherit;font-size:10pt;">&#8221;), by [____________ a ______________] (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tenant</font><font style="font-family:inherit;font-size:10pt;">&#8221;), with the understanding that Landlord, its current or prospective lenders and their respective counsel will rely on this Certificate in connection with the real property known as [_______________________], located at [___________________________] (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Property</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  Tenant hereby certifies as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;">The undersigned is Tenant under that certain lease dated ____________, ____ (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Lease</font><font style="font-family:inherit;font-size:10pt;">&#8221;) executed by Landlord or its predecessor in interest, as landlord, and Tenant, as tenant.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;">Pursuant to the Lease, Tenant has leased a portion of the Property consisting of approximately _____ rentable square feet (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Premises</font><font style="font-family:inherit;font-size:10pt;">&#8221;). </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:10pt;">The commencement date of the term of the Lease is ___________. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:10pt;">The expiration date of the term of the Lease is ________________. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:10pt;">The monthly basic rent is $________________, payable in advance on the first day of each calendar month. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:10pt;">The next rental payment in the amount of $________________ is due on _____________, 20__. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:10pt;">No rent has been prepaid except for the current month, and Tenant agrees not to pay rent more than one month in advance at any time.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:10pt;">The obligation to pay rent began on ________, _____. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:10pt;">The annual minimum rent is subject to rental increases as set forth in the Lease, and the last increase covers the period from _______, ____ through ___________, _____.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s payment of its share of Operating Expenses and Real Property Taxes is currently based on an annual amount of $______, which is currently being paid on an estimated basis in advance at the rate of $______ per month.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:10pt;">All rent has been paid through ________, 20__.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:10pt;">Tenant has paid a security deposit of $_________ in connection with the Lease.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">13.</font><font style="font-family:inherit;font-size:10pt;">Tenant does not have any right or option to renew or extend the term of the Lease or to expand into any additional space or to terminate the Lease in whole or in part prior to the expiration of the term except as follows: _______________________________________________________________________.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">14.</font><font style="font-family:inherit;font-size:10pt;">The Lease has been duly executed and delivered by, and is a binding obligation of, Tenant (and Guarantor, if applicable), and the Lease is in full force and effect.  The Lease is the entire agreement between Landlord (or any affiliated party) and Tenant (or any affiliated party) pertaining to the Premises.  A true, correct and complete copy of the Lease, together with any amendments, modifications and supplements thereto, is attached hereto as </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">, and except as attached hereto, there are no amendments, modifications, supplements, arrangements, side letters or understandings, oral or written, of any sort, modifying, amending, altering, supplementing or changing the terms of the Lease.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">15.</font><font style="font-family:inherit;font-size:10pt;">Tenant has unconditionally accepted the Premises and is satisfied with all the work done by and required of Landlord; Tenant has taken possession and is in occupancy of the Premises and is open for business; rent payments have commenced, and all tenant improvements in the Premises have been completed by Landlord in </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;E&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">accordance with plans and specifications approved by Tenant; and as of the date hereof Tenant is not aware of any defect in the Premises.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:10pt;">Except as set forth on </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:10pt;">&#32;attached to this Certificate:  Landlord has satisfied all commitments made to induce Tenant to enter into the Lease; there are no offsets or credits against rentals payable under the Lease; no free rent, tenant improvements, contributions or other concessions have been granted to Tenant; Landlord is not reimbursing Tenant or paying Tenant&#8217;s rent obligations under any other lease, and Tenant has not advanced any funds for or on behalf of Landlord for which Tenant has a right of deduction from, or set off against, future rent payments.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:10pt;">Except as set forth on </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:10pt;">&#32;attached to this Certificate, Landlord has no obligations to repair or maintain the Premises.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">18.</font><font style="font-family:inherit;font-size:10pt;">All obligations of Landlord under the Lease have been performed, and no event has occurred and no condition exists that, with the giving of notice or lapse of time or both, would constitute a default by Landlord under the Lease.  There are no offsets or defenses that Tenant has against the full enforcement of the Lease by Landlord.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">19.</font><font style="font-family:inherit;font-size:10pt;">Tenant has not assigned, transferred or hypothecated the Lease or any interest therein or subleased all or any portion of the Premises.  Tenant (and Guarantor, as applicable) is not insolvent and is able to pay its debts as they mature.  Tenant (and Guarantor, as applicable) has not declared bankruptcy or filed a petition seeking to take advantage of any law relating to bankruptcy, insolvency, reorganization, winding-up or composition or adjustment of debts, Tenant has no present intentions of doing so, and no such proceeding has been commenced against Tenant seeking such relief, and Tenant has no knowledge that any such proceeding is threatened.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">20.</font><font style="font-family:inherit;font-size:10pt;">Tenant does not have any right or option to purchase all or any part of the real property of which the Premises constitute a part.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">21.</font><font style="font-family:inherit;font-size:10pt;">Tenant agrees that no future modifications or amendment of the Lease will be enforceable unless the modification or amendment has been consented to in writing by Landlord.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.&#160;&#160;&#160;&#160;Tenant has no notice of any assignment of the Lease by Landlord, or any assignment, hypothecation or pledge of rents accruing under the Lease by Landlord, except in connection with prior mortgage financing obtained by Landlord.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">22.</font><font style="font-family:inherit;font-size:10pt;">Tenant has received no notice by any governmental authority or person claiming a violation of, or requiring compliance with, any applicable federal, state or local law or regulation intended to protect the environment and public health and safety (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Environmental Law</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The Premises are not, and during the term of the Lease have never been used to handle, treat, store, or dispose of oil, petroleum products, hazardous substances in any quantity, hazardous waste, toxic substances, regulated substances or hazardous air pollutants in violation of any Environmental Law.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">23.</font><font style="font-family:inherit;font-size:10pt;">The person executing this Estoppel Certificate is authorized by Tenant to do so and execution hereof is the binding act of Tenant enforceable against Tenant.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:  _________________, 20__&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TENANT:</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:&#160;&#160;&#160;&#160;____________________________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exhibits </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A &#8211; &#160;&#160;&#160;&#160;Complete copy of the Lease, together with any amendments</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:56px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">B &#8211; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exceptions to certifications (Note:  If no exceptions are noted on Exhibit B, then the word &#8220;none&#8221; shall be deemed to have been inserted therein)</font></div></td></tr></table><div style="line-height:120%;text-align:center;padding-left:56px;text-indent:-56px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">SAMPLE ONLY </font></div><div style="line-height:120%;text-align:center;padding-left:56px;text-indent:-56px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">NOT FOR EXECUTION</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;E&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s2CC40E46807C508265B0D1CD7021971B"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT &#8220;F&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RULES AND REGULATIONS</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant shall faithfully observe and comply with the following Rules and Regulations.  Landlord shall not be responsible to Tenant for the nonperformance of any of said Rules and Regulations by or otherwise with respect to the acts or omissions of any other tenants or occupants of the Project.  In the event of any conflict between the Rules and Regulations and the other provisions of this Lease, the latter shall control.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall not alter any lock or install any new or additional locks or bolts on any doors or windows of the Premises without obtaining Landlord&#8217;s prior written consent.  Tenant shall bear the cost of any lock changes or repairs required by Tenant.  Two keys will be furnished by Landlord for the Premises, and any additional keys required by Tenant must be obtained from Landlord at a reasonable cost to be established by Landlord.  Upon the termination of this Lease, Tenant shall restore to Landlord all keys of stores, offices, and toilet rooms, either furnished to, or otherwise procured by, Tenant and in the event of the loss of keys so furnished, Tenant shall pay to Landlord the cost of replacing same or of changing the lock or locks opened by such lost key if Landlord shall deem it necessary to make such changes.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;">All doors opening to public corridors shall be kept closed at all times except for normal ingress and egress to the Premises.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:10pt;">Landlord reserves the right to close and keep locked all entrance and exit doors of the Building during such hours as are customary for comparable buildings in San Diego County, California.  Tenant, its employees and agents must be sure that the doors to the Building are securely closed and locked when leaving the Premises if it is after the normal hours of business for the Building.  Any tenant, its employees, agents or any other persons entering or leaving the Building at any time when it is so locked, or any time when it is considered to be after normal business hours for the Building, may be required to sign the Building register.  Access to the Building may be refused unless the person seeking access has proper identification or has a previously arranged pass for access to the Building.  Landlord will furnish passes to persons for whom Tenant requests same in writing.  Tenant shall be responsible for all persons for whom Tenant requests passes and shall be liable to Landlord for all acts of such persons.  Landlord and his agents shall in no case be liable for damages for any error with regard to the admission to or exclusion from the Building of any person.  In case of invasion, mob, riot, public excitement, or other commotion, Landlord reserves the right to prevent access to the Building or the Project during the continuance thereof by any means it deems appropriate for the safety and protection of life and property.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:10pt;">Landlord shall have the right to reasonably prescribe the weight, size and position of all safes and other heavy property brought into the Building and also the times and manner of moving the same in and out of the Building.  Safes and other heavy objects shall, if considered necessary by Landlord, stand on supports of such thickness as is necessary to properly distribute the weight.   Landlord will not be responsible for loss of or damage to any such safe or property in any case.  Any damage to any part of the Building, its contents, occupants or visitors by moving or maintaining any such safe or other property shall be the sole responsibility and expense of Tenant.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:10pt;">The requirements of Tenant will be attended to only upon application at the management office for the Project or at such office location designated by Landlord.  Employees of Landlord shall not perform any work or do anything outside their regular duties unless under special instructions from Landlord.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:10pt;">No sign, advertisement, notice or handbill shall be exhibited, distributed, painted or affixed by Tenant on any part of the Premises or the Building without the prior written consent of Landlord.  Tenant shall not disturb, solicit, peddle, or canvass any occupant of the Project and shall cooperate with Landlord and the agents of Landlord to prevent same.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:10pt;">The toilet rooms, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which they were constructed, and no foreign substance of any kind whatsoever shall be thrown therein.  The expense of any breakage, stoppage or damage resulting from the violation of this rule shall be borne by the tenant who, or whose servants, employees, agents, visitors or licensees shall have caused same.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall not overload the floor of the Premises, nor mark, or drill into the partitions, woodwork or drywall or in any way deface the Premises or any part thereof without Landlord&#8217;s prior written consent.  </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;F&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall provide material safety data sheets for any Hazardous Material used or kept on the Premises.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall not without the prior written consent of Landlord use any method of heating or air conditioning other than that supplied by Landlord.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall not permit or allow the Premises to be occupied or used in a manner offensive or objectionable to Landlord or other occupants of the Project by reason of noise or vibrations, or interfere with other tenants or those having business therein, whether by the use of any musical instrument, radio, phonograph, or in any other way.  Tenant shall not throw anything out of doors, windows or skylights or down passageways.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall not bring into or keep within the Project, the Building or the Premises any animals (other than valid service animals), birds, aquariums, or, except in areas designated by Landlord, bicycles or other vehicles.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">13.</font><font style="font-family:inherit;font-size:10pt;">No cooking shall be done or permitted on the Premises, nor shall the Premises be used for the storage of merchandise, for lodging or for any improper, objectionable or immoral purposes.  Notwithstanding the foregoing, Underwriters&#8217; laboratory-approved equipment and microwave ovens may be used in the Premises for heating food and brewing coffee, tea, hot chocolate and similar beverages for employees and visitors, provided that such use is in accordance with all applicable Laws.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">14.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall not occupy or permit any portion of the Premises to be occupied as an office for a messenger-type operation or dispatch office, public stenographer or typist, or for the manufacture or sale of liquor, narcotics, or tobacco in any form, or as a medical office, or as a barber or manicure shop, or as an employment bureau without the express prior written consent of Landlord.  Tenant shall not engage or pay any employees on the Premises except those actually working for such tenant on the Premises nor advertise for laborers giving an address at the Premises.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">15.</font><font style="font-family:inherit;font-size:10pt;">Landlord reserves the right to exclude or expel from the Project any person who, in the judgment of Landlord, is intoxicated or under the influence of liquor or drugs, or who shall in any manner do any act in violation of any of these Rules and Regulations.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:10pt;">Tenant, its employees and agents shall not loiter in or on the entrances, corridors, sidewalks, lobbies, courts, halls, stairways, elevators, vestibules or any Building Common Areas or Project Common Areas for the purpose of smoking tobacco products or for any other purpose, nor in any way obstruct such areas, and shall use them only as a means of ingress and egress for the Premises.  Tenant shall not store any property in the Common Areas or use the Common Areas for any purpose not approved by Landlord in Landlord&#8217;s sole discretion.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall not waste electricity, water or air conditioning provided to the Building Common Areas and shall refrain from attempting to adjust any controls with respect thereto.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">18.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall deposit all of its trash, garbage and Hazardous Materials in receptacles within its Premises or in receptacles designated by Landlord outside of the Premises.  Tenant shall not place in any such receptacle any material that cannot be disposed of in the ordinary and customary manner of trash and garbage disposal.  Any Hazardous Materials transported through Common Areas shall be held in secondary containment devices provided by Tenant.  Tenant shall be responsible, at its sole cost and expense, for Tenant&#8217;s removal of its trash, garbage from the Premises to designated receptacles outside of the Premises and the removal of Hazardous Materials from the Premises and the Project pursuant to a separate contract maintained by Tenant.  If the Premises is or becomes infested with vermin as a result of the use or any misuse or neglect of the Premises by Tenant, its agents, servants, employees, contractors, visitors or licensees, Tenant shall forthwith, at Tenant&#8217;s expense, cause the Premises to be exterminated from time to time to the satisfaction of Landlord and shall employ such licensed exterminators as shall be approved in writing in advance by Landlord.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">19.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall comply with all orders, requirements and conditions now or hereafter imposed by applicable Laws or by Landlord for the Project (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Waste Regulations</font><font style="font-family:inherit;font-size:10pt;">&#8221;) regarding the collection, sorting, separation and recycling of waste products, garbage, refuse and trash generated by Tenant (collectively, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Waste Products</font><font style="font-family:inherit;font-size:10pt;">&#8221;), including (without limitation) the separation of Waste Products into receptacles reasonably approved by Landlord and the removal of such receptacles in accordance with any collection schedules prescribed by Waste Regulations.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;F&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">20.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any Governmental Authority.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">21.</font><font style="font-family:inherit;font-size:10pt;">No awnings or other projection shall be attached to the outside walls of the Building without the prior written consent of Landlord, and no curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the Premises other than Landlord standard drapes.  Neither the interior nor exterior of any windows shall be coated or otherwise sunscreened without the prior written consent of Landlord.  Tenant shall be responsible for any damage to the window film on the exterior windows of the Premises and shall promptly repair any such damage at Tenant&#8217;s sole cost and expense. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">22.</font><font style="font-family:inherit;font-size:10pt;">Tenant must comply with reasonable requests by Landlord concerning the informing of their employees of items of importance to Landlord.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">23.</font><font style="font-family:inherit;font-size:10pt;">Tenant must comply with any applicable &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NO-SMOKING</font><font style="font-family:inherit;font-size:10pt;">&#8221; ordinances.  If Tenant is required under the ordinance to adopt a written smoking policy, a copy of said policy shall be on file in the office of the Building.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">24.</font><font style="font-family:inherit;font-size:10pt;">Tenant hereby acknowledges that Landlord shall have no obligation to provide guard service or other security measures for the benefit of the Premises, the Building or the Project.  Tenant hereby assumes all responsibility for the protection of Tenant and its agents, employees, contractors, invitees and guests, and the property thereof, from acts of third parties, including keeping doors locked and other means of entry to the Premises closed, whether or not Landlord, at its option, elects to provide security protection for the Project or any portion thereof.  Tenant further assumes the risk that any safety and security devices, services and programs which Landlord elects, in its sole discretion, to provide may not be effective, or may malfunction or be circumvented by an unauthorized third party, and Tenant shall, in addition to its other insurance obligations under this Lease, obtain its own insurance coverage to the extent Tenant desires protection against losses related to such occurrences.  Tenant shall cooperate in any reasonable safety or security program developed by Landlord or required by Law.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">25.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall not use in any space or in the public halls of the Building, any hand trucks except those equipped with rubber tires and rubber side guards.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">26.</font><font style="font-family:inherit;font-size:10pt;">No auction, liquidation, fire sale, going-out-of-business or bankruptcy sale shall be conducted in the Premises without the prior written consent of Landlord.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">27.</font><font style="font-family:inherit;font-size:10pt;">No tenant shall use or permit the use of any portion of the Premises for living quarters, sleeping apartments or lodging rooms.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:10px;text-align:justify;text-indent:48px;"><font style="padding-bottom:10px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">28.</font><font style="font-family:inherit;font-size:10pt;">Tenant shall install and maintain, at Tenant&#8217;s sole cost and expense, an adequate, visibly marked and properly operational fire extinguisher next to any duplicating or photocopying machines or similar heat producing equipment, which may or may not contain combustible material, in the Premises.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord reserves the right at any time to change or rescind any one or more of these Rules and Regulations, or to make such other and further reasonable Rules and Regulations as in Landlord&#8217;s judgment may from time to time be necessary for the management, safety, care and cleanliness of the Premises, Building, the Building Common Areas and the Project Common Areas, and for the preservation of good order therein, as well as for the convenience of other occupants and tenants therein.  Provided that the Rules and Regulations are applied and enforced in a non-discriminatory manner, Landlord may waive any one or more of these Rules and Regulations for the benefit of any particular tenants, but no such waiver by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other tenant, nor prevent Landlord from thereafter enforcing any such Rules or Regulations against any or all tenants of the Project.  Tenant shall be deemed to have read these Rules and Regulations and to have agreed to abide by them as a condition of its occupancy of the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;F&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s983331C1FDC712083AEDD1CD704362A1"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT &#8220;G&#8221;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PARKING RULES AND REGULATIONS</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following rules and regulations shall govern the use of the Parking Area of the Project:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160;&#160;Except for the gross negligence or willful misconduct of Landlord, Landlord shall not be responsible for any damage to vehicles, injuries to persons, or loss of property, all of which risks are assumed by the party using the Parking Area.  All claimed damage, injuries, or loss must be reported, itemized in writing and delivered to the parking management office located within the Project within ten (10) days after any claimed damage, injuries, or loss occurs.  Any claim not so made is waived.  In any event, (a) the total liability of Landlord, if any, shall be limited to Two Hundred Fifty Dollars ($250.00) for all damages to any vehicle and/or loss of any property, and (b) Landlord shall not be responsible for the loss of use of any vehicle or property.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160;&#160;Tenant shall not park, nor permit Tenant&#8217;s Parking Invitees except visitors to park, in any parking areas designated by Landlord as areas for parking by visitors to the Project; nor shall Tenant and/or Tenant&#8217;s Parking Invitees park in parking areas designated by Landlord for the exclusive use of tenants or other occupants of the Project.  Neither Tenant, nor Tenant&#8217;s Parking Invitees, shall leave vehicles in the parking areas overnight or as extended term storage or park any vehicles in the parking areas other than automobiles, motorcycles, motor driven or non-motor driven bicycles or four wheeled trucks.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;Parking stickers or any other device or form of identification supplied by Landlord as a condition of use of the Parking Area shall remain the property of Landlord.  Such parking identification device must be displayed as requested and may not be mutilated in any manner.  The serial number of the parking identification device may not be obliterated.  Devices are not transferable and any device in the possession of an unauthorized holder will be void.  Landlord may charge a fee for parking stickers, cards or other parking control device supplied by Landlord.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160;&#160;Vehicles must be parked entirely within painted stall lines of a single parking stall.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160;&#160;All directional signs and arrows must be observed.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.&#160;&#160;&#160;&#160;The speed limit within all parking areas shall be five (5) miles per hour.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.&#160;&#160;&#160;&#160;Parking is prohibited:</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;in areas not striped for parking;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;in aisles;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;where &#8220;no parking&#8221; signs are posted;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;on ramps;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;in cross-hatched areas;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;in loading areas; and</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;in such other areas as may be designated by Landlord or Landlord parking operator.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.&#160;&#160;&#160;&#160;Every parker is required to park and lock his own vehicle.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.&#160;&#160;&#160;&#160;Loss or theft of parking identification devices must be reported to Landlord immediately, and a lost or stolen report must be filed by Tenant or user of such parking identification device at the time.  Landlord has the right to exclude any car from the Parking Area that does not have an identification device.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.&#160;&#160;&#160;&#160;Any parking identification devices reported lost or stolen found on any unauthorized car will be confiscated and the illegal holder will be subject to prosecution.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;G&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">11</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Washing, waxing, cleaning or servicing of any vehicle in any area not specifically reserved for such purpose is prohibited.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.&#160;&#160;&#160;&#160;The parking operators, managers or attendants are not authorized to make or allow any exceptions to these rules and regulations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">13</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant&#8217;s and Tenant&#8217;s Parking Invitees&#8217; continued right to use any parking spaces in the Parking Area is conditioned upon Tenant, and Tenant&#8217;s Parking Invitees, abiding by these rules and regulations and those contained in this Lease.  Further, if this Lease terminates for any reason whatsoever, Tenant&#8217;s, and Tenant&#8217;s Parking Invitees&#8217;, right to use the parking spaces in the Parking Area shall terminate concurrently therewith.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">14</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant agrees to sign a parking agreement with Landlord or Landlord&#8217;s parking operator within five (5) days of request, which agreement shall provide the manner of payment of monthly parking fees, if any, and otherwise be consistent with this Lease and these rules and regulations.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Landlord reserves the right to refuse the sale of monthly stickers or other parking identification devices to any tenant or person and/or his agents or representatives who willfully refuse to comply with these rules and regulations or any posted or unposted Laws.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.&#160;&#160;&#160;&#160;Landlord reserves the right to establish and change parking fees (except to the extent that same are specifically fixed pursuant to Section 1.8) and to modify and/or adopt such other reasonable and nondiscriminatory rules and regulations for the Parking Area as it deems necessary for the operation of the Parking Area.  Nothing herein shall require Landlord to charge a uniform monthly parking fee for the use of vehicle parking spaces in the Project, it being expressly acknowledged and agreed that parking fees may differ based on any factor deemed sufficient by Landlord, including without limitation the degree of a particular tenant&#8217;s participation in energy and/or traffic management programs of the type described in Section 8.2(a) of this Lease.  Landlord may refuse to permit any person who violates these rules to park in the Parking Area, and any violation of the rules shall subject the car to removal, at such car owner&#8217;s expense.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;A third party may own, operate or control the Parking Area, and such party may enforce these Parking Rules and Regulations relating to parking.  Tenant will obey any additional rules and regulations governing parking that may be imposed by the parking operator or any other person controlling the Parking Area serving the Project.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Tenant will be responsible for the observance of all of the Parking Rules and Regulations by Tenant (including, without limitation, all employees, agents, clients, customers, invitees and guests).</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">19</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Landlord may, from time to time, waive any one or more of these Parking Rules and Regulations for the benefit of Tenant or any other tenant, but no such waiver by Landlord shall be construed as a continuing waiver of such Parking Rules and Regulations in favor of Tenant or any other tenant, nor prevent Landlord from thereafter enforcing any such Parking Rules and Regulations against Tenant or any or all of the tenants of the Project.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;These Parking Rules and Regulations are in addition to, and shall not be construed to in any way modify or amend, in whole or in part, the other terms, covenants, agreements, and conditions of this Lease.  To the extent there is any conflict between any of the Parking Rule and Regulations and any express term or provision otherwise set forth in this Lease, such other express term or provision will be controlling.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;G&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sC5CE577C750D2D87A5DBD1CD70736178"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT &#8220;H&#8221;</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESERVED</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT &#8220;H&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s5AA16AFF5E3E715ADC64D1CD70C90C84"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX OF DEFINED TERMS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49%;"></td><td style="width:51%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Abandonment, 29</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Address, 1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Abated Rent Allowance, 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Fair Market Rental Value Notice, 5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Abated Rent Amount, 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laws, 12</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ADA, 12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease, 1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional Allowance, 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold Improvements, 19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional Rent, 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Letter of Credit. See Exhibit D-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alterations, 18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Letter of Credit Draw Event. See Exhibit D-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual Reconciliation, 10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Letter of Credit Expiration Date. See Exhibit D-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anti-Terrorism Law, 41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Letter of Credit FDIC Replacement Notice. See </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assignment, 32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit D-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic Rent, 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Letter of Credit Proceeds. See Exhibit D-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Broker(s), 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Major Alteration, 19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building, 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Memorandum of Lease Terms, 4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building Area, 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice, 16</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building Common Areas, 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of Default, 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building Systems, 19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offer, 43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Claims, 23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offer Space, 43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commencement Date, 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating Expenses, 7</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Areas, 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option, 4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comparable Transactions, 5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option Term, 4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consent Instrument, 34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Original Tenant, 4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction Documents. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outline of Premises, 2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Control, 32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outside Agreement Date, 5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Controlling, 32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Parking Area, 36</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Default Rate, 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permitted Alterations, 19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate, 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permitted Transfer, 35</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dispute Notice, 10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permitted Transferee, 35</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Early Access Period, 42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permitted Use, 2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective Date, 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase I Assessment, 42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emergency Generator. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase I Surrender Assessment, 42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Environmental Inspection, 42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase II Surrender Assessment, 42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated Statement, 9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Premises, 1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excess Costs. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prime Rate, 6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Order No. 13224, 41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prohibited Person, 41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expiration Date, 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Project, 2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair Market Rental Value, 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Project Common Areas, 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDIC. See Exhibit D-2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Project Site, 2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finish Options. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Project Site Plan, 2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Force Majeure, 39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property Manager, 19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Governmental Authority, 7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proposed Transferee, 32</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hazardous Material, 15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Real Property Taxes, 8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hazardous Material Laws, 15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursements, 9</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holder, 35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewal Failure. See Exhibit D-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HVAC, 21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent, 6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initial Allowance, 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rentable Square Feet, 1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initial Term, 1, 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Review Notice, 10</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Institutional Owner Practices, 7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ROFR, 43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest Rate, 7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rules and Regulations, 38</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuing Bank Replacement Failure. See Exhibit D-2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SEC, 37</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord, 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Security Deposit, 2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord Default, 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Security Deposit Laws. See Exhibit D-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord Indemnified Parties, 24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Security Instruments, 35</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Landlord&#8217;s Accountant, 11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SIR, 26</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Index of Defined Terms</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49%;"></td><td style="width:51%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Space Plan. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Personal Property, 19</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sublease, 32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term, 4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substantial Completion. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination Date, 43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substantially Complete. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination Fee, 43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental Equipment, 20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination Notice, 43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taking, 28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination Option, 43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant, 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Destruction, 27</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Default, 29</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer, 32</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Delay. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer Date, 32</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Estoppel Certificate, 35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer Instrument, 33</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Improvement Allowance, 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer Notice, 32</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Improvements. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transferee, 34</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Party, 13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upper Slab, 24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant Water Meter, 22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">USA Patriot Act, 41</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Address, 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Waste Products. See Exhibit F</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Emergency Generator Share. See Exhibit B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Waste Regulations. See Exhibit F</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Parking Invitees, 36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work Letter Agreement, 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant&#8217;s Percentage, 2, 9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work Schedule. See Exhibit B</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;padding-left:120px;text-indent:-120px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Index of Defined Terms</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>anab-33120x10qxexx311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE8815A9A860157BD9676865C44C71026"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:174%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Hamza Suria, certify that:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this quarterly report on Form 10-Q of AnaptysBio, Inc.;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control&#160;over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially&#160;affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">May&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.95726495726496%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Hamza Suria</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hamza Suria</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>anab-33120x10qxexx312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s375DFA6209B358E69AA7EF5F60CF707E"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:174%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Eric Loumeau, certify that:</font></div><div style="line-height:174%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this quarterly report on Form 10-Q of AnaptysBio, Inc.;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control&#160;over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially&#160;affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">May&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.89743589743589%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Chief Financial Officer and General Counsel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>anab-33120x10qxexx321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6D42964F9F3F598BA33301A412E93503"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Hamza Suria, Chief Executive Officer of AnaptysBio, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Quarterly Report on Form 10-Q of the Company for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">May&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.95726495726496%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Hamza Suria</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hamza Suria</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>anab-33120x10qxexx322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEDC0C786C0CC5D599216E22803123ABE"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.2 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Eric Loumeau, Interim Chief Financial Officer and General Counsel of AnaptysBio, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Quarterly Report on Form 10-Q of the Company for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">May&#160;6, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:59.401709401709404%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eric Loumeau</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Chief Financial Officer and General Counsel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>anab-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.anaptysbio.com/20200331" xmlns:anab="http://www.anaptysbio.com/20200331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anab-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BalanceSheetAccountsAndSupplementalDisclosures" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures">
        <link:definition>2107100 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails">
        <link:definition>2407403 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails">
        <link:definition>2407402 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsAndSupplementalDisclosuresTables" roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables">
        <link:definition>2307301 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchAndDevelopmentAgreements" roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements">
        <link:definition>2110100 - Disclosure - Collaborative Research and Development Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchAndDevelopmentAgreementsDetails" roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails">
        <link:definition>2410402 - Disclosure - Collaborative Research and Development Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchAndDevelopmentAgreementsTables" roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables">
        <link:definition>2310301 - Disclosure - Collaborative Research and Development Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingencies">
        <link:definition>2125100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>2425402 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails">
        <link:definition>2425403 - Disclosure - Commitments and Contingencies - Classification on the Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails">
        <link:definition>2425404 - Disclosure - Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails">
        <link:definition>2425405 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetailsCalc2" roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetailsCalc2">
        <link:definition>2425405 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2325301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementOfStockholdersEquity" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical">
        <link:definition>1002001 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.anaptysbio.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://www.anaptysbio.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans">
        <link:definition>2122100 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails">
        <link:definition>2422405 - Disclosure - Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansNarrativeDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails">
        <link:definition>2422402 - Disclosure - Equity Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansOptionActivityDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails">
        <link:definition>2422403 - Disclosure - Equity Incentive Plans - Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansOptionFairValueAssumptionsDetails" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails">
        <link:definition>2422404 - Disclosure - Equity Incentive Plans - Option Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables">
        <link:definition>2322301 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndAvailableForSaleInvestments" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments">
        <link:definition>2116100 - Disclosure - Fair Value Measurements and Available for Sale Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2416402 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails">
        <link:definition>2416404 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails">
        <link:definition>2416403 - Disclosure - Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails">
        <link:definition>2416405 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndAvailableForSaleInvestmentsTables" roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables">
        <link:definition>2316301 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayable" roleURI="http://www.anaptysbio.com/role/NotesPayable">
        <link:definition>2113100 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableDetails" roleURI="http://www.anaptysbio.com/role/NotesPayableDetails">
        <link:definition>2413401 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.anaptysbio.com/role/StockholdersEquity">
        <link:definition>2119100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>2419402 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>2419403 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables">
        <link:definition>2319301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.anaptysbio.com/role/SubsequentEventDetails">
        <link:definition>2426401 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventNotes" roleURI="http://www.anaptysbio.com/role/SubsequentEventNotes">
        <link:definition>2126100 - Disclosure - Subsequent Event (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2104100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2404403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails">
        <link:definition>2404404 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2304302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="anab_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" name="AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" name="AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" name="AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" name="AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_AnnualRentIncreasePercent" name="AnnualRentIncreasePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_AssetsAndLiabilitiesLesseeTableTextBlock" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_AvailableforsaleDebtSecuritiesRemainingMaturity" name="AvailableforsaleDebtSecuritiesRemainingMaturity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" name="CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="anab_CelgeneCorporationMember" name="CelgeneCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_ClearanceOfInvestigationalNewDrugFromFDAMember" name="ClearanceOfInvestigationalNewDrugFromFDAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_CommercialAndCorporateObligationsMember" name="CommercialAndCorporateObligationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" name="CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" name="CommonStockCapitalSharesReservedForFutureIssuanceIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_DebtInstrumentMaximumBorrowingCapacity" name="DebtInstrumentMaximumBorrowingCapacity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="anab_DebtInstrumentNumberOfLoanInstallments" name="DebtInstrumentNumberOfLoanInstallments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" name="EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" name="EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="anab_EmployeeAndNonemployeeStockOptionsMember" name="EmployeeAndNonemployeeStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_EmployeeStockPurchasePlan2017Member" name="EmployeeStockPurchasePlan2017Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_EquityIncentivePlan2017Member" name="EquityIncentivePlan2017Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_FilingofMMAMember" name="FilingofMMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_FilingofNDAMember" name="FilingofNDAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_InVivoToxicologyStudiesMember" name="InVivoToxicologyStudiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_LeaseArrangementAxis" name="LeaseArrangementAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_LeaseArrangementDomain" name="LeaseArrangementDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" name="LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_LesseeOperatingLeaseNumber" name="LesseeOperatingLeaseNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" name="LesseeOperatingLeaseOneYearRenewalOptionsNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="anab_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_OneOfficeLeaseMember" name="OneOfficeLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_Phase1ClinicalTrialInitiationMember" name="Phase1ClinicalTrialInitiationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_Phase2ClinicalTrialInitiationMember" name="Phase2ClinicalTrialInitiationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_Phase3ClinicalTrialInitiationMember" name="Phase3ClinicalTrialInitiationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_Phase3clinicaltrialinitiationsecondindicationDomain" name="Phase3clinicaltrialinitiationsecondindicationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_RentPerSquareFoot" name="RentPerSquareFoot" nillable="true" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" name="RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" name="RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" name="RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" name="RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" name="RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" name="RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" name="RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" name="RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" name="RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" name="RevenueRecognizedMilestoneMethodMilestonePaymentEarned" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" name="SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_TESAROInc.AndTESARODevelopmentInc.Member" name="TESAROInc.AndTESARODevelopmentInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_TermALoansMember" name="TermALoansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="anab_TermBLoansAndTermCLoansMember" name="TermBLoansAndTermCLoansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>anab-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements" xlink:href="anab-20200331.xsd#CollaborativeResearchAndDevelopmentAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails" xlink:href="anab-20200331.xsd#CollaborativeResearchAndDevelopmentAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables" xlink:href="anab-20200331.xsd#CollaborativeResearchAndDevelopmentAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingencies" xlink:href="anab-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetailsCalc2" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:href="anab-20200331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="anab-20200331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="anab-20200331.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="anab-20200331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="anab-20200331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="anab-20200331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:href="anab-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/DescriptionOfBusiness" xlink:href="anab-20200331.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:href="anab-20200331.xsd#EquityIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:href="anab-20200331.xsd#EquityIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayable" xlink:href="anab-20200331.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:href="anab-20200331.xsd#NotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquity" xlink:href="anab-20200331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:href="anab-20200331.xsd#StockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="anab-20200331.xsd#StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:href="anab-20200331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:href="anab-20200331.xsd#SubsequentEventDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEventNotes" xlink:href="anab-20200331.xsd#SubsequentEventNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_e0246bee-50f0-57fe-e0a8-0dc50b07e5d1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:to="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_e0246bee-50f0-57fe-e0a8-0dc50b07e5d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4401AA9C62336093C8E67611536C7FEA_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4401AA9C62336093C8E67611536C7FEA_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4401AA9C62336093C8E67611536C7FEA_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4401AA9C62336093C8E67611536C7FEA_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_4401AA9C62336093C8E67611536C7FEA_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4401AA9C62336093C8E67611536C7FEA_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_4401AA9C62336093C8E67611536C7FEA_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_293ecac9-0396-b0f6-2701-a4671048537d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_293ecac9-0396-b0f6-2701-a4671048537d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_b6679d8b-b58e-3a78-f1da-0dc50b112f72" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_b6679d8b-b58e-3a78-f1da-0dc50b112f72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_25f3d0af-ced3-016f-c911-7e8b9a22875d" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_25f3d0af-ced3-016f-c911-7e8b9a22875d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_591bbf45-d531-0671-adc1-cfca3447af6c" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_591bbf45-d531-0671-adc1-cfca3447af6c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_eb2870a2-925f-fea6-4889-e3edb4eb0bd6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_eb2870a2-925f-fea6-4889-e3edb4eb0bd6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2919f63b-33a2-2107-5264-212ca7a03283" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2919f63b-33a2-2107-5264-212ca7a03283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_F66D52DC43E95E5A8B2218496FC3C879" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2BF12BBB39C05DA0994FD6B7B5764F00" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_F66D52DC43E95E5A8B2218496FC3C879" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2BF12BBB39C05DA0994FD6B7B5764F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_D3E75A34A655540B9C0C3AF16B21AA70" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_F66D52DC43E95E5A8B2218496FC3C879" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_D3E75A34A655540B9C0C3AF16B21AA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50E0022E2C955BAD9AFA0D003627492B" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_F66D52DC43E95E5A8B2218496FC3C879" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50E0022E2C955BAD9AFA0D003627492B" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/NotesPayable" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B05DDD69F8725458B5C783830208F7D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0A653B3D7D1E50C2A26B8B77B010BD0D" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B05DDD69F8725458B5C783830208F7D0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0A653B3D7D1E50C2A26B8B77B010BD0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CD435FB07182522CA2DFA6E679297B77" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B05DDD69F8725458B5C783830208F7D0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CD435FB07182522CA2DFA6E679297B77" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SubsequentEventNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>anab-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements" xlink:href="anab-20200331.xsd#CollaborativeResearchAndDevelopmentAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails" xlink:href="anab-20200331.xsd#CollaborativeResearchAndDevelopmentAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables" xlink:href="anab-20200331.xsd#CollaborativeResearchAndDevelopmentAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingencies" xlink:href="anab-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:href="anab-20200331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="anab-20200331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="anab-20200331.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="anab-20200331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="anab-20200331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="anab-20200331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:href="anab-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/DescriptionOfBusiness" xlink:href="anab-20200331.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:href="anab-20200331.xsd#EquityIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:href="anab-20200331.xsd#EquityIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayable" xlink:href="anab-20200331.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:href="anab-20200331.xsd#NotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquity" xlink:href="anab-20200331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:href="anab-20200331.xsd#StockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="anab-20200331.xsd#StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:href="anab-20200331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:href="anab-20200331.xsd#SubsequentEventDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEventNotes" xlink:href="anab-20200331.xsd#SubsequentEventNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LaboratoryEquipmentMember" xlink:label="loc_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:to="loc_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:to="loc_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:to="loc_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_TESAROInc.AndTESARODevelopmentInc.Member" xlink:label="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:to="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CelgeneCorporationMember" xlink:label="loc_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:to="loc_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_InVivoToxicologyStudiesMember" xlink:label="loc_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:label="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase2ClinicalTrialInitiationMember" xlink:label="loc_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase3ClinicalTrialInitiationMember" xlink:label="loc_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase3clinicaltrialinitiationsecondindicationDomain" xlink:label="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_FilingofNDAMember" xlink:label="loc_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_FilingofMMAMember" xlink:label="loc_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase1ClinicalTrialInitiationMember" xlink:label="loc_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:to="loc_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:to="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:to="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:label="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:to="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" xlink:label="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:to="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" xlink:label="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:to="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:to="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LeaseArrangementAxis" xlink:label="loc_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:to="loc_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LeaseArrangementDomain" xlink:label="loc_anab_LeaseArrangementDomain_0938B0199A317E3EDC740DC53A5D6216_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:to="loc_anab_LeaseArrangementDomain_0938B0199A317E3EDC740DC53A5D6216_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LeaseArrangementDomain" xlink:label="loc_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:to="loc_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_OneOfficeLeaseMember" xlink:label="loc_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:to="loc_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LesseeOperatingLeaseNumber" xlink:label="loc_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="loc_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_569DBB6BC03453069ADF59D3B66260A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_569DBB6BC03453069ADF59D3B66260A2" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" xlink:label="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_926A6E65991151ACA45A08AE99A0816F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_926A6E65991151ACA45A08AE99A0816F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:to="loc_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:to="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:to="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:to="loc_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:to="loc_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A28866463CD49B823325D202D34898A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_StockholdersEquity_A28866463CD49B823325D202D34898A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85B7D13FB5D15CC5FE80D202D3485174" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85B7D13FB5D15CC5FE80D202D3485174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0FBB94F0D39D246B1DE4D202D349561E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_NetIncomeLoss_0FBB94F0D39D246B1DE4D202D349561E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3505C6A863FB5C538DBE2ADB82BA8507" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F0E3DC9EFA6A5594A2BABD4022AE53BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3505C6A863FB5C538DBE2ADB82BA8507" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F0E3DC9EFA6A5594A2BABD4022AE53BF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F0E3DC9EFA6A5594A2BABD4022AE53BF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F62FCACCDEF453E9C3D80DC539A0987A_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F62FCACCDEF453E9C3D80DC539A0987A_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9F914DF993DC54AF91803170767EE2EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9F914DF993DC54AF91803170767EE2EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99DFD6CCC1F555CD9E4515FB2FB71F9F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99DFD6CCC1F555CD9E4515FB2FB71F9F" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3505C6A863FB5C538DBE2ADB82BA8507" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_7F860995188C5D98AF98B6901A948BD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:to="loc_us-gaap_PlanNameAxis_7F860995188C5D98AF98B6901A948BD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_892D60346B2310873D4993247D519BFF_C22631B6949C5ACAA35D0B6E5FF9E1DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7F860995188C5D98AF98B6901A948BD8" xlink:to="loc_us-gaap_PlanNameDomain_892D60346B2310873D4993247D519BFF_C22631B6949C5ACAA35D0B6E5FF9E1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_59AE08D183985E728D11C8B9FEC79463" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7F860995188C5D98AF98B6901A948BD8" xlink:to="loc_us-gaap_PlanNameDomain_59AE08D183985E728D11C8B9FEC79463" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EquityIncentivePlan2017Member" xlink:label="loc_anab_EquityIncentivePlan2017Member_B6B8FC3AE6E350FAB2319453FE790FC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_59AE08D183985E728D11C8B9FEC79463" xlink:to="loc_anab_EquityIncentivePlan2017Member_B6B8FC3AE6E350FAB2319453FE790FC1" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeStockPurchasePlan2017Member" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_D7D39216091C5C19AF4DA7DC384CD1E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_59AE08D183985E728D11C8B9FEC79463" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_D7D39216091C5C19AF4DA7DC384CD1E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:to="loc_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D5B5EF9C4E99A0447A293247D5193E1_C22631B6949C5ACAA35D0B6E5FF9E1DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D5B5EF9C4E99A0447A293247D5193E1_C22631B6949C5ACAA35D0B6E5FF9E1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_58F9B1D5FAB2504F8DC3B005997CBA7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:to="loc_us-gaap_EmployeeStockMember_58F9B1D5FAB2504F8DC3B005997CBA7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3C0AD9F6F03455CBA8BC592E1BCE7537" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3C0AD9F6F03455CBA8BC592E1BCE7537" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeAndNonemployeeStockOptionsMember" xlink:label="loc_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:to="loc_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:to="loc_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0577D0C646318707ADF993247D5185EE_C22631B6949C5ACAA35D0B6E5FF9E1DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0577D0C646318707ADF993247D5185EE_C22631B6949C5ACAA35D0B6E5FF9E1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_8EB8B137701B558CBB94A51B6B5D8681" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:to="loc_srt_DirectorMember_8EB8B137701B558CBB94A51B6B5D8681" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F0A0937ACD995483952BBA51D6C26A15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F0A0937ACD995483952BBA51D6C26A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84CDDF17EFE7599693323B44E78E296A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84CDDF17EFE7599693323B44E78E296A" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B99477DB51065A34B6D78821C7F102AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B99477DB51065A34B6D78821C7F102AC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7C73928A7BE85D14A9AB7AF9B6EC1718" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B99477DB51065A34B6D78821C7F102AC" xlink:to="loc_us-gaap_AwardTypeAxis_7C73928A7BE85D14A9AB7AF9B6EC1718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3A0BECCAFC4EFC9594670DC53A6381A3_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7C73928A7BE85D14A9AB7AF9B6EC1718" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3A0BECCAFC4EFC9594670DC53A6381A3_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E24BC8FD24075D9D865FF850EC3B85F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7C73928A7BE85D14A9AB7AF9B6EC1718" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E24BC8FD24075D9D865FF850EC3B85F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E2883F560B5F59AC8673E23C148E52FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E24BC8FD24075D9D865FF850EC3B85F6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_E2883F560B5F59AC8673E23C148E52FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B52E3CD3EF5A5059AD457E34B582F865" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B52E3CD3EF5A5059AD457E34B582F865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0606648C72995CAEA5EF890C6B26CA63" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0606648C72995CAEA5EF890C6B26CA63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C5298A7DCD24592886A49AD26629B4FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C5298A7DCD24592886A49AD26629B4FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_083C64CA342052E3B7883B2A33F16E66" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_083C64CA342052E3B7883B2A33F16E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43AE629650805E1EBCF009A61DA7D4EF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43AE629650805E1EBCF009A61DA7D4EF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4468826A62CB331AC8340DC53AACB920_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4468826A62CB331AC8340DC53AACB920_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9F99680282FB5BF28EAAA8FF97830B69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9F99680282FB5BF28EAAA8FF97830B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9D4E3B13051520C953EB0DC53AAD76DC_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9D4E3B13051520C953EB0DC53AAD76DC_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4DA510BEC7875837B6103415EE636E20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4DA510BEC7875837B6103415EE636E20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E02223F994325D13B8EA50EADEE036AB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E02223F994325D13B8EA50EADEE036AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_230D999015985B5CA95EF4F1A655D983" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_230D999015985B5CA95EF4F1A655D983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9542A3FF633E7176E0FB0DC53AAEBA6D_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9542A3FF633E7176E0FB0DC53AAEBA6D_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B06BCEA24852566CA8D74C9BCA15045F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B06BCEA24852566CA8D74C9BCA15045F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaap_MutualFundMember_681C2A33CF7257CF8BFC56BB77112405" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:to="loc_us-gaap_MutualFundMember_681C2A33CF7257CF8BFC56BB77112405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_FC9FD4D986C95FCD9A7D4C7BAE7514C2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_FC9FD4D986C95FCD9A7D4C7BAE7514C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2A8CE175180DDE952D7E0DC53AAF3098_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_FC9FD4D986C95FCD9A7D4C7BAE7514C2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2A8CE175180DDE952D7E0DC53AAF3098_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_FC9FD4D986C95FCD9A7D4C7BAE7514C2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_DA558772A7DD516EA07E7BC395332930" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_DA558772A7DD516EA07E7BC395332930" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5B3C2ABB5062548287DAD45308D530D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5B3C2ABB5062548287DAD45308D530D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_239EF3C3372B52BE8B94FD2D7BDA7365" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_239EF3C3372B52BE8B94FD2D7BDA7365" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommercialAndCorporateObligationsMember" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_FD7547A1DBD457DAA9C701CA78D9E26E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_FD7547A1DBD457DAA9C701CA78D9E26E" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:label="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:to="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E19DE95702945D9BB564035351263C97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E19DE95702945D9BB564035351263C97" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_429B3DC47CDF7248CC790DC53A9FF0BF_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_429B3DC47CDF7248CC790DC53A9FF0BF_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_892A40709EFC5BAEAFC1548ACD487F26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_892A40709EFC5BAEAFC1548ACD487F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_42DDDDBD603B5BBF9443D70FA8A91B42" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:to="loc_us-gaap_CertificatesOfDepositMember_42DDDDBD603B5BBF9443D70FA8A91B42" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommercialAndCorporateObligationsMember" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_F53AAC3598205D999B6DF74896189F81" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_F53AAC3598205D999B6DF74896189F81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:to="loc_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D49A5FAE4DC880DE59F90DC53AA0BFC2_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:to="loc_srt_RangeMember_D49A5FAE4DC880DE59F90DC53AA0BFC2_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:to="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9310A4E57952575991B0BF5604D1599C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:to="loc_srt_MinimumMember_9310A4E57952575991B0BF5604D1599C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17787D7B1DF45A8AADA0CEE8E7CADAD0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:to="loc_srt_MaximumMember_17787D7B1DF45A8AADA0CEE8E7CADAD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4D69694F05EA5AA88E863295567AD6B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4D69694F05EA5AA88E863295567AD6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5CEAFB7256A75D0AB18878F1326E0A15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5CEAFB7256A75D0AB18878F1326E0A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0B217957D5275BB7878DACDEC5FD611A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0B217957D5275BB7878DACDEC5FD611A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40EA870E88DF5B37922F7190915C28D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40EA870E88DF5B37922F7190915C28D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0B78F3ADD40E5142994972BF9963585C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0B78F3ADD40E5142994972BF9963585C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_64CB7F94EA525DC7AA323ACF228D46E1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_64CB7F94EA525DC7AA323ACF228D46E1" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:label="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7D111E4A63C6EC39FB610DC53A695A0D_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7D111E4A63C6EC39FB610DC53A695A0D_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_18CF09EE4B425E169724DE7BB33192B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_18CF09EE4B425E169724DE7BB33192B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9EED639B76C25DBF942DEABFB8A37BA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9EED639B76C25DBF942DEABFB8A37BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BD57344955C65D7CB5F86E3158733728" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BD57344955C65D7CB5F86E3158733728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_AF8094E95F755702B97D5D4CCAED4459" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_AF8094E95F755702B97D5D4CCAED4459" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09998563C27E7AF40BBAE227C39D859D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09998563C27E7AF40BBAE227C39D859D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_74D83E7E82269694F1FBE227C39DBDA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09998563C27E7AF40BBAE227C39D859D" xlink:to="loc_us-gaap_FinancialInstrumentAxis_74D83E7E82269694F1FBE227C39DBDA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_74D83E7E82269694F1FBE227C39DBDA5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_74D83E7E82269694F1FBE227C39DBDA5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0A4F0AC4ED13F98B935FE227C39E8E75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0A4F0AC4ED13F98B935FE227C39E8E75" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommercialAndCorporateObligationsMember" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_8DD1E7E52B6064E99922E227C39E6BB3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_8DD1E7E52B6064E99922E227C39E6BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_180C9504289EEC002003E22945AF3E75" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_180C9504289EEC002003E22945AF3E75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/NotesPayable" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:to="loc_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:to="loc_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LoanAndSecurityAgreementMember" xlink:label="loc_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:to="loc_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_TermALoansMember" xlink:label="loc_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:to="loc_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_TermBLoansAndTermCLoansMember" xlink:label="loc_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:to="loc_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_DebtInstrumentMaximumBorrowingCapacity" xlink:label="loc_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_DebtInstrumentNumberOfLoanInstallments" xlink:label="loc_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:to="loc_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_621AB85A132BAEF9A03D0DC539BFC51E_09E86DBCC3F7538384856E2D63BF9939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:to="loc_us-gaap_PlanNameDomain_621AB85A132BAEF9A03D0DC539BFC51E_09E86DBCC3F7538384856E2D63BF9939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:to="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EquityIncentivePlan2017Member" xlink:label="loc_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:to="loc_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeStockPurchasePlan2017Member" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_152FB53CE0BB56F083EEB8A192190FA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_152FB53CE0BB56F083EEB8A192190FA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B1156EA801B054ABAA480FF20D7A9F8D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B1156EA801B054ABAA480FF20D7A9F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60DA991829CC53F5A12D08493F03AFF7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60DA991829CC53F5A12D08493F03AFF7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:to="loc_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:label="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RentPerSquareFoot" xlink:label="loc_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnnualRentIncreasePercent" xlink:label="loc_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SubsequentEventNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_957057F26D4D072CEE2C75D05F80C5DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_957057F26D4D072CEE2C75D05F80C5DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>anab-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_BB986A6D29668B25E5670DC53AE78EF6_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_54520EF091AD542D989BFE80CD3AC453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_54520EF091AD542D989BFE80CD3AC453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_54520EF091AD542D989BFE80CD3AC453" xlink:to="lab_us-gaap_DebtDisclosureAbstract_54520EF091AD542D989BFE80CD3AC453" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8A531B47B606201884690DC53AE7D39B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_5B1EA933E92656D5AA0604CD1319763C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8A531B47B606201884690DC53AE7D39B_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_5B1EA933E92656D5AA0604CD1319763C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5B1EA933E92656D5AA0604CD1319763C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_5B1EA933E92656D5AA0604CD1319763C" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_5B1EA933E92656D5AA0604CD1319763C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_C9AF523CEA7ECA3BDC280DC539889B7B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_F2E0C5483D2E522BB81B259AF544D0CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_F2E0C5483D2E522BB81B259AF544D0CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_F2E0C5483D2E522BB81B259AF544D0CA" xlink:to="lab_us-gaap_IncomeStatementAbstract_F2E0C5483D2E522BB81B259AF544D0CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E53F9499CDA49F2EC90E0DC53988DD73_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1E78C7EFE15455968C9E68173C44F4E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized income (loss) on available for sale securities, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_E53F9499CDA49F2EC90E0DC53988DD73_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1E78C7EFE15455968C9E68173C44F4E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1E78C7EFE15455968C9E68173C44F4E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1E78C7EFE15455968C9E68173C44F4E0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1E78C7EFE15455968C9E68173C44F4E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_10A43BBF38B554CC686C0DC5395F6C11_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_40FD929ABE925A6DAC8F07E1C8415777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_40FD929ABE925A6DAC8F07E1C8415777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_40FD929ABE925A6DAC8F07E1C8415777" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_40FD929ABE925A6DAC8F07E1C8415777" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7A097D54EC7E2FCB39530DC5395F85B5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C5CCC368777B57C98456C67FC4095B27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7A097D54EC7E2FCB39530DC5395F85B5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C5CCC368777B57C98456C67FC4095B27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C5CCC368777B57C98456C67FC4095B27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C5CCC368777B57C98456C67FC4095B27" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C5CCC368777B57C98456C67FC4095B27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_06E575996EA706652F9C0DC5395F181C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5605FD5EB1BE5333982C776BBA585B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_06E575996EA706652F9C0DC5395F181C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5605FD5EB1BE5333982C776BBA585B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5605FD5EB1BE5333982C776BBA585B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5605FD5EB1BE5333982C776BBA585B53" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5605FD5EB1BE5333982C776BBA585B53" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_18241308D6E733ABCA4187829D78C900_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_D4E6FCD98B425892B18F39C380994640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D4E6FCD98B425892B18F39C380994640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_D4E6FCD98B425892B18F39C380994640" xlink:to="lab_us-gaap_EquityAbstract_D4E6FCD98B425892B18F39C380994640" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A93831FC9D856C5D134F87829D78B089_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_45B3FA69E9B65F1DB36AB1A2F919FA43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A93831FC9D856C5D134F87829D78B089_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_45B3FA69E9B65F1DB36AB1A2F919FA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_45B3FA69E9B65F1DB36AB1A2F919FA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_45B3FA69E9B65F1DB36AB1A2F919FA43" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_45B3FA69E9B65F1DB36AB1A2F919FA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_43C43EDC1A8BC7DB30B287829D782E6C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_BA2DDA569E3B59AA985FE8097F32D827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_43C43EDC1A8BC7DB30B287829D782E6C_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_BA2DDA569E3B59AA985FE8097F32D827" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_BA2DDA569E3B59AA985FE8097F32D827" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_BA2DDA569E3B59AA985FE8097F32D827" xlink:to="lab_us-gaap_CommonStockSharesIssued_BA2DDA569E3B59AA985FE8097F32D827" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_DC48CF1990B64FB8C28487C6DFA1DD20_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3CD40C9D4E1052A29964D9E976D56A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_DC48CF1990B64FB8C28487C6DFA1DD20_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3CD40C9D4E1052A29964D9E976D56A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3CD40C9D4E1052A29964D9E976D56A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_3CD40C9D4E1052A29964D9E976D56A82" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3CD40C9D4E1052A29964D9E976D56A82" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_32D9D98B01AE73138E04A4DD4E32DAB7_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract_32D9D98B01AE73138E04A4DD4E32DAB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_32D9D98B01AE73138E04A4DD4E32DAB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_32D9D98B01AE73138E04A4DD4E32DAB7" xlink:to="lab_us-gaap_RevenueRecognitionAbstract_32D9D98B01AE73138E04A4DD4E32DAB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:to="lab_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:type="arc" />
    <link:label id="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65_terseLabel_en-US" xlink:label="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TESARO</link:label>
    <link:label id="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65_label_en-US" xlink:label="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TESARO, Inc. And TESARO Development, Inc. [Member]</link:label>
    <link:label id="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65_documentation_en-US" xlink:label="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TESARO, Inc. And TESARO Development, Inc. [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_TESAROInc.AndTESARODevelopmentInc.Member" xlink:label="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:to="lab_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:type="arc" />
    <link:label id="lab_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80_terseLabel_en-US" xlink:label="lab_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Celgene Corporation</link:label>
    <link:label id="lab_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80_label_en-US" xlink:label="lab_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Celgene Corporation [Member]</link:label>
    <link:label id="lab_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80_documentation_en-US" xlink:label="lab_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Celgene Corporation [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_CelgeneCorporationMember" xlink:label="loc_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:to="lab_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:to="lab_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Research And Development Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="lab_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:type="arc" />
    <link:label id="lab_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5_terseLabel_en-US" xlink:label="lab_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initiated in vivo toxicology studies using good laboratory practices (GLPs)</link:label>
    <link:label id="lab_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5_label_en-US" xlink:label="lab_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Vivo Toxicology Studies [Member]</link:label>
    <link:label id="lab_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5_documentation_en-US" xlink:label="lab_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In Vivo Toxicology Studies [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_InVivoToxicologyStudiesMember" xlink:label="loc_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:to="lab_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:type="arc" />
    <link:label id="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A_terseLabel_en-US" xlink:label="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IND clearance from the FDA</link:label>
    <link:label id="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A_label_en-US" xlink:label="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clearance Of Investigational New Drug From FDA [Member]</link:label>
    <link:label id="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A_documentation_en-US" xlink:label="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clearance Of Investigational New Drug From FDA [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:label="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:to="lab_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:type="arc" />
    <link:label id="lab_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E_terseLabel_en-US" xlink:label="lab_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 2 clinical trial initiation</link:label>
    <link:label id="lab_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E_label_en-US" xlink:label="lab_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 2 Clinical Trial Initiation [Member]</link:label>
    <link:label id="lab_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E_documentation_en-US" xlink:label="lab_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 2 Clinical Trial Initiation [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase2ClinicalTrialInitiationMember" xlink:label="loc_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:to="lab_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:type="arc" />
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6_terseLabel_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 3 clinical trial initiation</link:label>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6_label_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial Initiation [Member]</link:label>
    <link:label id="lab_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6_documentation_en-US" xlink:label="lab_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial Initiation [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase3ClinicalTrialInitiationMember" xlink:label="loc_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:to="lab_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:type="arc" />
    <link:label id="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC_terseLabel_en-US" xlink:label="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 3 clinical trial initiation - second indication [Domain]</link:label>
    <link:label id="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC_label_en-US" xlink:label="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 3 clinical trial initiation - second indication [Domain]</link:label>
    <link:label id="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC_documentation_en-US" xlink:label="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 3 clinical trial initiation - second indication [Domain]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase3clinicaltrialinitiationsecondindicationDomain" xlink:label="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:to="lab_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:type="arc" />
    <link:label id="lab_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221_terseLabel_en-US" xlink:label="lab_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Filing of the first NDA - first indication</link:label>
    <link:label id="lab_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221_label_en-US" xlink:label="lab_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Filing of NDA [Member]</link:label>
    <link:label id="lab_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221_documentation_en-US" xlink:label="lab_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Filing of NDA [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_FilingofNDAMember" xlink:label="loc_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:to="lab_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:type="arc" />
    <link:label id="lab_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C_terseLabel_en-US" xlink:label="lab_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Filing of the first MAA - first indication</link:label>
    <link:label id="lab_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C_label_en-US" xlink:label="lab_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Filing of MMA [Member]</link:label>
    <link:label id="lab_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C_documentation_en-US" xlink:label="lab_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Filing of MMA [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_FilingofMMAMember" xlink:label="loc_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:to="lab_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:type="arc" />
    <link:label id="lab_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2_verboseLabel_en-US" xlink:label="lab_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Phase 1 clinical trial initiation</link:label>
    <link:label id="lab_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2_label_en-US" xlink:label="lab_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Trial Initiation [Member]</link:label>
    <link:label id="lab_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2_documentation_en-US" xlink:label="lab_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Trial Initiation [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase1ClinicalTrialInitiationMember" xlink:label="loc_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:to="lab_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:to="lab_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:to="lab_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:type="arc" />
    <link:label id="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95_terseLabel_en-US" xlink:label="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-PD-1 (TSR042/Dostarlimab)</link:label>
    <link:label id="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95_label_en-US" xlink:label="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95_documentation_en-US" xlink:label="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:label="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:to="lab_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:type="arc" />
    <link:label id="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-TIM-3 (TSR022/Cobolimab)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" xlink:label="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:to="lab_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:type="arc" />
    <link:label id="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-LAG-3 (TSR033/Encelimab)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" xlink:label="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:to="lab_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:type="arc" />
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40_terseLabel_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-PD-1 (CC-90006)</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40_label_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]</link:label>
    <link:label id="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40_documentation_en-US" xlink:label="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:to="lab_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront license fee received</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3_label_en-US" xlink:label="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received</link:label>
    <link:label id="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:to="lab_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of outstanding research and development targets</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments, contingent upon preclinical and clinical trial events (up to)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement term following first commercial sale or expiration of the last to expire patent (in years)</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestones achieved during period</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestones achieved, amount</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum milestone payments per target</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298_label_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone</link:label>
    <link:label id="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298_documentation_en-US" xlink:label="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:to="lab_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:type="arc" />
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54_terseLabel_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Event</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54_label_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned</link:label>
    <link:label id="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54_documentation_en-US" xlink:label="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognized, Milestone Method, Milestone Payment Earned</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:to="lab_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_F0F6161FFB885487C4890DC539BE8724_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_F0F6161FFB885487C4890DC539BE8724_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_54429654222FD33F635C0DC539BE414A_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_54429654222FD33F635C0DC539BE414A_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:to="lab_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_621AB85A132BAEF9A03D0DC539BFC51E_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_621AB85A132BAEF9A03D0DC539BFC51E_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:to="lab_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:type="arc" />
    <link:label id="lab_anab_EquityIncentivePlan2017Member_91F4CB77C38620DA31C30DC539BF85B5_terseLabel_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_anab_EquityIncentivePlan2017Member_91F4CB77C38620DA31C30DC539BF85B5_label_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan, 2017 [Member]</link:label>
    <link:label id="lab_anab_EquityIncentivePlan2017Member_91F4CB77C38620DA31C30DC539BF85B5_documentation_en-US" xlink:label="lab_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan, 2017 [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_EquityIncentivePlan2017Member" xlink:label="loc_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:to="lab_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:type="arc" />
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_553485DF9FF5D525A69D0DC539BF700A_terseLabel_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_553485DF9FF5D525A69D0DC539BF700A_label_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, 2017 [Member]</link:label>
    <link:label id="lab_anab_EmployeeStockPurchasePlan2017Member_553485DF9FF5D525A69D0DC539BF700A_documentation_en-US" xlink:label="lab_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, 2017 [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeStockPurchasePlan2017Member" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:to="lab_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_D59A597503971E2403D10DC539BFC28E_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_D59A597503971E2403D10DC539BFC28E_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:to="lab_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_847BE6D848A27E91F5C30DC539C074AC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued and Outstanding:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_847BE6D848A27E91F5C30DC539C074AC_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F9B92961CD38842A8C4C0DC539C03601_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_152FB53CE0BB56F083EEB8A192190FA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options issued and outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F9B92961CD38842A8C4C0DC539C03601_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_152FB53CE0BB56F083EEB8A192190FA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_152FB53CE0BB56F083EEB8A192190FA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_152FB53CE0BB56F083EEB8A192190FA5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_152FB53CE0BB56F083EEB8A192190FA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8E5AF2415120E443BFE50DC539C08722_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B1156EA801B054ABAA480FF20D7A9F8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future award grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8E5AF2415120E443BFE50DC539C08722_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B1156EA801B054ABAA480FF20D7A9F8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B1156EA801B054ABAA480FF20D7A9F8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B1156EA801B054ABAA480FF20D7A9F8D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B1156EA801B054ABAA480FF20D7A9F8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_27907D341E1A6300DA2B0DC539C015FA_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60DA991829CC53F5A12D08493F03AFF7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_27907D341E1A6300DA2B0DC539C015FA_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60DA991829CC53F5A12D08493F03AFF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60DA991829CC53F5A12D08493F03AFF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60DA991829CC53F5A12D08493F03AFF7" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60DA991829CC53F5A12D08493F03AFF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_33736162349A7997A2EFE22CA83C4921_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_33736162349A7997A2EFE22CA83C4921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_33736162349A7997A2EFE22CA83C4921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_33736162349A7997A2EFE22CA83C4921" xlink:to="lab_us-gaap_SubsequentEventsAbstract_33736162349A7997A2EFE22CA83C4921" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:to="lab_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E" xlink:to="lab_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="lab_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of leased property (sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665" xlink:type="arc" />
    <link:label id="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C_terseLabel_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease termination term</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C_label_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C_documentation_en-US" xlink:label="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:label="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:to="lab_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:type="arc" />
    <link:label id="lab_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2_terseLabel_en-US" xlink:label="lab_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly base rate (usd per sqft)</link:label>
    <link:label id="lab_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2_label_en-US" xlink:label="lab_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rent Per Square Foot</link:label>
    <link:label id="lab_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2_documentation_en-US" xlink:label="lab_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rent Per Square Foot</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_RentPerSquareFoot" xlink:label="loc_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:to="lab_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:type="arc" />
    <link:label id="lab_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199_terseLabel_en-US" xlink:label="lab_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in annual rent</link:label>
    <link:label id="lab_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199_label_en-US" xlink:label="lab_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Rent Increase, Percent</link:label>
    <link:label id="lab_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199_documentation_en-US" xlink:label="lab_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Rent Increase, Percent</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_AnnualRentIncreasePercent" xlink:label="loc_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:to="lab_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:type="arc" />
    <link:label id="lab_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147_terseLabel_en-US" xlink:label="lab_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147_label_en-US" xlink:label="lab_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147_documentation_en-US" xlink:label="lab_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_LaboratoryEquipmentMember" xlink:label="loc_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:to="lab_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:type="arc" />
    <link:label id="lab_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F" xlink:to="lab_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14765821EFA18D1C3B51C80DDE685A38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14765821EFA18D1C3B51C80DDE685A38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14765821EFA18D1C3B51C80DDE685A38_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14765821EFA18D1C3B51C80DDE685A38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14765821EFA18D1C3B51C80DDE685A38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14765821EFA18D1C3B51C80DDE685A38" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14765821EFA18D1C3B51C80DDE685A38" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_42AC89F4E568A4802078C80DDE691A2B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_42AC89F4E568A4802078C80DDE691A2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Other Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_42AC89F4E568A4802078C80DDE691A2B_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_42AC89F4E568A4802078C80DDE691A2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_42AC89F4E568A4802078C80DDE691A2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_42AC89F4E568A4802078C80DDE691A2B" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_42AC89F4E568A4802078C80DDE691A2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9DB2028DAFDF9BB29A27C80DDE69E666_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9DB2028DAFDF9BB29A27C80DDE69E666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9DB2028DAFDF9BB29A27C80DDE69E666_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9DB2028DAFDF9BB29A27C80DDE69E666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9DB2028DAFDF9BB29A27C80DDE69E666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9DB2028DAFDF9BB29A27C80DDE69E666" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9DB2028DAFDF9BB29A27C80DDE69E666" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6CB7C152F73393AFFD48C81158D2B9F0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6CB7C152F73393AFFD48C81158D2B9F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrealized Loss and Fair Values in a Loss Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6CB7C152F73393AFFD48C81158D2B9F0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6CB7C152F73393AFFD48C81158D2B9F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6CB7C152F73393AFFD48C81158D2B9F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6CB7C152F73393AFFD48C81158D2B9F0" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6CB7C152F73393AFFD48C81158D2B9F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5BA0F1329A5EB1E8640375D05F78800C_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5BA0F1329A5EB1E8640375D05F78800C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5BA0F1329A5EB1E8640375D05F78800C_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5BA0F1329A5EB1E8640375D05F78800C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5BA0F1329A5EB1E8640375D05F78800C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5BA0F1329A5EB1E8640375D05F78800C" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5BA0F1329A5EB1E8640375D05F78800C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_DE23CB9D516C40D3090B75D05F78C20D_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_DE23CB9D516C40D3090B75D05F78C20D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_DE23CB9D516C40D3090B75D05F78C20D_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_DE23CB9D516C40D3090B75D05F78C20D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_DE23CB9D516C40D3090B75D05F78C20D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_DE23CB9D516C40D3090B75D05F78C20D" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_DE23CB9D516C40D3090B75D05F78C20D" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_4818021E901A1458112F75D05F787EAE_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_4818021E901A1458112F75D05F787EAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_4818021E901A1458112F75D05F787EAE_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_4818021E901A1458112F75D05F787EAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_4818021E901A1458112F75D05F787EAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_4818021E901A1458112F75D05F787EAE" xlink:to="lab_us-gaap_UseOfEstimates_4818021E901A1458112F75D05F787EAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8F3EBF9BD0475D05CA5A75D05F7825D2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_8F3EBF9BD0475D05CA5A75D05F7825D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8F3EBF9BD0475D05CA5A75D05F7825D2_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_8F3EBF9BD0475D05CA5A75D05F7825D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8F3EBF9BD0475D05CA5A75D05F7825D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_8F3EBF9BD0475D05CA5A75D05F7825D2" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_8F3EBF9BD0475D05CA5A75D05F7825D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7486B0B7B7882AAF7C5B75D05F784091_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7486B0B7B7882AAF7C5B75D05F784091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Pronouncements Recently Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7486B0B7B7882AAF7C5B75D05F784091_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7486B0B7B7882AAF7C5B75D05F784091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7486B0B7B7882AAF7C5B75D05F784091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7486B0B7B7882AAF7C5B75D05F784091" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7486B0B7B7882AAF7C5B75D05F784091" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_332E20554BC3219842950DC53ABE9F84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_661A598999AA554BAAB65CA1AFC21474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements and Available for Sale Investments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_332E20554BC3219842950DC53ABE9F84_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_661A598999AA554BAAB65CA1AFC21474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_661A598999AA554BAAB65CA1AFC21474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_661A598999AA554BAAB65CA1AFC21474" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_661A598999AA554BAAB65CA1AFC21474" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00C784C6394A51633119761153738053_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00C784C6394A51633119761153738053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00C784C6394A51633119761153738053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00C784C6394A51633119761153738053" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00C784C6394A51633119761153738053" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_189111E97C0B44F0C4D1761153734184_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_189111E97C0B44F0C4D1761153734184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_189111E97C0B44F0C4D1761153734184_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_189111E97C0B44F0C4D1761153734184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_189111E97C0B44F0C4D1761153734184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_189111E97C0B44F0C4D1761153734184" xlink:to="lab_us-gaap_OperatingLeaseCost_189111E97C0B44F0C4D1761153734184" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_0E7B8B75F91FF71AF9D576115374167F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_0E7B8B75F91FF71AF9D576115374167F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0E7B8B75F91FF71AF9D576115374167F_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_0E7B8B75F91FF71AF9D576115374167F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_0E7B8B75F91FF71AF9D576115374167F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_0E7B8B75F91FF71AF9D576115374167F" xlink:to="lab_us-gaap_OperatingLeasePayments_0E7B8B75F91FF71AF9D576115374167F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_E734827B5F7361E2333D75D9F216DC10_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_E734827B5F7361E2333D75D9F216DC10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_E734827B5F7361E2333D75D9F216DC10_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_E734827B5F7361E2333D75D9F216DC10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_E734827B5F7361E2333D75D9F216DC10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_E734827B5F7361E2333D75D9F216DC10" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_E734827B5F7361E2333D75D9F216DC10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_F469332748FF6C94A2CD75D9F2161B46_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_F469332748FF6C94A2CD75D9F2161B46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_F469332748FF6C94A2CD75D9F2161B46_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_F469332748FF6C94A2CD75D9F2161B46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_F469332748FF6C94A2CD75D9F2161B46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_F469332748FF6C94A2CD75D9F2161B46" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_F469332748FF6C94A2CD75D9F2161B46" xlink:type="arc" />
    <link:label id="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1_terseLabel_en-US" xlink:label="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research, development and manufacturing expenses</link:label>
    <link:label id="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1_label_en-US" xlink:label="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expenses, Current</link:label>
    <link:label id="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1_documentation_en-US" xlink:label="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expenses, Current</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1" xlink:to="lab_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_51ABC9AFCDC127A74E8675D9F2161310_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_51ABC9AFCDC127A74E8675D9F2161310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_51ABC9AFCDC127A74E8675D9F2161310_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_51ABC9AFCDC127A74E8675D9F2161310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51ABC9AFCDC127A74E8675D9F2161310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51ABC9AFCDC127A74E8675D9F2161310" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_51ABC9AFCDC127A74E8675D9F2161310" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4988A00CB370214029BD75D9F21702CD_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_4988A00CB370214029BD75D9F21702CD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4988A00CB370214029BD75D9F21702CD_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_4988A00CB370214029BD75D9F21702CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4988A00CB370214029BD75D9F21702CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4988A00CB370214029BD75D9F21702CD" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_4988A00CB370214029BD75D9F21702CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E26F7957C4242CF937B00DC53970DE8B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4F26FF8CF465D97ACFD5DB60A823B61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4F26FF8CF465D97ACFD5DB60A823B61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4F26FF8CF465D97ACFD5DB60A823B61" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4F26FF8CF465D97ACFD5DB60A823B61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3BB76252B0648E4550F60DC53970A12D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D70200250F68521185AD4322151AC33C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3BB76252B0648E4550F60DC53970A12D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D70200250F68521185AD4322151AC33C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D70200250F68521185AD4322151AC33C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D70200250F68521185AD4322151AC33C" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D70200250F68521185AD4322151AC33C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4519197FD6BCBA9436D60DC5397002F3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9C75A9C976E65D65A822E744A8DF295A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Weighted Average Assumptions in Stock Option Valuations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4519197FD6BCBA9436D60DC5397002F3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9C75A9C976E65D65A822E744A8DF295A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9C75A9C976E65D65A822E744A8DF295A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9C75A9C976E65D65A822E744A8DF295A" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9C75A9C976E65D65A822E744A8DF295A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_E925CD1AA499A470C0B50DC539708CC0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74E7D57A49825D308A17278406076B62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_E925CD1AA499A470C0B50DC539708CC0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74E7D57A49825D308A17278406076B62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74E7D57A49825D308A17278406076B62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74E7D57A49825D308A17278406076B62" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74E7D57A49825D308A17278406076B62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2FF128B11D844FEEF3C00DC53AE27C11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Subject to Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2FF128B11D844FEEF3C00DC53AE27C11_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA9D4BEECD7F1ADA593F0DC53AE348D9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71E8E81C675E5DD1B75BEB9B0DC51D43" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71E8E81C675E5DD1B75BEB9B0DC51D43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71E8E81C675E5DD1B75BEB9B0DC51D43" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71E8E81C675E5DD1B75BEB9B0DC51D43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F2EBFA898060A2B335EE0DC53AE34A8E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC9D0B5A37C15181AA5165B41B27F737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F2EBFA898060A2B335EE0DC53AE34A8E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC9D0B5A37C15181AA5165B41B27F737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC9D0B5A37C15181AA5165B41B27F737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC9D0B5A37C15181AA5165B41B27F737" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC9D0B5A37C15181AA5165B41B27F737" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8D547E909310245E5560DC53AE38C66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61D0760B6B90581B856735FD77C0918B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E8D547E909310245E5560DC53AE38C66_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61D0760B6B90581B856735FD77C0918B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61D0760B6B90581B856735FD77C0918B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61D0760B6B90581B856735FD77C0918B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61D0760B6B90581B856735FD77C0918B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2334AC78EE1E37F354660DC53AE34013_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3F5097BE84FF5B1E897B6F0158D05950" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures and cancellations (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2334AC78EE1E37F354660DC53AE34013_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3F5097BE84FF5B1E897B6F0158D05950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3F5097BE84FF5B1E897B6F0158D05950" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3F5097BE84FF5B1E897B6F0158D05950" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3F5097BE84FF5B1E897B6F0158D05950" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_486A4B59047BA633694B0DC53AE3FC6F_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0B5B2CB8BF97548B9559658576F72648" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0B5B2CB8BF97548B9559658576F72648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0B5B2CB8BF97548B9559658576F72648" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0B5B2CB8BF97548B9559658576F72648" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_00BE5D23EA4408E77B240DC53AE4E5E1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_97040EA457C35FB3A2BED139CE1BE529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_00BE5D23EA4408E77B240DC53AE4E5E1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_97040EA457C35FB3A2BED139CE1BE529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_97040EA457C35FB3A2BED139CE1BE529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_97040EA457C35FB3A2BED139CE1BE529" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_97040EA457C35FB3A2BED139CE1BE529" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_335B3BAD6F217A14B75E0DC53AE458D6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_335B3BAD6F217A14B75E0DC53AE458D6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3C68E4886A873C64EB650DC53AE48640_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E440E7822CD056AD9DD3A23B256E457E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3C68E4886A873C64EB650DC53AE48640_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E440E7822CD056AD9DD3A23B256E457E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E440E7822CD056AD9DD3A23B256E457E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E440E7822CD056AD9DD3A23B256E457E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E440E7822CD056AD9DD3A23B256E457E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_834EBE5435463C30E2BD0DC53AE4C70C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6CD399F87DFB599B9FE70CCBD808114D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_834EBE5435463C30E2BD0DC53AE4C70C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6CD399F87DFB599B9FE70CCBD808114D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6CD399F87DFB599B9FE70CCBD808114D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6CD399F87DFB599B9FE70CCBD808114D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6CD399F87DFB599B9FE70CCBD808114D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_DC7E9436600450718CB10DC53AE49BE4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_35FD571EB5CF5C2391547DD299011E7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercises (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_DC7E9436600450718CB10DC53AE49BE4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_35FD571EB5CF5C2391547DD299011E7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_35FD571EB5CF5C2391547DD299011E7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_35FD571EB5CF5C2391547DD299011E7B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_35FD571EB5CF5C2391547DD299011E7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_EADB27169710E754F2BF0DC53AE4ED3C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1750AE5FB72A5AA3B8936A539221C0F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures and cancellations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_EADB27169710E754F2BF0DC53AE4ED3C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1750AE5FB72A5AA3B8936A539221C0F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1750AE5FB72A5AA3B8936A539221C0F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1750AE5FB72A5AA3B8936A539221C0F3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1750AE5FB72A5AA3B8936A539221C0F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2C40A6E07CE06C3781AB0DC53AE5EF52_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C7FF5BACCD015A54AAC865157DB0018C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C7FF5BACCD015A54AAC865157DB0018C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C7FF5BACCD015A54AAC865157DB0018C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C7FF5BACCD015A54AAC865157DB0018C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_553AEB2BADA31152E97A0DC53AE50B7F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_25143B99B8545C2EA8F957358424C033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_553AEB2BADA31152E97A0DC53AE50B7F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_25143B99B8545C2EA8F957358424C033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_25143B99B8545C2EA8F957358424C033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_25143B99B8545C2EA8F957358424C033" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_25143B99B8545C2EA8F957358424C033" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0EDD60BBFF57F48CBC1D0DC53AE5CA79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0EDD60BBFF57F48CBC1D0DC53AE5CA79_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_77D6064A05F5C1A5AF950DC53AE5F6D2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4A05206F765856DF872D909F378A4E68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, options outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_77D6064A05F5C1A5AF950DC53AE5F6D2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4A05206F765856DF872D909F378A4E68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4A05206F765856DF872D909F378A4E68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4A05206F765856DF872D909F378A4E68" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4A05206F765856DF872D909F378A4E68" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E2F9900E2FA7A126F4740DC53AE50828_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4E99469ACD455A46943DE76F0ABBB4A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, options exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_E2F9900E2FA7A126F4740DC53AE50828_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4E99469ACD455A46943DE76F0ABBB4A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4E99469ACD455A46943DE76F0ABBB4A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4E99469ACD455A46943DE76F0ABBB4A6" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4E99469ACD455A46943DE76F0ABBB4A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E6D30B5222DC3EB7CBA20DC53AE55A44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CE4FEC519AB357FEB7E3694C132CE2ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E6D30B5222DC3EB7CBA20DC53AE55A44_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CE4FEC519AB357FEB7E3694C132CE2ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CE4FEC519AB357FEB7E3694C132CE2ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CE4FEC519AB357FEB7E3694C132CE2ED" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CE4FEC519AB357FEB7E3694C132CE2ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_32B51C2997C1C1F92B140DC53AE69BE1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5CA451EC36AD5201B3BBA648229B8A0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_32B51C2997C1C1F92B140DC53AE69BE1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5CA451EC36AD5201B3BBA648229B8A0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5CA451EC36AD5201B3BBA648229B8A0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5CA451EC36AD5201B3BBA648229B8A0F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5CA451EC36AD5201B3BBA648229B8A0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A935C93E1B4D7159CD850DC53ABC65E5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_AF3F10CEE1CE56D193BAF49A5542C7A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A935C93E1B4D7159CD850DC53ABC65E5_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_AF3F10CEE1CE56D193BAF49A5542C7A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_AF3F10CEE1CE56D193BAF49A5542C7A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_AF3F10CEE1CE56D193BAF49A5542C7A2" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_AF3F10CEE1CE56D193BAF49A5542C7A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2459456611F31BF484E4AE2AF21ADAB0_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_2459456611F31BF484E4AE2AF21ADAB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2459456611F31BF484E4AE2AF21ADAB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2459456611F31BF484E4AE2AF21ADAB0" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_2459456611F31BF484E4AE2AF21ADAB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:to="lab_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:to="lab_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE88B2C4BB8E7C957FA4AE2AF21A3E65_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE88B2C4BB8E7C957FA4AE2AF21A3E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE88B2C4BB8E7C957FA4AE2AF21A3E65_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE88B2C4BB8E7C957FA4AE2AF21A3E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE88B2C4BB8E7C957FA4AE2AF21A3E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE88B2C4BB8E7C957FA4AE2AF21A3E65" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE88B2C4BB8E7C957FA4AE2AF21A3E65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_D3766620C0FD309F6CB0AE2AF21B8D0A_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_D3766620C0FD309F6CB0AE2AF21B8D0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable from collaborative partners</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_D3766620C0FD309F6CB0AE2AF21B8D0A_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_D3766620C0FD309F6CB0AE2AF21B8D0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_D3766620C0FD309F6CB0AE2AF21B8D0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_D3766620C0FD309F6CB0AE2AF21B8D0A" xlink:to="lab_us-gaap_ReceivablesNetCurrent_D3766620C0FD309F6CB0AE2AF21B8D0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_C99545C81A8F68C72E77AE2AF21BF539_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_C99545C81A8F68C72E77AE2AF21BF539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_C99545C81A8F68C72E77AE2AF21BF539_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_C99545C81A8F68C72E77AE2AF21BF539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_C99545C81A8F68C72E77AE2AF21BF539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_C99545C81A8F68C72E77AE2AF21BF539" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_C99545C81A8F68C72E77AE2AF21BF539" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00F4D707293A01A9019BAE2AF21B6EDF_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00F4D707293A01A9019BAE2AF21B6EDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00F4D707293A01A9019BAE2AF21B6EDF_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00F4D707293A01A9019BAE2AF21B6EDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00F4D707293A01A9019BAE2AF21B6EDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00F4D707293A01A9019BAE2AF21B6EDF" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00F4D707293A01A9019BAE2AF21B6EDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_B50FBCE6E3C358F7204FAE2AF21BA97C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B50FBCE6E3C358F7204FAE2AF21BA97C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_B50FBCE6E3C358F7204FAE2AF21BA97C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B50FBCE6E3C358F7204FAE2AF21BA97C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B50FBCE6E3C358F7204FAE2AF21BA97C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_B50FBCE6E3C358F7204FAE2AF21BA97C" xlink:to="lab_us-gaap_AssetsCurrent_B50FBCE6E3C358F7204FAE2AF21BA97C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_94EF3B330E315D2BE73CAE2AF21BA55E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_94EF3B330E315D2BE73CAE2AF21BA55E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_94EF3B330E315D2BE73CAE2AF21BA55E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_94EF3B330E315D2BE73CAE2AF21BA55E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_94EF3B330E315D2BE73CAE2AF21BA55E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FBEE9A2A30C960145A08AE2AF21B38B6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FBEE9A2A30C960145A08AE2AF21B38B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FBEE9A2A30C960145A08AE2AF21B38B6_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FBEE9A2A30C960145A08AE2AF21B38B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FBEE9A2A30C960145A08AE2AF21B38B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FBEE9A2A30C960145A08AE2AF21B38B6" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FBEE9A2A30C960145A08AE2AF21B38B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_05A8639CFE71FB0954EAAE2AF21C6A6D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_05A8639CFE71FB0954EAAE2AF21C6A6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_05A8639CFE71FB0954EAAE2AF21C6A6D_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_05A8639CFE71FB0954EAAE2AF21C6A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_05A8639CFE71FB0954EAAE2AF21C6A6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_05A8639CFE71FB0954EAAE2AF21C6A6D" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_05A8639CFE71FB0954EAAE2AF21C6A6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5CCA003C4C360244A2A6AE2AF21C5CBE_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5CCA003C4C360244A2A6AE2AF21C5CBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5CCA003C4C360244A2A6AE2AF21C5CBE_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5CCA003C4C360244A2A6AE2AF21C5CBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5CCA003C4C360244A2A6AE2AF21C5CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5CCA003C4C360244A2A6AE2AF21C5CBE" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5CCA003C4C360244A2A6AE2AF21C5CBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_77C2CBBFF7D5F701AC77AE2AF21C11C3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_77C2CBBFF7D5F701AC77AE2AF21C11C3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_77C2CBBFF7D5F701AC77AE2AF21C11C3_label_en-US" xlink:label="lab_us-gaap_Assets_77C2CBBFF7D5F701AC77AE2AF21C11C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_77C2CBBFF7D5F701AC77AE2AF21C11C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_77C2CBBFF7D5F701AC77AE2AF21C11C3" xlink:to="lab_us-gaap_Assets_77C2CBBFF7D5F701AC77AE2AF21C11C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_72DE346A166C3AEAB7D3AE2AF21C937F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_72DE346A166C3AEAB7D3AE2AF21C937F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_72DE346A166C3AEAB7D3AE2AF21C937F_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_72DE346A166C3AEAB7D3AE2AF21C937F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_72DE346A166C3AEAB7D3AE2AF21C937F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_72DE346A166C3AEAB7D3AE2AF21C937F" xlink:to="lab_us-gaap_AccountsPayableCurrent_72DE346A166C3AEAB7D3AE2AF21C937F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8C2676CD288F68C641EFAE2AF21DC155_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_8C2676CD288F68C641EFAE2AF21DC155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8C2676CD288F68C641EFAE2AF21DC155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8C2676CD288F68C641EFAE2AF21DC155" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_8C2676CD288F68C641EFAE2AF21DC155" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_A5B0A39631F78FE4C8C6AE2AF21D4643_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_A5B0A39631F78FE4C8C6AE2AF21D4643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_A5B0A39631F78FE4C8C6AE2AF21D4643_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_A5B0A39631F78FE4C8C6AE2AF21D4643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_A5B0A39631F78FE4C8C6AE2AF21D4643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_A5B0A39631F78FE4C8C6AE2AF21D4643" xlink:to="lab_us-gaap_NotesPayableCurrent_A5B0A39631F78FE4C8C6AE2AF21D4643" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_73DB60DCC80ED3060FA2AE2AF21DDE50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_73DB60DCC80ED3060FA2AE2AF21DDE50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_73DB60DCC80ED3060FA2AE2AF21DDE50_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_73DB60DCC80ED3060FA2AE2AF21DDE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_73DB60DCC80ED3060FA2AE2AF21DDE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_73DB60DCC80ED3060FA2AE2AF21DDE50" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_73DB60DCC80ED3060FA2AE2AF21DDE50" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_72ADEDF88D8F97D276F9AE2AF21D2114_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_72ADEDF88D8F97D276F9AE2AF21D2114" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_72ADEDF88D8F97D276F9AE2AF21D2114_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_72ADEDF88D8F97D276F9AE2AF21D2114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_72ADEDF88D8F97D276F9AE2AF21D2114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_72ADEDF88D8F97D276F9AE2AF21D2114" xlink:to="lab_us-gaap_LiabilitiesCurrent_72ADEDF88D8F97D276F9AE2AF21D2114" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_FF340843DAC45373B0F0AE2AF21D8C4A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_FF340843DAC45373B0F0AE2AF21D8C4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_FF340843DAC45373B0F0AE2AF21D8C4A_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_FF340843DAC45373B0F0AE2AF21D8C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_FF340843DAC45373B0F0AE2AF21D8C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_FF340843DAC45373B0F0AE2AF21D8C4A" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_FF340843DAC45373B0F0AE2AF21D8C4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:to="lab_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_4CEE2A4CB2DFB3741254AE2AF21E003D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4CEE2A4CB2DFB3741254AE2AF21E003D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_4CEE2A4CB2DFB3741254AE2AF21E003D_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4CEE2A4CB2DFB3741254AE2AF21E003D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4CEE2A4CB2DFB3741254AE2AF21E003D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_4CEE2A4CB2DFB3741254AE2AF21E003D" xlink:to="lab_us-gaap_PreferredStockValue_4CEE2A4CB2DFB3741254AE2AF21E003D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_AFC5D717B470B7C24795AE2AF21E3802_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_AFC5D717B470B7C24795AE2AF21E3802" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value, 500,000 shares authorized, 27,277 shares and 27,255 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_AFC5D717B470B7C24795AE2AF21E3802_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_AFC5D717B470B7C24795AE2AF21E3802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_AFC5D717B470B7C24795AE2AF21E3802" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_AFC5D717B470B7C24795AE2AF21E3802" xlink:to="lab_us-gaap_CommonStockValue_AFC5D717B470B7C24795AE2AF21E3802" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_A1652B513C7D9C6FA34DAE2AF21EEAAD_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_A1652B513C7D9C6FA34DAE2AF21EEAAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_A1652B513C7D9C6FA34DAE2AF21EEAAD_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_A1652B513C7D9C6FA34DAE2AF21EEAAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_A1652B513C7D9C6FA34DAE2AF21EEAAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_A1652B513C7D9C6FA34DAE2AF21EEAAD" xlink:to="lab_us-gaap_AdditionalPaidInCapital_A1652B513C7D9C6FA34DAE2AF21EEAAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E75FFAE3CC9DA93D9DDEAE2AF21E216A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E75FFAE3CC9DA93D9DDEAE2AF21E216A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E75FFAE3CC9DA93D9DDEAE2AF21E216A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E75FFAE3CC9DA93D9DDEAE2AF21E216A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E75FFAE3CC9DA93D9DDEAE2AF21E216A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E75FFAE3CC9DA93D9DDEAE2AF21E216A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E75FFAE3CC9DA93D9DDEAE2AF21E216A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5740D97D85C4D5692774AE2AF21E554A_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5740D97D85C4D5692774AE2AF21E554A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5740D97D85C4D5692774AE2AF21E554A_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5740D97D85C4D5692774AE2AF21E554A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5740D97D85C4D5692774AE2AF21E554A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5740D97D85C4D5692774AE2AF21E554A" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5740D97D85C4D5692774AE2AF21E554A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_143DA27115AE25CECEE3AE2AF21F7543_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_143DA27115AE25CECEE3AE2AF21F7543" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_143DA27115AE25CECEE3AE2AF21F7543_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_143DA27115AE25CECEE3AE2AF21F7543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_143DA27115AE25CECEE3AE2AF21F7543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_143DA27115AE25CECEE3AE2AF21F7543" xlink:to="lab_us-gaap_StockholdersEquity_143DA27115AE25CECEE3AE2AF21F7543" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD7F82BE417C92739AEAE2AF21F629E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD7F82BE417C92739AEAE2AF21F629E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD7F82BE417C92739AEAE2AF21F629E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD7F82BE417C92739AEAE2AF21F629E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_AAD7F82BE417C92739AEAE2AF21F629E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_AAD7F82BE417C92739AEAE2AF21F629E" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_AAD7F82BE417C92739AEAE2AF21F629E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6F133A21EB865A31342E0DC53AEC6049_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_A11A612AFD4A5163B65DD1F463504424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6F133A21EB865A31342E0DC53AEC6049_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_A11A612AFD4A5163B65DD1F463504424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_A11A612AFD4A5163B65DD1F463504424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_A11A612AFD4A5163B65DD1F463504424" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_A11A612AFD4A5163B65DD1F463504424" xlink:type="arc" />
    <link:label id="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6_terseLabel_en-US" xlink:label="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classification on the Balance Sheet</link:label>
    <link:label id="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6_label_en-US" xlink:label="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6_documentation_en-US" xlink:label="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6" xlink:to="lab_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ECCF7AE11AD2D5B34D357611537FB74F_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_ECCF7AE11AD2D5B34D357611537FB74F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs Included in Cash Flow Statement</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ECCF7AE11AD2D5B34D357611537FB74F_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_ECCF7AE11AD2D5B34D357611537FB74F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ECCF7AE11AD2D5B34D357611537FB74F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_ECCF7AE11AD2D5B34D357611537FB74F" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_ECCF7AE11AD2D5B34D357611537FB74F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ACC4947E37763DCB9A287611537F5608_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ACC4947E37763DCB9A287611537F5608" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Annual Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ACC4947E37763DCB9A287611537F5608_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ACC4947E37763DCB9A287611537F5608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ACC4947E37763DCB9A287611537F5608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ACC4947E37763DCB9A287611537F5608" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ACC4947E37763DCB9A287611537F5608" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9FDDA55A5284977C574A0DC53A6CEAA6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_D5B72AF07B2F574E88A64D58D2F9E7C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Research and Development Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9FDDA55A5284977C574A0DC53A6CEAA6_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_D5B72AF07B2F574E88A64D58D2F9E7C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_D5B72AF07B2F574E88A64D58D2F9E7C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_D5B72AF07B2F574E88A64D58D2F9E7C4" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_D5B72AF07B2F574E88A64D58D2F9E7C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_011DA512D4161FA44A4C0DC53A5C77A4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_011DA512D4161FA44A4C0DC53A5C77A4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:type="arc" />
    <link:label id="lab_anab_LeaseArrangementAxis_76BD85A9A516B4A406D00DC53A5DACB9_terseLabel_en-US" xlink:label="lab_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_anab_LeaseArrangementAxis_76BD85A9A516B4A406D00DC53A5DACB9_label_en-US" xlink:label="lab_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_anab_LeaseArrangementAxis_76BD85A9A516B4A406D00DC53A5DACB9_documentation_en-US" xlink:label="lab_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_LeaseArrangementAxis" xlink:label="loc_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:to="lab_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:type="arc" />
    <link:label id="lab_anab_LeaseArrangementDomain_0938B0199A317E3EDC740DC53A5D6216_terseLabel_en-US" xlink:label="lab_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_anab_LeaseArrangementDomain_0938B0199A317E3EDC740DC53A5D6216_label_en-US" xlink:label="lab_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_anab_LeaseArrangementDomain_0938B0199A317E3EDC740DC53A5D6216_documentation_en-US" xlink:label="lab_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Lease Arrangement [Axis]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_LeaseArrangementDomain" xlink:label="loc_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:to="lab_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:type="arc" />
    <link:label id="lab_anab_OneOfficeLeaseMember_10C0796A9A700B30BB450DC53A5D2EA3_terseLabel_en-US" xlink:label="lab_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One office lease</link:label>
    <link:label id="lab_anab_OneOfficeLeaseMember_10C0796A9A700B30BB450DC53A5D2EA3_label_en-US" xlink:label="lab_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Office Lease [Member]</link:label>
    <link:label id="lab_anab_OneOfficeLeaseMember_10C0796A9A700B30BB450DC53A5D2EA3_documentation_en-US" xlink:label="lab_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Office Lease [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_OneOfficeLeaseMember" xlink:label="loc_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:to="lab_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_A4727773CFA3B02517D10DC53A5DCB46_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_A4727773CFA3B02517D10DC53A5DCB46_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:type="arc" />
    <link:label id="lab_anab_LesseeOperatingLeaseNumber_B5FBE2A8D5F43EDCB4EF0DC53A5EA131_terseLabel_en-US" xlink:label="lab_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cancellable office leases</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseNumber_B5FBE2A8D5F43EDCB4EF0DC53A5EA131_label_en-US" xlink:label="lab_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseNumber_B5FBE2A8D5F43EDCB4EF0DC53A5EA131_documentation_en-US" xlink:label="lab_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_LesseeOperatingLeaseNumber" xlink:label="loc_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:to="lab_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1F524E4D0D5F912DA9BE0DC53A5E4E0A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_569DBB6BC03453069ADF59D3B66260A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1F524E4D0D5F912DA9BE0DC53A5E4E0A_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_569DBB6BC03453069ADF59D3B66260A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_569DBB6BC03453069ADF59D3B66260A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_569DBB6BC03453069ADF59D3B66260A2" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_569DBB6BC03453069ADF59D3B66260A2" xlink:type="arc" />
    <link:label id="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_1ED6F26BDDB0AC1EE2BE0DC53A5E9200_terseLabel_en-US" xlink:label="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of one year renewal options</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_1ED6F26BDDB0AC1EE2BE0DC53A5E9200_label_en-US" xlink:label="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, One Year Renewal Options, Number</link:label>
    <link:label id="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_1ED6F26BDDB0AC1EE2BE0DC53A5E9200_documentation_en-US" xlink:label="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, One Year Renewal Options, Number</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" xlink:label="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:to="lab_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4DAB4A033CF679E491090DC53A5E4F72_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_926A6E65991151ACA45A08AE99A0816F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4DAB4A033CF679E491090DC53A5E4F72_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_926A6E65991151ACA45A08AE99A0816F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_926A6E65991151ACA45A08AE99A0816F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_926A6E65991151ACA45A08AE99A0816F" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_926A6E65991151ACA45A08AE99A0816F" xlink:type="arc" />
    <link:label id="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_11A4B4A5C7B7D33CC2760DC5396330C4_terseLabel_en-US" xlink:label="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_ED7085B6D51F5E06B32C3506FD14E1E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_11A4B4A5C7B7D33CC2760DC5396330C4_label_en-US" xlink:label="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_ED7085B6D51F5E06B32C3506FD14E1E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_11A4B4A5C7B7D33CC2760DC5396330C4_documentation_en-US" xlink:label="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_ED7085B6D51F5E06B32C3506FD14E1E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_ED7085B6D51F5E06B32C3506FD14E1E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_ED7085B6D51F5E06B32C3506FD14E1E3" xlink:to="lab_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_ED7085B6D51F5E06B32C3506FD14E1E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_63CF72FA980BEC5630710DC53A9E8032_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_63CF72FA980BEC5630710DC53A9E8032_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_A52DB35E5D9B7B846A030DC53A9FE98E_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_A52DB35E5D9B7B846A030DC53A9FE98E_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:to="lab_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_429B3DC47CDF7248CC790DC53A9FF0BF_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_429B3DC47CDF7248CC790DC53A9FF0BF_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_18227B6E8B503B031FFA0DC53A9FB527_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_892A40709EFC5BAEAFC1548ACD487F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_18227B6E8B503B031FFA0DC53A9FB527_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_892A40709EFC5BAEAFC1548ACD487F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_892A40709EFC5BAEAFC1548ACD487F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_892A40709EFC5BAEAFC1548ACD487F26" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_892A40709EFC5BAEAFC1548ACD487F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_4E63046B882203DE5F2E0DC53A9F6B8A_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_42DDDDBD603B5BBF9443D70FA8A91B42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_4E63046B882203DE5F2E0DC53A9F6B8A_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_42DDDDBD603B5BBF9443D70FA8A91B42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_42DDDDBD603B5BBF9443D70FA8A91B42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_42DDDDBD603B5BBF9443D70FA8A91B42" xlink:to="lab_us-gaap_CertificatesOfDepositMember_42DDDDBD603B5BBF9443D70FA8A91B42" xlink:type="arc" />
    <link:label id="lab_anab_CommercialAndCorporateObligationsMember_826246730C352049AB3A0DC53AA0CE24_verboseLabel_en-US" xlink:label="lab_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial and corporate obligations</link:label>
    <link:label id="lab_anab_CommercialAndCorporateObligationsMember_826246730C352049AB3A0DC53AA0CE24_label_en-US" xlink:label="lab_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial And Corporate Obligations [Member]</link:label>
    <link:label id="lab_anab_CommercialAndCorporateObligationsMember_826246730C352049AB3A0DC53AA0CE24_documentation_en-US" xlink:label="lab_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial And Corporate Obligations [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_CommercialAndCorporateObligationsMember" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:to="lab_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_EE308B7638954848F6B90DC53AA09B2E_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_F53AAC3598205D999B6DF74896189F81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_EE308B7638954848F6B90DC53AA09B2E_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_F53AAC3598205D999B6DF74896189F81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_F53AAC3598205D999B6DF74896189F81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_F53AAC3598205D999B6DF74896189F81" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_F53AAC3598205D999B6DF74896189F81" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_32B27F7EA31B326D0EC30DC53AA0FD9E_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_32B27F7EA31B326D0EC30DC53AA0FD9E_label_en-US" xlink:label="lab_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:to="lab_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_D49A5FAE4DC880DE59F90DC53AA0BFC2_terseLabel_en-US" xlink:label="lab_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_D49A5FAE4DC880DE59F90DC53AA0BFC2_label_en-US" xlink:label="lab_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:to="lab_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_200EA22A3EF3AEEB09E00DC53AA036B8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_9310A4E57952575991B0BF5604D1599C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_200EA22A3EF3AEEB09E00DC53AA036B8_label_en-US" xlink:label="lab_srt_MinimumMember_9310A4E57952575991B0BF5604D1599C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9310A4E57952575991B0BF5604D1599C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_9310A4E57952575991B0BF5604D1599C" xlink:to="lab_srt_MinimumMember_9310A4E57952575991B0BF5604D1599C" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_C45B0FDBBD29F093DDD30DC53AA149B2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_17787D7B1DF45A8AADA0CEE8E7CADAD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_C45B0FDBBD29F093DDD30DC53AA149B2_label_en-US" xlink:label="lab_srt_MaximumMember_17787D7B1DF45A8AADA0CEE8E7CADAD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17787D7B1DF45A8AADA0CEE8E7CADAD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_17787D7B1DF45A8AADA0CEE8E7CADAD0" xlink:to="lab_srt_MaximumMember_17787D7B1DF45A8AADA0CEE8E7CADAD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8EB73A883857A71CF09B0DC53AA19798_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8EB73A883857A71CF09B0DC53AA19798_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7C0773E0A85070A7F6490DC53AA18D0F_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4D69694F05EA5AA88E863295567AD6B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7C0773E0A85070A7F6490DC53AA18D0F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4D69694F05EA5AA88E863295567AD6B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4D69694F05EA5AA88E863295567AD6B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4D69694F05EA5AA88E863295567AD6B1" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4D69694F05EA5AA88E863295567AD6B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_81AE6F2563A03BC47AFD0DC53AA1D2E8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5CEAFB7256A75D0AB18878F1326E0A15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_81AE6F2563A03BC47AFD0DC53AA1D2E8_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5CEAFB7256A75D0AB18878F1326E0A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5CEAFB7256A75D0AB18878F1326E0A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5CEAFB7256A75D0AB18878F1326E0A15" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5CEAFB7256A75D0AB18878F1326E0A15" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6A8792BE19E3F482EEDA0DC53AA14EB2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0B217957D5275BB7878DACDEC5FD611A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6A8792BE19E3F482EEDA0DC53AA14EB2_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0B217957D5275BB7878DACDEC5FD611A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0B217957D5275BB7878DACDEC5FD611A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0B217957D5275BB7878DACDEC5FD611A" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0B217957D5275BB7878DACDEC5FD611A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_991C4A540AFAAC5640240DC53AA2233E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40EA870E88DF5B37922F7190915C28D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_991C4A540AFAAC5640240DC53AA2233E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40EA870E88DF5B37922F7190915C28D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40EA870E88DF5B37922F7190915C28D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40EA870E88DF5B37922F7190915C28D1" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40EA870E88DF5B37922F7190915C28D1" xlink:type="arc" />
    <link:label id="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E7FEC9328C5C1A1394550DC53AA26621_terseLabel_en-US" xlink:label="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments outstanding, maturity date range (in years)</link:label>
    <link:label id="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E7FEC9328C5C1A1394550DC53AA26621_label_en-US" xlink:label="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Remaining Maturity</link:label>
    <link:label id="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E7FEC9328C5C1A1394550DC53AA26621_documentation_en-US" xlink:label="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Remaining Maturity</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:label="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:to="lab_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B6D2DE27E02E6F5E11693247D5134C9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B6D2DE27E02E6F5E11693247D5134C9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_AF8214C07DF47ED8755693247D517882_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_AF8214C07DF47ED8755693247D517882_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:to="lab_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D5B5EF9C4E99A0447A293247D5193E1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D5B5EF9C4E99A0447A293247D5193E1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_B3A06C668FE32A559A7393247D5145CF_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_58F9B1D5FAB2504F8DC3B005997CBA7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_B3A06C668FE32A559A7393247D5145CF_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_58F9B1D5FAB2504F8DC3B005997CBA7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_58F9B1D5FAB2504F8DC3B005997CBA7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_58F9B1D5FAB2504F8DC3B005997CBA7C" xlink:to="lab_us-gaap_EmployeeStockMember_58F9B1D5FAB2504F8DC3B005997CBA7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_21A8A660A32476F945F493247D51AD03_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_3C0AD9F6F03455CBA8BC592E1BCE7537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_21A8A660A32476F945F493247D51AD03_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_3C0AD9F6F03455CBA8BC592E1BCE7537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3C0AD9F6F03455CBA8BC592E1BCE7537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_3C0AD9F6F03455CBA8BC592E1BCE7537" xlink:to="lab_us-gaap_EmployeeStockOptionMember_3C0AD9F6F03455CBA8BC592E1BCE7537" xlink:type="arc" />
    <link:label id="lab_anab_EmployeeAndNonemployeeStockOptionsMember_F5E81300E49B9FE1E9EC93247D5124AE_terseLabel_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee and nonemployee stock options</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeStockOptionsMember_F5E81300E49B9FE1E9EC93247D5124AE_label_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee And Nonemployee Stock Options [Member]</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeStockOptionsMember_F5E81300E49B9FE1E9EC93247D5124AE_documentation_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee And Nonemployee Stock Options [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeAndNonemployeeStockOptionsMember" xlink:label="loc_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:to="lab_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualAxis_ABF6BE3EDB9B2B8110F893247D5181E8_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_ABF6BE3EDB9B2B8110F893247D5181E8_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:to="lab_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0577D0C646318707ADF993247D5185EE_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0577D0C646318707ADF993247D5185EE_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:type="arc" />
    <link:label id="lab_srt_DirectorMember_73607D9A3FED222C637393247D51749F_terseLabel_en-US" xlink:label="lab_srt_DirectorMember_8EB8B137701B558CBB94A51B6B5D8681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director Stock options</link:label>
    <link:label id="lab_srt_DirectorMember_73607D9A3FED222C637393247D51749F_label_en-US" xlink:label="lab_srt_DirectorMember_8EB8B137701B558CBB94A51B6B5D8681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_8EB8B137701B558CBB94A51B6B5D8681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_8EB8B137701B558CBB94A51B6B5D8681" xlink:to="lab_srt_DirectorMember_8EB8B137701B558CBB94A51B6B5D8681" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23D55301B921EF98F30493247D519FDC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23D55301B921EF98F30493247D519FDC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:type="arc" />
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_BBDDC5F740B98325D92493247D5142E0_terseLabel_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase in number of shares available for issuance</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_BBDDC5F740B98325D92493247D5142E0_label_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_BBDDC5F740B98325D92493247D5142E0_documentation_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:to="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:type="arc" />
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_260FCC4FBFE4250049A793247D51E8C0_terseLabel_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital shares reserved for future issuance, increase (in shares)</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_260FCC4FBFE4250049A793247D51E8C0_label_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Increase</link:label>
    <link:label id="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_260FCC4FBFE4250049A793247D51E8C0_documentation_en-US" xlink:label="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved For Future Issuance, Increase</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:to="lab_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF66D2E381547D6DD0EB93247D51568E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F0A0937ACD995483952BBA51D6C26A15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF66D2E381547D6DD0EB93247D51568E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F0A0937ACD995483952BBA51D6C26A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F0A0937ACD995483952BBA51D6C26A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F0A0937ACD995483952BBA51D6C26A15" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F0A0937ACD995483952BBA51D6C26A15" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_93DB2B5B80DA67C72BFD93247D51EF1F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84CDDF17EFE7599693323B44E78E296A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_93DB2B5B80DA67C72BFD93247D51EF1F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84CDDF17EFE7599693323B44E78E296A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84CDDF17EFE7599693323B44E78E296A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84CDDF17EFE7599693323B44E78E296A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84CDDF17EFE7599693323B44E78E296A" xlink:type="arc" />
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_547BC0F8FC33CB98A9F293247D516C0F_terseLabel_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_547BC0F8FC33CB98A9F293247D516C0F_label_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_547BC0F8FC33CB98A9F293247D516C0F_documentation_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:to="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:type="arc" />
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_6E7059C5E8A95EB55F5093247D517904_terseLabel_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period remaining for amortization of unrecognized compensation cost (in years)</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_6E7059C5E8A95EB55F5093247D517904_label_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition</link:label>
    <link:label id="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_6E7059C5E8A95EB55F5093247D517904_documentation_en-US" xlink:label="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:to="lab_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1F09E4813335C72D69B1AE2AF1F68953_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1F09E4813335C72D69B1AE2AF1F68953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1F09E4813335C72D69B1AE2AF1F68953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1F09E4813335C72D69B1AE2AF1F68953" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1F09E4813335C72D69B1AE2AF1F68953" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_133C678F2B562ECB9489AE2AF1F7DBBA_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_133C678F2B562ECB9489AE2AF1F7DBBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_133C678F2B562ECB9489AE2AF1F7DBBA_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_133C678F2B562ECB9489AE2AF1F7DBBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_133C678F2B562ECB9489AE2AF1F7DBBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_133C678F2B562ECB9489AE2AF1F7DBBA" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_133C678F2B562ECB9489AE2AF1F7DBBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9F3D5B62C6DEA6E0C451AE2AF1F78C75_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_9F3D5B62C6DEA6E0C451AE2AF1F78C75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9F3D5B62C6DEA6E0C451AE2AF1F78C75_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_9F3D5B62C6DEA6E0C451AE2AF1F78C75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9F3D5B62C6DEA6E0C451AE2AF1F78C75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_9F3D5B62C6DEA6E0C451AE2AF1F78C75" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_9F3D5B62C6DEA6E0C451AE2AF1F78C75" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_ABB21483EFB27F03A238AE2AF1FCCE49_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_ABB21483EFB27F03A238AE2AF1FCCE49" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_ABB21483EFB27F03A238AE2AF1FCCE49_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_ABB21483EFB27F03A238AE2AF1FCCE49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_ABB21483EFB27F03A238AE2AF1FCCE49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_ABB21483EFB27F03A238AE2AF1FCCE49" xlink:to="lab_us-gaap_OperatingExpenses_ABB21483EFB27F03A238AE2AF1FCCE49" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2F76FABCBAC8B903CF4AAE2AF1FC9919_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_2F76FABCBAC8B903CF4AAE2AF1FC9919" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2F76FABCBAC8B903CF4AAE2AF1FC9919_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_2F76FABCBAC8B903CF4AAE2AF1FC9919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2F76FABCBAC8B903CF4AAE2AF1FC9919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_2F76FABCBAC8B903CF4AAE2AF1FC9919" xlink:to="lab_us-gaap_OperatingIncomeLoss_2F76FABCBAC8B903CF4AAE2AF1FC9919" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_DBAF50C65265A9B2838CAE2AF1FD0EE1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_DBAF50C65265A9B2838CAE2AF1FD0EE1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_DBAF50C65265A9B2838CAE2AF1FD0EE1_label_en-US" xlink:label="lab_us-gaap_InterestExpense_DBAF50C65265A9B2838CAE2AF1FD0EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_DBAF50C65265A9B2838CAE2AF1FD0EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_DBAF50C65265A9B2838CAE2AF1FD0EE1" xlink:to="lab_us-gaap_InterestExpense_DBAF50C65265A9B2838CAE2AF1FD0EE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_05D99DE6558D86DB83F7AE2AF1FDA6D0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_05D99DE6558D86DB83F7AE2AF1FDA6D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_05D99DE6558D86DB83F7AE2AF1FDA6D0_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_05D99DE6558D86DB83F7AE2AF1FDA6D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_05D99DE6558D86DB83F7AE2AF1FDA6D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_05D99DE6558D86DB83F7AE2AF1FDA6D0" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_05D99DE6558D86DB83F7AE2AF1FDA6D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_B2958C51C7F3678A0675AE2AF1FD9376_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_B2958C51C7F3678A0675AE2AF1FD9376" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_B2958C51C7F3678A0675AE2AF1FD9376_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_B2958C51C7F3678A0675AE2AF1FD9376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_B2958C51C7F3678A0675AE2AF1FD9376" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_B2958C51C7F3678A0675AE2AF1FD9376" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_B2958C51C7F3678A0675AE2AF1FD9376" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1C8B91BCDD9F1E3DE058AE2AF1FDCDCA_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1C8B91BCDD9F1E3DE058AE2AF1FDCDCA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1C8B91BCDD9F1E3DE058AE2AF1FDCDCA_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1C8B91BCDD9F1E3DE058AE2AF1FDCDCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1C8B91BCDD9F1E3DE058AE2AF1FDCDCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1C8B91BCDD9F1E3DE058AE2AF1FDCDCA" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1C8B91BCDD9F1E3DE058AE2AF1FDCDCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E6500F3D59C712AB4759AE2AF1FEE561_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E6500F3D59C712AB4759AE2AF1FEE561" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E6500F3D59C712AB4759AE2AF1FEE561_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E6500F3D59C712AB4759AE2AF1FEE561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E6500F3D59C712AB4759AE2AF1FEE561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E6500F3D59C712AB4759AE2AF1FEE561" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E6500F3D59C712AB4759AE2AF1FEE561" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3F93E5F8B3C13569C6DEAE2AF1FEA6CD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3F93E5F8B3C13569C6DEAE2AF1FEA6CD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3F93E5F8B3C13569C6DEAE2AF1FEA6CD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3F93E5F8B3C13569C6DEAE2AF1FEA6CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3F93E5F8B3C13569C6DEAE2AF1FEA6CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3F93E5F8B3C13569C6DEAE2AF1FEA6CD" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3F93E5F8B3C13569C6DEAE2AF1FEA6CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_FD1AC61FFB39AC7126C9AE2AF1FE12F2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FD1AC61FFB39AC7126C9AE2AF1FE12F2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_FD1AC61FFB39AC7126C9AE2AF1FE12F2_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FD1AC61FFB39AC7126C9AE2AF1FE12F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FD1AC61FFB39AC7126C9AE2AF1FE12F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_FD1AC61FFB39AC7126C9AE2AF1FE12F2" xlink:to="lab_us-gaap_NetIncomeLoss_FD1AC61FFB39AC7126C9AE2AF1FE12F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93A1398BD2555FDF620AAE2AF1FE3A0D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93A1398BD2555FDF620AAE2AF1FE3A0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized income on available for sale securities, net of tax of $0 and $115, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93A1398BD2555FDF620AAE2AF1FE3A0D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93A1398BD2555FDF620AAE2AF1FE3A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93A1398BD2555FDF620AAE2AF1FE3A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93A1398BD2555FDF620AAE2AF1FE3A0D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93A1398BD2555FDF620AAE2AF1FE3A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_EBF1B8A7D1DFD7A28AB2AE2AF1FEDE4E_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_EBF1B8A7D1DFD7A28AB2AE2AF1FEDE4E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_EBF1B8A7D1DFD7A28AB2AE2AF1FEDE4E_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_EBF1B8A7D1DFD7A28AB2AE2AF1FEDE4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_EBF1B8A7D1DFD7A28AB2AE2AF1FEDE4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_EBF1B8A7D1DFD7A28AB2AE2AF1FEDE4E" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_EBF1B8A7D1DFD7A28AB2AE2AF1FEDE4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_FF363F9245B1835D15D3AE2AF1FF3849_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_FF363F9245B1835D15D3AE2AF1FF3849" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_FF363F9245B1835D15D3AE2AF1FF3849_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_FF363F9245B1835D15D3AE2AF1FF3849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_FF363F9245B1835D15D3AE2AF1FF3849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_FF363F9245B1835D15D3AE2AF1FF3849" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_FF363F9245B1835D15D3AE2AF1FF3849" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares outstanding:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9EC23A5B7A1965F754CBAE2AF1FFD674_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9EC23A5B7A1965F754CBAE2AF1FFD674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9EC23A5B7A1965F754CBAE2AF1FFD674_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9EC23A5B7A1965F754CBAE2AF1FFD674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9EC23A5B7A1965F754CBAE2AF1FFD674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9EC23A5B7A1965F754CBAE2AF1FFD674" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9EC23A5B7A1965F754CBAE2AF1FFD674" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_79DE6EE4760B8036303B0DC53A64D230_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B52E3CD3EF5A5059AD457E34B582F865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_79DE6EE4760B8036303B0DC53A64D230_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B52E3CD3EF5A5059AD457E34B582F865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B52E3CD3EF5A5059AD457E34B582F865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B52E3CD3EF5A5059AD457E34B582F865" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B52E3CD3EF5A5059AD457E34B582F865" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_380A9CDDAE5EAD7215AC0DC53A649B4A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0606648C72995CAEA5EF890C6B26CA63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_380A9CDDAE5EAD7215AC0DC53A649B4A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0606648C72995CAEA5EF890C6B26CA63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0606648C72995CAEA5EF890C6B26CA63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0606648C72995CAEA5EF890C6B26CA63" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0606648C72995CAEA5EF890C6B26CA63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4B5A74B80B89514212B00DC53A64671B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C5298A7DCD24592886A49AD26629B4FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4B5A74B80B89514212B00DC53A64671B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C5298A7DCD24592886A49AD26629B4FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C5298A7DCD24592886A49AD26629B4FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C5298A7DCD24592886A49AD26629B4FF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C5298A7DCD24592886A49AD26629B4FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ACDE61B575040E87A4860DC53A64DD02_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_083C64CA342052E3B7883B2A33F16E66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ACDE61B575040E87A4860DC53A64DD02_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_083C64CA342052E3B7883B2A33F16E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_083C64CA342052E3B7883B2A33F16E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_083C64CA342052E3B7883B2A33F16E66" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_083C64CA342052E3B7883B2A33F16E66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A95D2FF498842D37E10F0DC53A64CC57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43AE629650805E1EBCF009A61DA7D4EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A95D2FF498842D37E10F0DC53A64CC57_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43AE629650805E1EBCF009A61DA7D4EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43AE629650805E1EBCF009A61DA7D4EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43AE629650805E1EBCF009A61DA7D4EF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43AE629650805E1EBCF009A61DA7D4EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_E73A3EA2320F7C72823A75D05F6F5956_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_E73A3EA2320F7C72823A75D05F6F5956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_E73A3EA2320F7C72823A75D05F6F5956_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_E73A3EA2320F7C72823A75D05F6F5956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_E73A3EA2320F7C72823A75D05F6F5956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_E73A3EA2320F7C72823A75D05F6F5956" xlink:to="lab_us-gaap_NumberOfReportableSegments_E73A3EA2320F7C72823A75D05F6F5956" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3FBE07898729A3CF00770DC5395B5597_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C3377C48F72E54658E7DB6404A9BB56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3FBE07898729A3CF00770DC5395B5597_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C3377C48F72E54658E7DB6404A9BB56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C3377C48F72E54658E7DB6404A9BB56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C3377C48F72E54658E7DB6404A9BB56F" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_C3377C48F72E54658E7DB6404A9BB56F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:to="lab_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Banks</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52" xlink:to="lab_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:to="lab_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:type="arc" />
    <link:label id="lab_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83_terseLabel_en-US" xlink:label="lab_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan and Security Agreement (LSA)</link:label>
    <link:label id="lab_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83_label_en-US" xlink:label="lab_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan And Security Agreement [Member]</link:label>
    <link:label id="lab_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83_documentation_en-US" xlink:label="lab_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan And Security Agreement [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_LoanAndSecurityAgreementMember" xlink:label="loc_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:to="lab_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:type="arc" />
    <link:label id="lab_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA_terseLabel_en-US" xlink:label="lab_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term A Loans</link:label>
    <link:label id="lab_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA_label_en-US" xlink:label="lab_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term A Loans [Member]</link:label>
    <link:label id="lab_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA_documentation_en-US" xlink:label="lab_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term A Loans [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_TermALoansMember" xlink:label="loc_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:to="lab_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:type="arc" />
    <link:label id="lab_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B_terseLabel_en-US" xlink:label="lab_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term B and Term C Loans</link:label>
    <link:label id="lab_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B_label_en-US" xlink:label="lab_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term B Loans And Term C Loans [Member]</link:label>
    <link:label id="lab_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B_documentation_en-US" xlink:label="lab_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term B Loans And Term C Loans [Member]</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_TermBLoansAndTermCLoansMember" xlink:label="loc_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:to="lab_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="lab_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:type="arc" />
    <link:label id="lab_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74_terseLabel_en-US" xlink:label="lab_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, maximum borrowing capacity</link:label>
    <link:label id="lab_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74_label_en-US" xlink:label="lab_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74_documentation_en-US" xlink:label="lab_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_DebtInstrumentMaximumBorrowingCapacity" xlink:label="loc_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:to="lab_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:type="arc" />
    <link:label id="lab_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D_terseLabel_en-US" xlink:label="lab_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of loan installments (in installments)</link:label>
    <link:label id="lab_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D_label_en-US" xlink:label="lab_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Loan Installments</link:label>
    <link:label id="lab_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D_documentation_en-US" xlink:label="lab_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Loan Installments</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_DebtInstrumentNumberOfLoanInstallments" xlink:label="loc_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:to="lab_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate borrowing capacity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate draw on term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A349BB55FF3261885730DC53AA6A701_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6295ECC935BE5323BD63A4FDD4288509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9A349BB55FF3261885730DC53AA6A701_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6295ECC935BE5323BD63A4FDD4288509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6295ECC935BE5323BD63A4FDD4288509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6295ECC935BE5323BD63A4FDD4288509" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6295ECC935BE5323BD63A4FDD4288509" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_560520839A0290007DA10DC539A09C3C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_560520839A0290007DA10DC539A09C3C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F62FCACCDEF453E9C3D80DC539A0987A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F62FCACCDEF453E9C3D80DC539A0987A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7DBB4993A24DD040E69E0DC539A009BB_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9F914DF993DC54AF91803170767EE2EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7DBB4993A24DD040E69E0DC539A009BB_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9F914DF993DC54AF91803170767EE2EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9F914DF993DC54AF91803170767EE2EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9F914DF993DC54AF91803170767EE2EC" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9F914DF993DC54AF91803170767EE2EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A8E6B62772D93B0D584F0DC539A1BB68_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_99DFD6CCC1F555CD9E4515FB2FB71F9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A8E6B62772D93B0D584F0DC539A1BB68_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_99DFD6CCC1F555CD9E4515FB2FB71F9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99DFD6CCC1F555CD9E4515FB2FB71F9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99DFD6CCC1F555CD9E4515FB2FB71F9F" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_99DFD6CCC1F555CD9E4515FB2FB71F9F" xlink:type="arc" />
    <link:label id="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_AD34C5F6FB3C876EB5660DC539A14D15_terseLabel_en-US" xlink:label="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_AD34C5F6FB3C876EB5660DC539A14D15_label_en-US" xlink:label="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:label id="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_AD34C5F6FB3C876EB5660DC539A14D15_documentation_en-US" xlink:label="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:to="lab_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_280AE9BDF69566DC50BF76115376BCD1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_280AE9BDF69566DC50BF76115376BCD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating ROU assets, Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_280AE9BDF69566DC50BF76115376BCD1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_280AE9BDF69566DC50BF76115376BCD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_280AE9BDF69566DC50BF76115376BCD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_280AE9BDF69566DC50BF76115376BCD1" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_280AE9BDF69566DC50BF76115376BCD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6EEA485D9E8E0093D556761153766C01_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_6EEA485D9E8E0093D556761153766C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6EEA485D9E8E0093D556761153766C01_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_6EEA485D9E8E0093D556761153766C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6EEA485D9E8E0093D556761153766C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_6EEA485D9E8E0093D556761153766C01" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_6EEA485D9E8E0093D556761153766C01" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5BEA8120177DCFC01D17761153768CA9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5BEA8120177DCFC01D17761153768CA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5BEA8120177DCFC01D17761153768CA9_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5BEA8120177DCFC01D17761153768CA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5BEA8120177DCFC01D17761153768CA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5BEA8120177DCFC01D17761153768CA9" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5BEA8120177DCFC01D17761153768CA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5C33129A340EA884567AC811B7D4087C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_5C33129A340EA884567AC811B7D4087C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5C33129A340EA884567AC811B7D4087C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_5C33129A340EA884567AC811B7D4087C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5C33129A340EA884567AC811B7D4087C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_5C33129A340EA884567AC811B7D4087C" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_5C33129A340EA884567AC811B7D4087C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_906470682A2E9C8477CFA4DD4E72F13A_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_906470682A2E9C8477CFA4DD4E72F13A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_906470682A2E9C8477CFA4DD4E72F13A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_906470682A2E9C8477CFA4DD4E72F13A" xlink:to="lab_us-gaap_NetIncomeLoss_906470682A2E9C8477CFA4DD4E72F13A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_90F714BD437A45959A69A4DD4E72559D_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_90F714BD437A45959A69A4DD4E72559D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_90F714BD437A45959A69A4DD4E72559D_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_90F714BD437A45959A69A4DD4E72559D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_90F714BD437A45959A69A4DD4E72559D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_90F714BD437A45959A69A4DD4E72559D" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_90F714BD437A45959A69A4DD4E72559D" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_81C7A1178E9125A1B188A4DD4E73EF56_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_81C7A1178E9125A1B188A4DD4E73EF56" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion/amortization of investments, net</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_81C7A1178E9125A1B188A4DD4E73EF56_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_81C7A1178E9125A1B188A4DD4E73EF56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_81C7A1178E9125A1B188A4DD4E73EF56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_81C7A1178E9125A1B188A4DD4E73EF56" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_81C7A1178E9125A1B188A4DD4E73EF56" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_96525F11FC78A62AD3B7A4DD4E73C0F2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_96525F11FC78A62AD3B7A4DD4E73C0F2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_96525F11FC78A62AD3B7A4DD4E73C0F2_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_96525F11FC78A62AD3B7A4DD4E73C0F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_96525F11FC78A62AD3B7A4DD4E73C0F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_96525F11FC78A62AD3B7A4DD4E73C0F2" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_96525F11FC78A62AD3B7A4DD4E73C0F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_E9F0DE6AB8D2913604BFA4DD4E7302BD_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_E9F0DE6AB8D2913604BFA4DD4E7302BD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Receivable from collaborative partners</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_E9F0DE6AB8D2913604BFA4DD4E7302BD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_E9F0DE6AB8D2913604BFA4DD4E7302BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_E9F0DE6AB8D2913604BFA4DD4E7302BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_E9F0DE6AB8D2913604BFA4DD4E7302BD" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_E9F0DE6AB8D2913604BFA4DD4E7302BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C83DF2B8F4EAA58773FBA4DD4E73AD50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C83DF2B8F4EAA58773FBA4DD4E73AD50" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C83DF2B8F4EAA58773FBA4DD4E73AD50_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C83DF2B8F4EAA58773FBA4DD4E73AD50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C83DF2B8F4EAA58773FBA4DD4E73AD50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C83DF2B8F4EAA58773FBA4DD4E73AD50" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C83DF2B8F4EAA58773FBA4DD4E73AD50" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_DC7DC0F1AA8558440D02A4DD4E74803E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_DC7DC0F1AA8558440D02A4DD4E74803E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_DC7DC0F1AA8558440D02A4DD4E74803E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_DC7DC0F1AA8558440D02A4DD4E74803E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_DC7DC0F1AA8558440D02A4DD4E74803E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_DC7DC0F1AA8558440D02A4DD4E74803E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_DC7DC0F1AA8558440D02A4DD4E74803E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7D2EF53EEE37F9319A76A4DD4E7402A3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7D2EF53EEE37F9319A76A4DD4E7402A3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7D2EF53EEE37F9319A76A4DD4E7402A3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7D2EF53EEE37F9319A76A4DD4E7402A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7D2EF53EEE37F9319A76A4DD4E7402A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7D2EF53EEE37F9319A76A4DD4E7402A3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7D2EF53EEE37F9319A76A4DD4E7402A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_F99E22004B1D77B83CBFA4DD4E74E48C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_F99E22004B1D77B83CBFA4DD4E74E48C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_F99E22004B1D77B83CBFA4DD4E74E48C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_F99E22004B1D77B83CBFA4DD4E74E48C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_F99E22004B1D77B83CBFA4DD4E74E48C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_F99E22004B1D77B83CBFA4DD4E74E48C" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_F99E22004B1D77B83CBFA4DD4E74E48C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EE9FB5E30B83BFD6BCF1A4DD4E74DDE2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EE9FB5E30B83BFD6BCF1A4DD4E74DDE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EE9FB5E30B83BFD6BCF1A4DD4E74DDE2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EE9FB5E30B83BFD6BCF1A4DD4E74DDE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EE9FB5E30B83BFD6BCF1A4DD4E74DDE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EE9FB5E30B83BFD6BCF1A4DD4E74DDE2" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EE9FB5E30B83BFD6BCF1A4DD4E74DDE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91B56F93599BF75DD887A4DD4E75C1CC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91B56F93599BF75DD887A4DD4E75C1CC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91B56F93599BF75DD887A4DD4E75C1CC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91B56F93599BF75DD887A4DD4E75C1CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91B56F93599BF75DD887A4DD4E75C1CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91B56F93599BF75DD887A4DD4E75C1CC" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91B56F93599BF75DD887A4DD4E75C1CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6168B5821B4F087905C5A4DD4E755049_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6168B5821B4F087905C5A4DD4E755049" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6168B5821B4F087905C5A4DD4E755049_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6168B5821B4F087905C5A4DD4E755049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6168B5821B4F087905C5A4DD4E755049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6168B5821B4F087905C5A4DD4E755049" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6168B5821B4F087905C5A4DD4E755049" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_ED899B9E0FF9E67D276CA4DD4E75382D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_ED899B9E0FF9E67D276CA4DD4E75382D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, upon the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_ED899B9E0FF9E67D276CA4DD4E75382D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_ED899B9E0FF9E67D276CA4DD4E75382D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ED899B9E0FF9E67D276CA4DD4E75382D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_ED899B9E0FF9E67D276CA4DD4E75382D" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_ED899B9E0FF9E67D276CA4DD4E75382D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_E39BF05AA0CEA642A363A4DD4E765A48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_E39BF05AA0CEA642A363A4DD4E765A48" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_E39BF05AA0CEA642A363A4DD4E765A48_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_E39BF05AA0CEA642A363A4DD4E765A48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_E39BF05AA0CEA642A363A4DD4E765A48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable_E39BF05AA0CEA642A363A4DD4E765A48" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable_E39BF05AA0CEA642A363A4DD4E765A48" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B7C2179D18CEDCB81D3BA4DD4E76BDA0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B7C2179D18CEDCB81D3BA4DD4E76BDA0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B7C2179D18CEDCB81D3BA4DD4E76BDA0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B7C2179D18CEDCB81D3BA4DD4E76BDA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B7C2179D18CEDCB81D3BA4DD4E76BDA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B7C2179D18CEDCB81D3BA4DD4E76BDA0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_B7C2179D18CEDCB81D3BA4DD4E76BDA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_B9F3ABA56F6CC304EAEAA4DD4E7609AB_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_B9F3ABA56F6CC304EAEAA4DD4E7609AB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_B9F3ABA56F6CC304EAEAA4DD4E7609AB_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_B9F3ABA56F6CC304EAEAA4DD4E7609AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_B9F3ABA56F6CC304EAEAA4DD4E7609AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_B9F3ABA56F6CC304EAEAA4DD4E7609AB" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_B9F3ABA56F6CC304EAEAA4DD4E7609AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678AF9D7342BF9F30704A4DD4E76A4DE_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678AF9D7342BF9F30704A4DD4E76A4DE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678AF9D7342BF9F30704A4DD4E76A4DE_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678AF9D7342BF9F30704A4DD4E76A4DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678AF9D7342BF9F30704A4DD4E76A4DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678AF9D7342BF9F30704A4DD4E76A4DE" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678AF9D7342BF9F30704A4DD4E76A4DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C1E78D4204A59BC48CCDA4DD4E763C69_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C1E78D4204A59BC48CCDA4DD4E763C69" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C1E78D4204A59BC48CCDA4DD4E763C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C1E78D4204A59BC48CCDA4DD4E763C69" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C1E78D4204A59BC48CCDA4DD4E763C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_8F1C2EB5D0D4AE7459E4A4DD4E764998_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_8F1C2EB5D0D4AE7459E4A4DD4E764998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_8F1C2EB5D0D4AE7459E4A4DD4E764998_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_8F1C2EB5D0D4AE7459E4A4DD4E764998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_8F1C2EB5D0D4AE7459E4A4DD4E764998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_8F1C2EB5D0D4AE7459E4A4DD4E764998" xlink:to="lab_us-gaap_InterestPaidNet_8F1C2EB5D0D4AE7459E4A4DD4E764998" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A02E84887F6259408CFFA4DD4E77FFA2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A02E84887F6259408CFFA4DD4E77FFA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts accrued for property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A02E84887F6259408CFFA4DD4E77FFA2_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A02E84887F6259408CFFA4DD4E77FFA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A02E84887F6259408CFFA4DD4E77FFA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A02E84887F6259408CFFA4DD4E77FFA2" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A02E84887F6259408CFFA4DD4E77FFA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_784DE5EBF5F58BF848DB0DC53965F40E_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28E6343C448652279B723347C4FDD18C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Accounts and Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_784DE5EBF5F58BF848DB0DC53965F40E_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28E6343C448652279B723347C4FDD18C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28E6343C448652279B723347C4FDD18C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28E6343C448652279B723347C4FDD18C" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28E6343C448652279B723347C4FDD18C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2BDB8E642277AD1011AAD202D34055F3_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_2BDB8E642277AD1011AAD202D34055F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2BDB8E642277AD1011AAD202D34055F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2BDB8E642277AD1011AAD202D34055F3" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_2BDB8E642277AD1011AAD202D34055F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957_label_en-US" xlink:label="lab_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:to="lab_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:to="lab_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599" xlink:to="lab_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75" xlink:to="lab_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:to="lab_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_A28866463CD49B823325D202D34898A8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A28866463CD49B823325D202D34898A8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A28866463CD49B823325D202D34898A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_A28866463CD49B823325D202D34898A8" xlink:to="lab_us-gaap_StockholdersEquity_A28866463CD49B823325D202D34898A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5" xlink:to="lab_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85B7D13FB5D15CC5FE80D202D3485174_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85B7D13FB5D15CC5FE80D202D3485174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock plans (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85B7D13FB5D15CC5FE80D202D3485174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85B7D13FB5D15CC5FE80D202D3485174" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85B7D13FB5D15CC5FE80D202D3485174" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_173BA374CFD7CBB09102D202D349EB28_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_173BA374CFD7CBB09102D202D349EB28" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_173BA374CFD7CBB09102D202D349EB28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_173BA374CFD7CBB09102D202D349EB28" xlink:to="lab_us-gaap_StockholdersEquity_173BA374CFD7CBB09102D202D349EB28" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_380708E3410C6DC49EE0D202D3496BA4_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_380708E3410C6DC49EE0D202D3496BA4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Ending Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_380708E3410C6DC49EE0D202D3496BA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_380708E3410C6DC49EE0D202D3496BA4" xlink:to="lab_us-gaap_SharesOutstanding_380708E3410C6DC49EE0D202D3496BA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8E1288DAE8957EB074B97611536F2DAE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8E1288DAE8957EB074B97611536F2DAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8E1288DAE8957EB074B97611536F2DAE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8E1288DAE8957EB074B97611536F2DAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8E1288DAE8957EB074B97611536F2DAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8E1288DAE8957EB074B97611536F2DAE" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8E1288DAE8957EB074B97611536F2DAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9D4B00E53C074576A9B87611536F7217_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9D4B00E53C074576A9B87611536F7217" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9D4B00E53C074576A9B87611536F7217_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9D4B00E53C074576A9B87611536F7217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9D4B00E53C074576A9B87611536F7217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9D4B00E53C074576A9B87611536F7217" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9D4B00E53C074576A9B87611536F7217" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_961178E2564EBA2AF1737611536FECB0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_961178E2564EBA2AF1737611536FECB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_961178E2564EBA2AF1737611536FECB0_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_961178E2564EBA2AF1737611536FECB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_961178E2564EBA2AF1737611536FECB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_961178E2564EBA2AF1737611536FECB0" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_961178E2564EBA2AF1737611536FECB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_AA799815F53AB50259A776115370675D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_AA799815F53AB50259A776115370675D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_AA799815F53AB50259A776115370675D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_AA799815F53AB50259A776115370675D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_AA799815F53AB50259A776115370675D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_AA799815F53AB50259A776115370675D" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_AA799815F53AB50259A776115370675D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_17CCD001837242F1AAEF76115370EF78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_17CCD001837242F1AAEF76115370EF78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_17CCD001837242F1AAEF76115370EF78_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_17CCD001837242F1AAEF76115370EF78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_17CCD001837242F1AAEF76115370EF78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_17CCD001837242F1AAEF76115370EF78" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_17CCD001837242F1AAEF76115370EF78" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8BCE72741A335DC32E4E7611537064CD_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8BCE72741A335DC32E4E7611537064CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8BCE72741A335DC32E4E7611537064CD_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8BCE72741A335DC32E4E7611537064CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8BCE72741A335DC32E4E7611537064CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8BCE72741A335DC32E4E7611537064CD" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8BCE72741A335DC32E4E7611537064CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42C5B0356A59C84F452A76115370E7BB_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42C5B0356A59C84F452A76115370E7BB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum payments required</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42C5B0356A59C84F452A76115370E7BB_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42C5B0356A59C84F452A76115370E7BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42C5B0356A59C84F452A76115370E7BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42C5B0356A59C84F452A76115370E7BB" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42C5B0356A59C84F452A76115370E7BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D4F19F250DF375879F5576115370C47B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D4F19F250DF375879F5576115370C47B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D4F19F250DF375879F5576115370C47B_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D4F19F250DF375879F5576115370C47B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D4F19F250DF375879F5576115370C47B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D4F19F250DF375879F5576115370C47B" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D4F19F250DF375879F5576115370C47B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_692A495257B032478F657611537034D3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_692A495257B032478F657611537034D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_692A495257B032478F657611537034D3_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_692A495257B032478F657611537034D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_692A495257B032478F657611537034D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_692A495257B032478F657611537034D3" xlink:to="lab_us-gaap_OperatingLeaseLiability_692A495257B032478F657611537034D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4A2D5FB43D724A6118A20DC539868F64_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5D58084116B254FBBE698C5213A92109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5D58084116B254FBBE698C5213A92109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5D58084116B254FBBE698C5213A92109" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5D58084116B254FBBE698C5213A92109" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_C87B7338DCA04E28696E0DC539866BCF_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_CF03A7715F0D54319466D2B835DBAA98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_C87B7338DCA04E28696E0DC539866BCF_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_CF03A7715F0D54319466D2B835DBAA98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_CF03A7715F0D54319466D2B835DBAA98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_CF03A7715F0D54319466D2B835DBAA98" xlink:to="lab_us-gaap_NatureOfOperations_CF03A7715F0D54319466D2B835DBAA98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities excluded from computation of net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76BD4022AB15D73F0EE10DC53AAC6E21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76BD4022AB15D73F0EE10DC53AAC6E21_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2940B2BF2F1CF0E83B490DC53AAC1347_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2940B2BF2F1CF0E83B490DC53AAC1347_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4468826A62CB331AC8340DC53AACB920_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4468826A62CB331AC8340DC53AACB920_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_DA77E0CEA6DD7EE17A050DC53AAC6605_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_9F99680282FB5BF28EAAA8FF97830B69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_DA77E0CEA6DD7EE17A050DC53AAC6605_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_9F99680282FB5BF28EAAA8FF97830B69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9F99680282FB5BF28EAAA8FF97830B69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_9F99680282FB5BF28EAAA8FF97830B69" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_9F99680282FB5BF28EAAA8FF97830B69" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5EDD366912D0CD6A771B0DC53AAD4256_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5EDD366912D0CD6A771B0DC53AAD4256_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9D4E3B13051520C953EB0DC53AAD76DC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9D4E3B13051520C953EB0DC53AAD76DC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9C1EFE1F308B923A04370DC53AADA2B6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_4DA510BEC7875837B6103415EE636E20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Market Prices for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9C1EFE1F308B923A04370DC53AADA2B6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_4DA510BEC7875837B6103415EE636E20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4DA510BEC7875837B6103415EE636E20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_4DA510BEC7875837B6103415EE636E20" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_4DA510BEC7875837B6103415EE636E20" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0F3DAB7FB934B2F43F690DC53AAD78C6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E02223F994325D13B8EA50EADEE036AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0F3DAB7FB934B2F43F690DC53AAD78C6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E02223F994325D13B8EA50EADEE036AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E02223F994325D13B8EA50EADEE036AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_E02223F994325D13B8EA50EADEE036AB" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_E02223F994325D13B8EA50EADEE036AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3A6E8DCF439287C3A2720DC53AAE031E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_230D999015985B5CA95EF4F1A655D983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3A6E8DCF439287C3A2720DC53AAE031E_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_230D999015985B5CA95EF4F1A655D983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_230D999015985B5CA95EF4F1A655D983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_230D999015985B5CA95EF4F1A655D983" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_230D999015985B5CA95EF4F1A655D983" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_A12771D0D513A5118E4B0DC53AAEF743_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_A12771D0D513A5118E4B0DC53AAEF743_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9542A3FF633E7176E0FB0DC53AAEBA6D_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9542A3FF633E7176E0FB0DC53AAEBA6D_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8569A3868AA47323853A0DC53AAED894_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B06BCEA24852566CA8D74C9BCA15045F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8569A3868AA47323853A0DC53AAED894_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B06BCEA24852566CA8D74C9BCA15045F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B06BCEA24852566CA8D74C9BCA15045F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_B06BCEA24852566CA8D74C9BCA15045F" xlink:to="lab_us-gaap_MoneyMarketFundsMember_B06BCEA24852566CA8D74C9BCA15045F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MutualFundMember_BCF19E4E76FF2191D4F70DC53AAEA52F_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember_681C2A33CF7257CF8BFC56BB77112405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_BCF19E4E76FF2191D4F70DC53AAEA52F_label_en-US" xlink:label="lab_us-gaap_MutualFundMember_681C2A33CF7257CF8BFC56BB77112405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaap_MutualFundMember_681C2A33CF7257CF8BFC56BB77112405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember_681C2A33CF7257CF8BFC56BB77112405" xlink:to="lab_us-gaap_MutualFundMember_681C2A33CF7257CF8BFC56BB77112405" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DAC024E5A3B095F6191B0DC53AB0E268_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DAC024E5A3B095F6191B0DC53AB0E268_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:type="arc" />
    <link:label id="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9C95A66B66A3B7D73AFE0DC53AB0CB19_terseLabel_en-US" xlink:label="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments at fair value</link:label>
    <link:label id="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9C95A66B66A3B7D73AFE0DC53AB0CB19_label_en-US" xlink:label="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</link:label>
    <link:label id="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9C95A66B66A3B7D73AFE0DC53AB0CB19_documentation_en-US" xlink:label="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:href="anab-20200331.xsd#anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:label="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:to="lab_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6645FA4BBEEB54C938EB0DC53AB0C616_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E19DE95702945D9BB564035351263C97" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E19DE95702945D9BB564035351263C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E19DE95702945D9BB564035351263C97" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E19DE95702945D9BB564035351263C97" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5_label_en-US" xlink:label="lab_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="lab_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_34B03E2AC19A353C8304746F8CFD8CE6_terseLabel_en-US" xlink:label="lab_dei_DocumentType_34B03E2AC19A353C8304746F8CFD8CE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_34B03E2AC19A353C8304746F8CFD8CE6_label_en-US" xlink:label="lab_dei_DocumentType_34B03E2AC19A353C8304746F8CFD8CE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_34B03E2AC19A353C8304746F8CFD8CE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_34B03E2AC19A353C8304746F8CFD8CE6" xlink:to="lab_dei_DocumentType_34B03E2AC19A353C8304746F8CFD8CE6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_9B149D4A7F53C787474D746F8CFD743E_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_9B149D4A7F53C787474D746F8CFD743E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_9B149D4A7F53C787474D746F8CFD743E_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_9B149D4A7F53C787474D746F8CFD743E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_9B149D4A7F53C787474D746F8CFD743E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_9B149D4A7F53C787474D746F8CFD743E" xlink:to="lab_dei_DocumentQuarterlyReport_9B149D4A7F53C787474D746F8CFD743E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_A983FB638E3BF294DE37746F8CFD604D_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_A983FB638E3BF294DE37746F8CFD604D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_A983FB638E3BF294DE37746F8CFD604D_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_A983FB638E3BF294DE37746F8CFD604D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_A983FB638E3BF294DE37746F8CFD604D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_A983FB638E3BF294DE37746F8CFD604D" xlink:to="lab_dei_DocumentPeriodEndDate_A983FB638E3BF294DE37746F8CFD604D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_EFA2B32ACCAEFA0EDCB3746F8CFE8416_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_EFA2B32ACCAEFA0EDCB3746F8CFE8416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_EFA2B32ACCAEFA0EDCB3746F8CFE8416_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_EFA2B32ACCAEFA0EDCB3746F8CFE8416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_EFA2B32ACCAEFA0EDCB3746F8CFE8416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_EFA2B32ACCAEFA0EDCB3746F8CFE8416" xlink:to="lab_dei_DocumentTransitionReport_EFA2B32ACCAEFA0EDCB3746F8CFE8416" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_5689FA7E86A430186D0A746F8CFE16EC_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_5689FA7E86A430186D0A746F8CFE16EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_5689FA7E86A430186D0A746F8CFE16EC_label_en-US" xlink:label="lab_dei_EntityFileNumber_5689FA7E86A430186D0A746F8CFE16EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_5689FA7E86A430186D0A746F8CFE16EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_5689FA7E86A430186D0A746F8CFE16EC" xlink:to="lab_dei_EntityFileNumber_5689FA7E86A430186D0A746F8CFE16EC" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_9E4F4B9892C1E44FB0A5746F8CFEDCB5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_9E4F4B9892C1E44FB0A5746F8CFEDCB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_9E4F4B9892C1E44FB0A5746F8CFEDCB5_label_en-US" xlink:label="lab_dei_EntityRegistrantName_9E4F4B9892C1E44FB0A5746F8CFEDCB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_9E4F4B9892C1E44FB0A5746F8CFEDCB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_9E4F4B9892C1E44FB0A5746F8CFEDCB5" xlink:to="lab_dei_EntityRegistrantName_9E4F4B9892C1E44FB0A5746F8CFEDCB5" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8C99413D29837214D6F1746F8CFEBB55_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_8C99413D29837214D6F1746F8CFEBB55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8C99413D29837214D6F1746F8CFEBB55_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_8C99413D29837214D6F1746F8CFEBB55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8C99413D29837214D6F1746F8CFEBB55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_8C99413D29837214D6F1746F8CFEBB55" xlink:to="lab_dei_EntityIncorporationStateCountryCode_8C99413D29837214D6F1746F8CFEBB55" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2222938AA99A488225D2746F8CFE7E05_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_2222938AA99A488225D2746F8CFE7E05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2222938AA99A488225D2746F8CFE7E05_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_2222938AA99A488225D2746F8CFE7E05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_2222938AA99A488225D2746F8CFE7E05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_2222938AA99A488225D2746F8CFE7E05" xlink:to="lab_dei_EntityTaxIdentificationNumber_2222938AA99A488225D2746F8CFE7E05" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_333A8B1972C7D93C7331746F8CFE2518_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_333A8B1972C7D93C7331746F8CFE2518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_333A8B1972C7D93C7331746F8CFE2518_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_333A8B1972C7D93C7331746F8CFE2518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_333A8B1972C7D93C7331746F8CFE2518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_333A8B1972C7D93C7331746F8CFE2518" xlink:to="lab_dei_EntityAddressAddressLine1_333A8B1972C7D93C7331746F8CFE2518" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine2_1C233DB5CA691D3F4B63746F8CFF94D0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_1C233DB5CA691D3F4B63746F8CFF94D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_1C233DB5CA691D3F4B63746F8CFF94D0_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_1C233DB5CA691D3F4B63746F8CFF94D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_1C233DB5CA691D3F4B63746F8CFF94D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_1C233DB5CA691D3F4B63746F8CFF94D0" xlink:to="lab_dei_EntityAddressAddressLine2_1C233DB5CA691D3F4B63746F8CFF94D0" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_FFF6D742175CC1CCF036746F8CFFEF14_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_FFF6D742175CC1CCF036746F8CFFEF14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_FFF6D742175CC1CCF036746F8CFFEF14_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_FFF6D742175CC1CCF036746F8CFFEF14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_FFF6D742175CC1CCF036746F8CFFEF14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_FFF6D742175CC1CCF036746F8CFFEF14" xlink:to="lab_dei_EntityAddressCityOrTown_FFF6D742175CC1CCF036746F8CFFEF14" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_7D759CF2A434CB28C138746F8CFFEA1C_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_7D759CF2A434CB28C138746F8CFFEA1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7D759CF2A434CB28C138746F8CFFEA1C_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_7D759CF2A434CB28C138746F8CFFEA1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_7D759CF2A434CB28C138746F8CFFEA1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_7D759CF2A434CB28C138746F8CFFEA1C" xlink:to="lab_dei_EntityAddressStateOrProvince_7D759CF2A434CB28C138746F8CFFEA1C" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_05B5BB4BF17398BEE890746F8CFF2695_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_05B5BB4BF17398BEE890746F8CFF2695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_05B5BB4BF17398BEE890746F8CFF2695_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_05B5BB4BF17398BEE890746F8CFF2695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_05B5BB4BF17398BEE890746F8CFF2695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_05B5BB4BF17398BEE890746F8CFF2695" xlink:to="lab_dei_EntityAddressPostalZipCode_05B5BB4BF17398BEE890746F8CFF2695" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_5028A5239CBB61E8F868746F8CFFC554_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_5028A5239CBB61E8F868746F8CFFC554" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_5028A5239CBB61E8F868746F8CFFC554_label_en-US" xlink:label="lab_dei_CityAreaCode_5028A5239CBB61E8F868746F8CFFC554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_5028A5239CBB61E8F868746F8CFFC554" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_5028A5239CBB61E8F868746F8CFFC554" xlink:to="lab_dei_CityAreaCode_5028A5239CBB61E8F868746F8CFFC554" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_5CFBE136C5DCCF86F49C746F8CFFD82E_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_5CFBE136C5DCCF86F49C746F8CFFD82E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_5CFBE136C5DCCF86F49C746F8CFFD82E_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_5CFBE136C5DCCF86F49C746F8CFFD82E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_5CFBE136C5DCCF86F49C746F8CFFD82E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_5CFBE136C5DCCF86F49C746F8CFFD82E" xlink:to="lab_dei_LocalPhoneNumber_5CFBE136C5DCCF86F49C746F8CFFD82E" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_0D9B14EB21D3C227970C746F8D00E5F0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_0D9B14EB21D3C227970C746F8D00E5F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_0D9B14EB21D3C227970C746F8D00E5F0_label_en-US" xlink:label="lab_dei_Security12bTitle_0D9B14EB21D3C227970C746F8D00E5F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_0D9B14EB21D3C227970C746F8D00E5F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_0D9B14EB21D3C227970C746F8D00E5F0" xlink:to="lab_dei_Security12bTitle_0D9B14EB21D3C227970C746F8D00E5F0" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_772F06655D9E5587BDB1746F8D002A8E_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_772F06655D9E5587BDB1746F8D002A8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_772F06655D9E5587BDB1746F8D002A8E_label_en-US" xlink:label="lab_dei_TradingSymbol_772F06655D9E5587BDB1746F8D002A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_772F06655D9E5587BDB1746F8D002A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_772F06655D9E5587BDB1746F8D002A8E" xlink:to="lab_dei_TradingSymbol_772F06655D9E5587BDB1746F8D002A8E" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_11CD6558984894CF9E4F746F8D006ADE_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_11CD6558984894CF9E4F746F8D006ADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_11CD6558984894CF9E4F746F8D006ADE_label_en-US" xlink:label="lab_dei_SecurityExchangeName_11CD6558984894CF9E4F746F8D006ADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_11CD6558984894CF9E4F746F8D006ADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_11CD6558984894CF9E4F746F8D006ADE" xlink:to="lab_dei_SecurityExchangeName_11CD6558984894CF9E4F746F8D006ADE" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_C0BFE007766ED8D85D17746F8D00206F_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C0BFE007766ED8D85D17746F8D00206F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_C0BFE007766ED8D85D17746F8D00206F_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C0BFE007766ED8D85D17746F8D00206F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C0BFE007766ED8D85D17746F8D00206F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_C0BFE007766ED8D85D17746F8D00206F" xlink:to="lab_dei_EntityCurrentReportingStatus_C0BFE007766ED8D85D17746F8D00206F" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4A9A4A72345B11DB680C746F8D00DE76_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_4A9A4A72345B11DB680C746F8D00DE76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4A9A4A72345B11DB680C746F8D00DE76_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_4A9A4A72345B11DB680C746F8D00DE76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_4A9A4A72345B11DB680C746F8D00DE76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_4A9A4A72345B11DB680C746F8D00DE76" xlink:to="lab_dei_EntityInteractiveDataCurrent_4A9A4A72345B11DB680C746F8D00DE76" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_4C69D47BF330345E7979746F8D00AE85_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_4C69D47BF330345E7979746F8D00AE85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_4C69D47BF330345E7979746F8D00AE85_label_en-US" xlink:label="lab_dei_EntityFilerCategory_4C69D47BF330345E7979746F8D00AE85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_4C69D47BF330345E7979746F8D00AE85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_4C69D47BF330345E7979746F8D00AE85" xlink:to="lab_dei_EntityFilerCategory_4C69D47BF330345E7979746F8D00AE85" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_15D846EE9612895E70BD746F8D01208A_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_15D846EE9612895E70BD746F8D01208A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_15D846EE9612895E70BD746F8D01208A_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_15D846EE9612895E70BD746F8D01208A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_15D846EE9612895E70BD746F8D01208A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_15D846EE9612895E70BD746F8D01208A" xlink:to="lab_dei_EntitySmallBusiness_15D846EE9612895E70BD746F8D01208A" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_B5A89CC9D75A2413F0ED746F8D019633_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_B5A89CC9D75A2413F0ED746F8D019633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_B5A89CC9D75A2413F0ED746F8D019633_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_B5A89CC9D75A2413F0ED746F8D019633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_B5A89CC9D75A2413F0ED746F8D019633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_B5A89CC9D75A2413F0ED746F8D019633" xlink:to="lab_dei_EntityEmergingGrowthCompany_B5A89CC9D75A2413F0ED746F8D019633" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_20982FAB48C308500564746F8D01A7A7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_20982FAB48C308500564746F8D01A7A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_20982FAB48C308500564746F8D01A7A7_label_en-US" xlink:label="lab_dei_EntityShellCompany_20982FAB48C308500564746F8D01A7A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_20982FAB48C308500564746F8D01A7A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_20982FAB48C308500564746F8D01A7A7" xlink:to="lab_dei_EntityShellCompany_20982FAB48C308500564746F8D01A7A7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E5092A117B6E9D77E27C746F8D0142FD_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E5092A117B6E9D77E27C746F8D0142FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E5092A117B6E9D77E27C746F8D0142FD_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E5092A117B6E9D77E27C746F8D0142FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E5092A117B6E9D77E27C746F8D0142FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_E5092A117B6E9D77E27C746F8D0142FD" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_E5092A117B6E9D77E27C746F8D0142FD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_234ACF9FA16B68B1E2BC746F8D0187CF_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_234ACF9FA16B68B1E2BC746F8D0187CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_234ACF9FA16B68B1E2BC746F8D0187CF_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_234ACF9FA16B68B1E2BC746F8D0187CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_234ACF9FA16B68B1E2BC746F8D0187CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_234ACF9FA16B68B1E2BC746F8D0187CF" xlink:to="lab_dei_EntityCentralIndexKey_234ACF9FA16B68B1E2BC746F8D0187CF" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4658EEF02F51CF82CDE5746F8D015B53_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_4658EEF02F51CF82CDE5746F8D015B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4658EEF02F51CF82CDE5746F8D015B53_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_4658EEF02F51CF82CDE5746F8D015B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4658EEF02F51CF82CDE5746F8D015B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_4658EEF02F51CF82CDE5746F8D015B53" xlink:to="lab_dei_CurrentFiscalYearEndDate_4658EEF02F51CF82CDE5746F8D015B53" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_E928C134B74B4E84C9C6746F8D013C03_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_E928C134B74B4E84C9C6746F8D013C03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_E928C134B74B4E84C9C6746F8D013C03_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_E928C134B74B4E84C9C6746F8D013C03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_E928C134B74B4E84C9C6746F8D013C03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_E928C134B74B4E84C9C6746F8D013C03" xlink:to="lab_dei_DocumentFiscalYearFocus_E928C134B74B4E84C9C6746F8D013C03" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_C4E99CAFCCB36C444FFD746F8D0218C8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_C4E99CAFCCB36C444FFD746F8D0218C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_C4E99CAFCCB36C444FFD746F8D0218C8_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_C4E99CAFCCB36C444FFD746F8D0218C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_C4E99CAFCCB36C444FFD746F8D0218C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_C4E99CAFCCB36C444FFD746F8D0218C8" xlink:to="lab_dei_DocumentFiscalPeriodFocus_C4E99CAFCCB36C444FFD746F8D0218C8" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_17D1DD11F54F23135F8C746F8D028ECB_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_17D1DD11F54F23135F8C746F8D028ECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_17D1DD11F54F23135F8C746F8D028ECB_label_en-US" xlink:label="lab_dei_AmendmentFlag_17D1DD11F54F23135F8C746F8D028ECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_17D1DD11F54F23135F8C746F8D028ECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_17D1DD11F54F23135F8C746F8D028ECB" xlink:to="lab_dei_AmendmentFlag_17D1DD11F54F23135F8C746F8D028ECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_535CFE4FC2C71D1CBA000DC53ACDFF13_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6DDF3E5974375962B7E752F821E2C6F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_535CFE4FC2C71D1CBA000DC53ACDFF13_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6DDF3E5974375962B7E752F821E2C6F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6DDF3E5974375962B7E752F821E2C6F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6DDF3E5974375962B7E752F821E2C6F4" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6DDF3E5974375962B7E752F821E2C6F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_05ACACE87E35DE2FE3A90DC53ACEF062_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_F0CA365CC61F548D9CD103508B2C8072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_05ACACE87E35DE2FE3A90DC53ACEF062_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_F0CA365CC61F548D9CD103508B2C8072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_F0CA365CC61F548D9CD103508B2C8072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_F0CA365CC61F548D9CD103508B2C8072" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_F0CA365CC61F548D9CD103508B2C8072" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6C59ACFC99A2287B4CFF0DC53ACED8D1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1F8F1EE9D26F59CFB8F8A1DA4CCA05CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6C59ACFC99A2287B4CFF0DC53ACED8D1_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1F8F1EE9D26F59CFB8F8A1DA4CCA05CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1F8F1EE9D26F59CFB8F8A1DA4CCA05CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_1F8F1EE9D26F59CFB8F8A1DA4CCA05CB" xlink:to="lab_us-gaap_PreferredStockSharesIssued_1F8F1EE9D26F59CFB8F8A1DA4CCA05CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_A6829CDFDF2000C83B8E0DC53ACE1097_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_B7E5805A700A5B9596516555DB63F2C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_A6829CDFDF2000C83B8E0DC53ACE1097_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_B7E5805A700A5B9596516555DB63F2C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_B7E5805A700A5B9596516555DB63F2C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_B7E5805A700A5B9596516555DB63F2C8" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_B7E5805A700A5B9596516555DB63F2C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_BE8F1EDE5AFA9AFE25050DC53ACED7A9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_28D22AF49A8057CD9E696C652A60CFA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_BE8F1EDE5AFA9AFE25050DC53ACED7A9_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_28D22AF49A8057CD9E696C652A60CFA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_28D22AF49A8057CD9E696C652A60CFA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_28D22AF49A8057CD9E696C652A60CFA3" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_28D22AF49A8057CD9E696C652A60CFA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_97C339676E7BB7B9B13F0DC53A68018C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_97C339676E7BB7B9B13F0DC53A68018C_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_38032CC43AA63BADCE2E0DC53A68845F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_38032CC43AA63BADCE2E0DC53A68845F_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_CDF322034C7C62680BDB0DC53A69391C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_CDF322034C7C62680BDB0DC53A69391C_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_7D111E4A63C6EC39FB610DC53A695A0D_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_18CF09EE4B425E169724DE7BB33192B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_7D111E4A63C6EC39FB610DC53A695A0D_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_18CF09EE4B425E169724DE7BB33192B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_18CF09EE4B425E169724DE7BB33192B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_18CF09EE4B425E169724DE7BB33192B3" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_18CF09EE4B425E169724DE7BB33192B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_B0F5F73E766670EA560E0DC53A69D93B_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9EED639B76C25DBF942DEABFB8A37BA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_B0F5F73E766670EA560E0DC53A69D93B_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9EED639B76C25DBF942DEABFB8A37BA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9EED639B76C25DBF942DEABFB8A37BA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9EED639B76C25DBF942DEABFB8A37BA0" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9EED639B76C25DBF942DEABFB8A37BA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_128B46E1D4BC2FE33F0D0DC53A696281_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BD57344955C65D7CB5F86E3158733728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_128B46E1D4BC2FE33F0D0DC53A696281_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BD57344955C65D7CB5F86E3158733728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BD57344955C65D7CB5F86E3158733728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BD57344955C65D7CB5F86E3158733728" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BD57344955C65D7CB5F86E3158733728" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_44CA087D0D2836B703280DC53A6A6B60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_44CA087D0D2836B703280DC53A6A6B60_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_2891F099928AD8F164F60DC53A6A6684_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_AF8094E95F755702B97D5D4CCAED4459" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_2891F099928AD8F164F60DC53A6A6684_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_AF8094E95F755702B97D5D4CCAED4459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_AF8094E95F755702B97D5D4CCAED4459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_AF8094E95F755702B97D5D4CCAED4459" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_AF8094E95F755702B97D5D4CCAED4459" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2FC24EE918BD3100DE5B0DC53A998CF3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ED4545A936AB57F2B2157AAB682F2D13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2FC24EE918BD3100DE5B0DC53A998CF3_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ED4545A936AB57F2B2157AAB682F2D13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ED4545A936AB57F2B2157AAB682F2D13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ED4545A936AB57F2B2157AAB682F2D13" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ED4545A936AB57F2B2157AAB682F2D13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_47D4D66E6AE93536B1ED0DC53AA47C53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7A2D59AC2C085E75A0504AE45EEA27E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_47D4D66E6AE93536B1ED0DC53AA47C53_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7A2D59AC2C085E75A0504AE45EEA27E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7A2D59AC2C085E75A0504AE45EEA27E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7A2D59AC2C085E75A0504AE45EEA27E1" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7A2D59AC2C085E75A0504AE45EEA27E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 Months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12 Months or Greater, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">12 Months or Greater, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>anab-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables" xlink:href="anab-20200331.xsd#BalanceSheetAccountsAndSupplementalDisclosuresTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements" xlink:href="anab-20200331.xsd#CollaborativeResearchAndDevelopmentAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails" xlink:href="anab-20200331.xsd#CollaborativeResearchAndDevelopmentAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables" xlink:href="anab-20200331.xsd#CollaborativeResearchAndDevelopmentAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingencies" xlink:href="anab-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables" xlink:href="anab-20200331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:href="anab-20200331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="anab-20200331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="anab-20200331.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="anab-20200331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="anab-20200331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="anab-20200331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/CoverPage" xlink:href="anab-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/DescriptionOfBusiness" xlink:href="anab-20200331.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:href="anab-20200331.xsd#EquityIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:href="anab-20200331.xsd#EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:href="anab-20200331.xsd#EquityIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables" xlink:href="anab-20200331.xsd#FairValueMeasurementsAndAvailableForSaleInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayable" xlink:href="anab-20200331.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:href="anab-20200331.xsd#NotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquity" xlink:href="anab-20200331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:href="anab-20200331.xsd#StockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="anab-20200331.xsd#StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:href="anab-20200331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:href="anab-20200331.xsd#SubsequentEventDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SubsequentEventNotes" xlink:href="anab-20200331.xsd#SubsequentEventNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="anab-20200331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D8191FE9F15A560693E0E9567B6C42AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28E6343C448652279B723347C4FDD18C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_D8191FE9F15A560693E0E9567B6C42AF" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_28E6343C448652279B723347C4FDD18C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2708B5017B8DB64A4F1275D9F215C624" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_E734827B5F7361E2333D75D9F216DC10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2708B5017B8DB64A4F1275D9F215C624" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_E734827B5F7361E2333D75D9F216DC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_F469332748FF6C94A2CD75D9F2161B46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2708B5017B8DB64A4F1275D9F215C624" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_F469332748FF6C94A2CD75D9F2161B46" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2708B5017B8DB64A4F1275D9F215C624" xlink:to="loc_anab_AccruedResearchAndDevelopmentExpensesCurrent_AA90A9CB536627E7023575D9F2162CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51ABC9AFCDC127A74E8675D9F2161310" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2708B5017B8DB64A4F1275D9F215C624" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51ABC9AFCDC127A74E8675D9F2161310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4988A00CB370214029BD75D9F21702CD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2708B5017B8DB64A4F1275D9F215C624" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4988A00CB370214029BD75D9F21702CD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_44709726F0354C5E99B775D9F20C0A89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_44709726F0354C5E99B775D9F20C0A89" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_F4C2809834027917B5BF75D9F20DDAEC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LaboratoryEquipmentMember" xlink:label="loc_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:to="loc_anab_LaboratoryEquipmentMember_9D6CBED5526BE7125AD875D9F20E0147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:to="loc_us-gaap_OfficeEquipmentMember_3DD1B4E77F3404BD322175D9F20EAC7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_AD2425158A1DB7570F9375D9F20ECE7C" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_F64328877EEFE043729875D9F20EED49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A2D00012A1688FFEFFE675D9F20DE4EE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_26F0E89AFAC404B2ED8575D9F20F17F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_089AC44AC397E36EE81F75D9F20F66DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AB93E6260078C47D6F7975D9F20FB4FF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_005EE94A24014530FA0075D9F20FAE21" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_40FD929ABE925A6DAC8F07E1C8415777" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C5CCC368777B57C98456C67FC4095B27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_40FD929ABE925A6DAC8F07E1C8415777" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C5CCC368777B57C98456C67FC4095B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5605FD5EB1BE5333982C776BBA585B53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_40FD929ABE925A6DAC8F07E1C8415777" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5605FD5EB1BE5333982C776BBA585B53" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_A9B0CFE9DC8B5505A625A32C81CB92FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_D5B72AF07B2F574E88A64D58D2F9E7C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_A9B0CFE9DC8B5505A625A32C81CB92FA" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_D5B72AF07B2F574E88A64D58D2F9E7C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_32D9D98B01AE73138E04A4DD4E32DAB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_32D9D98B01AE73138E04A4DD4E32DAB7" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:to="loc_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_F41AB3618A8AA7BB2CF2A4DD4E335AEB" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_TESAROInc.AndTESARODevelopmentInc.Member" xlink:label="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:to="loc_anab_TESAROInc.AndTESARODevelopmentInc.Member_A2795A5FB830A80961E6A4DD4E336E65" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CelgeneCorporationMember" xlink:label="loc_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4D9DB6BBC17FE61C0E65A4DD4E336ACB" xlink:to="loc_anab_CelgeneCorporationMember_41B7322BE70182C8481AA4DD4E34AD80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F92B1BFDCA7687C1FA01A4DD4E342F00" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4408C1BF0A1E757D7D2EA4DD4E34DFC3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_InVivoToxicologyStudiesMember" xlink:label="loc_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_InVivoToxicologyStudiesMember_639321BA0979898318FAA4DD4E35A7D5" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_ClearanceOfInvestigationalNewDrugFromFDAMember" xlink:label="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_ClearanceOfInvestigationalNewDrugFromFDAMember_F0C3A78C666D0A59F244A4DD4E35E99A" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase2ClinicalTrialInitiationMember" xlink:label="loc_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_Phase2ClinicalTrialInitiationMember_4D53E5D6ED1B28490B37A4DD4E35062E" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase3ClinicalTrialInitiationMember" xlink:label="loc_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_Phase3ClinicalTrialInitiationMember_695501E88561711B10B0A4DD4E3517F6" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase3clinicaltrialinitiationsecondindicationDomain" xlink:label="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_Phase3clinicaltrialinitiationsecondindicationDomain_C074CD5137E5DB109CC9A4DD4E366CAC" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_FilingofNDAMember" xlink:label="loc_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_FilingofNDAMember_659C8615B5F158EA1C39A4DD4E365221" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_FilingofMMAMember" xlink:label="loc_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_FilingofMMAMember_1B41DBEEDF8BD8384659A4E38E509B7C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_Phase1ClinicalTrialInitiationMember" xlink:label="loc_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_998BE9948AE349F8C918A4DD4E34BA81" xlink:to="loc_anab_Phase1ClinicalTrialInitiationMember_EE37124C607E6BF66E09A4DD4E365ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:to="loc_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_A7C22771D8DF4DA7B707A4DD4E36F2CE" xlink:to="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member" xlink:label="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:to="loc_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_C1582339B6DB3BE404FAA4DD4E360C95" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member" xlink:label="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:to="loc_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_138CCA982B6AE87F5987A4DD4E378226" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member" xlink:label="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:to="loc_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_12529C4E35B91874BAC2A4DD4E37EFCC" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member" xlink:label="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F6E36A8DBB232FFD2FE7A4DD4E36890A" xlink:to="loc_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_70C22A4A6E6FAC691131A4DD4E373C40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1860EDBE7AE101AE7EC1A4DD4E3216A0" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived" xlink:label="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived_33CB01DAF4F3BA0B04EDA4DD4E38C8E3" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets_164DD9C87F3FBE119E09A4DD4E38D23B" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents_08A3188684F90C84648DA4DD4E38B9A0" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals_680653CC8DEA22B3CDE2A4DD4E38F44B" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales_CA655CFF2E9937872435A4DD4E38F5C5" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent_D6E56FF756E57EBE1B2AA4DD4E388EEA" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod_5C71301280D093358EEEA4DD4E394C4F" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount_6F17C0D6C6E6C3FCDEE7A4DD4E39B1BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E09A1874F9B5415899DDA4DD4E39BA78" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone" xlink:label="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone_3605E686092D768C0CCBA4DD4E393298" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned" xlink:label="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_90B210D2296556ABBEADA4DD4E3793D2" xlink:to="loc_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned_83925485BA4EBF221D1EA4DD4E396C54" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_7AC37CD93A225707967F40FD613DB739" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7A2D59AC2C085E75A0504AE45EEA27E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_7AC37CD93A225707967F40FD613DB739" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7A2D59AC2C085E75A0504AE45EEA27E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_40F7EC65C0245AC48AAA5371A069761B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ED4545A936AB57F2B2157AAB682F2D13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_40F7EC65C0245AC48AAA5371A069761B" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ED4545A936AB57F2B2157AAB682F2D13" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FD397C8292B85527B9E50404CC3920A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FD397C8292B85527B9E50404CC3920A0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LeaseArrangementAxis" xlink:label="loc_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:to="loc_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LeaseArrangementDomain" xlink:label="loc_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anab_LeaseArrangementAxis_6FD945F3DA79572691725C2AFED8B54B" xlink:to="loc_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_OneOfficeLeaseMember" xlink:label="loc_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anab_LeaseArrangementDomain_03508166B0AC512ABCF1B4E36C0B5EC2" xlink:to="loc_anab_OneOfficeLeaseMember_A24AB069DC185C31A96CB9A32F09FDE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25611A536FCA5C6CAC29C94FB135C8A8" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LesseeOperatingLeaseNumber" xlink:label="loc_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="loc_anab_LesseeOperatingLeaseNumber_0A40D46A095F512D991AA39AE6943564" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_569DBB6BC03453069ADF59D3B66260A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_569DBB6BC03453069ADF59D3B66260A2" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber" xlink:label="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="loc_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber_957C20C75C0D5A6081BFA5D61A82FB77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_926A6E65991151ACA45A08AE99A0816F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_1D7B0E45FD5556B1A6F2EAE8154DB3D8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_926A6E65991151ACA45A08AE99A0816F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4944CC2342CB9F97CEF676115376DFC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_280AE9BDF69566DC50BF76115376BCD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4944CC2342CB9F97CEF676115376DFC4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_280AE9BDF69566DC50BF76115376BCD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6EEA485D9E8E0093D556761153766C01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4944CC2342CB9F97CEF676115376DFC4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6EEA485D9E8E0093D556761153766C01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5BEA8120177DCFC01D17761153768CA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4944CC2342CB9F97CEF676115376DFC4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5BEA8120177DCFC01D17761153768CA9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00C784C6394A51633119761153738053" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_189111E97C0B44F0C4D1761153734184" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00C784C6394A51633119761153738053" xlink:to="loc_us-gaap_OperatingLeaseCost_189111E97C0B44F0C4D1761153734184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_0E7B8B75F91FF71AF9D576115374167F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00C784C6394A51633119761153738053" xlink:to="loc_us-gaap_OperatingLeasePayments_0E7B8B75F91FF71AF9D576115374167F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8E1288DAE8957EB074B97611536F2DAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8E1288DAE8957EB074B97611536F2DAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9D4B00E53C074576A9B87611536F7217" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9D4B00E53C074576A9B87611536F7217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_961178E2564EBA2AF1737611536FECB0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_961178E2564EBA2AF1737611536FECB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_AA799815F53AB50259A776115370675D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_AA799815F53AB50259A776115370675D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_17CCD001837242F1AAEF76115370EF78" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_17CCD001837242F1AAEF76115370EF78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8BCE72741A335DC32E4E7611537064CD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8BCE72741A335DC32E4E7611537064CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42C5B0356A59C84F452A76115370E7BB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42C5B0356A59C84F452A76115370E7BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D4F19F250DF375879F5576115370C47B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D4F19F250DF375879F5576115370C47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_692A495257B032478F657611537034D3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_EA2C488B90461E10AE367611536F2DBA" xlink:to="loc_us-gaap_OperatingLeaseLiability_692A495257B032478F657611537034D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A9775E4A6F31B2E81F77611537EF297" xlink:type="locator" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A9775E4A6F31B2E81F77611537EF297" xlink:to="loc_anab_AssetsAndLiabilitiesLesseeTableTextBlock_4E9696AAB8645A3C5D247611537FDFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ECCF7AE11AD2D5B34D357611537FB74F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A9775E4A6F31B2E81F77611537EF297" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ECCF7AE11AD2D5B34D357611537FB74F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ACC4947E37763DCB9A287611537F5608" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8A9775E4A6F31B2E81F77611537EF297" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ACC4947E37763DCB9A287611537F5608" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2459456611F31BF484E4AE2AF21ADAB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2459456611F31BF484E4AE2AF21ADAB0" xlink:to="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:to="loc_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE88B2C4BB8E7C957FA4AE2AF21A3E65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_EE88B2C4BB8E7C957FA4AE2AF21A3E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_D3766620C0FD309F6CB0AE2AF21B8D0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:to="loc_us-gaap_ReceivablesNetCurrent_D3766620C0FD309F6CB0AE2AF21B8D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_C99545C81A8F68C72E77AE2AF21BF539" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_C99545C81A8F68C72E77AE2AF21BF539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00F4D707293A01A9019BAE2AF21B6EDF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00F4D707293A01A9019BAE2AF21B6EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B50FBCE6E3C358F7204FAE2AF21BA97C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10E5F74D6C17C2FC426AE2AF21AF544" xlink:to="loc_us-gaap_AssetsCurrent_B50FBCE6E3C358F7204FAE2AF21BA97C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_94EF3B330E315D2BE73CAE2AF21BA55E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_94EF3B330E315D2BE73CAE2AF21BA55E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FBEE9A2A30C960145A08AE2AF21B38B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_FBEE9A2A30C960145A08AE2AF21B38B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_05A8639CFE71FB0954EAAE2AF21C6A6D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_05A8639CFE71FB0954EAAE2AF21C6A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5CCA003C4C360244A2A6AE2AF21C5CBE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5CCA003C4C360244A2A6AE2AF21C5CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_77C2CBBFF7D5F701AC77AE2AF21C11C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D3BAB10BB0A903D38346AE2AF21A0502" xlink:to="loc_us-gaap_Assets_77C2CBBFF7D5F701AC77AE2AF21C11C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2459456611F31BF484E4AE2AF21ADAB0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_72DE346A166C3AEAB7D3AE2AF21C937F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:to="loc_us-gaap_AccountsPayableCurrent_72DE346A166C3AEAB7D3AE2AF21C937F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8C2676CD288F68C641EFAE2AF21DC155" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8C2676CD288F68C641EFAE2AF21DC155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_A5B0A39631F78FE4C8C6AE2AF21D4643" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:to="loc_us-gaap_NotesPayableCurrent_A5B0A39631F78FE4C8C6AE2AF21D4643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_73DB60DCC80ED3060FA2AE2AF21DDE50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_73DB60DCC80ED3060FA2AE2AF21DDE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_72ADEDF88D8F97D276F9AE2AF21D2114" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9CAC886949242A859B59AE2AF21CAF79" xlink:to="loc_us-gaap_LiabilitiesCurrent_72ADEDF88D8F97D276F9AE2AF21D2114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_FF340843DAC45373B0F0AE2AF21D8C4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_FF340843DAC45373B0F0AE2AF21D8C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4CEE2A4CB2DFB3741254AE2AF21E003D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:to="loc_us-gaap_PreferredStockValue_4CEE2A4CB2DFB3741254AE2AF21E003D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_AFC5D717B470B7C24795AE2AF21E3802" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:to="loc_us-gaap_CommonStockValue_AFC5D717B470B7C24795AE2AF21E3802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_A1652B513C7D9C6FA34DAE2AF21EEAAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:to="loc_us-gaap_AdditionalPaidInCapital_A1652B513C7D9C6FA34DAE2AF21EEAAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E75FFAE3CC9DA93D9DDEAE2AF21E216A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E75FFAE3CC9DA93D9DDEAE2AF21E216A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5740D97D85C4D5692774AE2AF21E554A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5740D97D85C4D5692774AE2AF21E554A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_143DA27115AE25CECEE3AE2AF21F7543" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8DE98CCBA207E7BDC8BBAE2AF21E4C14" xlink:to="loc_us-gaap_StockholdersEquity_143DA27115AE25CECEE3AE2AF21F7543" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_AAD7F82BE417C92739AEAE2AF21F629E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45F76720C66DACE77EEBAE2AF21CC809" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_AAD7F82BE417C92739AEAE2AF21F629E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E6343A4E5F1C5EFFB430B5987EEE81E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6DDF3E5974375962B7E752F821E2C6F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E6343A4E5F1C5EFFB430B5987EEE81E2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6DDF3E5974375962B7E752F821E2C6F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_F0CA365CC61F548D9CD103508B2C8072" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E6343A4E5F1C5EFFB430B5987EEE81E2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_F0CA365CC61F548D9CD103508B2C8072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1F8F1EE9D26F59CFB8F8A1DA4CCA05CB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E6343A4E5F1C5EFFB430B5987EEE81E2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1F8F1EE9D26F59CFB8F8A1DA4CCA05CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_B7E5805A700A5B9596516555DB63F2C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E6343A4E5F1C5EFFB430B5987EEE81E2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_B7E5805A700A5B9596516555DB63F2C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_28D22AF49A8057CD9E696C652A60CFA3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E6343A4E5F1C5EFFB430B5987EEE81E2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_28D22AF49A8057CD9E696C652A60CFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E378FACB87185DC88FA989C1EF711B31" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E6343A4E5F1C5EFFB430B5987EEE81E2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_E378FACB87185DC88FA989C1EF711B31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_721293239D3D577E9A23A3A05E8AF968" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E6343A4E5F1C5EFFB430B5987EEE81E2" xlink:to="loc_us-gaap_CommonStockSharesIssued_721293239D3D577E9A23A3A05E8AF968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_DEFE44F1FA4E50C3B8AF6DB87790502E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E6343A4E5F1C5EFFB430B5987EEE81E2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_DEFE44F1FA4E50C3B8AF6DB87790502E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2BDB8E642277AD1011AAD202D34055F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2BDB8E642277AD1011AAD202D34055F3" xlink:to="loc_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A58DFEEFFE63A71FBA6AD202D344B152" xlink:to="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:to="loc_us-gaap_CommonStockMember_9FC0B38C249F5467D7A1D202D3445599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1BF510D3F1C24FA8CB35D202D3478109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A0A48671BA558C462CE0D202D347F967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54C1EA1577FEA210E522D202D344BD06" xlink:to="loc_us-gaap_RetainedEarningsMember_1566E82A2946E5684354D202D347CC75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BD57783CD9E103268045D202D3431957" xlink:to="loc_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5B17BC22F4C0BE5924FAD202D347BB4F" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A28866463CD49B823325D202D34898A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_StockholdersEquity_A28866463CD49B823325D202D34898A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_SharesOutstanding_AF877276D419ED48318AD202D3489CE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2391DD821E8FD3B04A9DD202D348D346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85B7D13FB5D15CC5FE80D202D3485174" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_85B7D13FB5D15CC5FE80D202D3485174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_C7C5AF73128F7FAD9253D202D3491497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6668B12CE3DCB95536D3D202D349416D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0FBB94F0D39D246B1DE4D202D349561E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_NetIncomeLoss_0FBB94F0D39D246B1DE4D202D349561E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_173BA374CFD7CBB09102D202D349EB28" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_StockholdersEquity_173BA374CFD7CBB09102D202D349EB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_380708E3410C6DC49EE0D202D3496BA4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8F898E44701C0EEBD21AD202D348E758" xlink:to="loc_us-gaap_SharesOutstanding_380708E3410C6DC49EE0D202D3496BA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_906470682A2E9C8477CFA4DD4E72F13A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:to="loc_us-gaap_NetIncomeLoss_906470682A2E9C8477CFA4DD4E72F13A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_90F714BD437A45959A69A4DD4E72559D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_90F714BD437A45959A69A4DD4E72559D" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_DF6E76E56228A3ADE44AA4DD4E7276B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_DF6E76E56228A3ADE44AA4DD4E7276B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_81C7A1178E9125A1B188A4DD4E73EF56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_81C7A1178E9125A1B188A4DD4E73EF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_96525F11FC78A62AD3B7A4DD4E73C0F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_96525F11FC78A62AD3B7A4DD4E73C0F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6FC167D05DAE75FF565BA4DD4E72F2B4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_E9F0DE6AB8D2913604BFA4DD4E7302BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_E9F0DE6AB8D2913604BFA4DD4E7302BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C83DF2B8F4EAA58773FBA4DD4E73AD50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C83DF2B8F4EAA58773FBA4DD4E73AD50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_DC7DC0F1AA8558440D02A4DD4E74803E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60317BBD659E78419265A4DD4E7325EF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_DC7DC0F1AA8558440D02A4DD4E74803E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7D2EF53EEE37F9319A76A4DD4E7402A3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0B76566038D243867E33A4DD4E71D437" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7D2EF53EEE37F9319A76A4DD4E7402A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_F99E22004B1D77B83CBFA4DD4E74E48C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_F99E22004B1D77B83CBFA4DD4E74E48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EE9FB5E30B83BFD6BCF1A4DD4E74DDE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_EE9FB5E30B83BFD6BCF1A4DD4E74DDE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91B56F93599BF75DD887A4DD4E75C1CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91B56F93599BF75DD887A4DD4E75C1CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6168B5821B4F087905C5A4DD4E755049" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_51462907E2BD641981CCA4DD4E742EF0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6168B5821B4F087905C5A4DD4E755049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ED899B9E0FF9E67D276CA4DD4E75382D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ED899B9E0FF9E67D276CA4DD4E75382D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_E39BF05AA0CEA642A363A4DD4E765A48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_E39BF05AA0CEA642A363A4DD4E765A48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B7C2179D18CEDCB81D3BA4DD4E76BDA0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_A7B0750107D41790DC2AA4DD4E7578C8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_B7C2179D18CEDCB81D3BA4DD4E76BDA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_B9F3ABA56F6CC304EAEAA4DD4E7609AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_B9F3ABA56F6CC304EAEAA4DD4E7609AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678AF9D7342BF9F30704A4DD4E76A4DE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678AF9D7342BF9F30704A4DD4E76A4DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C1E78D4204A59BC48CCDA4DD4E763C69" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_C1E78D4204A59BC48CCDA4DD4E763C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_578912E10034CED06554A4DD4E717412" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_8F1C2EB5D0D4AE7459E4A4DD4E764998" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C" xlink:to="loc_us-gaap_InterestPaidNet_8F1C2EB5D0D4AE7459E4A4DD4E764998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_D689DF0318DF19C15C92A4DD4E765D1C" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A02E84887F6259408CFFA4DD4E77FFA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26631761FEE3818B0AA2A4DD4E773A2F" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A02E84887F6259408CFFA4DD4E77FFA2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1F09E4813335C72D69B1AE2AF1F68953" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1F09E4813335C72D69B1AE2AF1F68953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_133C678F2B562ECB9489AE2AF1F7DBBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_133C678F2B562ECB9489AE2AF1F7DBBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9F3D5B62C6DEA6E0C451AE2AF1F78C75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9F3D5B62C6DEA6E0C451AE2AF1F78C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_ABB21483EFB27F03A238AE2AF1FCCE49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0C4A409B3A32D66595BAAE2AF1F75851" xlink:to="loc_us-gaap_OperatingExpenses_ABB21483EFB27F03A238AE2AF1FCCE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2F76FABCBAC8B903CF4AAE2AF1FC9919" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_OperatingIncomeLoss_2F76FABCBAC8B903CF4AAE2AF1FC9919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_DBAF50C65265A9B2838CAE2AF1FD0EE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:to="loc_us-gaap_InterestExpense_DBAF50C65265A9B2838CAE2AF1FD0EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_05D99DE6558D86DB83F7AE2AF1FDA6D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_05D99DE6558D86DB83F7AE2AF1FDA6D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_B2958C51C7F3678A0675AE2AF1FD9376" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_B2958C51C7F3678A0675AE2AF1FD9376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1C8B91BCDD9F1E3DE058AE2AF1FDCDCA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_942E2BD61B066878D5BFAE2AF1FDBBBD" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1C8B91BCDD9F1E3DE058AE2AF1FDCDCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E6500F3D59C712AB4759AE2AF1FEE561" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E6500F3D59C712AB4759AE2AF1FEE561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3F93E5F8B3C13569C6DEAE2AF1FEA6CD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3F93E5F8B3C13569C6DEAE2AF1FEA6CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FD1AC61FFB39AC7126C9AE2AF1FE12F2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_NetIncomeLoss_FD1AC61FFB39AC7126C9AE2AF1FE12F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93A1398BD2555FDF620AAE2AF1FE3A0D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93A1398BD2555FDF620AAE2AF1FE3A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_EBF1B8A7D1DFD7A28AB2AE2AF1FEDE4E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_EBF1B8A7D1DFD7A28AB2AE2AF1FEDE4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_FF363F9245B1835D15D3AE2AF1FF3849" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1949F93606B851BE47D0AE2AF1FE61BC" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_FF363F9245B1835D15D3AE2AF1FF3849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_088D391C9B31E7E9091FAE2AF1F63D04" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9EC23A5B7A1965F754CBAE2AF1FFD674" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_58FE8C9AAC3B508EF6ECAE2AF1FF9CF1" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9EC23A5B7A1965F754CBAE2AF1FFD674" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_F2E0C5483D2E522BB81B259AF544D0CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1E78C7EFE15455968C9E68173C44F4E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_F2E0C5483D2E522BB81B259AF544D0CA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1E78C7EFE15455968C9E68173C44F4E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_34B03E2AC19A353C8304746F8CFD8CE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_DocumentType_34B03E2AC19A353C8304746F8CFD8CE6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_9B149D4A7F53C787474D746F8CFD743E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_DocumentQuarterlyReport_9B149D4A7F53C787474D746F8CFD743E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_A983FB638E3BF294DE37746F8CFD604D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_DocumentPeriodEndDate_A983FB638E3BF294DE37746F8CFD604D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_EFA2B32ACCAEFA0EDCB3746F8CFE8416" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_DocumentTransitionReport_EFA2B32ACCAEFA0EDCB3746F8CFE8416" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_5689FA7E86A430186D0A746F8CFE16EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityFileNumber_5689FA7E86A430186D0A746F8CFE16EC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_9E4F4B9892C1E44FB0A5746F8CFEDCB5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityRegistrantName_9E4F4B9892C1E44FB0A5746F8CFEDCB5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8C99413D29837214D6F1746F8CFEBB55" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8C99413D29837214D6F1746F8CFEBB55" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_2222938AA99A488225D2746F8CFE7E05" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityTaxIdentificationNumber_2222938AA99A488225D2746F8CFE7E05" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_333A8B1972C7D93C7331746F8CFE2518" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityAddressAddressLine1_333A8B1972C7D93C7331746F8CFE2518" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_1C233DB5CA691D3F4B63746F8CFF94D0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityAddressAddressLine2_1C233DB5CA691D3F4B63746F8CFF94D0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_FFF6D742175CC1CCF036746F8CFFEF14" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityAddressCityOrTown_FFF6D742175CC1CCF036746F8CFFEF14" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_7D759CF2A434CB28C138746F8CFFEA1C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityAddressStateOrProvince_7D759CF2A434CB28C138746F8CFFEA1C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_05B5BB4BF17398BEE890746F8CFF2695" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityAddressPostalZipCode_05B5BB4BF17398BEE890746F8CFF2695" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_5028A5239CBB61E8F868746F8CFFC554" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_CityAreaCode_5028A5239CBB61E8F868746F8CFFC554" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_5CFBE136C5DCCF86F49C746F8CFFD82E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_LocalPhoneNumber_5CFBE136C5DCCF86F49C746F8CFFD82E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_0D9B14EB21D3C227970C746F8D00E5F0" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_Security12bTitle_0D9B14EB21D3C227970C746F8D00E5F0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_772F06655D9E5587BDB1746F8D002A8E" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_TradingSymbol_772F06655D9E5587BDB1746F8D002A8E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_11CD6558984894CF9E4F746F8D006ADE" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_SecurityExchangeName_11CD6558984894CF9E4F746F8D006ADE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C0BFE007766ED8D85D17746F8D00206F" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityCurrentReportingStatus_C0BFE007766ED8D85D17746F8D00206F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_4A9A4A72345B11DB680C746F8D00DE76" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityInteractiveDataCurrent_4A9A4A72345B11DB680C746F8D00DE76" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_4C69D47BF330345E7979746F8D00AE85" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityFilerCategory_4C69D47BF330345E7979746F8D00AE85" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_15D846EE9612895E70BD746F8D01208A" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntitySmallBusiness_15D846EE9612895E70BD746F8D01208A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_B5A89CC9D75A2413F0ED746F8D019633" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityEmergingGrowthCompany_B5A89CC9D75A2413F0ED746F8D019633" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_20982FAB48C308500564746F8D01A7A7" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityShellCompany_20982FAB48C308500564746F8D01A7A7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E5092A117B6E9D77E27C746F8D0142FD" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_E5092A117B6E9D77E27C746F8D0142FD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_234ACF9FA16B68B1E2BC746F8D0187CF" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_EntityCentralIndexKey_234ACF9FA16B68B1E2BC746F8D0187CF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4658EEF02F51CF82CDE5746F8D015B53" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_CurrentFiscalYearEndDate_4658EEF02F51CF82CDE5746F8D015B53" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_E928C134B74B4E84C9C6746F8D013C03" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_DocumentFiscalYearFocus_E928C134B74B4E84C9C6746F8D013C03" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_C4E99CAFCCB36C444FFD746F8D0218C8" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_C4E99CAFCCB36C444FFD746F8D0218C8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_17D1DD11F54F23135F8C746F8D028ECB" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D793DBF099B1E56C4DA5746F8CFA61D5" xlink:to="loc_dei_AmendmentFlag_17D1DD11F54F23135F8C746F8D028ECB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5D58084116B254FBBE698C5213A92109" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_CF03A7715F0D54319466D2B835DBAA98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5D58084116B254FBBE698C5213A92109" xlink:to="loc_us-gaap_NatureOfOperations_CF03A7715F0D54319466D2B835DBAA98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2CEEE5015D5C5E798A8FE860391E885A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_AF3F10CEE1CE56D193BAF49A5542C7A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2CEEE5015D5C5E798A8FE860391E885A" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_AF3F10CEE1CE56D193BAF49A5542C7A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5AA663AE32E581A8F145AC680C4A25A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F0E3DC9EFA6A5594A2BABD4022AE53BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5AA663AE32E581A8F145AC680C4A25A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F0E3DC9EFA6A5594A2BABD4022AE53BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F0E3DC9EFA6A5594A2BABD4022AE53BF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C3851CDE948A5362AE239D45FE667192" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9F914DF993DC54AF91803170767EE2EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9F914DF993DC54AF91803170767EE2EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99DFD6CCC1F555CD9E4515FB2FB71F9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_D999B1FC557955BF86EA3F0574000170" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99DFD6CCC1F555CD9E4515FB2FB71F9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3505C6A863FB5C538DBE2ADB82BA8507" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F0E3DC9EFA6A5594A2BABD4022AE53BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3505C6A863FB5C538DBE2ADB82BA8507" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3505C6A863FB5C538DBE2ADB82BA8507" xlink:to="loc_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims_30B087E4A22351488F7A945B617D9636" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D0EEC23EB8125166A966E6917784E5F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D0EEC23EB8125166A966E6917784E5F7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_7F860995188C5D98AF98B6901A948BD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:to="loc_us-gaap_PlanNameAxis_7F860995188C5D98AF98B6901A948BD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_59AE08D183985E728D11C8B9FEC79463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7F860995188C5D98AF98B6901A948BD8" xlink:to="loc_us-gaap_PlanNameDomain_59AE08D183985E728D11C8B9FEC79463" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EquityIncentivePlan2017Member" xlink:label="loc_anab_EquityIncentivePlan2017Member_B6B8FC3AE6E350FAB2319453FE790FC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_59AE08D183985E728D11C8B9FEC79463" xlink:to="loc_anab_EquityIncentivePlan2017Member_B6B8FC3AE6E350FAB2319453FE790FC1" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeStockPurchasePlan2017Member" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_D7D39216091C5C19AF4DA7DC384CD1E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_59AE08D183985E728D11C8B9FEC79463" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_D7D39216091C5C19AF4DA7DC384CD1E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:to="loc_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6B3E96E8DD48527982C480718D2AA896" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_58F9B1D5FAB2504F8DC3B005997CBA7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:to="loc_us-gaap_EmployeeStockMember_58F9B1D5FAB2504F8DC3B005997CBA7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3C0AD9F6F03455CBA8BC592E1BCE7537" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3C0AD9F6F03455CBA8BC592E1BCE7537" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeAndNonemployeeStockOptionsMember" xlink:label="loc_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ED8D458E7E513FA453C6D09B00BBA9" xlink:to="loc_anab_EmployeeAndNonemployeeStockOptionsMember_C28924EEAB15553F94070A04FBD375AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:to="loc_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_3F08FD71027F576B9A5F34BC0BB37942" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_8EB8B137701B558CBB94A51B6B5D8681" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_92AD6C3820BE522CA5E224B826179DA5" xlink:to="loc_srt_DirectorMember_8EB8B137701B558CBB94A51B6B5D8681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7C0FB09FDAF05533B2C39DB4F98C945D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding_8B90860C708958EDA54E8E17E266823D" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease" xlink:label="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease_C209022C5BB05CCE945FAD218E1BA711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F0A0937ACD995483952BBA51D6C26A15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F0A0937ACD995483952BBA51D6C26A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84CDDF17EFE7599693323B44E78E296A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_84CDDF17EFE7599693323B44E78E296A" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions_B971CA2E2D3850D7A6C7223F39DCD1C5" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition" xlink:label="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35B2F015476D545BB5F39412A6548800" xlink:to="loc_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition_0FDF4A2016A2586FA558E39CCEAF53A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_170FD82AA5DB54099B9442CBE177BABA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_170FD82AA5DB54099B9442CBE177BABA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71E8E81C675E5DD1B75BEB9B0DC51D43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71E8E81C675E5DD1B75BEB9B0DC51D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC9D0B5A37C15181AA5165B41B27F737" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_EC9D0B5A37C15181AA5165B41B27F737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61D0760B6B90581B856735FD77C0918B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61D0760B6B90581B856735FD77C0918B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3F5097BE84FF5B1E897B6F0158D05950" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3F5097BE84FF5B1E897B6F0158D05950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0B5B2CB8BF97548B9559658576F72648" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B46A60ADDC3C5DC68D08EF3FDE0F4E2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0B5B2CB8BF97548B9559658576F72648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_97040EA457C35FB3A2BED139CE1BE529" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_170FD82AA5DB54099B9442CBE177BABA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_97040EA457C35FB3A2BED139CE1BE529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_170FD82AA5DB54099B9442CBE177BABA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E440E7822CD056AD9DD3A23B256E457E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E440E7822CD056AD9DD3A23B256E457E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6CD399F87DFB599B9FE70CCBD808114D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6CD399F87DFB599B9FE70CCBD808114D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_35FD571EB5CF5C2391547DD299011E7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_35FD571EB5CF5C2391547DD299011E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1750AE5FB72A5AA3B8936A539221C0F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1750AE5FB72A5AA3B8936A539221C0F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C7FF5BACCD015A54AAC865157DB0018C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_988EA0086C9D5CD6B05059522F4DC0EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C7FF5BACCD015A54AAC865157DB0018C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_25143B99B8545C2EA8F957358424C033" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_170FD82AA5DB54099B9442CBE177BABA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_25143B99B8545C2EA8F957358424C033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_170FD82AA5DB54099B9442CBE177BABA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4A05206F765856DF872D909F378A4E68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4A05206F765856DF872D909F378A4E68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4E99469ACD455A46943DE76F0ABBB4A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4E99469ACD455A46943DE76F0ABBB4A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CE4FEC519AB357FEB7E3694C132CE2ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CE4FEC519AB357FEB7E3694C132CE2ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5CA451EC36AD5201B3BBA648229B8A0F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_EF7A1FA26FF4553798EB532F128DDC83" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5CA451EC36AD5201B3BBA648229B8A0F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EBB7E4C5AA3255C8A1C2F4CCF407F4E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B99477DB51065A34B6D78821C7F102AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EBB7E4C5AA3255C8A1C2F4CCF407F4E8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B99477DB51065A34B6D78821C7F102AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7C73928A7BE85D14A9AB7AF9B6EC1718" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B99477DB51065A34B6D78821C7F102AC" xlink:to="loc_us-gaap_AwardTypeAxis_7C73928A7BE85D14A9AB7AF9B6EC1718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E24BC8FD24075D9D865FF850EC3B85F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7C73928A7BE85D14A9AB7AF9B6EC1718" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E24BC8FD24075D9D865FF850EC3B85F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E2883F560B5F59AC8673E23C148E52FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E24BC8FD24075D9D865FF850EC3B85F6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_E2883F560B5F59AC8673E23C148E52FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B99477DB51065A34B6D78821C7F102AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B52E3CD3EF5A5059AD457E34B582F865" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B52E3CD3EF5A5059AD457E34B582F865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0606648C72995CAEA5EF890C6B26CA63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0606648C72995CAEA5EF890C6B26CA63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C5298A7DCD24592886A49AD26629B4FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C5298A7DCD24592886A49AD26629B4FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_083C64CA342052E3B7883B2A33F16E66" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_083C64CA342052E3B7883B2A33F16E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43AE629650805E1EBCF009A61DA7D4EF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_773A74807A5F53B7B5DB89F64BBA2554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43AE629650805E1EBCF009A61DA7D4EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4F26FF8CF465D97ACFD5DB60A823B61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D70200250F68521185AD4322151AC33C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4F26FF8CF465D97ACFD5DB60A823B61" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_D70200250F68521185AD4322151AC33C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9C75A9C976E65D65A822E744A8DF295A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4F26FF8CF465D97ACFD5DB60A823B61" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9C75A9C976E65D65A822E744A8DF295A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74E7D57A49825D308A17278406076B62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B4F26FF8CF465D97ACFD5DB60A823B61" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74E7D57A49825D308A17278406076B62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5B607494F3425AD7BC257CADD4C9437C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_661A598999AA554BAAB65CA1AFC21474" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5B607494F3425AD7BC257CADD4C9437C" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_661A598999AA554BAAB65CA1AFC21474" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0B70719B7CF2599A8613B6982776464C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0B70719B7CF2599A8613B6982776464C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8043E5C7E1605FE69CC7033B22469148" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9F99680282FB5BF28EAAA8FF97830B69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_199239AAAD1C5D32A6AD3E9C6452A348" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9F99680282FB5BF28EAAA8FF97830B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8088B54DF30452B6B38BA7B85A329D4B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4DA510BEC7875837B6103415EE636E20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4DA510BEC7875837B6103415EE636E20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E02223F994325D13B8EA50EADEE036AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E02223F994325D13B8EA50EADEE036AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_230D999015985B5CA95EF4F1A655D983" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1299E7C89C2857D388446E89E0AA0218" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_230D999015985B5CA95EF4F1A655D983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3D98C5A74DF55025A0E161A69A3BA2BE" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B06BCEA24852566CA8D74C9BCA15045F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B06BCEA24852566CA8D74C9BCA15045F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaap_MutualFundMember_681C2A33CF7257CF8BFC56BB77112405" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9712D17471655365A980EFFB324C094F" xlink:to="loc_us-gaap_MutualFundMember_681C2A33CF7257CF8BFC56BB77112405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_FC9FD4D986C95FCD9A7D4C7BAE7514C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_FC9FD4D986C95FCD9A7D4C7BAE7514C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_FC9FD4D986C95FCD9A7D4C7BAE7514C2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_DA558772A7DD516EA07E7BC395332930" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_DA558772A7DD516EA07E7BC395332930" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5B3C2ABB5062548287DAD45308D530D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5B3C2ABB5062548287DAD45308D530D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_239EF3C3372B52BE8B94FD2D7BDA7365" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_239EF3C3372B52BE8B94FD2D7BDA7365" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommercialAndCorporateObligationsMember" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_FD7547A1DBD457DAA9C701CA78D9E26E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17E82962167A54DA86DE11942F26D8A5" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_FD7547A1DBD457DAA9C701CA78D9E26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BF1A9187413C5BAC852EFD03C43508B6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure" xlink:label="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:to="loc_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure_9351319209E35673ADD3755BD0F952E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E19DE95702945D9BB564035351263C97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3776C584973756A88D1DAD5C9C435558" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E19DE95702945D9BB564035351263C97" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3150253D79145E7990C60DA049D640DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3150253D79145E7990C60DA049D640DA" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32C4FDBD9D2D51C2B7DFE7485C8D1C91" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_892A40709EFC5BAEAFC1548ACD487F26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_892A40709EFC5BAEAFC1548ACD487F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_42DDDDBD603B5BBF9443D70FA8A91B42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:to="loc_us-gaap_CertificatesOfDepositMember_42DDDDBD603B5BBF9443D70FA8A91B42" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommercialAndCorporateObligationsMember" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_9D779B354CB85CE0AC07DFC5B1364215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_F53AAC3598205D999B6DF74896189F81" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5175E697E54850DA8A9033773A581D87" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_F53AAC3598205D999B6DF74896189F81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:to="loc_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_08D73CA1BB495D04AC6958CB903BA5BD" xlink:to="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9310A4E57952575991B0BF5604D1599C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:to="loc_srt_MinimumMember_9310A4E57952575991B0BF5604D1599C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17787D7B1DF45A8AADA0CEE8E7CADAD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3D556F3B016E5349B7B74B3D98687DB3" xlink:to="loc_srt_MaximumMember_17787D7B1DF45A8AADA0CEE8E7CADAD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1F18F95A14A4585AA141302E24E1A3C7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4D69694F05EA5AA88E863295567AD6B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4D69694F05EA5AA88E863295567AD6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5CEAFB7256A75D0AB18878F1326E0A15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5CEAFB7256A75D0AB18878F1326E0A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0B217957D5275BB7878DACDEC5FD611A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0B217957D5275BB7878DACDEC5FD611A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40EA870E88DF5B37922F7190915C28D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40EA870E88DF5B37922F7190915C28D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0B78F3ADD40E5142994972BF9963585C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0B78F3ADD40E5142994972BF9963585C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_64CB7F94EA525DC7AA323ACF228D46E1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_64CB7F94EA525DC7AA323ACF228D46E1" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AvailableforsaleDebtSecuritiesRemainingMaturity" xlink:label="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E01AF3F437F95D82BFF2EE62B7C5AF41" xlink:to="loc_anab_AvailableforsaleDebtSecuritiesRemainingMaturity_E664AF936D5C5F19B46995D680F4984A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_77CA1A31DB575FB09FD459805ED55E65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_77CA1A31DB575FB09FD459805ED55E65" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_890318BD4B4B5F23AC83223A67A6D3BE" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_18CF09EE4B425E169724DE7BB33192B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_18CF09EE4B425E169724DE7BB33192B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9EED639B76C25DBF942DEABFB8A37BA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9EED639B76C25DBF942DEABFB8A37BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BD57344955C65D7CB5F86E3158733728" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A775F243C46C531A970273E5C089A1D5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BD57344955C65D7CB5F86E3158733728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_D03771B5F4775C4AA701026D6F46DD6E" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_AF8094E95F755702B97D5D4CCAED4459" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_DF3CB7C732705B189B413BFF5E414B23" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_AF8094E95F755702B97D5D4CCAED4459" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_34F76E115CCFE6CAFFE2E227C39CCE1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09998563C27E7AF40BBAE227C39D859D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_34F76E115CCFE6CAFFE2E227C39CCE1E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09998563C27E7AF40BBAE227C39D859D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_74D83E7E82269694F1FBE227C39DBDA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09998563C27E7AF40BBAE227C39D859D" xlink:to="loc_us-gaap_FinancialInstrumentAxis_74D83E7E82269694F1FBE227C39DBDA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_74D83E7E82269694F1FBE227C39DBDA5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0A4F0AC4ED13F98B935FE227C39E8E75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0A4F0AC4ED13F98B935FE227C39E8E75" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_CommercialAndCorporateObligationsMember" xlink:label="loc_anab_CommercialAndCorporateObligationsMember_8DD1E7E52B6064E99922E227C39E6BB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:to="loc_anab_CommercialAndCorporateObligationsMember_8DD1E7E52B6064E99922E227C39E6BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_180C9504289EEC002003E22945AF3E75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3D6D12BAD4AB9C7AD8ADE227C39D863B" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_180C9504289EEC002003E22945AF3E75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_09998563C27E7AF40BBAE227C39D859D" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2D72E6E87FADE6B0F9BFE227C39E53B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_58FD118C40313C6D09F0E227C39EDEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_B037F43A28AEAD874780E227C39F8DEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE124123A980559007E4E227C39F73FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_DD549978DF48949E9466E227C39FB915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_36900C0508258FEA279DE227C39E7163" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_17A1D3076C9D8C14DAD7E227C39F264E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14765821EFA18D1C3B51C80DDE685A38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14765821EFA18D1C3B51C80DDE685A38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_42AC89F4E568A4802078C80DDE691A2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_42AC89F4E568A4802078C80DDE691A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9DB2028DAFDF9BB29A27C80DDE69E666" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9DB2028DAFDF9BB29A27C80DDE69E666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6CB7C152F73393AFFD48C81158D2B9F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0F5A4C377F4D935738BDC80DDE65A34F" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6CB7C152F73393AFFD48C81158D2B9F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/NotesPayable" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_54520EF091AD542D989BFE80CD3AC453" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5B1EA933E92656D5AA0604CD1319763C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_54520EF091AD542D989BFE80CD3AC453" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5B1EA933E92656D5AA0604CD1319763C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/NotesPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5CED848E5AD11D48AFF7E5421B17D00F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5CED848E5AD11D48AFF7E5421B17D00F" xlink:to="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DED8BF948F863CD193C8E5421B185850" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8D5B18E0F74D468D6BD8E5421B188820" xlink:to="loc_us-gaap_NotesPayableToBanksMember_7ACF8B8DB9F60449EDC0E5421B18DF52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:to="loc_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_002112C254AEB7301741E5421B199FBC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LoanAndSecurityAgreementMember" xlink:label="loc_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:to="loc_anab_LoanAndSecurityAgreementMember_9E6A3C3B8626F386D588E5421B192C83" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_TermALoansMember" xlink:label="loc_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:to="loc_anab_TermALoansMember_974313B52A96CF288240E5421B1AC5FA" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_TermBLoansAndTermCLoansMember" xlink:label="loc_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5813F18B054ED2F7F091E5421B19E359" xlink:to="loc_anab_TermBLoansAndTermCLoansMember_B5F6281B29FF06DCD40BE5421B1AAD3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F88B69577B4C1A96C0CDE5421B17EE04" xlink:to="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_DebtInstrumentMaximumBorrowingCapacity" xlink:label="loc_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_anab_DebtInstrumentMaximumBorrowingCapacity_510607D5641C20DBBBD9E5421B1AEA74" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_DebtInstrumentNumberOfLoanInstallments" xlink:label="loc_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_anab_DebtInstrumentNumberOfLoanInstallments_831489628F300F224EDDE5421B1AA82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_85245E5984251571E38CE5421B1B9579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_19410C0797D4FE1AA6EAE5421B1BA423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1D3C23C1E5FEB8E34B50E5421B1BA9B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_945AD5413A41C7435509E5421B1AB041" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_CABB52C08D69C5241FC1E5421B1B98F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7DE9D6B189505CE691D2526556D6A7B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6295ECC935BE5323BD63A4FDD4288509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7DE9D6B189505CE691D2526556D6A7B3" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6295ECC935BE5323BD63A4FDD4288509" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D4E6FCD98B425892B18F39C380994640" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_45B3FA69E9B65F1DB36AB1A2F919FA43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D4E6FCD98B425892B18F39C380994640" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_45B3FA69E9B65F1DB36AB1A2F919FA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_BA2DDA569E3B59AA985FE8097F32D827" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D4E6FCD98B425892B18F39C380994640" xlink:to="loc_us-gaap_CommonStockSharesIssued_BA2DDA569E3B59AA985FE8097F32D827" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3CD40C9D4E1052A29964D9E976D56A82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D4E6FCD98B425892B18F39C380994640" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3CD40C9D4E1052A29964D9E976D56A82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_5742BBED55FE51F980B0AAA89E898820" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5742BBED55FE51F980B0AAA89E898820" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:to="loc_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0E449D2BBFBE5486B9338B4F12D8DABE" xlink:to="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EquityIncentivePlan2017Member" xlink:label="loc_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:to="loc_anab_EquityIncentivePlan2017Member_367A596D64AA552780CEF8FA2AAAF41C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_EmployeeStockPurchasePlan2017Member" xlink:label="loc_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_C3982B165E36599CBCEEC445F661862C" xlink:to="loc_anab_EmployeeStockPurchasePlan2017Member_65FFF0E315555A73AC81FD78D7AD1812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18963E4F09C755E5B3E676D44DE9F3B4" xlink:to="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_152FB53CE0BB56F083EEB8A192190FA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3EABD63DE5BE59E7BB6698EA0ED7F4DA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_152FB53CE0BB56F083EEB8A192190FA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B1156EA801B054ABAA480FF20D7A9F8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_B1156EA801B054ABAA480FF20D7A9F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60DA991829CC53F5A12D08493F03AFF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7EB9075A8D1A571F84CAB3A4F1B9B5E9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60DA991829CC53F5A12D08493F03AFF7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_5305A35EE6605B98AF78626A72919F0E" xlink:type="locator" />
    <link:loc xlink:href="anab-20200331.xsd#anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_ED7085B6D51F5E06B32C3506FD14E1E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5305A35EE6605B98AF78626A72919F0E" xlink:to="loc_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_ED7085B6D51F5E06B32C3506FD14E1E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_33736162349A7997A2EFE22CA83C4921" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_33736162349A7997A2EFE22CA83C4921" xlink:to="loc_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7494409F0BFE38004256E22CA83C86CE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_80F98E39BD3A30CC70DFE22CA83DC348" xlink:to="loc_us-gaap_SubsequentEventMember_5934E46639FCC3307D12E22CA83D5B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5F8AFD1BB37C9BAF2314E22CA83C1F61" xlink:to="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1C0FE145806EFAEB4F9BE22CA83D4096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0AE684B939BAF41F0A61E22CAAF8F393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_0301830023046EBAA514E22CD61CA665" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod" xlink:label="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod_99E1A2923FA03B1E45FDE22CA83E815C" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_RentPerSquareFoot" xlink:label="loc_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_anab_RentPerSquareFoot_5E07D1E772F0CE08AEF7E22CA83EF4D2" xlink:type="arc" />
    <link:loc xlink:href="anab-20200331.xsd#anab_AnnualRentIncreasePercent" xlink:label="loc_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_A930D4C80E8BD3EC0B87E22CA83DB4BF" xlink:to="loc_anab_AnnualRentIncreasePercent_967ED7CCE1503733225EE22CA83EC199" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SubsequentEventNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_05DD7A93EAC8C9A82DB6C811B7D3812E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5C33129A340EA884567AC811B7D4087C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_05DD7A93EAC8C9A82DB6C811B7D3812E" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5C33129A340EA884567AC811B7D4087C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7CABAF41DA6C54DA8B5C85C5633CE060" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C3377C48F72E54658E7DB6404A9BB56F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7CABAF41DA6C54DA8B5C85C5633CE060" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_C3377C48F72E54658E7DB6404A9BB56F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_DE4746E136617FAB2B5D75D05F6F05D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_E73A3EA2320F7C72823A75D05F6F5956" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DE4746E136617FAB2B5D75D05F6F05D4" xlink:to="loc_us-gaap_NumberOfReportableSegments_E73A3EA2320F7C72823A75D05F6F5956" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5BA0F1329A5EB1E8640375D05F78800C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5BA0F1329A5EB1E8640375D05F78800C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_DE23CB9D516C40D3090B75D05F78C20D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_DE23CB9D516C40D3090B75D05F78C20D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_4818021E901A1458112F75D05F787EAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:to="loc_us-gaap_UseOfEstimates_4818021E901A1458112F75D05F787EAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8F3EBF9BD0475D05CA5A75D05F7825D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_8F3EBF9BD0475D05CA5A75D05F7825D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7486B0B7B7882AAF7C5B75D05F784091" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7AE9423F10546D0F56C975D05F77FAE6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7486B0B7B7882AAF7C5B75D05F784091" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B4FFD3F81881F399219A75D05F7E653A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B4FFD3F81881F399219A75D05F7E653A" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F25E0A48C55C10F8749575D05F7FA746" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_957057F26D4D072CEE2C75D05F80C5DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6AE91CDEB23767083EE775D05F8049F9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_957057F26D4D072CEE2C75D05F80C5DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4F5BC7F6CDCC542E302675D05F7F3AE2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_F27A463EDB72C03D8DF175D05F8153EC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C1E278F9442D6B23248175D05F819F29" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3F2FBCACADE35B3FA04F5160D8289CFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_A11A612AFD4A5163B65DD1F463504424" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3F2FBCACADE35B3FA04F5160D8289CFC" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_A11A612AFD4A5163B65DD1F463504424" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>newleaseimage1.gif
<TEXT>
begin 644 newleaseimage1.gif
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M)0 TA,& FV[V1&5Z57%IIVMRSEGAG7S.*>:?@ 8Z'XYH%JH;E$>MR0 RBQ:
M#%-[]BDI>G1666FD/^:YI7R"8L9I@I]V*NI;A!IJ:F^(QK2F35-.ZNIAE\;_
M%.NK7,8XZJVXYGI6J:?V:AT#4;9*Z["D83HGL5G:JNNRS':ZI*_02J@ILM3Z
M*&RUB2G;[+9*J@<3+.UT.!<Z,*$#BWM>VJ>>*MJ*2F:T\.YV+;;#SDLOO>UR
MJR]]VO3K[[_^7CH6L+%>RL!8=.Y[UKOQ-LR2O?=."G'$R.:K\+X\98.'QOT"
M '!Z[JU5*3H,'!Q6)3KHL$/(H5Z<UK,.Q_S1Q!3?27/-K\(4<,$)NXRKSMH\
M _#'GQ8#AR[76-)S671:L@XQ6""<KL]R :"!-@&0*//6$MV,LY9>?\TG3SL;
M1;115-\*4S:65.%O-L;LL ,5'J.MEKA32YWV9AX/_UUVF5P'+OC@+85-8$EC
M^UVW-GW[[?CCD$<N^>245V[YT#IGTTPVEW?N>>5UPY:W9!9/5I)F !C33#2L
M)#%%#G9T'#KC *1*^^TZDPW3,S<4<(/0?Q,N_/"!&SZ@)QM\X,<](]Q@PC;^
M*$+//Y!\\\\A&M! AT#O))"]'NW4H,,6]TRR0PW3)XYYP)__"_@_^,1CC#$T
MT,  #?/'@P_Q(,4_?_WWR]_^! (TS(TN/P>\#/-L0 %Z$&,".CC"/J)'#WA
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M (I-(1&TH)>KYT1!A;?V#$,.[S@INLCR"SB@RVXCE5&^+*K1@@ C 3Q98B
MX$0@"H ']/@# 'Y@D'<(  !FP.!1C6* G@JD%QPP2@"J,#V!X *I"KEJ4@LR
MB$IM8R#M$ &=0OF/KM+IJX< @ .J.A!;\/0?N:@4!#A84^QPM*- 4FA']DG
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M[T\$<@\1: !]FR@M,7HP#!]DH@56JT(G<DR#G@*C!C$PP#;>\0$8T\,?C="
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MBD*TBY?41X_P J5U"%_U#M$H?]1(5/  !-SX#_X "+WVB]\ C%+$!+OU5?"
M<;.XBCVV!IZ@1^Y8$+$H$.W@ R3W"'PPD 5I2>E(2/G(BK<H$+E@!NLX7/(H
MC.W8:[K( Q!)8SW @%\5D*<8DB*9?+F0!OX "7RW57!%!B3P#<,02OK807>
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M[S ".@ 'Q$ %OX!2[S +8D %O6L7N_,,JK !>D!&[H,VZI$).B ";( ;=%(
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M[+9>Z\[^;\M>8IS!@G:>JC"^YL2^[7!A[+0!YR/Q=<RN$B-$FI%7W[E0W[/
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M"$4X0A*6T(0G1&$*5;A"%K;0A2^$X0<5"*_\8,.&-\1A#G6X0Q[VT(<_]"$
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M^M-Q[NVE3\/I3G>2UK6>):5!G6( J.(&=$C&%K0Q;&(/&X)?+  #A@S!1S.
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M +2 2J9#.K0:.NS ]S  #;0:/-AI[A1 *L!IFB:I'+HI>R+JC1)JG)Y:[C"
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M,#(.)0U!VRE9<@]& ( ((RS(_1J2AH2XSP_# ( I_^',.[C/E.X+0 $*(
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MG8AM(Y46>Q;&WG5GZ39>_YEA;NNV;N-6:#EG8-5'!#3 WUAS%8?!!S*A!0!
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M,+&WY).@E-<305$42=&V !&1_O,W!91 #11!%;2@RPI+#P%"Z4%"*1223CH
M(7E<_,,[&8!/6@V3DWJJ&S"E=[$7VX=&A9$85_$8E=19<]3?O'J4@-0:QY!(
M#^Y(;?JKZ8%)G11*Z:(:M4%Y_ZT4-JGZ)L%*.ENKI'VC&?@Z(9IA1XS-GN^Z
ML$W,J@T[L=MF30JB&?"U -A.-P - "RXU;I9L3%;2! [LSD[F^UD/_#!DEM+
M^A3#KQ=B!P2BU?"ULUG;=7VYM6&[AN]D>5[)DM$BI']BM"R8<RX[EC XMH$[
MN(7[8YCCOY+GJ27$DN$Y)TR[(!A KU-N;X=[NJF[NG,"D_7#4<<BG>RB+!C
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MWA@R[ST@KW1!N!+B\-L(XEC@Y7]'\?:!&)J@I/P@9/_!:A_A#CA!.3<! UH
MD/C>[Q&KEBLH]/\>'D@_%]:@WH?!LAYAG#K_\Q=_!UJ@#B"?A?AMMHZI$>B
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MQ6"F5NM-<8\53385-M/?$>\U/1_B:]\.'6;/3W_]]M^/?_[Z[\]___[_#\
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M,2B#,TB#-6B#.)00)5@>$Z@_\" -.U=DIW$/T9 0[F ,)5$/JA(.QX UF*:
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..+8J>+@JC,2JC_!,0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>newleaseimage2.gif
<TEXT>
begin 644 newleaseimage2.gif
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M,YPV)[S%7EQ'6:=0Y3%;$*D97%K&OWO%VJ%]]]M#U96_7UP<$17'=%S'&I&
MCD.YHG$C+0N[WXA)RUJFL\I@EE,=&?0=I&O'BO^\R(SL(_SAI5$!16J2BWSA
M*) QL(V<$BEKQ)G<R9Y<&9#H@Y_,&"&I:*-\RJC\.E:X.3(1,ZZ;RK <R[(,
MNYG:-FF8P+.<R[J\RW:1H9S,R\ <S,(\S,1<S,9\S%H#"3<P$.N0 '90$*I
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MG9$-,B7YJ\KQ&."HQL"N?_IX9"0--$G0/,>05/P8=AYDR)8LTH?.<Q[LLO/
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M!_]P8 =#:(!>:0=Y^  A& BQJH5*P8.,B(0;H)"!((<$$ -]D(>!,(4#H 9
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M8.A(?0B&0N-%=N/8H!7:H:V,>-*V$1VX__!8HF7:IG7:HI"'8@B);&!7FWA
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M/U='KV__/NR^!O3.DYMM7 L,_ +,._HX91\Q'H5W($3D#978>#.P4!!Q#3$
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M61!0I$BIHD0TTHAT(JWIH,0G?)*G9N01#&ML@SGZP <E(_>39D7N1O, @&8
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MPH*H8P!X$,DI:F"06@!@ &#XX ?_]"A( -@A)+!HP!-+P<.1$ (!CU3% 1+
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MK&$%:ZP>D7,"$R_;BB]#WO1+XA,QNY(7=5*UKDX[PR_:BM4G>;(M@0+CY@I
MH:;^YB%9*RQ"B)11.Y0@+72 %) UEX)6=3$G)':!RC)%:RP[%Y8DV],25Q0[
M2Q9YP,1O>D\^B70EI\X+FTU:E2<7_Q4Z<U(_J<,F7':AEH,_7_!>5590BS$]
M#PYI>80*QRS'?&]T@(YN#!5 [^]&!S/=$HX6:X=PJFQ/^70D<L7FH#:AR/8A
MJ?$_9)-#@0U>%L(U:_,E_[J'6.430J=6*;MQS'C69NKO9S<")X_S*P_E+<9J
MQ&C0^SHQ*3#NV%I&;.@F>UQS6H(5:Y.557+4<3-V\B!-YWAO<]U%;%GU\SR3
M\FZM2@P7Q,HR9NM086?4VBK73C#W4-%O/@]P,/4VX<SL&DG0_T0T  /SQ42S
M/4MT-R]J96LC1V0UM6(L;@,V:=LQ<KL.=Z)W=GT$Z$3B,?H.,\2L-[_30[_Q
M.P?047Z7!\7*=8EV292W@DZ6SVXU14$O;6_G-K#7;:ZV>S(7;\5B+/<M '.F
M<;<C;;-/*PD0.(,2:-7B81-*?2]3:8,L<>\7> :5(0I5*B0G5]0P(?,+1IGS
MS_]N[*+\M+'09G7[) ];3@X)IWF/)4H*C8";247G!PTU<;J8HZHFV('PDX7M
MC7B=XA8,@#Q>PH1;</ $%L6XXX7;-X'FYGH[ LZHEQOK!C-SF(D+SW38(C<(
MXXJMDS_B5RT0I$V=.+/*<AV_A#ERIXK5N"]<0F.XN$WI1'"]0N_"+O9V->0D
M>(WU^#E<@FM08]4Z18Y79H&#[<B&EA=9:X\5&0HO=D+<6)!1(HY9!Z-:=,2>
M-R%<YE'&>)%=$R821F.@A!M1@ALG^2LJV<'*F#_9H<$XN95WHC?N#*,L:I2E
M)(*Y$I6?CC_16'U=F>?*1'UDF1=IN8A/0I:I&)L(+H__>WF9FZ*SMFV.A4+(
MB#@Q=0*2LXV7>\=6#>91_(N9O1DISL,N"".8X=B(^;4O!O&4&\@8F>.8O_F=
M2R*<EY&<[0M"N.[JR*HVEIA]F&.3X?F?FV2>W5E%_^Y<E-DGW%E__@LQ +JA
MET(F@)GK!%2:VP;D&H4H_-FA-=J"('J<N4Z%8<^ \!G(4!:&-_JDZT@OF VC
M[9DG3.2+N7&?47JF%4@\,/DL4>+AOE*=38(%;YJF@5J;'OD.A4R&Z6*L#MK3
MZ.1O@[JI!RAAN$:(A^*@_\ZB/<PZ"6-N9-JIN3I\+,240WG\8IJ477JL8-KD
MS+FK*T9F?K>MW?JMX3JNY7JN_^FZKNWZKO$ZK_5ZK_FZK]N:E0&CL<!L..J"
MGLV6YHI:+]SQ2+8#*#IMFM6Z7=C:KRF[LBW[LC$[LS5[LSD;  S[)*3*G9?Q
MIZ/98)*%W"R:*P),VQIBA3,ZLGEDLCE[MFF[MFW[MG&[M@%@VGPT176",5&6
M) >8GD?:+MIN=2$;MFE%MG.[N9W[N:$[NF<;L'=BMV?5([BFN*-YKK2"V[S-
MJC'3+68SN96;-4!"(I."N:5[O=F[O=W;O:G[) # ?G?BJ4CZ/KCOMY,7"=,Q
M<WXB<<^ZO#%Z(8793'(&;>SHO15\P1F\P3,[ODT"PD<"HJL9IJFZ,(Q,3LVZ
MUT[-B_]?NZNAXF)9A D-0A0F '"\(G8SRL%9O,5=_,5)4,))0L8!%BY*\H@W
M!@XWI>W\FXY=6,"GH[5!HDRL[#J0R .JX1ZT01Y80 9RX8B,Y8Y#0KUAO,JM
M_,J;FP6"F"AHW*+&.< CV2@,8W#3LL=WCH?5FC GY2Z(_+Y9I&=NB"7201B"
M@0&8@!C.(1=.QMNH',O]_,\!O;*UO F[?,()0F,8>^Z<N#RXH@FOFBNP>8+5
M/"I0A<T1-ZY@!# 0A06XH5[3(0%P(1B( 1MDM<\#_=11/=7C>M!-*RD2N;"3
MV@%C'7X7Y+A3(Q<3^IO57+[0Y"7N@F"T>ZY496"((1_,(1G_Z$%^3%W5F;W9
MF9W5>Z+0:8[""R/7(,:D"?8W>#Q9SCQ#(AW0#(=X=L8F[(-3]A-DRKVZG7W=
MV=W9H5V^F6)N'_V-S_@%9[T_@4/;#%>"C=J;'29%+ Q&;,XLR'M^<F36E[W=
M%7[A77S0>_S#I@6B%?O&Y9?[PN+A9RV4)1C,)WAN3B,E$@5*PADNZFL>_[BU
M&BOE29CA6;[EV?O=S8HOHW=NQ=DK C5.Y7>LYF:P3SM#<KWUFI@P*[8J0$/D
MOQU#L/T@# ##7+[IG=ZV8;ZLC8(!:D)CFKCV"AZQYS+K$U/U;.+G8W!+&H+J
M:23D/]SZL'T>EO[IV;[MH=M#/KN<_]\<5YR"Z\'2<+4X*$Z>S!?0-4^M3T&C
MS5$F49C,I-6>Z=T^\17_P:'9,%7[[(V[,47\HA\V):KDW@%MQC[%TFE$<6#X
M\!<_]$6?K^'>J0Y]03B^S"L?[S'_.73^UL%>M:Z$U]ECSHE!!L;E0]X"\OWC
M\]=^]($_^.&Z])GB4<!")ZX.%NW^([;^)+5SYY@ZLR1L149>'UB! 8#!&+8!
M&'3AUP/OQSNF9+LGY?F2JH3__-&?P(B_*<1D-ZRD]14=\YH84>#_$K&"F$&L
M3[]R1>3! (*A& !B'9UY+/09U$?LUL&%#!LZ?-B0'3&$\PX2F[&0P4)V$#MZ
M-#@#H\%;)/])6B1&S  +=BQ;NGP),Z;,F31KVKR),Z?.G3Q[^OP)-*C0F0 X
MZIMWJ^+'I0Z1*D69E*G4C0JG0C6*<.)4?>RB'JVZ-:S8L63+FCV+ENE%E!/9
MB=0G[T6,=YEN%3/0[B#!M&$GSM-J4./!&5C=\G4HL6M)DP?9%350=*CDR90K
M6[Z,.;-FFRP,&'5ZF&'7@[<DAF:(%.M2I"@;>[5:^K3LV;1KVT9\*R$Q=H(-
M!ILP3)J^="^89%1Z&V)5P/)0G)%G#!T:#W0.]N;*42+@T"8!>/_N?;/X\>3+
MFS^/GF7GSZ_3\C9H>F1"VZ.M)L3:.KG^_?S[D^W*%@.J]2;/# S_&&//2&#Y
MU]!N7&W7VSP,R,,-,+>X\$(RVU2W('P=GM5=0Y&E1V*))IZ(XGCK&03:8<0(
M%I\^N7T86FI3L0985\@QR&.//H8&X$5OZ;-21AL5]&-3.>H6FT'S64?,._EP
M$Q(VV;PC&HUCA<C0B"E^"6:88HZIGF<LMH<6,4\!-N-L["A5GU17G71:8DG>
MB>=9 -YB '(7+428D7D^Y"!$$N5FU S;;8<8<ZQ@LXXQY@ C##>+%+/-.]L,
MTXPQ[R!#FD( B$AFJ::>BNIE*WZU(Y!@E89F68MY9:-4K(%5*XBQ#LIKKZZ]
M2.MU?PZFFI9YQHA81+K]M11+4H$'+0"B_Y*::K767HMM3*LR^]"L4[W'%5AS
MFI5K1,8^I!A^YWZDF*_N^JJ8HDJQ@)R$"PT+DFKOD@;17[JMI:]:K8;%Y4)>
M9HOP3.8<$H Q[)"B@ 40&$,* PPDH$/%%^OPS"$(=/!#->QLHX Q)*O PS.!
M /'P #Q40XH'"QS  !D;6#S!+S<S\  P@6P1"LT6)U$--X(@D($'/0RS\P0.
ML\.-" QDD/,&/B/ @ )E1#UUU7.P8TX@6#-01L*K,D72P!"]6%&+  8L5GY-
M-2EG0DJ5JU:A^^[-8U>*QI;;0O3J)>R0?#>TZX(F'<J ;F]ZQ"U9!1L47L*6
MST2R,=QP(*DA//^PQ(D-(K,3>C6CB,[-!VJ ;L,SAK1^R,ND-/#+!V:P9(@.
MU6R3P LSH#&, K?(0 $Q>G11.MAZ<+'!U\/,P,0PO?\N\C:<MT0R,,LOXL$9
MU[.4N?(80)_,Y2Q$B[YW"F[%&T>UXH@6WE2QGQM@<D/.V.'ZWX9C:>P@*1_!
M[>@Z^UN;OD8FA;SHXSJ#&\D,ZN<XADPD'Z+ $L&FY2[UI848HZ*<L_1QL"]M
MHP')2)T:4G<[3D"@?*1;X<,<D(S9L= <>DA!#FJH.U+ D!VNB$#G7K8-'X*O
M <0(@1G,D8<R<$)W[ A% [37!9'I<!A"; D-@3"Z$0(C#V8X!,?T@,7_(3J,
MAF6[W$XZF+^M-&XD6)F1VL(2IX;(SR-0N1O='((2N!5PCV7!T6ZN\[^%!.X@
M#>0CVMHHCV3 10.+>(<K\("(#%C#.H!ZDV*TPBBF0 N#LND@1#SY$ W69AXA
M'%,>;6(.8K P/=PXY4Q:N<J8P-*,0NE@4<H2D@ ZB2UIN6.6Z*>W^YUI708T
MI#$W,J C"3*39DE(2?3HH_IA92_ZR$<[&) -3<CC$BQHP39^P81/ ! A%M''
M.JQ0"6A0:AQQ$,8PK)&),QC#'<$ AC$V"<+TZ7.?Z/,(*!TBRH.L8P9Q6 <:
MZ)DI?2##H-QPQ1R$$0QBN((.W;"@(&]12EIJ_W2CM?2@@,I"#!; RBM[>N-6
MGM0M:!+*;F=ZDS.9N11B'O-P>EN@,AN#EJX$;$'C'%21G+0@P<##' Q($(OL
M)Z=9D41:/_JGB)S:28Y*=:I L25\/OJ?-<K(?O?I)33CV"R2,'..Q9RI69V4
MS,:H5"HZ79N?AD3 /"TH4$X:TH)JVI%U6?4P4#68/T&9#UX,@QB4"L8Y*"6,
M9#QB&,.@0S[<.5AC"*,=V]B%40U&U<QJ]B;@V0A6R9++<+D&K/\YER\_PA:U
M";-;9VTM6@7GGM/*$4++;,PX9<H@0&X'MPA1Z5[-*0UT%!0*V@A&,,S1SG9L
M\QPS: ;P?B&<@_15NO]_-8LGIYO1S6HWLP"8B%/;9Q;'&(5NXP+15W=E*/3J
MB%!K=>V@_G*HWUE41GQ1#'H15UL6C?,Z@SQ*3_.$DGEH9ROG^FU:IDNYZI;E
MNI_<KH.W:\L^1>2S9&&!2.(4I-AV9+5TA&E6&,);]]X)+.D81B^,BBQ9^2F"
MADJK00J)4IL2$CG]/<HQ4^Q7$'9$N+&XA2NB$P=_"KDC 9U*;GXJ2&H]>,E3
M716?!@;>9GZ4-2>1;5C(&BZ3SNV-3L&K6$(LXK+\3U'R",8MYKO!'<5'(HUC
ML5[\9C^X5M(B09TS4/?(81WKF2_\+'*7_(RVNK*  2Q@ ;ZDR^1$-]E,,I+_
ML&@H#%JQYN]6&EZ;AU>*KDLOI:9:#K-9JE+F&9S!0(JJ;['N]:J_O;15AW)0
MJ>$C9V(U)M;Y.AQ\9=16 R<)P1_YT/_^RT%%"YNC3G:T9]N[Z5>3MZMGP;)8
M6F019#\$*2#VM)N,(@\37]95$ZGI=;Y]E*XT#E'*.C*-<T1K?;R:*^G6-(_N
M8QI=-U56#=%(C&64W6'K^UJ=4<J3)RSMCUC80[B6=*?S%AIAUI@IZX7/=B)G
M[4]S91$),, + IZ6=:^[OQI_(%2\W&JC" M7!9$')NS!7\!0,S"\0@I&$YPG
M7GND0S]%,K[WC7,S]GLDQFX,I,F"TOZRQ=VKL?)8_^#GH8,WB*71CGA.C1(+
M)$PRZ<F9YG[U<G5*'LK0I8'RLA@XCWR +09GJ 60)R! .@N*13VJ"DO<W".9
M=Q=N=ZTS:?*=\[R?:N>-AO+/<ZJF,S$]O*>I(VDPWM*1@%CI3F\(J8>!BZGG
MB:Y$0@[E+_\9"W\\8 (FR0R0HQ%XO&,>'M "&BSD A8HDN6$5%>2]5,5+86\
M/WU.'[_T*YJW8'0F;-&[[\=DH/E@5)\S&+2!+ 89IMX(J\'DI:^0GF4XO@;B
MY&P\:K&]#&[HPOB(OPVZ9PU^6-OV4+?P>,!F;Q@H?1,-#'@!&J*4?M;7NJZT
M"7S@&;ZLVOP3T#FFK_P!I?\56E(4;>$8>/=[!T@>9P-'!M!S2Q%:<9(:]_4C
MY65T'?$V&T%TUJ<5Z/ )9[855-9;;Z8?6?=_X.8D#% _Y"8:NK%N!$$ADW0=
MZQ9_,@82V]%]R(0=?70HCW-@_41DM[=N#"$8BE,23F6 "(B$F^$_-8%@#&
M<'0O7)5G20)]#7=2 :AF-VA6F&0@(A5P$&=W_S=*KK<^=V:&"#%2S^1U\J)+
M_K5V6X5U;UB!>'04&7@C<"<6 S@JO.9)"G%HJ*$1L<<8+P=*1YB$AT@B?)A3
MM.)&UO<5Q:)FCO@@AG)PBW)N:E>&7,%X9V&"\H<.!F ,E!1N!K!Y<I0N!.$G
M85C_>:$2AS,V<XI7=7@X%8JH>'$E08,X*WN(68C(BV%"BS#W+5HE-T,W*/=
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MA81DA:2%??$6\8<O\6<86R>+Y$=;HN@DS.@_L.6AFG@G2,$ WF$ E%>;4B&
M!%F<+SH>?;4-3/ .6A%0!>D143:,:OE\/!I]8E$?*9:;O4)]J/$1S.A_#LHB
M* @5N=$J?T$21H$O4_H6%UJA_QD6Z4:-WZ:97O9Q%1%C 88=/$6&_Z>B/^(6
M*O%,[/-?.O:<, JGFN%)\B ,Q& /^8 2">*;A<@7!_F(T]E>V_80@IHF@S>%
MJ&6#0]HKY4=HP(E'! B/D5I7Y&=^Y?9';[BE;YB,LB(NK]*I= :E(;&5&"A-
M 1A,54G_E9J*)YWA'5J55P&CB_D4I[-J&=*B$-N4#'?*#8IDHWQZ&+R!26FY
M6O+P 7AP$+1P R IDNY0K,>ZG7!QDLWFHU;X@8W8= 5DDZYA,1-JC9CJ<RF(
M5P+F3/[&)N7*BF?H9;-!@MWJH?-@ !#DI/>"5J\1@]\WHC)H5X,R \F'@DO7
M)7I6.;0JL+5D%'B:(&(G#\[96=0E&WZ:*[$)&,BZ$(49F(-9D<]J$-UI3@H
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M^ZT*XZ+K1O_@#&]8MI%"5,/"QC,(*5EQU&< %K#IYAA*$&"B-L%;QLPVC6;
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M"L?^:1_^P8CJ@Y1+4XJ:LZA>D(=WX(9;J#:W^<BED+4 K)T3V8O*8(C88!(
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M81]!O1@2Z='L^"7^T<JW3"B$\)]@93R,#0H/8(5?N 5KH*T"Q8XM/9_&V#(
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M(23V&!$S:K*$>=!!1/183%]&!!)DS*(;_Y7)1PS,8 6G5*06(T*+6M82C/J
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K%<L4][WO_NF!9!Z;(7]1O+,2,HOJ_%N64/ZM__[_8US[ >  $J!6! 0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>newleaseimage3.gif
<TEXT>
begin 644 newleaseimage3.gif
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MI%?GB!)))I/\4Q\XE2QS2R;_X.>16W+9A9<U=%7X%GQ1-3;?AB=1I:%#-@!
M0B(DEI@(:(L0] $ I!#DS0$ 1#$0:-04%.*()I*(8D&R2>(0-Z$UHY TH6'#
M4"J@:: .02( $(A!I1   "L#90" $@,- < '#?6#  "$<"CFF&26:69/[)TI
MT'L/V=..FG#&B51E<M:9D8=V4H2.-+A @PY)ZO"YS#;[Y&GHH8@F"F>:BA9D
MCS2-1BJI271&%)I![4C#S:3MX<GIIZ"&*NJHBSIVJ#S<,*.-/:2VZNI#E4+_
M="E#\ACY:E*>6L0$ !T@U"06!E7'94*2A :I0L4"<.Q OP:[I4(_ +""018
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M 2J*$$?)D6%*$:-WG@,A"5M@$.D0!%_J$(/P T  !#_@ TU <(IP R6  Y,
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M)G*IA:8,$:MHHY[:D2K (/1@ J9 $(2P Q@A 49*$(H@.Z' 0_\P ;CE#X(
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M)&8#)(]XL%A[T<S! ../$U"!,.480#4@4@X!S$X@/G#A/P:@D'\$P@2KJ(%
M C"O@A" B 41P#?J48%F%/&(.N2A#X'X#QC*<")&[$@2E]A$*M80(CBDH0W_
M@<-_K","_X#' ;3Q *408'0"Z<<(KJ= .M;18;X+7P&S\R#<=(0]<1&><Y+3
MQYL824<_8<*.S#>1!C#')X%XA8<*0AX5EN0*0@" $R 228I\X$.3[$[V!,(
M1U+$!>60I$#&(\KH+(0DW/ 9 O5HQU9F)X4I?,LM-9-+758R)[0$C#QV40W<
M[4)WP$1F,I6YS--P!@ )T%@TI6FB!0#_@(>7X2-@6+E(CPU2F^7#B'*$5!)]
M2&@I2-JF.)\"@ 8,4""Z ( !6*F<0 XD!-2!SRH$69QU+@ BV@"  !P$H8*
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MF%>05?>,5@?X@ _#@6].H,;[O-?[$SY@#X?I%2F(24  !AB$!MB%!V !!U@
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MKYS9MHG[^9N7=-M<KR0=&'\,+>&5E7G:*MCC_8P$$I(( ?#@%5%(U X"H?5
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M(6)"#5KB05C"+H3,03!B("H=T24<"+T'6E6.9+&A0+GA&A[0)[8B6<FA0G2
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MZ-P7AY1#*#@   1!ASEI"40I(5U>HQ3;$2  !1Q :"PBH&50*/! :!P !#S
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MBP  I*]\D^,'9($@W?=('/(BURHBXVI&./(SVV,F4[(EQS5##*LD+S5+K!X
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MSO*LSP*M1@QMT1[M@(7( S#M!S@MU.[$?+W"U.H=%"+$I/L&0_<SH96$2.]
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M)R7C2.##_PUF]O0@YRQ)-40@  ', R+H&((!$',!@1Y$! $0P "PBE4!!"
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M$22B "X5 AI>@ 9LH 9DH D2@A]J( ?@*15NHR L@09J# 988!*FM#2M]"[
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M("! Q#:VD0VX$(0#D^ &-8! @W^8'O6J9_WFA'_ZU*^^]0+AP0(T,1!\3.
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M#-UH4S?9$?[F$D0)'T:)C_/($/*P"^O8CN^HE%$IE5-9_Y,F 0""UWT , $
M0 O^^'##!2U2)DXW"9;J19;X%)!B.50R(793!I##2!&IB!#]92!$"(:A$ 45
MJ71$>2,?,)(%\3*Y\ #P8([NPY=TZ54#21 &0 MY*5/$IHD$^#ZE55KP,U>3
M&69M9IEZA9GB4YF9&76;^3XZ(F?] V?X>(S)N(R<Y6%H]4.IJ0V)$%:R*1")
MP&(#P5G!QI350$M0296_"9S!J7B^A97<!P ,D"[^B$)E:2("B3QGZ9S,F5-2
MU2S71236.68M 8JB2(H0&6F3V'A'TXH 8 JO&(N2Z'!-48NWF(LL>5D*UXO]
MTTWZ<%+#D@MCAPV0MQS148_#T?\<?XD7O16?^8APB2=D-D9A!BJ<,;&;^J +
MNN";"RJA$[J!S0$ MBA^ +   $ HRK6<"/J/X":=(6IVS]F/;XF=0LEEU=E4
M"@D #.F0WNE_!3.1>@D3%PD &;F1'7F>[A:2 ,H2)0D )YF2*QF1W>.2,"F?
M!\%9)<99Q3@0*881R(81V0"E(:9A+P9+]HD7S/ /Z:![^OD4U9 +NK ,S  -
MTR -S]4<N> ,NP -S; +N2 -$9HS8J8-2+%N.#.@2=$,<R8+5U"80@&H@LH2
M?^H1@3JH^*<2V-!'=*82RX!K]@81CHI8'R&IEXJ.3>F@$$JAGPJJW&>A#:"B
M+7657*G_G#PQHEZI0M"IEJL:52B*EG(UJ\TEEPU!EY/:3P11 7AIHS<!>3C3
MET * ($YF(M:0H=Y+XFYE@/!F(YY6F,D9N"1=N=0=P+Z$>QHIT+&G^H@ICC1
M#DHZ)<\E?%.1=I/8IR_X'!M0='4T !9CEP?A K/7$27PKC,Z$.QJ2   KXKY
M$/-*$?;:K\UJ' WZH-L:J@FKL"MEH7OW*ZPP"0+Q"NWA#TQ@#IAP$J'@I>B0
M!& D+^*:0*H*HJPJ2JXJHB,;JUVV3J6Z7G$5$]LYBJ7HGN")GN+IBES9HS1K
ME>IIB[C8 ;HHB_!I,^GZ%/PYK9<V$/EI811694WKM$]KM% K_[5/:W[PV1SQ
M5A=\ZBLR@".8H J!@%<PP;4W,@A?&[8M,;;B4;9@6R%0!0_+ +*J=#%O&[<@
M)9%P2X[=0[=Y*R0&ZZD+"[B!.U(6NJ&]$@II1P03.Q(6J[@5:PZK8 /TP ]$
MH AE] H_)&4BZYS3!55JR;FM>J(J&RZF19HQX:(PR@0",+,229$X@:,ZJ@T)
MP'\?Z:,BB1-"2J0JN;I(^I+,\9[=-"+V^;1.P91R)Q#@H OI4!/>J@L5%KS0
MY;QUX0U!<A#%ZQ1.BZY1)QY#)F>DQ;W=&S[?"[Z_&*_0,;4+]V_G2[[C.K7K
M"[U2Z[[*X;<(*[CU:[_!8J&"EJ%VU?^5*;MEL*I<G0MNGUNRH>NR;\DK*0J7
M0UEX<WDONEICO0JM21&LJG0OQ&JLA%DAROH!S.I1SMJ8O]K .KN?SZLSP/6M
M+W6^YVO"*SRU%+PSOT.T.3&\#($-'^ "XTAD3?LO.*S#-7P0-YS#GON="1J>
M4^*^AF=$2=QPCO=O3;S$+/L4\WN_56S%D$F<4JQ26HFJ_FMV $S 9FG ^X2R
M'JI'LPH1REB; ](.R3:"F240FQ56!^D3S[*=-="=,WNK-DN>YDF[.AM=3+&>
M/@NT-6M$,]S$EE4C4<N^XH7(?KH+;,&FT&NFVS -S !YUGN],9R]@P>-@8 M
MA8>]VPC*W='_M!<AJ:'\7J-\7P^Q#.1Y$! 0"BF@"OCZ#Z_<H0(1 I@P Z%7
MO@+QRJ80R[-<R[]\RQQZ$+O<R[8,/+NI0W][Q=$LS45KE<6Y?<>9G%[LELVI
MS=V\HB2*D&A,NJ)KN@O9D*F[NS3:NC?QNAH9N[.[0N'RH[=KDBBINT=:,$GJ
MN].J=/ULM-#KR+W"R$IA#X^,PIW<7N.KT O-T*?IC2IQ!'7[P0^Q T!:Q P1
MT9I*T1;-S&%$Q=,,TB%-;Q>JQ2EUJKF<4-Y,H-^LG.EDP.%,G0E<J_AQJWGV
MP/$JP2*<O@8ZK!&1P<A:E#R-F/'ZK#J=R%5VR$O[OM$+K";<R(<L_R3ZL QM
M,\FY4-#8H N[L PRPRF5X0SKMLF.K+5FY ,MPP "<*XN4=:$=-9I#1]K_0_P
MT-;:"[Z+5==T=M=^U;T2]M$B[==7W*8KO-0N3-@LW-"'C=@+/, M2Z(IS<UF
M#%HPC<#CS*)V'(IX++,^N,=*P8HW"XM_+%^TV+/MJ=FK/+2[,M OS%N"W12%
MG<*K++6&_-<@W=>S;=L46H_"NY^6=1+P,%'\0 GFT Z)P _S, A '13,T&.W
M;48L2L3(H< ]X@ W<LZJB\\14Z.N.X,;*;LY6R_S?!.A*![V;*07G<^]V]0D
MK!RI/<55ASO2L-PVH][,3=N<>K#TC=_SF/_;@_W(W I=\TTD\L -SD =0Q"_
M^8U=XGR=,[W!(VS3=>FO=SG!>\G3XN&7/BU>Q]K@4/S@'BRWBQG"OO.[0L+>
MR]$.[7 .3'TS%?8-[1#?QS'6"'[; %,)%>"4[BCC.3Y^^XW4Z\W;HMS?.572
M9,?24V><*TNKT3/DH:K(PJ$/Y8 -S, -YZ!##??/0>Z[6/Z>?<H/W[+/  Y'
M;@81^   ,MB]9L[0EFDCXRN#: YG,I@#F*C7B/WF<K[F=+[78OX09.[F;=;G
MXZO82G$]\##H8,>I3ZGCB2YLBJR*W^?:A7U9<HE E  .P"W<Q#T/&% 1E&[I
MPUW<6^ "\,+IP>W_Z?-@X G.$(*@"N P06)5N=.P"XHP":]@D%8+M0QU7BZM
M .$@#KWNZ[_^ZXW@ 47 "\#NZPJ@$EK "MLP"Z5 "5IQ":; !>I "(EY":M0
M"1&K[-L0L8-P"E^%VE7V6SOL5,M!(4L>[K$]64T.KL;;'5;^O*W-PT8LW\#*
MRD_LR?"C$M) D^VEB=D*UM"=G4OIWJ&IYX;#T6F&>-C0[R@3Z"PQZ(4^'.G@
M#"K.'$'^VBJ\XM#A%5JNZ&OWZ) NVY+H\?[<P 47\BD_[DZ+YP\7'1=A#]G1
M\#F1/2UO\S??O2E_R@@SOCHO[C;?$#YO93B_PSX/M#TO] MW\TD?O3Z?_[ZW
MOD.J6(G<A*WYCNY+&BQ3[_!7C_6_HO58'PKW I1]P=$@V'U\^ATE__%(9_%?
M#M CO_9Q+_<WU*8_Q?64Y3\J\_!I5BQ?S_=9O_=. ;(QCM"</.(Q;OC@B?CA
MF?B$+^\RG/9S'X]MG]Y//>*2C_F93RQU#Q'V .4$GDEW/UEY;V9>_A'VP \R
M%A/V8/H/@?KCM/JM_RBIK_HPP?HM\?JUC_NR?Q"Y;_>\4@[H=:"'7[.-S_B&
M3/B+7_S'?_G"0JXF$?F:_XB4SUMB?<32C_W97R)UGPX2+96D7UY]'_@F(_ZB
M?\#^KCWQTL_$_[O&O_SLK_COW_[,#^;V#OD9K__]:D?]^&[Y]>]%N0 0NW8Q
M<^9,VD&$"14N9-C0X4.($25.I%C1XD6,&35NY-C1XT>0(46.).D0FC-FS'3E
M^M?2Y4N8,6&RS 7 YDV<.0%P^<="YT^@084.)0H4GDRD294N9?H20,NG3:5.
MC?DT*E6L4ZUFY=IT:U>P2+^&)0OUW]6R5<]RS=76[5NX<>7.I5O7[EV\:?^Y
MW>LRU[>V>@4/)ES8\&'$B14++I<.*4N_@?TNIKSW6[O*3.VU._<-FS2#W\JU
MDY?9]&G4J56O9MU:'V?/H*5]NURZM4MID,O2''L[<2@ 'X[Z5AH5[>K>K),C
M7^M[>>KG>J-/;0>8K+S_;P;+V2-KKQSH;[;#XB7_MF_+OY*)KV??WOU[IMC.
M+=6]5_UY^%3_8LY/_'7GST*KK3\""S00L<W*^4:VV4;C[D#6<M.+M^8@;$J2
M41Z4"AQ=U''.K-NF.TU$TTC,S$3*4.SJ*W_VX:JZ^L#R#AMGN!&/JG:X<0:;
M[2:,$2R^=$OO1PN+-/+(_.S!1ANIZN-K,B1GNBQ**@5[+9UOM)&-F\OXJ_)+
MI1)<T"!L1&M'0S#3Q$K"M"@\3DVIRIFO*1>&4\RX#]]43<7%^+RS0N4 )<Q/
MF=K1)A=LF.'&2RISW+&<^Z2"00 <*@S2+\"(A'-33CN=BIFDG+Q/4R/W\_14
M_PO;P5)+@[A,AU'%Y&E'0=G*/.=,5',MD,W=]B*4TW:D>>D( (X0RR4]T\(S
M1$&92Q:U7P^+MK!I"1-65\2BPL;.EX;$]EMP^WL2R&Y'3=/4<-/-3-9ON)%-
MFV]NU<>]=JISUR!X7YU777X5XY4L-_N=*I1 (CGJJF?)6E8I*KYI21!M$MFF
M)8DISL8*A_]19&*I4&SXX8@YKOB?1)+(6&..O6I6IH__@7CDBA.Y^.2-M5HY
MII9?GACFF5VJN>.;8<J9"I%%[AEEFQ-&3!YGYB1,DAW*:0F>2(QU"6JI_Z':
MZI:PGKKJER+9 9NON?Y';+*U!MLEM,M6F+Y,!99[[O_$QNU*5"?/G9+N ^MM
M]]UO].4;3+_OE09>>0<W\-_Q? U:KRFDSD27EH;XQQ(KIN%G"4TT7\*274()
M E0G_M$ED9B66(S;"I4&:^% 7:^LVD$?+]'VV7%_W:;36/G !>!=^("2EWP/
M7GCB73(^^.&+_YWYY%M:'OCFE7^>^NB1\@810IPY5BEO%1=__*GL9JO<O,%$
M=WQ#MPP<5O+CWY1=P[&!?W#&R:U)=[)"\9Z(4.Q">I-P20!;8HDF" L6J@"=
MZ$AWNCTA2UI0X=U+E,2-$ZVE@BYI1],RN)QS,.-&?[H)3/2QH'VEZ"P;;(F2
MF)0[V:V(A61)Q0>6P:UE?"#_AO]0!2(0@9E5)"(0S?A',U!WN5UP01',: 87
M&/$*9@AB$,MHXA.->$ >^K =57P%T)9R+:? +5+R(V,9&S<7].CM?HKY#TP4
M5"\SQE&.G9*5@M#TJA%6)G]W<]P.^8:P":[0==[+E@:5)H^T3=!$G4F,568H
M$VF@B5J"9 JH"NE'K)1P,,O802=]$(AL\*] >LH%Y2RQC):<(I%*"]\<7?E*
MF= $2I A59'*<TM<YE*7N^1E+WWY2V &4YC#)&8QC7E,9"93F"D\(^W4%9@Q
MPE*:BM-D98 7DT   )77A$DVM^D";+I "/_@YDL"(4YR@K.;Z"RG2\XYSA7)
M! !O_XG;-.TY1YK8XU:YF!4M[_E/@ 94H,T4)=^$-%"$@JN:"86)GN;9ELGE
M@AFYR!I#+=HOFOCSHAOE:$?C%[ XFB>-'B4IDA;*4!P 8  .=<N;])$2?62#
MHB6E*94R.M*:YE2G.[5I'U]Y4,,8YY$Q40< ?$*4#A1%)X)TG4T24)2D'G4H
M226"(V6G5*SFQ">47(H]LOK5$IY4)O$ 0 [ BM6"(@8;S(0E2P\5PY<R(Z8S
MY6E=6Q,DD=JU6_:I"_AJ.1A9/A,_,QE16B])G+L4UK"*9,W^HA)8,D+SKZ^C
MX+.8QM9).C(IZ0#C81-&FSYQ52;Z<$8>,SO4%LJ5A*IAFO]I!_K0_8$EKG.M
MJ%YM:QB-FD^OD(V)/?)"&=Z"SR7VR([3DG+"IFEHLHL)KK.(X\S!H!9:(&(6
M)@GC6/1(IIAI7"XV7+O7C$YV4?39"R-= MKF"@9VSLW3<Q<;U/?6SKI)J^L\
M]1';P<Q6IK6];7_YJ%W_]N67E4EO+"LICQ<*EQ4N,<4K6-$/]!VFP-.=+WPK
M'-0+URZ^\FWL5YX43;;X<[DOT8<VM(%96>J6:<9E2F!I8UX!%W+#ZITQC3,<
MW1I+)\=E@6Y2>CQ-V-YX*OJE:X"-_!C[X/2V$V;/CV<7E*28@PI8:"C_7E&)
M?_B#">; !*BZ?,!=L(* +3&@RG;_>.4L;_G+__@RZ,1<0 $RA4]HUC*7O6Q)
M-X_Y'V66\YFQ7.<UMSG,>N9S<:B[%#JKV9*"?C.9XRQG*_]9T2U9LR4$0>A'
MQ]+#>/71I0 [6(#=MZ\CYLIZ(RAD':-:63OF,:O#XF2UJ%J:068-D?E[9-M"
MEM2=5IP]+,GD]8@5/M&IX" &0(I%[& #)-@  F1: @D0 -:O=C6U9<WC:U.[
MVI3--E:PR]>\_L,<W"@'/<PQG'&7&Q_>^(<V_#$3\Y#JW.:(1TN8E&Y\('G7
M\3!'EJ5ACFF(>Q[9X <&0P5J'&^[U I?>+?CZ?"&MY>Q/*5U>U[:EHG>&M<E
MU;4RZ3(W_T/%!-C/E2ZJILUM]T*\U"K/Y*%CU^'F?'C7?N7N=1&.F)%3EN$M
M9SE53O[PE$O<P@*U;L61@C&7Y$P;BC"'-K(0A9']+!'8*-W/F.[T*""])3^+
MB:TWWE%=GT:WV )MJ$"LE$8GVAP._$?IUJRPK5KH.&]RJ"'M'A-NK%6%FHV)
M-A*YVJ%F![/2XCM,W#7X28KV)>=P!N)/JZ=R-+YNFZ;ES,U>\T_SL]W52(<(
M;PZPSZ]ZYSX?/>E[3E^AO_PV>Y,? .#! -[)CD)Z@48EA.,2> QOP8;Q^M<#
M&G;3C-U3\6K2V9M<\O?,/>+(_P<A&<M\2S[?=9W%\ J9XGSX*O\>*=KX[JJ%
M#9-(%L:Q-_'X+><)V_*7Y_PR/KV9@YYZU;?FYU+IH..E8HY+(.(22,&__EG7
MDOZ[A/\3M_P30)D(P %$0)W3H*9H*<)@A":H 12P 2H(!=3H/=_#)_RP/( Q
M/H$1OO;XOOQ0OBJ+-:;*0"/[B;4(C/;+BOE[&Y4S->@H/=2KKO>3OYT30;)P
M 0I I9=XA06( G+J09@ 0B'D01]T"2,<PB1LB25$PB(,0B:,0B%\"7^8AWG@
M!Q^3(-F#!OQ*BA[HHIA8AB>PK@X(!)E8!AE # Q$0<4!OLP 02J1//UQ#WO0
M!D7IOK1X#=+HCGJ1)*Q( 0-(@(9B/C?_[*AER(G*6D&6:$&>2[X<=+E3NT$<
M=,2E>$'3RQ9#1(I0H( C.*</L!I+E#&74 =*J )&,+@P,@L (#Z9.!2^BJ%5
M6  *H!X7F)BB@X<C>)X/6  TO$"8VJ]#Q*@-3+^X2!/2$HR<2PP$4XZ$T0;'
M2,;BV(IDV:!LR( D<(9)R  0&(1=F 0'*  FT,%A]"AP0@M 8D&L"*(A2J(E
M<D=F6(: ZR%$H 4G$D.@\2-V)")XA$=YS*)ZO,=,#"3743J8,1JMXSI(DQV#
M+!J*,1F?29F%;(J&I)B=.1JDR4>*S!B=(1F$I!F)O$3=&1J'))FC44B1C,%-
MC(EL< $ 8!X*_Q@$&E2AEM '*\ ">(B"51 $3"A!!FR)Z+,'0F()=8HA4K )
M%U@  *" 4S L ' &EWS)IPJ$3*NU8"RR<NR4CC/&<#,2>Z"^"0D]]\ JGY J
MHH@NLSPKK<)$')P)F_B145Q OWA+M3 04EJ9441'"5+'L9Q)%XQ$OTQ)2HR_
M2H2_Z%I)K* $(8B$;F(":/@'Q61,<W),R%S,QGS,R+S,RI1,=Z+,S)S,QVPY
M5H0)9Y!(HI3$F C#-"S#K#C#-%Q#^+BX7) &7>BWK/P2."0P#WR/D*N;W70.
MQ#PR;0@.$4B!2* %]'B3FIBGNLP&Q;0 '=($U;" X/#%5("2;J'+AO^"C%0(
MA K0H;B4GN#  "$(A5"ZN4:4IY9HAE"  0W0(>Q+..IZ"G5\)!2:P?#LO#R*
M/< 4JW;PO+VS/IA@/$!\/IG(._O#,;$22A9K).W[!WE@AC7*+$UD.7,@ A;X
M'22P39>XT QU@0V%"0_54 X%0 PE41$]41 M47%3T1!=N-'\!Z%\B5\C)]24
MB5FL1>&Y1:?415[TQ2.9+7.HS=NTD-P$KM_TC;)#4@Z$EN#,*9L(!"D] N$Y
M@DA(!0*P #L93OZL"H?*!INP@9?H@0 0A%"(@M_9 2F5TB>-4BF- AY44UD@
M 0,XHI9X@"XM1/5<J%0P@ M8!E!T@37-IJ+_*P< 6-,=^)TH"(50(( 0L),H
ML(E$J#N',@6;P+*IT0 "H(50V$47^$0V-508G<\D*SRD4)(/J@Q4O41J9#_H
M2U!K$]#CBKZA<YW>5"3FTX8)]3[F<X8"3;4*O:<'& #B 20 @$:DL(ZBE(JC
M?$FE9$JGW(6H=(&IK,K4.(>_ PZSB8E0N+U_.((C(#*N'-?M*J,C9:XD31<Y
MC(DDR(>66 4Q>P)%0(=)D%=ZE08E<%?(E->0]+DGK:E_Q<NZ6SD7K#"'&MB"
M_<OYHE3U5-CQL)MT+5*)=:6LXH!?[<N\;(E$#$P33(S<"X6/%0PLD8I02(%M
MA0G5"JEE_, -; EI_]A577G9NQ)+U;C#/%0OYO1) OF1Y83+)A4[Y=3.52P0
MGA5:9/G9X#,PA/6-B)U8IPTH7Y4[CJVR\(S1T_C8D T+"IB P<B[BU6,+R,"
MM?L'4[@$1MBS_PD%4$&')% ,:#*C<WTI6 43.F1:FEV,9NR3G VC9A@ 2_"!
MG"#$S)B G."!7 @ (BK:O3W:?ZB "IB$$<B)!%L,X,")$0".#T@RMUQ<LX@$
M 6B&&\B)&C -:<,)'V"$ 3@*Q?79?SB G1 !G @ %DV,T V FY"!FJ@"],3+
M?Q@" @B%&L@))! [I'U:XZ4;MJ0P]L+/]<#:#[! ;MV %! $=2J1@*4*___Y
M!R+XAT3#!$DSAU6P 7K@!R)0!'1M6L$"JJ0(%CB9T?=866;9'7FZ"1=(@12(
M@DCXN_E-6*7 ADB(@A0H@:@<*@*FW_H5@D!HPOWE7Z2 AU<(!!L0X $^V/E%
MRA)(@4 (!8USBJ)3FF7XWP">X 4N1*0,8/Q58"]UV*0HAP>>@10 'F%[CIOX
MG1*P@4!XA0VV6F4LWN/M87Y)WL*JVI]D7J:H2(\T2:W+2+ (A0U8NY-U4B%F
M6OCEEW-5BG)0Q50!2_=85Y++, *6(08633VMRS#6"H,=X:'-I Z.IQ0F8S56
M83$.HZ6M064DQR#&G>J82*7(8U;%1%,UXX6]L6+_P0D"*(#2M8E7B.*QC(2<
M*( "P E&7KE )M@8G+&?082T^9DD#@2IF;K2D9DDAD&&X<B0L<B'!$GW2PHC
MAAF(W+I^W5/BZ%9XZ-1ANUZJH 0*2.!E0%-\_(=S",506(9NK4*WG>+TQ4ZN
M^-K;.(?))5KTA0Y;-MH;/1!I/@L>1E*1JV9%5AC.M68#(9+T=./;6,YMEN.5
MT8<R&<BFX"S3"BL'_5<[KF"UG&=ZKF=[OF=\+@J"3=A*+F<%75[E/0U9IF4(
MB>>R"((C>(5E^& 76(27((4/B(2%?H4HZ(!FQBTNEIL44[*PD-E_PBL/;-=W
MC==YK=>2QE=]I01^W1TO_W8H<W@D ) %?WY;%J14 / !F&@& ! "6: ,60#<
MF A=&78H2H!I35!D:!(U#MY3SLT" +B  2P,)I@$!(@)/%4"AJV*X'T +^5,
MRF &H_)G'6XU60-B'[8HLT[525SKPQCH)RX2@V97Z(6)WSD,X/D_;"B!NS%F
MRM"&<YC;=,!#746RO=;<:S:AJ,T,5^RIPQX,F[41G&W8,H9FR7[CR?:B,=99
M?PV1.39C.":]CM5LC;PN@Q;I?X!7DZ97>YV$'=#7?47)+;PV)TOKLT8HVMZ[
MDO-H^<IMF'TXWF8*6B9H3HGK.-F!PP#4Z^+K_) ''4%6CO8VPU8,7SL,W5:?
MN_^-E8O&L'PF;L+;;GCV;O"V9>D([X(-;_ 6/^XF(?/.YZF=QO6V9YQ][WH^
M3/F>YV!CJOK.[]ACOGH@;SON[_.VXUE01.'&EO3>B^I]B2A( A06C!UXXO\-
ML6<.ERI&C%<A"V90YBA1[AFL;0]W9J:0A@9]Y]7P:[@>01H;-OD,P0\WW@,O
M 12&AW8JC$ (@ACO@!"[;HUN6=5P[J60QES):,X6ZX2RAW?+"B.7"GO0PA;7
MCT8LBDX*4/:0A\@[B /O;OT&J_C.\J^B;RY'JR:?V"M'BDB8:[L&+ [_E@I'
MC>K^2G6=\!$1[S"?<\ :\Z%#\6>I6GB8 !%04SAM .C_+8<&^-1 H-($\,%0
M>  7B() V $1F(#A" 1%9_0=T  '< D1P !!/:<'8 +%2():E-(=P( +<(D7
MT'0I=0$,J!2MX7,_=P% ;PEL&/1/-'1$G_1&?_2HUHMEH/5"AW4?? 5</P(1
M:("L ?5-'_52;XE3WW159_4][_- @-,',',ZO\WT)H0G/@+C5@P>E(E0&%YO
M$W*65=_U("T-YQ1RY][O#30\&S1'X^:6CI$O[ _.[5F1@Y#5=4MJIG=IKO<1
MY-EF ?@.D_-_QO,M["\NX()!" 0M^(97$ 4MR )&:#QX^@8KX )NF(8F0,&R
M3DO[AC2TQ&>5$6?6V,=_B*) _X &+KJBRW$)E.]')8K'::#'+1)(Y'A22(\)
M;+B!7TR,99@"KW8)%PC-\DES;%ESQ3Z9WJ)55%EWT] '; 4-.R_@1PJ%2,A<
MRK"AGT>6&+;I'XGHH3^,,J> F+"!/%WJJG" 1XH"64@!RI#Q&_92G49C9 '3
M-\&&(XB"!B^,(Z"%;N?@+SY8 $"!F' !O0\^.Z=0JO"'>H.AA%<6UXL)> "
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MIP$  \!#,ZQ""F"6 "R;^2G* A1  E@ (C0#-K 8 )3@:<C 2KB5+#Q!!#!
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M$($ #( %($0B#,  ,$"5($02#$ -*,3Q)F]":$$N%@ !!   "  #T "(54(
M" #R-F_S"D  ="\ L,  ( #T%@0]1,  S,!8_L,H9 !R1 !!9('V%L  K$0!
M7  6,.P_1,$ "  ]5(4/A-)Q6  6U&GA2O $6U'B^ETN+,.R[L*CK&6(U5/C
M/B< ;,/KYL(V,,/W/>Z  H X;$(P_((7]((X<((CA(,XV/ -XW C>$ 1@ (.
MNQ&N;!VB+1H%(\2Q%&]&" $ D! \&   X()!H,\2>$,32XI!K   ( )")/$2
M-_$3&X3_$P  $1B$-N!80>0+(1P$*0J ,_[#('S-L_Z#&@; /"@$$P# "QQ$
MM,G 0$3;!F1%K<E30NP#,+(@$1OR(;>'!8<P^2&R0&4#*XCJ+L""/LA3/9@#
M-SPR.B12A?S#(T]#-M#C-\C"*K3G8.#P*=NP#O,P*K.RZDYN(V<D9.@,"<1"
M+=<R"@  ]1)$?34H(P!  (#80$   -P"E $ +=MR+."R+A,$&08"%7P "DQ
M]S( $A5$.ZQ$+"0$.#0Q 0" *2"$/FB*%AF$CBD'!8@J09R,#PQ$$H\ 16R
M$L/R/-.S/[ZR%IYC/<.6/^"#0.B#_29?*N]P#[-R0:.R*^NS_SUG:B;B\4'X
M#1L/LQ</A#^H  !<@#W8PTK \3\P-$(\-$'D"RE0!#.LQ+061/(  #M0Q/<
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M9R=$/0#B*11$-:S$!%P90>RX&!O$CI,0%_VT0GAS)AQ$$J\ 0R2QKQ,$C31
MQ.9 BP\$BX&Z0E@@.X/:2EQB0R"[1] X *"X0D3['K=S&!N$LZ/$MX=[0NA,
M"2Q$MUOZ>QJZH]-[O2\ZI'.HI /G4<\U2Y:'V*0DU@0\6_@DP/\[_\$//$J*
MQT? CPL1I<.;7GCX^\(/(\6[9%V+=TGDKQ6<& "TE$$880$+!$J#LT*0?,=_
M?$&$_$+HC!!JPM< 8Q8,Q"( @"\9A T<<R+H_,XG0A,O D)P0S *G9$O1 @
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M ( F#EH! $0&,GT$A1+Q+/:$A@  A8:( & "A5R'77;:;1]H^N01FKUV@I8
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M_W_ <2!S#$ =!7+'//XCE" )HQ@!0,9#!H(*'T#!!(+%@%<<I!V>,9A&8@
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M\(/>KBOFK=[^81&8;H;.+=W6K1FH<!LDSQS <(9PX(O^81588?'X+3S*P1F
M3>#RSH<,;_/@\.YL2-((#M,Z[SIT<"#X+_XRY./T<./N\..8 _$(C_-\([<J
M:@XU!_ &D0D[KA%MXN1^@A":"2', 0=XH =Z8 >2 "&^X0"@(1L68"!6X7H*
MHA1/,155@A^.H!W4(0@T(:;D(12JX!^<P!*RX7J^P0H&@@LH[Q^8H/ZX(!%8
M@0KL 1:PH!+4816H(!1"80LL80MHX1_D(0AX0!*P01JN( K&3B"<8;OB 1/K
M+!RWJPN3_^#8_H$+N& 0 B$8!8(+DD<<E\\;P8$<!2(?[?$;]0$+??'(F, )
M7B$1A" 1 D$4I+$>_D$%L$$:::$=WS$*5L$8J<@6UZ$))$$0N@K)K$ +LD 1
MI@!!;/$?ZK$;OW$@0F$2DL )\N$)4($9U4$:2P$:G^"+E& 9F_$AKS$0[E$@
MS+$DMRL1M#& AG(;3Q(<SY$?\;&9]A$I"6(2D. <*D >!C(1''(+5"$FB9$8
MHT >3&$+&($)0H$+(B$)<M):,%(2"$$?HN"\GC$4_J$)5B$FMX4H Q(LQ5(@
ML* *$F$2ZO($I@$MFZ"&U)(08J$B Q(NT?()#C(AMV AXY$PK?^R!P2""6@Q
M+YG 'T2@'#*!"GJM+$$1+&[ !99 QWY (*#A'/ !&B: "_[!!!)!(-@A )IA
M(, !-?]!-5G3-05"$4@ '*;! 7!O-UOS-?_A-X-S.)>B'"A@"1-Q()8!*'\B
M%&X "S>0V9QMS.R!%9HA%KYA&ZY ]:3!":KA'["!"@P&$52!"U(A$+;!V\ M
MK[C3.R-D/=OS/?&!&9B!$M;![?8,"DV$ _3"T0YNX21N$@LOX>P0X? P#A^1
M4?CR*O_1"B(R$#@/0NT.03W/*1)*B6YKB7PK0S-O1"\/57Q+SU;M*(0@U6S"
M'Y)@!.)A(/3A 2S('!C L J"1FT41P/_U$=_%$@70Q48@ 1(P $DH)G2X08*
M@A]J( >HK1P0P#;/DP#&3DF9U$FI[1]2@9$L@08$HDF?5""X=""\U"NB8 >>
MDT66@0+6<2G:(<6LL &X@NN\#BX4X<BFCM?V80 &0NP& @6<04^E#D\/(E )
M AVPH$5;30JA4"+>9K2LX]$*,0\7%!(/=)\,-.),Y"DZ%3PTE>- CD,#L419
MBU,]]5,/ST,35)\L3T0IU41=Y57K+O-2-,N"%%=S55=_M!UDH"/V 1RL3!Y\
MM2/XP1S*4"&,%5D)=%<?"U6?U5$U35H+CR>>]2FBC%4#$5-K=5-K%3PJD4&W
M==!0M%M3ZUM'_P^'=D))&@<JBF-4-<Y56TM<Y[5<Z354&2U6T+59]Y5?^]5?
M_Q5@P0)5.ZI3HY4FB@B+HLQ:L?5=:156354.&Q;SSC55L]5A!>=Q"A01*95B
M42A<*2[Q/C94X]7A'G92+_9D,6\H(!4Z0J,9GD(7?"]@9Y9F:]9F;Q97&Q4)
M*RY=[U40I]5G[15?A79<B=9H"X]<@U9>ZQ5?5E5B&4H1WS 2>>MHH5-IXZ(9
M;+,:8A9GNQ8G)J#M_L$M!8("!I @%*&K0F%I*D 7",(9$&#Y#( >#&(:"& A
M":(2-. ?$$!0!^((/O,?*" ;N( $KD(:+F @T.'IP)0$E,!<_D$&>/_-:R>7
M<B%+9TF/9\%"8RU695&6B/2.<T^T<V$+0H%V:D7U4KO54DTW84,V=4<V1%-6
M=$O6<_&U5!<C:_]A:V6V<GMW((+)&PAB!4I*'@! &(&16 5"'@Q@&HI7_=IA
M"2I@7IY  R17_ 3""3A@OO@A$2#@^#B ";2T$@J@IW9*^O3A T8 $V_A5@0"
M'2HL'[3K'^K!>GW7?N]W2MR)<SPH<[_"-D0K=%.$Z *84@;X:04XY3:V\E9.
M@8'$@$66#G/B@5_W<_J7@D\W=@V-@27V?P$8@NMN@S\8:[66:_'7A$\8A5,X
MA?771TF+974KA$5X)=[FQ+;A01[$AD^L-2K_=8)9-R)H&(=OV(;]Q(.%B.4:
MN#2 V(:W88F)^(5)MX<-T6EEN%4S6-)BV(>=0XF#.(>+6(,G>'^7(G>G(1<D
M1H7_U1)<8 1NX!0&@@B  (Y]0-E^HAT4X09*  =H:""DX ?B.!7^@8_]6""H
MX)7:(1%LX 1RX!+^ 0OZ& A\ !=IKP=*H 9R](PO&9,5Y+/">&U(*RT0]G,1
MHH56KH7RL&B7%AN.6$.IEI5;EI:R896'MFD;*I:M^)2O-H*!XXBE5O#,(W>K
M81=X-Y-S=0<B  $,B2!& 0)*SB9(H6<* A<:0" 8H )"  1$B9JM693^@0&8
M810ZX" <8 (R( ,P_V"^VH$%;$"8AYF=VSDM6)B3"9A9XYES:SE2L*&E7(A;
M<?F4.2(2#.P5 LB"99F?F39&+@(>XDB?>1EI0<5UL[B*HS9I<YF@.0*A \'
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MZ[O88YMB @#\++RS.$:Q3F;YDK/OHH0AR.,<(_@(0621 A&\)0.42(@D9G
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M( @&$05,\!8(0"@&00@N, H,: )"\0\)0%.G( &R1Q (P PKH#06V#G_U8
MVW +*D 0"2 -_M /^? X(UB")YA*0P "]&"!X* .LJ> ##@*#D@0J1 !"9&"
M)H@\^M""+U@0!H" ","!'@B"!I$*#X 0F: !,"B#!L&#*UB$9W&$(7@0!YB
M"]B #PB!$DB!^A>&V$%Z,51["I%ZL--)!N%ZL%>!+_$U9L@BZ<!Z!3&'_94-
MD3 2^:8O;W5!"U,CE/ -H< $VU )J* *E4 (I#47FL59G@5:HK6(PW<I[79\
M^)9^68$-NL,5\* KKG2)W;(MFO@6G3AQ%!=QXC='^?8M@3B(A7B(B2B)"4$2
MY> #2G 5B2 +K^").7)/[A<BQJ<5[< ,[R4@_[.&B:12*E(2%\,FAKUF#OF
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M5'H0B<)5_Q"FA7(H5@H.!8$ U6.G74H/ $!3!"$!__&E"*&H>*(G!]$G!"$
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M4DDE#7'2PD[CS5+$ )"GG7.T84:;3#7UT)YO%"0U54TK5=52 ** QQ*+2@!
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MITQ*O2%)/J3'K-3*5)$PL,LSL - ??1'@ /(NB-+1S3+!!3+1Z0]6>R[M&M
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MOCZC2+'TR#YS#6QYK[-1I_B+IY2)OXURJ/;Q*P=U:(=J\7AUF";&5B4G+@L
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MSAL.3! W2Q$'"   &"S[9_ @PH0*#>;*I="A08$ %D8$P"*01 &)X%'LF!
M1(0A)TZD"$ ) "Y))%*@Y5$DPY<R9S[\Y_!F3)HZ/>+<21%B2)]";1X,.O0H
MTJ1*ES)MZO0IU*A2A6)S@2W4!X[R=E73QVR7OJEBQY(M:_8LVK1JU[(=VO,E
MSH9&I3;,V3%DJ$E)_D5!]T]=$T:!(OW3\NV5)B$&OUE1YT02(R9:LC!R]I)D
MV\R:-\O$C+#D0=!J1?\C[9DSZM1D@:Z-2_1UQV_\MG&K9ZX</8/E[,WSQHWF
MVZ2L%7(KMTU=N7_>ZBW>_S:[MKE_N'7S]ITPY-RFH$EW!#!!(OCP%L63%YA
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M(#J>3ABB3#1B(D;B(GJ$)#9A6;Q/D4S%,GS !R@$X.&A)X(B (CB)R;$$;C
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MP[1HJP5IEW:.G39:,/(@M31" XG=3JZQ_@,"%, !T,CGB-1 &91)T:9!?!2
M>P2(0]1&G11*N7='I/A&C3A%<:Y.P/@]K3B)M[A*K92-BSA(YKB)@[5,]#A$
M(51M\H0]>_$JH]QO*5EP:\B3YTA"CRM#PW8P]S+B-30-271F-+B#VXA&0S!.
MLPS]\K:CQ70V:DDVP(,Y!,(@&$ H,,( "((%+(#84OET_S8TGD>=G@OG04MQ
MDM,2F90#HQ+X/PPZ<AR$T_9-[;1#/) ).(##=[+#Z;UE2^.#F/G#-E!-.WQD
M2M*.3$XY;5.WE5<XEK?P:'$Y9WCYEROJ3#')F)N,/20.A8L(FI\Z<BX  %P
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M/=1#BSTHH>'1*LG'-B0E>]:WAL9;<D[IM)-'^%+WKK)/O*F7O%JJ?9ZCTP,
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M9"8[&;P;DJ0C(8G8=2)+R&R!KWP%G&:7F!2S^'UOU;[R7^P,5<VV4<5[0@$
M%A2+M Q9[3]4(0!SR, ]-2 + MR3@TD0H%.I]3-[0O(  ("J/0.8+UB$\!YG
M * *JGQM;@4Q@%6\)WA;M6A4&^RK<\3RQV66""QES+:+4JYP!\$*)*N*8H3
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M(1"T(1&PP0G^01$.HQV:( B/<*1,2@_?!GV$PQ;) O\@_Z,74<8<^ 8#7
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M"VDC&Q@"!0;"')X@ '+A%;SN/>^30>TO$**@/H\@$I9!" A $ @"T4(SMQR
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M?5V%&!-BU$^*<M^[%NF?-NQ_<:(;L0'BG\"!! L:/(@PX;]< !HJ? @QHD$
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MY(87T2%*,'&$"5PB9\MX@.E:Q:U4. "("3E"*AH@"S'](Q+F@@< $)<-24#
M"5Q(" 9H<0% <<L'YMK9TVA!!!SL &,V'%Y$6/<YYM7P-OKXAC2TD8[79/ Y
M=70&-V9F&_<\99"G(:0A#SE(!")RD8.<#2,+^4A&&F6#""$!0@(QA*8$ GT$
MX?^DWD:F/[S,+R_:F-E([$'"4*[&,Z,I1Q[W=4$,#G"!6#O@!!]8P9[9$I?]
MHB72=@F> <X1F*Z+9;J&Z2%*&L0>_HB(/?@Q,)8];X$*X>%(?#@2:V8$FT,Q
M'5#414T:'9,HVL0(-_>%S!?M,604$61J0J._TNBI(O2+BS(1 I:)+< *FO"8
M4EYQA?5-["IF :4JU3+*M=@%*-*0QT$_64^EM&,(D4RD2<!'RUDB\)<2Y&4O
M-QI!>-Y2EB#594>#24'P'-"8[ DG0O86G776YCVAL- .5N12@UQ!&YD#@!+<
MB)!C60  *<!A1A+AC)[^U*B8:\@&F HQT9'.FYV<81/_62?2A\"N(++S)^EL
MASQSZ8YTO#M)*#8 @":X *K3^D"7CK6*1*CEGDI8T#\$](]5+*$__^%)@1KT
MDI@TB#_^>4)=!](@A=SS'X>]ZX+H0]C_'$@1Z  L3&1"DVU$%D"-36Q" * /
M=RHI?O)\)XTB.M<$)@06^2P? *31E:8L(PKHF$KY7$"!0=#%,@9]Z%(2RA1I
MK,RW33E+18^+W.02,IU(&ZWW2HL:U-Z&E4B:9TZ+^QG3FDFZJF'-V4(T&WA(
M0QK8T\=,KXN4:0:%23+8$ "BX,9C@0\7JAT(DSSY#R'-"X?R99M!Z)LW( J1
MB$8L#Q+AH40FJNZ)410(%2-B_T4L:I&+7@2C&.%!QHB842!H5",;92E%@E@1
M /!:X0=HX%^#< "]"&.Q/9GK-]%.SP8 6  #DF E/@$@"4VAVE;^X80&.&
M&8!4DJ;') 88( .((T!]:?9D@O @$@?!T(>54@,D%F09-N M_(C[6_AQ]R3,
M&*Y1],$,\X+Y+=259I0_JUW 25,R1\[J<[/KW.[%N<[BC%^<T\)2^=4S>B]V
M<5'4*Y0C3.@(D:"3:@D% %SLZ@CVN@BOCA *)A48S@"8!+2\56*A4!5=!21U
MP!+M$5[I6*Z<-L>EJ2Q'0QOK XH.Q X^4(I#PS@BJ:! K6^]/)HM1&%)P\8,
MUC0T O^^V6U(T\1$[,91>#)Y;2HT:3>7/9 I2(PJ'^ .?I'B ES@8-L4^[&7
MQ[SF_8E9*>=0<[J9PC]V8AMJHZ5B%"*QC&8$0%]Q64( 6+&,2,S-(M#5S&1V
MP 59E",!#0AQ4YJ!@ J40Q91V '!7<-GUU5$!%>(!#8F(8!JJZ4& 8#',JYP
M! !@K."A<0L CD"%9<"#R*(TP-)2<842$/P@W),@ %QPA51DJ@#=0:AT%QIK
M:5J/(@]H6PFPX8-WKR5TG"Q=J3]B5=5AM<]:C1U8#5([?^(.(F/M9%FE[KRA
M+*-"8#>T3"]2/J_.\-L7M8<[#VARE.K](ABKI02Q\;1TR7K_L01YQ:U=4#YA
M?6OJRZA$/KGMOE5^&>U$ 2[:V[$>W\:[8837#=Q<\XI F(TI784:1O'6:8-0
M(!*P5DI71D\03?4-HPE 6R!D40*F?"MT4#M:2&DD)-=@(UI7/LH15/&KKV&4
M@0   =B'OY8V/^0;IDS*VQ^T]']@H&T@,3?EDR+@(0JDB$>,5X*3;Q G0E&*
M#X9(A 62Q2UV$2%?#&.\,@R1#?^CPVO\?HN+TC'+((#+L , (FRR%H #N -:
MH&MW=U(DM7<J]7L:YU'?A&W?QG9JL0PL@!!1@ B2AV[^1QKK1A0&<QL-=5";
MQS"=%VWB5 ZZ,T@)L  )4"&O$'B3_Z%1!%$.H2 6"4 !!J F#4$)MM*"&M<,
MO_$40&@!OH9OU@:!\:(U._  %(  1/(4,I S?@=/Y4 *@V0 !Q !"[ #%_,Y
M\Q8V!8$-U'(!$+  ?C)(SF E6BA.\- ,%S!(!X  $% "4> 53GA,E $/H><"
M#$ !>#A(BO 3>'- V1 $@X0 !C !#3"&,B=.LL808:-<F:A<F*B)G9B)V2<4
M-Q0LS5  7QAL",$"5 ($AW-.#\$ZY3"*"T H#F<03;   G #AP-'(OA]HD@!
M+$ H3: 0SG C3$8OY61]S!4%)<",*' $T[!K%)$-1X "S+B'+K0P]G $UI@"
MOR),S+ #U?_(C-+2+\/6&H&F$3F82\QF9T\H:O,&#8^'6UEP=DRA%:(W%6-!
M">\3@KRH$)8G@G,12BJH$'$5"-:Q"UR@",R0D NY#-"H"HB "+3 !8R@90X3
M3LLW4A\%07XH9QP9@2XT@1\I>!4X3AZY:SB84B()3^BH6"G9&><822;@??[X
MAY^5=0.Q ]823&SE)>[2+6AU$-B@<^&B0'%4$0/@+I,V5!N2 0!@E#;Y4)@
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M.4#_^: #RE80FSL'FJ +.D .&J 1:JTXZ8#P1 M*( #4V3D), %3$3IM0YN
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M=&HZ,A*IA$#6&?M);&4M>UG,9E:SPL0&6,H1/S&&9Q?4V&QI37M:U*;VC=H
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MA )/"$038&  C[TZ 43@-A& P(&/9*",4L!U0L!A@H\X  A6"(031"   !A
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MO,,K/X:#NYSJKHD)BVE0E@&@0!0  $L8B'Y(.0NHAX%XO3T:B"U,EBY$B!(
M@$28!1 0$!9 !*9#B'/XB+%;""SXB!QP"$+8O15@!X1@ 0 P 2M(1"I8@@Z
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M@1A8@0^XS11$@!JH 1NP@1(H$  @!((@-P(8"$0 @/\"> $9@-4:6 $,N#4
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MB8BE"]WA)N?$-D'1(W(Z4N2DXSG)-?%T50QC%*6HQ)3( Q'+P$BBNJ*-  "
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M%;#C3-P+<F3$-!@-]F%$((QC B3$-(!6 9CCI2R !=B (.CCN!F-[FE$302
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M-$$PP5O'-4'<]%L_]*-2$%]3=4/#-4'(-3.0 B-L022D U@71CH$P14RC*B
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M$,0Z" ",_L,2''I")/]Z+1-$+&-$I;_RI7?L5$1"IZ<)-GR HV$%/:A")B3
MQ$TK@;K;#CCH-.!;A.[# "1$G0X>"CB#-RA'A$ZH/[CZ/\#Z/?\#KNMZ)DQ(
M+A3MN :JB"1YDB\$E2.&3%#!6C*#-IR#=@NCIA(RD98JJ8ZJMW-WJWY=71-$
M2"?S10/X>&_[!L8))2?RJB*LJ78[K,X[L-I[O8\R6RS![2%%/Q#!":AR,T1
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M^=37P=SP P 5:X@-ML 0 G"#)/_Q8 #Q&#**#)@0'".Q@1/^48X!5*,DY1
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M'_B%1---.X2W(?JT5Z&D@ \X?8HVC-H!696W*QX8@D5%@0&+,"?C.KBTG+2
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M8,4(@4.)1+"B$H'8!C26L(U0*/-1/?0AL0S"J7]XZA^X,LBSNNFI1&##"?\
M%7]:)!2;X22*=0EF*(99S&,F<YFU>U$[92.1QDRD,0 %:)T"VAAU-*8=!$VH
M0A?*4(#^,Z =$6A"O;'/Z 3T'*]#2/-0$CW8Y)&5KFD' )!E$"[(0%L&F(8]
M $ K5AR@: =Y@@86^ _*.($#B.1'(B! *PXP06O_J$0!,K/2]^CC R/8P4%N
MX4B#H&-G^?B )/Y1#YJ"]*I8S6I$(EBN/=EREE_]H.1"R$M# 0R&N6R8Z3XG
M01[**)7VL%?%>*;'__ZP,Z _D9&$YC)6D!P'  T-K& '2]C"&O:P"976'.?T
M4:W&*1WE\-T_TE$YB-C#'*A<B2TGYMC.>A:DKAP7#_]1C@[6**TQ06U=>EDP
MM()N8 ([*VP_&R?$VO:VC0$L8'.QVX;V]K"_72A1UM)6.!KWN!7$('*7>\$Q
M<BM2C:6M=*=+W>HZ++3BVA,]S&$O?IQCEIG[G*'*BITW*G>,+Q0O:P-4W,Z5
ME[FCG1&%*#0AY,475?!5GGPGJ%\,UG>VI\TO@,][H=5""B8$99&MTNL:U:KD
M&QPP+@.C:]T*6_C"&+8/=CV"VP[C]2D5R 8"#>)=#*AVP P^\(,B9*$,OO_7
MK7L]%%103!64J567(.&D'[WRUJ[HF%_Y7%!6!O9C'KLX+#\.89"1,F2SWOAC
M,3HR2R2J8.+B$W97]D@[2/J<99 Q*A3.\$SP00@9V$ 10/T'/@01A9=8(1:6
M%4(@$$(%( #!!TY )$*N, L6+6$Q64C"C]CQ@YUAX0=V]D$5_G'H1"\:(<SH
M00EJ *\K .$'/^#"?.PA9X6T(Q$V.$$.+L%H1-_YT9&>-+P,0H5;&"30@RYT
M0MJAB!N4  >3F*5!+(UI31NDT:?^!ZP/0NC4#0O.">'TG.F<Z#R+^=FKV7!&
MV.CA:B.(I1XTB#S.$5X5DQ6&PDDQ[HPCVR!G&<?_!G90C552#5&H0KQC:?>[
ME8QC)L<6)?*&-T;R3>\GV[LK3DYW>D'HU^)8&<6\.;=&G/$C/GE;X.*&N$;"
M#.V6.( ;!F'$D@X2B9.ZQ *DJ P$MD$#3!SD K0PB$C9D9 +I"(=%5"F03)0
M"4\:)!L0,(@&5I&0G5?$&0=H^#\R,))_I ($.1MYR0_BCPUH02$^1PC0A6Z0
M"O!\Z#5?(,X1XH\.#(+K*WCZT(M^=)U?_2 TM_D_MIX0D"=;Z28_><K_L?**
MVYTTTL[(9N3ALF](5B;G& C,W(D5HZ0#'O@PK5@1PHI%,$*33^[W1[J#<->J
M-^#CMM&,UVMCB,,6'I8(_Y61E8,[T%NUX$N.O,0Q8OI^P;CTH0=RO56O\)29
MZO+R^MS!8>-@E=BC?L_AJ[G1'7&%?VL7TKC>W5>B#0=@( %'2(@6A.42!^@B
M(?1H0!((D04!_,GY(8@ !("5D ;D  ,C=H"/.E#(92#]'PZ80 8R@ '<Q'_^
M]9\U"VPP'P=(H@87T ,/D7W;UWU_,@H= !'W1W^(U [[9S$,D"3PMW[M]WX&
M00H6H!"XT  &X7\ *( =*'\,.('ZP'[_X'X*87T(08#<YWT' 7[B1W[+-X-1
MD7?080\9Q7?.X'<M$7C28#@(D0LX>&T' 0[F\">+9S>4D FG,!,.-EN5UUI4
M8?\*@W RY#8R)6.%:45C#S=\&K$+H: )KD<=N .&8BAY )=-'V&&8TAZ6L&&
M:.B%Q(=ZD7=[!T$R)C.'X,8@N_<:O:<2^L ,=;4:PJ>'BQ(P*$9Q-'@1FF "
M!X$)X7,02X _+=$/ ;!J_Q /#.!'!C$*&6 0!$ @\],A"#$ V) .$6 )!S$
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ML9['+L2J@4\@&H.X?-#P7= P 5R $#?@ DO@$AU :MKP !(X-W5C$'=C$""
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M*H4H@'\(+UK\AXGH"'/(Q5W,H(V FUM,B& LO* X/"MDQF94O"4KN*O0!R%
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M 'AN@8ANV>#@[Q;=>@6,?B""$ZB'OQ  5!Y# (AEA+"!^2@' =! 'Z""?Q@
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M9M8 L -L>J2% )#%%4CRO !6DR1'("<S\:@-^.R0DI<R72"B&8IE\),D^03
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MPSGHH!$"I$\@H2Z@(S;LPB[<'R:67"XLPRX\)"G.1*<\TC^4PU^-8I P$.H
M@(&)! GQ2&1.9DA4YD=<9E!@DTKRE8W02$N*Q&=FY;^(IN+P1$S2)&NVYB39
MI..5G00:HQ<*8_2)V?4%93!N'FWFU0:RG1JZA#,! #1)4_=='G^AVT)H$S<)
M2R!I5CB-$PJ9$SJITW&*F3LI9]B!G#-@014D@C9P9]JLC3Y$P5]HP3>\@BAP
M 3>,IR $P4%\@Q5X)WC*I?=-)",B3TX89#L@8$SH@S<TPRXP@S-8(@Y63S:
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M#GDII] I7M:$/F!#D]P=GW*#NP1J<5 6 *P"3:@KN\Z$NAJ?()E#":2,"QB
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M<@"! , #-D3"-5T!3&"S-G,S 'CS2X#S-G>S%!=3ULC;B,QF#4-0UJ0 21
M#1?R2*PS212 ._>9.F_3/-=S"C/RP]YM)!>T03=AL8 O=:REJ'D+7+(:-1P$
M$I1,.5  M_(<*1?N$0>NX#K?*7]L%+\O%$\>O9E3281@+\]A9IF@U."R!O.A
M34R"UL#@D^4R&3/=33_P@0(SWL5$_L"?-+[?3G>;3_-T;0%)3H</5I@.2@%
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M"MD2L XWHH5>*(9F2&]*;/TX H=TZ-L:PH>@+PE+0FV(J" ^RR"2:(D$,:=
M!1=?@A%/0AJNQ!Y0Q(OV;!6M$3HN\1JU<1MA@A/)S1,7,10!X!4^H->BX C8
M*R28H0NYT3K4\,IP0@$W@I?4))562=(P@P5AJ2AFR2%JZ1=]:I<ZR9<:@A2#
MB94*C9B6\1/71\)0XAQ&ITJXH<.HL=':\2);(ALQ<B,Y<@S5*K5B8@H=0R!T
M 1;^81=@81^V015>P9Y40AZFL2-9$:/N:K9@42(ZBN;^(:02_RN37,VD4$JE
M> \D6NJE>G"NTF()*] A40(;*+([VB$FBXD99;(J04(CK3(K+](;GP<<=2J9
M9&AB_B$1!D(1_@$1VJ'.3"(=I%(KP6SX_BH'.4(;"*O'%J(8%^@O(I"Q0$(*
MNBZRA#"%+ L ,,LCCF@N.@LOGVU8%H*?NB]IOJ$<U*$=P&$@?$(=P$$R_Z$=
MXH$R+;,=(G,R0Q,TP>$IP5(,&5(;".PZRJ$MEY$JW3(VH>2Z($@V;?,:N?(A
M9N+0,N0<V&$@SF$=_L$W!Z(<XN$?U"$=R.T"FZT:^N$?_,$?",(%\N<A=($L
M"<(4+L%/IF U#4(?F '];C-,:%*];/_2^-1,#0% !!( O_0+!B,P0@1@$FY+
MP # .]W0P/[" B1 P1C,P=;"'+BA'.C!'.8A&_B!&[:!'_[!''[$'.#!0!&4
M&P240"NT0,^A-!."*5-"'L+3.NSA0U5"W\:S1&>3"TTT1;TP-]LGER*"0 <"
M')@&1@="&]2!ZI8S%W9!1 0"&^ZFQSY @:;""AI$"42!%N8A$%!D'GX@(CQ4
M.554:N 2!S<*/N&"S,PL*-#,RVAPS7;"S>PC2_.3/.9,+;\#SS0$-+S!&\H!
M-//A'\ A&_)A&QR48[Z!'K[A3>-T3=N43]O!&^I!'02%Q%"S)3Z,BZ!#'[[!
M&<1S1&\Q2E/_-$KB#U(I=?Y8]$%FPB)'% U) A^*IB#\X3@YHAV<@1N@M%+3
M!+[H4/B.+S&Z+2\'(MHB8=QJP^9$1H$R1R"TC=JNSRV\;;+ 3=S2E"')B$-=
MXARP01JX(3+9,23LH1W2X1NDH52;-2F5$E5+%!LFH!(L(41WH5JQ-5RWZU(W
M] *[,5-ATSGT@0/245SE\ 9752YY%?G@HM>2 BSF0N9.0"=WQE;_0B[HPBYN
MH ')P^<B)# V2^@. T"?PQF94$"NM1D?U5VS$ALH !M"X0/.X;J8X5LI]F/#
MBURQR5S3%*E:B2.Z<R H@4]>H1*@DPG,(11FA0C^03O]Y#H)(A10_R5L(% V
M6[$F80(N6XY>CZ39=&<+RJ=7(T3Z% 0 9,#&MNWZ?@YWFA8 FF]8&_:F)J(R
M_P$=T@$T)=,S&_0V))$"S<$?V"$Y2><?T@$<OJ$=Y(%KO78S1Y-KJP^,B!5D
ML]!'1[$<"2)*.A9<]79P,TAD8XMD72(A\Q'I_H%)_R$0?H0*OF$@!$$;$@$;
M8.A(DU0;B'0@E&!CLJ9G8_-GS3-H;W)?D 8 4E<5P^BG\$^#7%?BBBEO/[)0
M(\(<T,%KT:$<+E1"$Y1L(=:8\N$;]B&NMJ$?M.$YV78;<C<==K=!![1 #_1W
ML3!='9!@-2A2IB.AM-=>NC<G9'<Z.B4Z^/\V8^WU'P#78PEW?5<0-GLJ')/I
MIT C5!W"'J1S(SS5Y$376Z!/2?+/UMZQ74V754%6$5%"'T"SFAK581]"?+;A
M' K43_,43J'V&\OV6LU!&T)T'_YA3LLA,AT8@GU"@O6T@DET!B,N?CA%A5_W
M%'D(XN*'A3%%@$J7V2204ESXA1G0:"XCA1M.AE5Q?R/"?,UW(CA6?=DWB0O7
M?=\-?D=D*S0U'@7XQH0#C617B"F(='/X/.7570UX),J!&;[A4Z.'@1?1>K\1
MC:>2=H6D?Q]BC$UW5S:"&SA82J?8-9_"C1VB'0952B<.'<YW/;"X(,NQB#LB
M?057B169R1*217K_"JCZ%9*?6 /CT^&TMWLYI9)O(H!7HC'N QHGRRU6<U=N
M>"%6"9-Q>%(TV394V899.95A&94OV=B<0VCU]HL_XAP853<W](G9N"LO6(U?
M\Y<90H\;0H/CV%<V I3M&#;T@9DU*%@VXAS.P2:-V2"XH5'19Y!SMI#]-B00
M>9'%>7 8MT4I+/Q^@Y<G63+T(V/!YD7L!RN.8 <([!4N5IGAX0,"P7$"H1PW
M>8HO:"0]@IE#P35F*!*R5" 40!P8NJ$=^J$AVAJ@P .@P!?$00$B(AM8@4]0
M4B-&IQX$5*/182+_(:XT>AJR@6F^0196 9K?DI:1PY8+.&(]@E2[D#>T_S9%
M7-2"@Q<*R[DK:?I?KID@VB$BFWDTRJ&:DQDVM$&;MWGB%BZ,I-E)\=B]N)F(
MOYDDPGF<N;I=:*H3,S42Q?K/?- SSF+>3!(E59(2Q@0NE@$6TCHE5U(2;$D@
M7J$D3U*N56%?'<4@S/(?*L$<V@$1S-(;8"$1)J$?%N'< +JI">)% N$(LF$9
M<HS %/H1/H&A/>$:@*$3-@$8(%H<0$$'6J 3(!JC(4(05 $<_.0L_\$LIV$7
M%&$27N$<1"$2,H$^51L<*F$9;B$3_J&UQ;<\MWB NUA<<7F935.=8\N7Q_JY
MW2W]%A>Z'W%BA7JTY,&EI5J.(:(#I3B N4&IX_]XM#XLD3MHJ/^A_+X;)[ Z
MD$VD(IR!NN5[ONE;K+MZ&[^:IWD9NH&:13G1!?X:.\T2$2:A2)9!+ 7\+-LA
MU5P 3!,<$9C!%)-/"UAA&V:A%"AA"R[!%+A '0A!@;1[NIF3([Y!O+-FH4/;
MH26:HBTZQ2^Z(_P!'PA"'^X72\P0*6MYA2*HT:*8@I([(J2!C/M[F#BQOB.Q
M$8W<OJ-YJAV"&XQZJ=]"&DR\F2'BF9UZNRDK':(ZFH?Z&ZHZCV&BO5NB'9*\
MS,U\OIE!&G[YOFT-(88FJ-V7O].YE^$B"EZA'YXS.HO3-.#B ]HASVN\2!8"
MU? <.FN<;/IZ4\E0@*7_8;G#!L4A>K1+V\5/V\?+L,OBM4H7Y\;;5YA3YU0[
MT9<GF44XV;O0=<F->5'-.X2XNR#T01N^?)OWRAZ<8<K'&RFT_,JY/$A472=*
MG=4?X@A, +AU\]0; C2[*U.K:<W9G-;R&Y@QT <?0R R5JIR#!WE>0<<9X;B
M62#RF<C^(1+\.=$O*#,B S&0M8,@?<4KFM)='+4EB,?UHX:7_+C)V=R9W<;A
M'")"7)TOL,AUO*!V6JJ97!J9 =3!-]EN(KL;/::3K2#201J0^16A3U'%.,>A
MSQZX@1ELW9J3V1B;S2O.KV>0QOQ,_N0[_JR09MF;/1//<+^C'66X(E($O5.T
M_]<T-@4>5@SZ?IVZ+ATI:'UR0T@!2-NTW?WHX3V"5!>HBAEHM<G>!8<*!^K'
M]UCHL;8X1)* "4IQ45T&AN!M5UV0_V$(OM[1*=X>OKX<=-W7X8(#OCX=A-SA
MG?;MPWYS /J\"R)DLOH?)GZ/S_SO 5_.%8/E6[[6@CEU(-'3(1:2 [_QJ7L_
M[ %9.=X B]WQ+?_R,3_SJQO)YSM',9_SY7LJYQQ3K?OA!?X*T>?N/=X=57_U
MJZ/G77^[!T+OS]>E-?_V+7]%"+_P9ZT:^PR7JI<C[:'N>;_X);;'R9W^FO[U
M6__CF9^;0Y?U]U<J:!\B$%72<#_[RUSWD=_X5;[[@?^:BH+?^\F?]XV=9U-P
M^:D#]F-_N*$?_9\_:!=B[QWB;<-?1?"V>O%_$O._=_3M_P'BG\!< O\1+(@P
MH<*% W,1/&CPFT.&%"M:O(@QH\:-'#MZ_ @RI,B1)#TZA/@1Y4F$*$NZ? DS
MILR9-&O:O(DSI\Z=/'O:?-BR(H!_0WT:/5JTZ%&!0Y4N)0KU*=.H4IM*A>KT
M*#9]%"&J+.B5)5BQ \>:-4@6;=FS7]>J+;G2J\2@5^O:O8LWK\&)(57R=:LW
ML.#!A L;/HPXL<F]&JTJ?APUJU''5:D^I7S9,E+-/N5QJQB6[=FW;4FG+1W:
M+>K1(^."G0LYMNS9/5?V9?G_]RWMW;Q[^_X-/'A'H(TY"Z]L7.&J1(&:_=O%
M11$SZ-*73?NG"A$B6EP8O<*(N>+RYL^C3S=O/3NB=LVZ?[\8GN)XY]3/*YIT
M73U[]^"3*V=.7W22H)>?=OMYUY]D#,U77WW68:<==PC"YU].^CAC46JF :9A
M:JN)QN%H'K[DVD"P'8=BBKO9!I)?I:D(8XPRSDACC1<1EU%\-N*4U$5)Y"/0
M*JQ,\H0BZ!!IY"32* 'D/Y04N4V"&/T8Y)!%'GGE)#LTZ2244OK8I)!(8JD(
M(4MR^:0B45*HH$)4_B-FD81D>69!::YID8YNAJE$EG0R*="=7QJ5CC0WB@BB
M:J<A_QJBHHENJ%MK$\F5VXZ67GH3BRGA]B*FGGX*:JBBUH2C1?JTH^>H)/5H
MD3I-,!)()/]PX8U M-K*S3I-2$)(%EDP@B&;&+D*JZRWSEKKK-#L2H@^6OP:
M;)X5%D1LK,C:6BL7N3+K++2#5E2ML=DFJZVNO'8+[+<4A7MLN]ORZFNZPG;&
MC#P8=?@HOH[N"^F'^]+5XJ2O5:IJP08GI.EB8.4&\,$./PQQQ,*5BI ^VDAS
M#E<2P\1J9FWVE"I/(>\T<DXEP]2.--IH?"^CD+X\8KXR-_JRI \M3/#&.M>8
M\'"<IK5ST$(/3;11%/_#S59%E]3Q4B?S.*U.3]\T=4U5<_\$0-;,J)RQPKK%
MS"_8,,_\]:,VDW;BTFH#US-'+@*]=MQRSTWW6'^5HTW=(#6]V<<B1VTRX%#[
M+;7@'C65]1'_!(*-SS3K6W;8+D/N;\,F"6QBSGIO'EC;&[W-&N>BCTXZICA*
MTT[IQ1EN->NM$UXX[('+3K7K&UD%P!$+!+*,XY&/_?CDBP:?J.7#81Z1YJHO
MSY/G&H$.&//23T\]9,1A8V_U#/$]F>TS74T3^-]['Y/X.6(E4"BA^%[Y\/^Z
MWR_\8I]-J?':WW_V;3C#C7___O^?$Z"T(V\ G KY.'9 !-*N=@NTB?D4&#ZH
M+.,($WS/YX1'O/>1C7+NL]_GD)?_B[05<(3'\R!H?A8Z$JIPA2SLREZ&P(&L
MR7"&-&0>]WSR0 A>)8<OX2'3$BBM!C*$@QF,WP8QJ$&X@%"$+6PBPI27$>A%
M2C8GJ:(5KXC%+&IQBUSLHA>_",8PBG&,9"RC&<^(QC2J<8UL;*,;WPC'-,*%
M,1EAP3\FH+H;@@R(+O'A#X4804#*Q(_;\UX<#XE(,Z(-BDY<H?.BB,+H4?$;
MYVC'-[@A#6=( QN4;(<]&@G*4';D5.GXQL4TJ8UOI"-E)CQ4+@09&WB$X@/P
M*(P>_P;+\O'QCW4AI$A\J1 >6C(7Y\"&,[B1#MJT@QO,P,8Y[,'(YRTQFJ+\
MWR-;MK\4_UKO&ZF[""E-F4F5J;*;U2PG]>1A24QJDI/E\&1&I-'*#!D$F(+!
MA@MDJ;C!W))DNUQ5/T="S[W],R0!+8@P):(0>90CD^<@S#F<X8QR9.^)2KQ9
MYN)I3NI=\U#9E&1L0DA.DMBC'>7XAC0^61!Y3#2C+%752!.B#6YP<Z4D@><<
M7SE0PF # AFHI6#V&;M>YE2@N=2AQP(IDF%B1*'8*,=3%BK1*&*T*].<:DM5
M-\8A1G**'^5F9T**M&^T$Z57+>MC3G4.4Y+U'^@TBDU)\I""ZB44 * E88 Z
M.Z$6M8=#_8A<L=;7J>Q5J:-,AS:<H8UTL*PD^CB'-IB1V,5^L/^BB[2J6?_G
MU85(T;)Y :E@T/H-;(13INV@Z65/"Y.1EC2<TA"K.P7SUM;,,[!WH:M=;<D4
M&NIVM[SMK6]K^-O@"G>X62,*<8^+7!D:-[G,%>YRFPO=W=+VH)Q-B#V*R0QN
M@/4BZ6"F,]<J$FK>"X0;12T)#:75CG)UF]M]##HO&4Y.5E*RYBUK.TJI3G&N
MDC>Q#>]L]TH8V_K4,$F)KH&!>^ $%U?!"GXN@Z'KX <G=[I1F<<WS/$/<WA#
ME?[8!C[^T8YX6!(<Y"2L3.3Q#6<T5"'<B*AI253=G]6OOJ$\J0O5&V.[>-9&
M\M@::=M+X^6]UZ32<.J.^GL;G (X, +_5@Q>!Z?7*.^0MK>C<%'RH0V4@H,>
M_I"&.:YC#GB8XQPD+HB)9V*/3QK6&]JPESWH&Q/QWJBJ06[BA<"+L+U@<;V/
MV;&J+,E:U^*YS@8;:5I%J\G,%@S)+?IO<$J1.XZD8]![I')QENQ/3 /4TI>>
MLJ:#&95SF(. W+!'-@12CPW3PQOU4 <ZS(Q0E^C#L)!5K*D<B]ADPD3.&:(S
MH5484XXVI%.3!#+$0'M*:?SXU\)Y;W[EVPXX2XS1FU*R<-H148S80QK-P/"4
M.:VNODFY,I\F*E)#<N:.>,893:4T1^Q1#F-RX\4?=&-EF0W AZY8V'KF7U>-
M'3=G2V-K\L6W_UU*F>QECX[:B[$VBE*V-54:&I.MM0<SI(U# Q[5T^/>N,=U
M.=A8+S5UW:7WB57)5I-K-L?#OK?!I7<Q;D?4W>EMN3;[K&C\R0/AX7PY25J\
MR4X"D.$^<_BEF(&7)S.PXTX#=[@S7FZ$4)<AC75J8S'N$UN7HVM#1", KNAR
MGU//'I@$>)YQW!L_-Q*TB&[M3"^KVM"&T[4J5R'1W>;H2RTSZ1IO>M3]ZO1Y
MD9OCXPOY00S+;JXCIK&'3>S".@(/+FB\1,ECN=B79E*L<XAA:<_Y:>\+3E2.
M\WX"7V<G-9_1NU_0Z#MJ\T4"X8,4W+9U@1=*[6W_]\/=GB)_K7+NT?^'[D0*
M_Y",$   3/#U+U[>?]P@X(UM[E'V+E\@<6]MQ>H^*GVL51[*YJ;9?ZWZY^7=
M4IY/R!%R9T]9SGZ0?1<WX0?_?K\'4L+TK[_]#<S$Z5,O92=$.V_4KG\6T0X#
MB! H-E\I GK[]@_VL$JH%X "$7Z0Q'HV8@^-LQ#GET\"@0T H'X#AD"[MQ"]
MYWM,YWX?QS'$-03?YS  ,   @ -#E'\/R#P#]'S]=G.* 8 R"!)L-UIO=Q=Q
MUW:"IH,E$8$M,X$V8F,(@8$A:%#C X*@]GN %84C&'\EN!380',0,Q3-4  8
MH%DQ.(2EHPU MEF=IX)A2!*@EU^IU( C47K_XG2 :'@31>A*(F@8W.!4\+"$
MA=1^?=2'4$>"W3.%G09_2U&!2T,X522'TE,.1J809?A_Y;>(/@%>W  -V# -
MV@ -Z%4063B).4&'\G2$.](.E!!IMO>'_O2$"6&'YS.(KAB(>_2*%N$,#KB"
M&0*&GR@QY=5_T,=G."B)NB@3/.AC''$.TC!W8R6,H&AY<;6*D*$4N?=D\U$>
MTN$@!;(=_"%X%D&-#4(@^M$>$Q)$&=&-YD$=^ $AZQ&.%H1[Y @@U3@@U8&-
M!\*.O"<X#&*.!)*.$E*/A32+#"$/M:@VB9B+R^@PO%B#FF)Y4I&#!JD1Z+1:
MIE=)GO@2H)=PH^>0_Q\1BB<TBK>8BIL6-6\2)TGR)TTB*-M($2)I)229)%MB
M)UZ"D@RADF.")&8"*($"D^,()E52DR7YDFKR='L2)'W"DD=2)UT"E#%I(2HF
M$X,0 R1  B4P!=Y6$$X)E5))E0)AE5$Y!0KX#ULIE5X)EEV9$&/IE1U!D+R6
MD9Z"D#5G@]&'<V<HAPP8>OHEEWGQAO*%?9^XD2[4D:&"#5$ #]BP \7UD;]T
MF (1+M?"F.7"+/$2+>UX$8O9+N2R+.?R+/*BDZWR*M92F;/R+LV2F9%IC[)#
MF>."*^8BFMZBE K!+N1"+J$)F4%)$_J08GO)$<RP Q1@@05! 2X@"[K)F_\)
M\9NRT R[V9L"\9LV<)S#B1#+V9S)^0_0B9S$Z0(V(%"@49!K.2IMJ5E;M9!/
MT9 RR'VF5PX4*2.S5I=G.81]J55_"2KPX ).=7[1Z(3_*)F%:()6R)\]E#47
MTTR*%Q/EX (NH!"!  #+0* &FA (JJ %>J NL ,+&J$3"J$-*J$4BJ$[D)U=
ML9W<&2K>^8C@:8;XQH.:1%JX&31 F(ROQ6SN^9WP"2K+X )'4)]-R'[/V(3X
MF9_[*8A5Z)]XI!,7BA .^@]$6A!&BJ0"$0@2>J0,6J1.NJ2+(Z50FJ1."GC:
MJ98@NB,B>G:^&)Y+,9ZA-&3Q=7J-9)'AQ(9WN4+_,#JB,CH2VL %D\ ,U_$/
MC/ /RW )@A (T, ,? H-UM$,B2 0EB 0LC (D0 +!2$*BN"(,E$.BK,,WV&?
M.<JC_AB+LIBI_/1[RI43]+ *'Y"<\$ !J: .H"JJ"$&JIHJJHUJJ[-"JJOJJ
ML5H0JPJKH>JJJ< .%.$/\S /_,"''KJE7,HSPPHT"EFBC70Q,K5?8E>F ME(
M;IIG<"H2Z4 $YD )34 (A* $_S )55 )7# -DQ"NXRH-E* -0F /3_ /2_!)
ME8"G_S /0# +^K /A9.8V7FI3+BO_+JIG JD?628#A1<"?!;!NM;"-M;"LM;
M#+M;",L0Y3 %4= $6?"H_],20L9*K#+BI<?*>9'(IFKS30EQ#G&XL2!62@FQ
M==$V/=(J%M0:$J$P"4F@+?]0#E$P*TW@;5RPL]S !>KP#X@P!/^@#DX@"8S
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M2?RC$E8(A"K^L8I$!*(9S!#$();QC\ -;B6R&$0D8-$,+C#B%8=3GU]&F4J
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MD=@KD324":G A@1   ZH@0.8@$7(@!TH &8 0<Z;0O> PDXC07J3/)$0,]_
MG;"KIG[(LRPZN)CR0YD 1'NCPBI4NT/[PB?+0NLP/4O<1(H*%S(<F 1<&6F0
MG 9D&D?<"R78 0 (!!EP  /(!I^ 1+/C0]%ZO%/$"C\T$D"2(/A#)LMK)4:D
MK5O4P_VC18XZ1N*[Q??QOY<XL7,RLG_ FYXB,2%C)W<2,FG\!TM@LAM3,89A
MGY3A1''LQ#!T#*YS'VAB+=A[0$"!Q5A41F+,)%GT"GB4_[_YR\4P.Z8Q^SI@
M_,18G$?/2SM*%,A[##VYDQUF;(EK,[;MZ9[O*;5FJX2_:H9F:TCON;9FXP]P
M',!Q[,AT.\"Z\T<; 2,<%$F(8<<W20V55,G%(\B"=+Q' <B [)%\-+=]S+!@
M7$23M(UAE,FG<TG0 TIY5$8XH8(4L$<=P\25:+FHZZ$?LCF=VZ]7$ 6=XR$?
M&H*6<[J7T$2/[$KQV,E!"<5JP8U"$4N$BS=,$ ROJJI_( *>(@)62(5 :,+Z
MNS0K\<G\DT0'M$5C-,>:+(V;O)&<),<GU,L[TB;$',@56DG&;$S'?$S(C$S)
MG$S*K$S+K,Q<2 ?%<1&N[$IQ_/]*<S1+:4FC[4-#E+P*1,"&E8@NW%*$C1L"
MU_R'(?@'+) GYM,VH# 0#FB'G$&7V$F*W>Q-1 (0  A.:9"&X72-GS!.Y$R=
MK-A-6%FF8"E.WF23Y!R2ORP+7VRMDSK.XX0&?RQ%H\/+F.O+QA-*YS&MRUQ/
M]FQ/]WS/QWRHR$P<HGR*SO3,+P1->A%-0)D0-"O-JS@Q'LO&;40RYCM-LQBT
MNGS$/XQ"F\C-EK ';*!+-(D0>Y &HAFF"-&'FME+"YW06=D5"=$&FU&:#271
MP\C.Q C,8Z*(=D!1*=&0\!Q,Y>O)>KQ1\PS*_*C,(9"<5 ( !@" % @9I02+
M0?B * C_A".@@%#@B_O$3P+\RM4[QY5IJ;)4K5IC2.[QGG^8-MLLP?J4JW\<
MTW<,$ A]B7+8K-##M&]0TT/#-%CYD3-UB7-PTU(1T9? $BV!4\/A&17-(A8U
M-Q=="2GZCQG=2?V 3T5]T$5M5/EL5/=\5$AE3TF=5,LDSYCH4X":"7B  "*E
M3[MP@06( I>(A 5P 2<%Q_.#TL_TQ- $RT<339!#!Y^C.:><S973!)6"*P2-
M208ETT?,S3G5R%TM1F*;D&(=R@"YB70\C6%U"6=(UMO$4Y@810AQ%FOUTZPS
M)IM41\',A78P#J) T4-]0DN-U'-]STI-U\E<5W:-3'=]5\?$_]27Z!7)4@HB
M90Z[* $74$V7<($2\*=E^")L"$=6]4(IG5)8U1;^!)E>11M@-95Y?8UY(<DW
MG1>R7-.*W9 =759FY5CBHU:86$#=X#ML\-$;22VJ>;VG< 9LD 9S>5EHP""3
MV(7O:P><;8=I*%<2,LP'\ME>.D_DN-#*PM?H*5*K6 $7:"B6* <76 '">-*#
M=33]1,"%O0Y]R-"PO-I,>MCDB=CQXCM[V#DK%%M-34:/Y2"=.IYG!9/76<.7
M6%OU3!JYS3"IX-I$052DG$3%1,:^%=K1J%,(,]JE05JKP(4/> 75+(=7^(!2
M: RIG=H(2]@I=1Q[J%O.:MB]"U/E^_]5GX!,6GE :OC//11=#4V:;T!9/4K;
MF,@&D U!D86)U&6;!YS=V:'7G^R[>8,V'4W,OP5<X"T,+)'6G0@$"DC2*#A>
MES!>Y%7>EF#>0$A>4GW>XXU>YV4)Z)7>Y:U>[;4F7 3%S033R_R+R)7<R*K:
MD(P9>3C;S,5;C?+:B8G8YJ#8AU*+RF0!2F7))[M? ,#?2]5?(O/?R,1? :;4
M_:7, JY,4^F)?.C?R4Q@!89;EZ '!W[@"H9,7;2/>(R\GD7/]/3@P_S=OL 2
MK;4*46W2EHB"4_V'$W8)%4;5%D[A%8YAEGAA%EX %*[A&<9A%UYA/OO>)FD:
M=G !'XB"*,C_ A1&R']8ABV0 B,^ 7^]B_(UWU1"W_#0W!>YSBLU3<[%,OG%
MS8?2A 3@U0F8S Z 3UY- #,& "*(5/N%X,8\XS9N3S)>8W6%*SAFS#.^8[7(
M8SUF8W@=B2[>X!#<W;W]8-\-WI=,9#ZJB>/\!NU#"WZ%"8#]ATE^B4J^Y'\-
M6$UNB4Q&54SF9%#>9'<#XMMQK)Y ! HX@E=8AF5X!>/5!H1$TE!PY64(A \X
M KV88BH6*%?=3_=U$2IE,/BUF"^VRZCHXEXN**,59 W&W;R\4QO-T=[UVT4^
MR7A3VJQ9AJ?]!VUV"6Z&VF]NB7#V9A?8YFX>9Y8H9W5>B7)N"7"8_P1)@ :Q
M:\GV39I*> *86 8JD)T."(1]]H&]X.5EIA\K)H]@=@SB[;J$=IMBWA'&M$MD
MKM^"KN@QW8V9<.;#@6:C,V2.#E9J_DV@!2ULY@M+2%QX^ =X"(4/,)R3?H64
M7NF69HF7CFF6=FF45NF;INF<EFF<AFF=GFF7\ 9$( 2RO>BC1>6=V * ?@E^
M]N>F!N<=Z N"MNC'.6CLP&(3$5S"K+2'7A8P!F"KIF+)%)1!_N@4+$P0_MFU
M#MIK3K2O?C9YG>N59(EY& +K4P<I@*I?)5*EWHD@B((<QID/@ 6$I "F_0=L
M,-Z[\J>-'.LJ_F6KS1:N[NIU5.8#C4\)AO]L_(R]9MZ(LPYMM6;D:A;ATGYK
M/1HMS(ZI?T@%%VL)4E@UPF6(Q/GKG1B%#V !%W !)#UDF)B ?\#EW>;MP2;?
M$I,B*N)L7PY#A6WHOSB'$FXDYPZ5.I6&/(QK$X$'0<"XSUUMY8X9>$!5T-5H
MA1/M#B9MD6YK %%O.2OF<E@&(=B!'6""AO+N-5N)6W"";,"'<Q $46C0GR#-
ME=!,C!!B(C9B)/9MNV1B)XX"*.ZW91 1@_UN]\'J0]%J^X#NTJ!1O> &8DF3
M(1B"9W(0THV)8<'0(>  L*"I RB ,>YN"C_86Q91C#;K9S9O:1YIDK9FU.[Q
M1BZA4*" '0@$(H__7O$&E -A7\*5!SMU*<A8&I9F95>&90J0Y3NC95O&Y>E]
MK,>.\<GRQ.:>%@$2U.D&$RWN6$/ZAF:5$&S AHQAU .!#4I @ :X @B0!@O(
M 0AH@+R)72]WM+%:B;74A&G@AQF0R_R9<4M[4!O?:,[519/DW?1&;[Y5Y$F'
M:P:B@J@FYR=HFD!?RU ( H%Q@J0JJU"X'B(P=5'_!R?XAT!_*S%]B4'0MN_E
MADA>"5M_\IZHA"TGYWZ^BG\.Z$7K\C]G&0N'#PS7CC$G\^K@!HY43IB8$([M
M#]4UTP@L!WC(!D(0A .0!$T8 "5X  -PL<TN=@A+K]7DKD18U=I<B7+0_V6I
M^&RT!N/M@/3SCC)HG#(N8S):^++<Q7</TW>ULALO\\9HY@DM4RLJX\8K.WB
M/[(0&[&!K[(@\W>'OXD6$_@2HWA$Z'>#[VBV92 ?X&YPCH*F07?6U 9%, =M
MR((H0"[G2@1L:'7G6OF6)U5TS[;QO.^O(%L)'0P>L&V88.I]_G6K"':GGNKD
MJ&ISEQG)3M]$P;MOI8XU9QJ#,9QE'[;7T/J5&(0!( 5,: (.N($-0 !MH 42
MD  "*/>FKZP]^P<%I61(D7<<G[NU6(X<YPEI\S9J6S9;T_F)[HF]I[9O"S?
MCT+!Y[9CJS:__WOWHW>]5_QJ\[7&Q[;'#_S(!_\U)>![4VO\C/SWU.X*>/B
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MY\Z>/X.NNG>OWM \<Z$VK3JGMG.?1Z^N*BTV5:PYSV73)G7GRI2],1$ 0$$
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M6)<Q5G:9H*>BFFII/OJX7(^JLM9.:'N%6:NMM^*::Y2Y\HKD41/FQ$*OO>8
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M7 ,EX;;$MLH_S)&-X!@H 13(0"0F3E]M'?H54<!  Z!K( :@+LE5^T<V-@"
M"ES%  X 011>X?$LT0=/RXC$!RR@8P.MXF77OK8Y)H$D!%A@!/^1>#?SPBR7
M,1^%&7U:\&/:$> @LUG-[>8)-V2W[_WF9#: WI3B!7R4=/Q=P2__AN'U"W!!
M9S;8  CVQ?3-$'DLG">%' PBRZ+(Q0S&D0H"Z1MCBI*.+^0(E)9,RU!L^]OC
M/O>ZKU:)84XY5J&\Y1WV?&Q"73O,^WY-Q),ZSZ6%=(M9>>K/'Q2X>7[ML-=+
M5]-Y.=%R100 3$ EX1=6]\,4_D<=J5G"3]?+SP$ \M_J_,C:%?H!</;RA__[
M:%5S^:4DK/VSA#ST7ZT ($JLP_L-H*\@7U<E8 ,ZX .*2:^,$ 12H&K80^.U
MWL;] ^S]@^Q-A&2@QC>(X B.X+(   G_HF *JF (JF +IB +NF ,?@,,RF +
MAN#ZO=AFJ1 .OLA?71(/UDG )=\S+1^4F=+TF4@11E_S(6%5U%W57!_\9%_2
MB!L$C<:F4*"!_)].P)\#DE]ML-!9#1("XDH7\LK5Y(30Q!;]V<H6QE(:0B :
MPF'0B%NIH0L9-N!!R=D0T@LE9,5K]9ZJP$,CA<8W^"!%:%PH5  KC,D,:.!"
MM,,0G*&(Q=:0#*$.DAH09I;QH<0K5,(_^ ,3F ,FZ-T_D.)"6,(NL()U;> N
MJ(T0\B' I8MO2%^4-2$LT2(3VJ(40A_O1"'U,1BT_$@"R%_XN5SZ71XL[E:T
M((B4=$!5W)\R_PZ-K[C+).;)RX5+%FICF+#A-BJ@-W+C-H;"(*J>9E#>4;P"
M)<Q +E#!.E*$/F"@[T50(,KCR?V@H,09;7 B1:C'/P@">[S'>X3'>,S'GTAC
M+$[C+(*=+C+8+3JA$<IA$F)?+\;%+S:/H*4<0FKD1G(D_^'*$%2>)_%=\?21
M%ZT&.9)C9^155FA$3M2/1@)B+-+,[M&D)C+'!<X,/1Z%FZ")X[SB G8D2QPD
M\QWA+C8D11X=0THD+X:=]=7B1?),4$KE5%(E5<3CL8QDN)1D6"D'2A+B9F!#
M/H[%GLFD)28?S7"#N:F8/%PEC^CD\1EDDO2,,-(+M'#+!'J+SS3CMO^,$&RI
M'UZ"2UTBBPE]5[=@RUX.IK+XY7?I)2?99%5"9F2B6CJH)58"I>!=9AIFI5EX
M93F6!5EN!C=,#A_&)&F>')Z]6)GER%O:B#XHBC0P S8*Y;(HY9?X#FVFQ&,^
M!XL!E1ZRDDOAIBJ=$BH-SY9DI&0B9W)R6CN,YDAMYH-EIE ^)V<V4DIF!F5Z
M!CS.VW,P R$H K>M0B($0FO]0S\P 3K\ S,(PB L0S,$0B(,PCKHHUG6(_#]
M0YV-6#N\VVZRIG]P S/<6V>\U!N>RFTN37 6J.X,J&\:)W >J&Z2&'%:9(T<
MIW):Z(4.EC94)JH$7O%$9[A]Z$1T)F2$@@#_@-]G+!,W%%AL3,(4/$$E)$$^
M+,0JL (_N( Z_D,EA (A- ,E4,-"(,%\]B>J;1:<.1ASW@A]^H>%!.@T2E"(
M:@:S$-<)52+,K)#25"*49@9A/FGO7&E$M)!Q0BB&DFF9PHPVA"7.=&@VXI*6
M.L2(CD4H;$ *X( -_*AJM$.BR"9D),X@!,)21((^W!1[68$6?,,KB$))*,(4
MH&?Q*6G)8:(F>19J:M:0+D=:$N&!8E32+"B8!H^!UJ;4."CPI$HK/26%CJF9
MJNJJWH@\:(,SA"3,K&F<N&G\U B<\H2<IH @/"*?'20#E>8EVJ/\-"DHR=N/
M/&IS2&JF-E\,J)HJ_U!= &# URW'!P3 7C3#,L@ 5'$J@B+%7N36*V#)/T1
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MCN<_[ (7* (S++(B3,(T_(,J( (BM$,S< $CY%%6H*0%P(.)PJ[+1G"2)JO
MN7!#+&L#?4.Q5BHX$LUFRAI#R!\ -$ #/(",5:8R<I!*14$$-  #'("!()7S
MQ/)"3 +0 0 "+, $U$#1__GO43+$&@<"")C= A@( ; B&3^..5QMUCF !$P
MCX6R+LM<).# !#2 -1O( Q"H,$F?LSY= F" $(0"W344#U]*!#S  MP< !B
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MQ 3/2MUF:@(  3IP1B!X#$C3+BQ:>O(?51!)(%+O+MNM45'5>D"30Q?95+
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M3M/_,?3!!_^!&[K/&2L3*^.30=?NU?I"-B%4+S(#&R[ !Q:'%S]@0T+! HX
M0X\@!2CF'XX@!C$T"2Y@>'8 !C#4!8:  :C% ;X*0VN .:KB G" 19.@ @C"
M F1T<7S@ 0:B0B]T<79 0Z&D0S\T1 >"1'WT1&N.*/#11X^@ @(M$#+ 23=@
M>&XT1W=T('J418%42"T40XVT/QL43?5F/BV""&82/^E"!.0/'DS@/X]Q$!.$
MKPK"SE8K-95N->]M]+X"-M5/4 >5X0K54.N-W@+U_(IBWP8D0E4Q85)#?A*B
M=Z#4>Y;!#/\A=C0UUYQ%/Z.B4T-U5#_U)R\U(9QE4Z,"_U410E41HE0/(E8-
MHE+3U%9%0\_@H0-V(!3*)Q0ZX/V(8@>&(!"H!1Y>X0@HX/Y6KBGU[TX3Y'+4
M!023LEGC;37_A#,6M"8$RD\:!5"T=5M'Q4Q*Q4]LQ:*FXTK,M4_&9%W!E;_^
ME,[6["FP(0JBH$W<]5;S55]S[T%#H?(6!TE></Z6(1L61P5$Y/*.TDYC D!Y
M0AK4 4$#M%J;C,S"(U+G@BFF R<:EBZB(S<L%E\G1SI EF,QMCY.35P>5%*;
M;BBZ:B#J,&3C3DF((!2(B6:EA"!,X1*>1A-B80GF85^#5AH?U*I$Q I,3&!K
M(A#6(Q2LX%]#5<=*L^4$U#00D?_N)I8@"O ?*' "(Y 9++!3$"$#-[!0 88Z
M:B5C219MT]8WXHM'V+8W2G9A3O;3PD1E<4M>"8)$*4!$8U;J%$$3AR 1L,$)
M^N5?_D$4:&$> D$;%"$7AF 9&73Z("Y0#R]18]-R&PXJ]<P)-DYV$H,2\I H
MEN$*^/9S=R H%3;NJ%9SC A3)3;;H% *%8$*K1 +M;"!N'!F*M9;RW5MQ15;
MO<-O PI0QK5=U?5*>C=0?K=X+^IX%>11:RUO)Y4HD@ #_F%9*4(;_K D8 !A
M6$'E),(<B$!H"8((H#8A .D?$D 1"D/]%([ZV.M]&U6B!&1X$<*EB,0<-&$:
M^"'9<#;_%(( 20K7)(5$?V-JIFJ*('#*U-(+%Y:3($",+I;A"=S4-S=#:C7O
M6;O#&:8H_*@UVS#1F#B1"TC8$T%1%$FQ;-GM;#EU&03A" # /@5C$ #@" 1A
M&1(';C>VX\BR!.[7*5S@"E)!E3SV)T V?F2!"V)X5>FB8Z)@,WMB9-L6*?KP
M.>XW&P!@![A %LH',R[JLLHA%:)@![IG880P>DVCI+2!"R8A 5\!:09A&1:!
M("+AC>/X)Z7,/NC57IFN)HZ@,:(  _1$,A.B-EH"">!!8C@"D$>TD1  "2#B
M2T!E"139*&^UD3L   R  ,(7(5#@  (  D+!DOV&8 "5*O*M_^@0PA G]36'
MPMX U3"L+PS'C%V V" VZQ_F)1' 82!(2Q',01NR0.QTF9<]R[-$BR!T=[[B
MT!3.U 4NN2C*H0EF>" "(6$E@MK(;H--(UH- LCX%&O5^%JIV#7,H0 2H1F>
M@"T@N"J<@"V>H!G,00#68X>%PB%LP '@X776@@ $PQP&@"U6874*M^XT%BH"
M&C[2YY,$XP+80A"JY@"Z"Z&KN&/*@1#88@($(Q3:616< CF^>'T0EP#@ 4T&
MNG;0^&Z_J<#2@0C,(7>WH1)"@1": 1W*4@G\(:9GNJ9;S67_ 6;_N#$:^34
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M@( P051B:F(NV2/J"#'?B@'R#@.\EWPU"\A0$Q92CE<$0O8?P R@E\X04>R
M=:X+##6;.A87 /($)K MU7Q^= K_Q;KH1(>0/4[<?=0O>->-[C6Z)+(#/6E?
M5H,  "R92FRB/*@<5XB"#<Z.H?9?P=98ARO()B/P8 DO!@#2IBQ"  !14 /T
M=VSJMQ4/@@U"<$[\AQ+L]&*6 ( ?!B/E, A,L ,2A"TCMA)&MRN>]V>:\PHN
M@!@B8 $'X -!H#Z0P1?FD WF@ "*8!PR<&JT!0TYN(/&L3_]\S\!Y!<#5$ '
M-'D,L4 -]$!HTAH35$$7E$$;U$$&L7)=$4(&,4(E]'Y\(0@O!(0VJ$V:DH(H
ML0PN8% ,P0)^UG!B@1BJ]@%F&#GR<$8X 0 EH! 5, /JE'YI V1(80-NEQD?
MP7(5DA,7_Z 0&Q (0<-K#(=^!W$$$P!]+C A-J L@6 .]N "*0!]1G,LKE9^
MWA=TI'B*2%>"AL1\Z>=2YD  @7!/'U&'#.(#WS$)YC  T51_';8"$V .PZ<1
M I!W2V(. O 1 @4 29!7$.A2JA  !W6+RD(!WQ$*@6  .75A W@Z%B!N0_ 1
M#J LLJ@1/@0 Q<%L(/8/E"  \, %+J01!+<DJH@2Z< -^G2!]99VMX-:J)@L
MT]2$@9=-L5$:&<80W[1-KH40XU20"'%.H_&'_8A1_:&&JF9-G1=B[:=J+9B
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ML:>HM%=[P((H41 *0 $ 4D"H-C&?6_&@2Z!3!8" QN>HLL>H<F>KN)<5&<
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M\KS';NS+[)G(\QS([#S(%[H7#F/-^*LY$2!M&[ ,.& 8(HC)DJ=M0$9/\@9
M&H$+>_%!#OUB$"W)R&H^9Z(0 TW09 4 LSJ"#ZW"D]BUYF--#DVN7<'!$?^M
M/,>)$ .L/5UQKT#FAB8R?0:!#4'L%Y[S=1&(Q,;!BQ,F1[$"!._W"BB])#E
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MMP,=D,[76\WIK5,31]X*)FS,X-R&Q+W>6V'2+<QAA=O=5VE6B6!L)5=71]2
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MF4$$A0&? * #J7A9*CKP%XS)AC\%^> -#0*= "P+ %@S(5I06)\0,F$A1
M WC6 R8,@"$%.-P"%SA$&S(%  ?P#@ HD;@'JLM^1PMB]= GKR;9+2%D&4]+
M@ >\EUA (:%(@(L6L8 WKB44&S!'2[3R"C:"J )O-$"<OL0 1B7OCGF4DTN^
M:"$Q-BXV!J*%9OJ(M 4(,A2!;!0 ;-"7JW0O6^FS" 6,LX MKN\?D7!7<%@'
MRHB<(Y6_,@49]R6(5P('9#84%/W:MLO%44R74?,0XT1VA!,4TP51^$<:?T:6
M2'Q@ \9,$O_0E!3&A=#,FM?$I@8!I(\)4E-!]J"F!BDH#9[]"P"1$ %#4D$I
M_!4-<.>,1!;GQTL2_B4*@9'E2Z+C TM<@"%! ( 3?6G"?]'E+5E4Q4!!9LZ_
M'*$9#*78*GS@G1]4#$9=)$T[&^G-7YH// =)XUN4J49 (04!"R  92*2C04<
M@ &&A%9/M((-DR:@ ()LB#D0E0"8 M ED6 "!%8!$GA83I$ZPD8S'H )HS3D
M"*EX0#9 XJFY2$E,JZ# (+@0$0S(P@+96 \5A*6*F&"("#C8@<J@LCRDL*)9
M!T D1))P  %4X"IO\FDP\QF1&:B5+>M3P<&6\32T[!4B)%D(/%+_L+Z1O@(V
MBB2(/OP%N/K1<UX*!:-EY:31BK2&@2,MC,LX.MKNP,<>^B)M:DNK.*C)0W>&
M@RUGL_=.Q2A$&P@(0CE"@9%[N4"V*7J?!J1# P.X*1 [Z.UOM66<#QPA$AH9
M@!"H19%Y&D8J2U#(*@B@"FQDJ;>^7:3U:)L6<T   [WY37+7YY=O88IC\"!
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MDH6@8@!@!<X,6[ % $FXDUH5%/]%X*+&\=Y?]<(O$8)ED(5E,"#U50@L71G
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MU@:BYNS_A%!:KDUJ>/RB]YF("% (<Z".$-:.>YGJ;W$!04NU*T  ;$D(YP
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MO)%%R8IO+.0A$[G(NOH&-7*1#@TO^1_:^'!(ZFOD*5.YRE:^,I:SK&6,!@0
!.P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pipelineq12020a.jpg
<TEXT>
begin 644 pipelineq12020a.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%P<FEL($=A
M9V5L   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S,   DI(
M @    ,S,   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( P($I@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M_P"@AX9_\ 9__CM'VKXC?]!#PS_X S__ !VN@HHY4',SG_M7Q&_Z"'AG_P
M9_\ X[1]J^(W_00\,_\ @#/_ /':Z"BCE0<S.?\ M7Q&_P"@AX9_\ 9__CM'
MVKXC?]!#PS_X S__ !VN@HHY4',SG_M7Q&_Z"'AG_P  9_\ X[1]J^(W_00\
M,_\ @#/_ /':Z"BCE0<S.?\ M7Q&_P"@AX9_\ 9__CM'VKXC?]!#PS_X S__
M !VN@HHY4',SG_M7Q&_Z"'AG_P  9_\ X[1]J^(W_00\,_\ @#/_ /':Z"BC
ME0<S.?\ M7Q&_P"@AX9_\ 9__CM'VKXC?]!#PS_X S__ !VN@HHY4',SG_M7
MQ&_Z"'AG_P  9_\ X[1]J^(W_00\,_\ @#/_ /':Z"BCE0<S.?\ M7Q&_P"@
MAX9_\ 9__CM'VKXC?]!#PS_X S__ !VN@HHY4',SG_M7Q&_Z"'AG_P  9_\
MX[1]J^(W_00\,_\ @#/_ /':Z"BCE0<S.?\ M7Q&_P"@AX9_\ 9__CM'VKXC
M?]!#PS_X S__ !VN@HHY4',SG_M7Q&_Z"'AG_P  9_\ X[1]J^(W_00\,_\
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M4',SG_M7Q&_Z"'AG_P  9_\ X[1]J^(W_00\,_\ @#/_ /':Z"BCE0<S.?\
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MTCAO8=KF1N1]TD;??.*7+$?,Q_VKXC?]!#PS_P" ,_\ \=H^U?$;_H(>&?\
MP!G_ /CM;AN(0ZH9HPSC*KN&6^E(]U;QRB.2>-9#T0N 3^%/E0N9F)]J^(W_
M $$/#/\ X S_ /QVC[5\1O\ H(>&?_ &?_X[6ZLT3R-&DB,Z_>4,"1]17*^+
MO'B>&-1@L(=-DO[J2VDNV43)"J11_>.YNI]A2:BAIR>Q=^U?$;_H(>&?_ &?
M_P".T?:OB-_T$/#/_@#/_P#':TM$U:'7=!LM5MDDCBO(5F1)!AE##.#63<>.
MM)MO','A603_ &V9 1*$'E*Q4L$+9X8A2<8IN"3L+F;5R3[5\1O^@AX9_P#
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M[5\1O^@AX9_\ 9__ ([6ZDT4K,(Y$<J<,%8''UI]'*@YF<_]J^(W_00\,_\
M@#/_ /':/M7Q&_Z"'AG_ , 9_P#X[7044<J#F9S_ -J^(W_00\,_^ ,__P =
MH^U?$;_H(>&?_ &?_P".UT%%'*@YF<_]J^(W_00\,_\ @#/_ /':/M7Q&_Z"
M'AG_ , 9_P#X[7044<J#F9S_ -J^(W_00\,_^ ,__P =H^U?$;_H(>&?_ &?
M_P".UT%%'*@YF<_]J^(W_00\,_\ @#/_ /':/M7Q&_Z"'AG_ , 9_P#X[704
M4<J#F9S_ -J^(W_00\,_^ ,__P =H^U?$;_H(>&?_ &?_P".UT%%'*@YF<_]
MJ^(W_00\,_\ @#/_ /':/M7Q&_Z"'AG_ , 9_P#X[7044<J#F9S_ -J^(W_0
M0\,_^ ,__P =H^U?$;_H(>&?_ &?_P".UT%%'*@YF<_]J^(W_00\,_\ @#/_
M /':/M7Q&_Z"'AG_ , 9_P#X[7044<J#F9S_ -J^(W_00\,_^ ,__P =H^U?
M$;_H(>&?_ &?_P".UT%%'*@YF<_]J^(W_00\,_\ @#/_ /':/M7Q&_Z"'AG_
M , 9_P#X[7044<J#F9S_ -J^(W_00\,_^ ,__P =H^U?$;_H(>&?_ &?_P".
MUT%%'*@YF<_]J^(W_00\,_\ @#/_ /':/M7Q&_Z"'AG_ , 9_P#X[7044<J#
MF9S_ -J^(W_00\,_^ ,__P =H^U?$;_H(>&?_ &?_P".UT%%'*@YF<_]J^(W
M_00\,_\ @#/_ /':/M7Q&_Z"'AG_ , 9_P#X[7044<J#F9S_ -J^(W_00\,_
M^ ,__P =H^U?$;_H(>&?_ &?_P".UT%%'*@YF<_]J^(W_00\,_\ @#/_ /':
M/M7Q&_Z"'AG_ , 9_P#X[7044<J#F9S_ -J^(W_00\,_^ ,__P =H^U?$;_H
M(>&?_ &?_P".UT%%'*@YF<_]J^(W_00\,_\ @#/_ /':/M7Q&_Z"'AG_ , 9
M_P#X[7044<J#F9S_ -J^(W_00\,_^ ,__P =H^U?$;_H(>&?_ &?_P".UT%%
M'*@YF<_]J^(W_00\,_\ @#/_ /':/M7Q&_Z"'AG_ , 9_P#X[7044<J#F9S_
M -J^(W_00\,_^ ,__P =H^U?$;_H(>&?_ &?_P".UT%%'*@YF<_]J^(W_00\
M,_\ @#/_ /':/M7Q&_Z"'AG_ , 9_P#X[7044<J#F9S_ -J^(W_00\,_^ ,_
M_P =H^U?$;_H(>&?_ &?_P".UT%%'*@YF5_ >O:GKVCWSZX+7[79ZC/9LUHC
M)&XC(&0&)(S]:*H_#+_D'^(/^Q@O?_0Q16)J0:]_R6+2/^P)=_\ HZ"MVL+7
MO^2Q:1_V!+O_ -'05NUM'8REN%%<GXC\;IH/BC3=*^SI+%<,GVJ8R[3;AWV1
MG&.<M], 4VZ^)?A^WEOH(WNI[BS6?,:6LF)&B^^BMMP2.O';FG=6N*S.NHKS
MK4?BCY>G07ME:;(Y([29H[B*7S5268QM\FT9X!P03GTQ6S)\2_#4=E%<FYN"
M)#(&C6TD,D0C.'+H%R@4GDG%.X69UE%</K/Q+T^TUK3['3&-T)+H1W<@MY&1
M4\EI,(X^4O@+QR<'I70V/B?3=4CE.F3?:#':I='"D#8X)7GU('3K2NK7"QKT
M5YIX=^+]O?PS3ZY;6]M;K#%*);"9KD(9'V+$X"@J^>W-=*OQ!\/G4DL7N)XI
M6PI:6VD1$<IO\MF(P'V\[2<T7069TU%<=%\4_#$T;/'+>D"5(5'V";,C.I9
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MXZ# J.3P+X@E^(UQ<WD-VP;5ENK>^AMXF @!&$,Q<.HVY!0*0:]LHI)6:?\
M7]:%<VECQNP\#^)5\07VF+"UOIFDI>RZ/<EQM:2X7Y .XV9;FL72O 'B&+P[
MJR'3KV&[?2&M9(/LT,27$NY2#N60F1N#\S &O?J*7+I8?,SQ76O!^KSW.LPW
M?AR;5+N_MK=-)OPZ;=/*Q@,"2P*8;G*CFL_6]#N]3\3>*M,&ARZSJ9M;**"]
M1U M9O+_ -82Q!'3.X<\8[U[U4$5C:P7D]W#;11W%QM$TJH TFW@;CWQ1:Y*
M=CQW7OA]J=_!XNGN-*:\U%X;(:?<9&YG1 )&0YX.1UX-2:UX$UN*+Q/9^&+%
MK.WO+.R9$C8*L\BG,HZ\L1USU]:]EHHY1\QX?!X$U9_#-S FGW@BNM6LI6LY
M+>*V5$1OWC*D;L%&.O(S5K7?A]=OI/BVRT_04:U_M*UNM-ME50K* OF^6#P"
M<,,<9KV:BG;^ON_R"YS&M65E=^ 19OX9GN+*2)%;2H@D<D2\< ;@H*]< ]J\
MYG\%ZY=>$[9M1T>ZU*WL=<CGL[&^:.:[2RQAD))P<G^'/05[;11;6XKZ6/$/
M&?AGQ'J?B9YM+\.>0D,UK)9SP6T6X1KMW!I2^Y",$;%&"!61!]BOOB=-=:K"
MODG7YDM+W[,LKO-RJ1F0OD(#R!LX(ZU]#5F)X:T.+5CJD>CV*7Y.3=+;J)"?
M7=C-)1U_KR_R'?0\K^'/@K7M*\6V5WJ]O=P7%J)A=3BWB6.YW9P6E#EY.<$9
M7BK?Q0\*:OKWB8W#Z=>ZA:0VB_V6;+RV%O<;LMYJ.1N5L =QBO7**+:)=@YM
M6SC/ANGB6#2K^/QE;RQ7YN3*,.&AV,HPL6"< 8Z<<FN(O_"/C:ZLKWQ!%;VB
MWC:P-3ALVC;[5B,[$3?NV@%!TQWKVJBFUK?^OZT$GI8\9U/P3J5]#XCU5-$D
M&JS:W;W-A(<>8D0\O>5.>/XL^N*FU7P7<PZAX]CLO#6Z75;</87D,<>WE 'C
MSG();G&,'K7L%%+E5K?U_6@^9WN>5:?X<O+7Q?=3:UX9FU1[A+;[!?JR%;)4
MB"LI)8%,,"> <URT.C36%_X4TS7/#<^JRQZ+>"73UV%@3-\K$$@'&1WXSGM7
MOU0-8VKW\=\]M$UW&AC2<H-ZJ3DJ#UP<#BAJ[$G9'ANK>#/%A\(Z/I,^B+>/
M'IDB"80QW$D$I=BL9+N @"D?.H)R*Z'3_"5[;>,O#VJWV@F>5M#2VFNMB,UM
M=KC$CDG.0.-PR:]8HIV_K[_\PO\ U]W^1X5X5\!>*+6]=IX[NSU..UNXY+H0
M1)'.[JP4F4.7D^8J1E>*U? WA6]L/%_AV[_X1:;219:=-;7]P[)^_F(7Y_E8
MYS@_,>3GVKV"BA*W]?UW&Y7/+?'/A#5M:\5ZO?6%JY>+2H)+"88P;F*8N%'O
MCC\:S+7P;KXFL=0N]/=K^]TS4I=0*X^2XG V1]?0!1]*]EHI<JM;^M?Z_ .9
MWN>'3>"/%4N@WMO96<MO.^@V%N,L!O:-LR1=>N,CT-.M_ ]^/"FI++INK".X
MO()H[**SMX@K(K9/D>849#P""1GKVKV^BFU_7SN).RM_6UCR"U\(WRZIX*U7
M5O"=O(UK%-#>0VL49\@LP,3E2< +R>"=I)Q5:W\':T=2A@DT&9=:CUS[9)XA
M9TVM;;]VT-NW'*_+LQBO:**+:W_KN%]+'CD/@74(/(U&+2&35%\5M<&X&/,%
MH7;)SG[A';]*JZ'X'\10>.1=:E!>">+4)IVO88(@L\39PIGW[R""!MV\5[;1
M24;6_KM_D-R;O_7?_,\T^%^@:CH>L:BDNCRV=@8@([B\BC2YD?<259D8B0#^
M^0#7I=%%5TL3UN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45RX\3ZE>>*+RPT
MG3()K#3)4AOKJ:Y\ME9E#'8NTYVJP)R1[4R/XE^&9+>XG%W,L<"J^Y[61?,1
MGV!TROSKN(&5S2NAV9U=%<G9_$OPW>W!ABGNDD"RDB:SECP8P6="64?, ,[>
MN*9;?%#PQ=7$<,=Q=!I)(T!>RE51YG",25P%8\ G@TP.OHKE3\2O# EOT-\_
M^@1O)*_D/M94.UBAQA\$X.,TES\0]'6&06QN&N!:M<!9;2550 ,5\P[3LW;3
MC/)'0&E=6N%G>QU=%<=>?$33H+62W0NNJ'3GNX4>"3R9&$/F8#D -QVZTSQ%
MXWN=$\-Z%?I#8>=JA16:\N3;PQ$QER2V&P.,4-V"S.THKA].^)-M+907FK0"
MRBDL5N3&F^60L93& H"_,&(XQR<]*K?\+:TD:Y#N\Y-'FLO.$[6<H=7$QC.X
M8^5!CJ1U[T^M@LST&BN-3XG:*K:E]M@OK9;&\%H";21O.<C(V@+R>O'ISWKK
MX)DN+>.:(Y210ZDC&01D4+570A]%%% &3\,O^0?X@_[&"]_]#%%'PR_Y!_B#
M_L8+W_T,45@]S9;$&O?\EBTC_L"7?_HZ"MVL+7O^2Q:1_P!@2[_]'05NUK'8
MSEN<KJ_PZT'7+O4KO4X3/>7P0)<NJF2UVC"^42/EYY[\T0_#_3(O+WW%U+LF
MNICO9?G-PN'S@>_%=513LA79Q;_#+3YK2.&;5-2=XH(($FWH'589#)'R$QD$
MXZ= *:_PNTYK95CU75(KAA,MS=)*GF72RL&D5_EQ@D#[H!':NVHHL@NSD(OA
MOI=OK<%_;7=[%#!<+=)8JZ^2)!'Y>[&W/*\=:D\$^#AX9TC4;:<KOOKN64^6
MY81QDD(@)'9?ZUU=%%@N<Y'X(TN+PQ9:'$9([>SEAE61 H>1HG#+N.,')'/%
M4M3^'EI>ZA=WL-]=H9Y&N19LX^S_ &GR]@E( W9 QQG''2NPHH:3!-H\T\$_
M#?5-*AAC\0W</E6=W%=6L5IL/SHC(2S"-,@ANF"1CK6@/A+H@U/5;[[5>F74
MTD27+)\H=U<X.W)P5&-Q.!Q7=T4PNSGO^$,L/[0^U^=<;_[274L;EQY@B\K'
M3[N.?7/>NAHHH$%%%% &9J^A6^LW&FS7,DB-IUV+J((1AF"LN#D=,,:QYOAW
MI%RK)<R7,D;SW<SH6&&-RI#C@=!GC^M=712LAW9Q.B?"S1]"6W%K<7#?9[R.
M[0^5"A+(K*%.Q%R,.>O/O6;K'PALY$UR\TB[G_M+5(W3-PRA%#R*Y^8)N."O
M&2<=*](HHL%VC@KWX1Z-J=B(]0O+RYN_M)N6O)A%([,4"8*LA0C:H'W>U6F^
M&6F&\M9TO[Z%(!;%K>)HUCE:W.8V90G'T&!STKLZ*8''O\-M*E5X[B[O9K<R
MW,BP-(NU//4AU!"YQR2.<YK17PE$WA*[T"\U._O(;J-HVGG=3(JD  #"@# '
MI6_12LK6"YR[> =+>5W>:Y8/?+>LI9<%Q#Y.WITV_CFJ-G\+M,M&4OJ6I7/E
MBW2,32(?+2"3S(T&%' /'KCO7;44PNSA;WX4:7?:3_9D^J:FUBD_FP6S21LD
M(^;*A60@CYC][)'&#5A_AIIAM!:QWU_' =/BT^2-73$B1'*,<K]X<],#GI79
M446L%V<9-\,M*GN+II;Z_:WG^T,EH9%\N"292LCI\N<G<>I(&>E;NC^'+71;
MVYNK:25WN88(7$A! $2E5(P.I!YK6HH6@!1110(**** "BBB@ HK!\027#ZQ
MHME!>36D5U+*)6@(#$+&6')![BL.Q\4:HL$CB)[^2*# QC;(HG>/S=JKDDJH
M.!G/84KZCL=U17*Q^,'FM;R]@AMY+*P@669Q*P:0F/?\@*].@YQW]*1O%US9
M7OD:I:0JB>6TTT$I9$217*]0.=R8_P"! T7"QU=%<C;>,+^XU%+=='?"+']I
M.3^Z+IO'.,8&0#WZTG_"97D%A97%[I\2MJ5N)+...8G?*2H6,G'7YLY'8'TH
MN!U]% S@9Z]Z*8@HHHH **** "BBB@ HHHH **Y7Q7>7T>K6=K82WJM+:SNJ
M6:J2TBE A;(QCYCUP*CE\5ZE8VMP;NQBDDMYX;/]V[,9)G5"3@#A06/3)I7'
M8ZZBN8L_$>H:A,;8V$=I+#;B6Y$\A4C<[J-@Q_L$\XZ@5FZ1XBU".TM(D'VN
M>>.SC4W,N%!DC=BV0I/\//7/M1<1W-%<8OB^X,\$@@_>7$,4:PF3]TLK3M&3
MG;G'R]?IQ5B]\63VFK6^G2012&1E@FD@9B(I&1F')4#^$<9SS1?2X['5T5F>
M&II+CPMIDT[M))):QL[N<EB5&236G3$%%%% !1110 4444 %%%% !117 7&H
M:S+<:O):SWICMY;M)2X588XUC.S8<9W!MO3WS2;L-*YW]%<<GBR]M-.,-U;P
MM>HL'EJKN_FAXRW9<[@$;/;OFD'CUDM(KZYL##:2V/VJ,DL6E;RRY12!C( Z
M$@]Z;:5Q+4[*BL?0=4OM6LIWO++[%(K8C)!(<%00V#@]\?A3/"TUY+I]TFHW
M;7DT-[-%YK(%R W P. *.M@-NBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HK!\6W<]II]G]GEN(O-O8HG-JH,A4YR!P:P$UG7M*N
M#-?)YRPV/FRQ7$FU]GGL%.%!7?LQGZ4K_P!?*X/0[VBN1F\9W U>ZLK/3Q=[
M(I6@:-F'F-&ZJRY(P>6[9Z8IL?C:XN;RVM[#3OM;;$>Y,8<! TC1D#*C!&TD
MAL>E"=QV.PHKG_$LMRES8QZ;?31WTLR".V0*4= P,C.",[0N1G(ZCN:Z"F(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL+Q;=S
MVFG6AMY;B+S;V*)S;+F0J2<@<&N?36=>TJX,]ZAF6&Q,TD5Q)M?R_/8*2%!7
MS-F,_2E?^OE<#O:*Y&;QI<#6+JRL]/%WMBE:!HV8;VC959<D 'ENV>F*8GC:
MYN+NVM['3OM;[%>Y,8<! 9#&0,J,$;22&QZ4)W'8[&BN;\77-Y96Z7=E-=1B
M$JTC1F/RHUWC)=3\[9&1A0?PKI!R*8@HHHH **** "BBB@ HHHH YNX\%6TG
MB"XU2VU'4+/[8RM>6MO*!%<E1@%@02.  <$9'6L^V^&&EV\'E27^H7"HD45O
MYTB'[-%'()!&F%'&5&2<G ZUVE%*UAW9S$W@+39V9GGNANNKFZ.&7[T\91QT
MZ ,<?UIK> -,:*2,W%UB1+-#\R]+9MR=NYZ_IBNIHIA=G Q?!_0()M3:"6XC
M348Y(W18X<QAV#':^S?U'=B*V-0\#VE]J5S=KJ%_:B\MA;W4$$BA)P%*J6!4
MG(#'H0/4&NFHI65K!=WN<'_PJ/0SK3:F;J],S6[6^"4.%,/DG!V[ON\XS@'M
M707GA+3M0L](MKO?+#I3 Q(P4B3$93#@CG@]L<UN44PN><^(?A;YWA\6VA7D
MC7$44<$2WD@V")9O-"YV-TS@9## '%6=)^'#R>'_ +/XDO6>\DL&L'^R!%1(
MO,+J!\@!8=,X /I7>T4EH%V<AJ?PZL=334HVU*_AAU&99Y84,;(KA=I(#(>H
M ZYP1D8KJ+&TCT_3[>SA+M'!&L:EVW,0!@9/<U/13V$%%%% &3\,O^0?X@_[
M&"]_]#%%'PR_Y!_B#_L8+W_T,45@]S9;$&O?\EBTC_L"7?\ Z.@K=K"U^QDU
M#XPZ1%#>2V;#1+MO,B5&)_?0<?,"*V_^$8N_^ABO_P#OS!_\;JXR21+BVQU%
M-_X1B[_Z&*__ ._,'_QNC_A&+O\ Z&*__P"_,'_QNGSH7*QU%-_X1B[_ .AB
MO_\ OS!_\;H_X1B[_P"ABO\ _OS!_P#&Z.=!RL=13?\ A&+O_H8K_P#[\P?_
M !NC_A&+O_H8K_\ [\P?_&Z.=!RL=13?^$8N_P#H8K__ +\P?_&Z/^$8N_\
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M_A'I_P#H9KS_ +]V_P#\;HYD'*R6BHO^$>G_ .AFO/\ OW;_ /QNC_A'I_\
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MZ=:C[-_J<1+^[YSQZ<\U:_X1Z?\ Z&:\_P"_=O\ _&Z4>';@]/$M[_WZM_\
MXW2YDA\K96N]%TR_NDN;VPMYYXUVK+)&"RC.< ^F:NU'_P (Y<?]#+>_]^K?
M_P"-T?\ ".7'_0RWO_?JW_\ C='.@Y&245'_ ,(Y<?\ 0RWO_?JW_P#C='_"
M.7'_ $,M[_WZM_\ XW1SH.1DE%1_\(Y<?]#+>_\ ?JW_ /C='_".7'_0RWO_
M 'ZM_P#XW1SH.1DE%1_\(Y<?]#+>_P#?JW_^-T?\(Y<?]#+>_P#?JW_^-T<Z
M#D9)14?_  CEQ_T,M[_WZM__ (W1_P (Y<?]#+>_]^K?_P"-T<Z#D9)14?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M['.WIFM2Q_X]1]37'C_X/S/0RW^/\BS1117AGT04444 %%%% !1110 4444
M%%%% !1110 4444 =%X6^[<_5?ZUOU@>%ONW/U7^M;];QV/+K_Q&%%%%48A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% ''_#O_ %/B3_L8KW_T,44?#O\ U/B3_L8KW_T,44 %
MY_R6K2?^P#=_^CX*["N/O/\ DM6D_P#8!N__ $?!784 %%%% !1110 4444
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M^P6A38;:+;M9,;!C:QRP^A[TQ=+L$ECD2S@5XE"HPC&5'H*YFU=6U:']XPU
M7TXNB&(*P8?;GT7&S'Z55-Q;G0'@M+R.5%U1@9+B8O'MR2/-.<[3CCWQ4\Z[
M?UI_F/E>USL;;3K*R=GM+6&!F&&,:!21^%1KHVFIYNVPMQYPQ)B(?.,YP?7F
MJ_A@L?#EJ'SE=RY)R#ACRO\ L^GMBM:M4DT0[IC418T5$4*JC  ["M2Q_P"/
M4?4UFUI6/_'J/J:X<?\ P?F>CEO\?Y&3XB93J6CPSW,L%O+/()3'.T6X")B,
ME2#U K%M=:U*&%VA<7++ ?)>=_\ 61B=E5\%E#,4&>HSQS7:3VT%TH6YACF4
M'($B!@#^-$EM!*A66&-U(VD,@((]*\,^@<6V<Q%XKFGAN;F)[?R;:V641-&R
MR7)*%OERWRC(QC!Z&D'B+4S<):1RV,\DCP 7,<;>6@D#Y4C=R1MSU&0>U=1]
MEM_,23R(]\:[4;8,J/0'L*([6WA7;#!'&N[=A4 &?7ZT]!<K[G'MK>J7,RO)
M<PQ0MIMRSPHA&^2-]N5;=D=,]\?K5JVU_4?/CR+<VPGBMBI5C(2T(?=NSV)Z
M8Y]:Z9K6!MNZ",[<[<H.,]<?6G"&(=(T'.?NCKTS2#E?<X^7QI<BR@>WC@FF
MDMH'=4(/E/))L.<L!@>A(^M6]3O[R?P;'/>-]EG:YBCD:WFV_+YP4_,K'&1U
M 8XSC-=$+.U"NHMH0),[QY8^;/7/K2FV@:W\AH8S#C'EE!MQ].E/H'*^YQDF
MO7^F7D]EI1^V0-<,L$\\@D";8PS)N=USR>I8D<]<5<E\4ZA )T>SC:XMXGN7
MCC.<PB+<,'/)+G;GIP:Z8V=LUNL#6\1A7E8R@VC\.E2>4F\OL7<1M+8YQZ4#
MY7W.);7]1;[)>WL,9:!II$2%U_>@6[-@A7?'/O[XJS)XGOXI%@:XT^0O);@7
M2J1$GF[OE(W<D;0>HSGM7516MO"H6&"., D@(@&">IJO/I%C<11Q/;1B..43
M!%4!2PSU'?K1=7)Y96W.8?Q5JSV4DUNMG_H]N\SED8K-MF:/Y<-P"!G/./>I
M+WQ-JUK.UBD-O+=+.T?G*H6/ C5P,-(N#\V/O=B<=JZP6\(7:(H]NW;C:,8]
M/I22VMO,I6:".16.XAT!!/K0/E?<YN/7]4DO0&2UCA^TQVQ0*78,\0?=N#8(
M!/IR.]:'A.ZN[SPW;3ZC<I<W# [W1-N.>A&3S^5:WE1YSY:YSN^[W]:(X8X0
M1%&L88[B%4#)]:+C46GN=+X6^[<_5?ZUOU@>%ONW/U7^M;];1V/-K_Q&%%%%
M48A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% ''_#O_ %/B3_L8KW_T,44?#O\ U/B3_L8KW_T,
M44 %Y_R6K2?^P#=_^CX*["N/O/\ DM6D_P#8!N__ $?!784 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5PWC;_D,0_P#7 ?\ H1KN:X;QM_R&(?\ K@/_ $(UUX3^*<^(_AG.4445
MZYYH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %.\J3^XWY4VNW@\9:=';QHT=QE4 .%'I]:RJ3E&W+&YI",9?$['%>5)_P \
MV_[YH\J3_GFW_?-=Q_PFNF_\\KC_ +X'^-'_  FNF_\ /*X_[X'^-8^VJ_R&
MOLJ?\YP_E2?\\V_[YH\J3_GFW_?-=Q_PFNF_\\KC_O@?XT?\)KIO_/*X_P"^
M!_C1[:K_ "![*G_.</Y4G_/-O^^:/*D_YYM_WS7<?\)KIO\ SRN/^^!_C1_P
MFNF_\\KC_O@?XT>VJ_R![*G_ #G#^5)_SS;_ +YH\J3_ )YM_P!\UW'_  FN
MF_\ /*X_[X'^-'_":Z;_ ,\KC_O@?XT>VJ_R![*G_.</Y4G_ #S;_OFCRI/^
M>;?]\UW'_":Z;_SRN/\ O@?XT?\ ":Z;_P \KC_O@?XT>VJ_R![*G_.</Y4G
M_/-O^^:/*D_YYM_WS7<?\)KIO_/*X_[X'^-'_":Z;_SRN/\ O@?XT>VJ_P @
M>RI_SG#^5)_SS;_OFCRI/^>;?]\UW'_":Z;_ ,\KC_O@?XT?\)KIO_/*X_[X
M'^-'MJO\@>RI_P YP_E2?\\V_P"^:/*D_P">;?\ ?-=Q_P )KIO_ #RN/^^!
M_C1_PFNF_P#/*X_[X'^-'MJO\@>RI_SG#^5)_P \V_[YK3L8W%L,HW4]JZ7_
M (373?\ GE<?]\#_ !K0L]=M;VW$T2R!22/F S_.N;$RJ5(6E&QU85PHU.9.
MYR7EO_=;\J/+?^ZWY5VG]I0^C_E1_:4/H_Y5YWLF>G]<78XORW_NM^5'EO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ-CID "IZ*:T$%%%% &AIG23\*OU0TSI)^%7ZQEN:QV"BBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ./^'?\ J?$G_8Q7O_H8HH^'?^I\2?\ 8Q7O_H8HH +S_DM6D_\
M8!N__1\%=A7'WG_):M)_[ -W_P"CX*["@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N&\;?\ (8A_
MZX#_ -"-=S7#>-O^0Q#_ -<!_P"A&NO"?Q3GQ'\,YRBBBO7/-"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSJW117&>B<?\._\ 4^)/^QBO?_0Q11\._P#4^)/^QBO?_0Q10 7G_):M)_[
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MW\*WEK;V/V>_@CNK(R".5;1BKJX^;<ID)+$_-NW=>U=O_:4/H_Y4?VE#Z/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_7 ?^A&NO"?Q3GQ'\,YRBBBO7/-"BBB@ HHHH **** "BBB@ HHHH ****
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MK)Y6D>TA9V8LS% 225VD_P#?/'TKAK6ZL9YO#-HUU'!JB003SSRS[6";<",
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ)+)+';LERRA0RB/;L('&Y2#]010M0>AU5%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ:EHH *UM/\ ^/0?4UDUK:?_ ,>@^IJ)[%QW+-%%%9&@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q_P[_P!3
MXD_[&*]_]#%%'P[_ -3XD_[&*]_]#%% !>?\EJTG_L W?_H^"NPKC[S_ )+5
MI/\ V ;O_P!'P5V% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<9XPL[FXU:)H+>651" 2B$C.3Z5
MV=8VL>(XM'NT@D@>0LF_*D#N1_2MZ$I*=XJ[,JRBXVD['"_V9?\ _/E<?]^F
M_P */[,O_P#GRN/^_3?X5U?_  G-M_SYR_\ ?0H_X3FV_P"?.7_OH5Z'M:_\
MAQ>SI?S'*?V9?_\ /E<?]^F_PH_LR_\ ^?*X_P"_3?X5U?\ PG-M_P ^<O\
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M +]-_A75_P#"<VW_ #YR_P#?0H_X3FV_Y\Y?^^A1[6O_ "![.E_,<I_9E_\
M\^5Q_P!^F_PH_LR__P"?*X_[]-_A75_\)S;?\^<O_?0H_P"$YMO^?.7_ +Z%
M'M:_\@>SI?S'*?V9?_\ /E<?]^F_PH_LR_\ ^?*X_P"_3?X5U?\ PG-M_P ^
M<O\ WT*/^$YMO^?.7_OH4>UK_P @>SI?S'*?V9?_ //E<?\ ?IO\*/[,O_\
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M,O\ _GRN/^_3?X4?V9?_ //E<?\ ?IO\*]&_M-/^>;?G1_::?\\V_.CZW/\
ME#ZO'N><_P!F7_\ SY7'_?IO\*/[,O\ _GRN/^_3?X5Z-_::?\\V_.C^TT_Y
MYM^='UN?\H?5X]SSG^S+_P#Y\KC_ +]-_A1_9E__ ,^5Q_WZ;_"O1O[33_GF
MWYT?VFG_ #S;\Z/K<_Y0^KQ[GG/]F7__ #Y7'_?IO\*/[,O_ /GRN/\ OTW^
M%>C?VFG_ #S;\Z/[33_GFWYT?6Y_RA]7CW/.?[,O_P#GRN/^_3?X5VD$$PMX
MP8G!VC^$^E:7]II_SS;\ZN*=R@^HS6-6O*=KHUIT5'9F+Y$O_/-_^^31Y$O_
M #S?_ODUMT5ASFO(8GD2_P#/-_\ ODT>1+_SS?\ [Y-;=%'.'(8GD2_\\W_[
MY-'D2_\ /-_^^36W11SAR&)Y$O\ SS?_ +Y-'D2_\\W_ .^36W11SAR&)Y$O
M_/-_^^31Y$O_ #S?_ODUMT4<X<AB>1+_ ,\W_P"^31Y$O_/-_P#ODUMT4<X<
MAB>1+_SS?_ODT>1+_P \W_[Y-;=%'.'(8GD2_P#/-_\ ODT>1+_SS?\ [Y-;
M=%'.'(8GD2_\\W_[Y-:=BK+:@,"#D\$58HJ7*Z&HV"BBBI*"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./^'?
M^I\2?]C%>_\ H8HH^'?^I\2?]C%>_P#H8HH +S_DM6D_]@&[_P#1\%=A7'WG
M_):M)_[ -W_Z/@KL* ,\:[I[:W-I(F/VR"$3NFPX"?7H3R..O(]:H6_C?0;K
M2[?4(+PO;7"3.C")LXB&7R,9! '0UD1^$M935DUAM14W3WLTDMMA?+\F0;-H
M;;N)"K&>>,K66_P\U:)K1;.>V$']E2P7,)8@"Y:#R@ZG'0C&?]T&EK8.IUL?
MC'29;8RJUSO\U8A ;9Q*S,NY<)C)RO.?0'TIY\6Z4+>VN-\Y@N"%$HMW*QL7
MV .<?*=W&#T-<OIW@_6M/O+?4(8X0]M-%(+26]>7S"(7B=O-921D,N%Y V]L
MU8E\*:L^EP6?EP&8W#7;7"WCB.&1IC*1Y6W;(!D $_I5:7%T.D@\2Z9<:I]@
MCED\PN\:NT3"-W3[RJY&"1SP#V/I5S4=2MM+TR:_O'*V\*;V95+$CV Y)/8"
MN6M_#&II/;6T\=H]E97MS>1N926G,OF;49=OR@>:<G)Z=*T=6T2^U+2])L;9
MH=-AAECDN5@PPC$:Y5$!7!&\+U X%+H/J;4%_:W-G!=0S(8;A%>-B<;@1D=?
MK4#:U8+-+"L_FRP3)!+'$I=HW?&W('0?,.>@KCQX"O6LC9WCVU[';6=W;6<D
MWWAYC*T9("X4K@C(Z8&*LKX/NX[^]DCAM ;J[L[HW ;#GRO+#J?E_P!@D'/.
M:.HCHM6\16.BS1QWOGEI(WEQ# TFU$QN8[0< ;A5=/%^D27QMDEE/[U(?/\
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M;Q#HUO-)%/JUC%)$"9$>Y0%,'!R">.>*EDU?3HKA8)+^V69H_-6,S+N9,9W
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MS)/'&K6<EL5=2<EI(VS]/D(_&H9/"4K:XM\D\2QB^ENM@4]'MO)Q]<\UU%%
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M%%>8=P4444 0WMR+*PN+IE++!$TA4=3@9Q^E9D/B2WG:V6&)Y6N+)KP+$0S
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ME]IF_P">K_G1]IF_YZO^='MJW\P>SI=C-_X05/\ G_;_ +]?_7H_X05/^?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW<$(.&?[Q^ISS5=?#FC+>0W:Z7:BXMPJQ2"(9C"C QZ8''TK2HH RW\,:))
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MT#]5_P#!?+_\31_PDD'_ $#]5_\ !?+_ /$UL44 8_\ PDD'_0/U7_P7R_\
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M_P#"20?] _5?_!?+_P#$T?\ "20?] _5?_!?+_\ $UL44 8__"20?] _5?\
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MU#_P62?_ !-0_P#"1W/_ #RB_7_&C_A([G_GE%^O^-'UZEW#ZE5[$W]LZ?\
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MW/\ SRB_7_&CZY2[A]3J]BU_PD%K_P! S4__  72_P#Q-'_"06O_ $#-3_\
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MI_\ "1W/_/*+]?\ &C_A([G_ )Y1?K_C1]<H]P^IU2Y_PDD'_0/U7_P7R_\
MQ-'_  DD'_0/U7_P7R__ !-4_P#A([G_ )Y1?K_C1_PD=S_SRB_7_&CZY1[A
M]3JES_A)(/\ H'ZK_P""^7_XFC_A)(/^@?JO_@OE_P#B:I_\)'<_\\HOU_QH
M_P"$CN?^>47Z_P"-'URCW#ZG5+G_  DD'_0/U7_P7R__ !-'_"20?] _5?\
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M)!_T#]5_\%\O_P 35S[8_P#=6C[8_P#=6CVD0]G(I_\ "20?] _5?_!?+_\
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M/_=6CVD0]G(I_P#"20?] _5?_!?+_P#$T?\ "20?] _5?_!?+_\ $U<^V/\
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M31_PDD'_ $#]5_\ !?+_ /$U<^V/_=6C[8_]U:/:1#V<BG_PDD'_ $#]5_\
M!?+_ /$T?\))!_T#]5_\%\O_ ,35S[8_]U:/MC_W5H]I$/9R*?\ PDD'_0/U
M7_P7R_\ Q-'_  DD'_0/U7_P7R__ !-7/MC_ -U:/MC_ -U:/:1#V<BG_P )
M)!_T#]5_\%\O_P 31_PDD'_0/U7_ ,%\O_Q-7/MC_P!U:MJ<J#ZBJC)2V)E%
MQW,C_A)(/^@?JO\ X+Y?_B:/^$D@_P"@?JO_ (+Y?_B:V**HDQ_^$D@_Z!^J
M_P#@OE_^)H_X22#_ *!^J_\ @OE_^)K8HH Q_P#A)(/^@?JO_@OE_P#B:/\
MA)(/^@?JO_@OE_\ B:V** ,?_A)(/^@?JO\ X+Y?_B:/^$D@_P"@?JO_ (+Y
M?_B:V** ,?\ X22#_H'ZK_X+Y?\ XFC_ (22#_H'ZK_X+Y?_ (FMBB@#'_X2
M2#_H'ZK_ ."^7_XFC_A)(/\ H'ZK_P""^7_XFMBB@#'_ .$D@_Z!^J_^"^7_
M .)H_P"$D@_Z!^J_^"^7_P")K8HH Q_^$D@_Z!^J_P#@OE_^)H_X22#_ *!^
MJ_\ @OE_^)K8HH XOX:3"XL?$,JJZ!_$%ZP61"K#YQU!Y!HJ3X=_ZGQ)_P!C
M%>_^ABB@ O/^2U:3_P!@&[_]'P5V%<?>?\EJTG_L W?_ */@KL* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHJG=:OIME=1VUYJ%K;W$N/+BEF57?
M)QP"<GGB@"Y1144-U!<23)!(KM _ER@?P-@'!_ @_C0!+1110 44@(.<$'!P
M<4V*>*=6,$B2!6*,48'# X(^HH ?14,-Y;W$4DD,R,D3LDC9X5E.&!^E-LM0
MLM1B:33[N"[C5MK/!*' /ID'K0!8HHHH **** "N:\1_\A"/_KF/YFNEKFO$
M?_(0C_ZYC^9KCQG\([,'_%,FBBBO$/:"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KI(_P#5)_NBN;KI(_\ 5)_NBNS"[LX\
M5LA]%%%=QQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 44AZ<=:\^BU?5K*20FSU"[U%
MK:7SE+R[$GW (H0CRPIR,,IZ DT]Q'H5%>;3'Q++IMOIRPZD+BTFG#//</&T
MR>5NC8O$2&.3@#."1S5B6YU^"[>ZA>_N+2[N;6$J48-#Q&?,"]E.7#>AQ[T[
M:V)YM+GH-%><Q1WMYX=O6>74EOXYUQY5W=J^#-@_*<*/E[+D8K?UQKNW\+ZS
M%I\]U)+;JJP +()$^53@2<L_4G<.>W:ETN4=/17!:'K%W8W,3:F;YK3_ $D1
MDI-*'^9"@!9=YP"P!;G@]JO^$[[63<7BZS9WT?VF/[9 +@J0I).Z)2&.T ;,
M X/)XHL*YUU%>>^ ;N]AU:>VO;.['VI/,-Q(CA%(Y"'<HS)\S!CP#M7'I4$<
M_B;R$LG.H86Z6\-Q\VXQF4+Y.>O7)Q_=QVI\NM@YM+GI-%<!!KFO6UQJ5W)I
MFINE]$[V43J"J.K;8U !)3<K*QW!>0:T-,U'5[#PEJ$5S9W\VH63&.W%P TD
M^[!0EE)4\M@G/&.<4K:7'?4Z^BN#L-4UVSM[?3KP:A;>3.Z/=W%O]HDD&T-&
M#M+#G)!(/\/;-,N?$'B-=/B>(R"625A<[K1E%JPSA =K;@>.<'IUY%.PKG?T
M5P<FMZ]>7EU:0SLDR@QM%!:G;&#;[_,$A')WD #T/3O26FM^(Q>Z?!&&EA^S
MQ'=<1,IN"5.\GY.&!X'(Z<]:+!<[VM-/N+]*X#PA=7][J=[<ZA)<2;[6WXEM
MFA$;YD+H 0,X) S]*[]/N+]*UIJS9E4=T+1116QB%%%% !1110 4444 %%%%
M !1110 4444 %%%% ''_  [_ -3XD_[&*]_]#%%'P[_U/B3_ +&*]_\ 0Q10
M 7G_ "6K2?\ L W?_H^"NPKC[S_DM6D_]@&[_P#1\%=A0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<EJ$5W!\1H[U?MJ6CV,<1:WM?-5V$K$JQP=O
M!Z\5UM%'6X=+'G;6/BB#33)!-J33SVLQG#3%BI%PNT("<*WE;\8QGCO3;6QU
M"VFN&-OKBZ5/?2R$)(_VEOW,8C)(._;D..3GIGBO1J*5@//(]*\47,*/J%WJ
M4=RGV%3Y%P57!.)R0."<=3V/(J.\LO%/VB&V2[U""SCDN%AF5))Y,B4>66(D
M7(V="^Y?6O1Z*?6XC@+31+^WO[NWB_M.%;C7/.GD2>0*]NR$_*V>!G .W!Z>
MU4]:B\46]N\.EV]\CBZN)89(M[;OWPVJ0KJ,%<G+[A[9KTNBA:?UZ?Y#9QMQ
MHVH7'@O6K-(&\Z>^FE6(G'G1F7<5_P"!*"/QJMXKO-5O=)7_ (1S3-1M'97'
MF+"\;B0)^[7:K*<9.,L=HQT-=W12MI8#A19^)3<?;4EO?M)O%18WE/DB(VPR
M2F=N/,[XR#5"Y@U^;3-.2VDUFU!5AJ$DJS2R"?8,% LBMMSNZ'9G'&*])HI@
MM# \.V6H1WVHW&JSW<KF54@$KD)L\I,D(#M&7W>O?FM^BB@ KFO$?_(0C_ZY
MC^9KI:YKQ'_R$(_^N8_F:X\9_".S!_Q3)HHHKQ#V@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z2/\ U2?[HKFZZ2/_ %2?
M[HKLPN[./%;(?1117<<04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F6_
MB+2;IG6"]1BC!#E2,DMM&,CGYN,CO6G7&6_@FYLXB;>\1Y3M?]\7<!UG\T!<
MGY5(."!W .*:WU$[VT-^[\1Z38S"*ZO4C<N4Q@G!&,YP. -R\GCFK$&JV-S(
ML<%U&[MOPH//RMM;\FXKDM4\$ZAJ3^<;B!9IO/,H6:1%C,A3!&W[X78.&X-;
M">&5AOM1NU2VFEO)8'_?H2H"8)X['(+#'?&:>EA:FC>ZYING7*P7MVD4C '!
M!.T$X!8@84$]SBKOFQY8>8N5&3\W2N?U/0;ZYN-36SFMQ;ZM$(IVE!WQ87:2
MH'#<'H2,'UK&UOP=-;Z==7&G*LEQ(TQ?RX\O(LDB, >#NP%.1@_0TM!L[@31
M-MVR(=QPN&'--CNH95!20?,2!G@D@XZ'W!KA=*\'W,UC;,;>"V& K><F)(2L
MS2>9& HVE]W((7&!]*OCP0P4/))!)/'M\J0IRA%RTIP>V0P%.RN*[.N65'8J
MCJS+U .<4^N)\ :7=V%S?R7]B\4LH4&9T"DX9CM/RC<><[LMG/7BNVI,:(XX
M(HGD:*-4:5MSD#&XX R?P J2BBD,*TT^XOTK,K33[B_2MJ74QJ]!:***W, H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH X_X=_P"I\2?]C%>_^ABBCX=_
MZGQ)_P!C%>_^ABB@ O/^2U:3_P!@&[_]'P5V%<?>?\EJTG_L W?_ */@KL*
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M$=9%W1L&7U4YH 6BBDR-V,C/7% "T44CNL:EG8*HZDG% "T4 A@"#D'H110
M4444 %%%% !7->(_^0A'_P!<Q_,UTM<UXC_Y"$?_ %S'\S7'C/X1V8/^*9-%
M%%>(>T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !721_ZI/]T5S==)'_ *I/]T5V87=G'BMD/HHHKN.(**** "BBB@ HHHH
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M8V]6*,,/MP=C=2,$<XK)M_A\8]<N99)(_L5TSK/MEDWSPM'L$3*3M&.#N'/
MZ5O6_A2Q@N8[F26YN;F.1)!//)N8[%957@ 8 =OQ.30!GOX[LHQ]J=7^R-;1
M2*A0+('>1DPQ9@HP5QR0!ZU>T[Q')J'B:ZTO^S+B&."UAN!<.Z8/F;OE(#9!
M^7W[^V1?".GQPO';RW,!:+R2R2#.W>SXP00>7;J#Q4VE^&K'1[J.;3S-&$M4
MM?+WY5D0DJ3D9R-Q_.A>8&O1110 4444 8'C.&6;04"1R30+=0O=Q1J6+P!P
M7&!R1CJ.XS7-^=>:7J-_J_ANSF31EDA#6D=L4\]MCJ[*FW(P3%R ,[37H=%
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MNH?8U>8VOVEF,R9MB.K$MCS.F>_MBJ>K'7=+B@M8I+^874MOA9+PHSMY,AE
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MZ^9F_P!EWO\ S[2?E1_9=[_S[2?E6E_PDI_Y]1_WW_\ 6H_X24_\^H_[[_\
MK4>SPW\[_KY!SXG^5?U\S-_LN]_Y]I/RH_LN]_Y]I/RK2_X24_\ /J/^^_\
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M\^TGY4?V7>_\^TGY5I?\)*?^?4?]]_\ UJ/^$E/_ #ZC_OO_ .M1[/#?SO\
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M'P5V%<?>?\EJTG_L W?_ */@KL* "BBB@ HHHH **** "BBB@ HHHH ****
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ML48!W,5.&&W&1@D9STS6=XC_ .0A'_US'\S7'C/X)V8/^*9-%%%>(>T%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !721_P"J
M3_=%<W721_ZI/]T5V87=G'BMD/HHHKN.(**** "BBB@ HHHH **** "BBB@
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MFR^^WTJW52R^^WTJW733^$YJGQ!1116AF%%%% !1110 4444 %%%% !1110
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MS"O+JWN+MFL[9;:'HJ DG'J2:L61+2JHZDXK)C:NE\*61O-8BR,I%\[?A_\
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M_A1_PC=M_P ]I?T_PK ^T3?\]I/^^C1]HF_Y[2?]]&O-]M0_D/1]C7_G-_\
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MU#^0/8U_YS?_ .$;MO\ GM+^G^%'_"-VW_/:7]/\*P/M$W_/:3_OHT?:)O\
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M110 4444 <?\._\ 4^)/^QBO?_0Q11\._P#4^)/^QBO?_0Q10 7G_):M)_[
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MBF(**** "BBB@#C_ (=_ZGQ)_P!C%>_^ABBCX=_ZGQ)_V,5[_P"ABB@ O/\
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M-8HU]%48%3T44 %<UXC_ .0A'_US'\S72US?B($W\>!_RS'\S7'C/X1V8/\
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M7]V7_OD?XUS-%'UVKY!]3I>9TW_"067]V7_OD?XU=6\B900&P1GI7&5TD?\
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MM--N#,MTLI+3!=VP;-ORD[ADY['UIAT.S\U"I(=<+U.>E'F)E1O7+#(&>M<
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MN?\ Y[Q_D:/^$;G_ .>\?Y&CZM6_E#ZS1_F,:BMG_A&Y_P#GO'^1H_X1N?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$MY=BE,D8!YR:W*YKQ'_ ,A"/_KF/YFN3%R<:5TSJPD5*K9HK_VU?_\ /?\
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MU!(I7EN.T2[]IE_O?I5BUD:0-O.<52JU9='_  JX-N1$TE$M4445T'.%%%%
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M9_<+3\S?U'PL;R[O;N+5;R&>[MC;$?(41.> -H/&3@Y[UMP01VUO'!"H6.)
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M!_*N>KH;7_CTB_W!_*NO"_$SDQ7PHFK-O="L]0O#<W D\PK&ORM@8CD\Q?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML;3?+>/[%!L=/+9=@P5W%L?3<2?J:R]+\'VNEZTVHQ3LS[I6"^6BDF1MS;F
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M<@]*9I&LV.NV'VW2I_/MR[('VE<E3@]0.XZ]Z +U%%% !1110 4444 %%%%
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MK_X__P#6K"HH^MUN_P"0?5:/;\S=_P"$E/\ SZ_^/_\ UJ/^$E/_ #Z_^/\
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M(_\ D(1_]<Q_,UQXS^$=F#_BF31117B'M!1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ./^'?\ J?$G_8Q7O_H8HH^'?^I\2?\ 8Q7O_H8HH +S_DM6D_\
M8!N__1\%=A7'WG_):M)_[ -W_P"CX*["@ HHHH *P=;\)VWB'4DGU*><V\=K
M) L$,KQ<N1N8LK#.0 ,5O44 >9P^#-8MO$:"43W<(:*/[0SJ(3&(/+:0KOSY
MN,@':>O7TWHO!,S/;/?:DDKV:6\,!CMMG[N*0/\ -\QRQV@9& /2NNHH#R.5
ME\$B22=S=12>;]H_=S6^Y/WLJR<@,#QMQP0><\5/I'ABZTN_LKJ34_M3PVSV
M\WFQ,2ZE]Z[26)&WISN..]='10M "BBB@ HHHH **** "BBB@ HHHH ****
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M /7H_P"$:_Z>O_(?_P!>CZI6[?D'UNCW_,P:*WO^$:_Z>O\ R'_]>C_A&O\
MIZ_\A_\ UZ/JE;M^0?6Z/?\ ,P:*WO\ A&O^GK_R'_\ 7H_X1K_IZ_\ (?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_P5K_\ %4?4)?S!]?7\I%14O_"=0_\ 0D>)_P#P5K_\51_PG4/_ $)'B?\
M\%:__%4?4)?S!]?7\I%14O\ PG4/_0D>)_\ P5K_ /%4?\)U#_T)'B?_ ,%:
M_P#Q5'U"7\P?7U_*145+_P )U#_T)'B?_P %:_\ Q5'_  G4/_0D>)__  5K
M_P#%4?4)?S!]?7\I%14O_"=0_P#0D>)__!6O_P 51_PG4/\ T)'B?_P5K_\
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M[_A89_Z$[Q7_ ."T?_%T?\+#/_0G>*__  6C_P"+H [&BN._X6&?^A.\5_\
M@M'_ ,71_P +#/\ T)WBO_P6C_XN@#L:*X[_ (6&?^A.\5_^"T?_ !='_"PS
M_P!"=XK_ /!:/_BZ .QHKCO^%AG_ *$[Q7_X+1_\71_PL,_]"=XK_P#!:/\
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M;"ZL#>ZS=744-W'LD$;L"I([44 =A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786742160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text">Description of the Business <div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;) was incorporated in the state of Delaware in November 2005. We are a clinical stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;">. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, we have devoted our primary effort to raising capital and research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Management believes its currently available resources will provide sufficient funds to enable the Company to meet its operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803049776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">20,968<span></span>
</td>
<td class="nump">20,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,285<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,253<span></span>
</td>
<td class="nump">24,772<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,253)<span></span>
</td>
<td class="num">(24,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">1,897<span></span>
</td>
<td class="nump">2,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">2,675<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(8,262)<span></span>
</td>
<td class="num">(22,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,262)<span></span>
</td>
<td class="num">(22,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized income on available for sale securities, net of tax of $0 and $115, respectively</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (7,455)<span></span>
</td>
<td class="num">$ (21,651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average number of shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">27,264<span></span>
</td>
<td class="nump">26,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739038544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issued and Outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options issued and outstanding (in shares)</a></td>
<td class="nump">2,866,929<span></span>
</td>
<td class="nump">3,039,880<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance (in shares)</a></td>
<td class="nump">6,982,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issued and Outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future award grants (in shares)</a></td>
<td class="nump">3,118,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Issued and Outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future award grants (in shares)</a></td>
<td class="nump">997,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786727216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790548512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus pandemic, or COVID-19, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and social distancing guidelines, causing some businesses to suspend operations and or experience a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, included in our Annual Form 10-K. </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Consolidation</span></div><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span> reportable segment and our functional and reporting currency is the U.S. dollar. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Common Share </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text"><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Recently Adopted</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board &#8220;FASB&#8221; issued ASU 2019-12,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes (Topic 740)</span><span style="font-family:inherit;font-size:10pt;"> intended to simplify the accounting for income taxes. The guidance removes the following exceptions: 1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, 2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, 3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary and 4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: 1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, 2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, 3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), 4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date and 5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)</span><span style="font-family:inherit;font-size:10pt;">,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (AFS) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the recent coronavirus (COVID-19) pandemic on expected credit losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793285152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Accounts and Supplemental Disclosures</a></td>
<td class="text">Balance Sheet Accounts and Supplemental Disclosures <div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,018</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>820</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,413</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,297</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,679</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,618</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Expenses </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,152</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued research, development and manufacturing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,689</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,781</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,052</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793256384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of the </span><span style="font-family:inherit;font-size:10pt;"><span>500,000,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of common stock authorized, </span><span style="font-family:inherit;font-size:10pt;"><span>27,277,115</span></span><span style="font-family:inherit;font-size:10pt;"> shares were issued and outstanding as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:86%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issued and Outstanding:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,866,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares Reserved For:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017 Equity Incentive Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,118,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017 Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>997,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,982,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786978384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at End of Period Using:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Market<br/>Prices for<br/>Identical&#160;Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Other&#160;Observable<br/>Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">At March 31, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,685</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,685</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agency securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">At December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Agency securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date. </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value of Other Financial Instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of our other financial instruments estimated as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are presented below: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Available-for-sale Investments</a></td>
<td class="text">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of <span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agency securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,754</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,890</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,639</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,685</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246,029</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding agency securities, </span><span style="font-family:inherit;font-size:10pt;"><span>$14.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> have maturity dates of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$27.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding certificates of deposit, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding commercial and corporate</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">obligations, </span><span style="font-family:inherit;font-size:10pt;"><span>$82.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> have maturity dates of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding U.S. Treasury securities, </span><span style="font-family:inherit;font-size:10pt;"><span>$94.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> have maturity dates of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$18.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of Unrealized Loss and Fair Values in a Loss Position</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;</span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,431</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,431</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Treasury Securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787061920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787012880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Classification on the Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating ROU assets, Other long-term assets</a></td>
<td class="nump">$ 1,213<span></span>
</td>
<td class="nump">$ 1,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, Other current liabilities</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, Other long-term liabilities</a></td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790496560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text">Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at <span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows: </span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:86%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issued and Outstanding:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,866,929</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares Reserved For:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017 Equity Incentive Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,118,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017 Employee Stock Purchase Plan</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>997,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,982,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804000128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">3,021<span></span>
</td>
<td class="nump">2,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6738904416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details) - Subsequent event<br> ft&#178; in Thousands</strong></div></th>
<th class="th">
<div>May 04, 2020 </div>
<div>ft&#178; </div>
<div>$ / ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (sqft) | ft&#178;</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term</a></td>
<td class="text">124 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod', window );">Lease termination term</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RentPerSquareFoot', window );">Monthly base rate (usd per sqft) | $ / ft&#178;</a></td>
<td class="nump">4.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AnnualRentIncreasePercent', window );">Increase in annual rent</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AnnualRentIncreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Rent Increase, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AnnualRentIncreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent Per Square Foot</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6785739584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>lease </div>
<div>renewal_option</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LesseeOperatingLeaseNumber', window );">Non-cancellable office leases | lease</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.59%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LeaseArrangementAxis=anab_OneOfficeLeaseMember', window );">One office lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber', window );">Number of one year renewal options | renewal_option</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LesseeOperatingLeaseNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LesseeOperatingLeaseNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, One Year Renewal Options, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_LeaseArrangementAxis=anab_OneOfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_LeaseArrangementAxis=anab_OneOfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>anab-3312020x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:anab="http://www.anaptysbio.com/20200331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utreg="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="anab-20200331.xsd" xlink:type="simple"/>
    <context id="FD2020Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2020Q2May4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_anab_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_anab_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">anab:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2016Q4QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_us-gaap_TypeOfArrangementAxis_anab_Phase1ClinicalTrialInitiationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase1ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q2QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="FI2014Q1_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2014Q4Nov01-Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="D2014Q1Mar01-Mar31_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2011Q4YTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-01-01</startDate>
            <endDate>2011-12-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3ClinicalTrialInitiationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2011Q4_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FD2016Q3QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3clinicaltrialinitiationsecondindicationDomain">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3clinicaltrialinitiationsecondindicationDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2015Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3ClinicalTrialInitiationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase3ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="FD2015Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:InVivoToxicologyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:ClearanceOfInvestigationalNewDrugFromFDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_FilingofMMAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingofMMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:Phase2ClinicalTrialInitiationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_FilingofNDAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:TESAROInc.AndTESARODevelopmentInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anab:AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">anab:FilingofNDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anab:CelgeneCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="I2014Q4Dec24_us-gaap_DebtInstrumentAxis_anab_TermALoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermALoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-24</instant>
        </period>
    </context>
    <context id="I2016Q1Jan31_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="I2014Q4Dec24_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-24</instant>
        </period>
    </context>
    <context id="D2014Q4Dec24-Dec24_us-gaap_DebtInstrumentAxis_anab_TermALoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermALoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-24</startDate>
            <endDate>2014-12-24</endDate>
        </period>
    </context>
    <context id="D2014Q4Dec24-Dec24_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-24</startDate>
            <endDate>2014-12-24</endDate>
        </period>
    </context>
    <context id="I2014Q4Dec24_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-24</instant>
        </period>
    </context>
    <context id="I2016Q1Jan31_us-gaap_DebtInstrumentAxis_anab_TermBLoansAndTermCLoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">anab:TermBLoansAndTermCLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">anab:CommercialAndCorporateObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan01-Jan01_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="D2017Q1Jan26-Jan26_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-26</startDate>
            <endDate>2017-01-26</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_anab_EmployeeAndNonemployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anab:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2019Q1Jan1_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anab:EquityIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_anab_LeaseArrangementAxis_anab_OneOfficeLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="anab:LeaseArrangementAxis">anab:OneOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001370053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <unit id="installment">
        <measure>anab:installment</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="lease">
        <measure>anab:lease</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>anab:milestone</measure>
    </unit>
    <unit id="sqft">
        <measure>utreg:sqft</measure>
    </unit>
    <unit id="renewal_option">
        <measure>anab:renewal_option</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD_PER_sqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utreg:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="segment">
        <measure>anab:segment</measure>
    </unit>
    <unit id="target">
        <measure>anab:target</measure>
    </unit>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      id="Fact-E60DA6B901555B799B2AF2928FB48776-wk-Fact-E60DA6B901555B799B2AF2928FB48776">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      id="Fact-BBC7D637EB39559C82EB0B771D3EE29D-wk-Fact-BBC7D637EB39559C82EB0B771D3EE29D">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      id="Fact-AD58188957C55CCB9976EFCC90F87C30-wk-Fact-AD58188957C55CCB9976EFCC90F87C30">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      id="Fact-D59480E12DE3550588A625E834F4A14A-wk-Fact-D59480E12DE3550588A625E834F4A14A">P1Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <dei:AmendmentFlag
      contextRef="FD2020Q1YTD"
      id="Fact-D9C83308CAC15E2C8343E35CC2F1991A-wk-Fact-D9C83308CAC15E2C8343E35CC2F1991A">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q1YTD"
      id="Fact-FC07F35B543A534D81CE9C0E438E51D8-wk-Fact-FC07F35B543A534D81CE9C0E438E51D8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q1YTD"
      id="Fact-D9D6BAFB97BF598AA26FE76103115931-wk-Fact-D9D6BAFB97BF598AA26FE76103115931">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q1YTD"
      id="Fact-26CD4B1F4C3B52ECADAF493F86EC3519-wk-Fact-26CD4B1F4C3B52ECADAF493F86EC3519">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q1YTD"
      id="Fact-80DCC4AA3CC25D70971D04D98D94287D-wk-Fact-80DCC4AA3CC25D70971D04D98D94287D">0001370053</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-08BA1CCC32B450DF8C8A10D6A9654D29-wk-Fact-08BA1CCC32B450DF8C8A10D6A9654D29"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-FE7D96DEFC825610834B227DD287F63C-wk-Fact-FE7D96DEFC825610834B227DD287F63C"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-572287BF03FE528488A6A2E065D8BB2E-wk-Fact-572287BF03FE528488A6A2E065D8BB2E"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="-3"
      id="Fact-4ABE2D4364765C1BAD3CFB7CDDFB3FD6-wk-Fact-4ABE2D4364765C1BAD3CFB7CDDFB3FD6"
      unitRef="shares">27255000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q1"
      decimals="-3"
      id="Fact-52295793578C53F39482A3A89C087FD3-wk-Fact-52295793578C53F39482A3A89C087FD3"
      unitRef="shares">27277000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="-3"
      id="Fact-DDCFD020ED8D50F98321AD1AC30ACB42-wk-Fact-DDCFD020ED8D50F98321AD1AC30ACB42"
      unitRef="shares">27255000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1"
      decimals="-3"
      id="Fact-BBAEDDA80E8051148DCC37837518B0A1-wk-Fact-BBAEDDA80E8051148DCC37837518B0A1"
      unitRef="shares">27277000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-A1A6CC5D1E0A51B7A526AEEA234D1B23-wk-Fact-A1A6CC5D1E0A51B7A526AEEA234D1B23"
      unitRef="shares">27277115</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="Fact-1A51CA1C23A05DA1A6BB66E67AD6E18B-wk-Fact-1A51CA1C23A05DA1A6BB66E67AD6E18B"
      unitRef="usd">115000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="Fact-6920FAB1439250D499171782B1AF83AE-wk-Fact-6920FAB1439250D499171782B1AF83AE"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-0BEBDC9C11CD525691E684ED3C34BA90-wk-Fact-0BEBDC9C11CD525691E684ED3C34BA90"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-8FAE29D91BD85E138DC41E2837FEF59C-wk-Fact-8FAE29D91BD85E138DC41E2837FEF59C"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-F0EEB1E38B8E571F9EA3071B99A0A752-wk-Fact-F0EEB1E38B8E571F9EA3071B99A0A752"
      unitRef="shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-9B69D23FA5195FF9BB713E60C773BD3B-wk-Fact-9B69D23FA5195FF9BB713E60C773BD3B"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-519EFA70A50A5A41BF9D1801A73CE48F-wk-Fact-519EFA70A50A5A41BF9D1801A73CE48F"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-4D13B8F6426C5737A826C57778849BE0-wk-Fact-4D13B8F6426C5737A826C57778849BE0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-523D44B7DD8757B99D96DFEEFE479014-wk-Fact-523D44B7DD8757B99D96DFEEFE479014"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-B7DAE6CDEE6754A0A86B9A329032E0AE-wk-Fact-B7DAE6CDEE6754A0A86B9A329032E0AE"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="Fact-BFCF40578B1C5A53B0D83349CE92A34B-wk-Fact-BFCF40578B1C5A53B0D83349CE92A34B"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-0634B36B302E542090F13AB2AE09B4EA-wk-Fact-0634B36B302E542090F13AB2AE09B4EA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="FD2020Q1YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-3CAE2F4BB3E652F38544EC95AAC8743E-wk-Fact-3CAE2F4BB3E652F38544EC95AAC8743E">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dei:DocumentType
      contextRef="FD2020Q1YTD"
      id="d26767353e446-wk-Fact-C0AB596C56F554D295E361C149473310">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q1YTD"
      id="d26767353e478-wk-Fact-E34C679CDE4B5FFDBD0A445587FBB375">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q1YTD"
      id="d26767353e488-wk-Fact-A9996D0C8C5159DCAE4EA646B4C0B710">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q1YTD"
      id="d26767353e508-wk-Fact-CD3C58A444C85184A3DDE6CDB439C636">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q1YTD"
      id="d26767353e530-wk-Fact-4C2F23B4B18D5B569808173988391576">001-37985</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q1YTD"
      id="d26767353e550-wk-Fact-C97C6E68A7595614B4CC7984FDEDA0F3">ANAPTYSBIO,&#160;INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q1YTD"
      id="d26767353e588-wk-Fact-6BF1C69E925B580CBC2402B5128BD1BE">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q1YTD"
      id="d26767353e598-wk-Fact-CA2A81DBC1465BA787B2EAC02B56B797">20-3828755</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q1YTD"
      id="d26767353e625-wk-Fact-F860818978EA58348210AA894F010670">10421 Pacific Center Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="FD2020Q1YTD"
      id="d26767353e630-wk-Fact-4F9BB36900555DEE89B4CEA26BC847F9">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q1YTD"
      id="d26767353e636-wk-Fact-89C06BF15F6E59CABFD7E9EB1C60B128">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q1YTD"
      id="d26767353e641-wk-Fact-BCCA4ED20EF3546F8C57793B82F971F0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q1YTD"
      id="d26767353e646-wk-Fact-388D902F7A2C588484D5298AF41B893C">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q1YTD"
      id="d26767353e658-wk-Fact-FFFA208ABBA757AC9ADE2222FC43184F">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q1YTD"
      id="d26767353e663-wk-Fact-9BD16D2F461C5F7888BB87F1595D45C7">362-6295</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q1YTD"
      id="d26767353e718-wk-Fact-D4D8D49C44335293BFC2540AA2EC81FB">Common Stock, $0.001 par value </dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q1YTD"
      id="d26767353e723-wk-Fact-765BBC91F5AF5960BC5EF5081704736D">ANAB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q1YTD"
      id="d26767353e728-wk-Fact-85B5483E50855A518663CA652FD815F4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q1YTD"
      id="d26767353e735-wk-Fact-77067CAD3F5F522096A24CF0EDFE16DC">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q1YTD"
      id="d26767353e750-wk-Fact-183FFE6375B25750AD41D7A4BBCBF117">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q1YTD"
      id="d26767353e783-wk-Fact-4CA5FB21896B5BD1B47BD42D457CCB31">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q1YTD"
      id="d26767353e885-wk-Fact-FE6976362F4D5586A12B44D858195C35">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q1YTD"
      id="d26767353e957-wk-Fact-8EDAFE7D4AF45B32B8046D7B3BDA412C">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q1YTD"
      id="d26767353e968-wk-Fact-D86E2B31AAA4559E98ACAC1A4C82F013">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q2May4"
      decimals="INF"
      id="d26767353e984-wk-Fact-B79261DD62885F24B93AFA9A37035120"
      unitRef="shares">27277115</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e607-wk-Fact-C9BED6B1EAD35B2FB791B26FFA9C26CD"
      unitRef="usd">165317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e626-wk-Fact-C85187F818CE5C4086A4DCA40A58C3EB"
      unitRef="usd">171017000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e641-wk-Fact-4DE11D2C534C5479985687891D68CD25"
      unitRef="usd">5000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e660-wk-Fact-4671C832C00158F28A649D3C6F1C25A1"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e680-wk-Fact-3B4585770839581886FC9B338BE2BAD4"
      unitRef="usd">197166000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e699-wk-Fact-D8D00AAF1CBB5E92BD96B2E953F5F7F6"
      unitRef="usd">203210000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e719-wk-Fact-C5B2BBD7BE755D8FA09B2B0717D1910B"
      unitRef="usd">3572000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e738-wk-Fact-CB5E40B446785FCEAFC8AD92B46CE723"
      unitRef="usd">3506000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e758-wk-Fact-EA755D82DFEA5F36BBADB6CF4EB6289D"
      unitRef="usd">371055000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e777-wk-Fact-0BDA1F96E7E75CBD9F45423B58D4B543"
      unitRef="usd">377733000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e797-wk-Fact-77B923B2F7545A5BA7333B80DC4C00CB"
      unitRef="usd">1610000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e816-wk-Fact-9AD56001338F58CCA9EA54AE0A88A978"
      unitRef="usd">1618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e836-wk-Fact-578EA6D879C355B39D7F8D3A6460601A"
      unitRef="usd">50215000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e855-wk-Fact-8C4B6D52E2CD58BA91E444618E3EE2EB"
      unitRef="usd">54305000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e876-wk-Fact-A5D34AAB9374532CA22E939CF0BB760D"
      unitRef="usd">1293000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e895-wk-Fact-E787FC069CE45BB98F83B39334F47832"
      unitRef="usd">1481000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e915-wk-Fact-34A4AE007E415134802B1718B4616866"
      unitRef="usd">60000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e934-wk-Fact-017A99AFD29D50B988171FBBEE0E12B1"
      unitRef="usd">60000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e959-wk-Fact-F3012D8301BC542E99B62919A8C187BA"
      unitRef="usd">424233000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e978-wk-Fact-0FD64F1F33E150058FD836B4FBAB7BD5"
      unitRef="usd">435197000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1080-wk-Fact-783F5F96CAA454EE8F2D5CD91FDEAFCF"
      unitRef="usd">8571000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1099-wk-Fact-A9829F4EB622541E9ED482F778DEE63E"
      unitRef="usd">16237000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1114-wk-Fact-3D7922185AD859C8A5A768570583D1F3"
      unitRef="usd">13781000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1133-wk-Fact-097AF68DBD7C51DFA9CF38C3E6D66D81"
      unitRef="usd">11052000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1153-wk-Fact-BA1C8653AB8351B29C90FEDFF98986ED"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1172-wk-Fact-987CE74637AD52FFB4AD130C4EC7E37D"
      unitRef="usd">1375000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1192-wk-Fact-D0E792A54D4E5D959D50A4EAA29DACD9"
      unitRef="usd">898000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1211-wk-Fact-D63E42920E4854BA8F41C32C9FFEE1A1"
      unitRef="usd">871000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1231-wk-Fact-85AF4EA0F75A54808245314DB193655E"
      unitRef="usd">23250000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1250-wk-Fact-54D870E573FD58F1A19AA66887171560"
      unitRef="usd">29535000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1270-wk-Fact-7CCB0E9E0B0F51A789DC32181F97B230"
      unitRef="usd">419000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1289-wk-Fact-1B847BFE32E0551FA85F69368BB68896"
      unitRef="usd">654000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1351-wk-Fact-0F6FFF1221CE5A6CBEBB0EE3B6E6FA86"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1370-wk-Fact-2EAC4663585F583091D2B6C2E5AE2460"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1390-wk-Fact-45D82D2ED70F50C6841AF7F27D0194D1"
      unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1409-wk-Fact-69F355CE0F655AD79B41322D2F1BE001"
      unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1429-wk-Fact-0A5A5C39F0645BF3B3E8C38CA9065936"
      unitRef="usd">651680000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1448-wk-Fact-AB1CDE97FEE15134A724EA254599CB23"
      unitRef="usd">648669000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1468-wk-Fact-52DC2CBD7F47553682091A74682F47D8"
      unitRef="usd">1145000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1487-wk-Fact-B0455D64BEE752D2954E67D1CFBE51B4"
      unitRef="usd">338000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1507-wk-Fact-E235366FBB4B5D14A3A388BD595F384C"
      unitRef="usd">-252288000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1527-wk-Fact-DCDD3EFC48FF59D7B2826F6293595DFD"
      unitRef="usd">-244026000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1548-wk-Fact-BA3D0040F9635C9BA0B03ADDE6DC28BC"
      unitRef="usd">400564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1567-wk-Fact-8D8A49415E1F513098893930951B11A5"
      unitRef="usd">405008000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26769083e1592-wk-Fact-5473D9397D6356F39D634AE405BAB64A"
      unitRef="usd">424233000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26769083e1611-wk-Fact-C14C9B6C514E59058CDDF9E223D1675E"
      unitRef="usd">435197000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e529-wk-Fact-0A9DC609564D58618F3F124F99BDD9B6"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e548-wk-Fact-6F9DBA3DF66A5662B9E2E0216F32756B"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e604-wk-Fact-D6D940F8A70350229D223CC3F222A7C7"
      unitRef="usd">20968000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e623-wk-Fact-8434DB7277A8556C9134D62EDF25EC14"
      unitRef="usd">20631000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e643-wk-Fact-68ABEFF5ABCE50C69AC0D9F2434B2DF6"
      unitRef="usd">4285000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e662-wk-Fact-629E6BD63FA05BA3A38A1B7374D8596D"
      unitRef="usd">4141000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e682-wk-Fact-0C442EB0A7E65C9FAFA63235798759DE"
      unitRef="usd">25253000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e701-wk-Fact-DED983BD839A587A99C3A548E386F2E1"
      unitRef="usd">24772000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e721-wk-Fact-D7BAA8E44FE75F8D859B2BEA86996098"
      unitRef="usd">-10253000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e741-wk-Fact-94F1D5E283C6557896265871BFAA3CD6"
      unitRef="usd">-24772000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e803-wk-Fact-C3621DA26EEA568CB75E156BD3B4A50C"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e822-wk-Fact-EEC92EE2FDC5590DBE2B9B508CC5EB83"
      unitRef="usd">320000</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e843-wk-Fact-3E176A4E677A53E182CB3730C8632518"
      unitRef="usd">1897000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e862-wk-Fact-C21238D1B5AF5DAE9DD12B96EB17D448"
      unitRef="usd">2988000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e883-wk-Fact-CDCAA968147C519A8F26BA9844608AA1"
      unitRef="usd">94000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e902-wk-Fact-D79EC1A2B2EB53BBA2C8DF45A6BA1120"
      unitRef="usd">7000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e922-wk-Fact-3B76152191D95D38AFA1568CEB8A919A"
      unitRef="usd">1991000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e941-wk-Fact-992A0CD182655F7BBA6A9560EC15C8E7"
      unitRef="usd">2675000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e961-wk-Fact-8F1EAFFD699358C5B0DE87EE5BF0EDE7"
      unitRef="usd">-8262000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e981-wk-Fact-D48F370442D5527696B09B759AB78423"
      unitRef="usd">-22097000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e1002-wk-Fact-5C711A9621255F37A0D5908CD5CEE0FD"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e1021-wk-Fact-7EBE7BA160E65773B6A08BA18D6690CA"
      unitRef="usd">-19000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e1041-wk-Fact-4FEC981DE04E5C0996F403AB89D9CED4"
      unitRef="usd">-8262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e1061-wk-Fact-4398CD5ED3735E11A4522B2CFF2F0A8B"
      unitRef="usd">-22078000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e1123-wk-Fact-E4BD09B150ED5D9DAADF6D2BEEEAE564"
      unitRef="usd">807000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e1142-wk-Fact-3381CCE14AEC5988AF65FE7EF4564770"
      unitRef="usd">427000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e1167-wk-Fact-74CAADCB477356C39DD82D28B8228C77"
      unitRef="usd">-7455000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e1187-wk-Fact-BC36955CDC215E90B09B456766CCC4B3"
      unitRef="usd">-21651000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d26772186e1249-wk-Fact-3FD1F6269EA2515EB5E10F8D1675DA41"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d26772186e1269-wk-Fact-FCEA7715C5B0509ABDF775AC6E4DA30F"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772186e1327-wk-Fact-19175D5CB4C2586CA4F2DA3BC03C34BA"
      unitRef="shares">27264000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26772186e1346-wk-Fact-75FCDD3564E35449BD5A71A728072039"
      unitRef="shares">26981000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26772871e696-wk-Fact-E651F449067D5B3CA8826391975A0933"
      unitRef="shares">27255000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26772871e715-wk-Fact-530D3202E4E553A7B82A21DB731955C6"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d26772871e734-wk-Fact-CC1C07EDEB835E9B844119AB68EF5311"
      unitRef="usd">648669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d26772871e754-wk-Fact-8C812027341A5B78A6FC9F3CC8DBDDCC"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d26772871e773-wk-Fact-8D148D109B1E5A82ACEA80E34FF43FAC"
      unitRef="usd">-244026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26772871e793-wk-Fact-8D8A49415E1F513098893930951B11A5"
      unitRef="usd">405008000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26772871e809-wk-Fact-E6C1C3C0BE7F51E184623261B9C56631"
      unitRef="shares">22000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d26772871e842-wk-Fact-AFC30CE026FA53DA85D0F860F114E7A1"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772871e900-wk-Fact-58D1465B086C5F9A9D11BE59A6692DDC"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d26772871e954-wk-Fact-B8AD9BD33AD55441BB5B2D38F6C6AFE8"
      unitRef="usd">2975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772871e1012-wk-Fact-BBD3E282B3E653FAA499C7E9502D4D49"
      unitRef="usd">2975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d26772871e1086-wk-Fact-4AB2CDD39E4B59CF8AC326531E160428"
      unitRef="usd">807000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772871e1124-wk-Fact-87251A1814D45997A539309B4946E3D8"
      unitRef="usd">807000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d26772871e1217-wk-Fact-0951CD6D27355141BF76AB4D2BD86F6D"
      unitRef="usd">-8262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26772871e1237-wk-Fact-4FEC981DE04E5C0996F403AB89D9CED4"
      unitRef="usd">-8262000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26772871e1259-wk-Fact-A293B6BBAFAC5054851159079E173763"
      unitRef="shares">27277000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26772871e1278-wk-Fact-4C6981913B1A553BA12215D8F00F69D6"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d26772871e1297-wk-Fact-024236C3EE93548AA530397E3D30E810"
      unitRef="usd">651680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d26772871e1317-wk-Fact-013C6309AB4D5FA386873964AF8C483F"
      unitRef="usd">1145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d26772871e1336-wk-Fact-3B8D1EC0B45C52C5A837B17F15F25BB1"
      unitRef="usd">-252288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26772871e1356-wk-Fact-BA3D0040F9635C9BA0B03ADDE6DC28BC"
      unitRef="usd">400564000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26773816e694-wk-Fact-4A3ECDFBC3E356158C0FA507A7D32C1E"
      unitRef="shares">26922000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26773816e713-wk-Fact-C667A395DB6A527BB2B92F8846EFD660"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d26773816e732-wk-Fact-DC6CBFD1F7885C5185706030021CEE8C"
      unitRef="usd">633251000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d26773816e752-wk-Fact-EA1FA5AAA76C5A5D82D6EE21AC6E6087"
      unitRef="usd">-223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d26773816e772-wk-Fact-B82DCE8DC91E563789FB4BB5A2CF8DF2"
      unitRef="usd">-146690000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d26773816e792-wk-Fact-56573CE8610259B9AC99A7E5797B510B"
      unitRef="usd">486365000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26773816e808-wk-Fact-F9F6F49595425DFD9984F2A5DC0C2C90"
      unitRef="shares">84000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d26773816e841-wk-Fact-659A5E19EF075232A3B75F216051E5A5"
      unitRef="usd">574000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26773816e899-wk-Fact-97BF1F7DC9355E38B140299194A1D40C"
      unitRef="usd">574000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d26773816e953-wk-Fact-9F6CE1A90C0D5889900BCDA5DCEBDE76"
      unitRef="usd">2867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26773816e1011-wk-Fact-97D6D85BC08B54F4976C1A7DDA674A9D"
      unitRef="usd">2867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d26773816e1085-wk-Fact-A10F174A6E0C57E29307F494C2C8765E"
      unitRef="usd">427000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26773816e1123-wk-Fact-B94C0999068952D9830476E9DF1B4EDB"
      unitRef="usd">427000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d26773816e1216-wk-Fact-5EFF4B5A789A593688256AA73618E6B3"
      unitRef="usd">-22078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26773816e1236-wk-Fact-4398CD5ED3735E11A4522B2CFF2F0A8B"
      unitRef="usd">-22078000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26773816e1258-wk-Fact-A943FDE478E65245A87D515B437CDDCB"
      unitRef="shares">27006000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d26773816e1277-wk-Fact-76322A5F32CB50859FE0DAF77300094D"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d26773816e1296-wk-Fact-8679A2238555533FA0E5EB55AC34A9EE"
      unitRef="usd">636692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d26773816e1316-wk-Fact-E745883D33E755E2AE8E6DB71A099440"
      unitRef="usd">204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d26773816e1335-wk-Fact-4620434DBD015AD6910739A3C0260E00"
      unitRef="usd">-168768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-3"
      id="d26773816e1355-wk-Fact-DA5B79B04EF950E0B777BA366113939A"
      unitRef="usd">468155000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e569-wk-Fact-4FEC981DE04E5C0996F403AB89D9CED4"
      unitRef="usd">-8262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e589-wk-Fact-4398CD5ED3735E11A4522B2CFF2F0A8B"
      unitRef="usd">-22078000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e646-wk-Fact-F589F8A8BB1C5DA0B490C8D95EBFBE48"
      unitRef="usd">140000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e665-wk-Fact-CB6164149F0A5FF1A86C2F7CE613F1BA"
      unitRef="usd">115000</us-gaap:DepreciationDepletionAndAmortization>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e685-wk-Fact-1341CD9F811D57208C64AF7D213B450A"
      unitRef="usd">2975000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e704-wk-Fact-4DCA0F193B3D5FD08CB6F86FBAB8A919"
      unitRef="usd">2867000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e724-wk-Fact-FC9ED541CEF85970AEB550A8896F4648"
      unitRef="usd">8000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e744-wk-Fact-8D3EAB13B11356C1AC1D9C11665B96F7"
      unitRef="usd">1028000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e765-wk-Fact-E6B4627648545C5FA6AB57EAE82491E7"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e784-wk-Fact-1B5802E56B195306B73A653FEE140432"
      unitRef="usd">-164000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e845-wk-Fact-5039B0A0573456A4BD6E1338A6186502"
      unitRef="usd">5000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e865-wk-Fact-2A8E4B7BBED75982A741CD9D2C139E6E"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e886-wk-Fact-B6483139C70350E28DFB0FBCC03EA07D"
      unitRef="usd">-233000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e905-wk-Fact-59ACAA87723C5616936B42B402A9B8E3"
      unitRef="usd">1215000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e926-wk-Fact-9AAB934E3A925521840AB3B4ED7B1176"
      unitRef="usd">-5190000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e946-wk-Fact-1DDB395FA1D257298BDC9FC83516594F"
      unitRef="usd">5076000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e966-wk-Fact-A7FDA391383A59868332C2D5F723B296"
      unitRef="usd">-15112000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e986-wk-Fact-E37D6892380850779A8325715CCAE992"
      unitRef="usd">-16099000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1048-wk-Fact-65BDD8C163A158FBA08FDBF7E94B21AF"
      unitRef="usd">74013000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1068-wk-Fact-B2634A51C27F53A98431E2E600DCCFDD"
      unitRef="usd">79763000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1089-wk-Fact-F36040249D3A526EAAE2F320FE4FB9C4"
      unitRef="usd">84851000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1108-wk-Fact-9E3A3305783B55A099799BAB4676FC83"
      unitRef="usd">89600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1128-wk-Fact-F86ACCA50B135FE6BC28B770CFA359E3"
      unitRef="usd">87000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1148-wk-Fact-F249B0C326F35C8AADEF0AB29CB2DE9D"
      unitRef="usd">180000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1169-wk-Fact-B7EFDCF509C75AC9B8653E6086382020"
      unitRef="usd">10751000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1188-wk-Fact-3A3F3395D6FD57B2AEB4570F3A27841E"
      unitRef="usd">9657000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1249-wk-Fact-D5B5F6C10CD55C65B282E946AC157003"
      unitRef="usd">36000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1268-wk-Fact-D148CD3EAD5B5198AFAB055BF1E6AE9D"
      unitRef="usd">574000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1288-wk-Fact-083CEB20BC465A09B7C1ACD3D17D55E0"
      unitRef="usd">1375000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1308-wk-Fact-DE3CE51CA15050178A8B08F80BD0C7DD"
      unitRef="usd">1875000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1330-wk-Fact-4385F4123BCC5553A99B1A376DD53722"
      unitRef="usd">-1339000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1350-wk-Fact-D12EE98B593F56B3AF9E8E35DEEA4BDA"
      unitRef="usd">-1301000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1371-wk-Fact-351AE854EBD75A3886D62E7544AA1392"
      unitRef="usd">-5700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1391-wk-Fact-AFAEF339DC53505E950BA871F011AA9E"
      unitRef="usd">-7743000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26771629e1412-wk-Fact-5ABAA88CB93E56EC8077A3086C7BA9BC"
      unitRef="usd">171077000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d26771629e1431-wk-Fact-B2995FA9763B5CD79CC6733B1644F320"
      unitRef="usd">113656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26771629e1456-wk-Fact-CB118AB1E12B5BC5A66C3507702FC0A0"
      unitRef="usd">165377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q1"
      decimals="-3"
      id="d26771629e1475-wk-Fact-0C393FBFEFA651F9A69C532EBCD6A958"
      unitRef="usd">105913000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1536-wk-Fact-EB7906AF8263515AAC17AC84DE2F1A67"
      unitRef="usd">4000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1555-wk-Fact-BBDE983B6B695125ADCCE8CE9F36F10C"
      unitRef="usd">172000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26771629e1616-wk-Fact-110489D227995E898B67D1A80CECCA46"
      unitRef="usd">86000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26771629e1635-wk-Fact-45BE0D9C2B5C55C6853FAB57E4B829AA"
      unitRef="usd">233000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="FD2020Q1YTD"
      id="TextSelection-6C4907F6889D5AECBA5E1EF63B26E2D6-0-wk-Fact-45DDFB6FBCC6518D8FE99BDBFACA7961">Description of the Business &lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;AnaptysBio, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in November 2005. We are a clinical stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;in vitro&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Since our inception, we have devoted our primary effort to raising capital and research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Management believes its currently available resources will provide sufficient funds to enable the Company to meet its operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-81C0A1870BE05A86A652D840BF134129-0-wk-Fact-0385C59A84DE5F35ABDD157AEE2E2DA3">Summary of Significant Accounting Policies &lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus pandemic, or COVID-19, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and social distancing guidelines, causing some businesses to suspend operations and or experience a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, included in our Annual Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reportable segment and our functional and reporting currency is the U.S. dollar.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,359&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;padding-left:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the Financial Accounting Standards Board &#x201c;FASB&#x201d; issued ASU 2019-12,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; intended to simplify the accounting for income taxes. The guidance removes the following exceptions: 1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, 2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, 3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary and 4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: 1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, 2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, 3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), 4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date and 5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (AFS) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the recent coronavirus (COVID-19) pandemic on expected credit losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-C61CF9B9028F5346BD7C085511157B75-0-wk-Fact-76F4CFAF741151CFA35E8F0C5B34BA42">&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus pandemic, or COVID-19, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and social distancing guidelines, causing some businesses to suspend operations and or experience a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, included in our Annual Form 10-K. &lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-43A6134398095F15867A0D32D28BD5A0-0-wk-Fact-9D8A6E9FD34E51DCB65096E2960FBD6D">&lt;div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt; reportable segment and our functional and reporting currency is the U.S. dollar. </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d26767811e454-wk-Fact-4936F932B19A5D5E8F42355497EDC556"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:UseOfEstimates
      contextRef="FD2020Q1YTD"
      id="TextSelection-8DDB2D23507E5F2292AC0042926D96F0-0-wk-Fact-438FAF813C3553CFAAE52A1F93145A03">&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-40AC86DE7CFB5DA49974FF8D4FB17122-0-wk-Fact-F46BD7732F4356E4A9C49F3E461B6836">&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-1CBD175961C85CC98F9B374D678DCD39-0-wk-Fact-619763284653579FAD29CEE7A1ED462A">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,359&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d26767811e620-wk-Fact-9DB2A8962F885F70AE9E0BB33DDA00DB"
      unitRef="shares">3021000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d26767811e634-wk-Fact-F8F5F661C5745766878D26D2AAD5528E"
      unitRef="shares">2359000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-C49C71A09BE05FF099C053D4FE490CA8-0-wk-Fact-46403080BD9457EFA3104D3D61DF3245">&lt;div style="line-height:120%;padding-top:10px;text-align:left;padding-left:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the Financial Accounting Standards Board &#x201c;FASB&#x201d; issued ASU 2019-12,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; intended to simplify the accounting for income taxes. The guidance removes the following exceptions: 1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, 2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, 3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary and 4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: 1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, 2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, 3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), 4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date and 5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (AFS) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the recent coronavirus (COVID-19) pandemic on expected credit losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-03E3A93B29C8551CA60711D5B84FD1C9-0-wk-Fact-475906EC5B865EDC8D44B7F87B826E9E">Balance Sheet Accounts and Supplemental Disclosures &lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Office furniture and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued research, development and manufacturing expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-03770FF8A9F35395BCEF23D6ED352B58-0-wk-Fact-75D2CF5386845046AD06FAA80026F4DE">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,018&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Office furniture and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_anab_LaboratoryEquipmentMember"
      decimals="-3"
      id="d26766690e496-wk-Fact-7DACA2FB9D0254D488EF8AE6CE84E0D7"
      unitRef="usd">5018000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_anab_LaboratoryEquipmentMember"
      decimals="-3"
      id="d26766690e515-wk-Fact-10F940F5E0ED5A9D9691FEB7341BD523"
      unitRef="usd">4911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember"
      decimals="-3"
      id="d26766690e530-wk-Fact-90C6B11D5E425BAB97FD1D35857DCE8B"
      unitRef="usd">820000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember"
      decimals="-3"
      id="d26766690e549-wk-Fact-D241B94B98F955E39716BB6F61459382"
      unitRef="usd">811000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d26766690e569-wk-Fact-722162846EEA52BEB222EB9E0C6ADDF2"
      unitRef="usd">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d26766690e588-wk-Fact-DC9ECBD642755F279C40258A09552EC0"
      unitRef="usd">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26766690e608-wk-Fact-B569219BDC765F5F8829950525A02125"
      unitRef="usd">6413000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26766690e627-wk-Fact-893F5EFC35DF51F1A817D59C82557A63"
      unitRef="usd">6297000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26766690e647-wk-Fact-E05A2616C7465A65BD7C0CE24A44DFED"
      unitRef="usd">4803000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26766690e667-wk-Fact-116C1858C69F5882A6D9C7CE717A9EA4"
      unitRef="usd">4679000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26766690e693-wk-Fact-77B923B2F7545A5BA7333B80DC4C00CB"
      unitRef="usd">1610000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26766690e712-wk-Fact-9AD56001338F58CCA9EA54AE0A88A978"
      unitRef="usd">1618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-B373AA924C7F51909CA1BBC5D4AF340B-0-wk-Fact-F5F81CFDA034506FBC3916E0F6A83D8B">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued research, development and manufacturing expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26766690e808-wk-Fact-B3AA0C5EA305511AB3FCBD8228FDF877"
      unitRef="usd">1363000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26766690e827-wk-Fact-560A85B81E1956B8BD6280DC3D788534"
      unitRef="usd">2152000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26766690e842-wk-Fact-D71A337ED9645668AA2A1C6B563B7886"
      unitRef="usd">494000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26766690e861-wk-Fact-44F9CD800F7451AABCE164673FD5B79B"
      unitRef="usd">435000</us-gaap:AccruedProfessionalFeesCurrent>
    <anab:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26766690e881-wk-Fact-0359B6E1DCCE585C8BF1AC0FFF020D81"
      unitRef="usd">11689000</anab:AccruedResearchAndDevelopmentExpensesCurrent>
    <anab:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26766690e900-wk-Fact-8429E31BA2FF5893B875B1F958760F64"
      unitRef="usd">8196000</anab:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26766690e920-wk-Fact-A37A1F4E117B5482856FF64E3B569EF3"
      unitRef="usd">235000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26766690e939-wk-Fact-7A0FF367929953379282ACE9294F6C91"
      unitRef="usd">269000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26766690e964-wk-Fact-3D7922185AD859C8A5A768570583D1F3"
      unitRef="usd">13781000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26766690e983-wk-Fact-097AF68DBD7C51DFA9CF38C3E6D66D81"
      unitRef="usd">11052000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-BCFA8C8EC8AF53E98A3EAF1FD18824F4-0-wk-Fact-7ED8CD0F5618594F84C50A04A5E24B79">Collaborative Research and Development Agreements&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;TESARO Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2014, we entered into a Collaboration and Exclusive License Agreement, or the TESARO Agreement, with TESARO, Inc. and TESARO Development, Inc., or collectively, TESARO, an oncology-focused biopharmaceutical company now a part of GlaxoSmithKline. Under the terms of the agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy antibodies for subsequent preclinical, clinical, regulatory and commercial development to be performed by TESARO. Under the terms of the agreement, TESARO paid an upfront license fee of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in March 2014 and agreed to provide funding to us for research and development services related to antibody discovery programs for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; specific targets. In November 2014, we and TESARO entered into Amendment No.&#160;1 to the Agreement to add an antibody discovery program against an undisclosed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;th target for an upfront license fee of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For each development program, we are eligible to receive milestone payments of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$18.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; if certain preclinical and clinical trial events are achieved by TESARO, up to an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$90.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$165.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration. Unless earlier terminated by either party upon specified circumstances, the agreement will terminate, with respect to each specific developed product, upon the latter of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. Prior to the adoption of ASC 606, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we determined that the upfront license fees and research funding under the agreement, as amended, should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In December 2015, we determined that the research and development services would be extended through December 31, 2016. As a result, the period over which the unrecognized license fees and milestones were recognized was extended through December 31, 2016, and have since been recognized in full. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, TESARO, is a customer.&#160;We identified the following material promises under the TESARO Agreement: (1) the licenses under certain patent rights relating to six discovery programs (four targets) and transfer of certain development and regulatory information, (2) R&amp;amp;D services and (3) Joint Steering Committee meetings. We considered the research and discovery capabilities of TESARO for these specific programs, TESARO&#x2019;s inability to sub-license, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of the contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the steering committee participation would not have been provided without the R&amp;amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the transaction price includes the upfront payment, research reimbursement revenue, and milestones earned to date, which are allocated in their entirety to the single performance obligation. We earned and recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; clinical milestones for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. No other future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials, an outcome that is difficult to predict, and the licensees&#x2019; efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the IP license granted to TESARO and therefore have also been excluded from the transaction price. We will re-evaluate the variable transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Milestones recognized through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under the TESARO Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Anti-PD-1 &lt;br/&gt;(TSR042/Dostarlimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Anti-TIM-3 &lt;br/&gt;(TSR022/Cobolimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Anti-LAG-3 &lt;br/&gt;(TSR033/Encelimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Milestone Event&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:16px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Initiated &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;in vivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;toxicology studies using good laboratory practices (GLPs) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q4'15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q3'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;IND clearance from the FDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$4.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q1'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$4.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$4.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'17&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Phase 2 clinical trial initiation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'17&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q4'17&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q4'19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Phase 3 clinical trial initiation - first indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q3'18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Phase 3 clinical trial initiation - second indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Filing of the first NDA - first indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$10.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q1'20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Filing of the first MAA - first indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q1'20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in revenue under this agreement during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Antibody Generation Agreement with Celgene Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2011, we entered into a license and collaboration agreement with Celgene, now a part of Bristol-Myers Squibb, or the Celgene Agreement, to develop therapeutic antibodies against multiple targets. We granted Celgene the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The agreement provided for an upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from Celgene, which we received in 2011 and recognized through 2014, milestone payments of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$53.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We assessed this arrangement in accordance with ASC Topic 606 and concluded that the contract counterparty, Celgene, is a customer.&#160;We identified the following material promises under the Celgene Agreement: (1) the licenses under certain patent rights relating to four targets and transfer of certain development and regulatory information, (2) R&amp;amp;D services, (3) a written report documenting findings and (4) Steering Committee meetings. We considered the research and discovery capabilities of Celgene, Celgene&#x2019;s inability to sub-license the four targets, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of the contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the report of findings and steering committee participation would not have been provided without the R&amp;amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the transaction price includes the upfront payment, success fees, expense reimbursement, and milestones earned to date, which are allocated in their entirety to the single performance obligation.&#160;None of the future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors, including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials and the licensees&#x2019; efforts.&#160;Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the IP license granted to Celgene and therefore have also been excluded from the transaction price.&#160;We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Milestones achieved through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under the Celgene Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Anti-PD-1 &lt;br/&gt;(CC-90006)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Milestone Event&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:16px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Completion of first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;in vivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;toxicology studies using GLPs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$0.5M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Phase 1 clinical trial initiation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q4'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue from future contingent milestone payments will be recognized when it is more likely than not that the revenue will not be reversed in future periods. Cash is generally received within 30 days of milestone achievement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; revenue recognized under this agreement during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
      contextRef="D2014Q1Mar01-Mar31_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e422-wk-Fact-8263B42E33BC5BB8B99D43358DFD7788"
      unitRef="usd">17000000.0</anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived>
    <anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets
      contextRef="FI2014Q1_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e426-wk-Fact-76F70CAD9597597C96475B484486586B"
      unitRef="target">3</anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets>
    <anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets
      contextRef="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e430-wk-Fact-CAB6E6FF426D5053ACCF6CEB71442CC5"
      unitRef="target">4</anab:RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets>
    <anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
      contextRef="D2014Q4Nov01-Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e434-wk-Fact-538A1DC2B1C25F118687EF3D49D3DAD6"
      unitRef="usd">2000000.0</anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived>
    <anab:RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents
      contextRef="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e441-wk-Fact-067A67823B4F52B9AC433BBE3EF6A332"
      unitRef="usd">18000000.0</anab:RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents>
    <anab:RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals
      contextRef="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e445-wk-Fact-5D057425E6EF5222836C3E35391CAFBB"
      unitRef="usd">90000000.0</anab:RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals>
    <anab:RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales
      contextRef="I2014Q4Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e449-wk-Fact-17813BF5692C5048B70BA0DAA639A252"
      unitRef="usd">165000000.0</anab:RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales>
    <anab:RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent
      contextRef="D2014Q4Nov01-Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      id="d26774710e453-wk-Fact-CDAA68DD7000514E933E3AF34CCEFB44">P12Y</anab:RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent>
    <anab:RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod
      contextRef="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e471-wk-Fact-EF84024C840E136F21F775FA94621A09"
      unitRef="milestone">2</anab:RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2020Q1YTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3ClinicalTrialInitiationMember"
      decimals="-5"
      id="d26774710e475-wk-Fact-922F31F6B98777166EB6E56957306F9B"
      unitRef="usd">15000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-6B4B51DBFFB05B0FA4CFCE35588C8DBD-0-wk-Fact-A466B153E55255F7A1A9D0C21939BCED">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Milestones recognized through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under the TESARO Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Anti-PD-1 &lt;br/&gt;(TSR042/Dostarlimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Anti-TIM-3 &lt;br/&gt;(TSR022/Cobolimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Anti-LAG-3 &lt;br/&gt;(TSR033/Encelimab)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Milestone Event&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:16px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Initiated &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;in vivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;toxicology studies using good laboratory practices (GLPs) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q4'15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q3'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;IND clearance from the FDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$4.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q1'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$4.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$4.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'17&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Phase 2 clinical trial initiation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'17&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q4'17&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$3.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q4'19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Phase 3 clinical trial initiation - first indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q3'18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Phase 3 clinical trial initiation - second indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Filing of the first NDA - first indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$10.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q1'20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Filing of the first MAA - first indication&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$5.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q1'20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Milestones achieved through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under the Celgene Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Anti-PD-1 &lt;br/&gt;(CC-90006)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Milestone Event&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter Recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:16px;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Completion of first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;"&gt;in vivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;toxicology studies using GLPs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$0.5M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q2'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Phase 1 clinical trial initiation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;span&gt;$1.0M&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;Q4'16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2015Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember"
      decimals="-5"
      id="d26774710e615-wk-Fact-560D21D8285D52A88DD3C39A7464EA7F"
      unitRef="usd">1000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2015Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember"
      decimals="-5"
      id="d26774710e630-wk-Fact-1D5C7242C7C854468543B5798BC1EAF9"
      unitRef="usd">1000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2016Q3QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember"
      decimals="-5"
      id="d26774710e645-wk-Fact-DB8CA7B03FB75EF1B2B8FED8AE1EEE54"
      unitRef="usd">1000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2016Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember"
      decimals="-5"
      id="d26774710e661-wk-Fact-40132960711D5213B897843718DDEF3C"
      unitRef="usd">4000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2016Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember"
      decimals="-5"
      id="d26774710e676-wk-Fact-39D5AD298F6059F3A4C7E37AB07AEBBE"
      unitRef="usd">4000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2017Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_ClearanceOfInvestigationalNewDrugFromFDAMember"
      decimals="-5"
      id="d26774710e691-wk-Fact-A7299B2D6ABE510089F54C901FF09E09"
      unitRef="usd">4000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2017Q2QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember"
      decimals="-5"
      id="d26774710e707-wk-Fact-D4704D68F34A524E878D498B67EA012A"
      unitRef="usd">3000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2017Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember"
      decimals="-5"
      id="d26774710e722-wk-Fact-2615FE9D5BCC5D878F5763AD79ECF3B7"
      unitRef="usd">3000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2019Q4QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member_us-gaap_TypeOfArrangementAxis_anab_Phase2ClinicalTrialInitiationMember"
      decimals="-5"
      id="d26774710e737-wk-Fact-2C5A097A96795B7F2B0175F037C3F778"
      unitRef="usd">3000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3ClinicalTrialInitiationMember"
      decimals="-5"
      id="d26774710e753-wk-Fact-755EBA34416C54A7BFE787A135D2A273"
      unitRef="usd">5000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_Phase3clinicaltrialinitiationsecondindicationDomain"
      decimals="-5"
      id="d26774710e799-wk-Fact-09BC5AB9B26B5F1F8B8CE016BE8F3BAC"
      unitRef="usd">5000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_FilingofNDAMember"
      decimals="-5"
      id="d26774710e845-wk-Fact-D159AFCBC93D79A5901075E269982E2D"
      unitRef="usd">10000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
      contextRef="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_srt_ProductOrServiceAxis_anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member_us-gaap_TypeOfArrangementAxis_anab_FilingofMMAMember"
      decimals="-5"
      id="d26774710e891-wk-Fact-52E824B77E6123635F37A4E04F6DE500"
      unitRef="usd">5000000.0</anab:RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d26774710e939-wk-Fact-9642B58EEA4D5A26AF65510C33450F79"
      unitRef="usd">15000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d26774710e943-wk-Fact-3C2EB306E7A959E482110BC81D4B7C14"
      unitRef="usd">0.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
      contextRef="FD2011Q4YTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e965-wk-Fact-4D384D16CDC95059B85434586CB44294"
      unitRef="usd">6000000.0</anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived>
    <anab:RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone
      contextRef="FI2011Q4_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e969-wk-Fact-B2DC4B777A335FADB4E615F5D8D256A2"
      unitRef="usd">53000000.0</anab:RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone>
    <anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned
      contextRef="FD2016Q2QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_us-gaap_TypeOfArrangementAxis_anab_InVivoToxicologyStudiesMember"
      decimals="-5"
      id="d26774710e1049-wk-Fact-FEE4E92DD8B65C4192500252CD2FE7B7"
      unitRef="usd">500000</anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned>
    <anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned
      contextRef="FD2016Q4QTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_srt_ProductOrServiceAxis_anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member_us-gaap_TypeOfArrangementAxis_anab_Phase1ClinicalTrialInitiationMember"
      decimals="-5"
      id="d26774710e1065-wk-Fact-692E8206D3115E029D0E992079F9A094"
      unitRef="usd">1000000.0</anab:RevenueRecognizedMilestoneMethodMilestonePaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD_srt_CounterpartyNameAxis_anab_CelgeneCorporationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d26774710e1083-wk-Fact-4B1F3B42D6BE58A6B7319E381582988A"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-D2035C5C90D356448A48847D09F9548A-0-wk-Fact-20F75194FD675B0A88F5856B6E4595AC">Notes Payable &lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December&#160;24, 2014, we entered into a Loan and Security Agreement, as amended from time to time, the Loan Agreement, with a bank and a financial institution whereby we may borrow up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; separate draws of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; each. The Term A Loans, for an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, were drawn on December&#160;24, 2014 with a fixed interest rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.97%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the Loan Agreement was amended to combine Term B Loans and Term C Loans for a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; available for draw through December 31, 2016 and delay the beginning of our Term A Loans&#x2019; principal repayments from February&#160;1, 2016 until February&#160;1, 2017. The Term B Loans and Term C Loans became available for draw on July&#160;1, 2016. In December 2016, we further amended the Loan Agreement to (i)&#160;allow for the Term B Loans and Term C Loans to be drawn on December&#160;30, 2016, (ii)&#160;delay principal repayments of all Term Loans until February&#160;1, 2018 and (iii)&#160;amend the interest rate for each Term Loan. The Term B Loans and the Term C Loans were drawn on December&#160;30, 2016, and Term A, B and C Loans are now collectively referred to as the Term Loans. Principal repayments began in February 2018, and were paid in full, without penalty or premium on January 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The costs incurred to issue the Term Loans were deferred and were included in the discount to the carrying value of the Term Loans in the accompanying balance sheet. The Term Loans also included a final payment fee of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt; due at the earlier of prepayment or the maturity date of the Term Loans. The deferred costs and the final payment fee were amortized to interest expense over the expected term of the Term A Loans using the effective interest method.</us-gaap:DebtDisclosureTextBlock>
    <anab:DebtInstrumentMaximumBorrowingCapacity
      contextRef="I2014Q4Dec24_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember"
      decimals="INF"
      id="d26774703e418-wk-Fact-2FB64D27EC9E5D24BD270115FDB95069"
      unitRef="usd">15000000.0</anab:DebtInstrumentMaximumBorrowingCapacity>
    <anab:DebtInstrumentNumberOfLoanInstallments
      contextRef="D2014Q4Dec24-Dec24_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember"
      decimals="INF"
      id="d26774703e422-wk-Fact-D65EDC41CC0D5F6D8220D3C0FD3E4E23"
      unitRef="installment">3</anab:DebtInstrumentNumberOfLoanInstallments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2014Q4Dec24_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember"
      decimals="INF"
      id="d26774703e426-wk-Fact-544BB83C6E375EFBB9B9CFA4F9229C03"
      unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="D2014Q4Dec24-Dec24_us-gaap_DebtInstrumentAxis_anab_TermALoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember"
      decimals="-5"
      id="d26774703e430-wk-Fact-3F79E4E3DEE85263AF1A929AD44C9424"
      unitRef="usd">5000000.0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2014Q4Dec24_us-gaap_DebtInstrumentAxis_anab_TermALoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember"
      decimals="INF"
      id="d26774703e434-wk-Fact-D90C3BA8E3BF522591E93CD28A67D15D"
      unitRef="number">0.0697</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2016Q1Jan31_us-gaap_DebtInstrumentAxis_anab_TermBLoansAndTermCLoansMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember"
      decimals="INF"
      id="d26774703e441-wk-Fact-135A1539CFDF5A5599AE3E6E33D867B4"
      unitRef="usd">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="I2016Q1Jan31_us-gaap_DebtInstrumentAxis_anab_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember"
      decimals="-5"
      id="d26774703e448-wk-Fact-22D6FA9514845D16B220F5B252D5707D"
      unitRef="usd">800000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-452DF80E8DB252A898A56435BE68D0F4-0-wk-Fact-55587BE3E4F9576E80B77F792E737755">Fair Value Measurements and Available for Sale Investments&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our financial instruments consist principally of cash, cash equivalents, restricted cash, short-term and long-term investments, receivables, accounts payable, and notes payable. Certain of our financial assets and liabilities have been recorded at fair value in the consolidated balance sheet in accordance with the accounting standards for fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 3 - Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;padding-left:16px;text-indent:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at End of Period Using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Market&lt;br/&gt;Prices for&lt;br/&gt;Identical&#160;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;Other&#160;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;At March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;151,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;151,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Agency securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;At December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;162,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;162,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,619&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,619&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,428&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,428&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;Agency securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to estimate that value: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Marketable Securities.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. For fair values determined by Level 2 inputs, which utilize quoted prices in less active markets for similar assets, the level of judgment required to estimate fair value is also considered relatively low. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;text-indent:6px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of our other financial instruments estimated as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following methods and assumptions were used to estimate the fair value of our notes payable: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Notes Payable&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;We use the income approach to value the aforementioned debt instrument. We use a present value calculation to discount principal and interest payments and the final maturity payment on these liabilities using a discounted cash flow model based on observable inputs. We discount these debt instruments based on what the current market rates would offer us as of the reporting date. Based on the assumptions used to value these liabilities at fair value, these debt instruments are categorized as Level 2 in the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;The carrying amounts of certain of our financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Available for Sale&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.S. Treasury securities, which we classify as available-for-sale investments. These investments are carried at fair value and are included in the tables above. The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Agency securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;111,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;246,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;247,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Of our outstanding agency securities, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have maturity dates of less than one year and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Of our outstanding certificates of deposit, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of less than one year and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Of our outstanding commercial and corporate&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;obligations, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$82.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have maturity dates of less than one year and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(4)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Of our outstanding U.S. Treasury securities, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$94.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have maturity dates of less than one year and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$18.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;US Treasury Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-65E8970DE3675F82BDA3E3ACFA6B5D1C-0-wk-Fact-F3C44DD849585791BCC81906C36A21BA">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at End of Period Using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Market&lt;br/&gt;Prices for&lt;br/&gt;Identical&#160;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;Other&#160;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;At March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;151,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;151,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Agency securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;At December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;162,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;162,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,619&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,619&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,428&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,428&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;Agency securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date. &lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e731-wk-Fact-80FA241C4BAF5A079A609BF4307E8C8C"
      unitRef="usd">151542000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e750-wk-Fact-F83FE14E420156E495D810BD4FFE649C"
      unitRef="usd">151542000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e769-wk-Fact-51BBD123E8725BBE9AD2DB06DBA31F55"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e789-wk-Fact-8ED3B883F64156C68B0F880FB5B125CB"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e806-wk-Fact-5C47FB6313C95FFE8337B6E4B799B870"
      unitRef="usd">13883000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e825-wk-Fact-FDED3C0BAA9151BEAB2C53C7C608E24B"
      unitRef="usd">13883000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e844-wk-Fact-CCAF5287079C5285BD26A26F965160C5"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e864-wk-Fact-E4C0831EF348549DA24898A0EDD56FB3"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e886-wk-Fact-605CE8DE222153A796DBC72168F5084A"
      unitRef="usd">112933000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e905-wk-Fact-09E62CDF3B8655BCB5DD91FE3AEF52D7"
      unitRef="usd">112933000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e924-wk-Fact-37F305BC269D544EAF0A12EE338A6D0A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e944-wk-Fact-FD8DE654F33451B48079994A054FAEB1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e966-wk-Fact-562E2DD60B8C56D597F8DC5FB7C19C54"
      unitRef="usd">5685000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e985-wk-Fact-204F8C467E075A90BCD40F4D185422BA"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e1004-wk-Fact-6357FCEBA5FF55FE8BFF11BE9F2ECCA6"
      unitRef="usd">5685000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e1024-wk-Fact-BD8C1312C0F25B079AC0A8B11E6534BA"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e1046-wk-Fact-C05B4A4CCDD157349C357591468900DC"
      unitRef="usd">41890000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e1065-wk-Fact-1FAD0DE53EE75E0AADEAC17BB682B597"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e1084-wk-Fact-B4268A407B85522FABA30C1CF89D1025"
      unitRef="usd">41890000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e1104-wk-Fact-B9FA1AEA88C35352AD28F1E7F15E424A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e1126-wk-Fact-329C44F21A175AF2A9EE401125A904A8"
      unitRef="usd">86873000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e1145-wk-Fact-1E210E0CDE3F5053B8BF39F696D9A75B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e1164-wk-Fact-491AA8BCF4A55182BB57B7B7D334F564"
      unitRef="usd">86873000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e1184-wk-Fact-FE8CC6AD59675B78AB9D7D8EC2C37BFF"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e1293-wk-Fact-E9E6FF6BF2CA58F6AE498BBC585DA821"
      unitRef="usd">162928000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e1312-wk-Fact-84EBFA808F765B6FA3F75FFC055434BD"
      unitRef="usd">162928000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e1331-wk-Fact-DBE756C9321753FDA1D9B884C6D6C32D"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e1351-wk-Fact-9671537B6B2753459D91AA0EAC21B3F2"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e1369-wk-Fact-AD1430056DF45826B251DFCFE5075C7B"
      unitRef="usd">7619000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e1388-wk-Fact-F01BB9969E6D5D11B91F5C2660698AD7"
      unitRef="usd">7619000</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e1407-wk-Fact-1DB961B9AD4257A9B0DF255E12101217"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MutualFundMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d26781279e1427-wk-Fact-9120483FC69559B08F126E77A4232B14"
      unitRef="usd">0</anab:CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e1449-wk-Fact-9C118DAA1AB654C49DED1EDB4B4875DF"
      unitRef="usd">96434000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e1468-wk-Fact-CE5958091D5B5FDEBFE1E5184831026D"
      unitRef="usd">96434000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e1487-wk-Fact-1BAA0CCFEA4B50BDB8BE80C2D7157A3E"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e1507-wk-Fact-45BB2ED3B8D25279B550BC1CF8E88A6F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e1529-wk-Fact-3B493B35C40757C398902A6C3559985A"
      unitRef="usd">5428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e1548-wk-Fact-C9E5D86ABDCF51FDA501456F65798222"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e1567-wk-Fact-0345C2D8092456E99FB5EB8D25379752"
      unitRef="usd">5428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e1587-wk-Fact-FB5C39E0E2095EECAD4AED3D3AFFB2EB"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e1609-wk-Fact-3C4613A81B965029B35C7D4670E4BA9D"
      unitRef="usd">33623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e1628-wk-Fact-FD013F516C7B5B41B9B2ABBA6A1EC868"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e1647-wk-Fact-E584CE2DABC4520AB8942D61AB67FA9B"
      unitRef="usd">33623000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e1667-wk-Fact-8F77100D711F5EECB10166E94B09602C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e1689-wk-Fact-1D08604CF13E5744ABDEDB9A2FE2C991"
      unitRef="usd">122030000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e1708-wk-Fact-26D84DB2F3935BDAB825F32A13F3ABDE"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e1727-wk-Fact-CCB5EDE18C5A5485AB8BF01813567D36"
      unitRef="usd">122030000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e1747-wk-Fact-80FBFA9EDA7554F7AEAD02C82341A12B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-5160FD969B56550C9477FCEF9F821B2F-0-wk-Fact-54D286C2A91A5EAE9F0AF121117B9E47">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of our other financial instruments estimated as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Notes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-3"
      id="d26781279e2021-wk-Fact-7E7BD79B277457A39C6622B9BBA7504D"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-3"
      id="d26781279e2040-wk-Fact-63225103ACE858F5B55ADA0FCAF57E07"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-3"
      id="d26781279e2059-wk-Fact-5C709E9AF8485F38A8B6782A27826217"
      unitRef="usd">1375000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-3"
      id="d26781279e2079-wk-Fact-A8554548ACAB53FDB44926E3DC8B64F5"
      unitRef="usd">1365000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-248334431A8555C7AD67A832EE253D6B-0-wk-Fact-C07168D96BB8527E9A7B4C2AF8573791">The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Agency securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;41,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;86,873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;111,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;112,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;246,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;247,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Of our outstanding agency securities, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have maturity dates of less than one year and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(2)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Of our outstanding certificates of deposit, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of less than one year and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(3)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Of our outstanding commercial and corporate&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;obligations, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$82.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have maturity dates of less than one year and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(4)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Of our outstanding U.S. Treasury securities, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$94.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have maturity dates of less than one year and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$18.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have a maturity date of between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e2245-wk-Fact-B527F50D92F95C1BBEEF4DE272869B42"
      unitRef="usd">41754000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e2264-wk-Fact-5AA38C90AA9B55B7A89F59A6381717B5"
      unitRef="usd">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e2283-wk-Fact-2DB70CC29373573D8618141A9E6E66F5"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e2304-wk-Fact-87DDE2EB6F625D82941D2D0352A039B8"
      unitRef="usd">41890000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e2321-wk-Fact-D44FC38F1B5957EFBFF76EF8CCFD70B6"
      unitRef="usd">5639000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e2340-wk-Fact-C222D4FFC8755904B94BC7871DE5B3F3"
      unitRef="usd">46000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e2359-wk-Fact-F78B787A684C5DDDB231EDE733155899"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d26781279e2379-wk-Fact-F11C56811A4654FD985917BE39B1CB35"
      unitRef="usd">5685000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e2401-wk-Fact-4A9CAA51A0605DB793B69B4B09C6D3F2"
      unitRef="usd">86805000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e2420-wk-Fact-C580852B94535EC6B9E74A9D72162284"
      unitRef="usd">97000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e2439-wk-Fact-92074E9BC40253499A5BC4851B44A962"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e2460-wk-Fact-3AC957E72F2358428A759CB7D94C8749"
      unitRef="usd">86873000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e2482-wk-Fact-BBAF81D6F169546283DCDF3EE6F2FFF7"
      unitRef="usd">111831000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e2501-wk-Fact-35887D21737A59E6853012E315B14DD4"
      unitRef="usd">1102000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e2520-wk-Fact-AF257DA5F51652579F50588206F5999F"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e2540-wk-Fact-C072DE42442C540199D4AA2AD8B3C904"
      unitRef="usd">112933000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e2565-wk-Fact-DCBAF090C43450D3AF1BDDC51D2EFE9C"
      unitRef="usd">246029000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e2584-wk-Fact-127CE8DF8FB552C9BEB83D09ACC3DEC4"
      unitRef="usd">1384000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e2603-wk-Fact-46DEAE5E5F6B5372B1F9C1C15CFEDC3E"
      unitRef="usd">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e2624-wk-Fact-E2B50C28D92A5134A1092F6038701159"
      unitRef="usd">247381000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-5"
      id="d26781279e2637-wk-Fact-687B008618725BA08DCBDCC96EE45F41"
      unitRef="usd">14900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-5"
      id="d26781279e2641-wk-Fact-92E9EDE076F254998AB3917C139D0153"
      unitRef="usd">27000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      id="d26781279e2649-wk-Fact-563B66355C0D5061B4010928A6FFCED4">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-5"
      id="d26781279e2665-wk-Fact-18806EB3DEFE5CD595C66C82279AF2CC"
      unitRef="usd">5000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-5"
      id="d26781279e2669-wk-Fact-A2E70829610E567C8CD977EFB2FEE43D"
      unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      id="d26781279e2677-wk-Fact-C7D8B7E0E110587EAEBC3C720EDDC6CE">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-5"
      id="d26781279e2697-wk-Fact-F232641CCE1451C7BE066799542F489B"
      unitRef="usd">82600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-5"
      id="d26781279e2701-wk-Fact-9F57336DD3AC553ABE5D383ED75C9FFE"
      unitRef="usd">4300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      id="d26781279e2709-wk-Fact-D1DDDA82C84751AF8C3FE58E114EEAA8">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-5"
      id="d26781279e2725-wk-Fact-3E128BCB2FAA55BEB60FDCA9C0B31DE9"
      unitRef="usd">94700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-5"
      id="d26781279e2729-wk-Fact-B1E93726C3605282B627A6D198A6A7BE"
      unitRef="usd">18200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <anab:AvailableforsaleDebtSecuritiesRemainingMaturity
      contextRef="FD2020Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      id="d26781279e2737-wk-Fact-7101163B54FE5C4BBFA5DE18A1624BFF">P2Y</anab:AvailableforsaleDebtSecuritiesRemainingMaturity>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-7D3D40B18C87995223E2C80D61979AFC-0-wk-Fact-CB3CCC8A519FFD096AE5C811591CB515">&lt;div style="line-height:120%;padding-top:16px;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial and corporate obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;US Treasury Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e3171-wk-Fact-1B709B1997B3B0045253C813A1690727"
      unitRef="usd">1848000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e3190-wk-Fact-852B7105F0F1D15FC2C8C8147D69390B"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e3210-wk-Fact-D228D3BBFB396481256FC813FF9F98D4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e3230-wk-Fact-923CD332A3FB106417D5C814B7D35499"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e3249-wk-Fact-0521DE41A1AA42B49F6CC8143B623193"
      unitRef="usd">1848000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d26781279e3269-wk-Fact-07FAE0E4E86DF1E215DDC814FB679474"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3285-wk-Fact-3E6D937182D654464E7DC813A16FFF01"
      unitRef="usd">34431000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3304-wk-Fact-81BBF42A6500A15E36AFC8147D5F8F70"
      unitRef="usd">29000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3324-wk-Fact-7B1E5E32ADF6C16A8D28C813FF6B15D1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3344-wk-Fact-E0902B622F1ECBC26668C814B80B50A9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3363-wk-Fact-B6CFF3677F0BCDAECF11C8143B1F4FB8"
      unitRef="usd">34431000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3382-wk-Fact-26E7B73286FA8C9AB699C814FBB35EF5"
      unitRef="usd">29000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e3409-wk-Fact-5CD867354F8B8B825F14C813A1659A24"
      unitRef="usd">36279000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e3428-wk-Fact-3F95AC804B7F6190191BC8147D630FC2"
      unitRef="usd">32000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e3448-wk-Fact-E9DB7C2636DE920ABA1BC813FF528BE6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e3468-wk-Fact-63B7AA8E9339354E2A5EC814B7BB124B"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e3487-wk-Fact-D215D7330D1DB14FF06AC8143B1C8EE1"
      unitRef="usd">36279000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26781279e3507-wk-Fact-04CD55A9212F714B8886C814FB6A3A6A"
      unitRef="usd">32000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3926-wk-Fact-B583E119FE9263E17F66C8174237BD41"
      unitRef="usd">5986000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3945-wk-Fact-1BAD8000B712B8BB1B02C81744ABF3B6"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3965-wk-Fact-B5A57BF4388548A563C6C81747278DE2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e3985-wk-Fact-77DA9BFA10BEBC7A7761C817495DEA02"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e4004-wk-Fact-16D99BFCDF5A6F22B1A6C8174BB7B2A5"
      unitRef="usd">5986000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_anab_CommercialAndCorporateObligationsMember"
      decimals="-3"
      id="d26781279e4024-wk-Fact-19818FD8BB9B7BA4CDD8C8174DDB237A"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e4040-wk-Fact-D81C29E534E9A46244A9C8174F3A9543"
      unitRef="usd">17608000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e4059-wk-Fact-5E7D597B0EA63F8CBD27C81752262892"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e4079-wk-Fact-D74A0A4A194638524DBAC81754BE26A9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e4099-wk-Fact-CBB02CE4123D60DF9518C8175730DF09"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e4118-wk-Fact-FE37D3A3A9F1351B79AFC81759C5DA83"
      unitRef="usd">17608000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="d26781279e4137-wk-Fact-571502F0306C171F331FC8175C5FDE61"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26781279e4164-wk-Fact-85F63FCA34937A6C13D8C8175DE1BFA8"
      unitRef="usd">23594000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26781279e4183-wk-Fact-834B02C917B18AAC891AC8175EFBB570"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26781279e4203-wk-Fact-B27C96AFE5778B3D0343C817609B2226"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26781279e4223-wk-Fact-20E5D17BC563E2D6DFB3C81761CAC15F"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26781279e4242-wk-Fact-7BDD7C7E90FBACE33169C81762E2C667"
      unitRef="usd">23594000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26781279e4262-wk-Fact-84AC22D77DE5BFBF942CC81764110846"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-339135DB7EF95965BA823D8EA1C1EFCD-0-wk-Fact-62A010E9CCE55143AE832116A4322826">Stockholders&#x2019; Equity &lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;500,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of common stock authorized, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,277,115&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares were issued and outstanding as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Issued and Outstanding:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,866,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares Reserved For:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,118,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;997,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,982,943&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2020Q1"
      decimals="INF"
      id="d26776405e421-wk-Fact-9DF8B73F03F252F1946B6D40B8C83E60"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q1"
      decimals="INF"
      id="d26776405e425-wk-Fact-8A2F84FBA563578B83E9611C2771CE6B"
      unitRef="shares">27277115</us-gaap:CommonStockSharesIssued>
    <anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-7D38CC01C1FA5240951EA1AFFFF0460D-0-wk-Fact-3C626677165150F7A2ECC398CE248B11">Common stock reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at &lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows: &lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Issued and Outstanding:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,866,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares Reserved For:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,118,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;997,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,982,943&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2020Q1"
      decimals="INF"
      id="d26776405e480-wk-Fact-7470C53251935ED6B3F501C1F0681471"
      unitRef="shares">2866929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member"
      decimals="INF"
      id="d26776405e511-wk-Fact-7C1F5492286F5A0CABC4EF724513FCDF"
      unitRef="shares">3118332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member"
      decimals="INF"
      id="d26776405e526-wk-Fact-6AA34DF981775CADA5549B269C402381"
      unitRef="shares">997682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2020Q1"
      decimals="INF"
      id="d26776405e541-wk-Fact-F4EA6FC7DC635DA4B379FFBC1DF9419F"
      unitRef="shares">6982943</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-477F9B7D41845478B70F93C9DF3E2457-0-wk-Fact-FBB7FF7DF10F55D6BEF5BAF82FFFD8F6">Equity Incentive Plans &lt;div style="line-height:120%;padding-top:16px;text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Equity Incentive Plan, or the 2017 Plan. The 2017 Plan became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017, and replaced our existing 2006 Equity Incentive Plan, or the 2006 Plan. Under the 2017 Plan we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then our employees, officers, directors or consultants. In addition, the number of shares of stock available for issuance under the 2017 Plan will be automatically increased each January 1, beginning on January 1, 2018, by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The 2017 Plan automatically increased by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,090,203&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares as of January 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Employee Stock Purchase Plan or the ESPP. The ESPP became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017. In addition, the number shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2018, by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The ESPP automatically increased by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;272,550&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares as of January 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options granted to employees and non-employees generally vest over a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year period while stock options granted to directors vest over a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; period. Each have a maximum term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. A summary of the activity related to stock option awards during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;br/&gt;Subject to&lt;br/&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price per&lt;br/&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&#160;(in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,039,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(22,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeitures and cancellations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(266,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,866,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,423,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;92.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determine the appropriate risk free interest rate, expected term for employee stock based awards, contractual term for non-employee stock based awards, and volatility assumptions. The weighted-average expected option term for employee and non-employee stock based awards reflects the application of the simplified method, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches. Estimated volatility incorporates historical volatility of our stock price as well as similar entities whose share prices are publicly available. The risk free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the stock based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total non-cash stock based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,975&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.13 years&lt;/span&gt;&lt;/span&gt;.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding
      contextRef="D2017Q1Jan26-Jan26_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member"
      decimals="INF"
      id="d26776966e421-wk-Fact-707EA98E7DA4541EA5492B3D5F036C1A"
      unitRef="number">0.04</anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease
      contextRef="D2019Q1Jan1_us-gaap_PlanNameAxis_anab_EquityIncentivePlan2017Member"
      decimals="INF"
      id="d26776966e425-wk-Fact-C03EF072E59352E29739B34C0E5E0B6A"
      unitRef="shares">1090203</anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding
      contextRef="D2018Q1Jan01-Jan01_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member"
      decimals="INF"
      id="d26776966e435-wk-Fact-77BAA87161265A3F9068C667C40FD84F"
      unitRef="number">0.01</anab:CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding>
    <anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease
      contextRef="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_anab_EmployeeStockPurchasePlan2017Member"
      decimals="INF"
      id="d26776966e439-wk-Fact-06F36AAE76AF5940B984862E76460542"
      unitRef="shares">272550</anab:CommonStockCapitalSharesReservedForFutureIssuanceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2020Q1YTD_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d26776966e453-wk-Fact-F23897115484527F9B21747A3FA11C6C">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d26776966e457-wk-Fact-AB41819BA1295DB08435881FFA310D20">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-95CC3F64A6E557B9990F5326642B574B-0-wk-Fact-1C485C6528865018807C681741DCF39A">A summary of the activity related to stock option awards during the &lt;span style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is as follows: &lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;br/&gt;Subject to&lt;br/&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price per&lt;br/&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&#160;(in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,039,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;115,550&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(22,033&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeitures and cancellations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(266,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,866,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,423,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4"
      decimals="INF"
      id="d26776966e570-wk-Fact-F01065A9A9A359E998D6A3C94B89C961"
      unitRef="shares">3039880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d26776966e589-wk-Fact-78296963D56051C2886CF10544BF32EB"
      unitRef="usdPerShare">29.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d26776966e632-wk-Fact-F31C578806A559F7852F64C56EA5CF78"
      unitRef="shares">115550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d26776966e651-wk-Fact-B3B9BF916E8B591E85CD6F2030A3559D"
      unitRef="usdPerShare">15.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d26776966e697-wk-Fact-74C437BABEFE50B4AC0858C26AF67BD4"
      unitRef="shares">22033</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d26776966e717-wk-Fact-1F797D38EF8854E9948CB472A832B3AA"
      unitRef="usdPerShare">1.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d26776966e763-wk-Fact-B7AC59F7646C5ED2901FFA06AA04E559"
      unitRef="shares">266468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d26776966e783-wk-Fact-0CF782B96F68575FAB64A9C9233499D8"
      unitRef="usdPerShare">37.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2020Q1"
      decimals="INF"
      id="d26776966e829-wk-Fact-7470C53251935ED6B3F501C1F0681471"
      unitRef="shares">2866929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2020Q1"
      decimals="2"
      id="d26776966e848-wk-Fact-06D1978477C15F5E9D6E7A92900563C8"
      unitRef="usdPerShare">28.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2020Q1YTD"
      id="d26776966e862-wk-Fact-9D15E9696CCF518E8A695A050CD58669">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26776966e878-wk-Fact-F7E4D794382D5D7D98A2239563EE28C2"
      unitRef="usd">6683000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2020Q1"
      decimals="INF"
      id="d26776966e893-wk-Fact-7AEEF2D09D0E5BA39A6859E5BEF16144"
      unitRef="shares">1423084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2020Q1"
      decimals="2"
      id="d26776966e912-wk-Fact-AB702E4CFF6955B88C527C4BA0D00F64"
      unitRef="usdPerShare">26.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2020Q1YTD"
      id="d26776966e926-wk-Fact-78EDB19DBEB657E9A3061787153BAF2A">P5Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26776966e942-wk-Fact-21B6EE2C69B557A6AED7F1C96E425443"
      unitRef="usd">6565000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-09855F8DAF1B5DC48C034A5A83BD75E9-0-wk-Fact-D2225605F1885C859AC89CD2BCC60A37">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;92.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="d26776966e1070-wk-Fact-658AC999015D500BA444863833268272"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="d26776966e1090-wk-Fact-1A324E60A49B5A83810219D26194604A"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="d26776966e1111-wk-Fact-037507A138D4508AAA0C2DB1E4C1ADF8"
      unitRef="number">0.920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="3"
      id="d26776966e1131-wk-Fact-21F3F829D33C56128CEFDCD7A55188D8"
      unitRef="number">0.685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d26776966e1152-wk-Fact-288EC00E94015549BAD84E2FC30F3FCA"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d26776966e1172-wk-Fact-C9479A3F408F56B0A2E1DBFA6DBCCA6F"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d26776966e1193-wk-Fact-C6DDAABEF2E6541A85CE0B5FB1B9A52E">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d26776966e1212-wk-Fact-837B2CFF2453544D8FC0C2793A3DE197">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d26776966e1237-wk-Fact-885D1C3F10B55FC68133B590B50054E7"
      unitRef="usdPerShare">11.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d26776966e1256-wk-Fact-0FE45E14980B528E9CF022765A3DA362"
      unitRef="usdPerShare">43.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-2287628479885FA187F5BC115CD1F8F0-0-wk-Fact-BD2E05EC2C2756EF9B327D7C1D926F12">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total non-cash stock based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,975&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d26776966e1390-wk-Fact-1BF01FA6EC375D82BCA4DC6CFDDEDCDA"
      unitRef="usd">1146000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d26776966e1409-wk-Fact-28C535E42BA657FDBEE5EE3A79B8CFD9"
      unitRef="usd">1240000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d26776966e1424-wk-Fact-1EE2A60856AF52BFBEAC86F9FF182CF5"
      unitRef="usd">1829000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d26776966e1443-wk-Fact-6F88B8023AF25B12B5A6C06CABDD0EBC"
      unitRef="usd">1627000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26776966e1468-wk-Fact-1341CD9F811D57208C64AF7D213B450A"
      unitRef="usd">2975000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26776966e1487-wk-Fact-4DCA0F193B3D5FD08CB6F86FBAB8A919"
      unitRef="usd">2867000</anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims>
    <anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions
      contextRef="FI2020Q1"
      decimals="-5"
      id="d26776966e1509-wk-Fact-834B283AAF3E5498AF89D261922355AB"
      unitRef="usd">27700000</anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions>
    <anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_anab_EmployeeAndNonemployeeStockOptionsMember"
      id="d26776966e1513-wk-Fact-008C43B58EAF52089AD5A324CABF5E76">P3Y1M17D</anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-77FE4A1089D750DDBDE469D1EE8B16D5-0-wk-Fact-72221154CBA7555B8BBB72BE143ADDA1">Commitments and Contingencies&lt;div style="line-height:120%;padding-top:8px;text-indent:21px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; non-cancellable office leases with remaining lease terms of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, each of which are classified as operating leases. Both leases expire in 2021. Only one of our leases has remaining renewal options, which includes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; options to renew for one additional year. The exercise of lease renewal options is at our sole discretion, which we currently do not anticipate exercising and as such were not recognized as part of our ROU asset and lease liabilities. Our lease payments are fixed, and we recognize lease expense for these leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.59%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following costs are included in our cash flow statement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Classification on the Cash Flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the future minimum annual obligations under non-cancellable operating lease commitments in excess of one year are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total minimum payments required&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,405&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-indent:21px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Shareholder Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On March 25, 2020, a putative shareholder class action complaint was filed in the United States District Court for the Southern District of California against us and three of our current or former officers.&#160;The complaint purports to assert claims under Section 10(b) of the Exchange Act, Exchange Act Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019, or the Class Period.&#160; The complaint alleges that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab drug that artificially inflated our stock price.&#160;The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses.&#160;We believe that the claims in the action are without merit.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <anab:LesseeOperatingLeaseNumber
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d26775584e420-wk-Fact-D60F961D46025394B568F0B7315CBCDE"
      unitRef="lease">2</anab:LesseeOperatingLeaseNumber>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2020Q1"
      id="d26775584e424-wk-Fact-69BB7B12AA015690BADC30A57FED5BF2">P1Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <anab:LesseeOperatingLeaseOneYearRenewalOptionsNumber
      contextRef="FI2020Q1_anab_LeaseArrangementAxis_anab_OneOfficeLeaseMember"
      decimals="INF"
      id="d26775584e428-wk-Fact-06731957843B5EA4BA59A7FDE027EDFC"
      unitRef="renewal_option">3</anab:LesseeOperatingLeaseOneYearRenewalOptionsNumber>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2020Q1"
      decimals="4"
      id="d26775584e432-wk-Fact-8B687E0A74445CDE92603E40C4878A78"
      unitRef="number">0.0859</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <anab:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-6276D00A16775007AD633A6CB9BD1A23-0-wk-Fact-5C162183AC415006AF0847BF90C1647B">&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Classification on the Balance Sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"&gt;&lt;div style="padding-top:1px;text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,402&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</anab:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e546-wk-Fact-FE1324DBD54058B2A5941DC10EB92E6C"
      unitRef="usd">1213000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26775584e565-wk-Fact-9E8FCE003C4DF46AB8CB761D8973E5D7"
      unitRef="usd">1402000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e595-wk-Fact-C276E7829392517B987BA8E3F5CD3EA3"
      unitRef="usd">898000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26775584e614-wk-Fact-02CD49E4AB00A9FB62DD761D8A8AAFC8"
      unitRef="usd">871000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e649-wk-Fact-10B2EFEB941658FE97F3412EDDE9AF75"
      unitRef="usd">419000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d26775584e668-wk-Fact-08F1E58BBC1E186B6B0C761D8B6AB969"
      unitRef="usd">654000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-30BD109268A85ED2B4FFAB1357414ECC-0-wk-Fact-F425BE24CA4450C7995264A40688958B">&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following costs are included in our cash flow statement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Classification on the Cash Flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26775584e849-wk-Fact-3ED36EC0F921553AA5273CEBE9B199B7"
      unitRef="usd">220000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26775584e868-wk-Fact-AD0DC805D404564FA4ED761DCCE2D7B2"
      unitRef="usd">220000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d26775584e898-wk-Fact-C4C731283CFE59D0B0F61D51E5AC4D84"
      unitRef="usd">239000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d26775584e917-wk-Fact-35D2733672E95B3040AC761DCE0D39A9"
      unitRef="usd">231000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-DB76DECCB72B5385B6326D392BE7B57A-0-wk-Fact-BF2A4D31219B5B5991AB2ABE19413147">&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the future minimum annual obligations under non-cancellable operating lease commitments in excess of one year are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;676&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total minimum payments required&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,405&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e988-wk-Fact-DA42439B6C5A523C9518071EC4CB051B"
      unitRef="usd">729000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e1003-wk-Fact-111684EF74C554DDA1880E7E6AB3DEC4"
      unitRef="usd">676000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e1023-wk-Fact-1122742D25AA5ACFAAA5C55D9BEF2BAF"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e1043-wk-Fact-7AB315004BCF525C92E69AF437206AED"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e1063-wk-Fact-B1D062AE6F6C5DAA8921F3A1169D2FC4"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e1083-wk-Fact-C22DD8366ECE5A1590FADD1982316E9C"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e1103-wk-Fact-7C884F20CE275A9EAFB060CF7E7907E1"
      unitRef="usd">1405000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e1123-wk-Fact-704CA98C97D555CD916193FD425D844E"
      unitRef="usd">88000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2020Q1"
      decimals="-3"
      id="d26775584e1149-wk-Fact-6F447400C1DC5071A597F96C25819303"
      unitRef="usd">1317000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-2D26A9FC285BEE915C95C820CAE3B32C-0-wk-Fact-64E2E7BCA2A82BF08F83C820D6DB397A">Subsequent Events &lt;span style="font-family:inherit;font-size:10pt;"&gt;On May 4, 2020, we entered into a lease agreement, or Lease Agreement, with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121. Under the Lease Agreement, we agreed to lease approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of space in the 10770 Wateridge Circle Building for a term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, beginning on March 1, 2021 (or on such later date as described in the Lease Agreement). The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as well as a one-time option we have to terminate the lease after &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with the payment of a termination fee. The monthly base rent will be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per rentable square foot, and will be increased by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt; annually. </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="d26781317e414-wk-Fact-F37328D0F92D943A977EC8257F916139"
      unitRef="sqft">45000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d26781317e418-wk-Fact-1C074022B90290195034C822B3EB0471">P124M</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d26781317e422-wk-Fact-8A595BB37168CE843095C8277BE64547">P5Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <anab:LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod
      contextRef="D2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d26781317e426-wk-Fact-AA6ABB3975DA6C59AD07C8317EF2F88E">P7Y</anab:LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod>
    <anab:RentPerSquareFoot
      contextRef="D2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="2"
      id="d26781317e430-wk-Fact-738BE16AC27616305A1DC82A5EF17225"
      unitRef="USD_PER_sqft">4.20</anab:RentPerSquareFoot>
    <anab:AnnualRentIncreasePercent
      contextRef="D2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d26781317e435-wk-Fact-DCF25D5630953B81A6B5C82CA4F8914D"
      unitRef="number">0.03</anab:AnnualRentIncreasePercent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6802996384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized income (loss) on available for sale securities, tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6802877504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAPTYSBIO,&#160;INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3828755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10421 Pacific Center Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">362-6295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANAB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,277,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001370053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786969872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by U.S. GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Also, certain reclassifications have been made to 2019 financial information to conform to the current year presentation of prepaid expenses and other assets on the Consolidated Statements of Cash Flows. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Interim results are not necessarily indicative of results for a full year, particularly in light of the novel coronavirus pandemic, or COVID-19, and its impact on domestic and global economies. To limit the spread of&#160;COVID-19, governments have taken various actions including the issuance of stay-at-home orders and social distancing guidelines, causing some businesses to suspend operations and or experience a reduction in demand for many products from direct or ultimate customers. Accordingly, businesses have adjusted, reduced or suspended operating activities. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Our future research and development expenses and general and administrative expenses may vary significantly if we experience an increased impact from&#160;COVID-19 on the costs and timing associated with the conduct of our clinical trials and other related business activities. The financial statements should be read in conjunction with our audited financial statements for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, included in our Annual Form 10-K. </span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements include us and our wholly-owned Australian subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reportable segment and our functional and reporting currency is the U.S. dollar.  </span></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Common Share </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common equivalent shares outstanding for the period, as well as any dilutive effect from outstanding stock options and warrants using the treasury stock method. For each period presented, there is no difference in the number of shares used to calculate basic and diluted net loss per share.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,021</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Pronouncements Recently Adopted</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board &#8220;FASB&#8221; issued ASU 2019-12,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes (Topic 740)</span><span style="font-family:inherit;font-size:10pt;"> intended to simplify the accounting for income taxes. The guidance removes the following exceptions: 1) exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, 2) exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, 3) exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary and 4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. Additionally, the guidance simplifies the accounting for income taxes by: 1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, 2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, 3) specifying that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements (although the entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority), 4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date and 5) making minor improvements for income tax accounting related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method. The guidance will be effective for fiscal years and interim periods beginning after December 15, 2020. Different components of the guidance require retrospective, modified retrospective or prospective adoption, and early adoption is permitted.&#160;We early adopted this standard on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses:&#160;Measurement of Credit Losses on Financial Instruments&#160;(Topic 326)</span><span style="font-family:inherit;font-size:10pt;">,&#160;which changes the accounting treatment for recognizing the impairment of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also eliminates the other-than-temporary impairment model for available-for-sale (AFS) debt securities. Entities will begin to recognize credit losses on AFS debt securities as allowances rather than as reductions in the carrying value of the securities. Impairment that is not credit-related impairment will continue to be recognized in other comprehensive income and entities will no longer consider the length of time a security has been in an unrealized loss position when determining whether a </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">credit loss exists. ASU 2016-13 becomes effective for annual and interim periods beginning after December 15, 2019.&#160;We adopted this standard prospectively on January 1, 2020 and the adoption of the standard did not have a material impact to our consolidated financial statements as credit losses are not expected to be significant based on historical trends, the financial condition of our investments and external market factors. We will continue to actively monitor the impact of the recent coronavirus (COVID-19) pandemic on expected credit losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803156512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">27,277,115<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">27,277,115<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805748144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">$ 247,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">112,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">5,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">41,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">86,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">112,933<span></span>
</td>
<td class="nump">$ 96,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">5,685<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">41,890<span></span>
</td>
<td class="nump">33,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">86,873<span></span>
</td>
<td class="nump">122,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">151,542<span></span>
</td>
<td class="nump">162,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">13,883<span></span>
</td>
<td class="nump">7,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Market Prices for Identical Assets (Level 1) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">112,933<span></span>
</td>
<td class="nump">96,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Market Prices for Identical Assets (Level 1) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Market Prices for Identical Assets (Level 1) | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Market Prices for Identical Assets (Level 1) | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Market Prices for Identical Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">151,542<span></span>
</td>
<td class="nump">162,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Market Prices for Identical Assets (Level 1) | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">13,883<span></span>
</td>
<td class="nump">7,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">5,685<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">41,890<span></span>
</td>
<td class="nump">33,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">86,873<span></span>
</td>
<td class="nump">122,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787031248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and Development Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Research and Development Agreements</a></td>
<td class="text">Collaborative Research and Development Agreements<div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">TESARO Collaboration </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2014, we entered into a Collaboration and Exclusive License Agreement, or the TESARO Agreement, with TESARO, Inc. and TESARO Development, Inc., or collectively, TESARO, an oncology-focused biopharmaceutical company now a part of GlaxoSmithKline. Under the terms of the agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy antibodies for subsequent preclinical, clinical, regulatory and commercial development to be performed by TESARO. Under the terms of the agreement, TESARO paid an upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in March 2014 and agreed to provide funding to us for research and development services related to antibody discovery programs for </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> specific targets. In November 2014, we and TESARO entered into Amendment No.&#160;1 to the Agreement to add an antibody discovery program against an undisclosed </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;">th target for an upfront license fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each development program, we are eligible to receive milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> if certain preclinical and clinical trial events are achieved by TESARO, up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$90.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$165.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration. Unless earlier terminated by either party upon specified circumstances, the agreement will terminate, with respect to each specific developed product, upon the latter of the </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;">th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. Prior to the adoption of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">, we determined that the upfront license fees and research funding under the agreement, as amended, should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In December 2015, we determined that the research and development services would be extended through December 31, 2016. As a result, the period over which the unrecognized license fees and milestones were recognized was extended through December 31, 2016, and have since been recognized in full. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, TESARO, is a customer.&#160;We identified the following material promises under the TESARO Agreement: (1) the licenses under certain patent rights relating to six discovery programs (four targets) and transfer of certain development and regulatory information, (2) R&amp;D services and (3) Joint Steering Committee meetings. We considered the research and discovery capabilities of TESARO for these specific programs, TESARO&#8217;s inability to sub-license, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of the contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception of the arrangement. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price includes the upfront payment, research reimbursement revenue, and milestones earned to date, which are allocated in their entirety to the single performance obligation. We earned and recognized </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> clinical milestones for </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. No other future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials, an outcome that is difficult to predict, and the licensees&#8217; efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the IP license granted to TESARO and therefore have also been excluded from the transaction price. We will re-evaluate the variable transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones recognized through </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> under the TESARO Agreement are as follows:</span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:38%;"/><td style="width:10%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:10%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-PD-1 <br/>(TSR042/Dostarlimab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-TIM-3 <br/>(TSR022/Cobolimab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-LAG-3 <br/>(TSR033/Encelimab)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Milestone Event</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Initiated </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:8pt;">&#160;toxicology studies using good laboratory practices (GLPs) </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$1.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'15</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$1.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'15</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$1.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q3'16</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IND clearance from the FDA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$4.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q1'16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$4.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$4.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'17</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 2 clinical trial initiation</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$3.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'17</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$3.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'17</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$3.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'19</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 3 clinical trial initiation - first indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$5.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q3'18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 3 clinical trial initiation - second indication</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$5.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'19</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Filing of the first NDA - first indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$10.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q1'20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Filing of the first MAA - first indication</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$5.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q1'20</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in revenue under this agreement during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Antibody Generation Agreement with Celgene Corporation </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2011, we entered into a license and collaboration agreement with Celgene, now a part of Bristol-Myers Squibb, or the Celgene Agreement, to develop therapeutic antibodies against multiple targets. We granted Celgene the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The agreement provided for an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> from Celgene, which we received in 2011 and recognized through 2014, milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$53.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We assessed this arrangement in accordance with ASC Topic 606 and concluded that the contract counterparty, Celgene, is a customer.&#160;We identified the following material promises under the Celgene Agreement: (1) the licenses under certain patent rights relating to four targets and transfer of certain development and regulatory information, (2) R&amp;D services, (3) a written report documenting findings and (4) Steering Committee meetings. We considered the research and discovery capabilities of Celgene, Celgene&#8217;s inability to sub-license the four targets, and the fact that the discovery and optimization of these antibodies is proprietary and could not, at the time of the contract inception, be provided by other vendors, to conclude that the license does not have stand-alone functionality and is therefore not distinct.&#160;Additionally, we determined that the report of findings and steering committee participation would not have been provided without the R&amp;D services and license agreement. Based on these assessments, we identified all services to be interrelated, and therefore concluded that the promises should be combined into a single performance obligation at the inception the arrangement. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price includes the upfront payment, success fees, expense reimbursement, and milestones earned to date, which are allocated in their entirety to the single performance obligation.&#160;None of the future clinical or regulatory milestones have been included in the transaction price, as all milestone amounts were subject to the revenue constraint. As part of the constraint evaluation, we considered numerous factors, including the fact that the receipt of milestones is outside of our control and contingent upon success in future clinical trials and the licensees&#8217; efforts.&#160;Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur as they were determined to relate predominantly to the IP license granted to Celgene and therefore have also been excluded from the transaction price.&#160;We will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones achieved through </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> under the Celgene Agreement are as follows:</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:80%;"/><td style="width:11%;"/><td style="width:9%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-PD-1 <br/>(CC-90006)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Milestone Event</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Completion of first </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:8pt;">&#160;toxicology studies using GLPs</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$0.5M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'16</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 1 clinical trial initiation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$1.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'16</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from future contingent milestone payments will be recognized when it is more likely than not that the revenue will not be reversed in future periods. Cash is generally received within 30 days of milestone achievement. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:30px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> revenue recognized under this agreement during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786969072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">Equity Incentive Plans <div style="line-height:120%;padding-top:16px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Equity Incentive Plan</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Equity Incentive Plan, or the 2017 Plan. The 2017 Plan became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017, and replaced our existing 2006 Equity Incentive Plan, or the 2006 Plan. Under the 2017 Plan we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then our employees, officers, directors or consultants. In addition, the number of shares of stock available for issuance under the 2017 Plan will be automatically increased each January 1, beginning on January 1, 2018, by </span><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The 2017 Plan automatically increased by </span><span style="font-family:inherit;font-size:10pt;"><span>1,090,203</span></span><span style="font-family:inherit;font-size:10pt;"> shares as of January 1, 2020.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2017, our board of directors and stockholders approved and adopted the 2017 Employee Stock Purchase Plan or the ESPP. The ESPP became effective upon the execution and delivery of the underwriting agreement for our initial public offering on January 26, 2017. In addition, the number shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2018, by </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate number of outstanding shares of our common stock as of the immediately preceding December 31 or such lesser number as determined by our board of directors. The ESPP automatically increased by </span><span style="font-family:inherit;font-size:10pt;"><span>272,550</span></span><span style="font-family:inherit;font-size:10pt;"> shares as of January 1, 2020.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options granted to employees and non-employees generally vest over a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year period while stock options granted to directors vest over a </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> period. Each have a maximum term of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. A summary of the activity related to stock option awards during the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> is as follows: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares<br/>Subject to<br/>Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average<br/>Exercise<br/>Price per<br/>Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value&#160;(in<br/>thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,039,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercises</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,033</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeitures and cancellations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(266,468</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,866,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.30</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,683</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,423,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.33</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average grant date fair value per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine the appropriate risk free interest rate, expected term for employee stock based awards, contractual term for non-employee stock based awards, and volatility assumptions. The weighted-average expected option term for employee and non-employee stock based awards reflects the application of the simplified method, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches. Estimated volatility incorporates historical volatility of our stock price as well as similar entities whose share prices are publicly available. The risk free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the stock based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total non-cash stock based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,146</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,240</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,627</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,975</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,867</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$27.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of </span><span style="font-family:inherit;font-size:10pt;"><span>3.13 years</span></span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6591996304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,021</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6738884288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">$ 1,363<span></span>
</td>
<td class="nump">$ 2,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research, development and manufacturing expenses</a></td>
<td class="nump">11,689<span></span>
</td>
<td class="nump">8,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 13,781<span></span>
</td>
<td class="nump">$ 11,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793189952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and Development Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones recognized through </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> under the TESARO Agreement are as follows:</span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:38%;"/><td style="width:10%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:10%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-PD-1 <br/>(TSR042/Dostarlimab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-TIM-3 <br/>(TSR022/Cobolimab)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-LAG-3 <br/>(TSR033/Encelimab)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Milestone Event</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Initiated </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:8pt;">&#160;toxicology studies using good laboratory practices (GLPs) </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$1.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'15</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$1.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'15</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$1.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q3'16</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">IND clearance from the FDA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$4.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q1'16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$4.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$4.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'17</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 2 clinical trial initiation</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$3.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'17</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$3.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'17</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$3.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'19</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 3 clinical trial initiation - first indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$5.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q3'18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 3 clinical trial initiation - second indication</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$5.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'19</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Filing of the first NDA - first indication</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$10.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q1'20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Filing of the first MAA - first indication</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$5.0M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q1'20</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milestones achieved through </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> under the Celgene Agreement are as follows:</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:80%;"/><td style="width:11%;"/><td style="width:9%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Anti-PD-1 <br/>(CC-90006)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Milestone Event</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Completion of first </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:8pt;">&#160;toxicology studies using GLPs</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$0.5M</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q2'16</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Phase 1 clinical trial initiation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>$1.0M</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Q4'16</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793192128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Classification on the Balance Sheet</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification on the Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating ROU assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>898</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Costs Included in Cash Flow Statement</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following costs are included in our cash flow statement (in thousands):</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification on the Cash Flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Annual Obligations</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the future minimum annual obligations under non-cancellable operating lease commitments in excess of one year are as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>676</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum payments required</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,405</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(88</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,317</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793167168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Costs Included in Cash Flow Statement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6738767200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Option Fair Value Assumptions (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="nump">$ 43.96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M'WXW83<:>[#_V/@J*#OX]2_D%U!+ P04    " #*@:90F5R<(Q &  "<)P
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M"**/&U^+UW,_W(BWZTO^ZO_R_;?+<QNNXGN68U'YNBN:>M7ZTR;Z&9[V:(>
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M];KQ;9W+85+ 7:0&<S<TZK'3_ZEJ>]7ZO,FS5? \Y)DDVU&""PG,BD EGWM
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M:?ZUM0%0RN8&5ZC%!S8["NH0S3NTW;AFHQ-L-[T@-C_CXC=02P,$%     @
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MO75[/;WER;"JG\>4+/^*XB]02P,$%     @ RH&F4'>KK>BT 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL;5-M;YLP$/XKEG] '9QTZ2)
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M1ZIIED@Q(CG]K)[:.Q'L0W.8A0VZLW-[QJTRT7-&HEV"SU9HQN03AJPPP8+
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MU;\D_<#(=G@ER?A4%_\ 4$L#!!0    ( ,J!IE!%+X.I&P4  "PA   9
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M-K7O3M%3#Y!-/?5H#+,&,"O"\6F,H8[9!R4V0M$ZZ/7%MZ?>K3(E&2>"8=8
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M>[%\KDN@^.1N(KQ>A_5?4$L#!!0    ( ,J!IE"W].9>M@0  ,T9   9
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M#1\8AINF/(\?3X+K%YS-?U!+ P04    " #*@:90MH5.K5T#   P$   &0
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MJ.T&YL_%+&1*Q+$A06YA"HS:;F$1F8-,B6 _H<!/+ U2VT]0MP#83+=@YZ'
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M68%X(7 ?KU),$&(AO840WSVK-!]!OO,4;WJ*;SV1E:?X9J=P%^YV0; "%IM
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MD-BVX2"E%J:8)#*W^V0:PW%0B8/N7W/SKH;N:!AHV;K.+Q[;S\U_4$L#!!0
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MYT-['!:2=6/G1]/OI_@+4$L#!!0    ( ,J!IE ;9PFK+@(  (,&   9
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;(U5[8Z;,!!\%<0#G,%\A$0$Z9)3
MU4JM%%W5]K=#-@&=C:GMA.O;US:$4.*>\@?L969V9\%+WG'Q)BL Y;TSVLBU
M7RG5KA"2906,R"?>0J.?'+E@1.FM."'9"B '2V(4X2!($2-UXQ>YC>U$D?.S
MHG4#.^'),V-$_-D Y=W:#_UKX+4^5<H$4)&WY 3?0?UH=T+OT*ARJ!DTLN:-
M)^"X]I_#U38,#,$B?M;0R<G:,U;VG+^9S9?#V@],14"A5$:"Z-L%MD"I4=)U
M_!Y$_3&G(4[75_5/UKPVLR<2MIS^J@^J6ON9[QW@2,Y4O?+N,PR&$M\;W'^%
M"U --Y7H'"6GTEZ]\BP59X.*+H61]_Y>-_;>#?I7FIN !P(>"3KW1X1H($0W
M0FS-]Y59JR]$D2(7O/-$_[9:8CZ*<!7I9I8F:'MGGVFW4D<O19R$.;H8H0&S
MZ3%X@KDAD%8?4V!7B@V^H^-_$VSO$<O,G2%RFH@L/YJ:"/Y38NP4B*U /'48
M1;,N])C48IK>QG*1S)PX0%FZ<)>2.$M)[DL)L%L@=0JDCS=CX118/-",'I-,
M?(9AG,Z:X0#A.'"7DCE+R1S-B-P"2Z? \O%FZ&'D/"#! ^T80-/W'F9X.>N'
M"Y7B^=>!)D>7@3C9*2>]DI\;90[))#I.TF=LCOXLOC$3UHZ$FTP_GK\1<:H;
MZ>VYTH/%'O\CYPITD<&3?E^5_B.,&PI'998+O1;]6.PWBK?#R$?C?Z?X"U!+
M P04    " #*@:90%3,?W?@!  "!!0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6R-5-MNG# 0_17$!\3<=UD!4C95U4JMM$K5]-D+PT6Q,;7-DOY]
M;4,H8?W0%^P9GSEGQF8FFQA_%2V =-XHZ47NME(.)X1$V0+%XH$-T*N3FG&*
MI3)Y@\3  5<FB!(4>%Z"*.YZM\B,[\*+C(V2=#U<N"-&2C'_<P;"IMSUW7?'
M<]>T4CM0D0VX@1\@?PX7KBRTLE0=A5YTK'<XU+G[Z)_.J<8;P$L'D]CL'5W)
ME;%7;7RM<M?3"0&!4FH&K)8;/ $AFDBE\7OA=%=)';C=O[-_-K6K6JY8P!,C
MO[I*MKE[=)T*:CP2^<RF+[#4$[O.4OPWN %1<)V)TB@9$>;KE*.0C"XL*A6*
MW^:UZ\TZS2=)O(39 X(E(%@#PM#4,@N9S#]AB8N,L\GA\]T/6#^Q?PK4W93:
M::["G*GDA?+>BB@.,G331 OF/&."#<9?$4BQKQ*!3>(<W(5'<6@G"*TYAH8@
M_$ 0V0DB*T%D"*(/!/&NR!D3&TQO,(%=(K9*Q!:)9"=APQSL(HE5)+$0''<B
M-DQJ%SE810[W!(EG)SA:"8[__URIE2"U9.#ORDSOGFO_2Z%-"U#@C6E^X91L
M[,W@V7C7^?(8F!;Z!Y^'TW?,FZX7SI5)U8BF76K&)*A$O >50ZOFX6H0J*7>
M'M2>SU-A-B0;EH&'UJE;_ 502P,$%     @ RH&F4 2,5D'> 0  Y 0  !D
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MY3TB]1<(U@86%Z'316CYT8H?[$.W0.04B*Q _%>,:!-CPJ06TT^+A,$&5#I
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MH<ST4<_%</^&0/%V?%KP]+ZE_P%02P,$%     @ RH&F4#^Q F<7 @  @@8
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M_T9;YZF=#OJ#?F-4&@&(A_.5Z7A:_^I-NH0YKN_2I UWAY-!9S(X;9SL350
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M[F> .F_##% 0!\4%;A$&WTO"QBU]DR;KO<!>$5RQ?M0]ZWMX/8N6>(EQ9]V
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M#G)'2?P3Q9_43A*<"D"7PA9$;7-=J"3.I268QIB10W(&430?#:R&MA&5U=^
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MI9NE^NPRX<6@(-6;-_%6V%N9JS6OO'6<+K!Q'1PM7#QJT T\.H([R#9[.,:
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M)2+?$GXY<%[7"VTIX*(*?8M]OVB[%!(NW(!#RG96;1FV2:=>)):X"[G.E5S
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MNZ9N>V8>;O5"IBW/V'.=M#SSIS+1X[0]8X\S.0">MF?LN=J>L=?>]HP-S_B
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M[,^D>WK2J+1/T+RD?::/9V[ OB!%I-.6 "(#K=#K:T<G.U(^GF .,2/Z>P&
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M]>QXP3WQ0<DJ[=,=^+9[[M:\T-;Y=KWAGN.++MF7Y<4]X1(Z<I7\'8CN?/S
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M'>-:E<U?23ZU7A[FL^[/Q=DW4$L! A0#%     @ RH&F4!\CSP/     $P(
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M;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #*@:90>&X8&:<#  "
M$   &               @ %N#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL
M4$L! A0#%     @ RH&F4-"=> \] @  L0<  !@              ( !2Q
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,J!IE"JXQM9
M40,  ,$-   8              "  ;X2  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " #*@:90G:/;"=D!  !?!   &
M@ %%%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ RH&F
M4#.T?B.5 P  J0\  !@              ( !5!@  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( ,J!IE!/-?RJU ,  !D1   8
M      "  1\<  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" #*@:90B1)Z/+$!  #2 P  &               @ $I(   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ RH&F4$&-W.JS 0  T@,  !@
M             ( !$"(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( ,J!IE"GT+#=M $  -(#   9              "  ?DC  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ RH&F4.N33HBT 0
MT@,  !D              ( !Y"4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " #*@:90=J\FCK4!  #2 P  &0              @ '/
M)P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ,J!IE!%
MUP\>M $  -(#   9              "  ;LI  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ RH&F4&WE;XZT 0  T@,  !D
M     ( !IBL  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,J!IE (GM#<LP$  -(#   9              "
M 7DU  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ RH&F
M4.M 4-;% 0  -P0  !D              ( !8S<  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " #*@:90=ZNMZ+0!  #2 P  &0
M        @ %?.0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( ,J!IE!FC70!VP$   $%   9              "  4H[  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ RH&F4!0@Y3&W 0  T@,
M !D              ( !7#T  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " #*@:90X79:S=,!  "<!   &0              @ %*/P
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ,J!IE $KU)Q
MTP$  )P$   9              "  51!  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ RH&F4.0;E3RZ 0  T@,  !D
M ( !7D,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #*
M@:90:<)S>N8!  "E!   &0              @ %/10  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,J!IE!]C..64 (  !P(   9
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M970S,BYX;6Q02P$"% ,4    " #*@:90<3;="]D!   :!0  &0
M    @ %G60  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M ,J!IE"W].9>M@0  ,T9   9              "  7=;  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ RH&F4+:%3JU= P  ,!   !D
M             ( !9&   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " #*@:90DJM3=M\!  #_!   &0              @ 'X8P  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,J!IE!$ 3X+#@(
M !H&   9              "  0YF  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ RH&F4#N!<+B= @  F H  !D              ( !
M4V@  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #*@:90
M2:U%&M,"  "*"@  &0              @ $G:P  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ,J!IE"KI[49)P(  (H&   9
M      "  3%N  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ RH&F4!MG":LN @  @P8  !D              ( !CW   'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #*@:90%3,?W?@!  "!!0
M&0              @ 'T<@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( ,J!IE $C%9!W@$  .0$   9              "  2-U  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ RH&F4!G?+_OO
M 0  ZP0  !D              ( !.'<  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " #*@:90/[$"9Q<"  ""!@  &0
M@ %>>0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ,J!
MIE#(LW.*X@$  %,%   9              "  :Q[  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ RH&F4"7Y $V(30  <T8! !0
M         ( !Q7T  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @
MRH&F4(6;Z\1) @  ?@L   T              ( !?\L  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #*@:90*]9>XO<#   L'P  #P              @ 'S
MS0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ RH&F4"4:.3S$ 0  3QP
M !H              ( !%](  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ RH&F4+1F&&*[ 0  9!P  !,              ( !$]0
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #< -P#S#@  _]4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804127472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,262)<span></span>
</td>
<td class="num">$ (22,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">2,975<span></span>
</td>
<td class="nump">2,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Accretion/amortization of investments, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(1,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Receivable from collaborative partners</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">233<span></span>
</td>
<td class="num">(1,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="num">(5,190)<span></span>
</td>
<td class="nump">5,076<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,112)<span></span>
</td>
<td class="num">(16,099)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Acquisition of investments</a></td>
<td class="num">(74,013)<span></span>
</td>
<td class="num">(79,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">84,851<span></span>
</td>
<td class="nump">89,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">10,751<span></span>
</td>
<td class="nump">9,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock, upon the exercise of stock options</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on notes payable</a></td>
<td class="num">(1,375)<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,339)<span></span>
</td>
<td class="num">(1,301)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(5,700)<span></span>
</td>
<td class="num">(7,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">171,077<span></span>
</td>
<td class="nump">113,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">165,377<span></span>
</td>
<td class="nump">105,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for property and equipment</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786309312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">27,277,115<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">27,277,115<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1002001 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Collaborative Research and Development Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements</Role>
      <ShortName>Collaborative Research and Development Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.anaptysbio.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Fair Value Measurements and Available for Sale Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Subsequent Event (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.anaptysbio.com/role/SubsequentEventNotes</Role>
      <ShortName>Subsequent Event (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Collaborative Research and Development Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables</Role>
      <ShortName>Collaborative Research and Development Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/EquityIncentivePlans</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Collaborative Research and Development Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails</Role>
      <ShortName>Collaborative Research and Development Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.anaptysbio.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/NotesPayable</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2416404 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails</Role>
      <ShortName>Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Equity Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Equity Incentive Plans - Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Equity Incentive Plans - Option Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Option Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Commitments and Contingencies - Classification on the Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails</Role>
      <ShortName>Commitments and Contingencies - Classification on the Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2425404 - Disclosure - Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails</Role>
      <ShortName>Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2425405 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="anab-3312020x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2426401 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anaptysbio.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anaptysbio.com/role/SubsequentEventNotes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="anab-3312020x10q.htm">anab-3312020x10q.htm</File>
    <File>anab-20200331.xsd</File>
    <File>anab-20200331_cal.xml</File>
    <File>anab-20200331_def.xml</File>
    <File>anab-20200331_lab.xml</File>
    <File>anab-20200331_pre.xml</File>
    <File>anab-33120x10qxexx311.htm</File>
    <File>anab-33120x10qxexx312.htm</File>
    <File>anab-33120x10qxexx321.htm</File>
    <File>anab-33120x10qxexx322.htm</File>
    <File>wateridgelease.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pipelineq12020a.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>52
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "anab-3312020x10q.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "contextCount": 155,
   "dts": {
    "calculationLink": {
     "local": [
      "anab-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "anab-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "anab-3312020x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "anab-20200331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anab-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "anab-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 370,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 21,
    "http://www.anaptysbio.com/20200331": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 30
   },
   "keyCustom": 27,
   "keyStandard": 257,
   "memberCustom": 23,
   "memberStandard": 27,
   "nsprefix": "anab",
   "nsuri": "http://www.anaptysbio.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.anaptysbio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Collaborative Research and Development Agreements",
     "role": "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements",
     "shortName": "Collaborative Research and Development Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Notes Payable",
     "role": "http://www.anaptysbio.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Fair Value Measurements and Available for Sale Investments",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments",
     "shortName": "Fair Value Measurements and Available for Sale Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - Stockholders' Equity",
     "role": "http://www.anaptysbio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122100 - Disclosure - Equity Incentive Plans",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.anaptysbio.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126100 - Disclosure - Subsequent Event (Notes)",
     "role": "http://www.anaptysbio.com/role/SubsequentEventNotes",
     "shortName": "Subsequent Event (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304302 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Collaborative Research and Development Agreements (Tables)",
     "role": "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables",
     "shortName": "Collaborative Research and Development Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316301 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables",
     "shortName": "Fair Value Measurements and Available for Sale Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319301 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.anaptysbio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322301 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325301 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "anab:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)",
     "role": "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)",
     "role": "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails",
     "shortName": "Balance Sheet Accounts and Supplemental Disclosures - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Collaborative Research and Development Agreements (Details)",
     "role": "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails",
     "shortName": "Collaborative Research and Development Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "D2014Q4Nov01-Nov30_srt_CounterpartyNameAxis_anab_TESAROInc.AndTESARODevelopmentInc.Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember",
      "decimals": "INF",
      "lang": null,
      "name": "anab:RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "I2014Q4Dec24_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413401 - Disclosure - Notes Payable (Details)",
     "role": "http://www.anaptysbio.com/role/NotesPayableDetails",
     "shortName": "Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "I2014Q4Dec24_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416402 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416403 - Disclosure - Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Fair Value of Other Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416404 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)",
     "role": "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails",
     "shortName": "Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419402 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419403 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "role": "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422402 - Disclosure - Equity Incentive Plans - Narrative (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
     "shortName": "Equity Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "anab:EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422403 - Disclosure - Equity Incentive Plans - Option Activity (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails",
     "shortName": "Equity Incentive Plans - Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422404 - Disclosure - Equity Incentive Plans - Option Fair Value Assumptions (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails",
     "shortName": "Equity Incentive Plans - Option Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422405 - Disclosure - Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)",
     "role": "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "anab:SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "anab:LesseeOperatingLeaseNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425402 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "anab:LesseeOperatingLeaseNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "anab:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425403 - Disclosure - Commitments and Contingencies - Classification on the Balance Sheet (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails",
     "shortName": "Commitments and Contingencies - Classification on the Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "anab:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425404 - Disclosure - Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails",
     "shortName": "Commitments and Contingencies - Costs Included in Cash Flow Statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425405 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)",
     "role": "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426401 - Disclosure - Subsequent Event (Details)",
     "role": "http://www.anaptysbio.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "I2020Q2May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002001 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Description of the Business",
     "role": "http://www.anaptysbio.com/role/DescriptionOfBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "anab-3312020x10q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "anab_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Research And Development Expenses, Current",
        "label": "Accrued Research And Development Expenses, Current",
        "terseLabel": "Accrued research, development and manufacturing expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member]",
        "label": "AnaptysBio Generated Anti-LAG3 Antagonist Antibody (TSR-033) [Member]",
        "terseLabel": "Anti-LAG-3 (TSR033/Encelimab)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]",
        "label": "AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member]",
        "terseLabel": "Anti-PD-1 (CC-90006)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member]",
        "label": "AnaptysBio Generated Anti-TIM3 Antagonist Antibody (TSR-022) [Member]",
        "terseLabel": "Anti-TIM-3 (TSR022/Cobolimab)"
       }
      }
     },
     "localname": "AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member]",
        "label": "AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member]",
        "terseLabel": "Anti-PD-1 (TSR042/Dostarlimab)"
       }
      }
     },
     "localname": "AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_AnnualRentIncreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual Rent Increase, Percent",
        "label": "Annual Rent Increase, Percent",
        "terseLabel": "Increase in annual rent"
       }
      }
     },
     "localname": "AnnualRentIncreasePercent",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Classification on the Balance Sheet"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anab_AvailableforsaleDebtSecuritiesRemainingMaturity": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available-for-sale Debt Securities, Remaining Maturity",
        "label": "Available-for-sale Debt Securities, Remaining Maturity",
        "terseLabel": "Investments outstanding, maturity date range (in years)"
       }
      }
     },
     "localname": "AvailableforsaleDebtSecuritiesRemainingMaturity",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure",
        "label": "Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure",
        "terseLabel": "Investments at fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndRestrictedCashFairValueDisclosure",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_CelgeneCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Celgene Corporation [Member]",
        "label": "Celgene Corporation [Member]",
        "terseLabel": "Celgene Corporation"
       }
      }
     },
     "localname": "CelgeneCorporationMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_ClearanceOfInvestigationalNewDrugFromFDAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clearance Of Investigational New Drug From FDA [Member]",
        "label": "Clearance Of Investigational New Drug From FDA [Member]",
        "terseLabel": "IND clearance from the FDA"
       }
      }
     },
     "localname": "ClearanceOfInvestigationalNewDrugFromFDAMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_CommercialAndCorporateObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial And Corporate Obligations [Member]",
        "label": "Commercial And Corporate Obligations [Member]",
        "verboseLabel": "Commercial and corporate obligations"
       }
      }
     },
     "localname": "CommercialAndCorporateObligationsMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding",
        "label": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding",
        "terseLabel": "Annual increase in number of shares available for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Capital Shares Reserved For Future Issuance, Increase",
        "label": "Common Stock, Capital Shares Reserved For Future Issuance, Increase",
        "terseLabel": "Capital shares reserved for future issuance, increase (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceIncrease",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "anab_DebtInstrumentMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Maximum Borrowing Capacity",
        "label": "Debt Instrument, Maximum Borrowing Capacity",
        "terseLabel": "Debt instrument, maximum borrowing capacity"
       }
      }
     },
     "localname": "DebtInstrumentMaximumBorrowingCapacity",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_DebtInstrumentNumberOfLoanInstallments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Number Of Loan Installments",
        "label": "Debt Instrument, Number Of Loan Installments",
        "terseLabel": "Number of loan installments (in installments)"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfLoanInstallments",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition",
        "label": "Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition",
        "terseLabel": "Weighted average period remaining for amortization of unrecognized compensation cost (in years)"
       }
      }
     },
     "localname": "EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options",
        "label": "Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_EmployeeAndNonemployeeStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee And Nonemployee Stock Options [Member]",
        "label": "Employee And Nonemployee Stock Options [Member]",
        "terseLabel": "Employee and nonemployee stock options"
       }
      }
     },
     "localname": "EmployeeAndNonemployeeStockOptionsMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_EmployeeStockPurchasePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, 2017 [Member]",
        "label": "Employee Stock Purchase Plan, 2017 [Member]",
        "terseLabel": "2017 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2017Member",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_EquityIncentivePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Incentive Plan, 2017 [Member]",
        "label": "Equity Incentive Plan, 2017 [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2017Member",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_FilingofMMAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Filing of MMA [Member]",
        "label": "Filing of MMA [Member]",
        "terseLabel": "Filing of the first MAA - first indication"
       }
      }
     },
     "localname": "FilingofMMAMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_FilingofNDAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Filing of NDA [Member]",
        "label": "Filing of NDA [Member]",
        "terseLabel": "Filing of the first NDA - first indication"
       }
      }
     },
     "localname": "FilingofNDAMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_InVivoToxicologyStudiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In Vivo Toxicology Studies [Member]",
        "label": "In Vivo Toxicology Studies [Member]",
        "terseLabel": "Initiated in vivo toxicology studies using good laboratory practices (GLPs)"
       }
      }
     },
     "localname": "InVivoToxicologyStudiesMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_LeaseArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Arrangement [Axis]",
        "label": "Lease Arrangement [Axis]",
        "terseLabel": "Lease Arrangement [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementAxis",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "anab_LeaseArrangementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Lease Arrangement [Axis]",
        "label": "Lease Arrangement [Domain]",
        "terseLabel": "Lease Arrangement [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementDomain",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period",
        "terseLabel": "Lease termination term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotyetCommencedExpirationPeriod",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_LesseeOperatingLeaseNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number",
        "label": "Lessee, Operating Lease, Number",
        "terseLabel": "Non-cancellable office leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumber",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_LesseeOperatingLeaseOneYearRenewalOptionsNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, One Year Renewal Options, Number",
        "label": "Lessee, Operating Lease, One Year Renewal Options, Number",
        "terseLabel": "Number of one year renewal options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOneYearRenewalOptionsNumber",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loan And Security Agreement [Member]",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan and Security Agreement (LSA)"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_OneOfficeLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One Office Lease [Member]",
        "label": "One Office Lease [Member]",
        "terseLabel": "One office lease"
       }
      }
     },
     "localname": "OneOfficeLeaseMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase1ClinicalTrialInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 1 Clinical Trial Initiation [Member]",
        "label": "Phase 1 Clinical Trial Initiation [Member]",
        "verboseLabel": "Phase 1 clinical trial initiation"
       }
      }
     },
     "localname": "Phase1ClinicalTrialInitiationMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase2ClinicalTrialInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 2 Clinical Trial Initiation [Member]",
        "label": "Phase 2 Clinical Trial Initiation [Member]",
        "terseLabel": "Phase 2 clinical trial initiation"
       }
      }
     },
     "localname": "Phase2ClinicalTrialInitiationMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase3ClinicalTrialInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 3 Clinical Trial Initiation [Member]",
        "label": "Phase 3 Clinical Trial Initiation [Member]",
        "terseLabel": "Phase 3 clinical trial initiation"
       }
      }
     },
     "localname": "Phase3ClinicalTrialInitiationMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_Phase3clinicaltrialinitiationsecondindicationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 3 clinical trial initiation - second indication [Domain]",
        "label": "Phase 3 clinical trial initiation - second indication [Domain]",
        "terseLabel": "Phase 3 clinical trial initiation - second indication [Domain]"
       }
      }
     },
     "localname": "Phase3clinicaltrialinitiationsecondindicationDomain",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_RentPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rent Per Square Foot",
        "label": "Rent Per Square Foot",
        "terseLabel": "Monthly base rate (usd per sqft)"
       }
      }
     },
     "localname": "RentPerSquareFoot",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent",
        "label": "Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent",
        "terseLabel": "Agreement term following first commercial sale or expiration of the last to expire patent (in years)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales",
        "label": "Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales",
        "terseLabel": "Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals",
        "label": "Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals",
        "terseLabel": "Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events",
        "label": "Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events",
        "terseLabel": "Milestone payments, contingent upon preclinical and clinical trial events (up to)"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone",
        "label": "Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone",
        "terseLabel": "Maximum milestone payments per target"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount",
        "label": "Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount",
        "terseLabel": "Milestones achieved, amount"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period",
        "label": "Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period",
        "terseLabel": "Number of milestones achieved during period"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets",
        "label": "Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets",
        "terseLabel": "Number of outstanding research and development targets"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received",
        "terseLabel": "Upfront license fee received"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognized, Milestone Method, Milestone Payment Earned",
        "label": "Revenue Recognized, Milestone Method, Milestone Payment Earned",
        "terseLabel": "Milestone Event"
       }
      }
     },
     "localname": "RevenueRecognizedMilestoneMethodMilestonePaymentEarned",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims",
        "label": "Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "anab_TESAROInc.AndTESARODevelopmentInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TESARO, Inc. And TESARO Development, Inc. [Member]",
        "label": "TESARO, Inc. And TESARO Development, Inc. [Member]",
        "terseLabel": "TESARO"
       }
      }
     },
     "localname": "TESAROInc.AndTESARODevelopmentInc.Member",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_TermALoansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term A Loans [Member]",
        "label": "Term A Loans [Member]",
        "terseLabel": "Term A Loans"
       }
      }
     },
     "localname": "TermALoansMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "anab_TermBLoansAndTermCLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term B Loans And Term C Loans [Member]",
        "label": "Term B Loans And Term C Loans [Member]",
        "terseLabel": "Term B and Term C Loans"
       }
      }
     },
     "localname": "TermBLoansAndTermCLoansMember",
     "nsuri": "http://www.anaptysbio.com/20200331",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r42",
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director Stock options"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r109",
      "r158",
      "r159",
      "r253",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r110",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails",
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r138"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r50",
      "r51",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive securities excluded from computation of net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased property (sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r108",
      "r237",
      "r247"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r41"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r115",
      "r129"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r112",
      "r116",
      "r129"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total Fair Value",
        "verboseLabel": "Available-for-sale securities, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r114",
      "r129"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r114",
      "r129"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r164",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r26",
      "r79"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r73",
      "r79",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r73",
      "r212"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r192",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Research and Development Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Research And Development Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "totalLabel": "Common stock, shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Issued and Outstanding:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anaptysbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 500,000 shares authorized, 27,277 shares and 27,255 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r195",
      "r197",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r238",
      "r239",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r215",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate borrowing capacity"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Fixed interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r36",
      "r89",
      "r149",
      "r152",
      "r153",
      "r154",
      "r214",
      "r215",
      "r217",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r122",
      "r133",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Greater, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r122",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Greater, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r122",
      "r133",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r122",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less than 12 Months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r119",
      "r130",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r120",
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementByTypeTable": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue Arrangement, by Type [Table]",
        "terseLabel": "Deferred Revenue Arrangement, by Type [Table]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Revenue Arrangement [Line Items]",
        "terseLabel": "Deferred Revenue Arrangement [Line Items]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r77",
      "r106"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average number of shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r93",
      "r94",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails",
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r199",
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r199",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value of Other Financial Instruments"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r200",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r199",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r202",
      "r203",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Available for Sale Investments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r200",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Market Prices for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r200",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r200",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r204",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r132",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r107",
      "r190"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Receivable from collaborative partners"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r105",
      "r213",
      "r216",
      "r243"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r72",
      "r74",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Costs Included in Cash Flow Statement"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Annual Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum payments required"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r240",
      "r249"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]",
        "terseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r96",
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/DescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r73",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r52",
      "r55",
      "r60",
      "r78",
      "r94",
      "r242",
      "r252"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Notes payable, current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Notes Payable to Banks"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture and equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r223",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumAnnualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, Other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, Other long-term liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r220",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesCostsIncludedInCashFlowStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating ROU assets, Other long-term assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesClassificationOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r225",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r8",
      "r33"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r56",
      "r58",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Comprehensive income (loss), net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized income on available for sale securities, net of tax of $0 and $115, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r45",
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Unrealized income (loss) on available for sale securities, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r33"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r65",
      "r67",
      "r113"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Acquisition of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r164",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsFairValueOfOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r1",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Aggregate draw on term loan"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r65",
      "r66",
      "r113"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r186"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock, upon the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r137"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r139",
      "r251"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails",
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r9",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r17",
      "r23",
      "r250",
      "r255"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivable from collaborative partners"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r189",
      "r257"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r3",
      "r11",
      "r79",
      "r84",
      "r256"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r155",
      "r248"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r157",
      "r158"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "verboseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails",
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Available-for-sale Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r28",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosuresPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r164",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r168",
      "r174",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Assumptions in Stock Option Valuations"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r38",
      "r88",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule of Unrealized Loss and Fair Values in a Loss Position"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares reserved for future award grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Stock options exercisable, ending balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Forfeitures and cancellations (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeitures and cancellations (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r170",
      "r185"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock options outstanding, ending balance (in shares)",
        "periodStartLabel": "Stock options outstanding, beginning balance (in shares)",
        "terseLabel": "Stock options issued and outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails",
      "http://www.anaptysbio.com/role/StockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Subject to Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Stock options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Stock options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r163",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercises (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r179",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Stockholders' Equity, Ending Balance (in shares)",
        "periodStartLabel": "Stockholders' Equity, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r40",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r148",
      "r155",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercises (in shares)",
        "terseLabel": "Shares issued under employee stock plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity",
      "http://www.anaptysbio.com/role/EquityIncentivePlansOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r148",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued under employee stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r111"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Stockholders' Equity, Ending Balance",
        "periodStartLabel": "Stockholders' Equity, Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets",
      "http://www.anaptysbio.com/role/ConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SubsequentEventNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Accounts and Supplemental Disclosures"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/BalanceSheetAccountsAndSupplementalDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/CollaborativeResearchAndDevelopmentAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r160",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r160",
      "r162",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsAvailableForSaleInvestmentsDetails",
      "http://www.anaptysbio.com/role/FairValueMeasurementsAndAvailableForSaleInvestmentsScheduleOfUnrealizedLossAndFairValuesInLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Accretion/amortization of investments, net"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.anaptysbio.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r259": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r261": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r262": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r263": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793260512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Available for Sale Investments</a></td>
<td class="text">Fair Value Measurements and Available for Sale Investments<div style="line-height:120%;padding-top:16px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our financial instruments consist principally of cash, cash equivalents, restricted cash, short-term and long-term investments, receivables, accounts payable, and notes payable. Certain of our financial assets and liabilities have been recorded at fair value in the consolidated balance sheet in accordance with the accounting standards for fair value measurements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:16px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input levels based on the fair value hierarchy: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at End of Period Using:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Market<br/>Prices for<br/>Identical&#160;Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Other&#160;Observable<br/>Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">At March 31, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,685</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,685</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agency securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">At December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mutual funds</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,428</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Agency securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents or restricted cash in the accompanying consolidated balance sheets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in short-term or long-term investments in the accompanying consolidated balance sheets depending on the respective maturity date. </span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to estimate that value: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Marketable Securities.</span><span style="font-family:inherit;font-size:10pt;"> For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. For fair values determined by Level 2 inputs, which utilize quoted prices in less active markets for similar assets, the level of judgment required to estimate fair value is also considered relatively low. </span></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of our other financial instruments estimated as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are presented below: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying<br/>Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,365</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following methods and assumptions were used to estimate the fair value of our notes payable: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Notes Payable</span><span style="font-family:inherit;font-size:10pt;">&#8212;We use the income approach to value the aforementioned debt instrument. We use a present value calculation to discount principal and interest payments and the final maturity payment on these liabilities using a discounted cash flow model based on observable inputs. We discount these debt instruments based on what the current market rates would offer us as of the reporting date. Based on the assumptions used to value these liabilities at fair value, these debt instruments are categorized as Level 2 in the fair value hierarchy. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;The carrying amounts of certain of our financial instruments, including cash and cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term nature. </span></div><div style="line-height:120%;padding-top:24px;text-align:justify;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Available for Sale</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We invest our excess cash in agency securities, debt instruments of financial institutions and corporations, commercial obligations, and U.S. Treasury securities, which we classify as available-for-sale investments. These investments are carried at fair value and are included in the tables above. The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in cash equivalents, short-term and long-term investments as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br/>Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agency securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,754</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,890</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificates of deposit</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,639</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,685</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,933</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246,029</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #ffffff;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding agency securities, </span><span style="font-family:inherit;font-size:10pt;"><span>$14.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> have maturity dates of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$27.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding certificates of deposit, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding commercial and corporate</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">obligations, </span><span style="font-family:inherit;font-size:10pt;"><span>$82.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> have maturity dates of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of our outstanding U.S. Treasury securities, </span><span style="font-family:inherit;font-size:10pt;"><span>$94.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> have maturity dates of less than one year and </span><span style="font-family:inherit;font-size:10pt;"><span>$18.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> have a maturity date of between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of&#160;</span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, aggregated by investment category and the length of time that individual securities have been in a continuous loss position:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,431</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,431</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross<br/>Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial and corporate obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Treasury Securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793261200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events <span style="font-family:inherit;font-size:10pt;">On May 4, 2020, we entered into a lease agreement, or Lease Agreement, with Wateridge Property Owner, LP, with respect to facilities in the building at 10770 Wateridge Circle, San Diego, California 92121. Under the Lease Agreement, we agreed to lease approximately </span><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of space in the 10770 Wateridge Circle Building for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>124 months</span></span><span style="font-family:inherit;font-size:10pt;">, beginning on March 1, 2021 (or on such later date as described in the Lease Agreement). The terms of the Lease Agreement provide us with an option to extend the term of the lease for an additional </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, as well as a one-time option we have to terminate the lease after </span><span style="font-family:inherit;font-size:10pt;"><span>seven years</span></span><span style="font-family:inherit;font-size:10pt;"> with the payment of a termination fee. The monthly base rent will be </span><span style="font-family:inherit;font-size:10pt;"><span>$4.20</span></span><span style="font-family:inherit;font-size:10pt;"> per rentable square foot, and will be increased by </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span> annually. <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805198784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 246,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">247,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">197,166<span></span>
</td>
<td class="nump">$ 203,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">50,215<span></span>
</td>
<td class="nump">$ 54,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">41,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">41,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 5,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">5,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 86,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">86,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">82,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 111,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">112,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">94,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity', window );">Investments outstanding, maturity date range (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_AvailableforsaleDebtSecuritiesRemainingMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Debt Securities, Remaining Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_AvailableforsaleDebtSecuritiesRemainingMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0001370053-20-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001370053-20-000026-xbrl.zip
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MC[Q&K?+BG%Z[B<NM9*!>82M%"!1/BM+PV%E[W7(M%Z7>X6=]AMP-%X(_@7M
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M0U<:NW;6I'>,HJF+CZ&?%ZIH0AEOB^G35:7+E,7E.?+$9@H;Q1#VF42,.X9
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MS@AVYCOPFO?396\FLJY0Q>[^%VU_#LKJP]1MLN=4$FA]HE&2@.I""0Y'O\#
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M"!DWD4/1 4A]S0$75U?Y*#O,@+WE$VPMU,1Q[L,+0;3%",'UV)3AM33WK01
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M5$K%*&J+D6+*QMN2&*'!..YU%JN_0WUN-AT'VCG)4FVF\8,[TG6JQ]MO)!,
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MLP:U=,E9=:_:Y<WKU9>\W"P^U9ULMOPE_UVO[S]99[/58H?  H4$98H0HH'
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M>/HS,B'Q[ #^.?'LRD'[<@L\7^4Q!E&89HH :HBTA!APT&RCTZLO^?ICT;[
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M6R$W6 _HJ,C;J@^6-%6$>;*U)7D[65?&V$$]H$L'VC?=W;6!-TN?I[;W%NE
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MZD0SYY*KE') -<J@@8(@ +1(92-M$%MQM2G<IW@7SEJV3EQ[G$.6<N6:M%C
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MTA[!FHZ8G6/KC(0%(7D:PA7&E")")_03J5]+-]$RY69Q.]ODY57&( ,I-!Q
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MK@RUK^??WBZV@U*LYJJHE35?56NH!Q2'@WY .=U4!/%,8$@0@I!3 B%&%#&
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MIMS,5O/%ZM.[8KET!%3?O$JMA2F3$&J69=88B]1V$4*8E"KH=4-1)(@R(X(
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M@C]&A.IA?^ (U=<3(V36S?&YW>FYII+V=KVXSJL]1#>[/40(88FDT*2Z5D/
M3%+<+)-F;IK@=9_N"/ Y8T8 P(CB&BM-),#5S"9-;::5<U#D&-? ?-4<4FR
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M\L&#\&F2SD;? -Q.8^2$,>6;>!N,G]"%F5\<+;L!;J4Q7*0" <4)@!D6@#5
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M>S\GOWVHT];*O*2V;^@M=\$=="[Q':\W3",0C4G T\1[;%^\%.QF*_>?[=V
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M<8<6IYG)-'!CA+N&!9>F&2*9 5Y7/+5H#KOD64HB%4 91BZ5%MIBKI$D)"5
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M.8) 9 93CE-,JU,^T@T.3$"FH?N7BCSR=V#:#W!/3EX>XO'H\!ODS:-V028
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M^\^S=2ZKIT55<7N7K\JZ*Q^]-E_*A\//O)T]U#=%_#Y;S[=W-E97U*;:I-2
MU!"+#83$#>S,S2\@RA3OMC6E+RJJ@)75^\W" HP1DJE"7,O,<J:<UD0_F')T
M WL-\]7'^JG>8V.28VN2CP^/?G!G45*;U.WZV0%=W&Y>,4WO^@72@1T;>>M,
M3S^TVE8SE*^G,=L9P>Z3VW&&9;YUH:ANP/W*]OY8RU*8U0>N,VHTHQCOI84R
MYG77^.-/)A(93@S3.F,XI9RE*F. 0J93(1B/?H-9/;XK-)WNV_5DJ65A)QI!
MGK.1UMS$J=4<TW"N(-.)KFGH4$?L3TLK/1AHG8EV5JD#NM7\K>M@O\QN\]V5
MC5QCB8WE*JM?(LHR*M)FP'!D6M59H@($T UCG6%FJ'%)E!491HKH:D<QD%+P
M =6ITW6YXWBM99XY=8=U5\M1[LR-P>>YU'%,]TU#O<>EX&E".;X_VL82<WNW
M+![RO'YH9W=\I[K%BBA"F#4H%1AS05$C*AE67I>G/_?YF%DNH<96R!2#S#*M
MD#,"<TZ5%#3V$=D&4E)6F/Q$O!-=[30X-E-^$KHG:?MFUSBWZ#Q#R1D5[$/@
M-$2LEP5%N.[40T*V[P@WI\FA8((0(*K10*R; =NL&1E" ]192!ZU@A00FEMB
M <HP=H8PJ3!/#93*4(QB/ZFP>SDYV13)G?N1ST[2D^OM>W=]!<:/S XR$XU'
MSQ+A<]6^0[2\V#U*/@45.F:LK19U8GF"BM3-CG.ZU(.95IL-FL9<-O5+L<J_
M;?IPAYAA$ %@,BZY-=#P>JVU'EQI)EIML?)K4:6,IYDQ0D*,,7+CN3KLY419
M:D2Q&"P)JFZE71V0;C4K*>Y\;Z8-1W6+;02CL-PQ@:KN2#T"N4NHFJC1X7;:
M<$Q[[!@8A?%N6P5",=]NCT!;8DYM#@A.[ 1V!82WJ8C9%=O?,?-AL:F6B5ZO
MYHLOB_G];+E=:Y"62(.,EERFDD$(+&O&&8/M3N^=_G1D ;.:0I!2BRF1U1UL
M*)/*3?H1Y='?6JA!56NW!UC>ET5VI.U\(!B&,3_1[T!6L MJGN7B&=7IS]OX
M%];TQ%^$ZD$]E./OB\WG=_ER>ZWVY\7=A\*L-HO-0U/MPY1JH$A&$&044*$M
MWP\.;%I?/.O;+D^%)@JQ%$B#TU0);-(TDRPED'(M8I_[?78 >5]:&9SL#DHT
M(,\!-&JPBR\]>6JK7X'8GJ"RA;+LG.8%9:^-&NK%.K]V%.\2-8H(H)H+9(U.
M70,$'2KH-..M%AR>^5AF)),040J@Q-5]P9)G D-))-:,1+_-OT&SFW=X3:F[
MD/2R2$7DQT^#]M0,=W_?8]M/Z$I'@L:7C:[ B]Z=(_#6E5,+HV_VUV&EU;W
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M2HD%P)+CW'<V]:J*;T=9%VP68\OT @WC",4YF:;Q^)#<)_NSMXU/%]]8K>/
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M>W[;"2L.RMR!F9VVT/L#HRWTG-<>Q;W :>TGC2O^V L;&3O/&G1N7GNPJ=.
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M.KG68WA&S[<>B=R*F^TP\YN&W[J7E&<4@1IIQ&@-4(5(I2&5AW""(3)@6UA
MD,SM!/_\>=-\=D=*Q0XIAML8,^&1R<&!#8!35>QE77+&X]X<[RF/"#^G..<1
MD\;928]H7WSI\W;3WC3-8FML9J=;ZMT]]54I2\*(JHVV@,.:]^%X#;SV@PT.
M,AI]%IOY/XMVO3]?V'59P^ 3[Z(??$8Q, P^O:3"U8GBP8LVX[+G.6_.L&>P
MG=-@S_ TVL2/V9">S^D-8.]MO[Q9O&WLHV>[Z)^M  4E@++2R&A!NZO RJ,
M)@;TA0:%S<PGL_RS63R\-;+X9;XMYNY,5Z<Q\$37E(;'])I&\WI@/^K!%8Q7
MQ5YJ<:_UDIVK<QYZ=[>2%,0T()@CL;-=LH3>Q8%R?]CH\N9P'JE;E-\*.TAM
MVW7_K58T;^?+Q4QR(1"0)5682=M_K(RLCGU&.XR-QV9"$=DANIZOBJ^'<X\_
M-8$7[^;S/H:@%[)]($][U<?3ISO=[F;U3OGQV[NV^-@43OTE">OOL3=O,Q3;
M%.F;(\VS+,[FJ_=1I[OVYN]?VI6U>:O_<;?<?7?]9K7<WJS:[=VFN3]>D'%8
MNX,$D3$0X(I21.#^='N..2F#-B_Y1\6 (2TE@TAH! $4"D->&Z5J8!64N3NP
MIT+_6[&7&GBT:3J#_7A[&6_# /N4K=T0O+C7><E33GTM/,//],4P#6!FR.OQ
M<:>9G/-%XJOU37N[[QEWV[:<X>Y0??=B/<(E B6%C)> E65)%*_V)Q#SDDD8
M=&+&N3@24E1)I5E-.8(8< T@4[7ME&-,*I;[O)Z]M.*HK>C%11VB,<A0/^B-
MY648YJ)MS$*U,QZ=X5@*9Z=!KB29M.F?NR1T.KQV;S PDDL;U=0(:EN#%#U6
M)TJ\7J#TBZ088\+V01$B#"%A*-8<FA*1VM;BBN0^Q_!,U8HZDF.@K8,HE<'1
M9)RZR $=9WT*9U6@OY.F56@N?KR*<LB76.^:;6-_]PM?+U3SK5FU7UUH=T'@
M>MOT1YXI(6K&( ?NMM&ZU)CIOH*5=E 4PBV?>,RPJE;&1K1!:F[_1DMH,R28
M: UT[J/)>HG=.XZ+>Y%AS$IBK!^YQO8TC%\/[#S15QP$7NB\1 _3SL LI>73
M0%K2C-I\#V@8WGYKULUFOK*!^>)VN5YN=QO+U&_-P]B<:BPP( 0H!D6I$*W-
MH1Y60F : CB_B(PIH["4LC(((:F8KE&%C !&D,JPW%<%'41V57+^0&88Y!+9
MZX>Y\9T- ]VIJ0\57AAU7L:=@5U:XZ>!N\0YM3D?U8#W19ZY)GJ]>+7=WLVM
M,]>?NAD\^YU_GV^Z^R5-NWG?;+XM;YKM]4:NYLO;[8PK6$MW39N DA*L!<*X
MK[&UJI#W^R2)],!2E)3HF@, 4553:@AG-1*X(HIAF/L&R$[BX8K;FY,\ MY[
M&*M@SJ-TJF42N$#Q[,W$EKQ]$NZMB2Z-[KM](H7-I.A3*:XWQ3Z9"19DP LN
M$RS0N!=@1BQ8O]=DTCC[1--ZB7*;P&LV8V?<7JZ6A(U3KK\VKH>P_ORZL0K?
MN9N>KS_]==OP[;;9S0 MN69"&<PL)BPE2F$(KBH$"1925;-OS>9CZSM"&18K
MA *GLKPA<)17O+O^:S%WHK97Q?7N2[,I5L=K7O;?#QNM##39;Y0RGKMAC>:]
MK9VPJZ*3]FO[Z5<KKNC4C3LJ.6O4F=%(&H.G,0I)E$N;XQ$< K#7R_G'Y6JY
M^R[O-AO;#9AAK7E-D1WB4%V6#"J$<!\4R[#]20-#91XKW->SE9-7K [ZELV1
M8C=[I:<_&@*R<+-C2);5YX$H.VJ[*@[J+HFRQTYYLRS:XBG"+#Z9LS0;Z-%
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MZ@E#U*I+!=&0XOD)(1J4WA"(AON8&J+\DX7.40L54A- ZHI#B)2$0+N;O ]
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M)M3@8S18*QCT7EADC-PC_#;X_I=HM_RP.(918>!['G@CO\+UM#-GL#74RVF
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MY$DC= 6Q1,H.BR@V-9-]"$6!]UM^P1^<N7)W>HI.4/#2<+A)+U?RK/Z$5?0
M:U)4]L>9/U/AHPVZ?*6/E]XF>$#\*__A=(OO%?CX8;E;V4Z#<N\":@$J!24
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MMWZAPW(N8U2:H,,1 D/;+%&-.(.8"T0,$*!"A'.!*3! 56/L\#ZH+>;K1?%
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M5__SO_3?L?_Y.-\V__.__']02P,$%     @ RH&F4!;[EJ/960  :U($ !4
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M)4'AN/8L0R2Z4CBT8@K[?2HKC&D-$1C1O9;:6X/FH/89"UIH88Q5@G%#'?>
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M6-JYW_4>AOP.?JWD;#T\G'&+I76$1 ;+=^ Z:=TU5=:>VU5;37M8Q_*Q*W2
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M_)I7U(DZ(:B#Z]UT4RV@AX ]3 B=E:%8W-Y.EIP:3-:<>C>]+,J;P=.KU79
MLV(/F1=*^X@H5CYB[3!WFCQX"Q[7"<SWL%I.*P!LA]7=9<0!VV%ZI$)F'_9D
M"C][,E/I4HM@N4>>F2 9U^%!US.MSZTD=M-2?I7 5H>[7:ZDB?*'(QWKJ/YT
MM,$#]./9<%+,%F5>06/5[3HC0E L!8XA4(651<:L.2^I(>=6^K]E/'8LCNX
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M2H-Q#1J&!16P#$0(1>B9Y6AT";JBSX+L;C*L:6@,X^L.P6E#&L$2"3) W+D
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M(,GAGLHI6/B#\22-/W%DD-)STV5GRV]/9C,_C/6P$\&[FF4<T"*99I$R H:
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MYG8S&MH$S8Q:;D_0C&]F>O.=+,0[*EU\98SKT]+%5_LUGUNAB]<06;,"R:Q
M:NL^!J,]9F34@=/]SV5TIV M+[+!/+#?1MF3^)2&2?Z"@3^ER8.:X"=]X\*&
MV5=I$>5?PN?PKA?=IFZ8_'D@$=4QERR28ZP87M"C(::MHN:49VO)N3MVG=\K
M!EY /*'SZQ;,70Y3A?\W3!!8R7V:T$H!CPXF>A8/630CK*?.B\NI<P*<6>;!
M&EO*N1$N&LXTG+DWS)0SG'EA]+;1VVN:F2^X<(U].V<O;V:3VDV8UH"J =7V
M,G2E?7#<O-@Z;FB'6Z*5B5LJ$QT=5!\\HVGG-&TM<8X5I7;FE"P<5!>$<?:/
ML#>(W.?/49@/LE('!%GTKT&4=)[GF&QR[<R5^5>M/[(X>7C!KD&<A$FG3,;,
M<?PD)AEEFGDZ"D'SZWL9]=-\3,!#X=DU:#?EHG6(UQ [UY!^)FA93_N]\/2.
MCUSUPOQ1@87^I8^>^Q;V-*WGN.]SFD3/G\/LSZ@(!DGW)=;.S.SDS[\KI@FS
MSN/S)YVYJ1:,RZ0_*/+R E#_R$8$[5"$I'XRIOQ8/1M-2<-:<UDAJ(N3V7R/
M=H\;QR2T@V(0]C2'&'%]4W%],0]&4(]<4.=.NFU V%Y6@KR9$?K[S=_2;U&6
ME T/ZEUQE&LG8!04.9B5&TV*4+-%'P=K(Z_+&OL0Z5V?5OZ&\G>;E8]Y/@*)
M.S3^KB/]@2JI]KF +PN9C4UYP"Y@LP7-QK+<M= :"7LC"3/\W"HEM&M?RXB(
M\<T.7&B;#F_L.I:XTKT:KAE(GYZB3+=JMA]5QT?7=[W1LN7#=;1.,3K8A.LW
M7"ZQ'EL<65BCK2[<:49*3M$),[&;+32P49<G$Y<\->744+[;^'![3TX;7^DX
M#2R3"C;FUBFF@M_6^#I*!^?0^/LMW8D]<G1;8^BG[J&<8CS<^$P'I)S,8I63
M7:RR:YXV2>(6"8E)$A]'X., ;,HW#WP8F]($/8Q->0C:\S1C**>H_TQ49X^U
M'6]>IF7$UA1GM4QL=UT2;=)[IQ[.:5,R;=?Y\5;$=LPJM".*[1RP<]IBR_)H
M'<+CREL8C]!D4HY\Y<X)F*O&03P> _H HCQ&%[=+BHTN;H,N-I7A)CQ[,I[G
M\81GC0EMQ-88S49LV[5WKJD>W"#"W-Z]<P_8,C\4L_B-!=6D@HY"4 _8%#\4
MC7H 6M'$DD]3UQUK+'F/I4=MU9]&I$]3*QJ1-B)MTD-&BD\Q/6049T,B=U@,
MWB8U99Q)DU4Q[N/!954.P+IL43+T:/6>28T>CR8^D/R+29:835>/8\,@P\GF
ME*0WYN=C,K-,$,]85JT)XAV4(FJKZ!^*V+9)MYTB;AR3T.ZP LV(:YN<*B.H
MK1+4H\MMFRTF39+[ +:8/+I-KXY<[@R7MY'+S=J&5LC)@5N6!ZP:6RRH1[LV
MWP1<#UUJ3,#U4&(W9IGO46C8 ZY=:[&@'EW!YY'[D*<H/L:K?1-1?O/J!"/*
M1Y?%,*)\FJ)L_%XCP:WS>W<>L#HEO78H:+WSLM!36]%R2.LTWGKRCT']M1S4
MWWJ*CV"A:;N73^X\"&:T=ONT]LY]+"/5Q[4H6@YA^X];^<\\*_[Y-4P>HG)&
M]:?/X8_X:?"TH>]ZN#R@QOQA0H&SC_KC' GVY>^]!8LI-LH*J7!KI#J ^C=Y
MXJ1MYH8HZ<Y</JMIQBVMXLGC\";:PZ%O[:P<)[\>D_'TUKS:#MOL./GT"!SU
MMV;/-XT#M(@KUZNF=\,\GB^%\L(L>XZ3AZ^*8ED1=<53.DB*R=TRSCN]5-]^
M&.RX/$DQ&?X,WVPV_D-T3M;;5G"1-?R\B)\TS-]/[C@=OMAD\$<1AS),<7A,
MT1:D,$JD=4JD:;Q8;O7&B8DFS)G LP0QT836>6E;\>N1>6EOP:*G[J4UR)7'
M'N/:)WN:&-<^M/TQY;/>1K^?=#[KI7/RI1<F5^%3-$5#O<ZL>+Y,.GI@WR)]
M@?*1G,/@LO$LSPYKA$Q+QW6(SL0:4_G4[Z7/4713I)T_OPRRSF.8']&$KA[=
M(4[K2&O\IK3&>&85TZ9/:IQ*\'57/Z6=4I?.:8:_14F4E5I7=)\4L"KT"S6?
M^S_ZBI8'%C-8,N IDJ\UXI, =5F&(0W+'!++ +X1R^C+=V";;LHR7Z,\THMF
M% 6E7A23]O6EQ\LP:XS7((QAE]:QR]NBB^86]AOXOV&B.E'^G'"$^!YFW=OG
M?C2?#YLUY5ZXQ$=MULZ18R9%MDB/AOSCMMG1<TS+-F/:%Y<W'*ZYC8M>='U_
MF73C;W%W$/8FH1L99U&G2+,7C+H&:U_W-68<!HOJ"$TE#8;!FWDB-,2=ZXC#
M+ U/0?>.5*^"48.B!D5WHOH;1%'-K4[)K9!>E#]-J/%-N,#1TPKINESPXO(&
M=6DU9LU!D#*7K](D6D3Y \EMU.#0'"ZL&N.IJC*#"B>C&U:CPL$;S<:071U$
M,M/_1M/_QB'G<;ZR!/E/D3*/19;IBH#Y:ISK1'F<]W$G*B\YC'DO\;UJ2"/H
MKQK3 >8FA_@-/X?/TY+WF\%=7FY:5?C?U(\%67[1?ACS.1;8FL%-);IR=/L#
M<W)AXPW ?/;R5TKSI6&%MV6%>2&?G=DMA'R0Q,-I+>_M]71_9B?F:5BX/P2S
MF6O&CQNW3U^@G[CP]$'>_1)E-X]A%LT^O0PNSK&MON-J\!1E89'.!F>F;XKS
M%$/@?/C]1BYVXG_,=6/^03-OD%&2/L5)[3M&TZ.[FZ]ZR8MGC9LF0UM*EY[6
M"K7T+ELWI'0R>"E;\X/JJS\W?.13W(OR0KFPM1V=7+'AD_-_W5=RVZ#(HH</
MNG7#!V91$GT/>_],2Q.KMK_SEVW:Z9(MZBE<QS9+'ZJX^9]?_*__?$F1MDK(
MLAEJ4#X4;E01>ND(ET_>$')K.6/4ON%3E0)^B.H?.FQ>]<SW\0_%F'DZR#I1
M/OSX&(5=I3-^?:^H]?'7\D<X' 8!C 'N!9Z@G! 7"@9\CA"7/@D $<Z9NBF<
MN='*B^>>TJ&].(DN'J/XX;'X *#]EU^T,K@(>_%#\D&')Z+LEWNE(2[R^+^C
M#\#N%[^<S=W?#[O=.'FXZ$7WQ0>[_V-X?YQHA5M^GGU!DF9/8>^7\3U%VM>/
M_*$?681WO<CJ1+W>J/6O9_99^3GOAYWQY]%+RQ[=APIEGC_<*@6=6U?1=^MK
M^A0F+WO[I$@=)\/NA8,B'7^1E1TJO_D>=XO'#XB^0S8G$+'A3_"77^[23%'[
MHI/V>F$_CSZ,_YBED7YPV7\U*T774I>H_BIC 6B"%UW](YNTCKH_?"&P%;67
M7/5-K^WHA+W1B^[2HDB?QGT:?OH ^C^L/.W%7>O?[/*_7^;F RK:SA)[]O/H
M";-?#6D"AQ,R,\=Z%=1]+_W^X3'NJGG]932;1%VXR!MZ^%7S%">/RO0H%N_X
MW_\&J/W+K^_UC6,&G=+D?<D8D^]?Q[YTXR[J.\J/WX?ON$M[7?6(WZ\N;WUI
MW=R*6__&FN_[V_?NQO=^_WIY>ZFZ)JZDY?\_[^_BZF^^Y5U__GQY<W-Y?=6Z
M+O]GF#\J%E0FP[DEWWGO+&@3S!OJI4$M@UKM1JW9X;(Q.]:Q,]ZXR[A:Z(+K
MKY\G2##\J6R,)$U**S#NE)9%%U*'.HB@"&-Z\?W/BR#L%!>>+5S"J4=H0 B6
MD!,?4> !S+&#$%!,GX3:1>]&\0>9=LK5-]I15L(Q]#>_1O=S:8"J 2WM/+ O
M?IN0?Z[;'V>']#H*-863!H$, K4;@1;QY8"8=88Q7L-[<"7OX2GGO6SB=!.N
M5%39"<N]'.7Z:D-D<=BS?D_B3MJ-K,\W-;>N4!$.FZ@('V&/.MR3/G9)$$A7
MV@)C0I@3N"YR2)6*^&T09@HZ>\_#G3_JM85UK[FL^.M9K,:;1QTEYFGO+NSU
MTN(N_:&%@SN8_E*G&1:%IDTS!3=&!%BMOB;DM(;TM/J#+!^$26$5J743=72P
M:P@C %EI9@'R4_=G*[VWBL?(FBZ*M?P?G4>=R[)$I]#-@".\"],'KS)]ML/*
M*M-'C58/\E\3"@T#XU:D0*UK;6%!U+SHU\4'?7^,B^A"(UZD>/-[%O;/5D@5
MFTJ5X)Q3:7O,(X!PZ0D?^X)BZF+/=IUJP^M+.31_F.993Z8^=/7J!G7A8S=\
M?H["+$K./G[6"QHL!,XM?=,JV6J*@AO88&_#2]=?-^CBHI@;/7M<>G8%>B_3
MLW!=/4OL*2)X$GF$*=6*/48 PP))Z5-/NAAQCR):Z8IE89+'&OX;4;3XU!7M
ME)Y69C1MI:8MIB0:J=K[+'UJ3-.6@^E&';W)C'K'AX$"S4R38.(I[?]G<SIP
M^+PB;?:Y;T\S:Y=$>[>EY; R ->8;.@MDN)<5Y=80:PT]E69J_^P04R.('NB
M"+ ' XA<[ (FB4LH9S8##N*,(0Z(,Z<(_+*L1+]T^,Z-XG+S@[!M<($<SDAS
MT;C76X(F&F>B<0<<C5O&OG#M: PA4W#PN.-1GS+A$$XHP,I?])30XD#Z4M@!
M6@2'K]%#N2M&4NC5"UL$[EFU%(LK\>7VCQOW\OI\2+3+*Z\YZ*AYZ;O-'P7W
MDQ-X/2S^Y/]0,US.GS89L\F\66%NY?VHHPL?NU:<6'&16\J^U!&/GPV6&BP]
M>2P]9O;E\!TC#L!P]).^CGW12O8E=GW4!M0W8=ZR@,X.H7H=I3T3[*5N #S*
M?0Z5/<]LS_4@MJ%+ &2N!*Z_J+3UWC3#G5:54U%N4>/IK=.S9R_MKAGZ+:,\
MN;ZUGZ7?] MT[%=&O?![J$N%7QWH&>'6/G!IEV!TPBS*9Z*/0I>:2M<#F!)7
M.,QQH2\\S:74=;BSR**WX8_+T7*,X<9)*SU0:%\@!IE#R/K<UTXD89O.4HTY
M^U,IVCJ0F!;J%NN_!EF<=^,RS*ALP%K;[L5PP(I(1U/=C6=1J>QU]A F\7^7
MGW\VV'$D3'GY[NN[FW?6:&UKUC8NG$>=4;"MBOMV9F9NS$"_WF7O/S;O;RZ'
M=PK)!-X#1FT&&'>8+PA#F$%@"\$X#FQ@4\=>A'?1[691GH]^?5)=!*\(+@(;
M0V!]";4/V[&\<E"6,FFR8N?1QO,-PK!T-@P;<-=%E-LV(43Z/N,N]GP!J>LQ
M[ 1\'9+!5Y#L9A KU0!M^]#BL>N0>5J!RKAG:_N8!-0GW!-N(!V?^ZXRF&U7
M&<BU9/;4G]?9;?H]>0V15:N,HX>T76R(P80^KN<)[*LQ^0$BF ;,(X[#D<M@
MP!T0U$MN:5I<9U^4\:_T]F:!OQ?I#;$_%ER'.%/F08Q);L/ $=!3#A=F6!+(
MF0@P<!E'7BUQOJ1ZQ>O_%_>7^U,K2<,A@.!0!+0Q V%$1!VE[&>*N>)^V+.B
M'U%GH+?!45_KC1%R*TRZUG_'?4M72/S<^B3>3QNP()DZ3D$0"&@SX2JGB3C"
MXT+Z4/T7>!@!AH-9%M20);(H?"73,<)VSG(_;R*1%$W(P5T)J(0!IL C@<,8
M<UWF*'CG1&+BS?F1>L?=WI?'-'E]\A)1>$$AWT/NLFVR.$WO_.]_4U:=\TMN
M%5$OZFNR6L-%X^>6DM'>0,N4%2KV&PJD21R8Q,%)) Y>#(^]H,".-(RR+:?E
M8,-<7I1%W:J",@O G^XF562B4WPPLKE*-E]=O+HZ#X)H?;(#.O5MR-E"B)L1
MTA%!RH<L L&HM9S'A<:=QZC//I9[3VLVC\+.H]7IA7G^9C'#EE,J"TMM??/\
MI/3\3_G;Q5;7HM/P\O:1\6I42E'R6S0NR56 ^_TQ5M],47FKQ,->U6^[^74-
M)\$!4Y])8LDDYA[&""E_';F!!PFVA8"^QT#@SCH)(RWZ#.!=B1]+G 1=AJDF
MM]R+\=SZ=_N=;0.K'V;6-WW:M-5<RM-,^7I3#J=^H4.)ZWH<!$0$A%/;]8@?
M$%W8:F,'43D[Y2/T&X+?DOD65\(]RDEM*YZN->=3,6?$)9@A7TTS(8( 1BGR
M!"4PD R0 %>)^7CAQ/):Q84Z!PWNXQ*'6V5$7X5Y-_S7$ JLSV'V9U18GSYY
M&^:=#S%WM&1UR(8KB6M[I \/T4=56W?/5N<Q4A165OJ?2JE&91);.S'3J(3U
M$_AYZ,\]AKEU'_>4#Q3V>J/U-=HU^M<@UHZ1\H?NHM$%ZL&O7&QC=56KLJ#T
MI?TLZD2E/06@52Z&S*V?U/,4$UGY0!D"^6.J:RG'"UJ*Q[!X.8KOX7Q7=3^'
M-X\&\O-Y&>_\"<Z,]D[QH[KH[K_46/1-Y?7J3MV5T</T*JZ\[$G9TS O+&Y;
MW? Y_]#P<I3UQ!=-<X:.8U/'$Q(%)" 0VIP*B+W ]F7@ RHK@NO>(,O4>(9K
MT32"%V$QR)<@^!]Z/[VE(KEE[& ]2JU>*S]9?]Y ;V9_7J5-]1-.^XFW[V<S
MBW/?!F"TI"DA>XJ+0LEFU%/"EJ6)5O"]9RM2RO[9NM1@K'A:9R=D6(3#93HO
MH&?ZC-D8S=>!NA+;1 .+>NF@-ZPZN+FXM7[2L^?\ A%\-[J@>(S+RNR^KLS>
M-00-^SL!E2C_^=V;0,;,Z@3 4!#X%#G$A40U"(F!= 16II\; %!1138S,WIB
M1@AB(.-4(6-;*VDSR%!2&EH]O7NG%78Z"C*R4,N]EJ),Z_'*;RW%<A>5#?F3
MPAKUEFRL^!3[/JD1/)]KLT4]3JEY'<9\L!ZR]'OQ.&Y^IZR8J.Q;-[J/DW)5
M;9E5U:D<:/]2U\.R&?PROFSE!;7]&U^G+9?1M35='5\9)T-$5.[X!1S;8K,&
MV+N&8M>'MWO1_F+7SLK8-43;U? O"6LON0TNV>=AR6WHS>+D:^\LL$M/F:&9
M);^"!"X$C%.7Z"4!V'$EAA(3Q_-<!*J7_&:>$OF'-'O>Q%$N[RY1HC.Z6_O,
MGTJD$3- 4K[ K!)8.;XG]>Y>='";@+VP4LQ,'AK"S,CJ<*@C@6W%>%LQG^W;
MB&9CHWR;?-01E7O,;S9EAFV&?83#/C;3]^J%EVSTTE'KI9.=QL.2RIMA"&@X
MS$F"9OC1&X9X6C+X5DSN(<KH&C$'QF:6!/J4.Q11&&!)"*,"0!=CR0@#G'B(
M+,8<2AYR!WF<1/F2K%[C6TV>J.EKAFJ&:H9JAFJ&>GI^62N,(#,^,[X3'=\.
M/#!_G%C_VS"Q;KRN4_&Z.'&F-=&^%('O2"P"3%P$769C*AT7N5)@ "N**L=\
M,V2;$=?LV_NJJ80>%R>7?SYFTTJ-A^CB+HO"/R_"^R+*/H2][^%SKI/]C]GB
MC0V5#FU^"L"H=.A^28F.7CM=65D4#TM?LODZQ++Z,.I:25H6#P[R87F/ZO3P
M0)J*W?/3K'Q7[UF__'NL7JU>:R71=UT[E$7?XKPLZTG"I*-Y,>QT]$Z ^F)]
M*'PWS+JYI7?XB[MUJTO13^'/E:4Z*W?MWS(P>%#EHV4M6/X8]7KC.;=^4C-9
M5F0-M]M=+'A2Q*LOMOPCRNLJ]5;@!)U9(L6H#UT$A!"8$.YS)CSA 8$]!@,;
M5.SS?*.'\&IX:) 5&MF"81_UD,W4;;:K'E*4=81;#^9S^#RD*QX?$K7E@\ZU
MO&21]5W_:*8,.2CKA16PO9 >AJ>;)CD<4B EA8R1 &*7(Q$(+I!C(Z*FH&+I
M0KEVL%PO=/,89E%^/2A*?%7S-"]-EZ4P044A?&;I$][+;_/RIC,%&YWX*>SE
MZKJKX,S*E7$3E?6$LX=R)8.G;EJ,+CW[")USZ#CG $SVQ1P/\=6ES=:P7V/<
MJM@L9';1I)5.![W)J1NGN@F!V2"DE4&;YHW5L,2:W',"QC&W*>:($(J%;T/H
MNR[VJ @HY?J>L.Z-6PM08Z=;S9S88%U>>4U5:C=W^I9P/_G6=6!YUU>W_M7M
MS5OOH-;,.6/5[&KP]$TV=0&POA[=6;+AR^Q])C)\(N-["\6YDS7D7Y2.&VV4
M;#(=;Q-XW.'.E5_$UUOK\IT57%Z)*^]2?%+:/;C^^EG<7EY?G:!8MXJ?1VJ7
MG4YBU@QUCYRLD>LN[/SYD*6#I*NMIC3[\&^=3A3=W^^$$B]NH17AJ[G7@LD5
M(X/THOQFD6KA!B0;#7.DAE^>?YJD^NA3ZS'3@9E_RSW71R"0P(&2$NY+EWN<
M>8QYGF,CS^>;S]@ZK_]X641/%I@Z6>'ZJNCT)G27LZ4W!DM*PVU4CSY.I90[
MI \W8/EID(2#;JS:?]YTPL:VXC[G;!V[X@WE";PD7JLT\E%9F&M(;U.2B:7M
M8C^0E M!$'5=(M4_XB,D&>.4OEHRW;"G)#.R;AZC2,ED6(:M/X=9Y]%"8)B'
M*'<JD%$GTJ[,Z%O MQ39HY/,U3.TO63N%=]:([)MT\1-R;*/;.1PARH^X81C
M*%PG0-()?)=1%%#\:EF>T:U*B*_[T9!CAX="Z"QU%CU&2:XW9/J4YM,=T&Y5
M#R/K<UKND.27-1,5"/ *H3\=/;UZCJ'1TT>HIXGM <_U @R 33AR7:SX %"
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MHB9AX8:],.E$YY:,.E%9&XC N:73QF]=Y]#,HM.MZ+0ZO<\<$%$^S>[[E(
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M8Z!AE;]!$L,9"TKG*1TD)ZICS/C,^%H[OG9N#_7*;'$% $U6_\FH4U:FC!8
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M#B>=F8,C%3!Z/I,>!SZAR&$\<+'K$@&]@,D [@DG=[]<$&!Z3GFC.T$88#3
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M8TSI 2E$P9\QE1&GOLNIXPG'CX7$>Y)'0.$^9.OK:-?$I>17^>WL?T_5\<G
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M1&K42:ZKBK\2I6.C_9S?MGO1"P>5I?L^7&^&J:"-M@P/-,!';1<T$),T,BP
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M3B!XY(1A$,F(P7]\OG$3\5?I;T<W[F\WGT['E5-#)6.4VZ=7:3H+V[Y2]T8
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M  W3U<VR_L0^07@5OJW[9EG+W;*.EJ47%T9VM<^[UODEGU=AOFIL-)&CP(T
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MKKM?N_*_(!6_!92@@!*_KV$L#23+^12K[PW$8',S ]))7L-,GT5U[FU[ ,,
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M.)O[ONIEO!V/YM<_,6;%0\6\3W%*/HWN5L26:U_ZXB[ N@[WTQLKX.-W3/@
M8/9A.IPL1MG(&4^=(2"R]:KB'UE3/,[)"Z=8EJ6S/\/U\^O,28?#_ 9>>@<K
MCZ1:YI/Q*,6K+M()R);,*:^S;%Z>[P3,#8AZVX3; ?,_#$$[;V=OD'WH0^RS
M02&/8J@.-F+72AZ8+\OKO)B?@=2[04:<Y$CF^&$\_0Y,:12\I[(CID!G4]QO
M)[=W G_/<#V^9PZH::CJWCEXY[GSJ%U8X>6'UJK-J!*H;'WMS.?Q%.RAN>7
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M>;!2_$L<+=N->RNGQZMD=OSA,)2+I1\I$-1/A!LIFB@1DB"(XX1',?6I]%3
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MK[/VR-DCYX&1DS;(2=U81*"OAL)C,8V\* DL<I)0AT0D1W!JV0-I#Z0]D/9
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MW,(D/&V&X_H.MUB9-E[&H)9..K]7Q.T6;H^9YW.6B>XC';JD6@=8#+GH,I^
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M*"VO4=Y(2NA?>J.B=TGT\$&(W\!'J+BO-$NX*Q/A!:ZF,8F"1'M1$(;:2XX
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M.7O59=<FO:7>U2*;9K=IG2#8:(33X60QRIYM).SBP\9-['K <DKX$M6Y6/-
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M%TS'J9->P</+N;.P'=;GIAP5!I<NF@8F\"CD3!A:?GDY'F9%>6Y#I;"@9#/
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MKJ8TFQ7Y'V,4$ #H>V>K/&PJ2 )Z=\9;[7D2YC,J(ZR'$BG.M/+]&/91@+E
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M8JM/6KVF4J^-='<PMHVZ?ZE\D@/SD?RE_OHFO5O_"L%Z_;M9/D>W,_+L^D_
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MZVJQP82[R'!EEVO><^D)<6FE&R/15C&GRW U+!QWD1O=8X?*8S2CM)A/3:#
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M<2-3FCV&69]A?QE_R@9F<'_13*128#SOV'F:&RWHP#'89U5UL#+!Z;I*IE2
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M31WKZ"I9!W?I4"IZOLC8*I6=I?51HMPIGK9<DO5H38V"N8-P<&I;)+VI^E<
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M$RF-5OP0@@4;-N,IV*ABGF)'U(D]LS@PB;SIW8TC@Y,' Q5^8-^VI;J@8HX
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M19^3_G),2WY+%:1V IH-71E9@_WHGW00:+?<DGND,8RMY+W=B]UH]K3'SVI
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M6CZ4P7=TM"&#+Z7JNP9##!0EI#".R'/*Q9 A::V3?U%"L :&& D)X-I\P\>
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M9>U^A' 0*/=&]7;OZ'F6A+_,!LBR:'#4&<D<P0*7+!A2IKKD:#]"79"1<0]
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MBI6EHV<A?>@=LM+HEH#5%]2@TEBB2%]+!^:5]!> .X/EI:O/+UP?R9PEY*H
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M/K4XV,]>5TU/A$;A5+"%_3>N+4H*S&>[(AQ_- -6+8$^P--=-DWX5 LF=SD
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M?91.CZJQB\YF?^#P.RZ=?A7>'X$"LC,M3"BYBH1UQO_\'W(,FJH.!\&6^=H
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M1#SU:.K8N=^T!>-R8U@Q8+F4*UX0_^82@$BVQ-T6AB$/<0$K>5YA !LNN#?
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M!HQDEICO6XZ9I;9(]LP*/]1'SNC2]S"5;SK+@_Z109<X6PP(7W7O-A!E :
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M\%!&0EH"@(&! <*A_P#(TL,]<1=3(P"0DP/H  ! !.!@^(![T!(JM"(38 K
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M]((5Y2# .[W].W_HDKP^1H  A)D_8H<Z$/W$^K\1*Z<Z@$EYJ4':#;U!!0)
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M+INYS04=-V0OI*2ZXQ=ZP;8R5OMCTNJYG VQRG7KS^=(//9]B R;@ENZ7$<
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MX=!BX#N(#8BQRO+I4M!%V)4UV>=FT1(QY^_DGTBM:)G'G1(:40[Y>7#1+8U
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M,_ -O(*(SM2=D'&&%(CP. *_SC.OGU0_U5NFJL.U04'WC?G-IW@O]*T+NX]
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M#-E&C+S:.6X\99Q4E:^_]1YN+4I39VH88]I8N3G+H[-FO2XRK _8!(X>5(F
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M#(I;X>X^3R?S5>WNT5RG0553&,YHV6G"+$RX3XA>G.GN'5E8'C<AA%&9XAO
MB:J*B2I((BN(2SXKF,C@Q?,<-US""AT'KS2+FF;\INKX*MRE4^EZM!Z* >*E
M0+'O@)%^YW6[D+"ZXF#QRLD9^08/=@M-E;"%@5M'61KF+Z1?Z7'8[?HH_4L)
MD3BJ:QC*ES9Q-:WO\U:2Z\AYG7O)CW*TS&.Q7.06M)<6VGBA;T2 /XNH1M&C
MM72_TMF<>9F0.Q@ZIC@%^ABI(7T+OPA4L^X1"H#/6RMV39A1K*L)F+"L4?6
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M*<A"]*]Z%U7WULCLE4YP3(]^JO*C3ALGRBA;Z-+/&T>[VN+:V8YS\+SD4@
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M'RXG)4$&>K*P,AOH5Y2#(%S=]GP67)[*E-=TNM+&DUC[5BK/&*D'#4]96@@
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M,D14F5[TD=#G-%9=S2GJZB]Y.*_>K'",)EBLNINL?R+Y_9: ^Q3!27E(&IB
MKNUV<BE^9%/1W6GN5)DSHRD)YL^B/XO^O45%(*YSH8?M_$9=O\O")L9<3S]<
MM*X5-32+^9C+(BT5E"%SNTY7]/38!IFS=%JG[!TU_*'^K8MD?MN?W@F4GR(9
MKNM+*7\,G. 2IL?,<XMTYOKP9Z7_9RL99L]K9#+_J"-Q(]?*GB&NVL*')N^K
M]>^/6])+1?1>]61U\W]R<#LNW0OXEE^G$?RF#KBH)C]VRT0)YJI2Z3V%40C2
M)DS^T&9U?-B2IQSI9MXIQL2^YNYWB,D9%__2Q@TJ7HQF=O))P2LI=TZ8%B13
MFGIQ% 0W>.K-"P5;=V,-%>)QSVF@&0S 6U&??!&"Y[&K6FZ#\JKI;B9,] P*
M5?9=ZGS-T6Y?]D(WV,1,>5;ZJ)J&"^S9?>,DK[OD1?,>?@K5R)(LU9(K\5)J
MCBXVI(-G0^LD&VZ^Y.,Z?N3>(^"YJEJ;+91RHN'SCCVU:RL5#'BEEV6-N&;8
M;8BQQ(DC]VX:1]P->0Y-XF5ER2)"Z?7)Y-):+VDWL()0FY$A8(@GDQ]H1DVU
M[<:+TLLIJ7+04RS?,,T.G&P!+,2=]..'*H[HE+<56 T:J=Y65E6=LA>8GBA@
M=SK?V.6JM  '[-QFW4>UP('W"@NG\TQ.%YT<.QQGJ V5##'M-_0S?;9X)^RT
M+,$SZ+%>_ ( G2#K\,Z/>6$.;:(1:@GBH%62:RUCQ\_K8IM> BS-.YY#'_.4
ML[UTFDY%6?V#1-;]0@3ATOW7=-H ;5S.%EM>,,J^4\UTLQW/RW;!!1-4DP8/
M0[[NY9JY"."-'DAV B/7SRHX3B&5EJ9YC%'!H 4AO-S:")M%=>C];_HP15@/
MZ''&:Q\/<$2"*U)Q9R.Y#'P09H.Z3LY( !J;M^DE>\K2.Q$IZ#T.'J[)6Q*W
M[*')4E$]ZFSK;&YR I)'7V,6<<I&.&< U=6>;_1!4RX>.0 A['DF+EQ\RT^G
M#]4$&GO=;DFK9TU3@_&3IJ\K3EMPTR0[XM_7*SGE<(0RDCX"@)-]4LGH92 5
M%2$MW]T-5:1W&YW#F/D0M4)G0T[YQLLJ(FH"^X$4%2 )B\N/@0G^F5M]VLD6
MW(2W-IM)7%XC1?HAHSO4%7VY6O&K(UI]&(%8+V\;)>V*^)'$85-M$#?\7>1C
MG!Y2,Q45^]BC+5Y@B.WFTIO-RK[:=GB[MR-6>:R?.)FVVE/8'W.B*!8'";LA
M1Z(96H](F\PZ(7=$Y>1Z/K#E=[A5$B]";(H,$GHK&%O[Y5;IR"F9PS&;;Z5O
MSED-H\VU/FQFT35-*36HJS4?)6RP(RZI3-S50&-JZ8'[9NYF[&X0-'H MZ=X
M8$J"VD;8RWKV)BO'9"V94G#TP+8F3F"(HJN$]A%@_Q:=\2\^FJ0@ &0!(VV(
M,LFW@ .M(??QV_,TH&CP=/>0JN2S$3[BNL[,I">_5J@#0(WV#.L9(L_VSQM%
M,ZYR7<,^&2>J7:>,HU,_/W4%/:#,>#^\B^!#4_!WYOEG942HD;CO1MR/J"[8
MA#\"\B0N^>RT[/7Q*74X@>1%:_[_M@^4:MPQU%0-DVFJ)HGH&5AM4^+8:4&?
MVT=-W2-M"9&7CEX;*VAQH ^N D]AXX]IS,@F-I/95.;F#,\!HQ\4O]A8(:>L
M2+I4<M1MY>:.&F#*HO1P+KUDO(4*Z^4EN2;T!'/MW@TL7!RL)OE8CY(7?YC+
M:;A/O&$OK\"041O*[MK$JT;.#3+9R@M3?<?9+LMJ>M.8DK8[*E[MJYJW,]9]
M/ BI6D7B;Z^)B"VXG1X^OX')M)4WHNYHG]V6309F3*1^)I#3@E;&*VBP#VS7
M;<'U]&I?6\PWLNMS9>Q(\7M/XB<*.NC_S%&1D2810UWB[<42%,8RM/9) 6](
M-*L\CV9+\]N3)*Q[RR5(-2DQVGK!&[]';V<^C5V15^&&7=BI0>5P*(KH.HD>
M9L@QX>S,.84),?8CT,71)J%$A64K]QG";MD'BBF^JIV'# _OSBPR;ZZ+?!WJ
MLX(1-@ EG_U]!Z_E?EL.\&RME,,MEF,O(S6?#8$MWP=-2O!OBH)Q7;!3QY9G
MMPLMF,&HUA!%(%>+&RDM5C=8$=H6*LA#P@C58)U$X,U'/+L2!L#-KP>-0 Z7
M=K ^F<89W8/T0YD ZK^N!ORBEO3DXUT[;N3'ZV(GMI]*5&+_: $!U_VWZQ%2
MOU52 /6?3?A""?0]Z^UX9:;DL!Y7]F2U>FL0NO_S$ N>VSQCFM\8_S:8-Q@I
M>1HJ:D9,/5:3O7MH5CDZ.*41%<?)M"F%A'1+7:^M/IM3M-@RR"AWV)RT J7)
MUTV_E5(AJ7][9H3CCB7$T4<R*::+YI0^71%15M:=%S3GB7!R=MAU5HWIS1!K
MJE<53*JH%]A+3N C\:$;W15 9;G?H2B!H$1ZJNH7NWFX[T6W9M17D4L<=((D
M.K9W_T0]D<T'VT-<QN34:L'Z,1HMC#2'U9[P0YQ^"NV@?-NUD=I<ZCNYW*=^
M,&I4H<UFRB9+EI.*%BQIIXRF^@P?P@]-GSPQ%LRZ8"L_#N!T_D3$?ER!ZN0J
MIJ]\)=\Y)\FL;MJ?OO_>)DR(D+:+<HL* /DV(B@BZ/C30^,CX 3GH?'P]$WC
M,52;Y$@(R*3H;&XO JJ:DND$<9*0;)'+#R2Q(GKL%Z![=%X /4(4;4]-F9'Q
MY+($VPORPVYA0<X#F_*VI7:G,$ ]CK9FIB2GVHK8W$M>=%;9I<3'F0U'%W&Y
M1I3..;,"]F]:M?B2(/-R/[) 64C@WDHC9@JY:&CAIU%+P^5&5E!,H:3%1@X\
M%"?-?-QI9CE4&KGCKO)K"\W?G76YD*)N']XWU%KG_Y[I24-_Z60[Q.TTF53\
MU08L8NM+1,O'M&X6P7(BKDW@(U][1!-G"_EI;/$-_6 SR3=3I1 =;LO6B*&<
M[X9>ISAO0VURSF&J3XJ4292P#[RRH\'(;#IF2R-^1Z?QX?7Z1B!'5,,;+W5L
M8MX*\F1M<WGR-J1J&&U;8BAK8$_UE8OV%(TN2/"APV:P?#]:[+1UY#L*742%
MMG>-=?..RN0#6JG7)EL<:6UM;0AOF 1[0NQW>3EU !;$W/%'!HCD![:R(-?<
MB8?NR1'!'$DJST5^45J]EQ\4<,-@"M7'Z@7(4E>-"]_?TJUB+5?Z+JNR92'%
M@3<(F7BN76]O=31@=XY;C^?ZK"$,ZD$]A(,+WZ]:H/#5ZKP[Q#*OC+H$ZD),
MV0>P1&0K3RXWE)!!&>OZQ)9WV^J:QB._YI9ZKK'H)O!PA_<PP-G"+72\CGX/
ML%#5M.)G#5EC'+B>BE=/=\^_,AO4&8D6_*PL8"(S9!I2U)M@]4%4U8.^8BIU
MA!O?D;-P544"96>2M"B3@CADISXQ(RX@+M$T% #3W*,UA)4)<C7JDR@9?XL9
M8P\R1#SI6Z>HEZ9O._%"WH>DLO1R8,=52)7BQC<VS+G*NQ71,TZ85H9SGD$9
MG=;3$]!XRY8.M?YJ&I7270/:. EZ3Z'*\6P"<<H25IE/21@AJ!N"!++&9CE<
M30T-8FM*>3(;"4AERD!I7,.PT.WURJ0%7H^)S>O:G1RAPJIY*T@&XQ'0/EG%
M] @PJ&L,IZ$V):N+G:.YM3K@!0/$VW"1!??4 _@ %BB[;H0Q[7WPF!&%0 HL
M^(NANETZ/VMDXF;3Q8*:YK7X71>:]Q*^WS,GS,B23PRDE8*ZD?/1H8J&H0%G
MA4;_8Z(0LM9#"!5(C/VE;:CPY=TM<@*UC*1:#FFSAMIC^L"%@[2*1J$M+\;Y
M?D]%'<2K+X6A1E_><U9G=.G%6!G9B9A2F@K%KSS[>(:0^*HE'_I@G '6C AZ
M[5[XD*!AC>M],>ZQJM0HHTJAC<8TSP6+&2-&W//^YU5O9X"8.O 99N8RVX)Y
M4XUXDX7)1)DJ&</;DJU5P?3H(#T8%Q\T>)>V]5VVL3+TF6W: ;2Y^CB4"UK^
MV>9]K7&"S_M2B^HS.T<!Q0>:E:$L2 R>3PX&8[]A,!73S4!A1W(N3I\[:2MC
MO6AF>)QEY8T;]DY\0X$ =1.0X5Y<1*BH\$UU/"I14/<(&)VH*L3Q);^ Z.WH
M=[:$D>X(WC+>/1(SNH)L(K\<AN\0L_4GU 3JU6.)/!=SYA2S0ONFR[%Y&<$6
M_3G<+"1$D+C =/S40K4]A7WXRS2EUP=L?"))?709WW#)[H@IGOW8;*$V6TOU
M;"N:))PX?$3]DQTE,EP8G07;L43S61'\G+$I>^B7.K_IB4VF)D,]>C)3_]WV
M*O;!N,-]8'8^GKT($$XQHRE63<3<!W24SN9(A\T=5D+9F]M,:'<HW&(]^LZ8
MN+7\Q=V[;,'J5ZJ;SQ$8UF/L<%&M)%PN&8L_R]N]GGC^DR:'85YMX#3EO^4-
MP?H61CU7GI"@S6#$'K,10]S4I+QY;HKQL*=&JZ+,O73\04_&TD ='HX08B[<
M$^QAW7)>+)B6PJ,B,W VQU==/[+I.VI<F^VUN+@Y^# 0MR*9@:DD"&$948./
M5&FZ?6/;&&/N=LP]ZRR4_T&AJA(G"2[H_0(7T4YR6R)PSR#[:71ZK92_V^6O
M^L:HE3N#H4MFS#@'QRCZ:@ZQ "O^,][[2DZ.Q]11D7 ,E_ZFQ&4:Q'WPQ0W=
M8;0M)#Z=%@Y[ZMY"PC>*K\'L7>+'&&";M\G&?16H>9$!FO,NQ5RH8E@GG=R?
MTK'-U8WF+YUV3HM,??H[R6DF>P]$I#;+-JDS@M,;EZ&A/WD#]PMLU)C%XC9+
M2KT6A:"QT[E?8 ]RQN6/'WAF#;%,56J@&)X*9<TNJ'>+GES+^/O%E7 'X?AW
M4^"%N&F83#EF]M,P! J!UO8_"4I]O>J*"^,T[XR0'&6XEY.RI60QXW6<V:2Q
MVRJB&+?,D"JPI$@CAY#C!^![!6YCC-NB24E+_L4"TOW%'#(5R0U6]QKA0Z_U
M^']RFUOO(J5Y5?5T'CA6_V82)&N5B2=]OMFZHHU\. \N!^/MI2!_VYDUZ]YN
MJ\U+7@5_:"H[=-^:E>@-_0Y>NKZ(."E\?R4D<7<3>OM$2*' '4GV@ZO _9,I
M-UG,/+/2E/0(T" >V6I_!% \-.J97Z@=WMT*74O=QS@_ CA'W>0R'P$OWCT"
M4J0> :Z/@/.<1\#7R$? T-/?)\OE9MR9G?FT:6\=]RIE0V.J?^"A[\DJ3#'D
MHN#ZE8B*IA52KM-=KL.FATJ"(U#*]3G!Y=(C0#E4W_?!_M[%.^757?[-=5S3
MC'W3Z?[;#8%?\<O'_$1G^@.JS!,QZ0^WCX ]J>]'2X./@.(PZU7W*'<->N9;
MFLL'UXR[G']!/?H[$MU;A=VWQMV7W.^-.))QKI?.3Q!=)$Z*]S;U'@&ZBT\5
M*U*B"'[%KZSQ,XT_]UMYFSO;0R//4,"#W+U+_]*O?9O^*_9\D=_0^+L^NW P
MWW*?ZOYXS-7;5!R7\->^E77_*WK#GVCD^EN'X0\AW!W>7,-POKU6.#^E=_^W
M#FSZK^-*^.>P_CFL?P[K?\ZPRH'QZM,8GR-:4&3_Q&TA8^.\Q[4KO],4'^R(
MV(GP%H>AO-UFL+]+@'N-P0GIPTKNP]Q#UY[ G/OTO7'>\(&UNJL_^[]29E#!
MYK,U[=T=<^L;^D;CX'7*?M-WMPK7ZOO0R<#/-7\V^FTC(]B*'*U:T"H.>7JR
M1!,%/R37^#FC\[]:DS*)B:W;);]/\(!XT$[8T]?-M^B7*J%5CX#2FQ$#>[BA
M4C5J90;9$.J\= A930B1=9'[-IG[W]>!"7]_B8#/VS3/R/4+F;?FMP2%&'X6
M];?(/[8,MACYT4Q^)67P"],:Y&16GNSJQ A-1D0Y??U?F2Q\_>Z6Y+U1_^$/
MMG[09LP/Y  A_3-?#*LCZX]& W,Z>..$NLG3@&7/@!0?]8'/%]AS7]^  >^8
M0.#78N WPI1D[FC;):CX#V]<7U'?Y94>9X7>T74O\19]7#LJ&97#7 R)7:%%
M59!TMVSB^_(VT*9K>Q0I;Z+&MN_%P_JR*_\[ =I6L5E&S$71DHGT8[YX-!E4
MQ77LX F_TNPI$YV,HKBA']MJ-O_38\1%\H==T='*(:7ZC!FK8A^((<,#/>:L
M*QX!Y0U62#G?$/. _>8H.R_L&<N7VLN:"T8APP!2T5NIA+:0X3*&=1V^Q;BA
M6?.9K9V?&N>/P\.G2G&]%SUH1E0/$M9P1!:>3/<=^=X6DI-)0S)I>S/*RDBK
MX.2NR2*EJVS>IK NPYPVXCSZDG7-]XLPQ%YL(6D>C#E%QE+'29GU* /9>8O$
MI"WNL:G\0&*R4=CN(3Q7:P5SVS6S>!>[BV!KYQR$X69<<@#-II[V,'S(@N W
M!"#ENWH>??CP.776N:4ZLUMZ)HOIMV8KG>*(;"G"A=^N(O=H1?=-U_T+-6N:
M76=.D:M8[3K)(9V  V.5<R+W[\7K]9#Q/J$P2'V\+JVV)/#(>@]DD*_S7;#%
M$BW_2ELD0=0ID^S-43[IP6A0,(>$;.B4]+TJ&C.0?;CH4D[&HY:8< U*!R5\
MVZC0+X!S 6[)-3AUM&23K2M,MS517U\5%]?V;<C';PB]E/@2& :2<QT,=9'"
M(%_*,.N31"9^N@].6]E.\1+(.U*J8E Q(WX^S#U3+S\@J<>UX-IN>C#DQQ\3
MW'U]\I6+M*_C1P+;XWD/S<(UB'NL^DOY(>8[Q+%,._E?8 ^)3MK[/P+6B0CN
MK0GZI_#IK][J(5UEB:%)J1/M_V'"TW_D^NL2N;7MJ,!#+M<"^HS/0J)#8=@-
M>1HXA/ ?;![VZ]7<=*PJ+W^34)A1+J1E$;U*HA67%*7X_ [G[!O"#27L5?([
M6V,V''+.8;/"Z.V/43*7)I91,(<HXY[#VI/E6\>SLW,#')T);]I15Y8I*5*8
M>UR#8!_P'?$,9X#;>P9%VI+'-C>:'JH[.3H@[&S-&*-/7?CSRV%TX@<P>RIV
MLTF9HX(C(OU2!2!B> :M&(ON&TE,&BG5_>I [?!",G"YLPC.NGYEK2/$/+K(
M7=_=1TG!O;%*%0VT[6*#RW<Y_"/$7TF>"9'H:&J_)0X/:1[1K"WFT\D..#/D
M'"A[H*.)4B;V]H6WJ&59>YMEF3R!ZT8YVBZ9T!>[KQM9-3US:8&;)80+$3Y5
MB:%E8RJE-+PWJW-3.J8%5@!+MG=^2P$'SZ_AZD .H:?_Z&Q!W83WC4O"U7)4
MC;>N% LV8U?B1BG(4GSHJ;%_M%8BAZ>@6#9BBM!QU\KX@+[;[PK(WJV+9.6/
MX3CO:;<HLMQU1FJ?\C.Z69@$YS0LK(&$KI'Q45R?.WZ,UBP)K["->"AR5I)7
MH+))S,S >' 3W*T,]9^Z-.G)RJD(++>UOKHHDE^3K 6'-?2?"'>!2QEE&!0Z
M%-KEV]DFHH; J5ZI?O*9:$U<]25E*<JEN%V3.< X2J 4?QF042NNM%.<=;6P
MS:8-2UL-(Z'B[GVM*Q#+#,=C_:ZU%FLV2 ]IFER([93R!I^#%0B.KZQ5"_$=
M4DB&>:X:Y#REE;Z7[UCU+@3WC+-R"Z7!R/ 2 3>GUX('.@A:6^.Y' NX*X_]
MN][+),$&1@XFH(G$YJ?0^PWH)(W\K/@ZSH_;3V[BAW_R88&U>.[-4L:E:H^
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M]SR,&1Y?/-W,"HDPA/+EF$R="AZ!G!J_8Z4(> JX.Y)-]J&)\^RDW&>FP@K
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MZ1%NY-F9V>GV+V55OHMT5M+DK? WRS(R$N4ANR(Y^X0B ?PD45\@YIT3=2:
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M?E+1[O&T<KUT9_3%T33TUW;%GBVFR;Y7R3#$Y_F-",=DZ46[EURF"3K/WO1
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M">+C%"V=5>)6_EP]'8;0PN=551&Z H4;8C/6NJUA8J_K &PP)_D=^Q(5)'<
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MX&4JG<^-E5^P-G2S'1;@K8Q047$0]-R(,:Q^I@NC %=57>F&[$^W3="#B<?
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M-,A',=J=:W%HB6Y$>E*F1]^KG=]C3+Y/LEKM]"T^86"1)PG:39/V+$SE.GT
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M!*=@= 0M-2Z\2K[$KE._ _C>R[+]OJ"BW;^8OBPV7N.%W[+Z"! QA=T!_ -
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MQT8VNS<=%._U5^SEU-$M3F2NPAF;U^Q P3J_=L#H<$[;7SH7G9O.Y45>&J[
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M7:".AQO=46H3Z:=Q4@6 WL"ES15Q[0B&-9:>T\+)#&$Z&UZ3O9D$5,6$EDY
M7X3K):'$1.M3Z6'^Z.K-M:*;YRANI? F%?4L='8=PA4&:Z=Y=O:[<WG>N;EI
M;W0WZHTFH$I_>P.70;?;OCAM=Q&F^ZK;/N]<;S@8R :WF"HMHJT(:+$NZW;W
MRV7W''M0.Y]_5SW=5V^Z%0$]BX JH(/E$U"S^U^;GF^]R213Y<,M/V6G X8.
M!7D<^/]GG>;GSEGGYO?5F_ <26@#>[7M5SC5;T$\^7RW,U?T7,^-)ZLWYXI^
MGB6"JJS1I5-1Z_+B2^<4?6_-2O2L,>E4&:)+)YWSSG6K?7;6O&A??MMH5]O!
M!N*][Q]5.MOR2::;>#)R0'%SNO(V\:C1[D9GAFXHZ53^Z>4K:H$_]-Q^3'VI
MQ4-%->M'-953>OEAT:3?EU$4A"QUFE$$3Z]H9_UHI_).+S^@$P9#H!W&KOXB
M-QNW>D/)IO*H+=\M$(3QK;B5$M%!8MG?=/#0#:6<RJ&V=,HYE4/7IV8);.1P
M?&?UYEO1SA.T4U5<+YUV.@,XE%RPH^B'*WI6;\85]3Q!/57!]=*IYTL0]J5S
M+OZ0&X[EMJ$D4Y5:+YUD;F0X8J?:+U+@RS?;/3"UC>+[&&&!S/?T+_U#NY]^
MY#_O0OW:,9B(.[U0BN\[8@BC_"B\!S&)WJG;K0EYKB]W[B1-M][8^^G3 F9(
M'Q_X';W &^ &-S^?M;&:I'5)Q5GY$/>4F<XT:NOWF:.Q![M,OW=]U'/HL_T"
M/PA'PLN<GOH>GPS:'J<O/4]=_>>[O7?T.1J+OOY<LE(W[DA&SH5\<+K!2/CY
MT8Y$>.OZ/#R1Q('^@H\E??/@#N([N!LFWP-#1H8[_<#SQ#B2'_4?G_*4^<YP
M8K@%1NC_\]W!N^E\6KVB\=.G=P624]>F7SH^>.1G^^FU]9</]:JD<^D"HOT#
M;O"-.7*VZ4B>TT7$>I-.E2:S?-T*1,_JS:XBE:=(I4J+>8,@I1N$3O,VE')$
M2-)-^,\ __R+VB/K34%5BLSR4V3D/4+;;GSES*:23)49LW22Z<H^V//PTM6;
M8D4O3]%+E1+S!BDQ@S0T.01][0QTM W'A-Y4\JGR8I8?G71]X?==X6%[G%A6
MQLV:DDZ5%K-TTOGOQ)6QT_;_""9(-JLWT8IJGJ*:*AWF#6+[! 8ML(=4. Y"
M4MQJSI4(8Q_4MCMW[* 2YXY<;/%A<#?@[M%8^)OM12CS\6X E549-$NGLE;S
M>NR<NE'?"Z)-3SO;0*II:NB-2JU;OL^Z\_6B^76C6WML-,E4.MWRTW'^I]WZ
M=M/YM>U<=A$FNK[?:+PF=% 1T"H04*6N+9V ?FL"\1"\^K^_=7]W;KJ=YMGJ
MS7:.]%,6B]\0^BDM@ZCH9[%.!4)4=[KMJV[[NGW!N+>;C9NVR114I84NG8*:
MIZ<=[I'C7'4O?^U<5P2T?@1T4*^ !]_ ^O'OW3#P,08D/(2!DE&T^7'4S22?
M*LMZ^>0C0F_B- E+;?5F.4>**?.(K#_%5%G52Z>8+KX*Z]Z^N&$4.UTY3"+A
MK=Y\*]IY@G:J].HW2#\(3>7HY7CC\=/*$I(?@Q;03U\&+D#94:-_A..+$3PC
M:AX<?6Z='ISL'1VU&P<G]<_U]O%IO75ZU#YI-)K'37C">_&<T>?VHWXT_K$D
MI(.SSO4-^G7;__-+YW,G#W0PZXI;O\^<R77&-#@YV3T\;AP=G.A_%XYPL#<=
MJF!_^J7#HT=^5G\)P@$L_T)8RA.G?G[1/SK:CN.L""L-X%5#+WCX>.<.X/C/
M8X[_^%O]:.]3-;^ES.^)<SLW#>RZW:+^>-WVEW:W?=$JR_G8>.IM[G1>LNUK
M/MN=O]!<+Y,893X:BE>A'+G1RU"VWVCV<Z/N1JDO_*] SQ5!;^9<K\+@#]F/
MG6LWELZ5)UYDNE;DO)9[_GD-]KBBY5=D? 7A=^=,QF#7IP@S:S#_BIYGM#GZ
M=[O.YYT7A>G7?,I_);*^'HO^7T\VMW_<N3TW=LJ$U<93=&L-=KHBY5?AMH_0
M=CZ7HR 4_B 9&:A1AP"JUV MYE?&^5>D[-,UV.&*LE\^5Z5V S6W0CD N?67
M(^?CTD2WC2?H%Q5UKOE<_TH$K46UPI9H1S#DL?2<%LZ2P,%>5 &_[M3=**O@
MVWCB_K(&6UP1]RNR'1-/<C.8KKQ-/$K=^DL)Z_V_I*/LZQIL<47.KPABB? [
MO,;YRY/U*]NEK?GV_[(&6UR1]6M@JR,9WLL7==1==PK>*=O@A58E/#7S?&:@
MSB?^ '?.8<(KE258S;6:ZSSG.FM9Q.+J;UY2V;"7Y74+K]68K1-E6NGQ^4OK
M9/_XR^'G+\>-SZUFZZ!UR)4>S0\'7_8.\I4>K]Z5QHNGWYA6%35E$=YZJ^AC
MK@BEW;QN.\VOW7;[O'UQ\_K3E9.D?R11[ XGF5*3@SG1Z<TOG6LG-W!G*[YS
M(^<??_O0:*0T_,)'TV 'V&6#;(Z/";8+P)E39,!J)/@*U@+CJG_:=F",(S&0
M"'*+ 40Q<0YJ3F.OL>=L+6[L[>%0]F/W7CJGEK_SU9.H.;T)F6<]&3](Z3N_
M-6_:W<[IUS8"A%RUNS>_.Y>_7;2[->?LJN8(YU1ZXD&$TO$4=N_8@O1=X+S/
M8)!>$ [F,&.<;O.B>77S^_7GSF7-Z5RT=C-3ZZ>0Q8N<$ONQ9Y[0[LJ)D1+>
MU%2@/W7'9K&OF/-^XQ,<T/-KV,%3Y[3]I7-!@#;7+/"+_ZX%%_P2A$Y\)YUQ
M @<ODL1/B <2IZK1M6'@@;J$/I68^F9'=\+SG#L!G"![>2"'KN^2HX6.^D@*
M'[Z//L[MG"QN*4I.C@5V\THM</JAF(/,G94M?71^ SX>NH-;Z5R%P1@4\(ES
M^0 <]3D<=UVWM+$&6XK\M7[\*7*:@T%HH9:\8HM?50Y,.FW&]#HYF@^[>>S$
M$7_NOP^<SVX0]5WI]\U=KHQ 6/K]78=N.JP?.+^Z>#Z=,^'\"MP(.-5U@E4+
M^WM[3;[I.O"$+YS/4O3O:DZKZ9PT]HX/7[4>^H@N9$F:<0Q''B6T<QU+X*F?
M@9_"G%=OI',U')=,]OLK3/8S:F,?':?IBW$\B8!PF$RFZ93KNGL'*[][\V/9
M<]NC17'QQPP+[F@<!Z08MH+1"+DX5I[,9C.N_J( '\_1( FA^MY!H^Y<B3YF
M"3DMLG)@79(PU@*KL;?'XDKXSJDK;P,EJ^H--EA /(!D:(?P\[,@ 8TZ6?FU
M>.R -)6%L2*GHRQ8M<S3<7R\9VGA+3?LIZI,H_[2D_$";6\._/WEGLZI_/UP
MA?G[Y\3U<*EFD<\W=R)V^J#4"==_Q7,:J0?BU:.('P)GJ[&]$\5!.'%Z:E*.
M%V#RXL"!\4T]C=;Y@],Q#$(?=&\ZA[OSF<RZJ2-'*WQ<\T@,KU(GQ^,P^.&.
MX"AX$^?@L+9W>.R$"#^+T$W1GPFJE4,I"2,0_A:+]%5V]7NO^;U?X+US<,5&
M28]JW4%7$0,\/R2'7-\1?>R/+=#Z?'#C.V<!4[I&/WK@.XV9O!% 0#WI!0\U
M'#6+##\9]4#!0,D!WZ&4U=QK?J[:)=/:\0K36@>=G<*C\HY9Z.W2E\X=') 0
M&''\  LZV1F"CNALU1L'V\X(?G$7+7<#YRC;/ZSP!N9LMU_EG0LBS]$IA%1L
M.Q,GS>SLG1O"SD;N#]C8_:-M]*;2:R)ZC;/5#_S(A;V!KTA'#J5TMO8+]SW
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MWOA_+Z&#D3L8>'+#5GLA2_OW@]U&&=!?M;2S+VW]PTFML7^R6XJD^!1T5;7
M3R]PH]8XWJM].&[L?G@]6.5F+?326/+^3N.@XAL+8LG[9?U,JJ6= TL^.:B=
MU(]V#S]4+'E!+'E__T/MY.3#[LE1Q9*7RI(;ASO[96M>\8UYL.2#:FD7Q#'V
M]FK'1P>[>Q5+7A1+/M@[J=6/*I:\=):\?[QS\*)C7?&-%[#DP[(^0M72SH,E
M']6./QSO[E6.BX6QY _UVL'!0?D25RQY<2SYX&3GJ')X+HHE'U>.BP5QC'H#
MK.J]W:,7=6:O6/(+6/+AX6'M TB]_=?W'MVLA5X62SZJ[QR7K7G%-^;!DC\<
M5TN[()9\4MO_L/="9WW%DE_ DH_V@2T?[5>.BV6SY./]G0]5>&\QQ_IP=Z^2
M=@OB&(W#VLE1???X16>W8LDO8,G']7KM\&!O]T.97[-BR8MCR1\.=TK%8,4W
MYL&2ZY66O"". 2K<,?"+ESGK*Y;\$I9\TB#'16D$M6+)BV/))\<[]9>%K2O&
M\0*>7.J(JY9V'CSYI';<:.Q^J)S)B^+)'XZ/:D?'^[NECLV*)R^.)]?W3G;J
M54G#PIARE<^R*)YQ<%0[J1_L'E2*\J*8\LD1_ ^8<N6[6#93;F )7^507A13
M/JJ6=D$\X_"@MM^H[YZ\R!2IF/*S%WB_MG=8KWTXVM_=*SO#Q)3?$W1! 8M7
MO^A9H#CVTDY#R9G#?/[?E489(W XA8?E1@C5B'!W SD4B1<[!-AE UOUY"1
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M;4>05GB'H-_ ]+<.MYV)%*":+GS.<[%T-#Z ]4BUF\IJD-H>0,7-A:\&+L,
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M5_Q\9-6W A6=S&DK7"Q!3TM#>G@\X;AOPR@&VV PQ0P-Z$3R(0W6PT6YK;L
M$NEX\A9[U*?!?UA-!6$^E,\_*9F#D<N,3I=GR#YM7\;<)H%SB.E,LG?7\ B]
M$T*UR:#5+HGSUZR C=U0P9#E$Z2:Y0BH2V^)$)8(S4GD=4A2:CHZ*3",;X'!
M*9^AP!/@Y\Z;2<VQ@-41G3B"F?=A2T4XF;:$AI'JD4T_N[?;:>90)LL"\8'0
M@M:(97%0R[ /9@?XB7;86N(46YJ5;L/2#<.N*6ZM\"TIZJJ-&!?QC7MZO+#)
M"#()Y.S)\1WU)L6.GB+&W$)85IC!W;;SAP!E*0BYS3U#J=9,P_L:-P:M61E2
M< 1TWDFFM(7GY,E[EX#\->4$*;'V)C5E>I )!3:'BFT/U5S,L4>W $;6D_@9
M"TL95ZK!2\0+>.I&#!&' V["J=HZ:#C?=J]W6[N.25EKU/?J#M!!)/_<W<ZA
MA48<O"3P0AFKK[1(0ASOQ.-P),Z)CJ;$3&.OQ@D!N$>W9"37".+-(U,P\5W@
MN_#AEJ!_1]P@3R0@?GBM!2'8$H=->J A<E^D+4RR11?_XK25K_: FGI LP?9
MII 8)A=@!*7?3\:"9CQ\'O=RMRW2*8I26CC@ \]AEL#'(GR!T.D5$MC4[<12
MGG"?;T,Q0I;]![--8IE; CD03'? ?7GM+%Q!P&A]T-"#$?(8E8P"O'Y@1[F$
MEVD&/-:I5=F7]X')ABBK%K?QG<R8+I%5PRY@U^'^G!#N;EG,TJ*G/D?L1[7H
MB'E'OVT!(7,KR$J!9)UC7!)(5AD0?C*2G)?=$Q[R\6U4*]UM[5'MB[&+U.?:
M16Y9#A_1 E*)&IPS8LPXNKV33Q%"B-]BLV9"PN:4'05CS-P9EL@/1E;K9ML$
M0%JTI%Y-)38ID$T,[VF,;<UOC4Q,4W#3[VP[8#NOLF:,A)F4>QHFX8O#"'F9
MC!WQ9^*.V0"*)E&,<A\9L(J;HQ(@!^Q:Y.?*9[ ?+;?(XT=-;&%M/&R/'7&B
MM:O:"E%C"+.)!2F-6B42^D#)#[AJLIO#K&C("R"=")<FTI^)AZB09LK+ NO"
M2AFF#'#.E88R!MU-EAE&/ &,!>L .#X?V-_W[7S\UYPBP["F6W910BC)42W=
M@9J]16!+12#-LP\CE-*0KC]@32MKT@(+3=D7(V&4P035IS2M469M7W.F\;?V
M@3<G"&RV$,P\RUK0MDUF([3"DXUSX$-8LP."3(^_-8TA.H(5P#7F[5%$&KW#
M)B2_SR'YK(U2X\^8[33F'1LBQ*GCPR['DQU*+3!/.#G$1VA1BL:'MYU3,HVD
MI(I)%U&UE''(.<$"2 1;\H&:AAK+G11LF6"PQO74!U B[U4;87(6Y-:T]N0V
M4Q)\$'C94_1R*P84(I,":;O@M?UM!PQZ$S9FX[SG(:VWAJEXG"=#)35C3&(T
M@.QT+Z[I:'O*O/5SPT#WN:2F@6 G>06OASDBND+:9H8VQ9#?T4M&/5KY\OW
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M4L.JDRI/H)NI[CJ+\7)5R%R?(CB-4'R.!.69/[B8^\!0TP^(J='#2"_O#B6
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M. Z=-7V!1X"\8" HL[56)J$*0:?](7 =E;5"9TE!195P51-O=_-JJ6FCRE:
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MSO#C-P 3^,MWF,!WF,!1V2BL,ZA>CPM)H< 4'1G7SFZY+08ML6KVR!BVVL.
M!PYNWJK(X7>LMI7TI(C0V%V7+3+5(B&K"_QB[-3;0R1U$5-]#0XR/#[)VV=3
M$?"89\@AP"T:%!^I. I&!I)P)/YF(F\6J':RA1R,E <+8C=Y0)G5YW0N(&?@
M3QHT9I-BGJ^+200"X%NTPE:5>I_T:R@(-A$8(M,T=T<O"O>ZU'^R\V"9.$I5
M*^!P0"^54<$(2W8Q3(,'!DE%%!,[D>VX9(HSG#,(:=91/3LM@T?U=WK\G D<
M?<1)E%VLT1:(7UJ<&D:8=WAAHKOEJL\Y 4/<H[S-1>TM'@<_!JM*1\$,^E>.
M-_=-@3OSFC8/-PN0T@#0<;A5>YV/5ZN%BW0 PU'-W![^.?BPQI$WF&G*KZ&*
MAEZR_\:;81RO\Y<G]:.R>[0&#ZV8IU8-.!>RQ]\.Y6L>VBIOCVL'707:*6!?
M"G0_F/8L'+]=U]!)96^?[J/:L2U]^^Z]N\'YY0EG<!.C]O3)G="Q]P5,_PT7
M-BSVM\1Y>G=!,T8<$,%PYME*O.8 Y+#^Y!RBDE'$"A$&IGYV3!&W=_B<>S/'
M6K5V/&8%2<ZT+$PE6TPXZ5U6PHIX-H*H@TA51G"JM6Z\9A3$N?BU@19^IL8<
M(C'K: B?@V(:M1+AR3D#_P/&T07Y.,2_5QAC74+[9SOX4$-!:7#)%)OGG&+\
MS7V8,_-+^,0,Z]D@ 8,Q%63ID,"1*H4<UH_K685$*=A*BD<;O]U:.3RY'(&H
MG];_V?V/$H-F(M7F[N!\.!0+4"%4)&'*H$0/SVD;<)*DUP&S1D=0?#[IY!*M
M!PP<6[%I'[DF6T?Q? ?M"KIX2B*'))IJ(+(!#V,2E($PT,55(6U11RQ/['$"
M."-Q7GI>'MPE].RPW";E%+E..YD];&VCG0KBU&ZM$MD/_XIS*GA&GVC?DCL?
M]M'X.O;Y\-'35=.8[Z50"^<#3QV&(:.UM6!@]]2X+=!"L<J.D&9S;1[XG..=
M0IN#>:$F"$":&O-T!>D6_JM<;9PW$X,TU@_CMZ%7]4I)B\%(@LX6Y^8JZDM$
MW*(:>'B;G8TO'H:WF-'9*G=&$=5.*[<4 ;5@WVC+^^/'+=J!P0[Z;;:1SG?6
M3;3UT;<^+06 N9];*(887>N-=MYJQ2#/0N:?JF<)R>;5C1EP;-KMBGFQO'(Q
MJ5 &:Z';4*UC?=G>F7.L1HXB!Z&$-:+SYVUM[B)Z.MBCE1[=ZS(?P!/PG21:
M..II0SL=W$OG5CQR)_:>)6/0'$O-)([B-8U#/K@$@NL)H)PNW3/EB*#%WCT@
MYBGQ#U;=B2?/7B,Y@J=KO!^ROO@E,I$ 4DCWL9CQ?:SX'YB%%YX3D3W)#,4<
M).W]'7-1<4&'!1,>8ZP92D. ^2P:/OXX-.KE:B#$"Y!8P=[/_1!$#D.I7;%W
M=-N7'J:O9,B^G&\.#21<# 8(V)KI&V2&>0PA+'GR\E4]Y7_P4%J^P=L*,U<
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MGY$20TPFBA$^>6L47+3,P!;E#V \_;7H((GR6LW#D1F1GOZT5R3N&9%2F1H
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M[2%;$"U;X9I$6DE4C''& G_ER#+.^YWC;O^1C_S@+40_/N: F*)@!CK!,4T
M91<+<X<E"^?5@U4UK\>?J6>@AJ.AIQ%#U<S$:7H-!P ?_?D440JW:EZNVB*
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M+;H#^GUP(0'7U8')111)WHRO NH2)I<&OIYFT@X^@T_B369*VOL,TGLY@T>
M 6^6-Y,Y]VW=7!''&JU9>K02:RWNY@7VD0W)>Q$I-Z\'[KFJC3]0%H:UNKY=
M9R@A9AMU?JF*2\]1Q.@LI/IV\\/NH!6NAEWTSQ7;)R';Q5" /CM-O&&?_+9N
M=/B!*AS(B=C]A5?D0T$^L6HWZ/;N_N(\Q$%WVS0?:Z&24IC,@#0G$5P&,]CI
M)$@.4KJS1>\O/(Q9VW%3COK(YF%B6ZDSA MKF^]J^]F4&@7LIG6:\1WXEY2P
MYX+MW]"-"#RNM^Q:GDF032%L1IZ >M]S[^ #]+%K=_*TP0R6<IVT%.4MU_"Y
M\J@!)18U3,4(Z3MZ:[23,JZN;WM'=?2]6]^(TZ^../6&!/[ZAG;,S$BQ24N)
M(#[7,<J'JVT5?](Z^OY<8_\E#9'T.A>,#Y[G*Y9 /C(S!Z6R]DJS*3W''@!0
M!KT9\V9UR;;FH\@'%&8-'LK2?' !7 (-"WX!9Q%F=7+\AZ5H S*CO#'2#P94
MRZ!FG!$_YZ<E+O3L\$2\E$M]^_JWUW\_'WQZ/_AT_N[UNT]\LEP./GQ\_^'\
MXZ?_/>D,:DSJV_6PT$?DS=EW8Y+)W(F$N*JW1?T:W!IC3*Y 8SP^+(?+F4N[
M:!JY4K&3DPU"D9+8?6PY;4'7]#DPM/K3$I*9SM:X1T$'=,H\J4N0%(*+,P\#
M<C($E,;R W4VTD]UY;Q22 )[I*USPKM5,Z)0 +O&G(?)JO+S(O_<^N/'>MSV
M6/%\+T2[)S1.:&?<ZRY)7N7:#;Y;S>T"E#F=W2E!V1(.RJNRF'*L& ^C3?%*
M:G=%9&7^%O 6*U6XWOU8OMT1Z$=^M^6.>H<YD2Y13$MAASI1.T1GZ+FW,<"F
MK>UW_1I_!8R.=WU0ZW&:L<7)D)6:\"G,1Y6<@7,!@<M*.Z>\SD%-=8FM1!GI
MZN1M^8A^@4(V7_<2WT#Q^<7WXO/WXO/F(_\ @QN;I)Q*'\J2%M<<HFT><QA9
MG5#$B_JFF*"],/<1-)0XFJ8P10,XV?#@Y-82T7@_A*RQM[*"/X34$3%G:PM=
M)A$1I*%J(0DFFJ4ID0@RQ&B7I-#6,>4$#+\W"='CH6R$YYFZ7A!PE$TRW0*U
M)&E. 57_'_]]6Y?(QI9&4+KJN'1-M,&2E27V*X#H25<L]X?.FGQA6F2#1OX2
MIQ2I(.:$$:NXC1:[_P?C1CBJ"TQ:\OTS!)U24AW7>$5=^!4UXPI>GIT_]EC<
MI2#LPF0%\2O:2_J\3>#Q;>1R-)L6G4<F_Z':N3EV@]MRT&E;-Z79$]T/;;N1
M9VK2HYSYCK-&AEB'9(2](53E9HEL0/P[#ZL:=\*\#66BLAFO%@Q<Q?JE/&L&
M3@VE9"=1\M/6MB*OR">[*J\%WR9(D%BAS&"587^SUVU2.J(! ?UNU&0M(N1!
MO3\<X5PU, 3&D+?:=!;DX(X9-MT=-6+ZB:&XTU+A0PC+V4H%M,&R4@"AWT"6
M7A:$6RO%W'TS["RW@'"23CZM+,+AV;8%D77Y^\?7[]Z<GW"V(#%N &)ZP.U2
MD0VY$)MP*$;'+"9O&7""_2SW&L 8_%!G0LRUBPLZ(PS(6L@&I)#F=?B0&-+0
M X$KA9[#6]BU0EP 2#=4@:";#6\C4D<.\I*4/E \4=D)A*+%4U^H-?W;4=?I
MRY_"=?KU^UOT]!X_O=/"I!L^/OB2_B"GES^6\%^X/@PR!:9NWDHQ?V(K@N.Y
M.S,]F(/19:"7]-$=[AF#N@:WN*N44W)S.@&MZD4V&*_'<]2& KQ=/JDSYR^7
M\R#MY%931_^+Q+6L_N7&I2D_@YA'>5TB9\.BUE[I<>/"-&BAOH(3RSD4B_IS
MH>S3VY-!".UP:[[Z/"\H#85?\DJIG*? S%.1 U'S@MO%LT&U HYX: #_5]X
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MZ2LH>])1\M[SQ"HWZ"$E7ZYZ8O6,F=A5S3GKGX@6EG#F^4?=:6'_ N0QB,B
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MDI;A@RZ_8(W!)+1FQ6>2L1!=-DZP*IJ#:DM85[ITI[][S5] H4C*P/SI./0
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M%5Y58PP<"%7I@CK:V8MOU=V]RUC^&]S=MFBNT3O@PISM_^=& $3( *,Y\[W
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M(4C=8(X'O #C227@R-R'*S3_Z#S )S>3AV?:@$U?84R6O8T?6L_>6M77N0K
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MU-?>;RB%(:VLZ_&< >?-'IN0P&):8/IQD>1<'FW:7\R[.'7>:%B(#$D2'8,
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M("X)IEYG4B7?4AKY]G(J,*T)\9IJIB>P\CU'ML*74&SPX?%W_;K8X(45&SS
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ML%H5?B,IWG-;)DQ]_&V2#4WM9)JE#MR.-D:XL28J"F/R\K(:8:JA4 TT!4*
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M\"!Z0<WTT,4>-  &#@.68](7UGHB1.ERR+8&?$:8UH>Z5')5IQ%>IQN\()9
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M%V:?0\276#P,LP$UL8&+N!ERK2 .$KW2!%-4 ^UG;IRW6:&]O==[.]R?7CT
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M'2R1@40':%=W;AH2ITA6@2YL0Z.I&[4!!.Y\K@]$GB'4@EXZH N?Q0EH='Y
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MZG'% 3F#PE_L!<_;TIV/4U35S?A1TNI\VF/(-&=>EA]_=A^78FGET(?=Q,_
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M+M00XZ3&@TH>Y['/Z(+11 :;5!I&994J<8;*0!YVFWU?(=*+%Y!WBQ00,0I
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MZV3P2Q -R^8_R!OE96_>XL)+$]C.VW$-/^(!:]R->E^O<[@W^MBZEN4?_VT
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M)R@(8="=E,2FKA&6,@OI&>.L@%_2H)"9/4F935E'PL_43=C^L+?]>D=9VPY
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M!A,  8W8*.:RCXDI]-!YW).O1/,IXH!L21T^3LY45V(0QTV=&OYK7KQ5L;<
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MB*?CZH[@ES>@H;I1D?0"J88)_E)=R!#3&Z2[,'?>OV5,*46[P$P]]G;!=A"
M6"]"8S+*^>D_P2:\G6\34@S\TNTP-!7K$L"TV'"U/5$,,]B&RE[]W_:^M;EM
M9,GR\^ZO0/3.3M@1=+<>EI]S)T*6Y&[%M!\AN6_/?MH B:)8;1#@Q4.T^M=/
MG<RL!T!0MD6YVP1X/_2U)!*HJJQ'5N8Y)P_V!C'UG]Y]U-_F/-=GI MN;L/&
ML5J OZ@^ >SE^(?VKD03N:'7TF0@(/DG'RP4P_L@44E?"Y=, (7IOS_V;+-5
MT62%N1$>JRL:W<C/]Z'L]<\W&] XRVJSP\QUIN?UW&WV00)1]B"=30!KY MJ
MHQQ'X!M;7D,:$SJ#OQ$1J8?Q&"+20_F5YAW,:M:NW,[^?_\7Q?[>IK12![()
MR-&DM3O#I<+\\(Z85[B(G'T"DT]H+Q<(P[CKRH?X$\"Z+AS$/@ 8BB2?*W-E
MY?CQ(-GPBT0XH_V3OVV)C GY%65K!Z28D+AR\EA,%O$6^C\#-HB$'%/XK7%P
M8=3;"TI<@/X/Y097_N!N3V/8@1!H>%WKHILLL-'_H=Z<#N_5>)J<*+",%O:<
M)]R-DT!/UMSU&#)KKH8,ZQ*&C]54,AM7N1!!BQ83QET6.[!^ZR0\PQNG^(=!
MX/:S18&_\'\#F$(;1@+8<F[G2VI0YFVP%!-!V"T4.AU9#ED<C37G0@*'TC/]
MH@?XW,]U7)@?@%+5TP"]$PA*N2 #Z*DHV66<(E$Z8="@*RHDGZ-9E%4:[(P5
M.*@+[%J0:CP%*Y'.3 *S/ PO&^L_M."HM\!:."#)43_48P!C42$K9TYJ$8<E
MGHZJX*DM;AJ+"OH([3Q?;!J=$&!R9([GA!,]C' B=*89*"'T." ^AKRJXLE,
M*D^Q+.(W+-]P?.=)Q<;U2[K5;@'H6F'1M6,Q"@?"/+,H( 8J/Y6@U#")IHPL
M6]:FYTH \%CF5Q0Q1Y8W7N90>:?WW! OBE[/_TI9)B1\K^:J0:1#:HDN#@KH
MCZEV'>P^[C*;1,2\3U!G 8$]O1$6F$H::\SN,:69""6)4+A*)OC8,B\^FE,O
M4RS6D'C.9"#5\C+,,E3Q1_AT5+^OM-7=>,\!;6E!.#J7>6@VPCCV&04NK-[2
M2W85Y9I0\K%K(]62)J*F"H=Q#C2Y+&>YZ[EW> U=NX$T\U.!T/%V5:3]>I3-
M/;1A1T?YIG24-C]QD<;VQ++:,0ZFBRD?<"Y>"IZE(?DHU(J67L-2KMLDU:%(
M?;VU:@;@TFT0^3YSYZX/,>7?1"_=>@JO-B236O? BG,%V)<7 : =&[D_$:3,
ME1,=G<>)8M$::)$[TGG.ZE]6^DL.[)=-%R2?3LU8D1_!;-S2"?5PZ*YT>1I?
MS40>9+X^!7Z^(+FGCCU_Q (C>ER+6J/78L\F?!R%Y\ 5'&8>#+MT0BTS+)%"
MZ?FX+DK/WR3047S30>AD2-)*A5LOW)#ZL&-#^J2RH:5$&%A94M(QV)+V:(I9
M<10K>%!L+Z-3LYB-9>B:@-@E<20P0\W@V]$>66!YXX =P'+?(.72J^4^:JYV
M+,VPL@YIJ\::YJ"M*3FTDV&#[ ^BG.%XAHNWM:\%&Y)4M+&>K>-^P4#"^4_L
M7[S6E8AK 4(6@"BO]+4 >;Q&:AHO6)*"B.SPLW/D!)=YG2:!3!0)([$&0^@@
MM]K-P8+.G1V^! 7MVP6:0DTVBD"HC&(0-@G@!R4LR]C_F;9)6JQUDC!M.?%<
MY8(U&V<W"YQ"C$IMA"%QYCB2,AW6.I.R/18RUBE(T K5K E&-=37'WJ&6UB%
M&@&7@(,*IP#*7+:R(VA1.*N^^"5V,$1:) FEK2"!1S5*4+"PXA54*O71QI_,
M]96/X\K<7ZQSG,;+!OG*/V_DNH)_&R>[N(HS_:?(/2XY;O>H%D6P.47EK7!]
M@GECISYU>-1T#)#3+QE*(7J.M),D.<FMY&Z7( *N,#OQ)Q=@=%=EM_(L!5AZ
M++KIJ5;3#L<D\NQ%6LF.&QV\B\*$1!8ULZ[_2_5@X^3GER41%G4QF9%6?C>]
MO8E()]E%4<CV$8_&CHXO#\ \FV"T&[ 8FO"X<;";W P=PR VEMH\MXA>0(*?
M=+#)14:JH38?TWQ*L&9)%X:]-B1Y3&,U:?UM<B+^#0R>@\<__OO_V7^R]W+U
MO\U=QE>_HX!]0]VATR-PZK7^LZ/@@).Q7?#.E5.-:1PFDTE!@DAM!ZSQ9(FE
M=Z1*.;EF13]LB2S*RH@\5K.6=/\7V_WDKD7Y,@FF@B@#7P&*0^8%D*.N9GDA
ME&R1,R*524U:MM<Z3WUFC%C;B%1KTB^#L)L+IHW:JL-3+C4SBECU$HYR/C%O
MQ*E/#[*L^ 8QWVR^%8&.*$EVK8N<)RU.T85QG?0DFIE-FM)0253&4X5B--\.
M*W_FVV#:_FN\O!?:3R-*3XZ^L-V3N@BS-,VURE1Z4FZE/:TN><QF6!U(T\%A
MP'CGT+K#C4&7BYSO)KE.(5=5%7FJZCF&&;$,XQK-XC_C(LGKDJ7Q8,_2RB7_
M"]0'DK7RGUK&944IP4_&%/XK(VM0E80/@HOLOHJ+[R)/T]K\D5,)X?2B-ZX,
M]P .UPTI!K)H.>'-D^<6CJ>L]S\;>D)67%_2GO2@/+/A;4E9VVPYQ(Q]T#L\
MD9O>\-^KD("BL<F+:!6$P1"H=4?H??WWCA:E'YL,:F8<O]@L9$7_V2+!B'8#
MPB5Z>/CD?CRI5S<OUIGO-CS.=]:+M\;9[4,_/D#)_R_NR-\^KS=N /^(C[_0
MYL34DT[]"(Y[EU_A.W^#D3JFS/K^_LMHG9%/[@A!:G:+J903E:9RW/[CA[T?
MZ&=@_^S/'2W_H"%?_U8MHXM\'F<OH]5.5\;856*_O-1)-7MQ](1=AI^J!'^4
M?_Q$'VU\_!HGL?& 95S-^?S#5P$*5OR;.VUZS@JMO#VW?GU;7WZFL=]@QG!F
MR&9.)LZ1H=\\>)M3=O5\2A%]_U'QIQFQ[E(^HO,MZ)O$HCRR/%-6M:RCCH5/
M(FA4#I @+T*Y#SN&CVS^$\V_+QXKP:\T;'OD]%EDDWUTU-QDGW_M@#[_TJWB
M\OC-^U_/HG=O?_U_=]LMOK/^O'WW(7K][B(Z^^^SD]\^G+][^]VIS=RSEM8W
M/==VP*UO+Z5U<'+R>._L\9-G>T]/CO:>'3PY>K4'*:VG>P?[SY_NO]I):6UR
MFVK-E==;)*5U\=NO9Y?1\=O3Z.+LY]]^/<9N=KD5(>N&0.XT-@X<LM3&PQN+
M#*>%G]_X1+N7YK^ DJ80U9R09J@3ZDN+K8KO6L%DH>V:XU[0 '%0G1#JR&#Z
M=+X)89*PW TW4220++8^GG"*/I]KP4/91W-9#VH%?X+1NE7I<[WY'TP2. ^+
M*LGW468WU9.F7'1W.RT?003JO0!TJY8><S-):I-'CM!=>=K_2-OF62P_U0AK
MSUGL?/*1V4)E11+;YG="50IX1_A4R>"0M"IML;LDSQG]CY1VOBS; ("@$J9E
M<ZQ(JG,"16@"-L^U*DL=VS+GI9M<U')B!G"DEK%)004?7]35/&Z91Q_53>ER
M<=.ZR'0Y:^&][4JS/1AYE5P_&/2<U;=$\YH+#[K4#W&$O2!P135(7%T5Z@MK
M*Z.TUCA=:4Y8E?26\I*MXM\40&_4=,'OJ='8*O!7$#2FYC)B.UCEVMQ<HR+/
MYZ4K$.A'")R1QB:"5']M"4E!E0O=V@-HL>9< I :4.;^L:V& ^01-CHT-U=N
M(6Q"S" E%&X)22%V&LM$72A)O1$R(<5CS/M!@FKMN[@L0?.ZH98^!]Z#:]/Q
M].K_YK)!U@ZP-MD)S+ +&$:27:!HZ01_<]?3C\BD3HQ)6 B/F!H4N@@T*C(<
M<2#L7Q5(DE-<G__99H/UWC ;I%>"6KSDJ7 BQ-58(AO0V'Y4:D$K1V!="@49
M,\L"_(3"=VS?:;-8A:3[:*68?;X@;!8"&!/3Z7R.U305B%-<T)XWEJ]2^NPR
MSJ)3K:[RZ 1T?+.5>-UR=P*PN*,R[E5^XRI=7C'D7/;;LBX"_71NJLP37U<#
MY8I!A(9NF9U]YE'2ZR6B*ZF*K^U^XHXP39+X2#WAVB-N&,U.[C'*$=I"\/;T
ML&\%5Q&R*%T=&=E>Y"$:G+-A0<GLO&@TR_<G*#Y$C>=&FOV5>^30$.U/D)Y;
MH@JGZ\_]DCZYKG#GVAT:V>(286U=H"V:C2O4E2XKJBYQ3(*J*^9PCYE2%C@
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MP<@B@(D;.P#;W!<RP*LN)BZIVI5L7)-E)C"CV?:H="LRFHCT@Z\I+I83]W!
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MH=Q/$8)3JL_5XT/W'5,<S?9TQLPR,Y^?#L3*@SAVWTEYW2'XRL:HBYB5LC]
M-CN>2+*C"V'1DSZS?>E&-!0C<TG1<R*+2#2SJ^,]Z>\[\RZ-'*T5D1F*D5$P
M@1,V^83LW K@O>JQS>L*$%E<EGPQQB&$*XW=P5OJ=W["6)=*61\[31QV,X>
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M,#(P,#,S,5]C86PN>&UL4$L! A0#%     @ RH&F4$YH\,5P,P  !T8" !4
M             ( !,"<  &%N86(M,C R,# S,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( ,J!IE#,!$RG*Z(  *W@!P 5              "  =-:  !A;F%B+3(P
M,C P,S,Q7VQA8BYX;6Q02P$"% ,4    " #*@:90%ON6H]E9  !K4@0 %0
M            @ $Q_0  86YA8BTR,#(P,#,S,5]P<F4N>&UL4$L! A0#%
M  @ RH&F4-*B_QF,$ ( I/D2 !0              ( !/5<! &%N86(M,S,Q
M,C R,'@Q,'$N:'1M4$L! A0#%     @ RH&F4'C ]!@3"   4"$  !D
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M9U!+ 0(4 Q0    ( ,N!IE#IFY>0H9,! &@[#  2              "  <Z
J! !W871E<FED9V5L96%S92YH=&U02P4&      P #  J P  GQ0&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809094496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and Development Agreements (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Collaborative Research And Development Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived', window );">Upfront license fee received</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets', window );">Number of outstanding research and development targets | target</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents', window );">Milestone payments, contingent upon preclinical and clinical trial events (up to)</a></td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals', window );">Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)</a></td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales', window );">Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)</a></td>
<td class="nump">$ 165,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent', window );">Agreement term following first commercial sale or expiration of the last to expire patent (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod', window );">Number of milestones achieved during period | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (TSR042/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-TIM-3 (TSR022/Cobolimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-LAG-3 (TSR033/Encelimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | IND clearance from the FDA | Anti-PD-1 (TSR042/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | IND clearance from the FDA | Anti-TIM-3 (TSR022/Cobolimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | IND clearance from the FDA | Anti-LAG-3 (TSR033/Encelimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 2 clinical trial initiation | Anti-PD-1 (TSR042/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 2 clinical trial initiation | Anti-TIM-3 (TSR022/Cobolimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 2 clinical trial initiation | Anti-LAG-3 (TSR033/Encelimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 3 clinical trial initiation | Anti-PD-1 (TSR042/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Phase 3 clinical trial initiation - second indication [Domain] | Anti-PD-1 (TSR042/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Filing of the first NDA - first indication | Anti-PD-1 (TSR042/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member', window );">TESARO | Filing of the first MAA - first indication | Anti-PD-1 (TSR042/Dostarlimab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount', window );">Milestones achieved, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_CelgeneCorporationMember', window );">Celgene Corporation | Collaborative Research And Development Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived', window );">Upfront license fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone', window );">Maximum milestone payments per target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_CelgeneCorporationMember', window );">Celgene Corporation | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (CC-90006)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned', window );">Milestone Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anab_CelgeneCorporationMember', window );">Celgene Corporation | Phase 1 clinical trial initiation | Anti-PD-1 (CC-90006)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned', window );">Milestone Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognized, Milestone Method, Milestone Payment Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase3clinicaltrialinitiationsecondindicationDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase3clinicaltrialinitiationsecondindicationDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_FilingofNDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_FilingofNDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_FilingofMMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_FilingofMMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anab_CelgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anab_CelgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=anab_Phase1ClinicalTrialInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=anab_Phase1ClinicalTrialInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791501088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jan. 26, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock | Director Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=anab_EmployeeAndNonemployeeStockOptionsMember', window );">Employee and nonemployee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition', window );">Weighted average period remaining for amortization of unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding', window );">Annual increase in number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease', window );">Capital shares reserved for future issuance, increase (in shares)</a></td>
<td class="nump">1,090,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member', window );">2017 Employee Stock Purchase Plan | Employee stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding', window );">Annual increase in number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease', window );">Capital shares reserved for future issuance, increase (in shares)</a></td>
<td class="nump">272,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Reserved For Future Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_CommonStockCapitalSharesReservedForFutureIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not Yet Recognized, Period For Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee And Nonemployee Service Share-based Compensation, Nonvested Awards, Compensation Not Yet Recognized, Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=anab_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=anab_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anab_EmployeeStockPurchasePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6802793712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 486,365<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 633,251<span></span>
</td>
<td class="num">$ (223)<span></span>
</td>
<td class="num">$ (146,690)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,922,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">2,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,078)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Mar. 31, 2019</a></td>
<td class="nump">468,155<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">636,692<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="num">(168,768)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">405,008<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">648,669<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="num">(244,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued under employee stock plans</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued under employee stock plans (in shares)</a></td>
<td class="nump">22,033<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss), net</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity, Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 400,564<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 651,680<span></span>
</td>
<td class="nump">$ 1,145<span></span>
</td>
<td class="num">$ (252,288)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' Equity, Ending Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803109584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 165,317<span></span>
</td>
<td class="nump">$ 171,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivable from collaborative partners</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">197,166<span></span>
</td>
<td class="nump">203,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,572<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">371,055<span></span>
</td>
<td class="nump">377,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">50,215<span></span>
</td>
<td class="nump">54,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">424,233<span></span>
</td>
<td class="nump">435,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,571<span></span>
</td>
<td class="nump">16,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">13,781<span></span>
</td>
<td class="nump">11,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">23,250<span></span>
</td>
<td class="nump">29,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 500,000 shares authorized, 27,277 shares and 27,255 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">651,680<span></span>
</td>
<td class="nump">648,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,145<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(252,288)<span></span>
</td>
<td class="num">(244,026)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">400,564<span></span>
</td>
<td class="nump">405,008<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 424,233<span></span>
</td>
<td class="nump">$ 435,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793256384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text">Notes Payable <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December&#160;24, 2014, we entered into a Loan and Security Agreement, as amended from time to time, the Loan Agreement, with a bank and a financial institution whereby we may borrow up to </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> separate draws of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> each. The Term A Loans, for an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, were drawn on December&#160;24, 2014 with a fixed interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>6.97%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, the Loan Agreement was amended to combine Term B Loans and Term C Loans for a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> available for draw through December 31, 2016 and delay the beginning of our Term A Loans&#8217; principal repayments from February&#160;1, 2016 until February&#160;1, 2017. The Term B Loans and Term C Loans became available for draw on July&#160;1, 2016. In December 2016, we further amended the Loan Agreement to (i)&#160;allow for the Term B Loans and Term C Loans to be drawn on December&#160;30, 2016, (ii)&#160;delay principal repayments of all Term Loans until February&#160;1, 2018 and (iii)&#160;amend the interest rate for each Term Loan. The Term B Loans and the Term C Loans were drawn on December&#160;30, 2016, and Term A, B and C Loans are now collectively referred to as the Term Loans. Principal repayments began in February 2018, and were paid in full, without penalty or premium on January 1, 2020.</span></div><span style="font-family:inherit;font-size:10pt;">The costs incurred to issue the Term Loans were deferred and were included in the discount to the carrying value of the Term Loans in the accompanying balance sheet. The Term Loans also included a final payment fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span> due at the earlier of prepayment or the maturity date of the Term Loans. The deferred costs and the final payment fee were amortized to interest expense over the expected term of the Term A Loans using the effective interest method.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786969872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="line-height:120%;padding-top:8px;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> non-cancellable office leases with remaining lease terms of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1.5 years</span></span><span style="font-family:inherit;font-size:10pt;">, each of which are classified as operating leases. Both leases expire in 2021. Only one of our leases has remaining renewal options, which includes </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> options to renew for one additional year. The exercise of lease renewal options is at our sole discretion, which we currently do not anticipate exercising and as such were not recognized as part of our ROU asset and lease liabilities. Our lease payments are fixed, and we recognize lease expense for these leases on a straight-line basis over the lease term. Operating lease ROU assets and lease liabilities are recorded based on the present value of the future minimum lease payments over the lease term at commencement date. As our leases do not provide an implicit rate, we used our incremental borrowing rate based on the information available at effective date of adoption in determining the present value of future payments. The weighted-average discount rate used was </span><span style="font-family:inherit;font-size:10pt;"><span>8.59%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our balance sheet includes our ROU assets and lease liabilities as follows (in thousands):</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification on the Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating ROU assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>898</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following costs are included in our cash flow statement (in thousands):</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification on the Cash Flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the future minimum annual obligations under non-cancellable operating lease commitments in excess of one year are as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>676</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum payments required</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,405</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(88</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,317</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:24px;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder Lawsuit</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 25, 2020, a putative shareholder class action complaint was filed in the United States District Court for the Southern District of California against us and three of our current or former officers.&#160;The complaint purports to assert claims under Section 10(b) of the Exchange Act, Exchange Act Rule 10b-5, and Section 20(a) of the Exchange Act, on behalf of persons and entities who acquired our common stock between October 10, 2017 and November 7, 2019, or the Class Period.&#160; The complaint alleges that, during the Class Period, the defendants made material misrepresentations or omissions regarding our etokimab drug that artificially inflated our stock price.&#160;The plaintiff seeks, among other things, damages in an unspecified amount, as well as costs and expenses.&#160;We believe that the claims in the action are without merit.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790523760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">3,039,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">115,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises (in shares) | shares</a></td>
<td class="num">(22,033)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeitures and cancellations (in shares) | shares</a></td>
<td class="num">(266,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">2,866,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable, ending balance (in shares) | shares</a></td>
<td class="nump">1,423,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 29.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">15.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercises (in dollars per share) | $ / shares</a></td>
<td class="nump">1.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeitures and cancellations (in dollars per share) | $ / shares</a></td>
<td class="nump">37.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">28.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 26.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, options outstanding (in years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, options exercisable (in years)</a></td>
<td class="text">5 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding | $</a></td>
<td class="nump">$ 6,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, options exercisable | $</a></td>
<td class="nump">$ 6,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796248240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 36,279<span></span>
</td>
<td class="nump">$ 23,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">36,279<span></span>
</td>
<td class="nump">23,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">1,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">1,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember', window );">Commercial and corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">34,431<span></span>
</td>
<td class="nump">5,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">34,431<span></span>
</td>
<td class="nump">5,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (29)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=anab_CommercialAndCorporateObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796232800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable (Details) - Notes Payable to Banks<br></strong></div></th>
<th class="th">
<div>Dec. 24, 2014 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate borrowing capacity</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Loan and Security Agreement (LSA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_DebtInstrumentMaximumBorrowingCapacity', window );">Debt instrument, maximum borrowing capacity</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_DebtInstrumentNumberOfLoanInstallments', window );">Number of loan installments (in installments) | installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term A Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Aggregate draw on term loan</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="nump">6.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term B and Term C Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_DebtInstrumentMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_DebtInstrumentMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_DebtInstrumentNumberOfLoanInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Loan Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_DebtInstrumentNumberOfLoanInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=anab_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=anab_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=anab_TermALoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=anab_TermALoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=anab_TermBLoansAndTermCLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=anab_TermBLoansAndTermCLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787014640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:1px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Laboratory equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,018</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>820</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,413</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,297</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,679</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,618</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following: </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation and related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,152</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued research, development and manufacturing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,689</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,781</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,052</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788737920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Related to Stock Option Awards</a></td>
<td class="text">A summary of the activity related to stock option awards during the <span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> is as follows: </span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares<br/>Subject to<br/>Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average<br/>Exercise<br/>Price per<br/>Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value&#160;(in<br/>thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,039,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercises</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,033</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeitures and cancellations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(266,468</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,866,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.30</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,683</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,423,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.33</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions in Stock Option Valuations</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22630560928434%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average grant date fair value per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total non-cash stock based compensation expense for all stock awards that was recognized in the consolidated statements of operations and comprehensive loss is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,146</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,240</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,627</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,975</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,867</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795871616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,413<span></span>
</td>
<td class="nump">$ 6,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(4,803)<span></span>
</td>
<td class="num">(4,679)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=anab_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,018<span></span>
</td>
<td class="nump">4,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=anab_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=anab_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739108528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments required</a></td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 1,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739037872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Allocation of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,975<span></span>
</td>
<td class="nump">$ 2,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,829<span></span>
</td>
<td class="nump">$ 1,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anab_SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
